
<div>
<div>
</div>
</div>
<div>
<div><div><img><div>1</div><div>T<span></span>ABLE OF C<span></span>ONTENT<span></span>S</div><div>I.   C<span></span>ONT<span></span>ACT INF<span></span>ORMA<span></span>TION<span> <span> </span>3</span></div><div>II. <span></span>DISEASE PROCESSES &amp; SURGICAL PROCEDURES</div><div> <span> </span>T<span></span>ranscathe<span></span>ter Aortic Valve Replacement (T<span></span>AVR) <span> </span>6</div><div> <span> </span>Cardiac: T<span></span>AVR <span> </span>9</div><div> <span> </span>Aortic Regurgit<span></span>ation <span> </span>10</div><div> <span> </span>Mitral V<span></span>alve Disease <span> </span>12</div><div> <span> </span>T<span></span>ricuspid Valve Disease <span> </span>16</div><div> <span> </span>Coronary Arter<span></span>y Disease and CABG <span> </span>17</div><div> <span> </span>Diseases Of The Aort<span></span>a <span> </span>19</div><div> <span> </span>Atrial Fibrillation (AF) <span> </span>23</div><div> <span> </span>Hypertrophic Cardiomyop<span></span>athy  <span> </span>24</div><div> <span> </span>Infective Endocar<span></span>ditis/ Root Abscess  <span> </span>27</div><div> <span> </span>Myocardial Bridg<span></span>e <span> </span>29</div><div> <span> </span>Constrictive P<span></span>ericarditis <span> </span>31</div><div> <span> </span>Advanc<span></span>ed Heart Failure: V<span></span>entricular A<span></span>ssist Device (V<span></span>AD) <span> </span>32</div><div> <span> </span>Heart T<span></span>ransplant <span> </span>34</div><div> <span> </span>Ex<span></span>tracorpore<span></span>al Membrane Oxygenation (ECMO) <span> </span>37</div><div> <span> </span>Lung T<span></span>ransplant <span> </span>40</div><div>III. POST<span></span>-OP MANAGEMENT</div><div>1.  <span></span>NEUROL<span></span>OGIC</div><div> <span> </span>Delirium <span> </span>44</div><div> <span> </span>P<span></span>ain Control <span> </span>45</div><div> <span> </span>Seizures <span> </span>47</div><div> <span> </span>Spinal Cord Ischemia  <span> </span>50</div><div> <span> </span>Str<span></span>oke / CVA <span> </span>52</div><div>2.  <span></span>CARDIAC</div><div> <span> </span>Atrial Fibrillation &amp; Elec<span></span>trolyte R<span></span>eplacement <span> </span>53</div><div> <span> </span>Heart Blocks <span> </span>57</div><div> <span> </span>Chest P<span></span>ain <span> </span>58</div><div> <span> </span>Peric<span></span>ardial T<span></span>amponade <span> </span>59</div><div> <span> </span>Right Ventricular F<span></span>ailure <span> </span>60</div><div> <span> </span>Syst<span></span>olic Anterior Motion (SAM) <span> </span>62</div><div> <span> </span>Vasoplegia <span> </span>62</div><div> <span> </span>Heart F<span></span>ailure <span> </span>63</div><div>3.  <span></span>PULMONARY</div><div> <span> </span><span><span> </span></span></div><div> <span> </span>Pneumothor<span></span>ax <span> </span>65</div><div> <span> </span>Pulmonar<span></span>y Hypertension <span> </span>65</div><div> <span> </span>Acute Respir<span></span>ator<span></span>y Dis<span></span>tress Syndrome (ARDS) <span> </span>66</div><div> <span> </span>Atelec<span></span>tasis <span> </span>68</div><div>4.  <span></span>GI</div><div> <span> </span>Acute Hepa<span></span>tic Dysfunction <span> </span>69</div><div> <span> </span>Constip<span></span>ation And Illeus <span> </span>71</div><div> <span> </span>GI Bleeding <span> </span>71</div><div> <span> </span>Malnutrition (T<span></span>ube Feeding<span></span>/TPN) <span> </span>73 </div><div>5. <span> </span>GU/FEN </div><div> <span> </span>Acid Base Disturb<span></span>ances <span> </span>74</div><div> <span> </span>Kidney Disease <span> </span>77</div><div> <span> </span>Sodium Imbalanc<span></span>es <span> </span>79</div></div><div></div></div>
<div><div><img><div>2<span> </span><span>Contac<span></span>t Information<span> </span><span>3</span></span></div><div>6.  <span></span>HEMA<span></span>TOL<span></span>OGY</div><div> <span> </span>Acute Blood Loss Anemia And P<span></span>ost-Oper<span></span>ative Bleeding <span> </span>80</div><div> <span> </span>TEG<span> <span> </span></span>83</div><div> <span> </span>Heparin Induc<span></span>ed Thrombocytopenia (Hit) <span> </span>84</div><div> <span> </span>Deep Vein Thrombosis <span> </span>85</div><div>7.  <span></span>INFECTIOUS DISEASE</div><div> <span> </span>Sepsis <span> </span>86 </div><div> <span> </span>Cellulitis <span> </span>88</div><div> <span> </span>Pneumonia <span> </span>89</div><div><span> </span><span> </span></div><div> <span> </span>Urinar<span></span>y T<span></span>rac<span></span>t Infection <span> </span>91 </div><div>8.  <span></span>ENDOCRINE</div><div> <span> </span>Acute Hyperglyc<span></span>emia And Diabetes Management <span> </span>92</div><div><span> </span><span> </span></div><div>I<span>V<span></span>. PROCEDURES/DEVICES</span></div><div>1.  <span></span>PROCEDURES </div><div> <span> </span>Atrial Electr<span></span>ograms <span> </span>97 </div><div> <span> </span>Direct Curr<span></span>ent Cardioversion (DCCV) <span> </span>97</div><div> <span> </span>P<span></span>acer Wire (PW) Remov<span></span>al <span> </span>99</div><div> <span> </span>Rapid Sequence Induction <span> </span>101</div><div> <span> </span>Bronchoscopy <span> </span>103</div><div>2.  <span></span>DEVICES</div><div> <span> </span>IABP <span> </span>103 </div><div> <span> </span>Lumbar Dr<span></span>ains <span> </span>106</div><div> <span> </span>T<span></span>emporary Pac<span></span>emakers <span> </span>106</div><div> <span> </span>On Q Pumps <span> </span>109</div><div> <span> </span>Wound Vac <span> </span>110</div><div>V<span></span>.  <span></span>REFERENCE MA<span></span>TERIAL</div><div> <span> </span>Surgeon Pr<span></span>eferenc<span></span>es <span> </span>112 </div><div> <span> </span>Cardiac Surg<span></span>er<span></span>y Proc<span></span>edure Clearanc<span></span>e <span> </span>114 </div><div>1. <span> </span>PRE-OP</div><div> <span> </span>Check List <span> </span>115</div><div> <span> </span>Cardiac Surg<span></span>er<span></span>y P<span></span>atient Blood Management Pr<span></span>ogram <span> </span>116</div><div><span> </span><span> </span></div><div> <span> </span>Obt<span></span>aining Consent Procedure List <span> </span>120</div><div><span> </span><span></span><span> </span></div><div> <span> </span>Peripr<span></span>ocedural Antico<span></span>agulation Bridging <span> </span>122</div><div>2. <span> </span>POST<span></span>-OP </div><div> <span> </span>Imaging <span> </span>123</div><div> <span> </span>ABG Interpre<span></span>ta<span></span>tion <span> </span>124</div><div> <span> </span>Advanc<span></span>ed Hemodynamic Monitoring &amp; Pulmar<span></span>y Artery Catheters <span> </span>125</div><div> <span> </span>Common ICU Drips <span> </span>127</div><div> <span> </span>Common PO Meds <span> </span>128</div><div> <span> </span>Diagnosis T<span></span>ranslation E<span></span>xamples <span> </span>130</div><div> <span> </span>IICU Admission Requir<span></span>ements <span> </span>131</div><div> <span> </span>INR Goals <span> </span>132</div><div> <span> </span>Prophylactic Medica<span></span>tions (GI, VA-PNA, DVT<span></span>, Infection) <span> </span>134</div><div> <span> </span>Supplemental O2 &amp; V<span></span>entilator Management <span> </span>134</div><div> <span> </span>Vad Bowel Re<span></span>gimen Protocol <span> </span>138</div><div> <span> </span>End of Life Care <span> </span>139</div><div> <span> </span>P<span></span>atient Progression Checklis<span></span>t <span> </span>140 </div><div> <span> </span>Notes  <span> </span>141</div><div>PHONE NUMBERS</div><div>Emergency</div><div>Code Blue<span> </span>211</div><div>Str<span></span>oke Code<span> </span>211</div><div>T<span></span>ransfusion ST<span></span>A<span></span>T<span> </span>3-6445</div><div>X-r<span></span>ay ST<span></span>AT<span> </span>3-7030</div><div>Units</div><div>A31 Cardiac Clinic <span> </span>1-8999</div><div>SAU <span> </span>3-5163</div><div>ICU T<span></span>eam 1 <span> </span>650-206-3620 or 42829 *</div><div>8-9220</div><div>8-9218</div><div>ICU T<span></span>eam 2<span> </span>1-6454*</div><div>6-7749</div><div>8-9223</div><div>North ICU F<span></span>ront Desk<span> </span>3-6081</div><div>iICU Blue <span> </span>650-850-1830</div><div>iICU Green <span> </span>650-308-6625</div><div>iICU Floa<span></span>t<span> </span>650-304-9193</div><div>D3 F<span></span>ax<span> </span>650-725-4520</div><div>C1<span> </span>5-8106</div><div>D1 CC<span></span>U</div><div>D1 CSU</div><div>ED Unit Secret<span></span>ar<span></span>y</div><div>ED Charge RN</div><div>ED T<span></span>riage RN</div><div>CDU</div><div>8-4662</div><div>4-2243</div><div>5-4492</div><div>4-1710, NP: 39904</div><div>OR Front Desk<span> </span>3-7251</div><div>OR #8<span> </span>5-7208</div><div>OR #9<span> </span>5-7209</div><div>PA<span></span>CU<span> </span><span>3-6631</span></div><div>Resident Desk<span></span>-F<span></span>alk<span> </span>5-3832, 5-3835</div><div>Pharmacy/Lab</div><div>D3 Rx</div><div>D2 Rx</div><div>ICU Rx</div><div>B2 Rx</div><div>16777</div><div>55203</div><div>55923</div><div>36098</div><div>Core Lab<span> </span>3-6111/3-8891</div><div>Micro Lab<span> </span>4-4588/4-4589</div><div>T<span></span>ransfusion (Blood Bank)<span> </span>3-6444</div></div><div></div></div>
<div><div><img><div>4<span> </span><span>Contact Informa<span></span>tion<span> </span>Contac<span></span>t Information<span> </span><span>5</span></span></div><div>Hillview Lab (HIT studies)<span> </span>650-723-4813</div><div>Cytology<span> </span>4-0077</div><div>TEG</div><div>Imaging</div><div>See page 123</div><div>Ancillary St<span></span>a</div><div>PT Scheduler<span> </span>5-0299</div><div>Dialysis RN BA<span></span>T phone<span> </span>4-5350</div><div>PICC RN<span> </span>6-8322</div><div>RT Supervisor<span> </span>3-7709</div><div><span></span><span> </span><span>3-6940</span></div><div>Chaplain<span> </span>3-5151</div><div>E-29 Social Worker<span> </span>650-701-5397</div><div>Admin</div><div>Admitting</div><div>T<span></span>ransfer Center</div><div>Bed Control (Rooming)</div><div>ANS (for beds)</div><div>3-6221</div><div>3-4696</div><div>3-5327 (part of tr<span></span>ansfer center)</div><div>6-1767</div><div>Central service supply<span> </span>3-5047</div><div>Ser<span></span>vic<span></span>e Desk<span> </span>3-3333</div><div>Food services<span> </span>3-5538</div><div>F<span></span>acilities<span> </span>8-4400</div><div>Main Hospital</div><div>P<span></span>age Operat<span></span>or<span> </span>723-4000</div><div>723-6661, x288 in house</div><div>Security<span> </span>3-7222</div><div>Human Resourc<span></span>es<span> </span>650-723-4748</div><div>Guest Services<span> </span>8-3333</div><div>House keeping<span> </span>8-4400</div><div>Medical Rec<span></span>ords<span> </span>3-5721</div><div>Misc</div><div>P<span></span>ager Numbers</div><div>Main Hospital p<span></span>age operator 723-4000, 723-6661, x288 in house</div><div>Department<span> </span>P<span></span>ager #</div><div>Spanish Interpr<span></span>eter<span> </span>17726</div><div>RT (T<span></span>rach we<span></span>aning<span></span>)<span> </span>17709</div><div>Nephrology Consult<span> </span>24309</div><div>IR Consult, Body<span> </span>27237</div><div>Urology<span> </span>27155</div><div>Weekend CM<span> </span>16292</div><div>Acute P<span></span>ain<span> </span>27150 (2-P<span></span>AIN)</div><div>Psych Consult<span> </span>15984</div><div>Wound RN<span> </span>11003</div><div>EP NP<span> </span>15590</div><div>IR NP (Line placement<span> </span>35463 (3-LINE)</div><div>Neuro Critical Care<span> </span>14061 </div><div>Cardiac Surg<span></span>er<span></span>y Consult<span> </span>12182</div><div>E<span></span>xtensions</div><div>1- xxxx……..650-721-xxxx</div><div>3- xxxx……..650-723-xxxx</div><div>4- xxxx……..650-724-xxxx</div><div>5- xxxx……..650-725- xxxx</div><div>6- xxxx……..650- 736- xxxx</div><div>7- xxxx……..650- 497- xxxx</div><div>8- xxxx……..650-498- xxxx</div></div><div></div></div>
<div><div><img><div>6<span> </span><span>Disease Processes &amp; Sur<span></span>gical Proc<span></span>edures<span> </span>Disease Proc<span></span>esses &amp; Surgical Procedur<span></span>es<span> </span><span>7</span></span></div><div>AOR<span></span>TIC STENOSIS</div><div>P<span></span>athology:</div><div> <span></span><span></span></div><div><span></span><span></span><span></span></div><div><span></span></div><div> <span></span><span></span></div><div><span></span></div><div>hypertrophy and decre<span></span>ased L<span></span>V compliance</div><div> <span></span><span></span></div><div>P<span></span>atients with L<span></span>VH are at increased risk f<span></span>or subendocardial ischemia</div><div>Clinical Manifes<span></span>tations:</div><div> <span></span><span></span></div><div>Angina</div><div> <span></span><span></span></div><div>CHF symptoms (SOB, E<span></span>dema)</div><div> <span></span><span></span></div><div>Syncope</div><div> <span></span><span></span></div><div></div><div>Physical E<span></span>xamination:</div><div> <span></span><span></span></div><div>high pitched mid sys<span></span>tolic cresc<span></span>endo<span></span>-decresc<span></span>endo murmur at the right upper </div><div>st<span></span>ernal border<span></span>, which can radiat<span></span>e to the carotids, s<span></span>ternal notch, and apex </div><div></div><div> <span></span><span></span></div><div>ejection click sometimes he<span></span>ard with a bicuspid aortic valve</div><div>Diagnostic S<span></span>tudies:</div><div> <span></span><span></span></div><div>Echocardiogr<span></span>am: <span> </span></div><div>Severity Grade</div><div>Indicat<span></span>or<span> </span>Mild<span> </span>Modera<span></span>te<span> </span>Severe</div><div>Jet velocity (m/s)<span> </span>&lt; 3.0<span> </span>3.0 - 4.0<span> </span>&gt; 4.0</div><div>Mean gr<span></span>adient (mmHg<span></span>)<span> </span>&lt; 25<span> </span>25 - 40<span> </span>&gt; 40</div><div>Aortic valve are<span></span>a (cm2/m2)</div><div> <span></span><span></span></div><div>Cardiac ca<span></span>theteriz<span></span>ation: Allows for direct me<span></span>asurement of gradient by </div><div>crossing valve.  If critic<span></span>al aortic stenosis, sometimes impossible to cr<span></span>oss valve </div><div>with cathe<span></span>ter</div><div>Indications f<span></span>or Surgery:</div><div> <span></span><span></span></div><div>Presence of symp<span></span>toms</div><div> <span></span><span></span></div><div>Asymptomatic with any of the following:</div><div><span></span><span> </span><span>presence of L<span></span>V syst<span></span>olic dysfunction, L<span></span>VH &gt;15mm, and/or dila<span></span>tion </span></div><div><span></span><span> </span><span>Vtach</span></div><div><span></span><span> </span><span>L<span></span>VH&gt; 15 mm</span></div><div><span></span><span> </span><span>AVA &lt;0.6 cm squar<span></span>ed, peak gr<span></span>adient &gt; 50 mmHg </span></div><div> <span></span><span></span></div><div>If undergoing sur<span></span>gery for another indication (ie CABG), and AV<span></span>A &lt;1.1 cm </div><div>squared </div><div>Preoper<span></span>ative Consider<span></span>ations:</div><div> <span></span><span></span></div><div>Cardiac ca<span></span>theteriz<span></span>ation in anyone over age 40 or in younger p<span></span>atient with risk </div><div>fact<span></span>ors, angina, or a positive stress tes<span></span>t</div><div> <span></span><span></span></div><div><span></span><span></span><span></span></div><div> <span></span><span></span></div><div>If bicuspid aortic valve, C<span></span>TA ches<span></span>t to evaluate for aortic r<span></span>oot enlargement </div><div>Surgical Op<span></span>tions:</div><div> <span></span><span></span></div><div>Aortic valve rep<span></span>air or replacement via median st<span></span>ernotomy, minimally inv<span></span>asive, </div><div>or transc<span></span>athet<span></span>er (transluminal or tr<span></span>ansapical) approach.  Biopros<span></span>thetic </div><div><span></span><span></span></div><div>valve c<span></span>onduit (CVG).</div><div>Pos<span></span>toper<span></span>ative Consider<span></span>ations:</div><div> <span></span><span></span></div><div>Immediate pos<span></span>t op Considerations: </div><div><span></span><span> </span><span><span></span><span></span></span></div><div><span></span></div><div>volume replacement. </div><div><span></span><span> </span><span>Use vasodila<span></span>tors as needed for HTN and t<span></span>o prot<span></span>ect the suture line</span></div><div><span></span><span> </span><span>Maintain NSR</span></div><div> <span></span><span></span></div><div>Aspirin on all patients unless contr<span></span>aindicated</div><div> <span></span><span></span></div><div>Mechanical valves r<span></span>equire anticoagulation with Coumadin.  Consider Hep<span></span>arin </div><div><span></span><span></span><span></span></div><div>op (see “INR Goals” ref<span></span>erence chart on <span>page 132</span>)</div><div> </div><div>TRANSCA<span></span>THETER A<span></span>ORTIC  </div><div>VAL<span></span>VE REPLACEMENT (T<span></span>AVR)</div><div>T<span></span>ransfemor<span></span>al  <span> </span> T<span></span>ransapical </div><div>Approach:  <span> </span> Approach:</div><div> </div><div>Indications f<span></span>or Surgery:</div><div>AS &gt; 1/0cm2/</div><div>&lt;.05cm2/m</div><div>SYMPTOMS</div><div>NO SYMPTOMS</div><div>Evaluate for surgery </div><div>↓<span> LVEF<span>/ LA &gt; </span></span></div><div>4.5cm/ LV &gt; 180g/</div><div>m2</div><div>Consider ???<span></span>Co-Morbidty?</div><div>No </div><div>Yes</div><div>CATH</div><div>PFTs</div><div>CATH</div><div>PFTs</div><div>Dobutamine Stress </div><div>Echo</div><div>Fragility Assessment</div><div>PET for ischemic</div><div>Technical options </div><div>evaluation </div><div>Open AVR via Full </div><div>sternotomy or mini</div><div>Low risk </div><div>High Risk*<span> </span>Inoperable**</div><div>Vascular Access</div><div>Yes<span> </span>No </div><div>TF TAVR</div><div>TA TAVR</div><div>AS &lt; 0.8cm2</div><div>+ VEL &gt; 4m/s</div><div>Or gradiant &gt; 40</div><div>TF AVI<span> </span>BAV</div><div>Apico-</div><div>Descending</div><div>* Currently defined as surgeon assessed &gt; </div><div>15% risk of deat at STS &gt; 8%</div><div>** Defined as &gt; 50% risk of death or </div><div>irreversible serious post operative </div><div>mobidity as assessed by two surgeons </div><div>Indication for TAVR</div><div>References: </div><div>Up to Date, 2015</div></div><div></div></div>
<div><div><img><div>8<span> </span><span>Disease Processes &amp; Sur<span></span>gical Proc<span></span>edures<span> </span>Disease Proc<span></span>esses &amp; Surgical Procedur<span></span>es<span> </span><span>9</span></span></div><div>Approaches:</div><div> <span></span><span></span></div><div>T<span></span>ransfemor<span></span>al</div><div> <span></span><span></span></div><div><span></span><span></span></div><div> <span></span><span></span></div><div>T<span></span>ransaortic via small st<span></span>ernotomy</div><div>Po<span></span>tential Complica<span></span>tions:</div><div> <span></span><span></span></div><div>Str<span></span>oke</div><div> <span></span><span></span></div><div>Dist<span></span>al Embolization</div><div> <span></span><span></span></div><div>P<span></span>aravalvular L<span></span>eak</div><div> <span></span><span></span></div><div>Heart Block</div><div> <span></span><span></span></div><div>Thoracic Aortic Dissec<span></span>tion:</div><div> <span></span><span></span></div><div>Local V<span></span>ascular Injur<span></span>y</div><div> <span></span><span></span></div><div>Local bleeding<span></span>/hemat<span></span>oma</div><div> <span></span><span></span></div><div>Inadvertent blockag<span></span>e of the coronary ostia.</div><div>Pos<span></span>t-op Car<span></span>e/Considera<span></span>tions:</div><div>L<span></span>VH and diastolic dysfunction</div><div> <span></span><span></span></div><div><span></span><span></span></div><div>HTN</div><div> <span></span><span></span></div><div>Especially conc<span></span>erning for transapical/transaortic appro<span></span>ach. </div><div> <span></span><span></span></div><div>First line ag<span></span>ent Clevidipine </div><div>Conduction abnormalities</div><div> <span></span><span></span></div><div>Higher risk with CoreV<span></span>alve, Evolut valves </div><div><span></span><span> </span><span><span></span><span></span></span></div><div>removed by ICU t<span></span>eam if no p<span></span>acing required</div><div> <span></span><span></span></div><div>May require PPM</div><div>AVOID ALL NOD<span></span>AL BLOCKING AGENT<span></span>S IN THE POST OPERA<span></span>TIVE PERIOD<span> </span></div><div>(no bet<span></span>a blockers, calcium channel block<span></span>ers, digoxin, or amiodarone)</div><div>Antico<span></span>agulation:</div><div>Pos<span></span>t-<span></span>TA<span></span>VR Antiplatelet and Antic<span></span>oagulation Rec<span></span>ommendations</div><div><div>Conf<span></span>id<span></span>ent<span></span>ial<span></span> <span>–<span> </span><span>For<span></span> Discus<span></span>s<span></span>ion P<span></span>urp<span></span>oses <span></span>Only</span></span></div><div>Pos<span></span>t<span>-<span>TA<span></span>V<span></span>R A<span></span>n<span></span>t<span></span>ip<span></span>la<span></span>t<span></span>el<span></span>et<span></span> <span></span>an<span></span>d<span></span> <span></span>A<span></span>nt<span></span>ico<span></span>ag<span></span>u<span></span>la<span></span>ti<span></span>o<span></span>n <span></span>R<span></span>ec<span></span>omme<span></span>n<span></span>da<span></span>t<span></span>i<span></span>on<span></span>s<span></span> </span></span></div></div><div>•<span>P<span> </span>la<span> </span>vi<span></span>x <span></span>75 mg <span></span>d<span></span>ai<span></span>l<span></span>y <span></span>x<span></span> <span></span>6 month<span></span>s post-<span>TAVR</span></span></div><div>•<span>A<span></span>SA 81 m<span> </span>g d<span></span>ai<span></span>l<span></span>y indefin<span></span>i<span></span>tel<span></span>y </span></div><div>•<span>C<span> </span>o<span> </span>n<span></span>side<span></span>r <span></span>A<span></span>SA 81 <span></span>m<span></span>g <span></span>alon<span></span>e if<span></span> <span></span>high bleed<span></span>i<span></span>ng<span></span> risk o<span></span>r <span></span>o<span> </span>ther  <span></span> </span></div><div>e<span></span>x<span></span>tenu<span></span>at<span></span>ing<span></span> circumstan<span></span>ce</div><div>No CAD </div><div>No <span></span>AF<span></span> </div><div>•<span>Cont<span></span>i<span></span>nu<span></span>e<span></span> <span></span>pr<span></span>e<span></span><span>-TAV<span></span>R a<span></span>nti<span></span>coagu<span></span>l<span></span>ati<span></span>on <span></span>re<span></span>gi<span></span>men for <span></span>AF</span></span></div><div>•<span>No<span></span> ad<span></span>d<span></span>i<span></span>tional <span></span>a<span> </span>nti<span></span>platelet n<span></span>ecessary</span></div><div>•<span>C<span> </span>o<span> </span>n<span></span>side<span></span>r <span></span>b<span></span>ridging<span></span> w<span></span>ith<span></span> h<span></span>eparin <span></span>or loven<span></span>ox if <span></span>hi<span></span>gh<span></span> CVA<span></span> </span></div><div>ris<span> </span>k</div><div>AF</div><div>•<span>I<span> </span>f<span></span> <span></span>co<span></span>n<span></span>co<span></span>mitant PCI<span></span> w<span></span>ith<span> </span> DES <span></span>+ TAVR, <span></span>Plavix 75 <span></span>m<span></span>g <span></span>daily </span></div><div>x<span></span> 1 year mini<span></span>mum w<span></span>ith<span></span> <span></span>A<span></span>S<span></span>A 81 mg <span></span>indefinit<span></span>ely </div><div>•<span>CAD<span></span> <span></span>+<span></span>/<span>- Remo<span></span>te PCI: Pl<span></span>avi<span></span>x <span></span>75 <span></span>m<span></span>g <span></span>d<span></span>ai<span></span>ly f<span></span>or a<span></span> <span></span>m<span></span>i<span></span>n<span></span>i<span></span>m<span></span>u<span></span>m<span></span> </span></span></div><div>o<span></span>f 6 m<span></span>onth<span></span>s <span></span>(or mi<span></span>n 1 year <span></span>i<span></span>f r<span></span>ecently <span></span>p<span></span>ost<span></span> DES) and<span></span> A<span></span>SA<span></span> </div><div>81<span> </span> m<span></span>g <span></span>d<span></span>ai<span></span>l<span></span>y <span></span>i<span></span>n<span></span>def<span></span>i<span></span>nit<span></span>ely </div><div>CAD</div><div>•<span>Resu<span></span>m<span></span>e<span></span> <span></span><span>pre<span>-<span></span>TA<span></span>VR anticoag<span></span>ul<span></span>ation reg<span></span>imen</span></span></span></div><div>•<span>I<span> </span>f co<span></span>ncom<span></span>i<span></span>tant <span></span>PCI w<span></span>i<span></span>th DES <span></span>+ TAVR, <span></span>Plavix <span></span>7<span></span>5 <span></span>m<span></span>g <span></span>daily </span></div><div>x<span></span> 1 year w<span></span>ith<span></span> anti<span></span>coagu<span></span>l<span></span>ati<span></span>on and n<span></span>o ASA nec<span></span>essary; <span></span>if<span></span> </div><div>no<span> </span>t o<span></span>n <span></span>a<span></span>nti<span></span>coagulati<span></span>on, then<span></span> P<span></span>l<span></span>avix <span></span>7<span></span>5 <span></span>m<span></span>g <span></span>daily <span></span>f<span></span>or<span></span> a </div><div>m<span> </span>in<span></span>i<span></span>m<span></span>um <span></span>of<span></span> <span></span>one year <span></span>and ASA <span></span>81 m<span></span>g daily ind<span></span>efinitely</div><div>AF/CAD</div><div><div>Re<span></span>vise<span></span>d <span></span>2/10/16 MS/B<span></span>F </div></div><div>•<span> </span><span>If the<span></span>re is conce<span></span>rn about <span></span>high <span> </span>r<span></span>isk for bleeding<span></span>, discuss<span></span> <span></span>re<span></span>gime<span></span>n <span></span>with prima<span></span>ry<span></span> <span></span>ca<span></span>rdiolog<span></span>ist <span></span>bef<span></span>ore discha<span></span>rge</span></div><div>•<span> </span><span>If pla<span></span>telet <span></span>c<span></span>ount &lt;100K, disc<span></span>uss with TA<span></span>VR t<span></span>e<span></span>am</span></div><div>T<span></span>AVR, C<span></span>ONTINUED</div><div><span></span><span></span></div><div>&lt;1 cm2 and a mean aortic v<span></span>alve gradient great<span></span>er than 40 mmHg or a jet velocity </div><div>grea<span></span>ter than 4 meters a second.</div><div>T<span></span>AVR work<span></span>-up</div><div>Orders include:</div><div> <span></span><span></span></div><div>CT<span></span>A of chest, abdomen, and pelvis<span> (T<span></span>AVR prot<span></span>ocol: includes Gated proc<span></span>ess, </span></div><div>evaluation of iliofemor<span></span>al arteries with 3-D enhancement and measur<span></span>ements, </div><div>and Dr<span></span>. Fleischman’<span></span>s low dose contras<span></span>t protoc<span></span>ol) </div><div>Rationale: <span>Annulus sizing: The aortic annulus is a c<span></span>omplex 3-D structure.  </span></div><div>It is a three-pronged c<span></span>oronet rather than a cir<span></span>cular structure.  It has three </div><div>anchor points at the nadir of e<span></span>ach aortic cusp.  CT provides repr<span></span>oducible </div><div>measurement<span></span>s of the annulus that provide a granular assessment of </div><div>aortic root g<span></span>eometr<span></span>y and annulus sizing.  CT also reduc<span></span>es vascular acc<span></span>ess </div><div>complica<span></span>tions and allows for assessment of luminal diameters, vessel </div><div><span></span><span></span><span></span><span></span></div><div>identify other high-risk fe<span></span>atures such as dissections and atheromas.</div><div> <span></span><span></span></div><div>T<span></span>ransthor<span></span>acic echocardiogr<span></span>am </div><div>Rationale: <span>R<span></span>ecommended in the initial evalua<span></span>tion of patients with known </span></div><div><span></span><span></span></div><div>severity, assess hemodynamic consequenc<span></span>es, determine prognosis, and </div><div>evaluate timing of int<span></span>er<span></span>vention (AHA/<span></span>ACC, 2014)</div><div> <span></span><span></span></div><div>Coronary angiogram </div><div>Rationale:<span> In the se<span></span>tting of AS, ex<span></span>ertional dyspnea and ches<span></span>t pain may be </span></div><div>due to the combina<span></span>tion of AS and CAD.  Coronar<span></span>y angiogram with PCI alone </div><div>may resolve sympt<span></span>oms.  (Ramee et al., 2016)</div><div> <span></span><span></span></div><div>Pulmonary Function T<span></span>esting </div><div>Rationale: <span>In p<span></span>atients with AS evaluated f<span></span>or AVR, the ST<span></span>S risk score is </span></div><div><span></span></div><div>predominantly by PFT results. E<span></span>ven when lung disease is not suspected, </div><div>PFT<span></span>s are abnormal in many pa<span></span>tients underg<span></span>oing AVR. Moder<span></span>ate/severe lung </div><div>disease, diagnosed predominantly by PFT<span></span>s, is an independent predictor of </div><div><span></span><span></span><span></span><span></span><span></span></div><div><span></span><span></span><span></span></div><div>AVR. (Henn et al., 2016)</div><div> <span></span><span></span></div><div>Objective F<span></span>railty </div><div>Rationale:<span> Identifying fr<span></span>ailty has important implications f<span></span>or clinical care. </span></div><div>The presence of fr<span></span>ailty, worse health s<span></span>tatus, and more c<span></span>omorbid conditions </div><div>identify a subset of elderly pa<span></span>tients at higher risk of dying during the follow-</div><div><span></span></div><div> <span></span><span></span></div><div>Electrocar<span></span>diogram </div><div>Rationale: <span><span></span><span></span><span></span></span></div><div>existing c<span></span>onduction abnormalities such as arrhythmias and heart block.</div><div>Common valves used a<span></span>t St<span></span>anford:</div><div>1. <span> </span><span>Medtronic: <span>CoreV<span></span>alve Evolut R: Sheath delivered r<span></span>etrievable and </span></span></div><div><span></span><span></span></div><div>to higher incidence of he<span></span>art block associated with this device, a tempor<span></span>ar<span></span>y </div><div><span></span></div><div>2. <span> </span><span>Edwards Lif<span></span>esciences: <span>SAPIEN 3: A balloon exp<span></span>anded non-retrievable </span></span></div><div><span></span><span></span><span></span></div><div>ventricles is required t<span></span>o reduced turbulenc<span></span>e prior to deployment of the valve. <span></span> </div><div>Antiplat<span></span>elet and anticoagula<span></span>tion consider<span></span>ations</div><div><span></span><span></span><span></span></div><div>of heart disease and the risk of thr<span></span>ombus formation on the new valve.  Aspirin </div><div>81 mg a day and Plavix 75 mg a day is a st<span></span>andard regimen unless the pa<span></span>tient has </div><div>a condition that pr<span></span>ecludes it<span></span>, e.g., GI bleeding.  If a pa<span></span>tient is already taking an </div></div><div></div></div>
<div><div><img><div>10<span> </span><span>Disease Proc<span></span>esses &amp; Surgical Procedur<span></span>es<span> </span>Disease Processes &amp; Sur<span></span>gical Procedures<span> </span><span>11</span></span></div><div><span></span><span></span></div><div>condition and to pr<span></span>e<span></span>vent v<span></span>alve thrombus.  Please review full guideline posted in </div><div>your department.</div><div>Please see below for which meds pr<span></span>e<span></span>-<span></span>T<span></span>AVR should be held and when. </div><div>Of not<span></span>e, Plavix and ASA should still be ordered for morning of sur<span></span>gery on TF </div><div>patient<span></span>s when they are on C1. </div><div>THV Pre-proc<span></span>edure Medication Guideline</div><div>Medications t<span></span>o hold<span> </span>T<span></span>ransFemor<span></span>al (TF)<span> </span>T<span></span>ransApical (T<span></span>A)<span> </span>T<span></span>ransAortic (T<span></span>Ao)</div><div>Warfarin<span> (loveno<span></span>x </span></div><div>ridging per MD’<span></span>s  </div><div>discretion)</div><div>Hold 5 days before<span> </span>Hold 7 days before<span> </span>Hold 7 days before</div><div>Pradax<span></span>a<span> </span><span>Hold 4 days before<span> </span>Hold 4 days before<span> </span>Hold 4 days before</span></div><div>Eliquis<span> </span><span>Hold 48h before<span> </span>Hold 48h before<span> </span>Hold 48h before</span></div><div>Xarelt<span></span>o<span> </span><span>Hold 48h before<span> </span>Hold 48h before<span> </span>Hold 48h before</span></div><div>Eient<span> </span><span>Continue<span> </span>Hold 7 days before<span> </span>Hold 7 days befor<span></span>e</span></div><div>Plavix<span> </span><span>Continue<span> </span>Hold 7 days before<span> </span>Hold 7 days befor<span></span>e</span></div><div>Ticagrelor<span> </span><span>Continue<span> </span>Hold 7 days before<span> </span>Hold 7 days befor<span></span>e</span></div><div>Oral Diabe<span></span>tic </div><div>Medications</div><div>Hold Metformin 48 hours befor<span></span>e the procedure. Hold all other or<span></span>al </div><div>diabetic medicine the morning of the proc<span></span>edure.</div><div>Insulin<span> </span><span>T<span></span>ake half of the evening dose.  Hold the morning of the procedure.</span></div><div>Nodal blocking </div><div>agent</div><div> <span></span><span></span></div><div>Ca Channel </div><div>blockers</div><div> <span></span><span></span></div><div>Beta Block<span></span>ers</div><div> <span></span><span></span></div><div>Cardiac <span></span>glycoside </div><div>(Digoxin)</div><div> <span></span><span></span></div><div>Amiodarone</div><div> <span></span><span></span></div><div>Clonidine</div><div>Hold the morning of the procedur<span></span>e.</div><div> </div><div>AOR<span></span>TIC REGURGIT<span></span>A<span></span>TION</div><div>P<span></span>athology:</div><div> <span></span><span></span></div><div><span></span><span></span></div><div>aortic root dila<span></span>tion, or ascending aortic dissection.</div><div> <span></span><span></span></div><div><span></span><span></span><span></span></div><div><span></span><span></span></div><div>which over time will contribute t<span></span>o decreased ejection fr<span></span>action. </div><div>Clinical Manifes<span></span>tations:</div><div> <span></span><span></span></div><div>CHF symptoms</div><div>Physical E<span></span>xamination:</div><div> <span></span><span></span></div><div>Early diast<span></span>olic decrescendo murmur a<span></span>t LUSB. Incre<span></span>ased with leaning for<span></span>war<span></span>d </div><div>and expira<span></span>tion</div><div>Diagnostic S<span></span>tudies:</div><div> <span></span><span></span></div><div>Echocardiogr<span></span>am: </div><div>AR Grading<span> </span>Central Jet </div><div>width*</div><div>Regurgit<span></span>ant </div><div>Volume (per </div><div>beat) </div><div>EROA (eec<span></span>tive </div><div>Regurgit<span></span>ant </div><div>oriace ar<span></span>ea)</div><div>Mild<span> </span><span>&lt; 25% of L<span></span>VOT </span></div><div>width</div><div>&lt; 30mL<span> </span>&lt;0.1cm2</div><div>Modera<span></span>te<span> </span><span>25-65% of L<span></span>VOT </span></div><div>width</div><div>30-59mL<span> </span>0.1-0.3cm2</div><div>Severe<span> </span><span>&gt;65% of L<span></span>VOT </span></div><div>width</div><div>&gt;60mL<span> </span>&gt;0.3cm</div><div>Indications f<span></span>or Surgery:</div><div> <span></span><span></span></div><div>For severe Chronic AR:</div><div>Chronic Severe Mitral </div><div>Regurgitation </div><div>Clinical </div><div>Evaluation = </div><div>Echo</div><div>Symptoms? <span></span>No<span> </span>Yes </div><div>LV Function <span> </span>LV Function </div><div>Normal LV </div><div>Function </div><div>EF &gt; 60%</div><div>ESD &lt; 40mm</div><div>LV Dysfunction </div><div>EF &lt; 60%</div><div>and/or</div><div>ESD &gt; 40mm</div><div>EF &gt; 30%</div><div>ESD &lt; 55mm</div><div>EF &lt;30 %</div><div>and/or</div><div>ESD &gt; 55mm</div><div>New Onset Afib? </div><div>Pulmonary HTN? </div><div>Class I</div><div>Class I</div><div>MV Repair,</div><div>If not possible </div><div>MVR</div><div>Chordal </div><div>preservation </div><div>likely? </div><div>Yes </div><div>No? </div><div>Medical </div><div>therapy</div><div>Yes </div><div>No</div><div>MV repair </div><div>likely?</div><div>Class </div><div>IIa</div><div>Class </div><div>IIa</div><div>No? Clinical </div><div>eval/Echo every </div><div>6 months </div><div>Yes</div><div>Class </div><div>IIIA</div><div>Reference:</div><div>Nishimura, et. al. (2014). A Report of the American </div><div>College of Cardiology/American Heart Association Task </div><div>Focus on Practice Guidelines. AHA/ACC Valvular heart </div><div>disease guidelines, page 487.   </div><div> <span></span><span></span></div><div>For Mild to Moder<span></span>ate AR: </div><div><span></span><span> </span><span>L<span></span>V dysfunction or dilation</span></div><div><span></span><span> </span><span>Symptoms only is no<span></span>t an indication to opera<span></span>te</span></div><div> <span></span><span></span></div><div>Endocarditis with hemodynamic c<span></span>ompromise or embolic events</div><div> <span></span><span></span></div><div>If undergoing sur<span></span>gery for another indication, v<span></span>alve replacement is indicat<span></span>ed </div><div>for anything gre<span></span>ater than mild AR </div><div>Preoper<span></span>ative Consider<span></span>ations:</div><div> <span></span><span></span></div><div>Control hypertension. Avoid br<span></span>adycardia. </div><div> <span></span><span></span></div><div>Intra-aortic b<span></span>alloon pump is contraindica<span></span>ted </div><div>Surgical Pr<span></span>ocedures:</div><div> <span></span><span></span></div><div>Aortic valve rep<span></span>air or replacement via median st<span></span>ernotomy or minimally </div><div>invasive appro<span></span>ach.  </div><div><span></span><span> </span><span>Bioprosthe<span></span>tic or mechanical valve.</span></div><div> <span></span><span></span></div><div>If AR due to roo<span></span>t dilatation</div><div><span></span><span> </span><span>Valve sparing aortic r<span></span>oot replacement (Tirone David)</span></div><div><span></span><span> </span><span><span></span><span></span><span></span></span></div><div>Pos<span></span>toper<span></span>ative Consider<span></span>ations:</div><div> <span></span><span></span></div><div>Immediate pos<span></span>t op Considerations: </div><div><span></span><span> </span><span><span></span><span></span></span></div><div>secondary to dilated L<span></span>V</div><div><span></span><span> </span><span><span></span><span></span></span></div><div><span></span><span> </span><span>Maintain NSR</span></div></div><div></div></div>
<div><div><img><div>12<span> </span><span>Disease Proc<span></span>esses &amp; Surgical Procedur<span></span>es<span> </span>Disease Processes &amp; Sur<span></span>gical Procedures<span> </span><span>13</span></span></div><div> <span></span><span></span></div><div>Aspirin on all patients unless contr<span></span>aindicated</div><div> <span></span><span></span></div><div>Mechanical valves r<span></span>equire anticoagulation with Coumadin.  Consider Hep<span></span>arin </div><div><span></span><span></span><span></span></div><div>op. (see “INR Goals” r<span></span>eference chart on <span>page 132</span>)</div><div>Referenc<span></span>es:</div><div>Otto<span></span>, C.M., Gaaasch, W.H, Y<span></span>eon, S.B. (2016). Clinical manifest<span></span>ations and diagnosis of aortic stenosis in </div><div>adults. Up to Dat<span></span>e. </div><div>MITRAL V<span></span>AL<span></span>VE DISEASE</div><div>Mitral S<span></span>tenosis (MS):</div><div>3. <span> </span><span><span></span><span></span><span></span><span></span></span></div><div>4. <span> </span><span><span></span><span></span><span></span></span></div><div>pulmonar<span></span>y hypertension and subsequently right ventricular f<span></span>ailure and </div><div>tricuspid regurgit<span></span>ation.</div><div>5. <span> </span><span>Causes<span>:</span></span></div><div>• </div><div>Rheumatic v<span></span>alve disease; mos<span></span>t common cause (causes thickening  </div><div>and shortening of the chordae t<span></span>endineae).</div><div>• </div><div><span></span></div><div>common in older p<span></span>atients or those exposed t<span></span>o heavy r<span></span>adiation </div><div>trea<span></span>tment), Congenital Mitral V<span></span>alve deformities, Carcinoid syndrome, </div><div><span></span><span></span></div><div>Mitral R<span></span>egurgita<span></span>tion/Insuiciency (MR): </div><div>1. <span> </span><span>Acute MR </span></div><div>• </div><div><span></span></div><div>which may lead to acut<span></span>e pulmonar<span></span>y edema and cardiogenic shock</div><div>• </div><div>Causes: P<span></span>apillar<span></span>y muscle rupture/ischemic injur<span></span>y, endoc<span></span>arditis, chordae </div><div>rupture</div><div>2. <span> </span><span>Chronic MR </span></div><div>• </div><div><span></span><span></span></div><div>decreased LA/L<span></span>V compliance.</div><div>• </div><div>Causes:</div><div>i. <span> </span><span><span></span><span></span></span></div><div><span></span></div><div>1.  Rheumatic fever<span></span>, ruptured chordae t<span></span>endineae or chordae elongation, </div><div><span></span><span></span><span></span></div><div>annular dilat<span></span>ation, focal myocardial dysfunc<span></span>tion</div><div> <span></span><span></span><span></span></div><div> <span></span><span></span><span></span></div><div>is thickened, complex MR</div><div> <span></span><span></span><span></span></div><div><span></span></div><div>syndrome, or an ostium primum ASD)</div><div>ii. <span> </span><span>Functional Dise<span></span>ase (Secondar<span></span>y MR): not due t<span></span>o valve it<span></span>self<span></span>, but </span></div><div>dysfunction of struc<span></span>tures that hold valve</div><div> <span></span></div><div>2.  Mitral v<span></span>alve prolapse (MVP): </div><div><span></span></div><div>allowing a small amount of blood to leak b<span></span>ackward</div><div>b. Causes: myx<span></span>omatous degener<span></span>ation, Barlow’<span></span>s syndrome, Marfan’<span></span>s </div><div>syndrome, and rheumatic he<span></span>art disease</div><div>iii. <span> </span><span>Infective Endocar<span></span>ditis </span></div><div>iv<span></span>. <span> </span><span>Ischemic Cardiomyopa<span></span>thy</span></div><div>v.<span></span><span> <span> </span><span><span></span></span></span></div><div>Clinical Manifes<span></span>tations, Diagno<span></span>stic S<span></span>tudies/ Classication</div><div> <span></span><span></span></div><div>Echo: tes<span></span>t of choice for diagnosis</div><div>Mitral V<span></span>alve Echo V<span></span>alues</div><div>MS grading<span> </span>V<span></span>alve Area<span> </span>Mean gr<span></span>adient<span> </span>Pulmonary </div><div>artery pressure </div><div>(mmHg)</div><div>Mild<span> </span>&gt;1.5 cm2<span> </span>&lt;5mmHg<span> </span>&lt;30mmHg</div><div>Modera<span></span>te<span> </span>1.0-1.5 cm2<span> </span>5-10mmHg<span> </span>30-50mmHg</div><div>Severe<span> </span>&lt;1.0cm2<span> </span>&gt;10mmHg<span> </span>&gt;50mmHg</div><div>MR grading <span> </span>Jet are<span></span>a<span> </span>Regurgit<span></span>ant </div><div>Volume</div><div>EROA (eec<span></span>tive </div><div>Regurgit<span></span>ant </div><div>oriace ar<span></span>ea)</div><div>Mild<span> </span>&lt;20% of LA area<span> </span>&lt;30mL<span> </span>&lt;0.2cm2</div><div>Modera<span></span>te<span> </span>20-40% of LA are<span></span>a<span> </span>30-59mL<span> </span>0.2-0.39 </div><div>Severe<span> </span>&gt;40% of LA area<span> </span>&gt;60mL<span> </span>&gt;0.40cm2</div><div> <span></span><span></span></div><div>MS: </div><div><span></span><span> </span><span><span></span><span></span></span></div><div>Murmur<span></span>: Loud S1, opening snap<span></span>, diastolic low-pitched rumble/murmur </div><div>best he<span></span>ard at the apex</div></div><div></div></div>
<div><div><img><div>14<span> </span><span>Disease Proc<span></span>esses &amp; Surgical Procedur<span></span>es<span> </span>Disease Processes &amp; Sur<span></span>gical Procedures<span> </span><span>15</span></span></div><div> <span></span><span></span></div><div>MR: </div><div><span></span><span> </span><span>pan-sys<span></span>tolic murmur, some<span></span>times a late-sys<span></span>tolic murmur<span></span>, best hear<span></span>d at </span></div><div><span></span><span></span></div><div>Indications f<span></span>or Surgery:</div><div> <span></span><span></span></div><div>MS: </div><div><span></span><span> </span><span>Severely symptoma<span></span>tic patient<span></span>s (NYHA class III or IV) with se<span></span>vere mitr<span></span>al </span></div><div><span></span><span></span></div><div><span></span><span> </span><span>P<span></span>atients who have failed pr<span></span>e<span></span>vious percut<span></span>aneous balloon mitral </span></div><div>commissuro<span></span>tomy</div><div> <span></span><span></span></div><div>MR: </div><div>Chronic Severe Mitral </div><div>Regurgitation </div><div>Clinical </div><div>Evaluation = </div><div>Echo</div><div>Symptoms? <span></span>No<span> </span>Yes </div><div>LV Function <span> </span>LV Function </div><div>Normal LV </div><div>Function </div><div>EF &gt; 60%</div><div>ESD &lt; 40mm</div><div>LV Dysfunction </div><div>EF &lt; 60%</div><div>and/or</div><div>ESD &gt; 40mm</div><div>EF &gt; 30%</div><div>ESD &lt; 55mm</div><div>EF &lt;30 %</div><div>and/or</div><div>ESD &gt; 55mm</div><div>New Onset Afib? </div><div>Pulmonary HTN? </div><div>Class I</div><div>Class I</div><div>MV Repair,</div><div>If not possible </div><div>MVR</div><div>Chordal </div><div>preservation </div><div>likely? </div><div>Yes </div><div>No? </div><div>Medical </div><div>therapy</div><div>Yes </div><div>No</div><div>MV repair </div><div>likely?</div><div>Class </div><div>IIa</div><div>Class </div><div>IIa</div><div>No? Clinical </div><div>eval/Echo every </div><div>6 months </div><div>Yes</div><div>Class </div><div>IIIA</div><div>Reference:</div><div>Nishimura, et. al. (2014). A Report of the American </div><div>College of Cardiology/American Heart Association Task </div><div>Focus on Practice Guidelines. AHA/ACC Valvular heart </div><div>disease guidelines, page 487.   </div><div>Mitral Stenosis</div><div>Symptomatic <span> </span>Asymptomatic </div><div>MVA &gt;/= </div><div>1.5cm2</div><div>Exercise </div><div>Moderate to </div><div>Severe MS</div><div>MVA &lt; 1.5cm2</div><div>PASP &gt; 60mmHg</div><div>PAWP &gt;/= 25</div><div>No</div><div>Yes</div><div>Moderate to </div><div>severe MS</div><div>MVA &lt; 1.5cm2</div><div>Mild MS</div><div>MVA &gt;/= 1.5cm2</div><div>Medical </div><div>Management </div><div>Follow up every </div><div>12 months </div><div>Favorable </div><div>Morphology? </div><div>No</div><div>Yes </div><div>PSAP &gt; 50mmHg?</div><div>Yes</div><div> Investigation of </div><div>possible other </div><div>source of </div><div>symptoms </div><div>Consider PBMV </div><div>(exclude LA </div><div>clot, 3-4+ MR)</div><div>Favorable </div><div>Morphology</div><div>No</div><div>No</div><div>Consider </div><div>MVR/MV </div><div>Repair </div><div>MVA= mitral valve area</div><div>PMV = percutaneous mitral balloon valvotomy</div><div>PASP = pulmonary artery systolic </div><div>PAWP= pulmonary artery wedge pressure</div><div>Surgical Pr<span></span>ocedures:  </div><div>1. <span> </span><span>Repair is pr<span></span>eferred over replacement</span></div><div>2. <span> </span><span>Replacement (biopr<span></span>osthetic or mechanical v<span></span>alve):</span></div><div>i. <span> </span><span>Indications f<span></span>or replacement over r<span></span>epair<span></span>:</span></div><div> <span></span><span></span><span></span></div><div> <span></span></div><div> <span></span><span></span><span></span></div><div>3. <span> </span><span> <span></span>Surgical appro<span></span>aches:</span></div><div>i. <span> </span><span>Median St<span></span>ernotomy</span></div><div>ii. <span> </span><span>Mini-S<span></span>ternotomy </span></div><div>iii. <span> </span><span>Minimally Invasive via Right Thor<span></span>acotomy and groin c<span></span>annulation </span></div><div>Intra Op Consider<span></span>ations:</div><div> <span></span><span></span></div><div>When performing conc<span></span>omitant coronary bypass, the dist<span></span>al anastomoses are </div><div>complet<span></span>ed before mitral v<span></span>alve inter<span></span>vention</div><div> <span></span><span></span></div><div>When performing conc<span></span>omitant aortic valve r<span></span>eplacement<span></span>, the aortic v<span></span>alve </div><div><span></span><span></span></div><div>cutting of mitr<span></span>al annular sutures. Then the mitral proc<span></span>edure is performed </div><div>before the aortic v<span></span>alve replacement. </div><div> <span></span><span></span></div><div>When performing conc<span></span>omitant tricuspid valve sur<span></span>ger<span></span>y, a tr<span></span>ans<span></span>-sept<span></span>al </div><div><span></span><span></span><span></span><span></span></div><div>(Sellke &amp; del Nido &amp; Swanson; chap 80</div><div> <span></span><span></span></div><div>Minimally Invasive Mitr<span></span>al: consider size and presenc<span></span>e of calcium in femor<span></span>al </div><div>artery for cannulation; consider c<span></span>alcium in descending aorta for cannula<span></span>tion</div><div>Pos<span></span>t op consider<span></span>ations:</div><div> <span></span><span></span></div><div>Immediate P<span></span>ost-op Consider<span></span>ations:</div><div><span></span><span> </span><span>For MS:</span></div><div> <span></span><span></span></div><div>Maintain NSR</div><div> <span></span><span></span></div><div><span></span><span></span></div><div>pressures v<span></span>ar<span></span>y with degree of pre-exis<span></span>ting pulmonar<span></span>y hypertension</div><div> <span></span><span></span></div><div><span></span><span></span></div><div>diuresis</div><div><span></span><span> </span><span>For MR:</span></div><div> <span></span><span></span></div><div>Maintain NSR</div><div> <span></span><span></span></div><div>Resolution of MR leads t<span></span>o increased L<span></span>V wall stress leading t<span></span>o L<span></span>V </div><div><span></span><span></span></div><div> <span></span><span></span></div><div>Adequate volume r<span></span>esuscita<span></span>tion and inotropic support may be </div><div>required.  Be cautious with volume r<span></span>esuscitation in pa<span></span>tients with R<span></span>V </div><div>dysfunction. </div><div> <span></span><span></span></div><div>Closely monitor RV function especially in pa<span></span>tients with pre-existing </div><div>pulmonar<span></span>y hypertension.  Ino<span></span>tropic support<span></span>, pulmonary vasodilators, </div><div>and diuresis may be required.</div><div> <span></span><span></span></div><div><span></span><span></span><span></span><span></span></div><div>following MVR.  Ensure adequa<span></span>te prelo<span></span>ad and avoid hypotension with </div><div>the use of vasoc<span></span>onstrictors as nec<span></span>essar<span></span>y<span></span>.  Avoid inotropes.</div><div> <span></span><span></span></div><div>Syst<span></span>olic anterior motion (SAM) tha<span></span>t produces L<span></span>VOTO may be pr<span></span>esent </div><div>following mitr<span></span>al valve rep<span></span>air.  Manag<span></span>ement same as L<span></span>VOTO.</div><div> <span></span><span></span></div><div>Minimally Invasive Mitr<span></span>al: REMOVE SUTURE  </div><div><span></span><span>POD #3</span></div><div> <span></span><span></span></div><div>ASA unless contr<span></span>aindicatesd</div><div> <span></span><span></span></div><div>Mechanical valves r<span></span>equire anticoagulation with </div><div>Coumadin. Bridge with heparin drip<span></span>.</div><div> <span></span><span></span></div><div>Mechanical valves in mitr<span></span>al position require higher </div><div><span></span></div><div> <span></span><span></span></div><div>See “INR Goals” ref<span></span>erence chart on <span>page 132</span>)</div><div> </div><div>Referenc<span></span>es:</div><div>Sabiston, D. C., Sellk<span></span>e, F. W<span></span>., J., D. N., &amp; Swanson, S. J. (2010). Sabis<span></span>ton &amp; Spencer surgery of the chest. </div><div>Philadelphia: Saunders/Elsevier.</div><div> </div></div><div></div></div>
<div><div><img><div>16<span> </span><span>Disease Proc<span></span>esses &amp; Surgical Procedur<span></span>es<span> </span>Disease Processes &amp; Sur<span></span>gical Procedures<span> </span><span>17</span></span></div><div>TRICU<span></span>SPID VAL<span></span>VE DISEASE</div><div>Etiology &amp; P<span></span>athology</div><div> <span></span><span></span></div><div>T<span></span>S (tricuspid stenosis) is r<span></span>are, usually develops as a result of rheumatic </div><div>disease or associat<span></span>ed with mitral stenosis</div><div> <span></span><span></span></div><div>TR (tricuspid regurgit<span></span>ation) is usually “functional” in na<span></span>ture. Occurs as a </div><div>complica<span></span>tion of mitral valve dise<span></span>ase causing pulmonary hypertension, R<span></span>V </div><div>dilation, and tricuspid annular dilation.  A small de<span></span>gree of TR is present is </div><div>almost 70% of normal adults. </div><div> <span></span><span></span></div><div>A common cause of TR is endoc<span></span>arditis (usually caused by IV drug abuse, an </div><div>indwelling pac<span></span>emaker wire, or hemodialysis c<span></span>athet<span></span>er)</div><div>Clinical Manifes<span></span>tations</div><div> <span></span><span></span></div><div></div><div> <span></span><span></span></div><div>F<span></span>atigue</div><div> <span></span><span></span></div><div>With severe disease, right heart f<span></span>ailure symptoms may be present (right </div><div>abdominal pain, shortness of bre<span></span>ath, swelling in legs or abdomen)</div><div>Physical E<span></span>xam</div><div> <span></span><span></span></div><div>Syst<span></span>olic murmur that incre<span></span>ases with inspiration, prominent jugular </div><div>pulsations, and occ<span></span>asionally a pulsatile liver. </div><div> <span></span><span></span></div><div><span></span></div><div>Diagnostic S<span></span>tudies/Classica<span></span>tion <span>(Via Echocardiogr<span></span>am)</span></div><div>Signicant tricuspid st<span></span>enosis</div><div>Mean pressur<span></span>e gradient<span> </span>&gt;/= 5mmHg</div><div>T<span></span>ricuspid </div><div>Regurgit<span></span>ation</div><div>MILD<span> </span>MODERA<span></span>TE<span> </span>SEVERE</div><div>Jet are<span></span>a<span> </span>&lt; 5<span> </span>5-10<span> </span>&gt;10</div><div>RV<span></span>/RA/IVC Size<span> </span>Normal<span> </span>Normal or dilated<span> </span>Usually dialates</div><div> </div><div>Indications f<span></span>or Surgery</div><div>T<span></span>ricuspid stenosis:  Surg<span></span>er<span></span>y is indicated f<span></span>or class III-IV symptoms including </div><div>hepatic c<span></span>ongestion, ascites, and peripher<span></span>al edema that are refr<span></span>actory to salt </div><div>restric<span></span>tion and diuretics. </div><div>T<span></span>ricuspid Regurgit<span></span>ation:</div><div> <span></span><span></span></div><div>Class I: TV repair is indic<span></span>ated when severe TR is present with mitral v<span></span>alve </div><div>disease requiring mitr<span></span>al valve surgery</div><div> <span></span><span></span></div><div>Class II: TV repair or r<span></span>eplacement is reasonable for symp<span></span>tomatic, severe </div><div>primar<span></span>y TR.</div><div> <span></span><span></span></div><div>Class III: TV repair is r<span></span>easonable is less than severe TR is noted at the time of </div><div>mitral sur<span></span>gery, but pulmonar<span></span>y hypertension or dila<span></span>ted tricuspid annulus is </div><div>present. </div><div> <span></span><span></span></div><div>Persis<span></span>tent sepsis or recurrent pulmonary embolization from tricuspid v<span></span>alve </div><div>vege<span></span>ta<span></span>tion is an indication f<span></span>or surgery</div><div> <span></span><span></span></div><div>Class III: surgery should NOT be consider<span></span>ed in asymptomatic patient<span></span>s with a </div><div>P<span></span>A pressure &lt;60 and no mitral v<span></span>alve disease</div><div>Surgical Pr<span></span>ocedures</div><div> <span></span><span></span></div><div>T<span></span>ricuspid commissurot<span></span>omy can be performed for rheumatic T<span></span>S</div><div> <span></span><span></span></div><div>T<span></span>ricuspid ring annuloplasty with a ring or suture technique is f<span></span>easible and </div><div>preferred f<span></span>or the majority of patients with functional TR</div><div> <span></span><span></span></div><div><span></span><span></span><span></span><span></span></div><div>co<span></span>apt<span></span>ation prevent an annuloplasty technique from elimina<span></span>ting the TR. </div><div>Intra op &amp; P<span></span>ost op Consider<span></span>ations</div><div> <span></span><span></span></div><div>During TV repair<span></span>, sutures are plac<span></span>ed near the conduction sys<span></span>tem, thus </div><div>patient<span></span>s are <span>more likely t<span></span>o develop heart block<span>. If there ar<span></span>e concerns that </span></span></div><div>permanent pacing may be requir<span></span>ed, epicardial pacing leads should be plac<span></span>ed </div><div><span></span></div><div>TVRepair sur<span></span>ger<span></span>y) </div><div> <span></span><span></span></div><div>ASA unless contr<span></span>aindicated</div><div> <span></span><span></span></div><div>Mechanical valve r<span></span>equires anticoagulation with Coumadin (See “INR Go<span></span>als” </div><div>referenc<span></span>e chart on <span>page 132</span>)</div><div>Referenc<span></span>es:</div><div>Bojar<span></span>, Robert M. (2011) Manual of Perioper<span></span>ative Care in Adult Cardiac Surgery. (5th edition).  </div><div>C<span></span>ORONARY AR<span></span>TERY DISEASE AND CABG</div><div>P<span></span>athophysiology:</div><div> <span></span><span></span></div><div><span></span></div><div>but typically occurs a<span></span>t points of turbulence (e.g., vessel bifurca<span></span>tions)</div><div> <span></span><span></span></div><div>Risk F<span></span>actors f<span></span>or atherosclero<span></span>tic coronary arter<span></span>y disease: hypertension, </div><div>smoking, high LDL, low HDL, obesity, diabet<span></span>es, family history.</div><div>Clinical manifes<span></span>tations:</div><div> <span></span><span></span></div><div>CAD manifest<span></span>ed by MI, angina, or CHF</div><div> <span></span><span></span></div><div>Angina (st<span></span>able vs unstable)</div><div><span></span><span> </span><span>St<span></span>able angina = chest pain that oc<span></span>curs predictably and is r<span></span>eproducible</span></div></div><div></div></div>
<div><div><img><div>18<span> </span><span>Disease Proc<span></span>esses &amp; Surgical Procedur<span></span>es<span> </span>Disease Processes &amp; Sur<span></span>gical Procedures<span> </span><span>19</span></span></div><div>C<span></span>CS Func<span></span>tional Classication of Angina</div><div>Class<span> </span>Description</div><div>Class I<span> </span>Angina only during strenuous or pr<span></span>olonged physical activity</div><div>Class II<span> </span>Slight limita<span></span>tion, with angina only during vigorous physical activity</div><div>Class III<span> </span>Symptoms with ever<span></span>yday living activities   </div><div>(i.e. moder<span></span>ate limitation)</div><div>Class IV<span> </span>Inability to perform any activity without angina or  </div><div>angina at res<span></span>t (i.e. severe limitation)</div><div>Physical E<span></span>xam: </div><div></div><div>Diagnostic s<span></span>tudies:</div><div> <span></span><span></span></div><div>Cardiac ca<span></span>theteriz<span></span>ation is the gold st<span></span>andard for diagnosing CAD</div><div> <span></span><span></span></div><div>Myocardial perfusion scan </div><div> <span></span><span></span></div><div>Echocardiogr<span></span>am </div><div> <span></span><span></span></div><div>Str<span></span>ess tes<span></span>ting </div><div>Indications f<span></span>or surgery:</div><div> <span></span><span></span></div><div><span></span><span></span><span></span><span></span></div><div> <span></span><span></span></div><div><span></span><span></span></div><div></div><div> <span></span><span></span></div><div>Presence of 3 vessel dise<span></span>ase (especially if EF &lt; 40%)</div><div> <span></span><span></span></div><div>Presence of 2 vessel dise<span></span>ase with 70% stenosis of LAD</div><div>Surgical pr<span></span>ocedures: </div><div>(LIMA to LAD) is the single mos<span></span>t important det<span></span>erminant of long-<span></span>term </div><div>and event<span></span>-free survival for pa<span></span>tients who have undergone CABG</div><div> <span></span><span></span></div><div>T<span></span>raditional on pump CABG (via median st<span></span>ernotomy) </div><div><span></span><span> </span><span>Conduit choice: </span></div><div><span></span><span> </span><span>Arterial: LIMA (1s<span></span>t choice), RIMA,  Radial artery via endoscopic harvest</span></div><div><span></span><span> </span><span>Venous: Gre<span></span>ater Saphenous Vein via Open or endoscopic vein harvest</span></div><div> <span></span><span></span></div><div></div><div><span></span><span> </span><span>Consider for high risk pa<span></span>tients (&gt; 70 years old, CKD, increased risk s<span></span>troke </span></div><div>or caro<span></span>tid st<span></span>enosis)  </div><div> <span></span><span></span></div><div>Minimally invasive direc<span></span>t coronar<span></span>y artery bypass (MIDCAB) </div><div><span></span><span> </span><span>LIMA to LAD only</span></div><div><span></span><span> </span><span>LIMA is har<span></span>ves<span></span>ted endoscopically though three small ports plac<span></span>ed in the </span></div><div><span></span></div><div>through which the LIMA to LAD anas<span></span>tomoses is construct<span></span>ed via direct </div><div>vision</div><div><span></span><span> </span><span><span></span></span></div><div>to remaining lesion by int<span></span>er<span></span>ventional car<span></span>diologist </div><div>Preoper<span></span>ative Consider<span></span>ations:</div><div> <span></span><span></span></div><div>All patient<span></span>s with CAD must take be<span></span>ta blocker within 24 hours of induction for </div><div>surgery (or document why contraindic<span></span>ated)</div><div> <span></span><span></span></div><div><span></span><span></span><span></span></div><div>narrowing<span></span>/st<span></span>eal which precludes the use of the LIMA, diagnosed with c<span></span>arotid </div><div>ultrasound.</div><div><span></span><span> </span><span><span></span><span></span></span></div><div><span></span><span> </span><span>IF L radial pulse &lt;2+ or f<span></span>aint compared t<span></span>o R, needs tes<span></span>ting </span></div><div> <span></span><span></span></div><div><span></span></div><div><span></span><span> </span><span>Carotid ultr<span></span>asound for those with history of prior CVA</span></div><div><span></span><span> </span><span>Radial artery har<span></span>vest work up for those &lt; 70 </span></div><div><span></span><span> </span><span>Vein mapping (previous vein s<span></span>tripping, CABG, diabetes)</span></div><div>Pos<span></span>t-oper<span></span>ative Consider<span></span>ations</div><div>Immediat<span></span>e post<span></span>-opera<span></span>tive care: </div><div><span></span><span> </span><span><span></span><span></span></span></div><div><span></span><span> </span><span>If EVH or RAH complet<span></span>ed, ACE wrap to ex<span></span>tremity for 24 hours post op</span></div><div> <span></span><span></span></div><div>ASA unless contr<span></span>aindicated </div><div>Bet<span></span>a blocker and s<span></span>ta<span></span>tin therapy initiated prior to dischar<span></span>ge (or document why </div><div>contr<span></span>aindicated) </div><div>Referenc<span></span>es:</div><div>Cutlip, D., Levin, T<span></span>., Aroesty<span></span>, J.M. (2016) Rev<span></span>ascularization in p<span></span>atients with stable c<span></span>oronar<span></span>y artery disease: </div><div><span></span><span></span><span></span><span></span><span></span></div><div>DISEASES OF THE AOR<span></span>T<span></span>A</div><div>Denitions</div><div> <span></span><span></span></div><div>Aortic aneur<span></span>ysm – localiz<span></span>ed dilation (&gt; 50% increase in diameter) of the aortic </div><div>wall </div><div> <span></span><span></span></div><div>Aortic dissection – intimal te<span></span>ar of the aorta separ<span></span>ating intima from the medial </div><div>layers and crea<span></span>ting a false lumen</div><div> <span></span><span></span></div><div>Aortic intramur<span></span>al hematoma (IMH) – hematoma within the medial layer of the </div><div>aorta tha<span></span>t occurs when the vasa vasorum rup<span></span>tures.  Does not involve intimal </div><div>tear<span></span>.</div><div> <span></span><span></span></div><div>Pene<span></span>trating atheroscler<span></span>otic aortic ulcer (P<span></span>AU) – atheroscler<span></span>otic ulcer that </div><div>penetr<span></span>ates thr<span></span>ough the intima layer of the aorta and dissec<span></span>ts into the median </div><div>wall and forms a pseudo<span></span>aneur<span></span>ysm.             </div><div>Risk F<span></span>actors</div><div> <span></span><span></span></div><div>Atheroscler<span></span>osis</div><div> <span></span><span></span></div><div>Hypertension</div><div> <span></span><span></span></div><div>Conn<span></span>ectiv<span></span>e tiss<span></span>ue dis<span></span>ord<span></span>ers (i<span></span>.e. M<span></span>arfa<span></span>n, <span></span>Lo<span></span>eys-Di<span></span>etz, <span></span>Ehler’<span></span>s-Dan<span></span>los <span></span>syndr<span></span>ome)</div><div> <span></span><span></span></div><div>Drug abuse (cocaine, me<span></span>th)</div><div> <span></span><span></span></div><div>T<span></span>rauma: blunt, IABP<span></span>, cardiac or aortic surgery, car<span></span>diac cathe<span></span>teriz<span></span>ation</div><div> <span></span><span></span></div><div>Bicuspid aortic valve</div><div> <span></span><span></span></div><div>Aortitis (ie giant cell arteritis)</div><div> <span></span><span></span></div><div>Pregnancy</div><div>Clinical Manifes<span></span>tations</div><div> <span></span><span></span></div><div><span></span><span></span></div><div>ripping, chest p<span></span>ain that radiates t<span></span>o the back</div><div> <span></span><span></span></div><div><span></span><span></span><span></span><span></span></div><div>ischemia</div></div><div></div></div>
<div><div><img><div>20<span> </span><span>Disease Proc<span></span>esses &amp; Surgical Procedur<span></span>es<span> </span>Disease Processes &amp; Sur<span></span>gical Procedures<span> </span><span>21</span></span></div><div>Physical E<span></span>xam</div><div> <span></span><span></span></div><div><span></span><span>Note c<span></span>arotid, radial, and </span></div><div>femoral pulses bilater<span></span>ally</div><div> <span></span><span></span></div><div>Change in neurologic<span></span>al st<span></span>atus indicating compr<span></span>omise of cerebral perfusion</div><div> <span></span><span></span></div><div>Abdominal pain indica<span></span>ting bowel ischemia</div><div>Dissection Classica<span></span>tions:</div><div> <span></span><span></span></div><div></div><div><span></span><span> </span><span>T<span></span>ype I – Dissection originates in the ascending aort<span></span>a and may extend </span></div><div>down to the descending aort<span></span>a and/or abdominal aort<span></span>a</div><div><span></span><span> </span><span>T<span></span>ype II – Dissection is limited to ascending aort<span></span>a only</span></div><div><span></span><span> </span><span>T<span></span>ype III – Dissection originates in the descending aort<span></span>a and extends to </span></div><div>just above the diaphr<span></span>agm (type IIIa) or below the diaphragm (type IIIb)</div><div> <span></span><span></span></div><div><span></span></div><div><span></span><span> </span><span>T<span></span>ype A – Dissection originates in ascending aort<span></span>a and may extend into </span></div><div>descending aort<span></span>a</div><div><span></span><span> </span><span>T<span></span>ype B – Dissection originates in descending aort<span></span>a however may </span></div><div>retrogr<span></span>ade into the aortic arch </div><div>Aneurysm Classications:</div><div> <span></span><span></span></div><div><span></span><span></span><span></span></div><div><span></span><span> </span><span><span></span></span></div><div>ext<span></span>ends to the celiac axis and mesent<span></span>eric arteries</div><div><span></span><span> </span><span>T<span></span>ype II – Dissection includes type 1 but extends into infr<span></span>arenal aorta</span></div><div><span></span><span> </span><span>T<span></span>ype III – Dissection originates in the lower descending thor<span></span>acic aorta </span></div><div>and involves remainder of the aort<span></span>a</div><div><span></span><span> </span><span>T<span></span>ype IV – Dissection originates at the diaphr<span></span>agm and involves the entire </span></div><div>abdominal aorta</div><div>Management</div><div> <span></span><span></span></div><div>Inpatient/ICU Care:</div><div><span></span><span> </span><span>Obt<span></span>ain blood pressure in both arms.  </span></div><div> <span></span><span></span></div><div>Insert arterial line in right arm</div><div><span></span><span> </span><span>Control heart r<span></span>ate and blood pressure</span></div><div> <span></span><span></span></div><div><span></span><span></span><span></span><span></span></div><div>otherwise)</div><div> <span></span><span></span></div><div><span></span><span></span></div><div>otherwise)</div><div><span></span><span> </span><span>Manage pain </span></div><div><span></span><span> </span><span>Follow up with surgic<span></span>al team r<span></span>egarding whether or not acut<span></span>e surgical </span></div><div>intervention is indicated</div><div> <span></span><span></span></div><div>Acute type A aortic dissections ar<span></span>e always a surgical emer<span></span>gency.  </div><div> <span></span><span></span></div><div>Uncomplica<span></span>ted type B dissections are medically managed</div><div> <span></span><span></span></div><div>Outpatient c<span></span>are:</div><div><span></span><span> </span><span><span></span><span></span></span></div><div><span></span><span> </span><span>BP control</span></div><div> <span></span><span></span></div><div></div><div> <span></span><span></span></div><div><span></span></div><div> <span></span><span></span></div><div>No burst activity<span></span>/ex<span></span>ercise requiring Valsalv<span></span>a</div><div><span></span><span> </span><span>Follow up: </span></div><div> <span></span><span></span></div><div>Exp<span></span>ansion rate ~0.1cm/yr for T<span></span>AA, ~_.4cm/yr for A<span></span>AA</div><div> <span></span><span></span></div><div></div><div> <span></span><span></span></div><div>Screening for CAD, P<span></span>AD, Aneurysm else<span></span>where, esp poplit<span></span>eal. 25% of pt<span></span>s </div><div>with T<span></span>AA Will also have AAA. </div><div>Surgical indic<span></span>ations for Aortic Aneurysms: </div><div>of note, when looking at aortic measurements, must c<span></span>onsider ASI (aortic size index, </div><div>relation of height and weight to maximum aortic diame<span></span>ter)</div><div> <span></span><span></span></div><div>T<span></span>AA growing &gt; 1cm/yr</div><div> <span></span><span></span></div><div>Ascending &gt; 5.5cm; descending &gt;6cm.</div><div> <span></span><span></span></div><div>Marfan<span></span>’<span></span>s/Loey Dietz patient &gt; 4.5-5cm</div><div> <span></span><span></span></div><div>For any aneurysm &gt; 4cm if planning for AoV surgery</div><div> <span></span><span></span></div><div>Other Surgical T<span></span>riggers:</div><div><span></span><span> </span><span>4.5 cm in the setting of a f<span></span>amily hx positive for rupture or dissection</span></div><div><span></span><span> </span><span>5.0 cm with modera<span></span>te or worse aortic v<span></span>alve disease</span></div><div><span></span><span> </span><span>Primar<span></span>y f<span></span>ailure of aortic valve (AS/<span></span>AI)</span></div><div>Surgical indic<span></span>ations for Aortic Dissections</div><div><span></span><span> </span><span>T<span></span>ype A: emergent surgery indicated in all acute type A dissec<span></span>tions as well </span></div><div>as chronic type A</div><div><span></span><span> </span><span>T<span></span>ype B: usually treated medic<span></span>ally. Endov<span></span>ascular or surgical repairs in </span></div><div>complica<span></span>ted patients with chr<span></span>onic pain, unc<span></span>ontrolled hypertension, </div><div>evidence of aneur<span></span>ysmal exp<span></span>ansion or rupture, or vascular c<span></span>ompromise</div><div>Surgical int<span></span>er<span></span>vention </div><div>OPEN REP<span></span>AIR</div><div> <span></span><span></span></div><div>Ascending aortic dissection/<span></span>aneur<span></span>ysm: <span>aortic v<span></span>alve repair<span></span>/replacement, </span></div><div><span></span><span></span><span></span><span></span></div><div>place v<span></span>alve conduit. If tear ext<span></span>ends across arch, may replac<span></span>e entire arch </div><div><span></span></div><div><span></span><span></span><span></span></div><div> <span></span><span></span></div><div>Descending aortic dissection/<span></span>aneur<span></span>ysm:<span><span></span></span></div><div>replacement.  </div><div>Intra-oper<span></span>ative c<span></span>onsidera<span></span>tions</div><div> <span></span><span></span></div><div>DHCP: deep hypothermic circula<span></span>tor<span></span>y arrest</div><div><span></span><span> </span><span>Used when aorta c<span></span>annot be clamped to perf<span></span>orm aortic anastomosis</span></div><div><span></span><span> </span><span>P<span></span>atient is cooled for neur<span></span>oprotection</span></div><div><span></span><span> </span><span>SACP: selective ant<span></span>egr<span></span>ade cerebr<span></span>al perfusion</span></div><div> <span></span><span></span></div><div><span></span><span></span><span></span></div><div>arrest t<span></span>o perfuse brain</div><div><span></span><span> </span><span>RCP: retrogr<span></span>ade cerebr<span></span>al perfusion</span></div><div> <span></span><span></span></div><div>Cold, oxygenat<span></span>ed blood into SVC to maintain c<span></span>erebral hypothermia</div><div><span></span><span> </span><span>Ex<span></span>tensive cooling and rewarming is associat<span></span>ed with coagulopa<span></span>thy and </span></div><div>bleeding</div><div><span></span><span> </span><span>Neurologic rec<span></span>over<span></span>y may take up t<span></span>o 24 hours</span></div><div><span></span><span> </span><span>Decadron, mannit<span></span>ol and or Lasix may also be given for neuropro<span></span>tection</span></div></div><div></div></div>
<div><div><img><div>22<span> </span><span>Disease Proc<span></span>esses &amp; Surgical Procedur<span></span>es<span> </span>Disease Processes &amp; Sur<span></span>gical Procedures<span> </span><span>23</span></span></div><div> <span></span><span></span></div><div>Cross-clamping of the dist<span></span>al aorta can result in p<span></span>araplegia or renal f<span></span>ailure </div><div>(Referenc<span></span>e: section 3 post<span></span>-operative management of spinal c<span></span>ord ischemia)</div><div>MINIMALL<span></span>Y INVASIVE REP<span></span>AIR</div><div> <span></span><span></span></div><div>Endovascular s<span></span>tenting for complica<span></span>ted type B via TEVAR</div><div>i. <span> </span><span><span></span><span></span><span></span></span></div><div><span></span><span></span><span></span></div><div>ii. <span> </span><span>On pre-op CT<span></span>, look for c<span></span>ommunication between the true and f<span></span>alse lumen </span></div><div>to help det<span></span>ermine what are<span></span>as can be safely stent<span></span>ed.    </div><div>iii. <span> </span><span>It is also important t<span></span>o look at the diameter of the femor<span></span>al vessels to </span></div><div>determine whe<span></span>ther acc<span></span>ess needs to be gained higher than the groin </div><div>(typically acc<span></span>essed some<span></span>where ne<span></span>ar the level of the belly button or </div><div>slightly lower).   </div><div>iv<span></span>. <span> </span><span>Indications f<span></span>or TEVAR</span></div><div>a.  Asymptomatic p<span></span>atients with thoracic aortic aneurysms</div><div>b.<span> <span> </span>P<span></span>atients with descending thor<span></span>acic aortic aneur<span></span>ysms that is at le<span></span>ast </span></div><div>2 times grea<span></span>ter than the adjacent aorta, me<span></span>asuring at least 5cm.  </div><div><span></span></div><div>of the aneur<span></span>ysm in order t<span></span>o <span><span></span></span></div><div>aortic walls.</div><div>c.  Pa<span></span>tients that are elderly and/<span></span>or in poor overall health and would be </div><div>unlikely to survive an open operation</div><div>d. <span> </span>Can be used in chronic or acute dissections </div><div>v.<span></span><span> <span> </span><span>Contraindications for TEV<span></span>AR</span></span></div><div>a.  Symp<span></span>tomatic p<span></span>atients – those with symptoms typically r<span></span>equire open </div><div>repair of T<span></span>AA </div><div>b.<span> <span> </span><span>Pa<span></span>t<span></span>i<span></span>en<span></span>t<span></span>s<span></span> <span></span>w<span></span>i<span></span>t<span></span>h<span></span> <span></span>a<span></span>cc<span></span>e<span></span>s<span></span>s<span></span> <span></span>v<span></span>e<span></span>s<span></span>se<span></span>l<span></span>s<span></span> <span></span>l<span></span>e<span></span>s<span></span>s<span></span> <span></span>t<span></span>h<span></span>a<span></span>n<span></span> <span></span>8<span></span>m<span></span>m <span></span>o<span></span>r<span></span> <span></span>v<span></span>e<span></span>s<span></span>s<span></span>e<span></span>l<span></span>s<span></span> <span></span>t<span></span>h<span></span>at<span></span> <span></span>a<span></span>r<span></span>e<span></span> <span></span>t<span></span>o<span></span>rt<span></span>u<span></span>o<span></span>u<span></span>s<span></span>.</span></span></div><div> <span></span><span></span></div><div>(patient<span></span>s that do not have 2cm of suitable aortic dimension on either </div><div>side of the aneur<span></span>ysm).</div><div>d. <span> </span>P<span></span>atients who have branch vessels that will be oc<span></span>cluded by the stent<span></span>-</div><div><span></span></div><div>e.  P<span></span>atients with c<span></span>onnective tissue disorders such as Marfan<span></span>’<span></span>s in which it is </div><div>expected further tissue de<span></span>gener<span></span>ation may occur<span></span>.   </div><div>Pos<span></span>toper<span></span>ative Management</div><div> <span></span><span></span></div><div>Blood pressure manag<span></span>ement: </div><div><span></span><span> </span><span>Must b<span></span>alance risk of expansion of residual dissection/<span></span>aneur<span></span>ysm (if </span></div><div>present) with risk of end org<span></span>an/spinal cord ischemia</div><div><span></span><span> </span><span>Est<span></span>ablish hemodynamic goals with CT Sur<span></span>ger<span></span>y att<span></span>ending and ICU team</span></div><div> <span></span><span></span></div><div>Monitor for bleeding and c<span></span>orrect coagulop<span></span>athy</div><div> <span></span><span></span></div><div>Neuro monitoring:</div><div><span></span><span> </span><span>Q1H Pupillometry for patients who underwent circulatory arrest</span></div><div><span></span><span> </span><span>Lumbar<span></span> drain:<span></span> placed<span></span> preop<span></span>erativel<span></span>y for <span></span>patients <span></span>undergo<span></span>ing d<span></span>escendi<span></span>ng </span></div><div>aorta r<span></span>epair at high risk for par<span></span>aplegia (for more det<span></span>ail, see Referenc<span></span>e: Post<span></span>-</div><div>oper<span></span>ative man<span></span>agement: Spina<span></span>l c<span></span>ord <span></span>ischemi<span></span>a; Devices:<span></span> Lumb<span></span>ar dr<span></span>ains).  </div><div> <span></span><span></span></div><div><span></span></div><div>perfusion pressure &gt;80mmHg  </div><div> <span></span><span></span></div><div><span></span><span></span></div><div>exam int<span></span>act</div><div> <span></span><span></span></div><div>Monitor for end or<span></span>gan ischemia: </div><div><span></span><span> </span><span>T<span></span>rend UOP</span></div><div><span></span><span> </span><span>Serial lact<span></span>ate, BMP<span></span>, LFT<span></span>, SvO2</span></div><div>Referenc<span></span>es</div><div>Bojar<span></span>, Robert M. (2011) Manual of Perioper<span></span>ative Care in Adult Cardiac Surgery. (5th edition). </div><div>A<span></span>TRIAL FIBRILLA<span></span>TION (AF)</div><div>P<span></span>athology:</div><div> <span></span><span></span></div><div><span></span><span></span><span></span></div><div>rapid r<span></span>ates, producing an exc<span></span>eedingly rapid, erratic rhythm. </div><div> <span></span><span></span></div><div>Pos<span></span>t-oper<span></span>ative atrial brilla<span></span>tion:<span> occurs in 30-40% of pos<span></span>t op cardiac </span></div><div><span></span><span></span><span></span></div><div><span></span></div><div>Clinical manifes<span></span>tations:  </div><div> <span></span><span></span></div><div>Can be asymptoma<span></span>tic</div><div> <span></span><span></span></div><div>F<span></span>atigue, palpit<span></span>ations, dyspnea, lightheadedness, ches<span></span>t pain</div><div>Physical E<span></span>xam: </div><div> <span></span><span></span></div><div>Discrepancy be<span></span>tween ausculta<span></span>ted heart ra<span></span>te and palpable <span></span>pulse ra<span></span>te (minimal </div><div><span></span><span></span></div><div>Diagnostic S<span></span>tudies:</div><div> <span></span><span></span></div><div>12-lead EK<span></span>G: <span><span></span></span></div><div>Disorganiz<span></span>ed atrial activity between QRS c<span></span>omplexes occurring in an irregular </div><div>pat<span></span>tern. RVR = rapid ventricular response HR&gt; 150bpm</div><div>Classication</div><div>New onset <span> <span> </span>1st det<span></span>ected vs reoccurr<span></span>ence &gt; 2 episodes</span></div><div>P<span></span>aroxysmal<span><span> </span><span></span><span> </span></span></div><div> <span> </span><span>within 7-days or spontaneously</span></div><div>Persis<span></span>tent<span><span> </span><span></span><span> </span></span></div><div> <span> </span><span>with cardioversion</span></div><div>Permanent/ Chronic<span><span> </span><span></span><span></span><span></span><span> </span></span></div><div> <span> </span><span>or no plans for cardioversion</span></div><div>Secondary<span> <span> </span>Caused by a separ<span></span>ate underlying condition: </span></div><div> <span> </span><span>MI, cardiac surg<span></span>er<span></span>y, pulmonary disease.</span></div><div>Lone atrial brilla<span></span>tion<span> <span> </span>Age &lt; 60; no clinical or echoc<span></span>ardiographic reasons  </span></div><div> <span> </span><span>are found</span></div><div>Non-v<span></span>alvular<span> <span> </span>Not caused by v<span></span>alvular disease, prosthe<span></span>tic heart  </span></div><div> <span> </span><span>valves,  or v<span></span>alve repair </span></div><div> </div><div>Risk of str<span></span>oke from atrial brilla<span></span>tion – calculated with CHA2DS2V<span></span>ASc scor<span></span>e.</div><div>CHADS2 VASc Sc<span></span>ore (&gt;2 pts equals indica<span></span>tion for anticoagula<span></span>tion)</div><div>C (1)<span> </span><span><span></span><span></span></span></div><div>H (1)<span> </span><span>Hypertension</span></div><div>A  (2)<span> </span><span>Age &gt;74 years old </span></div><div>D (1)<span> </span><span>DM</span></div><div>S (2)<span> </span><span>Prior stroke or TIA or thromboembolism</span></div><div>V (1)<span> </span><span>Vascular disease (P<span></span>AD, MI)</span></div><div>A (1)<span> </span><span>Age 65-74 years old</span></div><div>S (1)<span> </span><span>Sex category female</span></div><div>Indications f<span></span>or Surgery</div><div> <span></span><span></span></div><div><span></span><span></span></div><div>advanc<span></span>ed disease patients</div><div> <span></span><span></span></div><div><span></span><span></span><span></span></div><div>who have failed prior ca<span></span>theter ablations</div></div><div></div></div>
<div><div><img><div>24<span> </span><span>Disease Proc<span></span>esses &amp; Surgical Procedur<span></span>es<span> </span>Disease Processes &amp; Sur<span></span>gical Procedures<span> </span><span>25</span></span></div><div> <span></span><span></span></div><div>Cox Maze pr<span></span>ocedure: c<span></span>an be performed for patient<span></span>s with non paro<span></span>x<span></span>ysmal </div><div><span></span><span></span><span></span></div><div>replacement, CABG)</div><div>Surgical Pr<span></span>ocedures</div><div>Atrial Fibrillation Treatment Options </div><div>Medication </div><div>Therapy</div><div>(Drugs)</div><div>Direct Current </div><div>Cardioversion<span> </span></div><div>(Shock)</div><div>Catheter <span>Ablation</span></div><div>Typically used to treat:</div><div>1. Paroxysmal atrial fibrillation</div><div>2. Duration &lt; 1 year</div><div>3. Left Atrium size &lt; 4.0cm </div><div>Hybrid <span>Ablation </span></div><div>CATHETER + SURGERY</div><div>Typically used to treat:</div><div>1. Non-paroxysmal atrial fibrillation</div><div>2. Average Duration ~ 4 years</div><div>3. Average Left Atrium size ~ 4.5cm </div><div>Cox Maze Procedure</div><div>Typically used to treat:</div><div>1. Non-paroxysmal atrial fibrillation</div><div>2. Average Duration ~ 6.5 years</div><div>3. Left Atrium size &gt; 5.0cm</div><div>“Internal  Ablation”</div><div>Completed by </div><div>Electrophysiologist</div><div>LEAST INVASIVE                                                                                                                                                                                    MOST EFFECTIVE        <span> </span></div><div><div> </div></div><div>“Open heart surgery” </div><div>Requires heart lung- </div><div>bypass machine </div><div>Part 1: <span>“External </span></div><div>Ablation” </div><div>Completed by </div><div>Cardiac Surgery</div><div>Part 2: <span>“ Internal </span></div><div>Ablation” </div><div>Completed by </div><div>Electrophysiologist</div><div>Performed </div><div>by Cardiac </div><div>Surgeon </div><div>(Dr. Lee)</div><div>“Minimally Invasive” </div><div>Bilateral video assisted </div><div>thoracospic (VATS)</div><div>My information </div><div>TYPE: _______________</div><div>DURATION: ___________</div><div>LA SIZE:_______________</div><div> </div><div>Anson<span> </span>M.<span> </span>Lee,<span> </span>MD</div><div>Assistant<span> </span>Professor<span> </span>of<span> </span>Cardiothoracic<span> </span>Surgery<span> </span>(Adult</div><div><div>C</div></div><div>ardiac<span> </span>Surgery)<span> </span>at<span> </span>the<span> </span>Stanford<span> </span>University<span> </span>Medical<span> </span>Center</div><div>Internal &amp; </div><div>External Ablation</div><div>Completed by </div><div>Cardiac Surgeon </div><div>Anterior Thoracotomy Incision </div><div>Traditional Sternotomy </div><div><div>Incision </div></div><div>Video Assisted Thoracoscopic Surgery (VATS) </div><div>Incision </div><div>Pos<span></span>t-oper<span></span>ative c<span></span>onsidera<span></span>tions: </div><div> <span></span><span></span></div><div><span></span><span></span><span></span></div><div>heart surg<span></span>er<span></span>y</div><div> <span></span><span></span></div><div>All patient<span></span>s will need to resume home antiarrhythmic agents and </div><div>antico<span></span>agulation (re<span></span>gardless of rhythm)</div><div> <span></span><span></span></div><div>Only consider DC<span></span>CV for post op Maze p<span></span>atients if unst<span></span>able or rate is very fast </div><div><span></span><span></span></div><div> <span></span><span></span></div><div><span></span><span></span></div><div>will be in NSR at 1 year pos<span></span>t operatively<span></span>.</div><div> <span></span><span></span></div><div>Consider st<span></span>arting Inspra (Aldactone) 25mg PO BID, onc<span></span>e creatinine, </div><div>pot<span></span>assium, and blood pressure will tolera<span></span>te and continue on discharge. </div><div>Referenc<span></span>e:</div><div>Bojar<span></span>, Robert, M., (2011) Manual of Periopera<span></span>tive Care in Adult Cardiac Surgery. (5th edition). </div><div>Am Fam Physician. 2011;83(1):61-68. Americ<span></span>an Academy of F<span></span>amily Physicians.</div><div>Lawrance, Chris<span></span>topher P<span></span>. (2015) Curr Opin Cardiol. January: 30(1): 58-64. </div><div>Pison MD, Laurent, La Meir MD PhD, Mark, Crijns MD PhD, Harr<span></span>y. (2013) Journal of Atrial Fibrilla<span></span>tion  </div><div>Vol-6; Issue2: 49-56.</div><div>HYPERTROPHIC CARDIOMY<span></span>OP<span></span>A<span></span>THY </div><div>Etiology</div><div> <span></span><span></span></div><div>HCM is the most c<span></span>ommon genetic cardiac disease, oc<span></span>curs in ~ 1/500 young </div><div>adults</div><div> <span></span><span></span></div><div><span></span><span>ie  HTN or valvular  </span></div><div>aortic st<span></span>enosis)</div><div>P<span></span>athology</div><div> <span></span><span></span></div><div>In the obstructive f<span></span>orm of HCM (~70% of patients w/ HCM), sep<span></span>tal hypertrophy </div><div>and abnormal SAM of the MV produce L<span></span>VO<span></span>T obstruction and v<span></span>ariable degrees </div><div>of MR</div><div><span></span><span> </span><span>SAM is the abrupt ant<span></span>erior motion of the mitral v<span></span>alve<span> in which the </span></span></div><div><span></span><span></span><span> </span></div><div>le ventricular outow tr<span></span>act obstruction (L<span></span>VO<span></span>TO) </div><div> <span></span><span></span></div><div>Consider SAM in setting of worsening hypo<span></span>tension with increased </div><div>inotropic support</div><div> <span></span><span></span></div><div><span></span></div><div>intraventricular sep<span></span>tum, papillar<span></span>y muscle displacement, and </div><div><span></span><span></span></div><div> <span></span><span></span></div><div>SAM of the mitral v<span></span>alve may also be present secondar<span></span>y t<span></span>o mitral v<span></span>alve </div><div>repair</div><div> <span></span><span></span></div><div>L<span></span>VOT obs<span></span>truction <span>produces markedly incr<span></span>eased intr<span></span>aventricular </span></div><div>pressures thereby incr<span></span>easing myocardial wall s<span></span>tress and oxygen </div><div>demand</div><div> <span></span><span></span></div><div> <span></span><span></span></div><div> <span></span><span></span></div><div><span></span><span></span><span></span></div><div>co<span></span>apt<span></span>ation</div><div> <span></span><span></span></div><div>Diast<span></span>olic dysfunction with incre<span></span>ased L<span></span>VEDP (dependent on atrial contr<span></span>action)</div><div>Clinical manifes<span></span>tations</div><div> <span></span><span></span></div><div>Syncope</div><div> <span></span><span></span></div><div>Dyspnea (L<span></span>V diastolic dysfxn/ MR)</div><div> <span></span><span></span></div><div>F<span></span>atigability</div><div> <span></span><span></span></div><div>Angina <span></span></div><div>Important His<span></span>tory Questions:</div><div> <span></span><span></span></div><div>Hist<span></span>or<span></span>y of vt<span></span>ach/ cardiac arrest<span></span>? AICD? </div><div> <span></span><span></span></div><div>F<span></span>amily Hx sudden cardiac de<span></span>ath</div><div> <span></span><span></span></div><div>Has genetic t<span></span>esting been perf<span></span>ormed? If so are they positive for gene? </div><div>Physical E<span></span>xam</div><div> <span></span><span></span></div><div>Syst<span></span>olic murmur @ LSB (can r<span></span>adiate across prec<span></span>ordium), <span></span> st<span></span>anding<span></span>/</div><div><span></span><span></span></div><div> <span></span><span></span></div><div>Crescendo-decresc<span></span>endo peak mid-late S1, end befor<span></span>e S2</div><div> <span></span><span></span></div><div>MR may produce sep<span></span>arate holosys<span></span>tolic murmur at apex </div><div> <span></span><span></span></div><div>4th heat sound if L<span></span>VH </div><div> <span></span><span></span></div><div></div></div><div></div></div>
<div><div><img><div>26<span> </span><span>Disease Proc<span></span>esses &amp; Surgical Procedur<span></span>es<span> </span>Disease Processes &amp; Sur<span></span>gical Procedures<span> </span><span>27</span></span></div><div>Diagnostic S<span></span>tudies</div><div> <span></span><span></span></div><div>Echo:</div><div><span></span><span> </span><span>Presence of SAM? MR? If MR, dila<span></span>ted LA? </span></div><div><span></span><span> </span><span>Dx of HCM based on L<span></span>VOT gr<span></span>adients:  (rest, Valsalv<span></span>a, peak exercise)</span></div><div> <span></span><span></span></div><div>peak gr<span></span>adient @ rest &gt; 50 + symptoms (no<span></span>t improved w/ med therapy) </div><div>(others say res<span></span>ting gradient as low as 30 mmHg)</div><div> <span></span><span></span></div><div>peak gr<span></span>adient @ rest &gt; 80 + asymptoma<span></span>tic </div><div> <span></span><span></span></div><div>Str<span></span>ess/Ex<span></span>ercise- induced gradient &gt;100mmHg</div><div><span></span><span> </span><span><span></span></span></div><div> <span></span><span></span></div><div>Ex<span></span>ercise Stress Echo </div><div><span></span><span> </span><span>BP response:  should incre<span></span>ase &gt;20 mmHg w/ exercise or pt @ higher risk </span></div><div>for SCD</div><div> <span></span><span></span></div><div><span></span></div><div><span></span><span> </span><span>If no delayed gadolinium enhanc<span></span>ement (DGE), means no scarring, lik<span></span>ely </span></div><div>don’t need ICD if no his<span></span>tor<span></span>y of VT </div><div><span></span><span> </span><span><span></span><span></span></span></div><div>thick)</div><div> <span></span><span></span></div><div>CA<span></span>TH:</div><div><span></span><span> </span><span>Pulm HTN (RVSP &gt; 35) in 50%, severe ( &gt;50) in 17% patients </span></div><div>Surgical Indic<span></span>ations: </div><div> <span></span><span></span></div><div>Sept<span></span>al thickness &gt;18mm</div><div> <span></span><span></span></div><div>Atypical sep<span></span>tal morphology</div><div> <span></span><span></span></div><div></div><div> <span></span><span></span></div><div><span></span><span></span><span></span></div><div>Surgical Pr<span></span>ocedures</div><div>1. Sept<span></span>al Ablation (done in cath lab b<span></span>y interventional Cards)</div><div> <span></span><span></span></div><div><span></span><span></span></div><div>myocardial inf<span></span>arction within the proximal ventricular sep<span></span>tum</div><div> <span></span><span></span></div><div>Leads t<span></span>o progressive thinning and reduction of the L<span></span>VOT obs<span></span>truction</div><div>2. Sept<span></span>al Myot<span></span>omy/Myect<span></span>omy with possible MV repair<span></span>/replacement </div><div> <span></span><span></span></div><div>Considered “<span></span>gold st<span></span>andard” for the trea<span></span>tment for HCM pa<span></span>tients refract<span></span>or<span></span>y to </div><div>optimal medical ther<span></span>apies</div><div> <span></span><span></span></div><div>Surgical proc<span></span>edure that relieves the L<span></span>VOT obstruc<span></span>tion by resection of a small </div><div>portion of muscle from the basal sep<span></span>tum in order to<span></span></div><div>obstruction</div><div> <span></span><span></span></div><div>Some patient<span></span>s may also require mitral v<span></span>alve repair if they also demonstra<span></span>te </div><div>syst<span></span>olic anterior motion (SAM) of the mitr<span></span>al valve that is also contributing the </div><div>L<span></span>VOT obstruc<span></span>tion.</div><div>Benet of surgic<span></span>al intervention vs. ablation: </div><div> <span></span><span></span></div><div>SURGERY: result<span></span>ant lower gradient and less requirement f<span></span>or post<span></span>-op PPM</div><div> <span></span><span></span></div><div><span></span><span></span><span></span><span></span></div><div><span></span><span></span><span></span><span></span></div><div>crea<span></span>tes “mush-like” infar<span></span>cted tissue </div><div>Pre- op consider<span></span>ations</div><div> <span></span><span></span></div><div>Pre-load dependent (gr<span></span>adient worse if dehydrated)(Avoid Jacuzzis; Avoid </div><div>lasix/<span></span>diuretics)</div><div> <span></span><span></span></div><div>AVOID ino<span></span>tropes</div><div> <span></span><span></span></div><div><span></span><span></span></div><div> <span></span><span></span></div><div><span></span></div><div><span></span><span></span><span></span><span></span><span></span></div><div><span></span></div><div> <span></span><span></span></div><div>Dual-chamber pacing with a short AV delay (or V<span></span>-pacing) to ensure complet<span></span>e </div><div><span></span><span></span><span></span></div><div>approxima<span></span>tely 35%. Septal dyssynchrony may ac<span></span>tually pull septum out  </div><div>of L<span></span>VOT</div><div>Intra-op c<span></span>onsidera<span></span>tions</div><div> <span></span><span></span></div><div>95% cases don’t r<span></span>equire MV repair if septum adequa<span></span>tely excised (SAM will </div><div>improve w/ myec<span></span>tomy alone)</div><div> <span></span><span></span></div><div>RISKS: Need for PPM (can<span></span>’t see bundle His/ looks like muscle)</div><div>Pos<span></span>t op consider<span></span>ations</div><div> <span></span><span></span></div><div><span></span><span></span></div><div>caution</div><div> <span></span><span></span></div><div>Avoid inotropes if possible</div><div> <span></span><span></span></div><div>Avoid tachyc<span></span>ardia (HR 60-80)</div><div> <span></span><span></span></div><div><span></span></div><div> <span></span><span></span></div><div><span></span><span></span></div><div>slow-normal HR)</div><div> <span></span><span></span></div><div>If no ICD pre-op &amp; plan to place pr<span></span>ophylactic ICD post-op (if risks f<span></span>or sudden </div><div>cardiac de<span></span>ath (SCD)) </div><div>Referenc<span></span>e:</div><div>Bojar<span></span>, Robert, M., (2011) Manual of Periopera<span></span>tive Care in Adult Cardiac Surgery. (5th edition). </div><div>Indian Journal of Anaesthesia, Vol. 58, No<span></span>. 1, Januar<span></span>y-February, 2014, pp. 51-54</div><div>INFECTIVE ENDOCARDITIS/ ROO<span></span>T ABSCES<span></span>S </div><div>Etiology</div><div> <span></span><span></span></div><div>Native v<span></span>alve endocarditis is mos<span></span>t commonly caused by <span>Streptoc<span></span>occus </span></div><div>viridans, Staphylococ<span></span>cus aureus<span>, or coagulase-neg<span></span>ative staph. </span></div><div> <span></span><span></span></div><div>T<span></span>ricuspid valve endocarditis is usually c<span></span>aused by IV drug abuse</div><div> <span></span><span></span></div><div>Incidence of pros<span></span>thetic valve endocar<span></span>ditis is approximately 0.5-1% per </div><div>patient<span></span>-year<span></span>. Most common cause is by s<span></span>taph organism</div><div>P<span></span>athology </div><div> <span></span><span></span></div><div><span></span><span></span></div><div>myo-cardial tissue, sys<span></span>temic emboliz<span></span>ation of valve vege<span></span>tations, or persist<span></span>ent </div><div>syst<span></span>emic sepsis. </div><div> <span></span><span></span></div><div>Emboliza<span></span>tion is more common with mitral v<span></span>alve involvement<span></span>, s<span></span>taphylococc<span></span>al </div><div>organ-ism, and lar<span></span>ge or mobile veget<span></span>ations.</div><div>Clinical manifes<span></span>tations</div><div> <span></span><span></span></div><div>Presence of moder<span></span>ate to severe c<span></span>ongestive heart f<span></span>ailure maybe present from </div><div>re-gurgit<span></span>ant lesions. </div></div><div></div></div>
<div><div><img><div>28<span> </span><span>Disease Proc<span></span>esses &amp; Surgical Procedur<span></span>es<span> </span>Disease Processes &amp; Sur<span></span>gical Procedures<span> </span><span>29</span></span></div><div> <span></span><span></span></div><div><span></span><span></span></div><div><span></span><span></span></div><div>pulmo-nar<span></span>y hypertension</div><div> <span></span><span></span></div><div>Complete he<span></span>art block<span></span>: More c<span></span>ommon in aortic valve endocarditis or annular </div><div>ab-scess</div><div> <span></span><span></span></div><div>Physical E<span></span>xam</div><div> <span></span><span></span></div><div>Splinter hemorrhages, Osler’<span></span>s nodes may be present</div><div>Diagnostic S<span></span>tudies/ Classication</div><div> <span></span><span></span></div><div>TEE (transesophog<span></span>eal echocar<span></span>diogram) is gold st<span></span>andard for identifying </div><div><span></span></div><div>echocardiogr<span></span>am) in identi-fying and quantifying the size and mobility of </div><div>the vege<span></span>ta<span></span>tions, detec<span></span>ting annular destruc<span></span>tion, and identifying valvular </div><div>abnormalities. </div><div> <span></span><span></span></div><div>Coronary angiography should be avoided, if possible, if mobile aortic valve </div><div><span></span><span></span></div><div> <span></span><span></span></div><div>Duke Crit<span></span>eria:</div><div>Dente Infec<span></span>tive Endocarditis is est<span></span>ablished in the presence of any of the </div><div>following:</div><div>P<span></span>athologic criteria<span> </span><span>Pathologic lesions</span>: veg<span></span>etation or intr<span></span>acardiac abscess </div><div>demonstr<span></span>ating active en-docartitis on hist<span></span>olog<span></span>y</div><div>Microorganism<span>: on culture/his<span></span>tology of a vegeta<span></span>tion or </span></div><div>intrac<span></span>ardiac abscess</div><div>Clinical criteria </div><div>(See major &amp; minor </div><div>clinical criteria under </div><div>Referenc<span></span>es)</div><div>2 major clinical criteria OR</div><div>1 major and 3 minor clinical criteria OR</div><div>5 minor clinical criteria</div><div>Possible Inf<span></span>ective endocarditis</div><div> <span></span><span></span></div><div>Presence of 1 major and 1 minor clinic<span></span>al criteria OR presence of 3 minor </div><div>clinical criteria</div><div>Reject<span></span>ed Infective Endocarditis</div><div> <span></span><span></span></div><div><span></span><span>OR</span></div><div> <span></span><span></span></div><div><span></span><span></span></div><div>therapy <span>OR</span></div><div> <span></span><span></span></div><div>No pathologic evidenc<span></span>e of infective endocar<span></span>ditis is found at surgery or </div><div><span></span></div><div>Preoper<span></span>ative c<span></span>onsidera<span></span>tions</div><div> <span></span><span></span></div><div>P<span></span>atients should ideally r<span></span>eceive 6weeks of antibiotic ther<span></span>apy prior to surgery </div><div>(de-creases risk for pr<span></span>osthetic valve endoc<span></span>arditis)</div><div> <span></span><span></span></div><div>Antibiotics decre<span></span>ase incidence of embolization</div><div> <span></span><span></span></div><div>Increasing in ve<span></span>getation siz<span></span>e while on antibiotic therapy may predict la<span></span>ter </div><div>emboli-za<span></span>tion. </div><div> <span></span><span></span></div><div>P<span></span>atients with aortic valve endoc<span></span>arditis have a greater chanc<span></span>e of heart block </div><div>due to the involvement of the conduc<span></span>tion system by periannular infection. </div><div>Therefore, a pr<span></span>eoperative placement of a tr<span></span>ansvenous pacing wire may be </div><div>necessary. </div><div>Indications f<span></span>or Surgery</div><div> <span></span><span></span></div><div>Native Valve Endoc<span></span>arditis </div><div><span></span><span> </span><span>Class I indications:</span></div><div> <span></span><span></span></div><div>Surgery should not be delayed if the patient is in c<span></span>ardiogenic shock</div><div> <span></span><span></span></div><div><span></span><span></span></div><div>L<span></span>VEDP<span></span>, ele<span></span>v<span></span>ated LA pressur<span></span>es, or moderate to severe pulmonary </div><div>hypertension</div><div> <span></span><span></span></div><div>Evidence of loc<span></span>al extension resulting in aortic or annular absc<span></span>ess, or </div><div><span></span><span></span><span></span><span></span></div><div>from aortic valve endoc<span></span>arditis) </div><div> <span></span><span></span></div><div>Organisms unlik<span></span>ely to be adequately tre<span></span>ated with antibio<span></span>tic therapy </div><div>alone, especially fungal endocar<span></span>ditis. </div><div> <span></span><span></span></div><div>Persis<span></span>tent sepsis or bacter<span></span>emia despite antibiotic trea<span></span>tment for at </div><div>leas<span></span>t 1 week<span></span>, especially with st<span></span>aph infections. However<span></span>, it should be </div><div>noted tha<span></span>t sur-ger<span></span>y during septic shock have a poor pr<span></span>ognosis, with an </div><div>opera<span></span>tive mortality r<span></span>ate exc<span></span>eeding 50%. </div><div><span></span><span> </span><span>Class II indications</span></div><div> <span></span><span></span></div><div>Recurrent emboliz<span></span>ation and persistent ve<span></span>getation despit<span></span>e antibiotic </div><div>trea<span></span>t-ment. </div><div><span></span><span> </span><span>Class IIb indications</span></div><div> <span></span><span></span></div><div>Mobile vege<span></span>ta<span></span>tions &gt;10mm in diameter<span></span>, even if embolization is absent. </div><div>These vege<span></span>ta<span></span>tions, especially on the mitral v<span></span>alve, have a greater risk of </div><div>emboliza-<span></span>tion. </div><div>Indications f<span></span>or surgery in prosthe<span></span>tic valve endocar<span></span>ditis </div><div> <span></span><span></span></div><div>Class I </div><div><span></span><span> </span><span>Heart f<span></span>ailure, valve dehiscenc<span></span>e (unstable pros<span></span>thesis or perivalvular leak), </span></div><div>evi-dence of increasing v<span></span>alvular obstruction or worsening re<span></span>gurgitation, </div><div>abscess forma<span></span>tion or heart block, or fungal etiology. </div><div> <span></span><span></span></div><div>Class II</div><div><span></span><span> </span><span>Persis<span></span>tent bacter<span></span>emia or recurrent emboli despite antibiotics, or </span></div><div>relapsing in-fection. </div><div>Surgical Pr<span></span>ocedures</div><div> <span></span><span></span></div><div>Removal of all inf<span></span>ected valve tissue, dr<span></span>ainage and debridement of abscess </div><div>cavities.</div><div> <span></span><span></span></div><div>Aortic valve replac<span></span>ement<span></span>, mitr<span></span>al valve replacement.</div><div> <span></span><span></span></div><div>T<span></span>ricuspid valve rep<span></span>air is recommended f<span></span>or tricuspid endocarditis, and should </div><div>be aggressively at<span></span>tempted especially in IV drug abusers who are mor<span></span>e prone </div><div>to rein-f<span></span>ection if a valve r<span></span>eplacement is performed. </div><div>Pos<span></span>t op consider<span></span>ations</div><div> <span></span><span></span></div><div>If intra-oper<span></span>ative cultures are positive, 6 weeks of post<span></span>-operative antibio<span></span>tic </div><div>trea<span></span>t-ment is recommended. </div><div> </div><div>Referenc<span></span>e:</div><div>Bojar<span></span>, Robert, M., (2011) Manual of Periopera<span></span>tive Care in Adult Cardiac Surgery. (5th edition). </div><div>MYOCARDIAL BRIDGE</div><div>P<span></span>athology:</div><div> <span></span><span></span></div><div>Myocardial muscle bride overlying c<span></span>oronar<span></span>y artery. Most are clinic<span></span>ally </div><div></div><div> <span></span><span></span></div><div>Severe bridging of the major coronary arteries can produc<span></span>e myocardial </div><div>ischemia/<span></span>inf<span></span>arction, coronary thrombosis, and pre dispose the patient t<span></span>o </div><div>atheroscler<span></span>osis or sudden cardiac de<span></span>ath. </div><div> <span></span><span></span></div><div>As the muscle bridge contrac<span></span>ts, it can cause hypo perfusion of the underlying </div><div>myocardium due t<span></span>o a buckling in the artery giving the patients angina</div></div><div></div></div>
<div><div><img><div>30<span> </span><span>Disease Proc<span></span>esses &amp; Surgical Procedur<span></span>es<span> </span>Disease Processes &amp; Sur<span></span>gical Procedures<span> </span><span>31</span></span></div><div>Clinical Manifes<span></span>tations:</div><div> <span></span><span></span></div><div> The most typical symp<span></span>toms are chest p<span></span>ain, dyspnea, and dizziness, but can </div><div>be any typical or atypic<span></span>al angina. </div><div>Physical E<span></span>xam:</div><div> <span></span><span></span></div><div><span></span></div><div>Diagnostic s<span></span>tudies: <span> <span>Most commonly diagnosed by cardiac c<span></span>atherization. </span></span></div><div>Cardiac ca<span></span>th:<span> compression of a segment of cor<span></span>onar<span></span>y arter<span></span>y during sys<span></span>tole </span></div><div>resulting in narrowing tha<span></span>t reverses during diastole </div><div>EKG: <span>usually normal    </span></div><div>Echo:<span> demonstr<span></span>ates sept<span></span>al buckling and apical sparing </span></div><div>CT angiogr<span></span>am:<span><span></span><span></span></span></div><div>Angiogram with FFR and Ivus: <span>t<span></span>o document and further map the length and </span></div><div><span></span><span> </span></div><div> </div><div>Example 1: Bridge during diastole<span> <span> </span></span>Example 2: Bridge during systole </div><div>Management:</div><div> <span></span><span></span></div><div>Prior to surg<span></span>er<span></span>y<span></span>, patients should be trialed on bet<span></span>a blockers and/<span></span>or non </div><div>dihydropyridine calcium channel block<span></span>ers (ie. diltiazem, ver<span></span>apamil)</div><div> <span></span><span></span></div><div>Nitra<span></span>tes may exac<span></span>erbate sympt<span></span>oms and are contraindic<span></span>ated </div><div>Indications f<span></span>or surgery</div><div> <span></span><span></span></div><div>Surgical ther<span></span>apy for those with persistent symp<span></span>toms in whom ischemic </div><div>changes are pr<span></span>oven, and for those with a high risk marker (such as lif<span></span>e </div><div>threa<span></span>tening ventricular arrhythmias, myocardial infar<span></span>ction)</div><div> <span></span><span></span></div><div>T<span></span>rial of medical therapy has f<span></span>ailed</div><div>Surgical pr<span></span>ocedure: </div><div> <span></span><span></span></div><div>Myocardial bridg<span></span>e <span></span>  (supr<span></span>a-arterial myot<span></span>omy): The muscle bridge </div><div>is divided directly over the c<span></span>oronar<span></span>y artery.  The surgery can be done either </div><div><span></span><span></span></div><div><span></span><span></span><span></span><span></span></div><div>st<span></span>and-by. </div><div>Pos<span></span>t-oper<span></span>ative manag<span></span>ement<span></span>: </div><div> <span></span><span></span></div><div>P<span></span>ain control: </div><div><span></span><span> </span><span>Pre-opera<span></span>tive placement of p<span></span>aravert<span></span>ebral ner<span></span>ve blocks. </span></div><div> <span></span><span></span></div><div>Placed day prior to sur<span></span>ger<span></span>y as outpatient pr<span></span>ocedure by pain service. </div><div> <span></span><span></span></div><div>Pos<span></span>t operatively pa<span></span>tient will receive continuous infusion of </div><div>bupivacaine + q6 hour boluses. </div><div> <span></span><span></span></div><div>Avoid OnQ pump or lidocaine infusion for p<span></span>atients with paravert<span></span>ebral </div><div>block</div><div> <span></span><span></span></div><div>P<span></span>aravertebr<span></span>al block discontinued day before discharg<span></span>e to ensure </div><div>adequate p<span></span>ain control with oral medic<span></span>ations</div><div> <span></span><span></span></div><div>Otherwise, standard pos<span></span>t cardiac surgery management</div><div>Referenc<span></span>es</div><div>Sorajja, P<span></span>., Iskandrian, A.E. (2016). Myocardial bridge of the c<span></span>oronar<span></span>y arteries. Up to da<span></span>te. </div><div>C<span></span>ONSTRIC<span></span>TIVE PERICARDITIS</div><div>Constrictive peric<span></span>arditis results from scarring of the peric<span></span>ardial sac leading to </div><div><span></span></div><div>Etiology/P<span></span>athophysiology </div><div> <span></span><span></span></div><div>Idiopathic or vir<span></span>al </div><div> <span></span><span></span></div><div>Pos<span></span>t-cardiac sur<span></span>gery </div><div> <span></span><span></span></div><div>Pos<span></span>t-radia<span></span>tion therapy </div><div> <span></span><span></span></div><div>Connective tissue disorder </div><div> <span></span><span></span></div><div>Pos<span></span>t-infectious (tuber<span></span>culous or purulent pericarditis) </div><div> <span></span><span></span></div><div>Miscellaneous causes (malignancy<span></span>, trauma, drug-induced, asbes<span></span>tosis, </div><div>sarcoidosis, ur<span></span>emic pericarditis)</div><div>Clinical manifes<span></span>tations</div><div> <span></span><span></span></div><div><span></span><span></span></div><div> <span></span><span></span></div><div>Symptoms r<span></span>elated to low cardiac output: dyspnea on exertion, f<span></span>atigue</div><div>Physical E<span></span>xam</div><div> <span></span><span></span></div><div>Elevated JVP</div><div> <span></span><span></span></div><div>Pulsus par<span></span>adoxus, Kussmaul’<span></span>s sign, pericardial knock, pericardial friction rub<span></span>, </div><div>edema, ascites, and/<span></span>or cachexia </div><div>Diagnosis</div><div> <span></span><span></span></div><div></div><div> <span></span><span></span></div><div>Echocardiogr<span></span>am/CT<span></span>scan gold st<span></span>andard</div><div>Opera<span></span>tive Proc<span></span>edures: P<span></span>ericardiectomy</div><div> <span></span><span></span></div><div><span></span></div><div> <span></span><span></span></div><div>As much of the thickened pericardium is removed as possible  </div><div>(“pericardial s<span></span>tripping”)</div><div> <span></span><span></span></div><div></div><div><span></span><span> </span><span>Prior radia<span></span>tion is associated with poor<span></span>er post<span></span>-operative outc<span></span>omes</span></div><div>Pos<span></span>t-op Manag<span></span>ement</div><div> <span></span><span></span></div><div><span></span><span></span><span></span></div><div>surfac<span></span>es</div><div> <span></span><span></span></div><div>May have low cardiac output and requir<span></span>e inotropic support due to:</div><div><span></span><span> </span><span>myocardial c<span></span>ontractile dysfunction </span></div><div><span></span><span> </span><span>longst<span></span>anding, irreversible ventricular remodeling </span></div><div> <span></span><span></span></div><div><span></span><span></span></div><div>present prior to sur<span></span>gery</div><div>Referenc<span></span>es</div><div>Bojar<span></span>, Robert M. (2011) Manual of Perioper<span></span>ative Care in Adult Cardiac Surgery. (5th edition). </div></div><div></div></div>
<div><div><img><div>32<span> </span><span>Disease Proc<span></span>esses &amp; Surgical Procedur<span></span>es<span> </span>Disease Processes &amp; Sur<span></span>gical Procedures<span> </span><span>33</span></span></div><div>ADV<span></span>ANCED HEART F<span></span>AIL<span></span>URE:  </div><div>VENTRICUL<span></span>AR ASSIS<span></span>T DEVICE (VAD)</div><div>Le V<span></span>entricular A<span></span>ssist Devic<span></span>e (L<span></span>VAD)</div><div> <span></span><span></span></div><div>Provides car<span></span>diac support and <span>o loading</span> of the L<span></span>V for patient<span></span>s with </div><div>advanc<span></span>ed heart failure (acut<span></span>e or chronic). Can be used for bridge to </div><div>rec<span></span>over<span></span>y<span></span>, bridge-<span></span>to-tr<span></span>ansplant or destina<span></span>tion therapy<span> </span></div><div> <span></span><span></span></div><div>These two are the most c<span></span>ommon L<span></span>VADs implanted. Mos<span></span>t VAD systems c<span></span>ontain </div><div>driveline/percut<span></span>aneous lead, ex<span></span>ternal controller and ex<span></span>ternal ba<span></span>ttery/power </div><div>source </div><div>Thora<span></span>tec HeartMat<span></span>e 2 (HM2)<span> </span>HeartW<span></span>are Ventricular Assist Device </div><div>(HW<span></span>, HVAD)</div><div> <span></span><span></span></div><div><span></span><span></span></div><div><span></span></div><div> <span></span><span></span></div><div><span></span></div><div>of L<span></span>V to Axial pump. Blood is then </div><div>propelled to asc<span></span>ending aorta </div><div></div><div> <span></span><span></span></div><div>Flow: 3 to 10 L/min </div><div> <span></span><span></span></div><div>Speed: 6000 -15000 RPM, 200 RPM </div><div>adjustment int<span></span>er<span></span>v<span></span>al </div><div> <span></span><span></span></div><div>Flow estima<span></span>tion is by pump speed </div><div>and power</div><div> <span></span><span></span></div><div>Pulsatility index (PI): the magnitude </div><div></div><div>pump relating t<span></span>o degree of </div><div>contr<span></span>actility during cardiac cycle </div><div>over intervals of 15 seconds</div><div> <span></span><span></span></div><div>Insertion: Median st<span></span>ernotomy; new </div><div>approach such as c<span></span>ombination </div><div><span></span></div><div>thorac<span></span>otomy</div><div><span></span><span></span></div><div>assist<span></span>-de<span></span>vic<span></span>e/</div><div> <span></span><span></span></div><div><span></span></div><div>Centrifugal Pump direc<span></span>tly sits at </div><div>apex of L<span></span>V and pumps blood to </div><div><span></span></div><div></div><div> <span></span><span></span></div><div>Small, no abdominal pocket </div><div>needed </div><div> <span></span><span></span></div><div>Flow: 2 to 10 L/min  </div><div> <span></span><span></span></div><div>Speed: 1800-4000 RPM, 20 RPM </div><div>adjustment int<span></span>er<span></span>v<span></span>al </div><div> <span></span><span></span></div><div>Flow estima<span></span>tion is by speed, power </div><div>and blood viscosity </div><div> <span></span><span></span></div><div><span></span></div><div></div><div>(delta) </div><div> <span></span><span></span></div><div>Insertion: Median st<span></span>ernotomy; new </div><div><span></span></div><div>or bilater<span></span>al thoracot<span></span>omy</div><div> </div><div>https://www<span></span>.heartware.c<span></span>om/</div><div>products-<span></span>technology</div><div>VAD P<span></span>arame<span></span>ters:</div><div>Speed (optimal)</div><div> <span></span><span></span></div><div>Produces normal CI</div><div> <span></span><span></span></div><div>Allows for normal L<span></span>V size</div><div> <span></span><span></span></div><div><span></span></div><div> <span></span><span></span></div><div>Allows for intermitt<span></span>ent opening of aortic valve (mitigates agains<span></span>t stasis of </div><div>blood in L<span></span>V)</div><div>Power</div><div> <span></span><span></span></div><div>Measured in wa<span></span>tts</div><div> <span></span><span></span></div><div><span></span></div><div> <span></span><span></span></div><div></div><div> <span></span><span></span></div><div>Important to monit<span></span>or trends (rising wat<span></span>ts worrisome for thrombus)</div><div>Flow</div><div> <span></span><span></span></div><div>Calculated, not me<span></span>asured (derived from motor power and speed)</div><div> <span></span><span></span></div><div><span></span></div><div> <span></span><span></span></div><div><span></span></div><div>Pulsatility Index (HM2)/ </div><div>Pulsatility on ow wave </div><div>(HW)</div><div> <span></span><span></span></div><div>Determined by pump speed and the degree of na<span></span>tive LV c<span></span>ontractility</div><div> <span></span><span></span></div><div>Pump speed determines the amount of L<span></span>V unloading (incre<span></span>ased speed, </div><div>increased unloading)</div><div> <span></span><span></span></div><div>As speed increases the PI/pulsatility decreases, as speed decr<span></span>eases the PI/</div><div>pulsatility increases</div><div> <span></span><span></span></div><div><span></span></div><div><span></span><span> </span><span>Increased prelo<span></span>ad = increased PI/pulsatility</span></div><div><span></span><span> </span><span>Decreased prelo<span></span>ad = decreased PI/pulsatility</span></div><div>Pos<span></span>t-op Car<span></span>e Considerations:</div><div>Main tenants o<span></span>f post-oper<span></span>ative car<span></span>e:</div><div> <span></span><span></span></div><div>Adjust speed for op<span></span>timal output (liters per min) and optimal bi-ventricular </div><div>shape, inter<span></span>atrial/inter<span></span>ventricular sept<span></span>al alignment</div><div> <span></span><span></span></div><div>Monitor and trend PI (HM2) or Flow pulsa<span></span>tility (HW)</div><div> <span></span><span></span></div><div>Monitor and trend power </div><div>Right Heart F<span></span>ailure</div><div> <span></span><span></span></div><div>Elevated CVP<span></span>, decreased st<span></span>ep<span></span>-up or P<span></span>API</div><div> <span></span><span></span></div><div><span></span></div><div> <span></span><span></span></div><div><span></span></div><div> <span></span><span></span></div><div>Elevated Lac<span></span>tate, Cr<span></span>, LFT<span></span>s and other end-organ enzymes</div><div> <span></span><span></span></div><div>monitor urine output </div><div> <span></span><span></span></div><div>TTE or TEE </div><div> <span></span><span></span></div><div>consider more ino<span></span>trope, iNO, Flolan; IABP and/or RVAD implant<span></span>ation, consult </div><div>with Cardiac Surg<span></span>er<span></span>y</div><div>Hypovolemia </div><div> <span></span><span></span></div><div>Ensure adequat<span></span>e pre-load</div><div> <span></span><span></span></div><div><span></span><span></span><span></span></div><div> <span></span><span></span></div><div>monitor urine output</div><div> <span></span><span></span></div><div>if suctioning, may turn down VAD speed t<span></span>emporarily<span></span>, consult with ICU </div><div>At<span></span>tending<span></span>/Cardiac Sur<span></span>gery </div><div> <span></span><span></span></div><div>administ<span></span>er volume PRN: may need to slow down bolus r<span></span>ate t<span></span>o protect RV </div><div>from overload</div><div>Blood Pressure</div><div> <span></span><span></span></div><div><span></span><span></span></div><div> <span></span><span></span></div><div>T<span></span>reat with clevidipine, milrinone, NT<span></span>G or SNP</div><div> <span></span><span></span></div><div>However, need t<span></span>o maintain MAP&gt;60 (even &gt;70) for RV and end-organ </div><div>perfusion</div></div><div></div></div>
<div><div><img><div>34<span> </span><span>Disease Proc<span></span>esses &amp; Surgical Procedur<span></span>es<span> </span>Disease Processes &amp; Sur<span></span>gical Procedures<span> </span><span>35</span></span></div><div>Bleeding</div><div> <span></span><span></span></div><div>Check cannulation, inv<span></span>asive procedural sit<span></span>es </div><div> <span></span><span></span></div><div>May need to delay or pause antic<span></span>oagulation, consult with Car<span></span>diac Surger<span></span>y </div><div> <span></span><span></span></div><div>PRN blood products tr<span></span>ansfusion</div><div> <span></span><span></span></div><div>consult with Cardiac Sur<span></span>ger<span></span>y before giving any proc<span></span>oagulant</div><div>Antico<span></span>agulation (when bleeding st<span></span>ops)</div><div> <span></span><span></span></div><div>ASA 81mg daily for HM2, ASA 325mg daily for HW</div><div> <span></span><span></span></div><div>Heparin infusion; if HIT positive, c<span></span>onsider Arga<span></span>troban infusion</div><div> <span></span><span></span></div><div> <span> </span>Titra<span></span>te to PTT g<span></span>oal (usually st<span></span>arts at 40-60, then 60-80), r<span></span>efer to Car<span></span>diac </div><div>Surgery T<span></span>eam  </div><div> <span></span><span></span></div><div>T<span></span>ransition to warf<span></span>arin when stable, adjus<span></span>t for INR goal (usually 2-3)</div><div> <span></span><span></span></div><div>Be cautious if invasive pr<span></span>ocedures are needed </div><div>Thrombosis </div><div> <span></span><span></span></div><div>If thrombus present <span>pre-pump<span><span></span></span></span></div><div> <span></span><span></span></div><div>If thrombus present <span>intr<span></span>a- or post<span></span>-pump<span>: power spikes, increased power and </span></span></div><div></div><div> <span></span><span></span></div><div>May need to incre<span></span>ase PTT or INR goal </div><div> <span></span><span></span></div><div>Consider integr<span></span>elin infusion, tP<span></span>A thrombolysis or VAD exchang<span></span>e, consult with </div><div>Cardiac Surg<span></span>er<span></span>y </div><div>Hemolysis</div><div> <span></span><span></span></div><div>Monitor CBC (with blood smear), c<span></span>oagulation panel, <span>LDH</span>, hap<span></span>toglobin, free </div><div>plasma hemoglobin</div><div> <span></span><span></span></div><div>Check LFT<span></span>s, renal panel, CK</div><div> <span></span><span></span></div><div>May need to incre<span></span>ase PTT or INR goal </div><div> <span></span><span></span></div><div><span></span></div><div>Surgery  </div><div>Referenc<span></span>es</div><div>Bojar<span></span>, R. (2011). Manual of Perioper<span></span>ative Care in Adult Cardiac Surgery.</div><div> </div><div>HEART TR<span></span>ANSPLANT</div><div>General Car<span></span>e Guidelines:</div><div>I.  Hemodynamic P<span></span>aramet<span></span>ers</div><div> <span></span><span></span></div><div>T<span></span>achycardia is normal and preferred</div><div> <span></span><span></span></div><div>Generally MAP<span></span>s&gt;65 and up to 100 (if not bleeding) are acc<span></span>eptable</div><div>II.  Inotr<span></span>opes</div><div> <span></span><span></span></div><div>Almost all p<span></span>atients will arrive on Epinephrine and Dopamine</div><div> <span></span><span></span></div><div>Inotropes ar<span></span>e not to be we<span></span>aned w/out discussion with tr<span></span>ansplant surgeons </div><div><span></span><span></span></div><div> <span></span><span></span></div><div><span></span><span></span></div><div>Clevidipine rather than we<span></span>aning inotropes</div><div>III.  Immunosuppression</div><div>A. Induction Agent<span></span>s: to be managed primarily by tr<span></span>ansplant cardiology team</div><div> <span></span><span></span></div><div>RA<span></span>TG 1mg<span></span>/kg on POD# 1, 2, 3</div><div><span></span><span> </span><span>Requires premedic<span></span>ation with hydrocortisone, diphenhydr<span></span>amine, and </span></div><div>acet<span></span>aminophen</div><div> <span></span><span></span></div><div>Methylprednisolone</div><div><span></span><span> </span><span>500mg IV in OR followed by 125mg q8 x 3</span></div><div>B. Maintenanc<span></span>e Immunosuppression</div><div> <span></span><span></span></div><div>T<span></span>acrolimus (Prograf<span></span>)</div><div><span></span><span> </span><span>St<span></span>arted on POD #1</span></div><div><span></span><span> </span><span>Goal 12-hour trough 10-15</span></div><div> <span></span><span></span></div><div>goal tr<span></span>ough and dosing adjusted for renal dysfunc<span></span>tion</div><div> <span></span><span></span></div><div><span></span></div><div><span></span><span> </span><span>St<span></span>arted on POD #0</span></div><div><span></span><span> </span><span>IV and PO doses equivalent</span></div><div><span></span><span> </span><span>May be held for leukopenia</span></div><div> <span></span><span></span></div><div>Prednisone</div><div><span></span><span> </span><span>St<span></span>arted once induction methylpr<span></span>ednisolone completed</span></div><div>IV<span></span>.  Opportunistic Infection Prophylaxis</div><div> <span></span><span></span></div><div>CMV: dependent on Donor vs. Recipient CMV st<span></span>atus</div><div><span></span><span> </span><span>CMV IGG </span></div><div><span></span><span> </span><span>ganciclovir<span></span>/valganciclovir</span></div><div><span></span><span> </span><span>Acyclovir</span></div><div> <span></span><span></span></div><div>Aspergillus</div><div><span></span><span> </span><span>Inhaled amphotericin</span></div><div><span></span><span> </span><span>Itrac<span></span>onazole</span></div><div> <span></span><span></span></div><div>PCP</div><div><span></span><span> </span><span>Bactrim</span></div><div><span></span><span> </span><span>Atov<span></span>aquone if sulfa allergy</span></div><div>Pos<span></span>t-oper<span></span>ative Care: Critic<span></span>al Concep<span></span>ts</div><div>I.  Right Heart Dysfunction/F<span></span>ailure </div><div>A. Etiology</div><div> <span></span><span></span></div><div>Pre-Exis<span></span>ting pulmonar<span></span>y hypertension</div><div> <span></span><span></span></div><div>Sub-optimal preservation during procurement (pr<span></span>olonged ischemic time)</div><div> <span></span><span></span></div><div>Coronary spasm</div><div> <span></span><span></span></div><div>Air down the coronary arteries</div><div>B. Clinical Manifes<span></span>tations</div><div> <span></span><span></span></div><div>CVP &gt;15 or rising CVP</div><div> <span></span><span></span></div><div>Hypotension</div><div> <span></span><span></span></div><div>CVP tracing suspicious of TR</div><div> <span></span><span></span></div><div>Signs of end organ hypoperfusion</div><div><span></span><span> </span><span>Low UOP</span></div><div><span></span><span> </span><span>Rising crea<span></span>tinine and LFT<span></span>s</span></div><div><span></span><span> </span><span>Rising lact<span></span>ate</span></div><div>C. Diagnositc S<span></span>tudies</div><div> <span></span><span></span></div><div>TTE</div><div><span></span><span> </span><span>T<span></span>ricuspid regurgit<span></span>ation</span></div><div><span></span><span> </span><span>Elevated RVSP</span></div><div><span></span><span> </span><span>Assessment of bi-ventricular function</span></div><div><span></span><span> </span><span>Septum bowing tow<span></span>ards L<span></span>V</span></div><div>D. T<span></span>reatment</div><div> <span></span><span></span></div><div>Management of pa<span></span>tient’<span></span>s volume st<span></span>atus</div><div><span></span><span> </span><span>Aggressive diuresis</span></div><div> <span></span><span></span></div><div>Lasix or Bumex gtt</div></div><div></div></div>
<div><div><img><div>36<span> </span><span>Disease Proc<span></span>esses &amp; Surgical Procedur<span></span>es<span> </span>Disease Processes &amp; Sur<span></span>gical Procedures<span> </span><span>37</span></span></div><div> <span></span><span></span></div><div>Diuril in addition to loop diure<span></span>tic</div><div> <span></span><span></span></div><div>Nesiritide infusion</div><div> <span></span><span></span></div><div>Consider early initiation of CVVH if inadequat<span></span>e  response to diuretics</div><div> <span></span><span></span></div><div>Escalation of ino<span></span>tropic support</div><div><span></span><span> </span><span>Consider increasing HR (Isupr<span></span>el vs. pacing<span></span>)</span></div><div><span></span><span> </span><span>Rest<span></span>art or increase epinephrine</span></div><div><span></span><span> </span><span>Consider milrinone </span></div><div> <span></span><span></span></div><div>Hypotensive or v<span></span>asodilated patient may no<span></span>t be able to tolera<span></span>te</div><div> <span></span><span></span></div><div>Use cautiously in pa<span></span>tients with renal failure</div><div> <span></span><span></span></div><div>Pulmonar<span></span>y v<span></span>asodilatation</div><div><span></span><span> </span><span>Inhaled Nitric Oxide/Flolan</span></div><div><span></span><span> </span><span></span></div><div>II.  Brady<span></span>cardia</div><div> <span></span><span></span></div><div>T<span></span>ransplanted he<span></span>art is dener<span></span>vated ther<span></span>efore the resting he<span></span>art rate should be </div><div>higher</div><div> <span></span><span></span></div><div>F<span></span>ast<span></span>er heart r<span></span>ate allows less time in diastole ther<span></span>eby protecting the R heart </div><div>from over<span></span>-dist<span></span>ention</div><div> <span></span><span></span></div><div><span></span><span></span></div><div> <span></span><span></span></div><div>Monitor HR as inotr<span></span>opes are being weaned. Bradycar<span></span>dia may not become </div><div>evident until then.</div><div> <span></span><span></span></div><div><span></span><span></span></div><div>A. Etiology </div><div> <span></span><span></span></div><div>Mechanical injury to the conduction sys<span></span>tem of the heart</div><div> <span></span><span></span></div><div>Suture line edema</div><div> <span></span><span></span></div><div>Rejection </div><div>B. T<span></span>reatment</div><div> <span></span><span></span></div><div>Isuprot<span></span>erinol</div><div> <span></span><span></span></div><div>Oral theophylline +/- albut<span></span>erol</div><div> <span></span><span></span></div><div>Epicardial p<span></span>acing if available</div><div>III.  Rejection</div><div>Rare in the early pos<span></span>t-<span></span>transplant phase due t<span></span>o induction immunosuppression and </div><div>crossmat<span></span>ching of the donor and recipient</div><div>A. Clinical Manifes<span></span>tations</div><div> <span></span><span></span></div><div>Hypotension, poor c<span></span>ardiac output</div><div> <span></span><span></span></div><div>New S3 or S4</div><div> <span></span><span></span></div><div>Unexplained heart f<span></span>ailure symptoms</div><div>B. Diagnostic S<span></span>tudies</div><div> <span></span><span></span></div><div>TTE</div><div><span></span><span> </span><span>Diminished L<span></span>VEF</span></div><div><span></span><span> </span><span>L<span></span>V thickening</span></div><div> <span></span><span></span></div><div>Endomyocardial Biopsy</div><div><span></span><span> </span><span>Normally done weekly beginning 14 days post<span></span>-tr<span></span>ansplant</span></div><div><span></span><span> </span><span>Can be done earlier if high index of suspicion for r<span></span>ejection</span></div><div>IV<span></span>.  Primar<span></span>y Gr<span></span>a Dysfunction</div><div> <span></span><span></span></div><div><span></span><span></span><span></span></div><div>of transplant and is no<span></span>t associated with a diagnosable cause . PGD is a </div><div>diagnosis of exclusion. </div><div> <span></span><span></span></div><div>Unclear etiology, the f<span></span>ollowing may contribute to the development of PGD: </div><div>existing donor he<span></span>art disease, injur<span></span>y to the donor heart during br<span></span>ain death, </div><div>organ ischemia during r<span></span>ecover<span></span>y and reimplant<span></span>ation, or re-perfusion injur<span></span>y</div><div> <span></span><span></span></div><div>Management</div><div><span></span><span> </span><span>High dose inotropy</span></div><div><span></span><span> </span><span>Addition of IABP</span></div><div><span></span><span> </span><span>ECMO if the above trea<span></span>tments fail </span></div><div>Referenc<span></span>es</div><div>Bojar<span></span>, R. (2011). Manual of Perioper<span></span>ative Care in Adult Cardiac Surgery.</div><div><span></span><span></span></div><div>EX<span></span>TRAC<span></span>ORPOREAL MEMBRANE  </div><div>O<span></span>XYGENA<span></span>TION (ECMO)</div><div>Veno-Art<span></span>erial ECMO</div><div>Provides cardiopulmonary support (end-organ perfusion, ventilation/</div><div>oxygenation and po<span></span>tentially <span></span> L<span></span>V depends on cannulation sites) for </div><div>patient<span></span>s with se<span></span>vere acut<span></span>e cardiogenic shock.</div><div>Peripher<span></span>al Cannulation Str<span></span>ate<span></span>gies<span> </span>Central Cannulation S<span></span>tra<span></span>tegies</div><div> <span></span><span></span></div><div>Peripher<span></span>al cannulated VA ECMO </div><div>mostly provides end-or<span></span>gan </div><div>perfusion and oxygenation </div><div> <span></span><span></span></div><div><span></span></div><div><span></span><span></span></div><div> <span></span><span></span></div><div><span></span><span></span><span></span></div><div>artery (B)</div><div> <span></span><span></span></div><div><span></span><span></span></div><div>femor<span></span>al artery</div><div> <span></span><span></span></div><div></div><div>artery</div><div> <span></span><span></span></div><div>Central c<span></span>annulated V<span></span>A ECMO can </div><div><span></span></div><div>in addition to providing end-or<span></span>gan </div><div>perfusion and oxygenation</div><div> <span></span><span></span></div><div><span></span></div><div><span></span></div><div> <span></span><span></span></div><div><span></span></div><div> <span></span><span></span></div><div><span></span></div><div> </div><div>Po<span></span>tential Complica<span></span>tions</div><div> <span></span><span></span></div><div>Hemorrhage due to sys<span></span>temic anticoagula<span></span>tion </div><div> <span></span><span></span></div><div>Local V<span></span>ascular Injur<span></span>y from cannulation</div><div> <span></span><span></span></div><div>Local bleeding<span></span>/hemat<span></span>oma</div><div> <span></span><span></span></div><div>Str<span></span>oke </div><div> <span></span><span></span></div><div>PE</div><div> <span></span><span></span></div><div>Dist<span></span>al Embolization</div><div> <span></span><span></span></div><div>Infection</div><div>Pos<span></span>t-op Car<span></span>e Considerations:</div><div>General Consider<span></span>ations:</div><div> <span></span><span></span></div><div>Adjust speed for blood ow/<span></span>desired cardiac output (liter<span></span>s per min)</div><div> <span></span><span></span></div><div>Adjust sweep rate for C<span></span>O2 removal (liters per min)</div></div><div></div></div>
<div><div><img><div>38<span> </span><span>Disease Proc<span></span>esses &amp; Surgical Procedur<span></span>es<span> </span>Disease Processes &amp; Sur<span></span>gical Procedures<span> </span><span>39</span></span></div><div> <span></span><span></span></div><div>Keep negative venous drainage pressures (p<span></span>Vein) 0 to -100</div><div> <span></span><span></span></div><div>Know Pre and Post o<span></span>xygenator pressures and their trends</div><div><span></span><span> </span><span>“Delta P” = Pre o<span></span>xygenator pressur<span></span>e – Post o<span></span>xygenator pressure</span></div><div><span></span><span> </span><span>Increase Delta P c<span></span>ould mean thrombus within oxygenator</span></div><div><span></span><span> </span><span>Increase in Pre and P<span></span>ost oxygenator pressures may be indic<span></span>ative of </span></div><div>increased resistanc<span></span>e distal to oxygenator (thr<span></span>ombus or kink in cannula)</div><div> <span></span><span></span></div><div>Can control t<span></span>emperature circuit (heat exchanger)</div><div> </div><div>Hypovolemia </div><div> <span></span><span></span></div><div>Ensure adequat<span></span>e pre-load</div><div> <span></span><span></span></div><div><span></span><span></span><span></span><span></span><span></span><span></span></div><div> <span></span><span></span></div><div><span></span><span></span><span></span></div><div>Cardiac Surg<span></span>er<span></span>y </div><div> <span></span><span></span></div><div>administ<span></span>er volume PRN</div><div>HTN</div><div> <span></span><span></span></div><div><span></span><span></span><span></span></div><div>function </div><div> <span></span><span></span></div><div>T<span></span>reat with clevedipine, NT<span></span>G or SNP</div><div>Antico<span></span>agulation</div><div> <span></span><span></span></div><div>consider ASA 81mg daily </div><div> <span></span><span></span></div><div>Heparin infusion; if HIT positive, c<span></span>onsider Arga<span></span>troban infusion</div><div><span></span><span> </span><span>Titra<span></span>te to P<span></span>TT or ACT g<span></span>oal (typically A<span></span>CT goal 140-160), ref<span></span>er to Cardiac </span></div><div>Surgery T<span></span>eam</div><div><span></span><span> </span><span><span></span><span></span><span></span></span></div><div>formation in the cir<span></span>cuit  </div><div> <span></span><span></span></div><div>Be cautious if invasive pr<span></span>ocedures are needed </div><div> <span></span><span></span></div><div>Inspect for clo<span></span>ts in circuit, oxygenat<span></span>or and pump</div><div>Bleeding</div><div> <span></span><span></span></div><div>Check cannulation, inv<span></span>asive procedural sit<span></span>es </div><div> <span></span><span></span></div><div>May need to pause antic<span></span>oagulation, consult with Car<span></span>diac Surger<span></span>y </div><div> <span></span><span></span></div><div>PRN blood products tr<span></span>ansfusion</div><div> <span></span><span></span></div><div>Consult with Cardiac Surg<span></span>er<span></span>y befor<span></span>e give any procoagulant</div><div><span></span><span> </span><span>Feiba c<span></span>an be given by the perfusionist post<span></span>-oxygenator</span></div><div>Hypox<span></span>emia</div><div> <span></span><span></span></div><div><span></span></div><div> <span></span><span></span></div><div>Inspect for clo<span></span>ts in oxygena<span></span>tor </div><div> <span></span><span></span></div><div>T<span></span>rend Pre and P<span></span>ost o<span></span>xygenator pr<span></span>essures</div><div> <span></span><span></span></div><div>Maintain adequa<span></span>te Hgb for O2 carr<span></span>ying cap<span></span>acity</div><div>Hemolysis</div><div> <span></span><span></span></div><div>Monitor CBCs, co<span></span>agulation panels, LDH, haptoglobin, F<span></span>ree plasma </div><div>hemoglobin </div><div> <span></span><span></span></div><div>Check LFT<span></span>s, renal panels, CK </div><div> <span></span><span></span></div><div>May need to incre<span></span>ase PTT or AC<span></span>T goal </div><div> <span></span><span></span></div><div><span></span></div><div>Surgery  </div><div>Veno-<span></span>Venous ECMO</div><div>It only provides pulmonary support (oxyg<span></span>enation) for pa<span></span>tients with severe </div><div>respir<span></span>atory failure (ARDS, end-s<span></span>tage lung disease bridg<span></span>e to transplant, acut<span></span>e </div><div>lung injury by H1N1 etc). <span>It does NO<span></span>T contribute t<span></span>o any cardiac output.<span> </span></span></div><div>Peripher<span></span>al cannulation s<span></span>tra<span></span>tegies:</div><div> <span></span><span></span></div><div>Internal jugular – femor<span></span>al vein</div><div> <span></span><span></span></div><div>Internal jugular only (Dual lumen ca<span></span>theter<span></span>, Avalon, Pro<span></span>tek Duo)</div><div> <span></span><span></span></div><div>Femor<span></span>al -femor<span></span>al (uncommon)</div><div>Po<span></span>tential Complica<span></span>tions</div><div> <span></span><span></span></div><div>Hemorrhage due to sys<span></span>temic anticoagula<span></span>tion </div><div> <span></span><span></span></div><div>Local V<span></span>ascular Injur<span></span>y</div><div> <span></span><span></span></div><div>Local bleeding<span></span>/hemat<span></span>oma</div><div> <span></span><span></span></div><div>PE</div><div> <span></span><span></span></div><div>Dist<span></span>al Embolization</div><div> <span></span><span></span></div><div>Infection</div><div> <span></span><span></span></div><div>Str<span></span>oke</div><div>Pos<span></span>t-op Car<span></span>e/Considera<span></span>tions:</div><div>General Consider<span></span>ations</div><div> <span></span><span></span></div><div>Adjust speed/ow for blood ow (liters per min)</div><div> <span></span><span></span></div><div>Adjust sweep rate for C<span></span>O2 removal (liters per min)</div><div> <span></span><span></span></div><div>Keep negative venous drainage pressures 0 t<span></span>o -100</div><div><span></span><span> </span><span>Patient neck/head position c<span></span>an greatly aect negative venous pressure </span></div><div>and ow</div><div> <span></span><span></span></div><div>Know Pre and Post o<span></span>xygenator pressures and their trends</div><div><span></span><span> </span><span>“Delta P” = Pre o<span></span>xygenator pressur<span></span>e – Post o<span></span>xygenator pressure</span></div><div><span></span><span> </span><span>Increase Delta P c<span></span>ould mean thrombus within oxygenator</span></div><div><span></span><span> </span><span>Increase in Pre and P<span></span>ost oxygenator pressures may be indic<span></span>ative of </span></div><div>increased resistanc<span></span>e distal to oxygenator (thr<span></span>ombus or kink in cannula)</div><div> <span></span><span></span></div><div>Can control t<span></span>emperature through circuit (heat ex<span></span>changer)</div><div>Hypox<span></span>emia</div><div> <span></span><span></span></div><div><span></span></div><div> <span></span><span></span></div><div>Inspect for clo<span></span>ts in oxygena<span></span>tor </div><div> <span></span><span></span></div><div>T<span></span>rend Pre and P<span></span>ost o<span></span>xygenator pr<span></span>essures</div><div>Hypovolemia </div><div> <span></span><span></span></div><div>Ensure adequat<span></span>e pre-load</div></div><div></div></div>
<div><div><img><div>40<span> </span><span>Disease Proc<span></span>esses &amp; Surgical Procedur<span></span>es<span> </span>Disease Processes &amp; Sur<span></span>gical Procedures<span> </span><span>41</span></span></div><div> <span></span><span></span></div><div><span></span><span></span><span></span></div><div> <span></span><span></span></div><div><span></span><span></span><span></span></div><div>Cardiac Surg<span></span>er<span></span>y </div><div> <span></span><span></span></div><div><span></span></div><div>Avalon cannula</div><div>Bleeding</div><div> <span></span><span></span></div><div>Check cannulation, inv<span></span>asive procedural sit<span></span>es </div><div> <span></span><span></span></div><div>May need to pause antic<span></span>oagulation, consult with Car<span></span>diac Surger<span></span>y </div><div> <span></span><span></span></div><div>PRN blood products tr<span></span>ansfusion</div><div> <span></span><span></span></div><div>Consult with Cardiac Surg<span></span>er<span></span>y befor<span></span>e giving any procoagulant</div><div><span></span><span> </span><span>Feiba c<span></span>an be administered by perfusionis<span></span>t post-oxygena<span></span>tor</span></div><div>Hemolysis</div><div> <span></span><span></span></div><div>Monitor CBCs, co<span></span>agulation panels, LDH, haptoglobin, F<span></span>ree plasma </div><div>hemoglobin</div><div> <span></span><span></span></div><div>Check LFT<span></span>s, renal panels, CK </div><div> <span></span><span></span></div><div>May need to incre<span></span>ase PTT or AC<span></span>T goal </div><div> <span></span><span></span></div><div><span></span></div><div>Surgery  </div><div>Antico<span></span>agulation</div><div> <span></span><span></span></div><div>consider ASA 81mg daily </div><div> <span></span><span></span></div><div>Heparin infusion; if HIT positive, c<span></span>onsider Arga<span></span>troban infusion titra<span></span>te to P<span></span>TT </div><div>or AC<span></span>T goal, r<span></span>efer to Cardiac Surgery T<span></span>eam  </div><div> <span></span><span></span></div><div>Be cautious if invasive pr<span></span>ocedures are needed </div><div> <span></span><span></span></div><div>Inspect for clo<span></span>ts in circuit, oxygenat<span></span>or and pump</div><div> </div><div>Referenc<span></span>es</div><div>Cont Education Anes<span></span>thesia Critical Care &amp; P<span></span>ain (2012). Oxford University Pr<span></span>ess</div><div> </div><div>L<span></span>UNG TRANSPLANT</div><div>Fluid and Hemodynamic Management</div><div> <span></span><span></span></div><div><span></span><span></span><span></span><span></span><span></span><span></span><span></span><span></span><span></span><span></span><span></span><span></span><span></span><span></span><span></span><span></span></div><div>whic<span></span>h are<span></span> susc<span></span>eptib<span></span>le to<span></span> pulmo<span></span>nar<span></span>y <span></span>edema <span></span>as a r<span></span>esult <span></span>of dis<span></span>rupti<span></span>on to<span></span> the </div><div><span></span><span></span><span></span><span></span></div><div> <span></span><span></span></div><div><span></span></div><div> <span></span><span></span></div><div><span></span><span></span></div><div>Monitor indica<span></span>tors of adequat<span></span>e perfusion such as lactate, Sc<span></span>VO2, urine </div><div>output, and mental st<span></span>atus.</div><div><span></span><span> </span><span>A P<span></span>A catheter is helpful t<span></span>o guide therapy</span></div><div><span></span><span> </span><span>If cardiac function is normal, low-dose phenylephrine is pr<span></span>eferred since it </span></div><div><span></span><span></span></div><div>Respir<span></span>atory Management</div><div> <span></span><span></span></div><div>Ventilat<span></span>or </div><div><span></span><span> </span><span>Set initial tidal volume (VT) at 8-10 mL/k<span></span>g</span></div><div><span></span><span> </span><span>Titra<span></span>te FiO2 to achieve a P<span></span>aO2 &gt; 80 mmHg.  Att<span></span>empt to wean FiO2 as </span></div><div>much as possible in order to minimiz<span></span>e oxygen to<span></span>xicity and atelectasis.</div><div><span></span><span> </span><span>Keep peak airway and plate<span></span>au pressures &lt; 30 mmHg. Utilize PEEP for </span></div><div>hypoxia (keep in mind airway anast<span></span>omosis).  </div><div><span></span><span> </span><span><span></span><span></span></span></div><div><span></span><span> </span><span>E<span></span>xtremely Import<span></span>ant: Monitor native lung hyperina<span></span>tion in patient’<span></span>s </span></div><div>with single lung transplant (e.g. C<span></span>OPD)</div><div> <span></span><span></span></div><div>Respir<span></span>atory care post ex<span></span>tubation</div><div><span></span><span> </span><span>Encour<span></span>age frequent coughing and use of incentive spir<span></span>ometer<span></span>.  The </span></div><div><span></span><span></span></div><div>susceptibility t<span></span>o respiratory infection and aspir<span></span>ation.</div><div><span></span><span> </span><span>St<span></span>art Albuteral and Atr<span></span>ovent for bronchospasms which is common </span></div><div>secondary to reperfusion injur<span></span>y</div><div>P<span></span>ain Control</div><div> <span></span><span></span></div><div>An epidural is pr<span></span>eferred for p<span></span>ain (e.g. thoraco<span></span>tomy or clamshell)</div><div> <span></span><span></span></div><div>Avoid medications tha<span></span>t are sedating or c<span></span>ause respir<span></span>atory depression</div><div>Bleeding</div><div> <span></span><span></span></div><div>Monitor ches<span></span>t output (Call surgeons/pulmonologis<span></span>t if output &gt; 200 cc/h x 2 h) </div><div> <span></span><span></span></div><div>Correct c<span></span>oagulopathy</div><div><span></span><span> </span><span>Consider blood products f<span></span>or Hgb &lt; 7, platelet count &lt; 100, INR &gt; 1.5 </span></div><div> <span></span><span></span></div><div>Keep chest tubes s<span></span>tripped</div><div>Immunosuppresion</div><div> <span></span><span></span></div><div>Induction ther<span></span>apy </div><div><span></span><span> </span><span><span></span><span></span></span></div><div> <span></span><span></span></div><div>Maintenance ther<span></span>apy </div><div><span></span><span> </span><span>Methylprednisone</span></div><div> <span></span><span></span></div><div>In OR - Methylprednisolone 500 mg x1 per lung (i.<span></span>e. for double lung </div><div>transplant, administ<span></span>er 1000 mg IV x1)</div><div> <span></span><span></span></div><div>POD #0 - Methylprednisolone 125 mg IV Q8H x 3 </div><div> <span></span><span></span></div><div>POD #1 - St<span></span>art Prednisone 0.5mg<span></span>/kg BID on </div><div><span></span><span> </span><span>Cellcept (myc<span></span>ophenolate mofetil)</span></div><div> <span></span><span></span></div><div><span></span><span></span><span></span><span></span><span></span><span></span><span></span><span></span><span></span><span></span><span></span><span></span><span></span><span></span><span></span><span></span><span></span><span></span><span></span><span></span><span></span><span></span><span></span><span></span><span></span><span></span><span></span></div><div> <span></span><span></span></div><div>Star<span></span>t Tacro<span></span>li<span></span>mus<span></span> 0<span></span>.5<span></span> mg<span></span> BI<span></span>D <span></span>(A<span></span>dju<span></span>st <span></span>by <span></span>12<span></span>-ho<span></span>ur<span></span> tr<span></span>oug<span></span>h <span></span>le<span></span>ve<span></span>ls)<span></span> o<span></span>n P<span></span>OD<span></span> # <span></span>1.</div><div> <span></span><span></span></div><div>  Goal trough 12-15-ng<span></span>/ml</div><div>Infection Pr<span></span>ophylaxis</div><div> <span></span><span></span></div><div>Bacterial </div><div><span></span><span> </span><span>Vanc<span></span>omycin1 gm. IV Q12H.  Adjust dose t<span></span>o goal tr<span></span>ough le<span></span>vels 15-20</span></div><div><span></span><span> </span><span>Cefepime 1000 mg IV Q8H</span></div><div> <span></span><span></span></div><div>PCP (choose one)</div><div><span></span><span> </span><span>Bactrim DS Q MWF  (1st choic<span></span>e therapy)</span></div><div><span></span><span> </span><span>Dapsone 100 mg PO QD </span></div><div><span></span><span> </span><span>Pent<span></span>amidine inhaled 300 mg Q month via nebulizer<span></span>.  Need to use with </span></div><div><span></span></div><div><span></span><span> </span><span>Mepron (At<span></span>ovaquone) 1500 mg PO QD</span></div><div> <span></span><span></span></div><div>Fungal</div><div><span></span><span> </span><span>St<span></span>art Itraconazole 100 mg PO BID on POD #2-3</span></div><div><span></span><span> </span><span>Inhaled Amphotericin B 20 mg BID via nebuliz<span></span>er (as inpatient only).  Need </span></div><div><span></span><span></span></div><div> <span></span><span></span></div><div>CMV</div><div><span></span><span> </span><span>Donor CMV (-) / Recipient CMV (-)</span></div><div> <span></span><span></span></div><div>Acyclovir 200 mg PO BID </div><div><span></span><span> </span><span>Donor CMV (+) / Recipient CMV (-)</span></div><div> <span></span><span></span></div><div>Cytog<span></span>am 150 mg<span></span>/kg PO.  T<span></span>aper cytogam to 100 mg<span></span>/kg on POD #14</div><div> <span></span><span></span></div><div>POD #1 - DHPG / Ganciclovir (if unable to toler<span></span>ate PO meds) 5 mg<span></span>/kg </div><div>BID</div><div> <span></span><span></span></div><div>Change to V<span></span>alc<span></span>yte if t<span></span>aking orals</div></div><div></div></div>
<div><div><img><div>42<span> </span><span>Disease Proc<span></span>esses &amp; Surgical Procedur<span></span>es<span> </span>Disease Processes &amp; Sur<span></span>gical Procedures<span> </span><span>43</span></span></div><div> <span></span><span></span></div><div>Valcyte 900 mg PO BID x 14 days then 900 mg QD through 6 months </div><div><span></span></div><div><span></span><span> </span><span>Donor CMV (+ or -) / Recipient CMV (+)</span></div><div> <span></span><span></span></div><div>POD #1 - DHPG / Ganciclovir (if unable to toler<span></span>ate PO meds) 5 mg<span></span>/kg BID</div><div> <span></span><span></span></div><div>Change to V<span></span>alc<span></span>yte if t<span></span>aking orals</div><div> <span></span><span></span></div><div>Valcyte 900 mg PO BID x 14 days then 900 mg QD through 6 months </div><div><span></span><span></span></div><div> <span></span><span></span></div><div>Oral Candida Albic<span></span>ans (choose one)</div><div><span></span><span> </span><span><span></span></span></div><div><span></span><span> </span><span>Nyst<span></span>atin 5 ml, swish and swallow, TID</span></div><div> <span></span><span></span></div><div>T<span></span>oxoplasmosis</div><div><span></span><span> </span><span>Donor (+) / Recipient (-) and not on Bac<span></span>trim</span></div><div> <span></span><span></span></div><div>Pyrimethamine 25 mg QD for 6 weeks</div><div> <span></span><span></span></div><div>Folinic Acid 10 mg QD for 6 weeks</div><div>Pos<span></span>toper<span></span>ative Complica<span></span>tions in Lung T<span></span>ransplant</div><div> <span></span><span></span></div><div><span></span><span></span></div><div><span></span><span> </span><span></span></div><div> <span></span><span></span></div><div><span></span><span></span></div><div><span></span><span></span></div><div><span></span><span></span><span></span></div><div><span></span><span></span><span></span></div><div>transplant<span></span>ation.</div><div><span></span><span> </span><span>Risk F<span></span>actors</span></div><div> <span></span><span></span></div><div>Lung injury related to org<span></span>an procurement, stor<span></span>age, and reperfusion</div><div> <span></span><span></span></div><div>Donor charac<span></span>teris<span></span>tics include female, African-Americ<span></span>an race, age &gt; 45</div><div> <span></span><span></span></div><div>Recipient char<span></span>acteris<span></span>tics include preexisting pulmonary HTN and </div><div><span></span></div><div><span></span><span> </span><span>Grade severity</span></div><div> <span></span><span></span></div><div>Grade 0 - P<span></span>aO2/FiO2 &gt;300 and normal chest r<span></span>adiograph</div><div> <span></span><span></span></div><div><span></span><span></span></div><div> <span></span><span></span></div><div>Grade 2 - P<span></span>aO2/FiO2 between 200 and 300</div><div> <span></span><span></span></div><div>Grade 3 - P<span></span>aO2/FiO2 &lt;200</div><div><span></span><span> </span><span>T<span></span>reatment</span></div><div> <span></span><span></span></div><div>T<span></span>reatment is f<span></span>ocused on providing supportive car<span></span>e</div><div> <span></span><span></span></div><div>For hypox<span></span>emia, increase FiO2 and PEEP<span></span>.  </div><div> <span></span><span></span></div><div>Consider increasing seda<span></span>tion to improve ventilator synchrony</div><div> <span></span><span></span></div><div>Avoid neuromuscular blockade (risk for myop<span></span>athy)</div><div> <span></span><span></span></div><div>Inhaled pulmonar<span></span>y v<span></span>asodilators such as iNO and Flolan are used to </div><div>improve ventilation-perfusion misma<span></span>tch and lower mean pulmonary </div><div>artery pressures</div><div> <span></span><span></span></div><div>Use lung prot<span></span>ective ventilation str<span></span>ate<span></span>gies with low tidal volume</div><div> <span></span><span></span></div><div>Diuresis for g<span></span>oal CVP &lt; 5</div><div> <span></span><span></span></div><div>Consider extr<span></span>acorporeal membr<span></span>ane oxygenation (ECMO) for p<span></span>atients </div><div>with severe PGD who do not respond t<span></span>o maximal conventional </div><div>trea<span></span>tment and inhaled pulmonar<span></span>y vasodilators</div><div> <span></span><span></span></div><div></div><div> <span></span><span></span></div><div>Acute Rejec<span></span>tion</div><div><span></span><span> </span><span>Acute cellular r<span></span>ejection</span></div><div> <span></span><span></span></div><div>A1 – Repea<span></span>t biopsy in 4-6 weeks</div><div> <span></span><span></span></div><div>T<span></span>reat b<span></span>ased on clinical symptoms</div><div> <span></span><span></span></div><div>A2-A3</div><div> <span></span><span></span></div><div>Methylprednisone 10 mg<span></span>/kg IV daily x 3d</div><div> <span></span><span></span></div><div>Valvyte 900 mg PO daily x14d</div><div> <span></span><span></span></div><div>Repea<span></span>t biopsy in 4-6 weeks</div><div> <span></span><span></span></div><div>A4</div><div> <span></span><span></span></div><div>Methylprednisone 10 mg<span></span>/kg IV daily x3d</div><div> <span></span><span></span></div><div>Valcyte 900 mg PO daily x14d</div><div> <span></span><span></span></div><div>Prednisone t<span></span>aper dose 1 mg<span></span>/kg over 14d then back to b<span></span>aseline dose</div><div> <span></span><span></span></div><div>Repea<span></span>t biopsy in 4-6 weeks</div><div><span></span><span> </span><span>Acute antibody mediat<span></span>ed rejection (AMR)</span></div><div> <span></span><span></span></div><div>Day 1-5</div><div> <span></span><span></span></div><div>Plasmapheresis daily x5d.  One volume exchang<span></span>e with albumin.  If </div><div><span></span></div><div> <span></span><span></span></div><div>Day 6-7</div><div> <span></span><span></span></div><div>IVIG 1 gm/kg (IBW) x2d.  </div><div> <span></span><span></span></div><div>Premedica<span></span>te with T<span></span>ylenol 650 mg PO and Benadr<span></span>yl 50 mg PO/IV </div><div>with each dose</div><div> <span></span><span></span></div><div>Days 8 &amp; 15</div><div> <span></span><span></span></div><div>Rituximab 375 mg<span></span>/sq meter BSA IV weekly x2 weeks</div><div> <span></span><span></span></div><div>For refr<span></span>actor<span></span>y AMR</div><div> <span></span><span></span></div><div>Consider the following:</div><div> <span></span><span></span></div><div><span></span><span></span></div><div>Rituximab and RA<span></span>TG dose.</div><div> <span></span><span></span></div><div>If patient has worsening AMR, c<span></span>an give 3-5 doses of RAT<span></span>G (1.5mg<span></span>/</div><div>kg<span></span>/<span></span>day) QOD.        </div><div> <span></span><span></span></div><div>Bortezomib IV</div><div> <span></span><span></span></div><div>Photopher<span></span>esis  </div><div>Referenc<span></span>es:</div><div>Moten et al. (2013). P<span></span>ostopera<span></span>tive T<span></span>ransplant in the Critical Care Unit. American Association of Critical </div><div>Care Nurses, 24(4): 345-350. </div><div><span></span><span></span></div><div>Lung T<span></span>ransplant Protoc<span></span>ol        </div></div><div></div></div>
<div><div><img><div>44<span> </span><span>Pos<span></span>t-Op Management<span> </span>Pos<span></span>t-Op Management<span> </span><span>45</span></span></div><div>POS<span></span>T<span></span>-OP:<span> <span>NEUROL<span></span>OGIC:<span> DELIRIUM</span></span></span></div><div> <span></span><span></span></div><div>Represents an acut<span></span>e change in a patient’<span></span>s mental st<span></span>atus that is associated </div><div>with a global impairment in c<span></span>ognitive function</div><div> <span></span><span></span></div><div>Common, incidence 8-10% over<span></span>all (up to 20% in elderly patients)</div><div> <span></span><span></span></div><div>Etiology frequently not cle<span></span>ar</div><div><span></span><span> </span><span>may result from microemboliz<span></span>ation associated with CPB and associa<span></span>ted </span></div><div>aortic manipulations</div><div><span></span><span> </span><span>may result from mild c<span></span>erebral hypo perfusion</span></div><div> <span></span><span></span></div><div><span></span></div><div>Common Contributing Causes:</div><div> <span></span><span></span></div><div>medication t<span></span>oxicity (including benzodiaz<span></span>epines and analgesics_</div><div> <span></span><span></span></div><div>met<span></span>abolic disturb<span></span>ances</div><div> <span></span><span></span></div><div>Prolonged IC<span></span>U st<span></span>ay</div><div> <span></span><span></span></div><div>alcohol withdr<span></span>awal</div><div> <span></span><span></span></div><div>low cardiac output syndromes</div><div> <span></span><span></span></div><div><span></span><span></span></div><div>threshold for c<span></span>erebral infar<span></span>ction</div><div> <span></span><span></span></div><div>hypoxia</div><div> <span></span><span></span></div><div>sepsis</div><div> <span></span><span></span></div><div>recent/new strok<span></span>e</div><div>Manifes<span></span>tations:</div><div> <span></span><span></span></div><div><span></span></div><div>wake cycle</div><div> <span></span><span></span></div><div>lethargy or agita<span></span>tion</div><div> <span></span><span></span></div><div>par<span></span>anoia and hallucinations</div><div>Ev<span></span>aluation:</div><div> <span></span><span></span></div><div>Consider psych consult for severe delirium </div><div> <span></span><span></span></div><div>review of current medications and drug levels</div><div> <span></span><span></span></div><div>identify possible hist<span></span>or<span></span>y of rec<span></span>ent alcoholism or subst<span></span>ance abuse</div><div> <span></span><span></span></div><div><span></span><span></span><span></span><span></span></div><div> <span></span><span></span></div><div>ABG, electrolyt<span></span>es, BUN, crea<span></span>tinine, CBC, Mg, calcium, cultures</div><div>Management:</div><div> <span></span><span></span></div><div><span></span></div><div> <span></span><span></span></div><div>correc<span></span>t metabolic abnormalities</div><div> <span></span><span></span></div><div>st<span></span>op inappropriat<span></span>e medications</div><div> <span></span><span></span></div><div>select appropria<span></span>te medica<span></span>tion to contr<span></span>ol agitation in the delirious st<span></span>ate</div><div><span></span><span> </span><span>Haldol 2.5-5mg PO/IV q6h mos<span></span>t commonly prescribed (risk of torsades)</span></div><div> <span></span><span></span></div><div>check daily EKG to ev<span></span>al QTC</div><div> <span></span><span></span></div><div>sometimes makes delirium worse!</div><div><span></span><span> </span><span>Seroquel 12.5-50mg, TID </span></div><div><span></span><span> </span><span>Precedex drip may be needed while in the IC<span></span>U. Consider PO version </span></div><div>(T<span></span>enex) </div><div><span></span><span> </span><span>Zyprex<span></span>a 5-10 mg daily</span></div><div> <span></span><span></span></div><div></div><div> <span></span><span></span></div><div>Use melatonin 3-6 mg qhs t<span></span>o help reorient sleep/wake cycle</div><div> <span></span><span></span></div><div>When in doubt, call psychiatry to aid in management</div><div> <span></span><span></span></div><div>Benzos may exac<span></span>erbate acute delirium and should be used only when </div><div>managing concurrent alc<span></span>ohol withdrawal</div><div> <span></span><span></span></div><div>Manage suspect<span></span>ed alcohol withdr<span></span>awal</div><div><span></span><span> </span><span>Benzos usually indica<span></span>ted for several days then should be gr<span></span>adually </span></div><div>taper<span></span>ed</div><div><span></span><span> </span><span><span></span><span></span><span></span></span></div><div>extub<span></span>ation if self-destructive behavior</div><div><span></span><span> </span><span>Also give thiamine 100 mg bid and folic acid 1 mg daily</span></div><div>Referenc<span></span>es:</div><div>Bojar<span></span>, Robert M. (2011) Manual of Perioper<span></span>ative Care in Adult Cardiac Surgery. (5th  <span></span>edition).</div><div>POS<span></span>T<span></span>-OP:<span> <span>NEUROL<span></span>OGIC:<span> P<span></span>AIN C<span></span>ONTROL</span></span></span></div><div>St<span></span>anding P<span></span>ain medication orders:</div><div>Ace<span></span>taminophen</div><div>Dosing:</div><div> <span></span><span></span></div><div>650 - 1000 mg, oral/r<span></span>ect<span></span>al, ever<span></span>y 6-8 hours (IV T<span></span>ylenol should ne<span></span>ver be used)</div><div><span></span><span> </span><span>Abnormal liver function: 500 mg ever<span></span>y 6 hours</span></div><div>Gabapentin</div><div>Dosing:</div><div> <span></span><span></span></div><div>CrCl &gt; 60: 300 mg, oral, thr<span></span>ee times daily</div><div> <span></span><span></span></div><div>CrCl &gt; 15 but &lt; 60: 100 mg, oral, thr<span></span>ee times daily</div><div> <span></span><span></span></div><div>CrCl &lt; 15 and dialysis: 100 mg, oral, daily</div><div><span></span><span> </span><span>If patient no<span></span>t sedated and having pain, it is re<span></span>asonable to titrate </span></div><div>gabapentin t<span></span>o 600 mg TID or <span>higher</span> over 2-3 days</div><div> <span></span><span></span></div><div>Works well in adjunt with T<span></span>ylenol</div><div> <span></span><span></span></div><div><span></span><span></span><span></span><span></span></div><div>discharge</div><div> <span></span><span></span></div><div><span></span></div><div>PRN P<span></span>ain Medication Orders:  </div><div>(must specify indication mild, moderat<span></span>e, or severe)</div><div>Oxyc<span></span>odone <span> 5-15 mg, oral, ever<span></span>y 3 hours as needed </span></div><div>Hydromorphone <span> 0.2-0.5 mg, intr<span></span>avenous, e<span></span>very 2 hours as needed</span></div><div>T<span></span>ramadol  <span>50 mg q6h prn CrCl &lt;30: avoid use</span></div><div><span></span><span> </span><span>Next s<span></span>tep if Tylenol no<span></span>t enough. Usually best for mild to moder<span></span>ate pain</span></div><div><span></span><span> </span><span><span></span><span></span></span></div><div>Ro<span></span>xicodone <span> 5-15 mg q4h prn</span></div><div><span></span><span> </span><span>Next s<span></span>tep if Tylenol and tr<span></span>amadol not enough for pain. Usually bes<span></span>t for </span></div><div>modera<span></span>te to severe p<span></span>ain. </div><div><span></span><span> </span><span><span></span><span></span><span></span></span></div><div>drowsiness/<span></span>delirium </div><div> <span></span><span></span></div><div>Delirium more prevalent in elderly</div><div>Per<span></span>coc<span></span>et  <span>5/325 mg 1-2 tab PO q4h prn p<span></span>ain</span></div><div><span></span><span> </span><span>Good for severe pain no<span></span>t relieved with roxicodone</span></div><div><span></span><span> </span><span>Do not use if pa<span></span>tient already on st<span></span>anding Tylenol given risk of T<span></span>ylenol </span></div><div>overdose</div></div><div></div></div>
<div><div><img><div>46<span> </span><span>Pos<span></span>t-Op Management<span> </span>Pos<span></span>t-Op Management<span> </span><span>47</span></span></div><div>Dilaudid <span> 2-4 mg PO q4h prn pain, 0.5-1mg IV q3h prn pain, PCA</span></div><div><span></span><span> </span><span>Used if pain not r<span></span>elie<span></span>ved by ro<span></span>xicodone</span></div><div><span></span><span> </span><span>Also grea<span></span>t for acute pain exac<span></span>erbations</span></div><div><span></span><span> </span><span>If require PCA, c<span></span>ontact pain service to help manage </span></div><div>Oxyc<span></span>odone <span>10-20mg PO q12 hours</span></div><div><span></span><span> </span><span>Consider if not achieving adequate PO p<span></span>ain control with short acting </span></div><div>Roxic<span></span>odone</div><div><span></span><span> </span><span>Scheduled q12 intervals. Short acting Roxic<span></span>odone can be taken in </span></div><div>addition for bre<span></span>akthrough pain</div><div>Ibuprofen  <span>400 mg, or<span></span>al, ever<span></span>y 6 hours as needed (Needs surgical te<span></span>am approval)</span></div><div><span></span><span> </span><span>CrCl &gt; 30 but &lt; 60 or age &gt; 65: 200 mg, or<span></span>al, ever<span></span>y 6 hours as needed</span></div><div><span></span><span> </span><span>CrCl &lt;30: avoid use</span></div><div><span></span><span> </span><span>Avoid use with dual antiplatele<span></span>t therapy</span></div><div>Ket<span></span>orolac  <span>15-30 mg, intravenous, ever<span></span>y 6 hours as needed (Needs surgical t<span></span>eam </span></div><div>approval)</div><div><span></span></div><div><span></span><span> </span><span>CrCl &lt;30: avoid use</span></div><div><span></span><span> </span><span>Avoid use with dual antiplatele<span></span>t therapy</span></div><div><span></span><span> </span><span>Only if oral r<span></span>oute unav<span></span>ailable; otherwise give oral pain medica<span></span>tion</span></div><div>IV pain medication IS NO<span></span>T the rst line for patients on the oor<span></span>. Consider increasing </div><div>the dose of oral meds for be<span></span>tter control. The goal is to prepar<span></span>e the patient for </div><div>discharge to home.</div><div>Additional medications y<span></span>ou may see that you can c<span></span>onsider<span></span>:</div><div>Fent<span></span>anyl<span>  25-50mg IV </span></div><div><span></span><span> </span><span>Reserve for severe pain not relieved by roxic<span></span>odone</span></div><div><span></span><span> </span><span>Commonly given prior to ches<span></span>t tube removal f<span></span>or pain prevention, but the </span></div><div>jur<span></span>y is out on whether this is nec<span></span>essar<span></span>y or not!</div><div><span></span><span> </span><span>Caution with this given heavily sedating </span></div><div>Lidocaine infusion  </div><div><span></span><span> </span><span>Commonly st<span></span>arted by ICU team</span></div><div><span></span><span> </span><span>Requires checking daily lidocaine levels</span></div><div><span></span><span> </span><span>Contraindic<span></span>ations:</span></div><div> <span></span><span></span></div><div>First and sec<span></span>ond degree heart block due to risk of worsening he<span></span>art </div><div>block. </div><div><span></span><span> </span><span></span></div><div> <span></span><span></span></div><div><span></span></div><div>numbness and unusual sensations around mouth, me<span></span>tallic t<span></span>aste in </div><div>mouth, ringing in the ears, or lightheadedness and dizziness</div><div> <span></span><span></span></div><div><span></span><span></span></div><div>nausea and vomiting, severe dizziness, decre<span></span>ased hearing, tremors, </div><div>changes in blood pressur<span></span>e and pulse. </div><div> <span></span><span></span></div><div>At serum levels grea<span></span>ter than 12 mcg<span></span>/ml: drowsiness, confusion, </div><div>muscle twitching, convulsions, loss of c<span></span>onsciousness, cardiac </div><div>arrhythmias, cardiac arres<span></span>t</div><div><span></span><span> </span><span><span></span><span></span><span></span></span></div><div>Ket<span></span>amine  <span>0.1 mg<span></span>/kg<span></span>/hr drip, intravenous, continuous</span></div><div><span></span><span> </span><span>Consult acute pain service</span></div><div>Local/R<span></span>egional anesthetic p<span></span>ain modalities</div><div>Epidural</div><div><span></span><span> </span><span>Managed by pain service</span></div><div><span></span><span> </span><span>Commonly used for T<span></span>AAA</span></div><div>Bupivacaine via On Q pump</div><div><span></span><span> </span><span>See referenc<span></span>e <span>page 109</span></span></div><div><span></span><span> </span><span>Commonly used for anterior thor<span></span>acotomy</span></div><div>P<span></span>aravertebr<span></span>al Nerve Block</div><div><span></span><span> </span><span>Managed by pain service</span></div><div><span></span><span> </span><span>Commonly used for myocardial bridg<span></span>e </span></div><div>POS<span></span>T<span></span>-OP:<span> <span>NEUROL<span></span>OGIC:<span> SEIZURES</span></span></span></div><div>A seizure is a “single event char<span></span>acterized by the abnormal exc<span></span>essive synchronized </div><div><span></span><span></span><span></span></div><div>(Kurle, 2010). </div><div>Etiology:</div><div> <span></span><span></span></div><div>The most c<span></span>ommon cause of seizures is str<span></span>oke, 43% within 24 hours of the </div><div>strok<span></span>e</div><div><span></span><span> </span><span>8.9% - hemispheric strok<span></span>e</span></div><div><span></span><span> </span><span>8.6% – ischemic strok<span></span>e</span></div><div><span></span><span> </span><span>10.6% - hemorrhagic strok<span></span>e</span></div><div> <span></span><span></span></div><div>Intraoper<span></span>ative hypoxia, or air or particulat<span></span>e emboli, metabolic </div><div>encephalop<span></span>athy<span></span>, cerebr<span></span>al edema</div><div> <span></span><span></span></div><div>Medications</div><div><span></span><span> </span><span>Lidocaine</span></div><div><span></span><span> </span><span>T<span></span>ranexamic acid (a pro-c<span></span>oagulant not used at SHC).  Amicar is used a<span></span>t </span></div><div><span></span><span></span><span></span></div><div>seizures (though higher r<span></span>ates of renal dysfunction) (Martin, 2011).</div><div><span></span><span> </span><span>Cefazolin (a r<span></span>are complica<span></span>tion), especially in patients with renal </span></div><div></div><div>function</div><div>Incidence:</div><div> <span></span><span></span></div><div>0.1% (CABG) to 5% (complex aortic) (Golds<span></span>tone et al, 2011, Manji et al, 2011, </div><div>McGar<span></span>vey et al, 2013)</div><div> <span></span><span></span></div><div>59% experience 1 recurr<span></span>ence (Manji, 2011), 89% of those are within 24 hours</div><div> <span></span><span></span></div><div>Most lik<span></span>ely to occur be<span></span>tween hours 5-8 postoper<span></span>atively<span> (Manji, 2012)</span></div><div>Risk fac<span></span>tors </div><div> <span></span><span></span></div><div>Intraop:</div><div><span></span><span> </span><span>Dura<span></span>tion of aortic cross-clamp time</span></div><div><span></span><span> </span><span></span></div><div><span></span><span> </span><span>Deep hypothermic circula<span></span>tor<span></span>y arrest</span></div><div><span></span><span> </span><span>Open chamber surgery</span></div><div><span></span><span> </span><span>Complex aortic repair (Sharma, 2014, Golds<span></span>tone, 2011)</span></div><div> <span></span><span></span></div><div>Pos<span></span>top:</div><div><span></span><span> </span><span>Met<span></span>abolic derang<span></span>ements (McGarve<span></span>y<span></span>, 2013)</span></div></div><div></div></div>
<div><div><img><div>48<span> </span><span>Pos<span></span>t-Op Management<span> </span>Pos<span></span>t-Op Management<span> </span><span>49</span></span></div><div>Considera<span></span>tions</div><div>Preopera<span></span>tive<span> </span>Note p<span></span>atients with preexis<span></span>ting seizure disorders and consult Neuro </div><div>Critical Care prior to sur<span></span>ger<span></span>y to make a pos<span></span>top plan.</div><div>Intraoper<span></span>ative<span> </span>These procedures may decr<span></span>ease the incidence of neurologic </div><div>complica<span></span>tions (Goldstone e<span></span>t al, 2011):</div><div> <span></span><span></span></div><div>Epi-aortic scanning before aortic c<span></span>annulation</div><div> <span></span><span></span></div><div></div><div> <span></span><span></span></div><div>Cerebral o<span></span>x<span></span>ygen sa<span></span>turation monitoring</div><div> <span></span><span></span></div><div>Retrogr<span></span>ade cerebral perfusion with hypo<span></span>thermia or deep </div><div>hypothermia during circulat<span></span>or<span></span>y arrest</div><div> <span></span><span></span></div><div>Echocardiogr<span></span>aphy-guided de-airing</div><div>Pos<span></span>toperative</div><div> <span></span><span></span></div><div>Review of medications and labs to identify  </div><div>pro-convulsive agent<span></span>s or toxic serum levels</div><div> <span></span><span></span></div><div>Generally are isola<span></span>ted events.  </div><div> <span></span><span></span></div><div><span></span><span></span><span></span></div><div><span></span><span></span></div><div>Neuro Critical Care t<span></span>eam</div><div>* The terms simple partial, complex partial, and sec<span></span>ondarily generalized are no </div><div>longer used</div><div>Classication<span> </span><span>Origin<span> </span>Clinical </span></div><div>manifest<span></span>ations</div><div>Guide to </div><div>trea<span></span>tment</div><div>Focal seizur<span></span>e </div><div>(previously </div><div>‘partial’)</div><div>Origin and spread </div><div>limited to one </div><div>hemisphere, </div><div>arising from the </div><div>subcortical or </div><div>neocortical r<span></span>egions</div><div>Can involve twitching of </div><div>a limb, a sense of fear<span></span>, an </div><div>unpleasant smell (aur<span></span>a) </div><div>and patient<span></span>s may be </div><div>conscious of having them </div><div>(Schachter<span></span>, 2016).</div><div>EEG, CT he<span></span>ad, </div><div>consider Keppr<span></span>a </div><div>load and BID </div><div>therapy<span></span>. Lorazepam </div><div>if not self-limiting.</div><div>Generalized<span> </span>St<span></span>arts in both </div><div>hemispheres </div><div>at once, arising </div><div>from a cortic<span></span>al </div><div>or subcortical </div><div>region, may be </div><div>asymmetric</div><div>Most c<span></span>ommonly tonic-</div><div>clonic (previously known </div><div>as grand mal, with </div><div>convulsive jerking in all </div><div>limbs), absence (previously </div><div>known as petit mal, with </div><div>st<span></span>aring or lip smacking, </div><div>and myoclonic seizures </div><div>(muscle spasms, can be </div><div></div><div>EEG, CT he<span></span>ad, </div><div>consider Keppr<span></span>a </div><div>load and </div><div>BID therapy<span></span>. </div><div>Loraz<span></span>epam, if not </div><div>self-limiting.</div><div>St<span></span>atus epilepticus </div><div>(SE)</div><div>Any type of seizure </div><div>can evolve into </div><div></div><div>“more than 30 </div><div>minutes of either </div><div>continuous seizur<span></span>e </div><div>activity or two or </div><div>more sequential </div><div>seizures without </div><div>full recovery of </div><div>consciousness </div><div>between </div><div>(American Epilepsy </div><div>Society Guideline, </div><div>2016)”<span></span>.</div><div>Charact<span></span>erized as </div><div>convulsive or non-</div><div>convulsive.  This is a </div><div>medical emergency<span></span>.</div><div>1st line – lor<span></span>azepam </div><div>or diazepam</div><div>2nd line – </div><div>fosphenytoin</div><div>3rd line –  </div><div>general anes<span></span>thesia</div><div>* See below for </div><div>doses</div><div>T<span></span>rea<span></span>tment</div><div> <span></span><span></span></div><div>Pharmacologic tre<span></span>atment is <span>not always nec<span></span>essar<span></span>y<span><span></span></span></span></div><div>seizure, especially if the etiology is obvious and addressed (ie, met<span></span>abolic </div><div>derang<span></span>ement).</div><div> <span></span><span></span></div><div>P<span></span>atients with <span>focal neur<span></span>ological decits, epileptiform dischar<span></span>ges on </span></div><div>EEG or structur<span></span>al brain lesions are a<span></span>t higher risk for repeat seiz<span></span>ures<span> and </span></div><div>should receive antic<span></span>onvulsive therapy (Kurle &amp; Rutecki, 2010).</div><div>Pharmacologic<span></span>al treatment:</div><div> <span></span><span></span></div><div>Loading f<span></span>ollowed by a maintenance dose of <span>levetir<span></span>acet<span></span>am (Keppra)<span> is </span></span></div><div><span></span><span></span><span></span><span></span></div><div></div><div><span></span><span> </span><span>Do<span><span></span><span></span></span></span></div><div> <span></span><span></span></div><div>Additional antiepileptic pharmaco<span></span>therapy based on the EEG, C<span></span>T<span></span>, and clinical </div><div>manifest<span></span>ations of the seizure(s) and response t<span></span>o treatment.</div><div> <span></span><span></span></div><div>T<span></span>o break a seiz<span></span>ure:</div><div><span></span><span> </span><span>1st line: IV <span>lor<span></span>azepam<span><span></span><span></span></span></span></span></div><div><span></span><span></span></div><div> <span></span><span></span></div><div><span></span><span></span></div><div>depression</div><div><span></span><span> </span><span>2nd line: IV <span>fosphenytoin</span> a<span></span>t 20mg<span></span>/kg, (can also do VP<span></span>A 40mg<span></span>/kg or </span></div><div>Keppra 60mg<span></span>/kg lo<span></span>ad – discuss with NCC). Fosphenytoin is bet<span></span>ter </div><div>toler<span></span>ated over Phenyt<span></span>oin.</div><div><span></span><span> </span><span>3rd line, gener<span></span>al anesthesia with <span>propofol or V<span></span>ersed gtts.</span></span></div><div>Seizures mus<span></span>t be <span>dierentiat<span></span>ed from myoclonus<span> (4 types)</span></span></div><div> <span></span><span></span></div><div>Physiologic (muscle jerks when falling asleep, c<span></span>auses no disability)</div><div> <span></span><span></span></div><div><span></span><span></span></div><div> <span></span><span></span></div><div>Epileptic (myoclonic jerks in the set<span></span>ting of epilepsy)</div><div> <span></span><span></span></div><div>Symptoma<span></span>tic (occurring in the setting of a sep<span></span>arate neurologic<span></span>al disorder) </div><div>(Caviness, 2015).</div><div>Calling a consult:</div><div> <span></span><span></span></div><div>Neuro Critical Care P<span></span>ager number: 14061</div><div> <span></span><span></span></div><div>Describe the seizure-like ac<span></span>tivity</div><div><span></span><span> </span><span>Evolution<span>: describe the p<span></span>at<span></span>tern (ie did it st<span></span>art with gaze deviation and </span></span></div><div>unilater<span></span>al shaking which then spread to the opposite side)</div><div><span></span><span> </span><span>Bilat<span></span>eral<span> or c<span></span>onvulsive involvement</span></span></div><div><span></span><span> </span><span>What were the eyes doing (nyst<span></span>agmus, gaze deviation et<span></span>c)</span></div><div><span></span><span> </span><span>T<span></span>ermination<span>: spont<span></span>aneously or with Ativan</span></span></div><div><span></span><span> </span><span>Physical ex<span></span>am ndings</span></div><div> <span></span><span></span></div><div>Autonomic chang<span></span>es in absence or foc<span></span>al seizures: tachycar<span></span>dia, </div><div>diaphoresis, exc<span></span>ess salivation, pupillary dilation, incontinence (K<span></span>urle &amp; </div><div>Rutecki, 2010).</div><div> <span></span><span></span></div><div>T<span></span>onic-clonic seizures: hypert<span></span>ension, tachycardia, met<span></span>abolic acidosis, </div><div>hypoxia, hyperc<span></span>arbia (Kurle &amp; Rutecki, 2010).</div><div>Diagnostic s<span></span>tudies:</div><div> <span></span><span></span></div><div>Head CT<span> without c<span></span>ontrast: Perf<span></span>orm early to identify potentially r<span></span>e<span></span>versible </span></div><div>causes (Goldst<span></span>one, 2011)</div><div> <span></span><span></span></div><div>Continuous EEG:<span> identify a focal are<span></span>a of seizure activity or the presenc<span></span>e of </span></div><div>non-convulsive s<span></span>tatus epilepticus (Marcuse, 2014)</div><div> <span></span><span></span></div><div>MRI: <span><span></span><span></span><span></span></span></div><div>devices (L<span></span>VAD, ECMO etc), Epicardial wir<span></span>es, certain ICD<span></span>/PPMs etc.</div></div><div></div></div>
<div><div><img><div>50<span> </span><span>Pos<span></span>t-Op Management<span> </span>Pos<span></span>t-Op Management<span> </span><span>51</span></span></div><div>POS<span></span>T<span></span>-OP:<span> <span>NEUROL<span></span>OGIC:<span> SPINAL C<span></span>ORD ISCHEMIA </span></span></span></div><div>Who<span></span>’s a<span></span>t risk? </div><div><span></span><span></span><span></span><span></span><span></span></div><div>branching art<span></span>eries (Interc<span></span>ostal arteries) pr<span></span>oviding blood supply to the spinal cord, </div><div>potentially r<span></span>esulting in spinal cord hypoperfusion, ischemia and infarc<span></span>tion</div><div>4. <span> </span><span>Endovascular rep<span></span>air </span></div><div>a. <span> </span><span>Incidence: SCI may occur in up t<span></span>o 4% of cases</span></div><div>b.<span> <span> </span><span><span></span><span></span><span></span></span></span></div><div>5. <span> </span><span>Open repair</span></div><div>a. <span> </span><span>Incidence: SCI may occur in up t<span></span>o 8% of cases</span></div><div>b.<span> <span> </span><span><span></span><span></span></span></span></div><div>Intra-op Me<span></span>asures to prevent spinal c<span></span>ord ischemia:</div><div>1. <span> </span><span>Minimize spinal cor<span></span>d ischemic time</span></div><div>2. <span> </span><span>Increase t<span></span>olerance to ischemia </span></div><div>a. <span> </span><span>Deliberat<span></span>e mild systemic hypothermia</span></div><div>b.<span> <span> </span><span>Ischemic prec<span></span>onditioning (“st<span></span>aged repair”) to allow development of </span></span></div><div>collat<span></span>eraliza<span></span>tion of blood supply</div><div>3. <span> </span><span>Augment spinal cor<span></span>d perfusion</span></div><div>a. <span> </span><span>Deliberat<span></span>e proximal and dist<span></span>al HTN</span></div><div>b.<span> <span> </span><span>C<span></span>SF drainage (via lumbar dr<span></span>ain placement pre-procedur<span></span>e)</span></span></div><div>c. <span> </span><span>Reimplanta<span></span>tion of spinal arteries</span></div><div>d. <span> </span><span>Preser<span></span>ve subclavian artery and hypogastric artery</span></div><div>4. <span> </span><span>Early detec<span></span>tion of spinal cord ischemia</span></div><div>a. <span> </span><span>Intra-oper<span></span>ative neurophysical monitoring (MEP mot<span></span>or e<span></span>voked po<span></span>tentials, </span></div><div>SSEP somat<span></span>osensor<span></span>y evoked potentials)</div><div>b.<span> <span> </span><span>Early and serial pos<span></span>t-op neuro exam</span></span></div><div>Pos<span></span>t-op IC<span></span>U Measures to pr<span></span>event spinal cord ischemia</div><div>1. <span> </span><span>CSF Dr<span></span>ainage:</span></div><div>a. <span> </span><span>Lumbar dr<span></span>ain typically placed pre-opera<span></span>tively by anesthesia.  </span></div><div>See <span>page 106.</span></div><div>b.<span> <span> </span><span>Go<span></span>al to optimize cer<span></span>ebral perfusion pr<span></span>essure (CPP): perfusion to spinal </span></span></div><div>cord</div><div>1. <span></span><span>Measured as CPP = Mean Art<span></span>erial Pressure – ICP</span></div><div>2. <span></span><span>We can decrease ICP by r<span></span>emoving CSF<span></span>, thus improving CPP</span></div><div>c. <span> </span><span>Goal ICP ~10 mmHg<span> (refer t<span></span>o ICU Lumb<span></span>ar drain protoc<span></span>ol)</span></span></div><div>1. <span></span><span>Lumbar dr<span></span>ain is set open to drain a<span></span>t 10mmHg (14cm H20)</span></div><div>2. <span></span><span>When/<span></span>if ICP is gr<span></span>eat<span></span>er than 10mmHg, the lumbar drain will act as a </span></div><div>“pop-o” valve and CSF will dr<span></span>ain</div><div>d. <span> </span><span>Must be careful t<span></span>o not OVER DRAIN C<span></span>SF too rapidly</span></div><div>1. <span></span><span>Symptomatic intr<span></span>acranial hypotension:</span></div><div>a. <span></span><span>Headache</span></div><div>b.<span> <span></span><span>Subdural hematoma</span></span></div><div>2. <span></span><span>Goal: may drain up t<span></span>o 10mL at a time, not t<span></span>o exceed 20mL/hr</span></div><div>2. <span> </span><span>Augment Mean Art<span></span>erial Blood Pressure</span></div><div>a. <span> </span><span>Goal hemodynamic par<span></span>ameters mus<span></span>t be discussed with the surgical </span></div><div>at<span></span>tending, as the patient may have r<span></span>esidual aneur<span></span>ysm/dissec<span></span>tion or </div><div>bleeding to t<span></span>ake into c<span></span>onsideration when es<span></span>tablishing goal MAP</div><div>b.<span> <span> </span><span><span></span><span></span></span></span></div><div>used to augment MAP</div><div>c. <span> </span><span>Typical MAP g<span></span>oal 90-100, CPP goal &gt;80</span></div><div>3. <span> </span><span>Early detec<span></span>tion through close neurologic monit<span></span>oring</span></div><div>a. <span> </span><span></span></div><div>b.<span> <span> </span><span>Q1H Pupillometry while CSF is dr<span></span>ained</span></span></div><div>4. <span> </span><span>May est<span></span>ablish blood transfusion goal f<span></span>or Hct &gt;25 to optimize perfusion</span></div><div>5. <span> </span><span>Lumbar dr<span></span>ain removal</span></div><div>a. <span> </span><span><span></span><span></span></span></div><div>b.<span> <span> </span><span>POD 2: Clamp x 24 hours</span></span></div><div>1. <span></span><span>Continue to monitor neuro exam, if chang<span></span>es, resume CSF drainag<span></span>e</span></div><div>c. <span> </span><span>POD 3: Remove if neuro exam int<span></span>act, monitor for HA or CSF dr<span></span>ainage post </span></div><div>removal. Fla<span></span>t for 6 hours post drain r<span></span>emoval </div><div>If The E<span></span>xam Changes:</div><div>1. <span> </span><span>Alert ICU at<span></span>tending and surgical te<span></span>am immediately</span></div><div>2. <span> </span><span>Increase MAP<span></span>/CPP</span></div><div>a. <span> </span><span>Increase dose of v<span></span>asopressors</span></div><div>b.<span> <span> </span><span>Consider blood/volume tr<span></span>ansfusion</span></span></div><div>3. <span> </span><span>Drain C<span></span>SF (safely) to decrease ICP and incr<span></span>ease CPP</span></div><div>a. <span> </span><span>Goal ICP &lt;10 </span></div><div>b.<span> <span> </span><span>Dr<span></span>ainage not to exc<span></span>eed 20mL/hr</span></span></div><div>4. <span> </span><span>Perf<span></span>orm thorough neurologic exam</span></div><div>a. <span> </span><span><span></span><span></span></span></div><div>b.<span> <span> </span><span><span></span></span></span></div><div>5. <span> </span><span>Consider consult to neur<span></span>ocritical care</span></div><div>6. <span> </span><span>Consider advanc<span></span>ed imaging (CT<span></span>/MRI) when st<span></span>abilized to assess extent of </span></div><div>infarc<span></span>t</div><div>Referenc<span></span>es:</div><div>Referenc<span></span>es Bojar, Robert M. (2011) Manual of P<span></span>erioperative Car<span></span>e in Adult Cardiac Surger<span></span>y<span></span>. (5th edition).</div><div> </div></div><div></div></div>
<div><div><img><div>52<span> </span><span>Pos<span></span>t-Op Management<span> </span>Pos<span></span>t-Op Management<span> </span><span>53</span></span></div><div>POS<span></span>T<span></span>-OP:<span> <span>NEUROL<span></span>OGIC:<span> S<span></span>TROKE / CV<span></span>A</span></span></span></div><div>Risk F<span></span>actors:</div><div>Pre-Op: </div><div> <span></span><span></span></div><div>Hist<span></span>or<span></span>y of previous s<span></span>troke or TIA (44% of p<span></span>atients with history of strok<span></span>e </div><div></div><div> <span></span><span></span></div><div>Comorbidities: HTN, DM, Smoking, PVD, Renal dysfunction</div><div> <span></span><span></span></div><div></div><div> <span></span><span></span></div><div>Age &gt; 75 (risk of up to 10%)</div><div> <span></span><span></span></div><div>Carotid dise<span></span>ase (Risk is less in unilateral s<span></span>tenosis but as high as 10-15% in </div><div>bilater<span></span>al stenosis &gt; 75%)</div><div> <span></span><span></span></div><div>Emergent sur<span></span>gery (Type A dissection)</div><div>Intra Op: </div><div> <span></span><span></span></div><div><span></span></div><div>CBP &gt; 2 hours</div><div> <span></span><span></span></div><div>High transfusion r<span></span>equirement (especially plat<span></span>elets)</div><div> <span></span><span></span></div><div>L<span></span>V thrombus</div><div> <span></span><span></span></div><div>Air emboliza<span></span>tion from opening of cardiac chamber</div><div> <span></span><span></span></div><div>Peri-oper<span></span>ative HTN or cardiac arres<span></span>t</div><div>Pos<span></span>t op:</div><div> <span></span><span></span></div><div></div><div>Pre-Op &amp; Perioper<span></span>ative prev<span></span>ention:</div><div> <span></span><span></span></div><div>Avoid hypotension, c<span></span>ontinue pre-operative ASA, consider need f<span></span>or pre-op </div><div>caro<span></span>tid studies </div><div>Incidence/Mechanism:</div><div> <span></span><span></span></div><div>Embolic, most c<span></span>ommon (~ 2/3 of post op strok<span></span>es)</div><div> <span></span><span></span></div><div>Cerebr<span></span>al hyper perfusion  </div><div> <span></span><span></span></div><div>Hemorrhagic  </div><div>Present<span></span>ation:</div><div> <span></span><span></span></div><div>Think<span> BE F<span></span>AST<span> (</span>B<span>alance, </span>E<span>yes (vision changes), </span>F<span>ac<span></span>e drooping, <span>A</span>rm </span></span></div><div>weakness, <span>S<span><span></span><span>T<span>ime — how long since onset of symptoms)</span></span></span></span></div><div>Physical E<span></span>xam:</div><div> <span></span><span></span></div><div>Full Neuro ex<span></span>am (CN 2-12)</div><div><span></span><span> </span><span>Str<span></span>engths of extr<span></span>emities</span></div><div><span></span><span> </span><span>Pupil exam</span></div><div> <span></span><span></span></div><div>“ Blown pupil:” something acutely b<span></span>ad is happening on one side (rising </div><div>ICP compresses ar<span></span>ea that holds one of optic nerves)</div><div> <span></span><span></span></div><div>“Fixed and dilat<span></span>ed” pupils – indicate a prolonged hypo<span></span>xic injur<span></span>y to the </div><div>brain. </div><div><span></span><span> </span><span>T<span></span>ongue midline</span></div><div>Work<span></span>-up:</div><div> <span></span><span></span></div><div>Call Str<span></span>oke code (dial 211)</div><div> <span></span><span></span></div><div>CT he<span></span>ad without contras<span></span>t, to rule in/<span></span>out hemorrhage</div><div> <span></span><span></span></div><div><span></span><span></span></div><div> <span></span><span></span></div><div>MRI/MRA brain with perfusion sequenc<span></span>es (Stroke pro<span></span>tocol) </div><div> <span></span><span></span></div><div>Carotid Doppler U<span></span>S study t<span></span>o evaluate f<span></span>or carotid occlusive dise<span></span>ase</div><div>Medical Management</div><div> <span></span><span></span></div><div>Blood pressure p<span></span>arameters as det<span></span>ermined by consulting teams, but </div><div>SBP should not exc<span></span>eed 180mmHg for ischemic and 140-160mmHg for </div><div>hemorrhagic cases</div><div> <span></span><span></span></div><div>Glucose c<span></span>ontrol between 80-140 mg<span></span>/dL as elev<span></span>ated levels &gt; 200 mg<span></span>/<span></span>dL during </div><div><span></span><span></span><span></span><span></span></div><div>neurologic outc<span></span>ome</div><div> <span></span><span></span></div><div>Avoid hyperthermia</div><div> <span></span><span></span></div><div>DC all antico<span></span>agulation as pa<span></span>tient’<span></span>s condition can worsen, or c<span></span>an be </div><div>contr<span></span>aindication for tP<span></span>A administr<span></span>ation</div><div> <span></span><span></span></div><div>ASA 162mg or 325mg orally or r<span></span>ect<span></span>ally</div><div> <span></span><span></span></div><div>Antiepileptic ther<span></span>apy as determined by consulting te<span></span>ams</div><div>Indications f<span></span>or surgery</div><div>General guidelines:</div><div> <span></span><span></span></div><div>P<span></span>atients with large hemispheric s<span></span>troke involving more than two-<span></span>thirds of MCA </div><div>territory (usually only on right-side)</div><div> <span></span><span></span></div><div>Development of herniation syndrome (i.e. ipsila<span></span>ter<span></span>al weakness on side of </div><div>strok<span></span>e, lower cranial neuropa<span></span>thies, lethargy)</div><div> <span></span><span></span></div><div>Uncontrolled intr<span></span>acranial pressure, as dic<span></span>tated by monitor</div><div>Surgical Pr<span></span>ocedures: </div><div> <span></span><span></span></div><div>Suboccipit<span></span>al craniectomy<span></span>/cr<span></span>aniotomy (for post<span></span>erior circulation)</div><div> <span></span><span></span></div><div>Cranio<span></span>tomy/Cr<span></span>aniectomy f<span></span>or evacuation of hemat<span></span>oma</div><div> <span></span><span></span></div><div>Hemicraniec<span></span>tomy</div><div> <span></span><span></span></div><div>Carotid endart<span></span>erectomy</div><div>Referenc<span></span>e:</div><div>Winn, H. Richard.  Y<span></span>ouman’<span></span>s Neurological Surg<span></span>ery, 6th ed.  2011.</div><div>CARDIAC: <span>A<span></span>TRIAL FIBRILLA<span></span>TION &amp;  </span></div><div>ELECTROL<span></span>YTE REPL<span></span>ACEMENT</div><div>Classication o<span></span>f AF:</div><div> <span></span><span></span></div><div>P<span></span>aroxysmal (self-<span></span>terminating) vs Persist<span></span>ent (sustained &gt; 7d) vs P<span></span>ermanent  </div><div>(typically &gt; 1 year and when c<span></span>ardioversion has failed or is forg<span></span>one)</div><div> <span></span><span></span></div><div>Valvular (rheumatic MV dise<span></span>ase, prosthetic v<span></span>alve, or valve repair) vs Non </div><div>valvular</div><div> <span></span><span></span></div><div>Lone AF = age &lt; 60 and w<span></span>/o clinical or echo evidence of c<span></span>ardiac disease </div><div>(including HTN)</div><div> <span></span><span></span></div><div><span></span><span></span><span></span></div><div>patient<span></span>s</div><div>Management of AF: (see below f<span></span>or treatment alg<span></span>orithm)</div><div> <span></span><span></span></div><div><span></span><span></span><span></span><span></span></div><div> <span></span><span></span></div><div>For uns<span></span>table p<span></span>atient<span></span>, car<span></span>diovert immediately if able</div><div> <span></span><span></span></div><div>If the patient c<span></span>ontinues to have episodes, consider antico<span></span>agulation  </div><div>(see CHADs score below)</div><div>Pos<span></span>t-oper<span></span>ative Electrolyt<span></span>e Goals:</div><div>Po<span></span>tassium (K+)<span> </span>5.0</div><div>Magnesium (Mg+)<span> </span>2.5</div><div>Calcium (CA+)<span> </span>8.0</div></div><div></div></div>
<div><div><img><div>54<span> </span><span>Pos<span></span>t-Op Management<span> </span>Pos<span></span>t-Op Management<span> </span><span>55</span></span></div><div>Rat<span></span>e Control for AF: (goal HR 60-80, 90-115 with e<span></span>xertion)</div><div>Agent<span> </span>Acut<span></span>e IV<span> </span>Maint (PO)<span> </span>Comments</div><div>Metopr<span></span>olol (BB)<span> </span>5mg over 2min, </div><div>may repea<span></span>t </div><div>q5min x3</div><div>25-100mg BID </div><div>or TID</div><div>↓BP (Rx w/</div><div>glucagon). </div><div>Wat<span></span>ch for CHF &amp; </div><div>Bronchospasm </div><div>Preferr<span></span>ed if CAD</div><div>Amiodarone<span> </span>150mg over 10 </div><div>min. Then 1mg<span></span>/</div><div>min 6 hours, </div><div>0.5mg<span></span>/min for </div><div>18 hours</div><div>400mg TID with </div><div>taper</div><div>Diltiazem (C<span></span>CB)<span> </span>0.25mg<span></span>/kg over </div><div>2 min, may </div><div><span></span></div><div>min. 5-15mg<span></span>/h </div><div>infusion</div><div>120-360mg<span></span>/<span></span>d in </div><div>divided doses</div><div></div><div>gluc). Wat<span></span>ch for </div><div>CHF<span></span>. Preferred if </div><div></div><div>levels</div><div>Ver<span></span>apamil (CCB)<span> </span>5-10mg over 2 </div><div>min, may repea<span></span>t </div><div>in 30 min</div><div>120-360mg<span></span>/<span></span>d in </div><div>divided doses</div><div></div><div>gluc). Wat<span></span>ch for </div><div>CHF<span></span>. Preferred if </div><div></div><div>levels</div><div>Propr<span></span>anolol (BB)<span> </span>1mg q2min<span> </span>80-240mg<span></span>/<span></span>d in </div><div>divided doses</div><div></div><div>glucagon). </div><div>Wat<span></span>ch for CHF &amp; </div><div>Bronchospasm</div><div>Preferred if CAD</div><div>Digoxin <span> </span>0.25mg q2h up to </div><div>1.5mg</div><div>0.125- 0.375mg </div><div>qday (adjust for </div><div>CrCl)</div><div>Consider in HR </div><div>or Low BP<span></span>. P<span></span>oor </div><div>exertional HR crtl.</div><div>Rhythm Control: </div><div>Amiodarone </div><div>(Class III)</div><div>5-7mg<span></span>/kg IV </div><div>over 30-60min </div><div><span>1mg<span></span>/min to </span></div><div>achieve 10g load</div><div>200-400mg qD </div><div>(most e<span></span>ective </div><div>drug)</div><div>↑QT but T<span></span>dP </div><div>rar<span></span>e. Pulm, liver<span></span>, </div><div>thyroid to<span></span>xicity<span></span>. </div><div>Check PFT<span></span>s, </div><div>LFT<span></span>s, TFT<span></span>s</div><div>Sot<span></span>alol (Class III)<span> </span>n/a<span> </span>90-160mg BID<span> </span><span><span></span><span></span></span></div><div></div><div>Propaf<span></span>enone </div><div>(Class IC)</div><div>600mg PO x1<span> </span>150-300mg TID<span> </span>PreRx w/</div><div>AVN blocker<span></span>. </div><div>Contraindic. If </div><div>structural or </div><div>ischemic heart </div><div>disease</div><div>Procainamide<span> </span>10-15mg<span></span>/kg IV </div><div>over 1 hr</div><div>1-2g bid of slow </div><div>release</div><div><span></span><span></span></div><div>PreRx w/<span></span>AVN </div><div>blocker</div><div>Consider need for Antic<span></span>oagulation:</div><div> <span></span><span></span></div><div><span></span><span></span><span></span><span></span></div><div> <span></span><span></span></div><div>Risk of strok<span></span>e ~ 4.5% per year in non valvular AF<span></span>. Risk factors include: prior </div><div>strok<span></span>e, TIA, DM, HTN, Older age (&gt;/= 65), HF<span></span>, CAD, EF &lt; 35%</div><div> <span></span><span></span></div><div>Who to tre<span></span>at<span></span>: </div><div><span></span><span> </span><span>Utilize CHAD Scor<span></span>e to evaluate pa<span></span>tient’<span></span>s risk and need for anticoagulation</span></div><div><span></span><span> </span><span><span></span><span></span></span></div><div>(with no hist<span></span>or<span></span>y), c<span></span>onsider need for short term (2-3 months pos<span></span>t op) </div><div>antico<span></span>agulation (discuss with at<span></span>tending)</div><div>Agent<span> </span>Class<span> </span>Dosing<span> </span>Time to </div><div>Peak  </div><div>Antico<span></span>ag- </div><div>ulation</div><div>Half-</div><div>life</div><div>Renal </div><div>E<span></span>xcre<span></span>tion </div><div>(%)</div><div>Antidot<span></span>e</div><div>W<span></span>a<span></span>r<span></span>f<span></span>a<span></span>ri<span></span>n </div><div>(Coumadin)</div><div>V<span></span>i<span></span>t <span></span>K </div><div>Antagonis<span></span>t</div><div>0<span></span>.<span></span>5-<span></span>10<span></span>mg </div><div>QD</div><div>3-5 days<span> </span><span>4<span></span>0 </span></div><div>hours</div><div>0<span> </span><span>Vitamin K</span></div><div>Clopidogrel (Plavix)<span> </span><span>P<span></span>l<span></span>a<span></span>t<span></span>e<span></span>l<span></span>e<span></span>t </span></div><div>inhibitor</div><div>7<span></span>5<span></span>mg <span></span> </div><div>QD</div><div>Prasugrel (Effient)<span> </span><span>P<span></span>l<span></span>a<span></span>t<span></span>e<span></span>le<span></span>t </span></div><div>inhibitor</div><div>5<span></span>-<span></span>10<span></span>mg </div><div>QD</div><div>7 <span></span> </div><div>hours</div><div>D<span></span>a<span></span>bi<span></span>g<span></span>a<span></span>tr<span></span>a<span></span>n </div><div>(Pradaxa)</div><div>D<span></span>i<span></span>r<span></span>ec<span></span>t </div><div>T<span></span>h<span></span>r<span></span>om<span></span>bi<span></span>n </div><div>inhibitor</div><div>150mg<span></span><span> </span></div><div>BID</div><div>1-2 hours<span> </span><span>1<span></span>4<span></span>-1<span></span>7 </span></div><div>hours</div><div>-80<span> </span>None</div><div>Rivaro<span></span>xaban </div><div>(Xarelto)</div><div>Fac<span></span>tor-Xa </div><div>Inhibitor</div><div>15-20mg </div><div>QD</div><div>2.5-4hours<span> </span>11-13 </div><div>hours</div><div>35<span> </span>None</div><div>Apixaban<span> </span></div><div>(Eliquis)</div><div>F<span></span>ac<span></span>t<span></span>o<span></span>r<span></span>-<span></span>X<span></span>a </div><div>Inhibitor</div><div>2<span></span>.<span></span>5-<span></span>5m<span></span>g </div><div>BID</div><div>3 hours<span> </span>8-15<span></span> </div><div>hours</div><div>25<span> </span>None</div><div>Endoxab<span></span>an<span></span><span> </span></div><div>(Savaysa)</div><div>F<span></span>ac<span></span>t<span></span>o<span></span>r<span></span>-<span></span>X<span></span>a </div><div>Inhibitor</div><div>6<span></span>0<span></span>mg <span></span> </div><div>QD</div><div>1-2 hours<span> </span>9-12<span></span><span> </span></div><div>hours</div><div>60<span> </span>None</div><div>CHAD Scor<span></span>e (&gt;2 equals indication for antic<span></span>oagulation)</div><div>C<span> </span><span><span></span><span></span></span></div><div>dysfunction)</div><div>H<span> </span>Hypertension</div><div>A  (2)<span> </span>Age &gt;/= 75</div><div>D<span> </span>DM</div><div>S (2)<span> </span>Prior strok<span></span>e or TIA or thromboembolism</div><div>V<span> </span>Vascular disease (P<span></span>AD, MI)</div><div>A<span> </span>Age 65-74</div><div>Sc<span> </span>Sex cat<span></span>egor<span></span>y female</div><div>Referenc<span></span>es:</div><div>Bojar<span></span>, Robert M. (2011) Manual of Perioper<span></span>ative Care in Adult Cardiac Surgery. (5th  <span></span>edition).</div></div><div></div></div>
<div><div><img><div>56<span> </span><span>Pos<span></span>t-Op Management<span> </span>Pos<span></span>t-Op Management<span> </span><span>57</span></span></div><div>CT Surgery Post</div><div>Op Atrial</div><div>Fibrillation</div><div>Treatment</div><div>Algorithm</div><div>CHRONIC?</div><div>NEW ONSET?<span> (will occur in 30-</span></div><div>40% of patients)</div><div>-The<span> </span>goal<span> </span>is<span> </span>always<span> </span>first<span> </span>NSR</div><div>-If<span> </span>NSR<span> </span>cannot<span> </span>be<span> </span>attained,<span> </span>the</div><div>goal<span> </span>then<span> </span>becomes<span> </span>rate<span> </span>control</div><div>STABLE?</div><div>UNSTABLE?</div><div>Amiodarone</div><div>150mg/min<span> </span>bolus<span> </span>+</div><div>drip<span> </span>@<span> </span>1mg/min</div><div>OR</div><div>Diltiazem<span> </span>0.25mg/</div><div>kg<span> </span>bolus<span> </span>+<span> </span>drip<span> </span>@</div><div>5mg/hr<span> </span>(titrate<span> </span>to</div><div>heart<span> </span>rate)</div><div>DCCV</div><div>(direct<span> </span>current</div><div>cardioversion)</div><div>Successful<span> </span>=</div><div>Converts<span> </span>to</div><div>Sinus</div><div>Unsuccessful</div><div>=<span> </span>Remains<span> </span>in</div><div>Afib</div><div>Continue<span> </span>Amio/</div><div>Diltiazem<span> </span>drip<span> </span>until</div><div>loaded</div><div>Repeat<span> </span>DCCV</div><div>Continue<span> </span>Amio/</div><div>Diltiazem<span> </span>drip<span> </span>until</div><div>loaded</div><div>Transition<span> </span>to<span> </span>PO</div><div>Amiodarone</div><div>starting<span> </span>with</div><div>400mg<span> </span>PO<span> </span>TID</div><div>Consider<span> </span>Daily</div><div>EKG<span> </span>to<span> </span>eval<span> </span>QT</div><div>interval.</div><div>AF<span> </span>reoccurs?</div><div>1.<span> </span>Restart<span> </span>Amio/</div><div>Diltiazem<span> </span>bolus<span> </span>+</div><div>drip</div><div>2.<span> </span>Consider</div><div>DCCV</div><div>3.<span> <span>Evaluate the </span></span></div><div>need for </div><div>Anticoagulation<span> </span></div><div>Remains<span> </span>in<span> </span>NSR<span> </span>&gt;</div><div>24-48<span> </span>hours</div><div>Discharge<span> </span>home</div><div>with<span> </span>amio<span> </span>taper</div><div>Amiodarone</div><div>150mg/min<span> </span>bolus<span> </span>+</div><div>drip<span> </span>@<span> </span>1mg/min</div><div>OR</div><div>Diltiazem<span> </span>0.25mg/</div><div>kg<span> </span>bolus<span> </span>+<span> </span>drip<span> </span>@</div><div>5mg/hr<span> </span>(titrate<span> </span>to</div><div>heart<span> </span>rate)</div><div>Afib<span> </span>persists</div><div>&gt;<span> </span>24<span> </span>hours</div><div>Converts<span> </span>to</div><div>Sinus</div><div>Continue<span> </span>amio<span> </span>drip</div><div>@<span> </span>1mg/min<span> </span>for<span> </span>6</div><div>hours<span> </span>followed<span> </span>by</div><div>0.5mg/min<span> </span>for<span> </span>18</div><div>hours</div><div>If HR or BP <span>↓<span>,<span> </span>first</span></span></div><div>decrease<span> </span>drip<span> </span>to</div><div>0.5mg<span> </span>early.<span> </span>If<span> </span>no</div><div>resolution,<span> </span>stop</div><div>drip.</div><div>S/P<span> </span>MAZE</div><div>Goal<span> </span>is<span> </span>RATE</div><div>CONTROL</div><div>1.<span> </span>Restart<span> </span>Home</div><div>meds</div><div>2.<span> </span>Restart<span> </span>home</div><div>anticoagulation</div><div>NSR</div><div>Heart<span> </span>rate<span> </span>&gt;<span> </span>60</div><div>Heart<span> </span>rate<span> </span>&lt;<span> </span>60</div><div>Hold<span> </span>home<span> </span>rate</div><div>controlling/</div><div>antiarrhythmic</div><div>medications</div><div>Restart<span> </span>home<span> </span>rate</div><div>controlling/</div><div>antiarrhythmic</div><div>medications</div><div>(Amio,<span> </span>Sotolol,<span> </span>etc)</div><div>NO<span> </span>MAZE</div><div>Atrial<span> </span>fibrillation</div><div>(will<span> </span>occur<span> </span>in<span> </span>30%</div><div>of<span> </span>patients)</div><div>Restart<span> </span>home</div><div>Antiarrhythmic/</div><div>anticoagulation</div><div>medications</div><div>MEDICATION DOSING  </div><div>Amiodarone bolus = 150mg/min over 10 min (max 6-8 boluses in first </div><div>24 hours)</div><div>Amiodarone drip = 1mg/min x 6 hours, then decrease to 0.5mg/min </div><div>x 18 hours (this will load the patient with 1g in the first 24 hours)</div><div>If patient becomes hypotensive (occurs in 25% of patients) decrease </div><div>the drip to 0.5mg/min early. </div><div>After 24 hours on the drip, transition to 400-1200mg PO per day in 2-</div><div>3 divided doses. Continue</div><div> this loading dose until you have reached </div><div>10g total (between IV and PO). Then decrease to maintenance dose </div><div>of 200-400mg/day</div><div>If QTC interval &gt; 500ms, decrease or discontinue Amiodarone. </div><div>Hypotension is more likely to occur in daily doses of Amiodarone &gt; </div><div>2g/day. <span>Amiodarone drip should be stopped if 2</span></div><div>nd</div><div> degree heart </div><div>block or higher occurs or if long pauses are present. </div><div>Loading dose of Amiodarone = 10g</div><div>D</div><div>iltiazem bolus = 0.25mg/kg over 2 min</div><div>Diltiazem drip = 5mg/hour and titrate based on heart rate</div><div>Due to strong negative inotropic effect, IV Beta blockers should be </div><div>avoided.<span> </span></div><div>For patients with</div><div>chronic atrial</div><div>fibrillation who have</div><div>undergone MAZE</div><div>procedure, 90% will</div><div>be in NSR at 1 year</div><div>post operatively</div><div>Restart<span> </span>home</div><div>medications/</div><div>anticoagulation</div><div>References</div><div>Lee, Richard. Atrial fibrillation and flutter </div><div>after cardiac surgery. In: UpToDate, Saperia, </div><div>SM (Ed.), UpToDate, Waltham, MA, 2016. </div><div>Only<span> </span>consider<span> </span>DCCV<span> </span>for<span> </span>post<span> </span>op</div><div>MAZE<span> </span>patients<span> </span>if<span> </span>patient<span> </span>is</div><div>unstable<span> </span>or<span> </span>rate<span> </span>is<span> </span>very<span> </span>fast</div><div>(DCCV<span> </span>will<span> </span>usually<span> </span>not<span> </span>work<span> </span>until</div><div>patient<span> </span>is<span> </span>4<span> </span>weeks<span> </span>post<span> </span>op)</div><div>Continue<span> </span>to</div><div>use<span> </span>IV<span> </span>Amio</div><div>bolus<span> </span>until</div><div>HR<span> </span>&lt;<span> </span>10</div><div>ANTICOAGULATION</div><div>1. Depends on attending preferences </div><div>2. Should be considered for any patient having paroxysmal atrial </div><div>fibrillation with CHAD score &gt; 2</div><div>SPECIAL CONSIDERATIONS</div><div>Those with a Low EF or mechanical Mitral valve may benefit from </div><div>early DCCV even if they are stable. </div><div>CARDIAC: <span>HEAR<span></span>T BL<span></span>OCKS</span></div><div>Pos<span></span>t-oper<span></span>ative tr<span></span>ansient disturbanc<span></span>es of AV nodal c<span></span>onduction are </div><div>more c<span></span>ommon in patients with:</div><div> <span></span><span></span></div><div>Low EF<span></span>, HTN</div><div> <span></span><span></span></div><div>Severe CAD </div><div> <span></span><span></span></div><div>Long Aortic clamp time</div><div> <span></span><span></span></div><div>Low intr<span></span>a-op myocardial t<span></span>empera<span></span>tures</div><div> <span></span><span></span></div><div>Aortic/mitral/tricuspid valve r<span></span>eplacement<span></span>/rep<span></span>air</div><div>Pos<span></span>t-oper<span></span>ative c<span></span>onduction abnormalities may occur bec<span></span>ause of:</div><div> <span></span><span></span></div><div>Myocardial edema</div><div> <span></span><span></span></div><div>Suturing</div><div> <span></span><span></span></div><div>Debridement near AV node/His bundle</div><div>First De<span></span>gree AV Block</div><div> <span></span><span></span></div><div>Prolonga<span></span>tion of PR inter<span></span>val</div><div> <span></span><span></span></div><div>T<span></span>reatment c<span></span>onsiderations: </div><div><span></span><span> </span><span>Epicardial DDD pacing</span></div><div><span></span><span> </span><span>Avoid nodal-blocking agents</span></div><div>Second De<span></span>gree AV Block: Mobitz Type I (Wenck<span></span>ebach)</div><div> <span></span><span></span></div><div>Progressive PR prolong<span></span>ation leading to non-c<span></span>onducting P wave with no QRS </div><div>complex</div><div> <span></span><span></span></div><div>T<span></span>reatment c<span></span>onsiderations:</div><div><span></span><span> </span><span>Epicardial DDD pacing </span></div><div><span></span><span> </span><span>Avoid nodal blocking agents</span></div><div> <span> </span>       ht<span></span>tp://www.zuniv.net/physiology/book/<span></span>chapter11.html</div><div>Second De<span></span>gree AV Block: Mobitz Type II</div><div> <span></span><span></span></div><div>Const<span></span>ant PR inter<span></span>vals and  </div><div>intermit<span></span>tent dropped QR<span></span>S  </div><div>complexes (no w<span></span>arning!)</div><div> <span></span><span></span></div><div></div><div>syst<span></span>em</div><div> <span></span><span></span></div><div>More likely t<span></span>o progress to  </div><div>complet<span></span>e heart block</div><div> <span></span><span></span></div><div>T<span></span>reatment c<span></span>onsiderations:</div><div><span></span><span> </span><span>Epicardial DDD pacing</span></div><div><span></span><span> </span><span>Stop all nodal blocking agents</span></div><div><span></span><span> </span><span>Consider permanent </span></div><div>pacemaker</div><div>Third Degr<span></span>ee (Complete) Heart Block:</div><div> <span></span><span></span></div><div>F<span></span>ailure of AV c<span></span>onduction of any atrial activity (AV disassociation)</div><div> <span></span><span></span></div><div>Variable r<span></span>ates for P and QRS c<span></span>omplexes</div><div> <span></span><span></span></div><div>T<span></span>reatment c<span></span>onsiderations:</div><div><span></span><span> </span><span>Epicardial DDD P<span></span>acing</span></div><div> <span></span><span></span></div><div>If atria in AF<span></span>/A.utter <span><span>must use VVI pacing</span></span></div><div><span></span><span> </span><span>Stop all nodal blocking agents</span></div><div><span></span><span> </span><span>Consider permanent pacemaker</span></div><div>Heart Block P<span></span>oem</div><div>If the <span>R</span> is far from <span>P</span>,  </div><div>then you have a <span>First De<span></span>gree</span></div><div>Long<span></span>er<span></span>, longer<span></span>, longer<span></span>—DROP!<span> </span></div><div>Then you have a <span>Wenckeb<span></span>ach</span></div><div>If some P’<span></span>s don’t go thr<span></span>ough,  </div><div>then you have a <span>Mobitz II</span></div><div>If <span>P</span>’<span></span>s and <span>Q</span>’<span></span>s don’t agree,  </div><div>then you have a <span>Third Degree </span></div></div><div></div></div>
<div><div><img><div>58<span> </span><span>Pos<span></span>t-Op Management<span> </span>Pos<span></span>t-Op Management<span> </span><span>59</span></span></div><div>AV Junctional Rhythm/<span></span>Junc<span></span>tional T<span></span>achycardia</div><div> <span></span><span></span></div><div>Occurs when junctional tissue has f<span></span>aster intrinsic r<span></span>ate than the sinus node</div><div> <span></span><span></span></div><div>“<span></span>Junctional escape rhythm:” HR &lt; 60bpm </div><div> <span></span><span></span></div><div>“<span></span>Junctional t<span></span>achycardia:” HR 70-130 bpm</div><div> <span></span><span></span></div><div>Could be associated with decr<span></span>eased car<span></span>diac output due to lack of </div><div>synchronous atrial and ventricular c<span></span>ontractions</div><div> <span></span><span></span></div><div>Diagnosis: regular r<span></span>ate with no visible P<span></span>-waves or retrogr<span></span>ade P waves</div><div> <span></span><span></span></div><div>T<span></span>reatment c<span></span>onsiderations:</div><div><span></span><span> </span><span>Stop all nodal blocking agents</span></div><div><span></span><span> </span><span>Chronotropic Be<span></span>ta-1 agonists to stimulate SA node (ie Isuprel, Dopamine, </span></div><div>Epinephrine)</div><div><span></span><span> </span><span>Epicardial atrial or DDD pacing</span></div><div>For more inf<span></span>ormation on Medtronic t<span></span>emporary pacemaker bo<span></span>x,</div><div> <span>See <span>page 106.</span></span></div><div>CARDIAC: <span>CHES<span></span>T P<span></span>AIN</span></div><div>The most important etiology in the di<span></span>erential diagnosis is myocardial ischemia. </div><div>Fortunately<span></span>, it is very uncommon in the post op cardiac sur<span></span>gery patient.</div><div>P<span></span>atient E<span></span>xam:</div><div> <span></span><span></span></div><div>Can the pain be repr<span></span>oduced by palpita<span></span>tion, positional changes, or deep </div><div>inspira<span></span>tion? If so, much less likely t<span></span>o be ischemic in nature. The most </div><div>common cause of ches<span></span>t pain following cardiac sur<span></span>ger<span></span>y is musculoskelet<span></span>al in </div><div>nature. </div><div>Obt<span></span>ain Ekg: </div><div> <span></span><span></span></div><div>Compare with pr<span></span>e op and early post op EKGs</div><div> <span></span><span></span></div><div><span></span><span></span><span></span></div><div>If Y<span></span>ou Suspect T<span></span>rue Angina Follow Mona:</div><div> <span></span><span></span></div><div>Morphine</div><div> <span></span><span></span></div><div>O2 via Nasal Cannula</div><div> <span></span><span></span></div><div>Nitroglycerin (0.4 SL or 1” Nitr<span></span>o Pas<span></span>te)</div><div> <span></span><span></span></div><div>ASA 325mg</div><div> <span></span><span></span></div><div>Bet<span></span>a Blocker (met<span></span>oprolol 5mg IV<span></span>, may repeat in 5 min. </div><div> <span></span><span></span></div><div>Cardiac Enzymes for 24 hours (q8H x3) --<span></span>T<span></span>roponin/Ck-MB, CK</div><div>Consider: </div><div> <span></span><span></span></div><div>Did the patient of angina pr<span></span>e op? If so, is the pain the same as the pain now? </div><div> <span></span><span></span></div><div>Any pre oper<span></span>ative ca<span></span>th to review? </div><div> <span></span><span></span></div><div><span></span><span></span><span></span></div><div> <span></span><span></span></div><div><span></span></div><div>pneumothor<span></span>ax<span></span>, pneumonia, pulmonary embolism, sternal wound infec<span></span>tion, </div><div>aortic dissection, GERD</div><div>For inpa<span></span>tient cardiac catheriz<span></span>ation procedures, p<span></span>age the inter<span></span>ventional </div><div>cardiology fellow on call to arr<span></span>ange.</div><div>CARDIAC: <span>PERICARDIAL T<span></span>AMPONADE</span></div><div>P<span></span>athophysiology: </div><div> <span></span><span></span></div><div><span></span><span></span></div><div><span></span></div><div> <span></span><span></span></div><div><span></span></div><div>Manifes<span></span>tations / Physical E<span></span>xam:</div><div> <span></span><span></span></div><div><span></span><span></span><span></span><span></span></div><div> <span></span><span></span></div><div><span></span><span></span></div><div> <span></span><span></span></div><div>Sudden st<span></span>op in chest tube output</div><div> <span></span><span></span></div><div>Equilibr<span></span>ation dias<span></span>tolic pressures</div><div> <span></span><span></span></div><div><span></span></div><div>early dias<span></span>tole) </div><div> <span></span><span></span></div><div><span></span></div><div>Diagnostics:</div><div> <span></span><span></span></div><div><span></span></div><div><span></span><span> </span><span>(If you have st<span></span>arted 2 inotropes, and given volume, and the pa<span></span>tient is </span></div><div>doing badly (CI &lt; 2.0), you mus<span></span>t rule out tamponade)</div><div> <span></span><span></span></div><div>Chest xr<span></span>ay (widened mediastinum)</div><div> <span></span><span></span></div><div>CBC, Coagulation s<span></span>tudies </div><div>T<span></span>rea<span></span>tment:</div><div> <span></span><span></span></div><div>Give volume, st<span></span>art an inotrope, alert surgical t<span></span>eam</div><div> <span></span><span></span></div><div>Assure chest tube pat<span></span>enc<span></span>y</div><div><span></span><span> </span><span>If visible clot within ches<span></span>t tube obstruc<span></span>ting drainag<span></span>e, discuss with surgical </span></div><div>resident/fellow about using suction ca<span></span>theter t<span></span>o suction out the ches<span></span>t </div><div>tube with st<span></span>erile technique</div><div> <span></span><span></span></div><div>If patient acut<span></span>ely decompensating, may require r<span></span>e-sterno<span></span>tomy in the  </div><div>ICU or OR</div><div>Delayed t<span></span>amponade: </div><div> <span></span><span></span></div><div><span></span><span></span></div><div>usually resolve comple<span></span>tely</div><div> <span></span><span></span></div><div><span></span><span></span><span></span></div><div>clinical sympt<span></span>oms as patients enter a low car<span></span>diac output stat<span></span>e </div><div><span></span><span> </span><span>Gradual incr<span></span>ease in cre<span></span>atinine/BUN</span></div><div><span></span><span> </span><span>Gradual incr<span></span>ease in heart r<span></span>ate</span></div><div><span></span><span> </span><span>Gradual decr<span></span>ease in urine output</span></div><div><span></span><span> </span><span>Decrease in ex<span></span>ercise toleranc<span></span>e</span></div><div> <span></span><span></span></div><div>Diagnostics: Echoc<span></span>ardiogram gold s<span></span>tandard</div><div> <span></span><span></span></div><div>T<span></span>reatment: as above if unst<span></span>able. If stable, c<span></span>onsider pericardial window vs </div><div>need to re-open ches<span></span>t in opera<span></span>ting room</div><div> </div></div><div></div></div>
<div><div><img><div>60<span> </span><span>Pos<span></span>t-Op Management<span> </span>Pos<span></span>t-Op Management<span> </span><span>61</span></span></div><div>CARDIAC:<span> RIGHT VENTRIC<span></span>ULAR F<span></span>AIL<span></span>URE</span></div><div>P<span></span>athophysiology</div><div> <span></span><span></span></div><div>The RV is a thin-walled, crescent<span></span>-shaped structure char<span></span>acterized by low </div><div>resist<span></span>ance, high complianc<span></span>e, and low impedence</div><div> <span></span><span></span></div><div><span></span></div><div> <span></span><span></span></div><div>Ventriculoart<span></span>erial coupling is a major determinant of RV function</div><div>Etiology</div><div>1. <span> </span><span>Preexisting RV dysfunction sec<span></span>ondar<span></span>y to severe coronary disease, pulmonary </span></div><div>hypertension, v<span></span>alvular heart disease, and/<span></span>or RV infarc<span></span>tion</div><div>2. <span> </span><span>Pos<span></span>tsurgical RV dysfunction secondary to long cardiopulmonary bypass </span></div><div>(CPB) time, suboptimal myocar<span></span>dial prot<span></span>ection, and/or c<span></span>oronar<span></span>y embolism</div><div>3. <span> </span><span><span></span><span></span><span></span><span></span></span></div><div>excessive blood tr<span></span>ansfusions, pulmonar<span></span>y embolism, prot<span></span>amine reaction, </div><div>ischemia-reperfusion injury, tension pneumothor<span></span>ax</div><div>4. <span> </span><span>RV pressure overload sec<span></span>ondar<span></span>y to intrinsic pulmonar<span></span>y disease, pulmonary </span></div><div>embolism, and/<span></span>or acute respira<span></span>tory distress syndrome (ARDS)</div><div>Diagnosis</div><div> <span></span><span></span></div><div>High right atrial pressur<span></span>e (RAP) and pulmonar<span></span>y capillary wedge (PCW) </div><div>pressure.  No<span></span>te this is unreliable when L<span></span>V dysfunction is also present</div><div> <span></span><span></span></div><div>May consider TTE to assess IV<span></span>C, tricuspid regurgita<span></span>tion, right ventricle size, </div><div>and sept<span></span>al positioning to guide volume sta<span></span>tus.  </div><div> <span></span><span></span></div><div>Monitor CVP tr<span></span>acing.  With worsening TR and RV dilation, will see rising V </div><div>wave on CVP tr<span></span>acing.  </div><div> <span></span><span></span></div><div>Calculate s<span></span>tep-up (mean P<span></span>A pressure - CVP pressure)</div><div><span></span><span> </span><span>Goal &gt; 10</span></div><div> <span></span><span></span></div><div>Calculate pulmonary arter<span></span>y pulsatility index (P<span></span>APi)</div><div><span></span><span> </span><span>Studied t<span></span>o predict RVAD need in L<span></span>VAD patient<span></span>s</span></div><div><span></span><span> </span><span>P<span></span>APi = (systolic P<span></span>A pressure - dias<span></span>tolic P<span></span>A pressure) / CVP</span></div><div> <span></span><span></span></div><div>P<span></span>APi &gt;2: good RV function</div><div> <span></span><span></span></div><div>P<span></span>APi 1-2: at risk for RV failure</div><div> <span></span><span></span></div><div>P<span></span>APi &lt;1: RV failure</div><div> <span></span><span></span></div><div>For more inf<span></span>ormation on Adv<span></span>anced hemodynamic monitoring and P<span></span>A </div><div>cathe<span></span>ters see <span>page 125.</span></div><div>Management</div><div>1. <span> </span><span>Prevent elevated pulmonary vascular resis<span></span>tance</span></div><div>a. <span> </span><span>Avoid hypoxemia, hyperc<span></span>apnia, and acidosis which increase PVR</span></div><div>2. <span> </span><span>Optimize pr<span></span>eload</span></div><div>a. <span> </span><span>Fluid Administr<span></span>ation</span></div><div>i. <span> </span>Adminis<span></span>ter cr<span></span>yst<span></span>alloids/c<span></span>olloids and/or blood pr<span></span>oducts slowly for low </div><div>cardiac output as long as CVP is low or within t<span></span>arget r<span></span>ange  </div><div>ii.  Do not give additional volume if the cardiac output/blood pressure </div><div>does not improve sinc<span></span>e additional volume may lead to worsening RV </div><div>function acc<span></span>ording to Fr<span></span>ank-S<span></span>tarling mechanism</div><div>b.<span> <span> </span><span>Fluid remov<span></span>al</span></span></div><div>i. <span> </span>Initia<span></span>te diuretics promptly f<span></span>or volume overload and RV dilation/TR.  </div><div>St<span></span>art with Lasix bolus of 10-50 mg IV<span></span>.  If no response to bolus, consider </div><div>rebolus, st<span></span>arting Lasix infusion, and/or adding Diuril IV<span></span>.  </div><div>ii.  If no response to Lasix/Diuril, consider swit<span></span>ching to Bumex infusion </div><div>or st<span></span>arting Nesiritide infusion.  (Note Nesiritide causes sys<span></span>temic </div><div><span></span><span></span></div><div>with loop diuretics).  </div><div>iii. If all the above interventions fail, initiat<span></span>e dialysis.</div><div>3. <span> </span><span><span></span></span></div><div>a. <span> </span><span>Flolan: inhaled epoprost<span></span>enol </span></div><div>i. <span> </span>Pr<span></span>ostacyclin inhibitor that is a pulmonary vasodilat<span></span>or</div><div>ii.  Starting dose 0.05 mc<span></span>g<span></span>/kg<span></span>/min.  When weaning ther<span></span>apy, titra<span></span>te down </div><div>by 0.01 mcg<span></span>/kg<span></span>/min as toler<span></span>ated</div><div><span></span><span></span></div><div>be st<span></span>opped if suspected </div><div>b.<span> <span> </span><span>iNO</span></span></div><div>i. <span> </span>Selec<span></span>tive pulmonar<span></span>y vasodilator only av<span></span>ailable in aerosol </div><div>administr<span></span>ation.  </div><div>ii.  Use only if patient not r<span></span>esponsive to inhaled Flolan</div><div>iii. S<span></span>tarting dose 20 ppm.  When weaning ther<span></span>apy, titr<span></span>ate down by 5 </div><div><span></span><span></span><span></span></div><div><span></span><span></span></div><div>c. <span> </span><span></span></div><div>i. <span> </span>Phosphodies<span></span>terase (PDE) inhibitor tha<span></span>t is both a pulmonar<span></span>y and </div><div>syst<span></span>emic vasodila<span></span>tor<span></span>.</div><div>ii.  Available in oral doses of 5-20 mg TID</div><div>4. <span> </span><span>Optimize c<span></span>ardiac output</span></div><div>a. <span> </span><span>Dopamine</span></div><div><span> </span><span></span><span></span></div><div>doses.</div><div>ii.  Drip rate r<span></span>anges between 1-5 mcg<span></span>/kg<span></span>/min.  May tr<span></span>ansfer out of ICU on </div><div>4 mcg<span></span>/kg<span></span>/min</div><div>b.<span> <span> </span><span>Epinephrine</span></span></div><div><span> </span><span></span><span></span><span></span><span></span><span></span></div><div>kg<span></span>/min</div><div>ii.  Drip rate r<span></span>anges between 0.01-0.2 mcg<span></span>/kg<span></span>/min.  Drip titr<span></span>ated by 0.01 </div><div>mcg<span></span>/kg<span></span>/min</div><div>iii. Import<span></span>ant considerations</div><div>1.  May cause arrthymias at higher doses</div><div>2.  Closely monitor CVP<span></span>/CI/lact<span></span>ates when titra<span></span>ting drip rate</div><div>c. <span> </span><span>Milrinone </span></div><div>i. <span> </span>PDE III inhibit<span></span>or. Provides ino<span></span>tropy and reduces PVR/SVR</div><div>ii.  Drip rate r<span></span>anges between 0.1 – 0.5 mcg<span></span>/kg<span></span>/min</div><div>iii. Import<span></span>ant considerations</div><div>1.  Long half-lif<span></span>e of 1.5-2 hours</div><div>d. <span> </span><span>Dobutamine</span></div><div><span> </span><span></span><span></span></div><div>SVR</div><div>ii.  Drip rate r<span></span>anges between 1-20 mcg<span></span>/kg<span></span>/min.  Half-lif<span></span>e 2 minutes</div><div>iii. Import<span></span>ant considerations</div><div>1.  Causes mild tachyc<span></span>ardia and hypotension</div><div>2.  Incre<span></span>ases myocardial o<span></span>xygen demand</div><div> <span></span><span></span></div><div>5. <span> </span><span>Optimize right he<span></span>art perfusion pressure</span></div></div><div></div></div>
<div><div><img><div>62<span> </span><span>Pos<span></span>t-Op Management<span> </span>Pos<span></span>t-Op Management<span> </span><span>63</span></span></div><div>a. <span> </span><span><span></span><span></span><span></span><span></span></span></div><div>b.<span> <span> </span><span>V<span></span>asopressin</span></span></div><div>i. <span> </span>May c<span></span>ause pulmonar<span></span>y vasodilation at low doses</div><div>ii.  Drip rate r<span></span>anges between 0.01-0.04 units/min</div><div>c. <span> </span><span>Norepinephrine</span></div><div><span> </span><span></span></div><div>ii.  Does increase PVR at higher doses</div><div>iii. Drip r<span></span>ate ranges be<span></span>tween 1-20 mcg<span></span>/min</div><div>d. <span> </span><span>Phenylephrine</span></div><div><span> </span><span></span></div><div>ii.  Like Norepinephrine dose incre<span></span>ase PVR at high doses</div><div>iii. Infusion r<span></span>ates 5-200 mcg<span></span>/min</div><div>6. <span> </span><span>Monitor adequat<span></span>e end organ perfusion:</span></div><div>a. <span> </span><span>SvO2 (either from CC<span></span>O swan or VBG)</span></div><div>b.<span> <span> </span><span>Lact<span></span>ate </span></span></div><div>c. <span> </span><span>UOP<span></span>/Creatinine</span></div><div>d. <span> </span><span>LFT’<span></span>s (R heart failure le<span></span>ads to hepatic cong<span></span>estion)</span></div><div>7. <span> </span><span><span></span><span></span><span></span></span></div><div>consider mechanical cir<span></span>culator<span></span>y support</div><div>a. <span> </span><span>RVAD</span></div><div>b.<span> <span> </span><span>VA ECMO</span></span></div><div>CARDIAC: <span>S<span></span>YS<span></span>TOLIC ANTERIOR MO<span></span>TION (SAM) </span></div><div>OF THE MITRAL V<span></span>AL<span></span>VE</div><div> <span></span><span></span></div><div><span></span><span></span><span></span></div><div>syst<span></span>ole.  T<span></span>ypically seen in patients with HOCM or mitr<span></span>al valve repair<span></span>.</div><div> <span></span><span></span></div><div>Consider in setting of worsening hypo<span></span>tension with increased inotr<span></span>opic </div><div>support</div><div> <span></span><span></span></div><div><span></span></div><div>intraventricular sep<span></span>tum, papillar<span></span>y muscle displacement, and redundant </div><div><span></span><span></span></div><div>Clinical pearls:</div><div>T<span></span>o prevent SAM, the goal is to slow the heart rate t<span></span>o prolong the L<span></span>V lling time </div><div> <span></span><span></span></div><div>Avoid inotropic support, use vasopr<span></span>essors in setting of hypotension</div><div> <span></span><span></span></div><div>Avoid hypovolemia, cautious use of diuretic ther<span></span>apy</div><div> <span></span><span></span></div><div>Once s<span></span>tabilized, consider be<span></span>ta blocker therapy f<span></span>or long term treatment </div><div> <span></span><span></span></div><div>Referenc<span></span>e<span> page 24 </span><span> </span></div><div>CARDIAC: <span>V<span></span>ASOPLEGIA</span></div><div> <span></span><span></span></div><div>Persis<span></span>tent hypot<span></span>ension<span> despite adequate cardiac output fr<span></span>om <span>low systemic </span></span></div><div>vascular resis<span></span>tanc<span></span>e</div><div> <span></span><span></span></div><div><span></span><span></span><span></span><span></span><span></span><span></span></div><div>response. Risk fac<span></span>tors include history of use of <span>ACE inhibitors, ARBs</span>, C<span></span>CBs, </div><div>Amiodarone, B-blockers, and Hep<span></span>arin.</div><div> <span></span><span></span></div><div>T<span></span>reatment:</div><div><span></span><span> </span><span><span></span></span></div><div><span></span><span> </span><span>Phenylephrine<span></span>Norepinephrine<span><span></span></span></span></div><div><span></span><span></span></div><div>needed</div><div><span></span><span> </span><span>Methylene Blue<span> (1-2mg<span></span>/kg bolus) inhibits NO synthase and is used in </span></span></div><div>the trea<span></span>tment of refractory hypotension</div><div>CARDIAC: <span>HEAR<span></span>T F<span></span>AIL<span></span>URE</span></div><div><span></span><span>pos<span></span>t surger<span></span>y because mos<span></span>t </span></div><div><span></span><span>pos<span></span>t surgical st<span></span>ate. However </span></div><div>there are some princip<span></span>als that can help you manage the patient<span></span>s. </div><div>Medications: </div><div> <span></span><span></span></div><div>Do not hold heart f<span></span>ailure medications (bet<span></span>a blockers, ACE inhibitors, </div><div>spironolact<span></span>one) for low blood pressure. Ac<span></span>cept a lower blood pressur<span></span>e </div><div>for heart f<span></span>ailure patients c<span></span>onsider giving them even if your systolic blood </div><div>pressure is in the 90’<span></span>s (e<span></span>ven in the high 80’<span></span>s in some cases). </div><div> <span></span><span></span></div><div><span></span><span></span></div><div>may be harmful in asymptoma<span></span>tic patients with low L<span></span>VEF and no symptoms of </div><div></div><div> <span></span><span></span></div><div>Bet<span></span>a blockers: </div><div><span></span><span> </span><span>Bet<span></span>a blockers should be used in all pa<span></span>tients with a reduced EF to pr<span></span>e<span></span>vent </span></div><div>symptoma<span></span>tic HF<span></span>, even if they do not have a history of MI.  </div><div><span></span><span> </span><span>Consider Coreg ins<span></span>tead of Metopr<span></span>olol for beta blockade: one s<span></span>tudy </span></div><div><span></span></div><div>Metopr<span></span>olol for heart f<span></span>ailure with reduced EF </div><div> <span></span><span></span></div><div>Aerlo<span></span>ad reduction:</div><div><span></span><span> </span><span><span></span><span></span></span></div><div>reduction due t<span></span>o kidney dysfunction. The kidneys will appreciate bet<span></span>ter </div><div><span></span><span></span></div><div>problem</div><div><span></span><span> </span><span><span></span><span></span><span></span></span></div><div>patient<span></span>s who cannot tolera<span></span>ted ACEs or ARBs or who are African Americ<span></span>an </div><div><span></span><span> </span><span>ACE inhibitors should be used in all p<span></span>atients with a reduced EF t<span></span>o prevent </span></div><div>symptoma<span></span>tic HF<span></span>, even if they do not have a history of MI. </div><div> <span></span><span></span></div><div>Diuretics: <span>See volume manag<span></span>ement below </span></div><div>Volume Manag<span></span>ement<span></span>: </div><div> <span></span><span></span></div><div>Don’t over<span></span>-diurese patients with pr<span></span>eser<span></span>ved ejection fraction. They are very </div><div>responsive to volume and c<span></span>ardiac output can disproportiona<span></span>tely drop with </div><div>minimal changes in prelo<span></span>ad. </div><div> <span></span><span></span></div><div>Consider Aldactone or Epler<span></span>enone for pa<span></span>tients that are on a bet<span></span>a blocker and </div><div>ace inhibitor without hyperk<span></span>alemia</div><div> <span></span><span></span></div><div>Lasix is a threshold drug- titr<span></span>ate daily dose until you see a r<span></span>esponse (for </div><div>example- if no response to 20mg daily<span></span>, increase40mg daily inst<span></span>ead of 20mg </div><div>BID). While inpatient, use IV<span></span>. </div><div> <span></span><span></span></div><div>20mg lasix IV = 40 PO = 1 Bumex IV= 10 T<span></span>orsemide PO </div><div> <span></span><span></span></div><div>Consider Diuril or Metolaz<span></span>one for pa<span></span>tients who are diuretic resis<span></span>tant</div><div> <span></span><span></span></div><div>If hyponatremic, it is lik<span></span>ely a hyper<span></span>volemic issue. Diuresis is the appropriate </div><div>response, r<span></span>ather than giving salt t<span></span>abs</div><div> <span></span><span></span></div><div>No pre hydr<span></span>ation for c<span></span>ardiac cathe<span></span>terization or C<span></span>T scan</div><div>Consults: </div><div> <span></span><span></span></div><div>Consider consult to he<span></span>art failure CNS for assis<span></span>tance with c<span></span>omplex patients or </div><div>if you have questions. They are also a gre<span></span>at education resour<span></span>ce for p<span></span>atients. </div><div>Enter as epic order<span></span>.</div></div><div></div></div>
<div><div><img><div>64<span> </span><span>Pos<span></span>t-Op Management<span> </span>Pos<span></span>t-Op Management<span> </span><span>65</span></span></div><div>PULMONARY<span></span>: <span>PLEURAL EFFUSIONS</span></div><div>Type of </div><div>Pleural </div><div>Eusion</div><div>Denition<span> </span><span>Presenta<span></span>tion:<span> </span>Common </span></div><div>causes</div><div>Pleural Fluid </div><div>Interpre<span></span>ta<span></span>tion </div><div>(Lights Criteria)</div><div>Diagnosis<span> </span>T<span></span>reatment </div><div>T<span></span>ransudate</div><div> <span></span><span></span></div><div></div><div>capillaries from: hydros<span></span>tatic </div><div>psi/<span></span>incre<span></span>ased pressure </div><div>(CHF<span></span>, etc) </div><div> <span></span><span></span></div><div></div><div>from nutrition, nephrotic </div><div>syndrome, cirrhosis)</div><div> <span></span><span></span></div><div>Usually occurs bilat<span></span>erally </div><div>Small eusion:<span> </span></div><div>likely </div><div>asymptomatic </div><div>Larger eusion:<span> </span></div><div>dyspnea, cough, </div><div>hypoxia</div><div>Physical exam: </div><div>percussion </div><div></div><div></div><div>absent brea<span></span>th </div><div>sounds over </div><div></div><div> <span></span><span></span></div><div>CHF (most </div><div>common - </div><div>90%)</div><div> <span></span><span></span></div><div>Cirrhosis</div><div> <span></span><span></span></div><div>Nephrosis</div><div> <span></span><span></span></div><div>Prot<span></span>ein ≤ 3 gm% </div><div> <span></span><span></span></div><div></div><div>protein/serum </div><div>protein&lt;0.5</div><div> <span></span><span></span></div><div></div><div>serum LDH &lt; 0.6 </div><div> <span></span><span></span></div><div></div><div>&lt; 2/3 upper limit </div><div>normal</div><div> <span></span><span></span></div><div>CXR P<span></span>A &amp; Lateral, </div><div>later<span></span>al decubitus</div><div> <span></span><span></span></div><div>CT may be indica<span></span>ted </div><div>to evaluat<span></span>e etiolog<span></span>y of </div><div></div><div> <span></span><span></span></div><div>US-Guided Diagnostic </div><div>horac<span></span>entesis  </div><div>c.  <span></span></div><div>protein &amp; lac<span></span>tate </div><div>hydrogenase </div><div></div><div>transudat<span></span>es vs. </div><div>exudates. </div><div>d. <span></span><span>b) PH, tot<span></span>al &amp; </span></div><div><span></span></div><div>counts, gluc<span></span>ose, </div><div>cytology, gram </div><div>st<span></span>ain, culture, etc </div><div><span></span></div><div>exudate subtypes (if </div><div>indicated)</div><div> <span></span><span></span></div><div>Correct underlying c<span></span>ondition</div><div> <span></span><span></span></div><div>Common in immediate pos<span></span>t op setting, </div><div>consider need for diur<span></span>esis</div><div> <span></span><span></span></div><div>Therapeutic thor<span></span>acentesis for severe dyspnea</div><div>E<span></span>xudate</div><div> <span></span><span></span></div><div></div><div>abnormal capillaries leaking </div><div></div><div>drainage such as c<span></span>ancer).</div><div> <span></span><span></span></div><div>Exudat<span></span>es imply local pleural </div><div>diseases</div><div> <span></span><span></span></div><div>Exudat<span></span>es – subtypes: </div><div>e. <span> </span><span>Empyema’<span></span>s: direct </span></div><div>infection of an exudat<span></span>es. </div><div>f.<span></span><span> <span> </span><span>Hemothorax: gross blood </span></span></div><div>in pleural sp<span></span>ace from </div><div>trauma. </div><div>g. <span> </span><span>Chylothorax: thor<span></span>acic </span></div><div>duct disruption causes </div><div>cholester<span></span>ol complex </div><div>accumulation, usually </div><div>associated with </div><div>lymphoma and thoracic </div><div>surgery.</div><div> <span></span><span></span></div><div>Can occur bilat<span></span>erally or </div><div>Unilater<span></span>ally </div><div>Usually </div><div>inammatory </div><div>causes:</div><div> <span></span><span></span></div><div>Bacterial </div><div>Pneumonia</div><div> <span></span><span></span></div><div>Cancer</div><div> <span></span><span></span></div><div>T<span></span>rauma</div><div> <span></span><span></span></div><div>Prot<span></span>ein ≥ 3 gm% </div><div> <span></span><span></span></div><div></div><div>protein/serum </div><div>protein &gt; 0.5</div><div> <span></span><span></span></div><div></div><div>serum LDH &gt; 0.6</div><div> <span></span><span></span></div><div></div><div>&gt; 2/3 upper limit </div><div>normal</div><div>Exudat<span></span>es associated with pneumonias = </div><div>par<span></span>apneumonic pleural eusions. </div><div>Step 1: tr<span></span>eat pneumonia. </div><div></div><div> <span></span><span></span></div><div><span></span></div><div><span></span></div><div>antibiotic.  </div><div> <span></span><span></span></div><div><span></span></div><div><span></span></div><div>thorac<span></span>ostomy  (ches<span></span>t tube) or surger<span></span>y<span></span>. </div><div> <span></span><span></span></div><div><span></span></div><div>decortica<span></span>tion usually)</div><div>Exudat<span></span>es associated with malignancy = </div><div>malignant pleural eusions <span>(L<span></span>ung or breast </span></div><div>cancer c<span></span>ommon)</div><div>T<span></span>reatment options:</div><div> <span></span><span></span></div><div>T<span></span>reat the canc<span></span>er</div><div> <span></span><span></span></div><div><span></span></div><div>may help with symptoms (shortness of bre<span></span>ath, </div><div>dyspnea, et<span></span>c). </div><div> <span></span><span></span></div><div>Pleurodesis.</div><div>PULMONARY<span></span>: <span>PNEUMO<span></span>THORAX</span></div><div>Presence of air or gas in the pleur<span></span>al cavity (ie, the potential space be<span></span>tween the </div><div>visceral and parie<span></span>tal pleura of the lung), which can impair o<span></span>xygenation and/or </div><div>ventilation</div><div>1. <span> </span><span>Etiology</span></div><div>a. <span> </span><span>Entering the pleural sp<span></span>ace during surgery or with sternal wire plac<span></span>ement</span></div><div>b.<span> <span> </span><span>Rup<span></span>tured bleb in pa<span></span>tient with underlying lung disease</span></span></div><div>c. <span> </span><span>Barotr<span></span>auma from alveolar overdis<span></span>tention during mechanical ventilation </span></div><div>may manifest as pneumo<span></span>thorax, subcutaneous emphysema or </div><div>pneumomediastinum </div><div>2. <span> </span><span>Clinical manifes<span></span>tations</span></div><div>a. <span> </span><span>Hypoxia, dyspnea, t<span></span>achypnea</span></div><div>b.<span> <span> </span><span>Airle<span></span>ak on chest tube: may indicate loose c<span></span>onnections along the drainage </span></span></div><div>syst<span></span>em or pneumothor<span></span>ax</div><div>c. <span> </span><span>Subcutaneous emphysema: may develop if air exists under positive </span></div><div>pressure where the pleur<span></span>a has been violated. </div><div>d. <span> </span><span>T<span></span>ension pneumothor<span></span>ax: <span>collapsed lung causing cardiac c<span></span>ompression, </span></span></div><div><span></span><span></span></div><div>output</div><div>e. <span> </span><span><span></span></span></div><div><span> </span><span></span></div><div>3. <span> </span><span> <span></span>T<span></span>reatment consider<span></span>ations</span></div><div>a. <span> </span><span><span></span></span></div><div>assure chest tube is a<span></span>ttached t<span></span>o suction, look for kinks in tubing</div><div>b.<span> <span> </span><span><span></span><span></span></span></span></div><div>oxygen and c<span></span>onsider placement of chest tube/pigtail </div><div>c. <span> </span><span>If patient asympt<span></span>omatic and pneumothorax small, appropria<span></span>te to </span></div><div>obser<span></span>ve with serial ches<span></span>t x-rays</div><div>Referenc<span></span>es:</div><div>Bojar<span></span>, Robert M. (2011) Manual of Perioper<span></span>ative Care in Adult Cardiac Surgery. (5th  <span></span>edition).</div><div> </div><div>PULMONARY<span></span>: <span>PULMONARY HYPER<span></span>TENSION</span></div><div>1. <span> </span><span>Etiology: relat<span></span>ed to primary pulmonar<span></span>y arterial HTN or secondary to </span></div><div>elevations of pressur<span></span>e in the pulmonar<span></span>y venous and capillar<span></span>y sys<span></span>tems</div><div>a. <span> </span><span>Chronic Pulmonar<span></span>y HTN</span></div><div>i. <span> </span>Cong<span></span>enital heart disease, Connec<span></span>tive tissue disease (lupus, </div><div>rheumatoid arthritis, scler<span></span>oderma), Medication/toxin induc<span></span>ed</div><div>ii.  Chronic thromboembolic disease</div><div>iii. <span>Lung dise<span></span>ase: </span></div><div><span> <span></span><span></span><span></span><span></span><span></span><span></span><span></span><span></span><span></span><span></span><span></span><span></span></span></div><div>OSA</div><div>2.  Result of pulmonary vascular remodeling from chr<span></span>onic hypoxia and </div><div></div><div>iv. <span>Le Heart Dise<span></span>ase: <span><span></span><span></span></span></span></div><div>venous pressure</div><div>1.  L<span></span>V systolic or dias<span></span>tolic heart f<span></span>ailure</div><div>2.  Mitral and aortic v<span></span>alve disease </div><div>b.<span> <span> </span><span>Acute Pulmonary HTN</span></span></div><div>i. <span> </span>Pr<span></span>otamine reac<span></span>tion</div><div>1.  T<span></span>ype 3 protamine r<span></span>eaction may result in<span> severe pulmonary </span></div><div>vasoc<span></span>onstriction, sys<span></span>temic v<span></span>asodilation<span> and</span> acute right heart </div><div>failure </div></div><div></div></div>
<div><div><img><div>66<span> </span><span>Pos<span></span>t-Op Management<span> </span>Pos<span></span>t-Op Management<span> </span><span>67</span></span></div><div>2.  T<span></span>ypically improves within 10 minutes of s<span></span>topping protamine</div><div>ii.  <span>Acidosis/Hypox<span></span>emia<span>: lead to increased pulmonary vascular </span></span></div><div>resist<span></span>ance</div><div>iii. T<span></span>ension Pneumothorax</div><div>iv. Pulmonar<span></span>y embolism</div><div>v.<span> <span> </span><span>Acute MR</span> (ie papillary muscle rupture)/<span>L<span></span>V failure<span> leading t<span></span>o high LA </span></span></span></div><div>pressure and pulmonary edema</div><div><span></span><span></span></div><div>2. <span> </span><span>T<span></span>reatment in the acut<span></span>e setting</span></div><div>a. <span> </span><span>Identify underlying cause/<span></span>contributing fact<span></span>ors</span></div><div>b.<span> <span> </span><span>Pulmonary Vasodilators</span></span></div><div>i. <span> </span><span>Indic<span></span>ations<span>: severe pulmonar<span></span>y hypertension (mP<span></span>AP &gt; 25 mmHg; RAP &gt; </span></span></div><div>15 mmHg; CI &lt; 2.0 L/min), right ventricular failure, ARDS with persis<span></span>tent </div><div>hypoxia (P:F &lt; 200), and pos<span></span>t-op lung tr<span></span>ansplant with reperfusion </div><div><span></span><span></span><span></span></div><div>ii.  Inhaled aerosol results in <span>dila<span></span>tion of the pulmonary vascular bed </span></div><div>thereby <span>reducing pulmonary artery pressure</span>, pulmonary vascular </div><div>resist<span></span>ance, and <span>right ventricular aerlo<span></span>ad<span>. This results <span>in improved </span></span></span></div><div>in VQ mismat<span></span>ch and oxygena<span></span>tion<span>.  </span></div><div>1.  <span>Flolan (epopros<span></span>teronol) *Preferr<span></span>ed*</span></div><div> <span> </span>a.  Av<span></span>ailable as IV or aerosol administr<span></span>ation.  IV administra<span></span>tion  </div><div> <span>(rar<span></span>ely used) causes syst<span></span>emic vasodilation</span></div><div> <span> </span><span>b.</span> <span> </span>Starting dose 0.05 mcg/kg<span></span>/min.  When weaning therapy,  </div><div> <span>titra<span></span>te down by 0.01 mcg<span></span>/kg<span></span>/min ever<span></span>y hour as toler<span></span>ated </span></div><div>2.  <span>iNO</span></div><div> <span> </span>a.  Only av<span></span>ailable in aerosol administr<span></span>ation.  </div><div> <span> </span><span>b.</span> <span> </span>Starting dose 20 ppm.  When we<span></span>aning therapy, titr<span></span>ate down by </div><div><span></span><span></span><span></span></div><div><span></span><span></span><span></span></div><div>iii. <span>Sildenal:</span> PDE inhibitor pr<span></span>e<span></span>vents de<span></span>grada<span></span>tion of cGMP and reduces </div><div>pulmonar<span></span>y v<span></span>ascular tone</div><div>a.  S<span></span>tarting dose 10-20mg TID</div><div><span><span> </span><span></span><span></span><span></span></span></div><div><span></span><span></span></div><div>Sussex, UK: Wiley-Blackwell</div><div> </div><div>PULMONARY<span></span>: <span>AC<span></span>UTE RESPIRA<span></span>T<span></span>ORY DIS<span></span>TRESS </span></div><div>SYNDROME (ARDS)</div><div>1. <span> </span><span>P<span></span>athophysiology</span></div><div>a. <span> </span><span><span></span></span></div><div>lungs</div><div>b.<span> <span> </span><span><span></span></span></span></div><div>capillaries</div><div>c. <span> </span><span>Results in non-cardiog<span></span>enic interstitial edema</span></div><div>d. <span> </span><span><span></span><span></span></span></div><div>e. <span> </span><span>Hypoxic and ventilator f<span></span>ailure </span></div><div>2. <span> </span><span>Pre-disposing conditions: </span></div><div>a. <span> </span><span><span></span><span></span></span></div><div><span> </span><span></span><span></span><span></span><span></span><span></span></div><div>however ARDS only occurs in &lt;1% of pa<span></span>tients underg<span></span>oing open heart </div><div>surgery</div><div>ii.  Sepsis</div><div>3. <span> </span><span>Diagnostic Crit<span></span>eria</span></div><div>a. <span> </span><span>Acute onset</span></div><div>b.<span> <span> </span><span><span></span><span></span><span></span><span></span></span></span></div><div>c. <span> </span><span>PCWP &lt;18, or no clinical evidence of L heart f<span></span>ailure, non-cardiogenic </span></div><div>pulmonar<span></span>y edema</div><div>d. <span> </span><span><span></span><span></span><span></span><span></span></span></div><div>i. <span> </span>P<span></span>/F r<span></span>atio = PaO2 ÷ FiO</div><div>1.  Ex: P<span></span>aO2 90 on FiO2 40% = 90 ÷ 0.4 = 225</div><div>ii.  <span>P<span></span>/F &lt; 200 is associated with signicant shunt and indic<span></span>ates ARDS</span></div><div>iii. P<span></span>/F 200-300 indicat<span></span>es acute lung injur<span></span>y</div><div>4. <span> </span><span>Management</span></div><div>a. <span> </span><span>Optimize hemodynamics and volume s<span></span>tatus, diurese when indica<span></span>ted</span></div><div>b.<span> <span> </span><span>Op<span></span>timize nutrition</span></span></div><div>c. <span> </span><span><span></span><span></span></span></div><div></div><div>d. <span> </span><span>Lung Prot<span></span>ective Ventilation (LPV) Pr<span></span>otoc<span></span>ol: <span>Limits ventilator induced </span></span></div><div>lung injur<span></span>y</div><div>i. <span> </span>Purpose: T<span></span>o maximize gas exchange using low tidal volumes (4-6 mL/</div><div>kg) and minimizing plateau pr<span></span>essures (&lt; 30 cm H2O) in all patients </div><div>with ARDS</div><div> <span></span><span></span><span></span></div><div></div><div>iii. <span>Goals: VT 6 mL/k<span></span>g, pH 7.30 – 7.45, Pplat &gt; 30 cm H2O, EIP</span></div><div>iv. Prescriber must de<span></span>termine ventilat<span></span>or mode (VCV or PCV) and PEEP </div><div>(st<span></span>andard or high)</div><div>v.<span></span><span> <span> </span>Volume Control Ventila<span></span>tion (VCV)</span></div><div>1.  Set VT at 8 mL/k<span></span>g using patient’<span></span>s predicted body weight (PBW).  </div><div>Slowly decrease VT by 1 mL/k<span></span>g until target VT is achieved </div><div>2.  Set respir<span></span>atory rate to b<span></span>aseline minute ventilation (do not exc<span></span>eed 35 </div><div>brea<span></span>ths/min)</div><div>3.  Add PEEP at 5-7 cm H2O to g<span></span>oal P<span></span>aO2 &gt; 55 and SaO2 &gt; 88% (see </div><div>table below)</div><div>4.  Adjust VT t<span></span>o achie<span></span>ve t<span></span>arget plate<span></span>au pressure (Pplat)</div><div> <span> </span>a.  If Ppla<span></span>t &gt; 30 cm H2O, decrease VT by 1 mL/kg until Pplat &lt; 30 or  </div><div> <span>VT 4 mL/kg</span></div><div> <span> </span><span>b.</span> <span> </span>If Pplat &lt; 25 and VT &lt; 6 mL/kg, increase VT by 1 mL/k<span></span>g until Pplat  </div><div> <span>&gt; 25 or VT 6 mL/kg</span></div><div> <span> </span>c.  If Pplat &lt; 30 and vent dysnchrony, may incr<span></span>ease VT by 1 mL/kg to <span></span> </div><div> <span>8 mL/kg and/<span></span>or increase sedation</span></div><div>5.  Adjust r<span></span>espiratory rate t<span></span>o achie<span></span>ve t<span></span>arget pH </div><div>6.  If pH &lt; 7.30, incre<span></span>ase RR to max 35 bre<span></span>aths/min</div><div>7.  If pH &lt; 7.15 and RR 35 bre<span></span>aths/min, incre<span></span>ase VT by 1 mL/kg to a max </div><div>of 8 mL/kg until pH &gt; 7.15</div><div>vi. <span></span> Pressure Control V<span></span>entilation (PCV)</div><div>1.  PCV is similar to above however end-inspira<span></span>tor<span></span>y pressure (EIP) is </div><div>adjust<span></span>ed to achieve goal VT (tidal volume).</div><div>2.  If EIP &lt; 10 cm H2O and VT &gt; 7 mL/kg, incre<span></span>ase EIP in order to </div><div>increase t<span></span>o a maximum EIP 35 cm H2O </div><div>3.  If EIP is decre<span></span>ased to 10 cm H2O &gt; PEEP and VT &gt; 7 mL/kg or if </div><div>patient exhibiting incr<span></span>eased work of breathing, c<span></span>onsider increasing </div><div>sedation.  If unable to incr<span></span>ease sedation, may incr<span></span>ease VT by 1 mL/</div><div>kg to max VT 8 mL/k<span></span>g.</div><div>4.  Once work of br<span></span>eathing decreased, decr<span></span>eased EIP b<span></span>ack to t<span></span>arge<span></span>t VT </div><div>5-7 mL/kg</div></div><div></div></div>
<div><div><img><div>68<span> </span><span>Pos<span></span>t-Op Management<span> </span>Pos<span></span>t-Op Management<span> </span><span>69</span></span></div><div>vii. PEEP<span></span>/FiO2 titration</div><div>1.  Goal SaO2 88-95% or P<span></span>aO2 55-80%</div><div>FiO2<span> </span>30%<span> </span>40%<span> </span>50%<span> </span>60%<span> </span>70%<span> </span>80%<span> </span>90%<span> </span>100%</div><div>St<span></span>andard PEEP<span> </span>5<span> </span>5-8<span> </span>8-10<span> </span>10<span> </span>10-14<span> </span>14<span> </span>14-18<span> </span>18-20</div><div>High PEEP<span> </span>8-10<span> </span>10-12<span> </span>12-14<span> </span>14-16<span> </span>16-18<span> </span>18-20<span> </span>20-22<span> </span>22-24</div><div>Sources:</div><div><span></span><span></span></div><div>UK: Wiley-Blackwell</div><div>Marino, P<span></span>. (2009). The Little ICU Book. Philadelphia, P<span></span>A: Lippincott Williams &amp; Wilkins</div><div> </div><div>PULMONARY<span></span>: <span>A<span></span>TELECT<span></span>ASIS</span></div><div>At<span></span>elect<span></span>asis:<span> collapse or closure of a lung r<span></span>esulting in reduced or absent gas </span></div><div>exchange</div><div>1. <span> </span><span>Etiology:</span></div><div>a. <span> </span><span>Obstructive: block<span></span>age in the pro<span></span>ximal air<span></span>way leads t<span></span>o nonventilated </span></div><div>alveoli that collapse</div><div>b.<span> <span> </span><span>P<span></span>assive/Compressive:<span><span></span></span></span></span></div><div><span></span></div><div>c. <span> </span><span><span></span><span></span><span>  pain (splinting), over-seda<span></span>tion, or prolonged </span></span></div><div>supine positioning</div><div>2. <span> </span><span>Clinical manifes<span></span>tations</span></div><div>a. <span> </span><span>Hypoxia, dyspnea</span></div><div>b.<span> <span> </span><span><span></span></span></span></div><div>c. <span> </span><span>Fever, elev<span></span>ated WBC count, PNA</span></div><div>3. <span> </span><span>T<span></span>reatment c<span></span>onsiderations</span></div><div>a. <span> </span><span>Identify and address underlying causes: </span></div><div>i. <span> </span>Achieve adequat<span></span>e pain control, decre<span></span>ase sedation</div><div> <span></span></div><div>iii. Assess for evidence of PNA and trea<span></span>t appropriately</div><div>b.<span> <span> </span><span>Alveolar R<span></span>ecruitment Maneuvers: </span></span></div><div>i. <span> </span>Using incr<span></span>eased PEEP via ventilator or CP<span></span>AP </div><div>1.  Incre<span></span>ase mean airway pressure to open closed alveoli t<span></span>o increase </div><div>surfac<span></span>e area for gas ex<span></span>change</div><div>2.  Decre<span></span>ase VQ mismat<span></span>ch/<span></span>intr<span></span>apulmonar<span></span>y shunting (improves </div><div>ventilation to perfused ar<span></span>eas)</div><div>ii.  Incentive spiromet<span></span>er. Goal volume &gt;1L.</div><div>1.  Maintains F<span></span>unctional Reser<span></span>ve Cap<span></span>acity (FRC)</div><div>2.  Prevents and improves a<span></span>telectasis</div><div>c. <span> </span><span>Bronchial Hygiene Therap<span></span>y (“Pulmonary T<span></span>oilet”)</span></div><div>1.  Purpose: T<span></span>o help loosen and mobilize pulmonary secretions </div><div>2.  Indications: mobiliz<span></span>ation of ret<span></span>ained secretions, atelec<span></span>tasis, optimize </div><div>deliver<span></span>y of bronchodila<span></span>tors</div><div>3.  Contraindic<span></span>ations: hemodynamic instability<span></span>, recent f<span></span>acial/<span></span>oral/<span></span>cranial </div><div><span></span><span></span><span></span><span></span></div><div>active hemoptysis, nause<span></span>a/vomiting, radiographic evidence of bled/</div><div>bullae, frac<span></span>tured ribs or unst<span></span>able chest, untreat<span></span>ed pneumothorax, and </div><div>compromised c<span></span>ardiac sta<span></span>tus or arrhythmias.</div><div>4.  Therapies (may be c<span></span>ombined with bronchodilating nebulizers for  </div><div></div><div>Acapella<span> </span>Intrapulmonary Per<span></span>cussive </div><div>Ventilation (IPV)</div><div>Chest Physio<span></span>therapy (CPT)</div><div>A resistive/vibr<span></span>ator<span></span>y device </div><div>that is used to open the </div><div>airways and provide </div><div>oscillating vibra<span></span>tions to help </div><div>loosen secretions</div><div>Pneumatic device that </div><div>delivers pressurized </div><div>minibursts of g<span></span>as at rates of </div><div>100-225 cycles per minute </div><div>through a mouthpiece t<span></span>o </div><div>achieve alveolar recruitment</div><div>T<span></span>echnique that uses manual </div><div>or mechanical ext<span></span>ernal </div><div>percussion and vibra<span></span>tion </div><div>to loosen secretions and </div><div>promote cle<span></span>arance</div><div>Sources:</div><div><span></span><span></span></div><div>UK: Wiley-Blackwell</div><div>Adams, G. (2006). On Call Surgery, 3rd Edition. Philadelphia, P<span></span>A: Saunders Elsevier</div><div>Marino, P<span></span>. (2009). The Little ICU Book. Philadelphia, P<span></span>A: Lippincott Williams &amp; Wilkins</div><div>GI: <span>AC<span></span>UTE HEP<span></span>A<span></span>TIC D<span></span>YSFUNCTION</span></div><div>About 25% of patients will develop transient hyperbilirubinemia a<span></span>er open heart </div><div>surgery, but f<span></span>ewer than 1% of patients will have signicant hepatocellular damage </div><div>leading to chronic hepatitis or liver failur<span></span>e</div><div>1. <span> </span><span>Risk F<span></span>actors</span></div><div>a. <span> </span><span>Preexisting liver dise<span></span>ase: </span></div><div>i. <span> </span>Elev<span></span>ated liver enzymes (AS<span></span>T<span></span>/AL<span></span>T), elevated bilirubin, or evidence of </div><div>synthetic dysfunction (low albumin, high INR)</div><div>ii.  Elevated bilirubin in p<span></span>atient w/hx CHF is s<span></span>trongest predic<span></span>tor of post-op </div><div>liver dysfunction</div><div>b.<span> <span> </span><span>Comorbidities: CHF (high right sided pressur<span></span>e leading to conges<span></span>tive </span></span></div><div>hepat<span></span>omegaly), DM, HTN</div><div>c. <span> </span><span>Preopera<span></span>tive cardiogenic shock: may have evidence of “shock liver” prior </span></div><div>to surg<span></span>er<span></span>y</div><div>d. <span> </span><span>Operative risk f<span></span>actors:</span></div><div>i. <span> </span>L<span></span>ong cardiopulmonar<span></span>y bypass time</div><div>ii.  Complex operations (ie c<span></span>ombined CABG-valve, multiple valves)</div><div>iii. Multiple blood tr<span></span>ansfusions</div><div>e. <span> </span><span>Post<span></span>-operative risk f<span></span>actors</span></div><div>i. <span> </span>L<span></span>ow cardiac output syndrome</div><div>ii.  Use of multiple inotropes/IABP</div><div>II.  <span>E<span></span>tiolog<span></span>y:<span> <span>may result f<span></span>rom either decreased liver perfusion or systemic </span></span></span></div><div>congestion</div><div>Hepat<span></span>ocellular Necrosis<span> </span>Hyperbilirubinemia</div><div> <span></span><span></span></div><div>Low car<span></span>diac output stat<span></span>es <span>(requiring </span></div><div>inotropes/v<span></span>asopressors) </div><div><span> decreased </span></div><div>hepatic perfusion</div><div> <span></span><span></span></div><div>Right heart failur<span></span>e/severe TR<span> <span></span></span></div><div>chronic passive hep<span></span>atic congestion</div><div> <span></span><span></span></div><div>Medications (T<span></span>ylenol, Plavix, sta<span></span>tins)</div><div> <span></span><span></span></div><div>Pos<span></span>t-tr<span></span>ansfusion hepatitis/CMV (late </div><div>manifest<span></span>ation)</div><div> <span></span><span></span></div><div>Hemolysis<span> (par<span></span>avalvular leak, long </span></div><div>pump run, sepsis, multiple transfusions, </div><div>ECMO, drugs)</div><div> <span></span><span></span></div><div>Intrahep<span></span>atic choles<span></span>tasis<span> (hep<span></span>atitis, </span></div><div>hepat<span></span>ocellular necrosis, TPN, b<span></span>acterial </div><div>infections, medica<span></span>tions, benign </div><div>cholest<span></span>asis)</div><div> <span></span><span></span></div><div>E<span></span>xtr<span></span>ahepatic cong<span></span>estion<span> (biliar<span></span>y tr<span></span>act </span></div><div>obstruction)</div></div><div></div></div>
<div><div><img><div>70<span> </span><span>Pos<span></span>t-Op Management<span> </span>Pos<span></span>t-Op Management<span> </span><span>71</span></span></div><div>2. <span> </span><span>Clinical manifes<span></span>tations</span></div><div>a. <span> </span><span>Jaundice</span></div><div>b.<span> <span> </span><span>Co<span></span>agulopathy</span></span></div><div>c. <span> </span><span>Refract<span></span>or<span></span>y acidosis</span></div><div>d. <span> </span><span>Hypoglycemia</span></div><div>e. <span> </span><span>Renal failure (hep<span></span>atorenal syndrome)</span></div><div>f.<span></span><span> <span> </span><span>Encephalopa<span></span>thy</span></span></div><div>3. <span> </span><span>Work<span></span>-up: <span>in addition to basic labs/LFT’<span></span>s consider further investigation with the </span></span></div><div>following</div><div>a. <span> </span><span>Order T<span></span>ot<span></span>al and Fractiona<span></span>ted bilirubin: </span></div><div>i. <span> </span>Mos<span></span>tly <span>Conjugat<span></span>ed<span> (Direct): biliary obstruction (s<span></span>tone, mass, PSC) or </span></span></div><div>cholest<span></span>asis (sepsis/hypoperfusion sta<span></span>tes, choles<span></span>tasis, TPN)</div><div>ii.  Mostly <span>Unconjug<span></span>ated<span> (Indirec<span></span>t): hemolysis, hepatic conges<span></span>tion/</span></span></div><div>decreased bili up<span></span>take (heart f<span></span>ailure)</div><div>b.<span> <span> </span><span>Assess for <span>hemolysis</span>: LDH, haptoglobin, plasma fr<span></span>ee hemoblogin, </span></span></div><div>reticulocyte c<span></span>ount</div><div>c. <span> </span><span>A<span></span>ssess for <span>right he<span></span>art failure<span>/ </span></span></span></div><div>TR: echo</div><div>d. <span> </span><span>A<span></span>ssess for <span>biliary obstruc<span></span>tion/cholecys<span></span>titis<span>: Alk Phos, right upper </span></span></span></div><div><span></span><span></span><span></span></div><div>i. <span> </span>Acut<span></span>e Cholec<span></span>ys<span></span>titis: gall bladder wall thickening, str<span></span>anding, </div><div></div><div>ii.  Stone/<span></span>obstruction: s<span></span>tone, ductal dilit<span></span>ation</div><div>e. <span> </span><span>Revie<span></span>w medica<span></span>tions for hepato<span></span>toxicity</span></div><div>f.<span></span><span> <span> </span><span>A<span></span>ssess for acut<span></span>e hepatitis: hepatitis p<span></span>anel</span></span></div><div>g. <span> </span><span>A<span></span>ssess for synthe<span></span>tic dysfunction: coag p<span></span>anel, albumin, glucose, lactat<span></span>e</span></div><div>h. <span> </span><span>A<span></span>ssess for encephalop<span></span>athy: exam, ammonia level</span></div><div>4. <span> </span><span>Management<span>: <span>elevat<span></span>ed bilirubin usually benign and self-limited post-oper<span></span>ative </span></span></span></div><div>occurrenc<span></span>e. Will gradually improve with normal hemodynamics unless severe </div><div>underlying liver pathology is present</div><div>a. <span> </span><span>Address underlying cause</span></div><div>i. <span> </span>Right he<span></span>art failure/TR: Refer t<span></span>o “Right Heart Failure<span></span>” section</div><div>ii.  Bilar<span></span>y obstruc<span></span>tion, consider:</div><div>1.  ERCP<span></span>/MRCP: for st<span></span>one in common bile duct w/<span></span>acute cholangitis (GI </div><div>medicine consult)</div><div>2.  P<span></span>ercut<span></span>aneous cholecystos<span></span>tomy tube (placed by IR)</div><div>3.  Cholecystec<span></span>tomy (General surgery consult)</div><div>b.<span> <span> </span><span>Monitor and tr<span></span>eat hypoglycemia</span></span></div><div>c. <span> </span><span>Judicious reversal of coagulop<span></span>athy if present</span></div><div>d. <span> </span><span>Avoid hepatot<span></span>oxic medications</span></div><div>e. <span> </span><span>If Ammonia elevated and evidence of enc<span></span>ephalopathy: consider </span></div><div>Lactulose 30 Q8</div><div>f.<span></span><span> <span> </span><span>Monitor for <span>lactic acidosis </span>(imp<span></span>aired lacta<span></span>te met<span></span>abolism) and correct pH </span></span></div><div>with sodium bicarb when indica<span></span>ted</div><div>Sources:</div><div><span></span><span></span></div><div>UK: Wiley-Blackwell</div><div>Roy-Chowdhury, N. Diagnostic appro<span></span>ach to the adult with jaundice or asymp<span></span>tomatic </div><div>hyperbilirubinemia. www.uptoda<span></span>te.com</div><div>GI: <span>C<span></span>ONSTIP<span></span>A<span></span>TION AND ILLEU<span></span>S</span></div><div>Cardiac Surg<span></span>er<span></span>y P<span></span>ost<span></span>-Operative Bo<span></span>wel regimen:</div><div>Medication<span> </span>Dose<span> </span>Frequency<span> </span>Onset of <span></span>Action</div><div>Docusate (Colac<span></span>e) <span> </span>200mg PO<span> </span>BID<span> </span>24-72 hours</div><div>Polyethylene Glyc<span></span>ol (Miralax)<span> </span>17g Pack<span></span>et<span> </span>Daily<span> </span>1-4 days</div><div>Senna (Senokot)<span> </span>2 tabs PO<span> </span>qHS PRN<span> </span>6-12 hours</div><div>Bisacodyl (Dulcolax) Supposit<span></span>or<span></span>y<span> </span>10mg Rec<span></span>tal<span> </span>Daily PRN<span> </span>15-60 minutes</div><div>Magnesium hydroxide (MOM)<span> </span>30mL Oral<span> </span>Q8 hours PRN</div><div>Magnesium Citrat<span></span>e<span> </span>150-300mL Oral<span> </span>Once<span> </span>30 minutes- 3 hours</div><div>Lactulose<span> </span>20mg<span> </span>TID<span> </span>Up to 24 -48 hours</div><div>St<span></span>anford BOMB<span> </span>Sterile wa<span></span>ter for </div><div>irrigation 300mL, </div><div>magnesium citrat<span></span>e </div><div>200mL, Glucerin Bulk </div><div>100% 199mL</div><div>Once<span> </span>Immediate</div><div> </div><div>*For VAD bowel r<span></span>egimen pro<span></span>tocol see r<span></span>eference mat<span></span>erials VAD BOWEL REGIMEN </div><div>page 138.</div><div>Ileus Management:</div><div> <span></span><span></span></div><div>Management of ileus s<span></span>tart<span></span>s with correc<span></span>tion of underlying medical conditions, </div><div>such as sepsis, electrolyt<span></span>e abnormalities, particularly hypokalemia, </div><div>hyponatremia, and hypomagnesemia. </div><div> <span></span><span></span></div><div>Consider need for NG or rect<span></span>al tube for decompression. F<span></span>or se<span></span>vere illeus- </div><div>consider c<span></span>onsult to general surg<span></span>er<span></span>y or GI. </div><div> <span></span><span></span></div><div>Bowel regimen for ileus manag<span></span>ement can include BID suppositor<span></span>y<span></span>/enema. </div><div>DO NOT U<span></span>SE PERIST<span></span>AL<span></span>TIC AGENT<span></span>S FOR ILLEUS MANAGEMENT<span></span>. </div><div> <span></span><span></span></div><div>For pro<span></span>tracted ileus, contr<span></span>ast studies may be r<span></span>equired to rule out mechanical </div><div>obstruction.</div><div> <span></span><span></span></div><div>Discontinue and limit the use of medica<span></span>tions that produce ileus (eg, opia<span></span>tes, </div><div>narco<span></span>tics), and use (NSAIDs) instead (unless c<span></span>ontraindicated). </div><div> <span></span><span></span></div><div>Advisable to delay or<span></span>al feeding until ileus resolves clinic<span></span>ally. Consider need </div><div></div><div> <span></span><span></span></div><div>Most cases of pos<span></span>toperative ileus r<span></span>esolve with watchful waiting and </div><div>supportive trea<span></span>tment<span></span>. </div><div><span></span><span>see <span>page 91.</span></span></div><div>GI: <span>POS<span></span>T<span></span>-OPERA<span></span>TIVE GI BLEEDING</span></div><div>1.<span> <span> </span><span>Upper GIB<span>: <span>may pr<span></span>esent<span></span> as he<span></span>matem<span></span>esis<span></span>, bloo<span></span>dy NG/<span></span>OG tub<span></span>e outp<span></span>ut, or m<span></span>elena </span></span></span></span></div><div>a. <span> </span><span>Most commonly fr<span></span>om: </span></div><div>i. <span> </span>S<span></span>tress ulcers (peptic, duodenal, g<span></span>astric)</div><div>ii.  Esophagogas<span></span>tritis</div><div>b.<span> <span> </span><span><span></span><span></span><span></span><span></span></span></span></div><div>reperfusion injury and increased gas<span></span>tric acidity from any of the following:</div><div> <span></span><span></span></div><div> <span></span></div><div>3.  Low car<span></span>diac output stat<span></span>es</div></div><div></div></div>
<div><div><img><div>72<span> </span><span>Pos<span></span>t-Op Management<span> </span>Pos<span></span>t-Op Management<span> </span><span>73</span></span></div><div>4.  Critical illness</div><div>c. <span> </span><span>Risk Fact<span></span>ors</span></div><div>i. <span> </span>Pr<span></span>e<span></span>-oper<span></span>ative: older age, history if PUD/GERD</div><div>ii.  Intra-opera<span></span>tive: long duration of CPB, valve oper<span></span>ations, re-operations</div><div>iii. P<span></span>ost-oper<span></span>ative: low CO, prolong<span></span>ed mechanical ventilation (&gt;48 hours), </div><div>co<span></span>agulopathy<span></span>, anticoagulation, anti-pla<span></span>telet therapy</div><div>d. <span> </span><span>Preventative measur<span></span>es</span></div><div><span> </span><span></span><span></span></div><div>mucosa that helps maint<span></span>ain mucosal struc<span></span>tural and functional </div><div>integrity </div><div>ii.  Acid suppression</div><div>1. <span></span>Indications for s<span></span>tress ulcer prophylaxis</div><div> <span></span><span></span></div><div>echanical ventilation for </div><div>&gt;48 hours</div><div> <span></span><span></span></div><div>Spinal cord injury</div><div> <span></span><span></span></div><div>Use of 2 anti-plt agents </div><div>(Plavix, ASA, cilost<span></span>azol, </div><div>ticagrelor<span></span>, dipyridamole)</div><div> <span></span><span></span></div><div>Coagulopa<span></span>thy (Plt &lt;50, INR </div><div>&gt;1.5, or PTT 2x b<span></span>aseline)</div><div> <span></span><span></span></div><div>Solid organ tr<span></span>ansplant in </div><div>ICU set<span></span>ting</div><div> <span></span><span></span></div><div>Any 2 of the following:</div><div><span></span><span> </span><span>Sepsis</span></div><div><span></span><span> </span><span>ICU st<span></span>ay &gt;7 days</span></div><div><span></span><span> </span><span>Occult bleed las<span></span>ting &gt;6 days</span></div><div><span></span><span> </span><span>High dose ster<span></span>oids w/daily dose </span></div><div> <span></span><span></span></div><div> &gt;250mg hydrocortisone</div><div> <span></span><span></span></div><div> &gt;50mg </div><div>methylprednisolone</div><div> <span></span><span></span></div><div>&gt;60mg prednisone</div><div> <span></span><span></span></div><div>&gt;10mg dexamethasone</div><div> <span></span><span></span></div><div>Hx GERD/GI ulc<span></span>ers/acid suppressant </div><div>therapy</div><div>2. <span></span>Prot<span></span>on pump inhibitors (PPI’<span></span>s):<span></span></div><div>H2 blockers in reducing incidenc<span></span>e of hemorrhagic gastritis and </div><div>ulcer<span></span>ation</div><div>a.  P<span></span>antopr<span></span>azole 40mg IV<span></span>/PO daily</div><div>b.<span> <span> </span>Use is not without risk!</span></div><div><span></span><span><span> </span><span></span><span></span></span></div><div> <span></span><span>ii. <span> </span>PPI use is independent risk factor f<span></span>or nosocomial PNA</span></div><div> <span></span><span>iii. <span> </span>May cause hypomagnasemia</span></div><div>3. <span></span>H2 Blockers: </div><div>a.  F<span></span>amotidine 20mg IV Q12</div><div>b.<span> <span> </span>Associated with thrombocytopenia</span></div><div>e. <span> </span><span>Tr<span></span>eatment consider<span></span>ations:</span></div><div><span> </span><span></span><span></span></div><div>1. <span></span><span>Correct co<span></span>agulopathy when indicat<span></span>ed</span></div><div>2. <span></span><span>Consider DDAVP for suspect<span></span>ed platelet dysfunction if uremia is pr<span></span>esent</span></div><div>3. <span></span><span>T<span></span>ransfuse blood if hemodynamically unst<span></span>able </span></div><div>ii.  Monitor vital signs for shock. Assess volume sta<span></span>tus</div><div>iii. Flush NG/OG tube if pr<span></span>esent</div><div>iv. <span>If bleeding continues, pa<span></span>tient is hemodynamically unst<span></span>able and/or </span></div><div>there is an inappropria<span></span>te response to blood tr<span></span>ansfusion consider </div><div>GI consult f<span></span>or EGD (esophagogastr<span></span>oduodenoscopy)</div><div><span><span> </span><span></span><span></span></span></div><div></div><div>vi. <span>Acid suppression (trea<span></span>tment dosing):</span></div><div>1.<span> <span></span>Pepcid 20mg IV q8</span></div><div>2. <span></span><span>Protonix 80mg IV push + c<span></span>ontinuous infusion 8mg<span></span>/hr </span></div><div>2. <span> </span><span>Lower GIB: <span>dark t<span></span>o bright red blood from the rectum. Color of blood is </span></span></div><div>associated with the length of time in the GI tr<span></span>act</div><div>a. <span> </span><span>Etiologies: </span></div><div>i. <span> </span>Hemorrhoids</div><div>ii.  Mesenteric ischemia/<span></span>ischemic colitis</div><div>1.  P<span></span>eriods of prolonged hypoperfusion fr<span></span>om</div><div>a.  Low c<span></span>ardiac output sta<span></span>te</div><div>b.<span> <span> </span>Atheroscler<span></span>otic embolism or mesenteric thr<span></span>ombosis</span></div><div>2.  May present as prof<span></span>ound ileus, abdominal pain out of proportion </div><div>3.  May be associated with elev<span></span>ated lacta<span></span>te, GIB, sepsis (bacterial </div><div>transloc<span></span>ation)</div><div>iii. Diverticulosis</div><div>iv. Arteriovenous malformations (A<span></span>VM’s): See L<span></span>VAD pos<span></span>t-oper<span></span>ative </div><div>consider<span></span>ations</div><div>v.<span> <span> </span>Ulcera<span></span>tion/tissue breakdown fr<span></span>om rect<span></span>al tube</span></div><div>b.<span> <span> </span><span>Work up:</span></span></div><div>i. <span> </span>E<span></span>xamine patient looking for hemorrhoid or tissue br<span></span>eakdown</div><div>ii.  Consider placing NG/OG tube to assess for presenc<span></span>e of upper GIB</div><div>iii. <span></span><span><span></span><span></span></span></div><div>1.<span> <span></span>Correct co<span></span>agulopathy when indicat<span></span>ed</span></div><div>2. <span></span><span>Consider DDAVP for suspect<span></span>ed platelet dysfunction if uremia is </span></div><div>present</div><div>3. <span></span><span>T<span></span>ransfuse blood if hemodynamically unst<span></span>able </span></div><div>iv. <span>If bleeding continues, pa<span></span>tient is hemodynamically unst<span></span>able and/or </span></div><div>there is an inappropria<span></span>te response to blood tr<span></span>ansfusion consider </div><div>GI consult f<span></span>or EGD and/or sigmo<span>idoscopy<span></span>/<span></span>colonoscopy </span></div><div>1.  If these are neg<span></span>ative, source may be small bowel</div><div>v.<span> <span> </span>KUB/CT sc<span></span>an to assess for evidence of ischemic bowel</span></div><div>1.  Pneumotosis (air in the bowel w<span></span>all), venous gas, bowel wall </div><div>thickening</div><div> <span></span><span></span><span></span><span></span></div><div>vi. Radionuclide scanning (ie tagg<span></span>ed RBC scan) to localize sourc<span></span>e of bleed</div><div>vii. Angiography: </div><div>1.  May be diagnostic and ther<span></span>apeutic if bleeding can be localized</div><div> <span></span><span></span></div><div>detec<span></span>tion</div><div>Sources:</div><div><span></span><span></span></div><div>UK: Wiley-Blackwell</div><div>Adams, G. (2006). On Call Surgery, 3rd Edition. Philadelphia, P<span></span>A: Saunders Elsevier</div><div>Marino, P<span></span>. (2009). The Little ICU Book. Philadelphia, P<span></span>A: Lippincott Williams &amp; Wilkins</div><div>GI: <span>MALNUTRITION (TUBE FEEDING/TPN)</span></div><div>T<span></span>ube Feeding: </div><div> <span></span><span></span></div><div>Consult with dietician to evalua<span></span>te adequate or<span></span>al intak<span></span>e vs need for tube </div><div>feeding.</div><div> <span></span><span></span></div><div>Use <span>IP GEN T<span></span>ube Feeding order se<span>t to plac<span></span>e the following orders:</span></span></div><div><span></span><span> </span><span>Consult to nutrition </span></div><div><span></span><span> </span><span>Place K<span></span>OF (Small bore feeding tube)</span></div><div> <span></span><span></span></div><div>If Feeding tube plac<span></span>ed via super user RN with Cortrak<span></span>, no need for K<span></span>UB </div></div><div></div></div>
<div><div><img><div>74<span> </span><span>Pos<span></span>t-Op Management<span> </span>Pos<span></span>t-Op Management<span> </span><span>75</span></span></div><div>to evaluat<span></span>e location</div><div> <span></span><span></span></div><div>If feeding tube is plac<span></span>ed without use of Cortrak<span></span>, obtain K<span></span>UB to ensure tip </div><div>of feeding tube is post pyloric</div><div> <span></span><span></span></div><div>If feeding tube is unable to be plac<span></span>ed post pyloric, consider use of </div><div>Reglan t<span></span>o promot<span></span>e motility<span></span>. </div><div> <span></span><span></span></div><div>In some cases, trickle tube feeds may be s<span></span>tarted while the tip </div><div>of feeding tube is in the st<span></span>omach (be<span></span>war<span></span>e of increased risk of </div><div>aspira<span></span>tion)</div><div><span></span><span> </span><span>T<span></span>ube feeds are typically s<span></span>tarted @ 20cc/hr and incr<span></span>eased by 20 q8 hours </span></div><div>until goal r<span></span>ate is achieved. (T<span></span>rickle or trophic TF rat<span></span>e 10-20cc/hr)</div><div><span></span><span> </span><span>Obt<span></span>ain daily labs: CMP<span></span>, Phos, Mag, Pre albumin (3x weekly)</span></div><div><span></span><span> </span><span>Glucose management via subQ insulin (Gluc<span></span>ose checks q6) or insulin drip </span></div><div>TPN= T<span></span>otal p<span></span>arenter<span></span>al nutrition </div><div> <span></span><span></span></div><div><span></span><span></span><span></span></div><div>Prolonged ileus. Consult with die<span></span>tician to assess nutrition needs. </div><div> <span></span><span></span></div><div>Needs centr<span></span>al access (TPN is administ<span></span>ered via dedicated line), c<span></span>onsider need </div><div>for PIC<span></span>C line placement. </div><div> <span></span><span></span></div><div>TPN must be order<span></span>ed by 1400.  Use IP GEN TPN/PPN Adult Protocol or<span></span>der set  </div><div>to place the f<span></span>ollowing orders</div><div><span></span><span> </span><span>Consult to nutrition  </span></div><div><span></span><span> </span><span>PICC Line plac<span></span>ement if needed for adequate acc<span></span>ess</span></div><div><span></span><span> </span><span>TPN + Lipids</span></div><div><span></span><span> </span><span>Obt<span></span>ain daily labs: CMP<span></span>, Phos, Mag, T<span></span>riglycerides</span></div><div><span></span><span> </span><span>Glucose c<span></span>ontrol via insulin placed in TPN mixture or Insulin drip (some </span></div><div>patient<span></span>s may require both)</div><div> <span></span><span></span></div><div><span></span><span></span><span></span><span></span></div><div>dysturb<span></span>ances, loss of gut barrier<span></span>, acalculus cholecystitis, refeeding syndr<span></span>ome, </div><div>&amp;  hyperosmolality</div><div>GU<span></span>/FEN: <span>ACID BASE DISTURBANCES </span></div><div>The normal buering systems of the body (bic<span></span>arbonate, hemoglobin, phosphate, </div><div>and protein) are f<span></span>requently overwhelmed by disease states or altered f<span></span>rom the </div><div>eects of car<span></span>diopulmonar<span></span>y bypass.</div><div>referenc<span></span>e see <span>page 124.</span></div><div>Met<span></span>abolic Acidosis: </div><div>accumulation of acids in the serum. </div><div>1. <span> </span><span>Anion Gap<span> = Na – (Cl + HCO3).  Normal A<span></span>G 8-12 mmol/L. </span></span></div><div>a. <span> </span><span>Correct for hypo<span></span>albuminemia.  AG + (2.5 x (4-albumin)).   </span></div><div>Elevated A<span></span>G &gt; 13 mmol/L</div><div>High Anion Gap Acidosis<span> </span>Normal Anion Gap Acidosis</div><div> <span></span><span></span></div><div>Lactic acidosis (see below)</div><div> <span></span><span></span></div><div>Renal failur<span></span>e (reduced acid </div><div>secretion)</div><div> <span></span><span></span></div><div>Rhabdomyolysis</div><div> <span></span><span></span></div><div>Medications (ASA, ethylene, </div><div>methanol)</div><div> <span></span><span></span></div><div>Keto<span></span>acidosis</div><div> <span></span><span></span></div><div>Diarrhea (high bicarb loss)</div><div> <span></span><span></span></div><div>Renal T<span></span>ubular Acidosis (loss of bicarb </div><div>resorption)</div><div> <span></span><span></span></div><div>Carbonic anhydrase inhibitors (ie Diamo<span></span>x, </div><div>increased bicarb secr<span></span>etion by kidneys)</div><div> <span></span><span></span></div><div>Hyperchloremia <span>(incre<span></span>ased HCl acid in </span></div><div>blood)</div><div> <span></span><span></span></div><div>Blood transfusions (addition of aci</div><div>2. <span> </span><span>Lactic acidosis</span></div><div>a. <span> </span><span>Type A: Imp<span></span>aired tissue oxygenation and anaerobic me<span></span>tabolism from </span></div><div>circulat<span></span>or<span></span>y f<span></span>ailure </div><div>i. <span> </span>IC<span></span>U, immediate post<span></span>-op considerations—May be result of:</div><div>1.  Pre-existing r<span></span>enal dysfunction</div><div>2.  Long pump runs</div><div>3.  Intraoper<span></span>ative vasopressor use</div><div>4.  Inadequate O2 delivery during bypass that c<span></span>ontributes to </div><div>splanchnic and renal ischemia with acidosis perpetua<span></span>ted by a low </div><div>cardiac output syndrome</div><div>ii.  Several days post<span></span>-op<span></span>—May be result of:</div><div>1.  Mesenteric ischemia</div><div>2.  Sepsis</div><div>3.  Acute hep<span></span>atic dysfunction (decreased lact<span></span>ate utiliz<span></span>ation)</div><div>4.  Low car<span></span>diac output stat<span></span>e, malperfusion</div><div>b.<span> <span> </span><span>T<span></span>ype B: Not associated with tissue hypo<span></span>xia. Low-dose Epinephrine </span></span></div><div><span></span><span></span></div><div>acid production. </div><div>i. <span> </span>No<span></span>t commonly seen</div><div>ii.  Consider when cardiac output is adequate and lac<span></span>tic acidosis seems </div><div>out of proportion with tissue perfusion</div><div>3. <span> </span><span>Adverse Eec<span></span>ts of Acidosis: <span>typically do no<span></span>t occur until pH is &lt; 7.2</span></span></div><div>a. <span> </span><span>Cardiovascular:<span> </span></span></div><div>i. <span> </span>Decr<span></span>eased contrac<span></span>tility and cardiac output, decreased liver and renal </div><div>perfusion</div><div> <span></span><span></span><span></span><span></span></div><div>iii. Incre<span></span>ased Pulmonar<span></span>y Vascular Resis<span></span>tance (may lead t<span></span>o Right heart </div><div>failure)</div><div><span></span><span></span></div><div>decreased SVR</div><div>v.<span> <span> </span>Increased risk of ventricular arrhythmias</span></div><div>b.<span> <span> </span><span>Respir<span></span>atory<span>:</span></span></span></div><div>i. <span> </span>Decr<span></span>eased respirat<span></span>or<span></span>y muscle strength</div><div>ii.  Dyspnea/tachypnea fr<span></span>om compensat<span></span>or<span></span>y mechanism</div><div>c. <span> </span><span>Metabolic<span>:</span></span></div><div>i. <span> </span>Hyper<span></span>glycemia (tissue insulin resist<span></span>ance)</div><div>ii.  Hyperkalemia</div><div>d. <span> </span><span>Neurologic<span>:</span></span></div><div>i. <span> </span>Inhibition of br<span></span>ain metabolism</div><div>ii.  Obtundation/<span></span>coma</div><div>4. <span> </span><span>T<span></span>reatment of Me<span></span>tabolic Acidosis</span></div><div>a. <span> </span><span>Identify and treat the underlying c<span></span>ause</span></div><div>i. <span> </span>Assess tissue perfusion and cardiac output: VBG/SvO2, Echo, P<span></span>A </div><div>cathe<span></span>ter C<span></span>O/CI</div><div> <span></span><span></span><span></span><span></span></div><div>iii. Assess for mesenteric ischemia: lact<span></span>ate, abdominal exam, KUB/C<span></span>T</div><div>iv. A<span></span>ssess for sepsis: CBC, pr<span></span>o<span></span>-calcit<span></span>onin, cultures, fever cur<span></span>ve</div><div>b.<span> <span> </span><span>Bicarbona<span></span>te supplementation</span></span></div><div>i. <span> </span>Normalizing pH may impr<span></span>ove cardiac function, improve </div><div><span></span><span></span></div><div>ii.  Goal is to r<span></span>aise the pH, not to correct bic<span></span>arbonate levels</div><div>iii. Keep in mind that IV Sodium bic<span></span>arb may result in:</div><div>1.  Hypernatremia—monit<span></span>or serial labs, consider D5W<span></span>/free water </div><div>supplementa<span></span>tion</div></div><div></div></div>
<div><div><img><div>76<span> </span><span>Pos<span></span>t-Op Management<span> </span>Pos<span></span>t-Op Management<span> </span><span>77</span></span></div><div>2.  Fluid overload fr<span></span>om hyperosmolarity—monitor CVP<span></span>/<span></span>exam, diurese </div><div>when appropriat<span></span>e</div><div> <span></span><span></span></div><div>SvO2</div><div>4.  Incre<span></span>ased CO2 pr<span></span>oduction from metabolism of bic<span></span>arbonate</div><div>a.  May result in <span>r<span></span>espirat<span></span>or<span></span>y acidosis <span>if pa<span></span>tient not adequately </span></span></div><div>ventilated</div><div>b.<span> <span> </span>Monitor ABG, incre<span></span>ase respiratory rat<span></span>e on ventilator if able</span></div><div>Respir<span></span>atory Acidosis</div><div>1. <span> </span><span>Common etiologies: <span>accumulation of C<span></span>O2 in blood due to hypoventilation</span></span></div><div>a. <span> </span><span>Medications: narc<span></span>otics, benzodiazepines, residual anes<span></span>thesia, paralytics</span></div><div>b.<span> <span> </span><span>S<span></span>troke/<span></span>intr<span></span>acranial bleed</span></span></div><div>c. <span> </span><span>Acute airway obstruction: sleep apnea, aspir<span></span>ation</span></div><div>d. <span> </span><span>Hx parenchymal lung disease (O2 delivery may decrease respir<span></span>ator<span></span>y </span></div><div>drive): COPD</div><div>e. <span> </span><span>Splinting<span></span>/Limit of inspiration due to p<span></span>ain</span></div><div>f.<span></span><span> <span> </span><span>Pneumothorax</span></span></div><div>Management:</div><div>a. <span> </span><span>T<span></span>reat reversible causes: ob<span></span>tain CXR, consider head C<span></span>T for acutely altered </span></div><div>mental s<span></span>tatus</div><div>b.<span> <span> </span><span>Consider Narc<span></span>an for narcotic over<span></span>dose: <span>Narcan 0.1-0.2 mg q2 minutes</span> </span></span></div><div>for partial r<span></span>e<span></span>versal</div><div>c. <span> </span><span><span>umaz<span></span>enil 0.2mg IV q30 </span></span></div><div>seconds-1min</div><div>d. <span> </span><span>Tr<span></span>eat hypoventilation</span></div><div>i. <span> </span>BiP<span></span>ap support ventilation (See Respirat<span></span>or<span></span>y Care under referenc<span></span>es)</div><div>ii.  Consider intubation </div><div>Met<span></span>abolic Alkalosis</div><div>1. <span> </span><span>Common etiologies:</span></div><div>a. <span> </span><span>Exc<span></span>essive diuresis leading to</span></div><div>i. <span> </span>P<span></span>otassium loss: direc<span></span>tly increases bicarb resorp<span></span>tion</div><div>ii.  Depletion of H+ ions and Chloride (acid loss)</div><div>iii. <span>“Contraction alk<span></span>alosis”<span> = Hypovolemia: stimulates aldos<span></span>terone </span></span></div><div><span></span><span></span></div><div>increased bic<span></span>arb resorption</div><div>b.<span> <span> </span><span>Acid loss from high NG tube output/<span></span>emesis</span></span></div><div>c. <span> </span><span>Sub-Acute/Chronic respir<span></span>ator<span></span>y acidosis: renal r<span></span>esponse to chronic </span></div><div>acidosis (ie increased bic<span></span>arbonate synthesis) takes 12 hours t<span></span>o become </div><div>apparent and is maximum a<span></span>t 3-5 days</div><div>d. <span> </span><span>Exc<span></span>essive bicarbonat<span></span>e administr<span></span>ation, or administr<span></span>ation of agent<span></span>s </span></div><div>met<span></span>abolized to bic<span></span>arb </div><div>i. <span> </span><span>Citr<span></span>ate (in blood produc<span></span>ts)<span> may result in metabolic alk<span></span>alosis</span></span></div><div>ii.  Lactat<span></span>e (in LR)</div><div>2. <span> </span><span>Adverse Eec<span></span>ts of Alkalosis (pH &gt;7.45)</span></div><div>a. <span> </span><span><span></span></span></div><div>b.<span> <span> </span><span><span></span><span></span></span></span></div><div>acidosis)</div><div>c.<span> <span> </span></span><span><span></span></span></div><div>d. <span> </span><span><span></span><span></span><span></span><span></span></span></div><div>potential hypo<span></span>xia</div><div>3. <span> </span><span>T<span></span>reatment of Acut<span></span>e Metabolic Alkalosis</span></div><div>a. <span> </span><span><span></span><span></span></span></div><div>b.<span> <span> </span><span>Gas<span></span>tris losses: acid suppressant therapy (H2 blockers or PPI’<span></span>s)</span></span></div><div>c. <span> </span><span>P<span></span>atients with tot<span></span>al body water overload (ie pos<span></span>t-opera<span></span>tive or CHF) </span></div><div>consider:</div><div>i. <span> </span>Diamo<span></span>x (acetaz<span></span>olamide): carbonic anhydr<span></span>ase inhibitor that inhibit<span></span>s </div><div>bicarbonat<span></span>e resorption in pr<span></span>oximal tubule</div><div>1.  Weak diur<span></span>etic when used alone</div><div>2.  Consider use in conjunc<span></span>tion with loop diuretic</div><div>ii.  K-sparing diure<span></span>tic (spironolactone/<span></span>eplerenone)</div><div>Respir<span></span>atory Alkalosis</div><div>1. <span> </span><span>Common Etiologies:<span> <span>decr<span></span>eased CO2 in blood stream due to hypoventilation</span></span></span></div><div>a. <span> </span><span>Hypoxia (increased r<span></span>espiratory drive)</span></div><div>b.<span> <span> </span><span>Anxiety</span></span></div><div>c. <span> </span><span>P<span></span>ain</span></div><div>d. <span> </span><span>Fever/infection/sepsis</span></div><div>2. <span> </span><span> <span></span><span>Management:<span> trea<span></span>t underlying cause  </span></span></span></div><div>Sources: </div><div><span></span><span></span></div><div>UK: Wiley-Blackwell</div><div>Adams, G. (2006). On Call Surgery, 3rd Edition. Philadelphia, P<span></span>A: Saunders Elsevier </div><div>GU<span></span>/FEN:<span> KIDNEY DISEASE</span></div><div>Acute Kidney Injury</div><div>Denition:</div><div> <span></span><span></span></div><div>Increase in serum cr<span></span>eatinine by 0.3mg<span></span>/dL or mor<span></span>e within 48 hours  </div><div>or</div><div> <span></span><span></span></div><div>Incr<span></span>eas<span></span>e i<span></span>n se<span></span>rum cr<span></span>eat<span></span>inine <span></span>to 1.<span></span>5 time<span></span>s b<span></span>aseli<span></span>ne o<span></span>r mor<span></span>e with<span></span>in the<span></span> las<span></span>t 7 <span></span>days <span></span> </div><div>or</div><div> <span></span><span></span></div><div>Urine output less than 0.5 mL/kg<span></span>/h for 6 hours</div><div>Cause:</div><div> <span></span><span></span></div><div><span></span><span></span></div><div>hypotension, hypovolemic, HF<span></span>, renal arter<span></span>y s<span></span>tenosis, renal vein thrombosis, </div><div>Cardiac t<span></span>amponade</div><div><span></span><span> </span><span><span></span><span></span><span></span></span></div><div>due to</div><div> <span></span><span></span></div><div><span></span></div><div> <span></span><span></span></div><div><span></span><span></span></div><div> <span></span><span></span></div><div><span></span><span></span><span></span><span></span></div><div> <span></span><span></span></div><div>Intra R<span></span>enal:<span> Problems with the kidney itself, A<span></span>TN/<span></span>AIN</span></div><div> <span></span><span></span></div><div>Pos<span></span>trenal:<span></span></div><div>kidney stone, BPH, obs<span></span>tructed urinar<span></span>y ca<span></span>theter etc;<span> a bladder scan or a pos<span></span>t </span></div><div>void residual t<span></span>o rule out urinary retention</div><div>Diagnosis:</div><div> <span></span><span></span></div><div><span></span><span></span></div><div> <span></span><span></span></div><div>Urinalysis: presence of pr<span></span>otein (albumin), hemoglobin, granular cas<span></span>ts, or </div><div>epithelial cell cas<span></span>ts may indicate AKI</div><div> <span></span><span></span></div><div>Urine sodium:</div><div><span></span><span> </span><span>FENa:<span><span></span><span></span></span></span></div><div>an oliguric patient (no<span></span>t accurat<span></span>e if patient has received r<span></span>ecent diuretic </div><div>therapy) </div><div>FENa, % = (UNA x SCr<span></span>/ SNA X UCr) x 100 </div><div> <span> </span><span>FENa &lt; 1 = pre renal dise<span></span>ase </span></div><div> <span> </span>FENa &gt; 2 = A<span></span>TN </div></div><div></div></div>
<div><div><img><div>78<span> </span><span>Pos<span></span>t-Op Management<span> </span>Pos<span></span>t-Op Management<span> </span><span>79</span></span></div><div><span></span><span> </span><span>FEU-rea (used f<span></span>or patient who have received r<span></span>ecent diuretic therapy) </span></div><div>FEU-rea, % = ((SCr x Urine Urea) x 100)) / BUN x Urine Creatinine </div><div> <span> </span>FEU-re<span></span>a &lt; 35% = pre renal disease </div><div> <span> </span>FEU-re<span></span>a &gt; 50% = ATN</div><div> <span></span><span></span></div><div>Oliguria:<span> &lt; 0.3ml/kg per hour or &lt; 500mL/<span></span>day of urine output</span></div><div> <span></span><span></span></div><div>Anuria: <span><span></span></span></div><div> <span></span><span></span></div><div>Renal US:<span> evalua<span></span>te for urinar<span></span>y tr<span></span>act obstruction, renal mass, and kidney size </span></div><div>(diagnosis hydronephrosis)</div><div>T<span></span>rea<span></span>tment: </div><div> <span></span><span></span></div><div> Focused on removing the c<span></span>ause of the kidney injur<span></span>y/ f<span></span>ailure. </div><div><span></span><span> </span><span>Discontinue nephro<span></span>toxic medications (NSAIDS, Iodina<span></span>ted contr<span></span>ast, </span></div><div>metformin, some antibio<span></span>tics such as gent<span></span>amicin.)</div><div><span></span><span> </span><span>Correct low BP or use ino<span></span>tropic meds to incr<span></span>ease heart func<span></span>tion to </span></div><div>provide good r<span></span>enal perfusion </div><div><span></span><span> </span><span>Avoid IV contr<span></span>ast if possible while crea<span></span>tinine is still up trending</span></div><div><span></span><span> </span><span>Correct urinary tract obs<span></span>truction if present (ie insertion of foley cathet<span></span>er)</span></div><div> <span></span><span></span></div><div>Continue to trend cr<span></span>eatinine and elec<span></span>trolytes closely (cautious electrolyt<span></span>e </div><div>replacement)</div><div> <span></span><span></span></div><div>Monitor volume s<span></span>ta<span></span>tus closely to ensure adequa<span></span>te hydration without volume </div><div>overload  </div><div><span></span><span> </span><span>Diuretics may be used for a limit<span></span>ed period to relive signs and symptoms </span></div><div>of volume overload. </div><div><span></span><span> </span><span><span></span><span></span></span></div><div> <span></span><span></span></div><div>Indications f<span></span>or dialysis: (consult renal) <span>A-E-I-O-U!</span> </div><div><span></span><span> </span><span>A: Acidosis (pH &lt; 7.1 in those that canno<span></span>t tolerate c<span></span>orrection with sodium </span></div><div>bicarb)</div><div><span></span><span> </span><span>E: Electrolyt<span></span>e Disturb<span></span>ances (ie. Hyperkalemia when k &gt; 6.5 and refrac<span></span>tor<span></span>y </span></div><div>to medical manag<span></span>ement)</div><div><span></span><span> </span><span>I: Inges<span></span>tion/Intoxic<span></span>ation</span></div><div><span></span><span> </span><span>O: Overload. (Refr<span></span>actor<span></span>y to diur<span></span>etics)</span></div><div><span></span><span> </span><span>U: Uremia (alter<span></span>ed mental s<span></span>tatus, uremic pla<span></span>telet<span></span>s)</span></div><div>Chronic Kidney Disease  </div><div>Denition:</div><div>St<span></span>age<span> </span>Descrip<span></span>tion </div><div>St<span></span>age I<span> </span>With normal of high GFR (GFR &gt; 90mL/min)</div><div>St<span></span>age II<span> </span>Mild CKD (GFR = 60-89mL/min)</div><div>St<span></span>age IIIa<span> </span>Modera<span></span>te CKD (GFR = 45-59mL/min)</div><div>St<span></span>age IIIb<span> </span>Moderat<span></span>e CKD (GFR = 30-44mL/min)</div><div>St<span></span>age IV<span> </span>Severe CKD (GFR = 15-29mL/min)</div><div>St<span></span>age V<span> </span>End St<span></span>age CKD (GFR &lt; 15mL/min)</div><div>Always document stage 3 ck<span></span>d or higher in h&amp;p, progress not<span></span>es, and </div><div>discharge summary</div><div>Pos<span></span>t op management: </div><div> <span></span><span></span></div><div>Monitor pos<span></span>t op crea<span></span>tinine closely. Not uncommon t<span></span>o see rising crea<span></span>tinine </div><div>in the initial post op period (Acut<span></span>e on Chronic Kidney Injur<span></span>y) but cre<span></span>atinine </div><div>should return t<span></span>o baseline by discharg<span></span>e if managed properly </div><div><span></span><span> </span><span>Ensure adequat<span></span>e blood pressure f<span></span>or renal perfusion</span></div><div><span></span><span> </span><span>Avoid nephrot<span></span>oxic agents (NSAIDs, metformin, c<span></span>ertain antibiotics)</span></div><div>Referenc<span></span>es: </div><div>Okusa, M.D., P<span></span>alevsky, P<span></span>.M., &amp; Scheidan, A.M. (2016). Overvie<span></span>w of the management of acut<span></span>e kidne<span></span>y injury </div><div>(acute renal f<span></span>ailure). Up to dat<span></span>e. </div><div>GU<span></span>/FEN:<span>SODIUM IMBALANCES</span></div><div>HYPERNA<span></span>TREMIA, serum NA &gt;145</div><div> <span></span><span></span></div><div>Etiologies:</div><div><span></span><span> </span><span>T<span></span>ube feeding due to lack of free wa<span></span>ter</span></div><div><span></span><span> </span><span>Ex<span></span>cessive water loss fr<span></span>om diuresis or diarrhea</span></div><div><span></span><span> </span><span>Salt loading from medic<span></span>ations (saline drips, sodium bicarb, albumin)</span></div><div> <span></span><span></span></div><div>T<span></span>o trea<span></span>t</div><div><span></span><span> </span><span>Add free wa<span></span>ter to tube f<span></span>eed formula in divided doses (ie 200mL q6h)</span></div><div><span></span><span> </span><span>Add D5W infusion</span></div><div><span></span><span> </span><span>And/<span></span>or encourage w<span></span>ater intake if able t<span></span>o take PO</span></div><div> <span></span><span></span></div><div><span></span></div><div> <span></span><span></span></div><div>Determine Ra<span></span>te of Correc<span></span>tion</div><div><span></span><span> </span><span>Chronic Hypernatr<span></span>emia<span>: present for &gt;48 hours</span></span></div><div> <span></span><span></span></div><div>Correct Sodium by NO MORE THAN 10-12mEq/<span></span>day</div><div> <span></span><span></span></div><div>Rapid correc<span></span>tion—at risk for <span>cerebr<span></span>al edema<span> (encephalopa<span></span>thy, </span></span></div><div>lethargy, seizur<span></span>es)</div><div><span></span><span> </span><span>Acute Hyperna<span></span>tremia<span>: present f<span></span>or &lt; 48 hours</span></span></div><div> <span></span><span></span></div><div>Correct Sodium t<span></span>o normal over 24 hours</div><div> <span></span><span></span></div><div>Monitor serum sodium frequently and adjus<span></span>t free water int<span></span>ake as necessary </div><div>HYPONA<span></span>TREMIA, serum NA &lt;135 </div><div>[mild 130-135, modera<span></span>te 120-129, severe &lt;120]</div><div> <span></span><span></span></div><div>Need to det<span></span>ermine type of hyponatremia:</div><div><span></span><span> </span><span>Hyper<span></span>volemic: Na dilution from ex<span></span>cessive tot<span></span>al body water</span></div><div> <span></span><span></span></div><div>Volume overload, CHF<span></span>, cirrhosis</div><div><span></span><span> </span><span>Hypovolemic: Na and/<span></span>or water loss</span></div><div> <span></span><span></span></div><div>Diarrhea, thiazide diure<span></span>tics</div><div><span></span><span> </span><span>Normovolemic hyponatremia </span></div><div> <span></span><span></span></div><div>Low salt int<span></span>ake, SIADH: syndrome of inappropriate antidiur<span></span>etic </div><div>hormone (Dx of exclusion)</div><div> <span></span><span></span></div><div>Low serum sodium in our pos<span></span>top pa<span></span>tients usually indicates to<span></span>tal body water </div><div>overload (hypervolemic hyponatremia)</div><div> <span></span><span></span></div><div>In our patient popula<span></span>tion, most of concern when Na &lt;130. Otherwise usually </div><div>just monit<span></span>or</div><div> <span></span><span></span></div><div>Symptoms help de<span></span>termine need to treat (ie he<span></span>adache, nausea, vomiting, </div><div>fa<span></span>tigue, gait dis<span></span>turbances, and confusion)</div><div> <span></span><span></span></div><div>Aim to corr<span></span>ect serum Sodium by 4-6mEq/<span></span>day, no more than 8mEq/<span></span>day</div><div> <span></span><span></span></div><div>Risk of rapid c<span></span>orrection: <span>osmotic demyelina<span></span>tion </span></div><div> <span></span><span></span></div><div><span></span><span></span><span></span><span></span></div><div> <span></span><span></span></div><div>If on IV medications, c<span></span>onsider giving them in NS versus the standing D5W – </div><div>will need to discuss this with the pharmacy</div><div><span></span><span> </span><span>If euvomic/hypovolemic hyponatremia: also c<span></span>onsider giving salt tablets </span></div><div>three times daily with meals.</div><div><span></span><span> </span><span>Also can tre<span></span>at with hypertonic 3% saline. If have to go this rout<span></span>e, consult </span></div><div>nephrology. </div><div> <span></span><span></span></div><div>Monitor serum sodium frequently</div><div> </div></div><div></div></div>
<div><div><img><div>80<span> </span><span>Pos<span></span>t-Op Management<span> </span>Pos<span></span>t-Op Management<span> </span><span>81</span></span></div><div>HEMA<span></span>T<span></span>OLOGY<span></span>: <span>ACUTE BL<span></span>OOD LOS<span></span>S ANEMIA AND </span></div><div>POS<span></span>T<span></span>-OPERA<span></span>TIVE BLEEDING</div><div>Acute blood loss anemia and bleeding are expected a<span></span>er cardiac surgery </div><div>(especially for cases on c<span></span>ardiopulmonary bypass)</div><div>Contributing fac<span></span>tors to pos<span></span>t op bleeding: </div><div>Plat<span></span>elets<span><span></span><span></span><span></span></span></div><div>Hemodilution occurs when the circuit is primed and this alone c<span></span>an reduce </div><div>platele<span></span>ts by 30-50% (Bojar<span></span>, 2011).  And the longer a patient is on byp<span></span>ass, the more </div><div><span></span><span></span><span></span></div><div>mechanical str<span></span>ess of going through the circuit, as well.</div><div>Hepariniza<span></span>tion: <span><span></span></span></div><div>prot<span></span>amine itself can will transiently r<span></span>educe the plat<span></span>elet count by about 30%.  </div><div><span></span><span></span></div><div>on board.  HIT alw<span></span>ays becomes a concern in a p<span></span>atient who is thrombocytopenic </div><div>and has received hep<span></span>arin.  This is an e<span></span>ven higher risk in pt<span></span>s who have been on </div><div>heparin gt<span></span>ts prior to going into surg<span></span>er<span></span>y and should be evaluated by tes<span></span>ting for </div><div>antibodies if the patient is showing signs of bo<span></span>th bleeding and clotting. (For more </div><div>information on HIT see p<span></span>age *** Section IV &gt; 6 &gt; 3. HIT)</div><div>Fibrinolysis: <span><span></span></span></div><div>ext<span></span>ent can be evaluat<span></span>ed using aPTT<span></span>, INR and D-Dimer but those are very non-</div><div><span></span><span></span><span></span></div><div>Incomple<span></span>te surgical hemos<span></span>tasis:<span> with ac<span></span>companying chest w<span></span>all bleeding or </span></div><div><span></span><span></span></div><div>anyone with friable tissues.</div><div>Preop medica<span></span>tions <span>can also play a role in postop bleeding.  Any p<span></span>atient who’<span></span>s </span></div><div>had ASA in the last 7 days will have circula<span></span>ting platelets tha<span></span>t are no longer </div><div><span></span><span></span></div><div>fondipar<span></span>anux within 48hrs prior to surgery may have worse postop bleeding since </div><div>neither can be comple<span></span>tely reversed with heparin. </div><div>Managing a bleeding pa<span></span>tient:  </div><div>Chest T<span></span>ubes</div><div> <span></span><span></span></div><div>Milk tubes as needed </div><div> <span></span><span></span></div><div>Careful assessment of hourly output</div><div>Warm pa<span></span>tient</div><div> <span></span><span></span></div><div>Hypothermia causes imp<span></span>aired platelet function and suppr<span></span>ession of </div><div>co<span></span>agulation casc<span></span>ade</div><div> <span></span><span></span></div><div>Active warming may be c<span></span>ontraindicated in some p<span></span>atients</div><div>Control HTN</div><div> <span></span><span></span></div><div>SNP<span></span>, NTG, nicar<span></span>dipine, etc.</div><div>Sedation/P<span></span>ain Control</div><div> <span></span><span></span></div><div>Continue sedation/<span></span>analgesia until bleeding slows and pa<span></span>tient is stable for </div><div>weaning<span></span>/<span></span>extuba<span></span>tion</div><div>Re-E<span></span>xploration</div><div> <span></span><span></span></div><div>Consider re-explora<span></span>tion for</div><div><span></span><span> </span><span>&gt;400ml/hr x 1hr</span></div><div><span></span><span> </span><span>&gt;300ml/hr x 2-3hrs</span></div><div><span></span><span> </span><span>&gt;200ml/hr x 4 hrs</span></div><div>Always consider Cardiac T<span></span>amponade as a dierential diagnosis, especially in the </div><div>immediate post<span></span>-operative period. For mor<span></span>e information on pericar<span></span>dial tamponade </div><div>see <span>see <span>page 59.</span></span></div><div>Lab V<span></span>alues to monitor:</div><div>PT<span></span>/INR</div><div> <span></span><span></span></div><div><span></span></div><div> <span></span><span></span></div><div><span></span><span></span><span></span><span></span><span></span><span></span><span></span><span></span><span></span></div><div> <span></span><span></span></div><div>T<span></span>reat eleva<span></span>ted INR with FFP</div><div>PTT</div><div> <span></span><span></span></div><div><span></span><span></span></div><div> <span></span><span></span></div><div>If elevated P<span></span>TT in isolation or with slight elevation in INR c<span></span>onsider treatment </div><div>with <span>Pro<span></span>tamine<span> </span></span></div><div>Plat<span></span>elet Count</div><div> <span></span><span></span></div><div>CPB can decre<span></span>ase platelet count as well as c<span></span>ause platele<span></span>t dysfunction</div><div> <span></span><span></span></div><div>Consider platele<span></span>t transfusion in bleeding p<span></span>atient with platelet &lt;100k or if </div><div>patient<span></span>s were taking ASA , Plavix, or IIB/IIIA inhibitors pre-op or are ur<span></span>emic</div><div>Fibrinogen</div><div> <span></span><span></span></div><div>Promot<span></span>es platelet aggreg<span></span>ation and enhances platele<span></span>t adhesion to the </div><div>endothelium</div><div> <span></span><span></span></div><div>Consider <span>transfusion of cryo if Fibrinog<span></span>en &lt;100 in bleeding patient</span></div><div>TEG</div><div>For TEG interpr<span></span>et<span></span>ation see <span>page 83.</span></div><div>Blood Product<span></span>s/Tr<span></span>ansfusion Threshold</div><div>PRBCs</div><div> <span></span><span></span></div><div>Clarify transfusion thr<span></span>eshold with surgeon</div><div> <span></span><span></span></div><div>Consider maintaining Hc<span></span>t  ~25 in an actively bleeding pa<span></span>tient</div><div> <span></span><span></span></div><div>Each unit should increase Hc<span></span>t by ~3%</div><div>CellSaver</div><div> <span></span><span></span></div><div>May cont<span></span>ain a small amount of heparin but is devoid of clotting f<span></span>actors</div><div> <span></span><span></span></div><div><span></span><span></span></div><div>Plat<span></span>elets</div><div> <span></span><span></span></div><div>Each unit should increase pla<span></span>telet count by ~42-60k per 6-pk</div><div>FFP</div><div> <span></span><span></span></div><div>Contains all clo<span></span>tting fact<span></span>ors</div><div> <span></span><span></span></div><div>4 units of FFP will incre<span></span>ase clotting fac<span></span>tors by~10%</div><div>Cryoprecipita<span></span>te</div><div> <span></span><span></span></div><div><span></span><span></span><span></span></div><div> <span></span><span></span></div><div><span></span><span></span><span></span></div><div> <span></span><span></span></div><div><span></span></div><div>Medications</div><div>Pro<span></span>tamine</div><div> <span></span><span></span></div><div>Given for elevat<span></span>ed PTT d/t residual heparin or rele<span></span>ase of heparin from tissue </div><div>st<span></span>ores</div><div> <span></span><span></span></div><div>25-50mg</div><div> <span></span><span></span></div><div>Half-life 5min, elimina<span></span>tion from blood s<span></span>tream in 20-30min</div><div> <span></span><span></span></div><div>Ex<span></span>cessive use of Prot<span></span>amine may increase ACT<span></span>, cause platelet dysfunction, </div><div><span></span></div></div><div></div></div>
<div><div><img><div>82<span> </span><span>Pos<span></span>t-Op Management<span> </span>Pos<span></span>t-Op Management<span> </span><span>83</span></span></div><div>DDAVP</div><div> <span></span><span></span></div><div>Increases the levels of cert<span></span>ain factors (VIII pr<span></span>ecursors, von Wildebrand’<span></span>s, </div><div>tissue-type plasminogen ac<span></span>tivator)</div><div> <span></span><span></span></div><div><span></span><span></span></div><div> <span></span><span></span></div><div>Can cause hypot<span></span>ension and peripheral vasodilat<span></span>ation</div><div>Feib<span></span>a</div><div> <span></span><span></span></div><div>F<span></span>actor Eight Inhibit<span></span>or Bypassing Ac<span></span>tivity</div><div> <span></span><span></span></div><div>Developed to trea<span></span>t bleeding in pts with Hemophilia A/B. </div><div> <span></span><span></span></div><div><span></span><span></span><span></span><span></span><span></span></div><div><span></span><span></span></div><div> <span></span><span></span></div><div><span></span><span></span></div><div>mostly when p<span></span>ts are given &gt;200unit<span></span>s/kg<span></span>/<span></span>day.  </div><div> <span></span><span></span></div><div>St<span></span>art with a quarter dose, or 250 units, up to a full dose of 1000 units f<span></span>or </div><div>severe bleeding.  </div><div> <span></span><span></span></div><div>FEIBA is made from human plasma, so the same risk of tr<span></span>ansmission of </div><div>infectious dise<span></span>ase is present as when you are giving blood products. </div><div> <span></span><span></span></div><div>Novo Seven</div><div> <span></span><span></span></div><div>Promot<span></span>es localized hemost<span></span>asis at site of tissue injury and improves INR</div><div> <span></span><span></span></div><div>Can cause syst<span></span>emic thrombosis</div><div>Imaging</div><div>CXR</div><div> <span></span><span></span></div><div></div><div>indicative of clo<span></span>t around the great vessels</div><div>Echo</div><div> <span></span><span></span></div><div>TTE or TEE </div><div>St<span></span>able acute blood loss anemia</div><div> <span></span><span></span></div><div><span></span><span></span><span></span><span></span></div><div>like “E<span></span>xpected acute blood loss anemia”</div><div> <span></span><span></span></div><div>Cont to monitor H/H daily or every other day. H/H usually returns t<span></span>o patients </div><div><span></span><span></span></div><div> <span></span><span></span></div><div>T<span></span>reatment: (once able to t<span></span>olerate PO medic<span></span>ations)</div><div><span></span><span> </span><span>Ferrous Sulf<span></span>ate, Slow FE 140mg PO BID</span></div><div><span></span><span> </span><span>Vitamin C 500mg PO BID</span></div><div><span></span><span> </span><span>Consider need for epogen injec<span></span>tion for severe anemia</span></div><div><span></span><span> </span><span>Oral Ir<span></span>on and Vit C are usually continued f<span></span>or 1 month post operatively </span></div><div>HEMA<span></span>T<span></span>OLOGY<span></span>: <span>TEG</span></div><div>TEG®<span> </span>Clot phase<span> </span>Normal Values<span> </span>Abnormalities<span> </span>T<span></span>reatment</div><div>R Time<span> </span><span>Clot initiation</span></div><div><span></span></div><div>4.6 - 8.8 min<span> </span><span><span></span><span></span></span></div><div>Shortened in hyperc<span></span>oagulable s<span></span>tat<span></span>es.</div><div>Increased R time </div><div>= FFP</div><div>K<span> </span><span>Clot Kinetics</span></div><div>Time taken t<span></span>o achie<span></span>ve a c<span></span>ertain level of clot s<span></span>trength</div><div>1.2 - 2.4 min<span> </span><span><span></span><span></span></span></div><div>and platelet dysfunc<span></span>tion.</div><div>Alpha </div><div>Angle</div><div>Clot Kinetics</div><div></div><div>takes plac<span></span>e ( rate of clot f<span></span>ormation)</div><div>57.7 - 72.9 deg<span> </span><span><span></span></span></div><div>thrombocytopenia, and platele<span></span>t dysfunction.</div><div>Decreased Angle </div><div>= Cr<span></span>yo</div><div>MA<span> </span><span>Clot S<span></span>trength</span></div><div>Maximal clot str<span></span>ength achie<span></span>ved via GP IIb/IIIa-</div><div><span></span><span></span></div><div>59.3 - 76.5 mm<span> </span><span><span></span><span></span></span></div><div><span></span><span></span></div><div>thrombocytopenia</div><div>Decreased MA = </div><div>Platelet<span></span>s</div><div>G<span> </span><span>Clot Strength</span></div><div>Maximal clot str<span></span>ength achie<span></span>ved via GP IIb/IIIa-</div><div><span></span><span></span></div><div>6.4 - 15.0 k d/</div><div>sec</div><div>Abnormally high in platelet hyper<span></span>coagulability.</div><div>EPL </div><div>(Estima<span></span>ted </div><div>Perc<span></span>ent of </div><div>L<span></span>ysis)</div><div>Clot L<span></span>ysis</div><div><span></span></div><div>0 - 15 %<span> </span><span><span> </span></span>Fibrinolysis  = </div><div>Aprotonin or </div><div>T<span></span>ransexamic Acid</div></div><div></div></div>
<div><div><img><div>84<span> </span><span>Pos<span></span>t-Op Management<span> </span>Pos<span></span>t-Op Management<span> </span><span>85</span></span></div><div>HEMA<span></span>T<span></span>OLOGY<span></span>: <span>HEP<span></span>ARIN INDUCED </span></div><div>THROMBOCY<span></span>T<span></span>OPENIA (HIT)</div><div>Epidemiology:</div><div> <span></span><span></span></div><div>1-5% of adults tre<span></span>ated with heparin, and a smaller proportion of those who </div><div>are tre<span></span>ated with low-molecular weight heparin, will develop heparin-induced </div><div>thrombocytopenia (HIT).</div><div> <span></span><span></span></div><div>HIT is associated with a high risk of venous and art<span></span>erial thrombosis if heparin </div><div>is not withdr<span></span>awn</div><div>Diagnosis:</div><div> <span></span><span></span></div><div>The initial signal is a <span>drop in<span><span></span><span></span><span></span></span></span></div><div>noticed, use the 4 T’<span></span>s score to c<span></span>alculate the lik<span></span>elihood of HIT<span></span>. </div><div> <span></span><span></span></div><div>If post op platelet c<span></span>ount is low, continue to observe and wait until at least POD </div><div>#3 prior to sending HIT panel</div><div>1. <span> </span><span>Thrombocytopenia</span></div><div><span></span><span> </span><span><span></span><span></span></span></div><div><span></span><span> </span><span><span></span><span></span></span></div><div><span></span><span> </span><span><span></span><span></span></span></div><div>2. <span> </span><span>Timing</span></div><div><span></span><span> </span><span><span></span><span></span></span></div><div><span></span></div><div><span></span><span> </span><span><span></span><span></span></span></div><div><span></span></div><div><span></span><span> </span><span><span></span><span></span></span></div><div><span></span></div><div>3. <span> </span><span>Thrombosis</span></div><div><span></span><span> </span><span></span></div><div><span></span><span> </span><span><span></span><span></span><span></span></span></div><div></div><div><span></span><span> </span><span>Other causes of thrombocytopenia  </span></div><div><span></span><span> </span><span><span></span></span></div><div><span></span><span> </span><span><span></span></span></div><div><span></span><span> </span><span><span></span></span></div><div>4. <span> </span>Other causes of thrombocytopenia:<span> </span></div><div><span></span><span> </span><span><span></span></span></div><div><span></span><span> </span><span><span></span></span></div><div><span></span><span> </span><span><span></span></span></div><div>Clinical Manifes<span></span>tations</div><div> <span></span><span></span></div><div>Thrombocytopenia, but r<span></span>arely with bleeding e<span></span>vents</div><div> <span></span><span></span></div><div>Markedly eleva<span></span>ted r<span></span>ate of thr<span></span>omboembolic events (venous &gt; arterial [4:1 </div><div>ra<span></span>tio])</div><div> <span></span><span></span></div><div><span></span><span></span><span></span><span></span></div><div>7 days)</div><div>Diagnosis</div><div> <span></span><span></span></div><div>HIT functional assay</div><div> <span></span><span></span></div><div>T<span></span>o order: User HIT panel to order HIT antibody (anti-platele<span></span>t factor 4 or PF4) </div><div>AND Functional assay</div><div><span></span><span> </span><span><span></span></span></div><div>Interpre<span></span>tation:</div><div>0-3 points = Low pr<span></span>obability</div><div>4-5 points = Intermedia<span></span>te </div><div>probability</div><div>6-8 points = High prob<span></span>ability </div><div><span></span><span> </span><span></span></div><div><span></span><span> </span><span>If the PF4 results are inde<span></span>terminate (0.4-2.0), the functional assay may be </span></div><div><span></span><span> </span></div><div>We ty<span></span>pic<span></span>ally se<span></span>nt functiona<span></span>l assay<span></span> at the same<span></span> time a<span></span>s HIT antibo<span></span>dy as </div><div>the fun<span></span>ctional assa<span></span>y is a<span></span> send o<span></span>ut lab that <span></span>requi<span></span>res 48-72 <span></span>hours<span></span> for <span></span>results. </div><div>Acute T<span></span>re<span></span>atment:</div><div> <span></span><span></span></div><div>When HIT is suspected, a HIT antibody and func<span></span>tional assay should be sent, </div><div>and all heparin should be disc<span></span>ontinued immediately<span></span>. </div><div> <span></span><span></span></div><div>An alternative antic<span></span>oagulant should be st<span></span>arted, <span>EVEN IF THERE IS NO OTHER </span></div><div>REASON FOR ANTIC<span></span>OAGULA<span></span>TION. <span>We typically use Arga<span></span>troban.</span></div><div> <span></span><span></span></div><div>Obt<span></span>ain bilateral LE ultr<span></span>asounds to rule out occult DVT<span></span>, which can dict<span></span>ate a </div><div>longer course of antic<span></span>oagulation (3-6 months if thrombosis present vs &lt; 1 </div><div>month if no thrombosis present)</div><div>Long t<span></span>erm treatment</div><div> <span></span><span></span></div><div><span></span></div><div> <span></span><span></span></div><div><span></span><span></span><span></span><span></span></div><div>until platele<span></span>t recovery (usually great<span></span>er than 100). Early initiation of coumadin </div><div>has been shown to exac<span></span>erbate thrombosis and should be avoided. </div><div> <span></span><span></span></div><div><span></span><span></span><span></span></div><div>be overlapped for 3-5 days. Coumadin should be continued f<span></span>or at least 1 </div><div>month. </div><div> <span></span><span></span></div><div>As a general rule<span>, p<span></span>atients with documented HIT should not be exposed t<span></span>o </span></div><div>heparin again.</div><div> <span></span><span></span></div><div>However, it has been shown tha<span></span>t heparin may be used again in pa<span></span>tients who </div><div>were previously HIT antibody positive if the pa<span></span>tient no longer has a positive </div><div>HIT ELISA antibody titer and the use of heparin is <span>absolut<span></span>ely necessary <span>(ex </span></span></div><div>cardiopulmonary bypass) </div><div>Referenc<span></span>es: </div><div>Cuker A &amp; Clines DB. (2012). How I tre<span></span>at heparin induced thrombocytopenia. Blood.  119: 2209-2218. </div><div> </div><div>HEMA<span></span>T<span></span>OLOGY<span></span>: <span>DEEP VEIN THROMBOSIS</span></div><div>Denition:</div><div> <span></span><span></span></div><div>Condition in which a blood clot (thrombus) f<span></span>orms in a view. The clot can limit </div><div><span></span></div><div> <span></span><span></span></div><div>Thrombus most c<span></span>ommonly occurs in the deep veins in the legs, thigh, or </div><div>pelvis (Deep Vein Thrombosis, or D<span></span>VT)</div><div>Risk F<span></span>actors: </div><div> <span></span><span></span></div><div>Obesity, smoking, he<span></span>art failure, hist<span></span>or<span></span>y of previous DVT<span></span>, immobility, canc<span></span>er, </div><div>some medications (such as: erythropoietin, birth contr<span></span>ol pills, hormone </div><div>replacement ther<span></span>apy)</div><div> <span></span><span></span></div><div>Undergoing a sur<span></span>gical proc<span></span>edure increases risk of DVT development</div><div> <span></span><span></span></div><div>Diagnosis: </div><div> <span></span><span></span></div><div>Classis symptoms include: swelling, p<span></span>ain, warmth, and redness of the </div><div><span></span><span></span></div><div> <span></span><span></span></div><div>Symptoms ar<span></span>e usually asymmetrical. Symmetrical swelling is unlike t<span></span>o </div><div>represent DVT</div><div> <span></span><span></span></div><div><span></span></div><div><span></span><span></span><span></span></div><div>increase risk of developing a DVT (ther<span></span>efore treatment with antic<span></span>oagulation is </div><div>not indica<span></span>ted)</div><div> <span></span><span></span></div><div><span></span><span></span><span>US RADIOL<span></span>OGY VEIN (UPPER/</span></div><div>L<span></span>OWER/BILA<span></span>TERAL) EX<span></span>TERMITIES RULE OUT DVT</div></div><div></div></div>
<div><div><img><div>86<span> </span><span>Pos<span></span>t-Op Management<span> </span>Pos<span></span>t-Op Management<span> </span><span>87</span></span></div><div> <span></span><span></span></div><div><span></span><span></span><span></span><span></span></div><div> <span></span><span></span></div><div>D-dimer may also be elevated in p<span></span>atients with DVT </div><div>Prevention &amp; T<span></span>re<span></span>atment </div><div> <span></span><span></span></div><div>The main goal of tr<span></span>eatment is to prevent a pulmonary embolism, preventing </div><div>DVT from bec<span></span>oming larger<span></span>, and pre<span></span>venting new blood clots fr<span></span>om forming</div><div> <span></span><span></span></div><div>Primary treatment is antic<span></span>oagulation for a minimum of 3 months</div><div><span></span><span> </span><span>Low molecular weight heparin (SubQ hep<span></span>arin or lovenox)</span></div><div><span></span><span> </span><span>Unfrac<span></span>tionated hep<span></span>arin (continuous heparin drip)</span></div><div><span></span><span> </span><span>Direct or<span></span>al anticoagulation: Riv<span></span>aroxaban (X<span></span>arelto), Dabigatr<span></span>an (Sayaysa), </span></div><div>and Apixaban (Eliquis) </div><div><span></span><span> </span><span>Coumadin with goal INR 2-3</span></div><div> <span></span><span></span></div><div>Pos<span></span>t op DVT prevention includes</div><div><span></span><span> </span><span>Bilate<span></span>arl LE SCDs on all patients</span></div><div><span></span><span> </span><span>SubQ heparin (if no c<span></span>ontraindic<span></span>ation) on pa<span></span>tients while in the ICU. </span></div><div>Continue for high risk pa<span></span>tients while on iICU. </div><div><span></span><span> </span><span>See referenc<span></span>e material see <span>page 134.</span></span></div><div>Referenc<span></span>es: </div><div>P<span></span>ai, M, Douketis, J. (2017) P<span></span>atient education: deep vein thrombosis (DVT) beyond the basics. Up t<span></span>o date. </div><div> </div><div>INFECTIOU<span></span>S DISEASE: <span>SEPSIS</span></div><div>Sepsis</div><div> <span></span><span></span></div><div><span></span><span></span></div><div> <span></span><span></span></div><div>Include two or more of the following:</div><div><span></span><span> </span><span>T<span></span>emperatur<span></span>e &gt; 38°C or &lt; 36°C</span></div><div><span></span><span> </span><span>Heart r<span></span>ate &gt; 90 bpm</span></div><div><span></span><span> </span><span>Respir<span></span>atory rate &gt; 20 bpm</span></div><div><span></span><span> </span><span>WBC count &gt; 12,000/mm3 or &lt; 4,000/mm3 or &gt; 10% immatur<span></span>e </span></div><div>neutrophils</div><div> <span></span><span></span></div><div>Clinical signs of org<span></span>an dysfunction</div><div><span></span><span> </span><span>Neuro: alter<span></span>ed LOC, hypo/hyperthermia</span></div><div><span></span><span> </span><span>Pulmonar<span></span>y: hypox<span></span>emia, ARDS</span></div><div><span></span><span> </span><span>Cardiac: hypot<span></span>ension</span></div><div><span></span><span> </span><span>Renal: AKI (Cr &gt; 2 mg<span></span>/<span></span>dL)</span></div><div><span></span><span> </span><span>GI: hyperbilirubinemia &gt; 2 mg<span></span>/<span></span>dL</span></div><div><span></span><span> </span><span><span></span></span></div><div><span></span><span> </span><span>Hyperlact<span></span>atemia </span></div><div>Septic Shock</div><div> <span></span><span></span></div><div>Severe sepsis with hypotension tha<span></span>t does not resolve with adequa<span></span>te volume </div><div>resuscit<span></span>ation</div><div> <span></span><span></span></div><div></div><div>Sepsis Screening T<span></span>ool</div><div> <span></span><span></span></div><div>Goals of Resuscit<span></span>ation</div><div> <span></span><span></span></div><div><span></span></div><div> <span></span><span></span></div><div>Goals:</div><div><span></span><span> </span><span>CVP 8-12 mmHg, MAP &gt; 65 mmHg, urine output &gt; 0.5 mL/kg<span></span>/hr<span></span>, Sc<span></span>vO2 &gt; </span></div><div>70% or SvO2 &gt; 65%, normal lact<span></span>ate levels</div><div>Surviving Sepsis Bundle</div><div> <span></span><span></span></div><div>Resuscit<span></span>ation</div><div><span></span><span> </span><span><span></span><span></span><span></span><span></span></span></div><div>large volumes of crystalloids ar<span></span>e required</div><div><span></span><span> </span><span><span></span><span></span><span></span></span></div><div>to maint<span></span>ain MAP &gt; 65</div><div><span></span><span> </span><span><span></span></span></div><div><span></span><span> </span><span>Add Epinephrine if additional agent needed to maint<span></span>ain MAP</span></div><div><span></span><span> </span><span>Vasopressin c<span></span>an be used in combination with Norepinephrine if unable </span></div><div>to maint<span></span>ain MAP</div><div><span></span><span> </span><span>Consider Dopamine in select<span></span>ed patients with marked L<span></span>V dysfunction.  Not </span></div><div>recommended f<span></span>or renal protection</div><div><span></span><span> </span><span><span></span></span></div><div>or CO subop<span></span>timal</div><div><span></span><span> </span><span><span></span></span></div><div>pressures and MAP<span></span>.  </div><div> <span></span><span></span></div><div>Diagnosis</div><div><span></span><span> </span><span>Obt<span></span>ain cultures before st<span></span>art of antimicrobial therapy if does not delay </span></div><div>trea<span></span>tment (&gt; 45 min)</div><div><span></span><span> </span><span>Blood cultures (one percut<span></span>aneous and one from each vascular device in </span></div><div>place &gt; 48 hours)</div><div><span></span><span> </span><span>Other possible sites of infec<span></span>tion (CSF<span></span>, sputum, urine, etc.)</span></div><div><span></span><span> </span><span><span></span><span></span></span></div><div> <span></span><span></span></div><div>Antimicrobial Ther<span></span>apy</div><div><span></span><span> </span><span>Administ<span></span>er broad spec<span></span>trum antibiotics within one hour of diagnosis</span></div><div><span></span><span> </span><span>Empiric combination antimicr<span></span>obial therapy for neutropenic p<span></span>atients or </span></div><div>highly multidrug-resist<span></span>ant infections</div><div><span></span><span> </span><span>Empiric antifungal ther<span></span>apy for high risk invasive candidiasis</span></div><div><span></span><span> </span><span>Reassess antibio<span></span>tics daily for descalation</span></div><div><span></span><span> </span><span>Limit antimicrobial ther<span></span>apy to 7-10 days *</span></div><div><span></span><span> </span><span>Limit empiric combination ther<span></span>apy to 3-5 days</span></div><div><span></span><span> </span><span>Narrow cover<span></span>age following suscep<span></span>tibility results</span></div><div><span></span><span> </span><span>St<span></span>op antimicrobial ther<span></span>apy if cause of SIRS is uninf<span></span>ectious</span></div><div> <span></span><span></span></div><div>Source Contr<span></span>ol</div><div><span></span><span> </span><span><span></span></span></div><div><span></span><span> </span><span>Radiographic imaging if needed</span></div><div><span></span><span> </span><span>Remove intr<span></span>avascular devices if po<span></span>tentially infected</span></div><div><span></span><span> </span><span><span></span><span></span><span></span></span></div><div><span></span><span> </span><span>Surgical resec<span></span>tion of infected tissues</span></div><div> <span></span><span></span></div><div>Other Support Modalities</div><div><span></span><span> </span><span>Mechanical ventilation</span></div><div><span></span><span> </span><span>Glucose c<span></span>ontrol</span></div><div><span></span><span> </span><span>Renal replac<span></span>ement therapy</span></div><div><span></span><span> </span><span>Blood product adminis<span></span>tration</span></div><div><span></span><span> </span><span>Nutrition</span></div><div><span></span><span> </span><span>Deep vein thrombus prophylaxis</span></div><div><span></span><span> </span><span>Str<span></span>ess ulcer prophylaxis</span></div><div><span></span><span> </span><span><span></span><span></span></span></div><div>resuscit<span></span>ation and v<span></span>asopressor ther<span></span>apy.  Indica<span></span>ted if random cortisol level </div><div>&lt;18 mg<span></span>/<span></span>dL in patient<span></span>s with septic shock</div><div> </div></div><div></div></div>
<div><div><img><div>88<span> </span><span>Pos<span></span>t-Op Management<span> </span>Pos<span></span>t-Op Management<span> </span><span>89</span></span></div><div>INFECTIOU<span></span>S DISEASE: <span>CELL<span></span>ULITIS</span></div><div>Microbiology:</div><div> <span></span><span></span></div><div>Most c<span></span>ommon pathogens are be<span></span>ta-hemolytic s<span></span>treptococ<span></span>ci (groups A, B, C, G, </div><div>and F), <span>Staphylococ<span></span>cus aureus<span>, including MRSA and gram-ne<span></span>gative aer<span></span>obic </span></span></div><div>bacilli</div><div> <span></span><span></span></div><div>Staphylococ<span></span>cus aureus: <span>Periorbit<span></span>al and orbital cellulitis and IV drug users</span></div><div> <span></span><span></span></div><div>Pseudomonas aeruginosa<span>: Diabetics and other immunoc<span></span>ompromised </span></div><div>patient<span></span>s</div><div> <span></span><span></span></div><div>Aeromonas hydrophila<span> and Vibrio <span>vulnicus</span>: Cellulitis caused by w<span></span>aterborne </span></div><div>pathog<span></span>ens</div><div> <span></span><span></span></div><div>Pasteur<span></span>ella multocida<span> and</span> Capnocytophaga canimorsus<span>: Cellulitis prec<span></span>eded </span></div><div>by bites</div><div> <span></span><span></span></div><div>Str<span></span>eptoc<span></span>occus<span> iniae</span>: Immunocompromised hos<span></span>ts</div><div> <span></span><span></span></div><div>Rare causes: Myc<span></span>obacterium, fungal (muc<span></span>ormycosis, aspergillosis, syphilis)</div><div>Diagnosis: </div><div> <span></span><span></span></div><div>For pa<span></span>tients with signs of systemic disease (f<span></span>e<span></span>ver or hypothermia, he<span></span>ar rate </div><div>[HR] &gt;100 bpm, or syst<span></span>olic blood pressure [SBP] &lt;90 mm Hg) include blood </div><div>cultures, drug suscep<span></span>tibility, CBC, crea<span></span>tinine, bicarbonat<span></span>e, CPK, and CRP </div><div>levels </div><div> <span></span><span></span></div><div>Consider use of CT or MRI if suspicious f<span></span>or deeper infection (os<span></span>teomyelitis/</div><div>mediastinis)</div><div>T<span></span>rea<span></span>tment</div><div>Medication<span> (see Stanf<span></span>ord Antibiogram).</span></div><div>First Line</div><div>T<span></span>reat 5–15 days or long<span></span>er, depending on response, and guided by culture when </div><div><span></span><span></span><span></span></div><div>cellulitis (5) [B]. Empiric ther<span></span>apy should be guided by local resist<span></span>ance pat<span></span>terns. </div><div><span></span><span></span><span></span></div><div> <span></span><span></span></div><div><span></span><span></span></div><div>strep<span></span>tococci and me<span></span>thicillin-susceptible S. aureus)</div><div><span></span><span> </span><span> Oral diclo<span></span>xacillin, cephalexin, clindamycin, or IV cef<span></span>azolin, oxacillin, or </span></div><div>nafcillin.</div><div> <span></span><span></span></div><div>P<span></span>arenteral ther<span></span>apy if severely ill or unable to tolera<span></span>te oral therapy</div><div><span></span><span> </span><span><span></span><span></span></span></div><div>cephalosporin; if penicillin-allergic, use clindamycin or v<span></span>ancomycin.</div><div> <span></span><span></span></div><div>Necrotizing f<span></span>asciitis and gas gangrene</div><div><span></span><span> </span><span>P<span></span>arenteral clindamycin and penicillin.</span></div><div> <span></span><span></span></div><div>In patient<span></span>s with recurrent infection underlying predisposing c<span></span>onditions, </div><div>previous episode of proven MRSA inf<span></span>ection, or sys<span></span>temic to<span></span>xicity, use agents </div><div>with activity agains<span></span>t MRSA</div><div><span></span><span> </span><span>P<span></span>arenteral v<span></span>ancomycin, daptomycin, linezolid or or<span></span>al trimethoprim-</span></div><div>sulfametho<span></span>xazole (TMP<span></span>/SMX), doxycycline or minocycline, or clindamycin </div><div>(3)[C].</div><div> <span></span><span></span></div><div>Mild early-suspect<span></span>ed streptoc<span></span>occal etiology</div><div><span></span><span> </span><span>Penicillin G, 600,000 U<span></span>, and then IM procaine penicillin at 600,000 U </span></div><div>q8h–12h.</div><div> <span></span><span></span></div><div>Recurrent s<span></span>treptococ<span></span>cal cellulitis</div><div><span></span><span> </span><span>Penicillin IV 250 mg b<span></span>.i.d., or if penicillin-allergic, use er<span></span>ythromycin 250 </span></div><div>mg b.i.d.</div><div>Alert</div><div> <span></span><span></span></div><div>If community-ac<span></span>quired MRSA is a concern, tr<span></span>eatment options (7–14 days) </div><div>include trimethoprim/sulf<span></span>amethox<span></span>azole: DS (160 mg TMP and 800 mg of SMX) </div><div>1–2 PO b.i.d. daily; do<span></span>x<span></span>ycycline: 100 mg PO b.i.d., or clindamycin: 300–600 mg </div><div>PO t.i.d.</div><div>Second Line</div><div> <span></span><span></span></div><div>Mild infection:</div><div> <span></span><span></span></div><div>If Penicillin aller<span></span>g<span></span>y: Er<span></span>ythromycin 500 mg PO q6h</div><div> <span></span><span></span></div><div><span></span><span></span></div><div>cellulitis at curr<span></span>ent estimated MR<span></span>SA levels.</div><div> <span></span><span></span></div><div>0.5 mg<span></span>/kg<span></span>/<span></span>d for 5–8 days) if partial response to antibiotics in hemorrhagic or </div><div>bullous cellulitis</div><div>Ongoing Care</div><div>Follow-Up R<span></span>ecommendations</div><div> <span></span><span></span></div><div>Repea<span></span>t blood count if patient is to<span></span>xic. Repeat lumbar punc<span></span>ture in case of </div><div>meningitis.</div><div> <span></span><span></span></div><div>Consider prophylaxis of deep vein thrombosis.</div><div> <span></span><span></span></div><div><span></span><span></span><span></span></div><div>bact<span></span>erial antigens. Symptomatic improvement usually oc<span></span>curs in 24–48 hours, </div><div>but visible improvement may t<span></span>ake up to 72 hours.</div><div> </div><div>INFECTIOU<span></span>S DISEASE: <span>PNEUMONIA</span></div><div>Description</div><div>Community-acquired pneumonia (CAP): L<span></span>ower-respira<span></span>tor<span></span>y trac<span></span>t infection no<span></span>t </div><div>acquired in a hospit<span></span>al, long-term c<span></span>are facility, or during o<span></span>ther recent cont<span></span>act with </div><div>the health car<span></span>e system </div><div>Hospital-ac<span></span>quired pneumonia (HAP): Pneumonia that occurs 48 hours or more </div><div><span></span></div><div>Ventilat<span></span>or-associated pneumonia (VAP): Pneumonia tha<span></span>t de<span></span>velops more than </div><div><span></span></div><div>Health car<span></span>e<span></span>–associat<span></span>ed pneumonia (HCAP): Pneumonia that occurs in a </div><div>nonhospitaliz<span></span>ed patient with ex<span></span>tensive health car<span></span>e cont<span></span>act<span></span>, such as:</div><div> <span></span><span></span></div><div>IV therapy or wound c<span></span>are within the pas<span></span>t 30 days</div><div> <span></span><span></span></div><div>Residing in a nursing home or long-<span></span>term care facility</div><div> <span></span><span></span></div><div>Hospitaliz<span></span>ation in an acute care hospit<span></span>al for 2 or more days within the  </div><div>pas<span></span>t 90 days</div><div> <span></span><span></span></div><div>Visited a hospit<span></span>al or hemodialysis clinic within the past 30 days (2)</div><div>Ev<span></span>aluation</div><div> <span></span><span></span></div><div>Symptoms: f<span></span>e<span></span>ver<span></span>, chills, cough, increased sputum, SOB, pleuritic CP<span></span>. Note </div><div>that the presenting symp<span></span>toms can be subtle – weakness, malaise, AMS</div><div> <span></span><span></span></div><div><span></span></div><div> <span></span><span></span></div><div>Other studies:</div><div><span></span><span> </span><span>Blood culture – before antibio<span></span>tic administra<span></span>tion</span></div><div><span></span><span> </span><span>ABG when patient is severely dyspneic or t<span></span>achypneic</span></div><div><span></span><span> </span><span>Consider tes<span></span>ting for Le<span></span>gionella (culture and urinary assay), Mycoplasma </span></div><div>(cold agglutinins), Pneumoc<span></span>cocus (urine antigen), Chlamydia (acute and </div><div>conv<span></span>alescent serology), or respirat<span></span>or<span></span>y vir<span></span>al panel if clinical course atypic<span></span>al </div><div>or enigmatic</div></div><div></div></div>
<div><div><img><div>90<span> </span><span>Pos<span></span>t-Op Management<span> </span>Pos<span></span>t-Op Management<span> </span><span>91</span></span></div><div><span></span><span> </span><span>Sputum gram s<span></span>tain and culture: while contr<span></span>oversial, it is helpful if </span></div><div>performed before antibio<span></span>tics; an adequate sample has &gt;25 PMNs and &lt; </div><div>10 epithelial cells.</div><div><span></span><span> </span><span>Consider HIV tes<span></span>ting if never previously tested or risk f<span></span>actors for HIV</span></div><div><span></span><span> </span><span>In Immunocompromised p<span></span>atients, consider diagnos<span></span>tic workup for </span></div><div>opportunistic p<span></span>athogens (PCP<span></span>, TB, fungi)</div><div> <span></span><span></span></div><div><span></span><span></span></div><div>microbiologic diagnosis reduc<span></span>es mortality compar<span></span>ed to empiric treatment. </div><div>Management</div><div> <span></span><span></span></div><div>Antibiotic re<span></span>gimen depends on severity of illness, potential for r<span></span>esist<span></span>ant </div><div>organisms or opportunis<span></span>tic pathogens</div><div> <span></span><span></span></div><div>Consult hospital antibiogr<span></span>am and antibiotic guidelines. Adjust for r<span></span>enal/</div><div><span></span></div><div>within 4-6 hours of present<span></span>ation</div><div> <span></span><span></span></div><div>Pseudomonas risk fac<span></span>tors: structur<span></span>al lung disease (bronchiect<span></span>asis), </div><div>cortic<span></span>osteroid ther<span></span>apy (&gt;10 mg of prednisone per day), broad spectrum </div><div>antibiotics for &gt; 7 d in the p<span></span>ast month, recent hospit<span></span>alization, malnutrition</div><div> <span></span><span></span></div><div>Community acquired MR<span></span>SA risk<span></span>: immunocompr<span></span>omised, injection drug use, </div><div><span></span><span></span><span></span></div><div>necrotizing pneumonia</div><div> <span></span><span></span></div><div>High risk of multi-drug resist<span></span>ant (MDR) pathogens: la<span></span>te-onset HAP or VAP </div><div><span></span></div><div>last 90 days, high frequency of antibio<span></span>tic resistanc<span></span>e in the community, </div><div>immunocompromised, or any risk f<span></span>actor for HCAP above. </div><div>Medication</div><div>Pa<span></span>tient Subset<span> </span>Common organisms<span> </span>Ex<span></span>ample empiric antibiotic therapy</div><div>CAP</div><div>- Inpatient</div><div>- Not in ICU</div><div> <span></span><span></span></div><div>T<span></span>ypical: <span>Streptoc<span></span>occus </span></div><div>pneumoniae, Haemophilus </div><div>inuenzae, </div><div> <span></span><span></span></div><div>Atypical: <span>Legionella </span>sp<span></span>., </div><div>Mycoplasma pneumoniae, </div><div>Chlamydophila <span></span>pneumoniae</div><div></div><div>Doxycycline 100mg PO BID</div><div>(if severe penicillin allergy, consider </div><div><span></span></div><div>CAP</div><div>- Inpatient</div><div>- In ICU</div><div>ASSESS risk of </div><div>MDR pathog<span></span>en </div><div>(see above)</div><div>As above plus drug resistant S. </div><div>penumoniae, St<span></span>aphylococcus </div><div>aureus, other gr<span></span>am-negative rods</div><div></div><div>Azithromycin 500mg PO/IV x 1 then</div><div>250mg PO/IV qday</div><div>If risk for CAMRSA: ADD V<span></span>ancomycin</div><div>If risk for Pseudomonas, Pipercillin/</div><div>tazob<span></span>actam 4.5 gm IV q 6h replaces </div><div></div><div>HCAP<span></span>, HAP<span></span>, VAP </div><div>(any acuity)</div><div>Assess risk of </div><div>MDR pathogen </div><div>(see above)</div><div>Staphylococ<span></span>cus aureus, </div><div>Pseudomonas aeruginosa, </div><div>drug-resistant Strept<span></span>ococcus </div><div>pneumoniae<span>, and other resis<span></span>tant </span></div><div>gram-neg<span></span>ative rods. </div><div><span></span></div><div>risk fact<span></span>ors for MDR pathog<span></span>ens – </div><div>empiric therapy should acc<span></span>ount for </div><div>each individual’<span></span>s risk factors and </div><div>level of acuity. </div><div>Low Risk of MDR pa<span></span>thogens:</div><div></div><div>Doxycycline 100mg PO BID AND</div><div>Vancomycin and chang<span></span>e doxyc<span></span>ycline to </div><div>azithromycin in ICU pa<span></span>tients. </div><div>High Risk of MDR pathog<span></span>ens:</div><div>Vancomycin AND</div><div>Pipercillin/tazob<span></span>actam 4.5gm IV q6h AND</div><div><span></span></div><div>INFECTIOU<span></span>S DISEASE:  </div><div>C. DIFF (CL<span></span>OSTRIDIUM DIFFIC<span></span>UL<span></span>T)</div><div>Causes: </div><div> <span></span><span></span></div><div>Produces ent<span></span>erotoxin ( t<span></span>oxin A ) and cytot<span></span>oxic ( toxin B )</div><div> <span></span><span></span></div><div>Associated with ALL antibiotics and hospitaliz<span></span>ation itself</div><div>Symptoms:  a v<span></span>ariety of syndromes are possible from asymp<span></span>tomatic inf<span></span>ection -&gt; </div><div>diarrhea -&gt; pseudomembr<span></span>anous (PMC) -&gt; toxin mega c<span></span>olon -&gt; fulminant colitis. </div><div> <span></span><span></span></div><div>Flu-like sympt<span></span>oms:  Fever, chills, abdominal pain, w<span></span>ater<span></span>y diarrhea. </div><div> <span></span><span></span></div><div>Fecal inc<span></span>ontinence common.</div><div>Diagnose: </div><div> <span></span><span></span></div><div><span></span></div><div> <span></span><span></span></div><div><span></span><span></span></div><div>a false positive sample</div><div> <span></span><span></span></div><div>Order only for p<span></span>atients who have had several wat<span></span>er<span></span>y stools. Cannot be </div><div>ret<span></span>est<span></span>ed before 7 days.</div><div> <span></span><span></span></div><div><span></span><span></span><span></span></div><div>48 hours. </div><div>T<span></span>rea<span></span>tment:  </div><div> <span></span><span></span></div><div>d/<span></span>c antibiotic if possible</div><div> <span></span><span></span></div><div>place in c<span></span>ontact isolation</div><div> <span></span><span></span></div><div>Mild: Metronidazole ( Flagyl ) IV</div><div> <span></span><span></span></div><div>Modera<span></span>te –severe: Vanc<span></span>omycin oral</div><div>DO NOT U<span></span>SE ANTI-PERIST<span></span>AL<span></span>TIC AGENT<span></span>S FOR C-DIFF<span></span>. </div><div>INFECTIOU<span></span>S DISEASE:<span> </span></div><div>URINARY TR<span></span>ACT INFECTION</div><div>Denitions:</div><div> <span></span><span></span></div><div>Lower UTI: Ure<span></span>thritis, cystitis</div><div> <span></span><span></span></div><div>Upper UTI: Pyelonephritis, renal/perinephric abscess</div><div> <span></span><span></span></div><div>Uncomplica<span></span>ted UTI: Lower UTI in a non-pregnant woman with normal GU </div><div>anatomy</div><div> <span></span><span></span></div><div>Complicat<span></span>ed UTI: Anyone else including upper UTI in women, any UTI in men, </div><div>pregnant women or women with s<span></span>tructural or neurological GU dise<span></span>ase.</div><div>Etiology/Risk F<span></span>act<span></span>ors:</div><div> <span></span><span></span></div><div>Organisms: SEEEKS PP: Serr<span></span>atia, E.Coli (80%), Enterobac<span></span>ter, Ent<span></span>ercoccus, </div><div>Klebsiella, St<span></span>aph. Saprophyticus, Proteus, P<span></span>seudomonas</div><div> <span></span><span></span></div><div>Risk F<span></span>actors: F<span></span>emale (short urethr<span></span>a), sexual intercourse, indwelling </div><div>urinar<span></span>y ca<span></span>theters, or recent ins<span></span>trumentation, diaphr<span></span>agm/spermicide use, </div><div><span></span><span></span></div></div><div></div></div>
<div><div><img><div>92<span> </span><span>Pos<span></span>t-Op Management<span> </span>Pos<span></span>t-Op Management<span> </span><span>93</span></span></div><div>T<span></span>rea<span></span>tment:</div><div> <span></span><span></span></div><div>Uncomplica<span></span>ted UTI: </div><div><span></span><span> </span><span><span></span><span></span><span></span></span></div><div>resist<span></span>ance is &gt; 20%</div><div> <span></span><span></span></div><div>Lower UTI in Pre<span></span>gnant women: </div><div><span></span><span> </span><span>Amoxicillin/Clauvulana<span></span>te (Augmentin) and Cephalexin are preferred</span></div><div> <span></span><span></span></div><div>Complicat<span></span>ed lower UTI: Remove ca<span></span>theter<span></span>/stent if pr<span></span>esent (high incidence of </div><div>Pseudomonas and Candida). </div><div><span></span><span> </span><span><span></span><span></span></span></div><div> <span></span><span></span></div><div>Uncomplica<span></span>ted pyelonephritis: Low grade fever<span></span>, WBC count only slightly </div><div>elevated, no nause<span></span>a/vomiting. </div><div><span></span><span> </span><span><span></span><span></span></span></div><div>Augmentin for 14 days. </div><div>ENDOCRINE: <span>AC<span></span>UTE HYPERGL<span></span>Y<span></span>CEMIA AND </span></div><div>DIABETES MANAGEMENT</div><div>1. <span> </span><span>General Pr<span></span>e op consider<span></span>ations: </span></div><div>a. <span> </span><span>Always obt<span></span>ain hemoglobin A1c on pre op labwork</span></div><div>b.<span> <span> </span><span>For outp<span></span>atients: instruc<span></span>t them to hold oral meds on the same morning </span></span></div><div>of OR day; if they are on basal  insulin, only give 1/3 -1/2 does the night </div><div>before or on the same morning of OR. </div><div>c. <span> </span><span><span></span></span></div><div>continue home DM meds( exc<span></span>ept metformin) &amp; insulin the night befor<span></span>e </div><div>surgery; hold oral meds and only give 1/2 -1/3 does basal insulin on the </div><div>same morning  of OR.</div><div>2. <span> </span><span>Hyperglycemia oc<span></span>curs in virtually all CT surgery patients due t<span></span>o:</span></div><div>a. <span> </span><span>A. <span> </span>Increased ex<span></span>trac<span></span>ellular glucose, decreased insulin secre<span></span>tions and </span></div><div>increase peripher<span></span>al resist<span></span>ance to insulin due to: </div><div>o <span> </span>exposure to extr<span></span>acorporeal circula<span></span>tion</div><div>o <span> </span>hypothermia</div><div>o <span> </span>release of endogenous ca<span></span>techolamines, cortisol, and glucagon</div><div>b.<span> <span> </span><span>P<span></span>ost-op g<span></span>oal blood gluc<span></span>ose is &lt; 180 mg<span></span>/<span></span>dL</span></span></div><div>c. <span> </span><span>For pa<span></span>tients with known high HgbA1c pre op or for any pa<span></span>tient </span></div><div>whose gluco<span></span>se is diicult to manag<span></span>e, low threshold t<span></span>o consult </div><div>Endocrine. </div><div>3. <span> </span><span>P<span></span>atients will be admitt<span></span>ed to the CVICU on an insulin drip. P<span></span>atient should </span></div><div>remain on an insulin drip until blood glucose r<span></span>emains within target r<span></span>ange </div><div>with st<span></span>able drip titrations (+/- no more than 1 f<span></span>or pas<span></span>t 4 hours)</div><div>a. <span> </span><span><span></span></span></div><div> </div><div>b.<span> <span> </span><span><span></span><span></span></span></span></div><div>NS @ 50mL/hr and d/<span></span>c D5 ½ NS.</div><div>Prepar<span></span>ation<span> </span>Onset<span> </span>Peak ac<span></span>tion<span> </span>Duration</div><div>Rapid Acting</div><div>Insulin Lispro (Humulog)</div><div>Insulin aspart (NovoLog)</div><div> </div><div>9-30 min </div><div>15 min</div><div> </div><div>30 min-2.5 hrs </div><div>30 min-1 hr</div><div> </div><div>3-4 hrs </div><div>1-3 hrs</div><div>Short Acting</div><div>Regular insulin </div><div>30 min- 1 hr<span> </span>2-5 hrs<span> </span>3-8 hrs</div><div>Intermediat<span></span>e Acting</div><div>NPH</div><div>1-4 hrs<span> </span>4-10 hrs<span> </span>10-16 hrs</div><div>Long Acting</div><div>Insulin glargine (Lantus)</div><div>2-4 hrs<span> </span>None<span> </span>24 hrs</div></div><div></div></div>
<div><div><img><div>94<span> </span><span>Pos<span></span>t-Op Management<span> </span>Pos<span></span>t-Op Management<span> </span><span>95</span></span></div><div>c. <span> </span><span>Special Circumst<span></span>ances</span></div><div>4. <span> </span><span>Preparing f<span></span>or discharge: </span></div><div>a. <span> </span><span>For patient<span></span>s with no previous histor<span></span>y of diabet<span></span>es, the goal is to wean </span></div><div><span></span></div><div>i. <span> </span>If no f<span></span>ormal diagnosis of Diabetes, but pre op A1C &gt; 6.4%, consider </div><div>consult to endocrine or initia<span></span>tion of oral anti diabetic agents</div><div>ii.  If  a patient is being discharg<span></span>ed home with any ne<span></span>w diabetic </div><div>medications (or<span></span>al or injection), Diabetes educa<span></span>tion must be order<span></span>ed </div><div>(~2 days prior to discharg<span></span>e) and complet<span></span>ed by with DM Nurse or the </div><div>bedside RN</div><div>iii. Diabetic t<span></span>each orders in Epic</div><div>1.  “Diabetes educ<span></span>ation” = Bedside Nursing</div><div>a.  Can also plac<span></span>e nursing communication order f<span></span>or RN to initiat<span></span>e </div><div>DM T<span></span>eaching Video</div><div>2.  Nsg Referr<span></span>al to Diabetes RN = CNS Specialis<span></span>t (*Preferred)</div><div>b.<span> <span> </span><span>For those p<span></span>atients with diabetes, slowly r<span></span>estart any or<span></span>al anti-diabetic </span></span></div><div>agents and or insulin. P<span></span>atients will lik<span></span>ely be on much lower doses of </div><div>medications or insulin a<span></span>t discharge than a<span></span>t pre op</div><div>i. <span> </span>Medic<span></span>ations can slowly be up titrat<span></span>ed as needed in the outpatient </div><div>setting as p<span></span>atients diet and appetit<span></span>e returns to normal</div><div>ii.  Oral Antidiabetic agent<span></span>s: </div><div>1.  Metformin</div><div>a.  Contr<span></span>aindicated in the presc<span></span>ence of renal dysfunction (Cre<span></span>at &gt; </div><div>~1.5)</div><div>b.<span> <span> </span>Metformin should t<span></span>emporarily be held pr<span></span>e and post </span></div><div>administr<span></span>ation of IV contras<span></span>t </div><div>c.  Typically held 48 hours prior t<span></span>o any major surger<span></span>y. R<span></span>esume </div><div><span></span><span></span></div><div>returned t<span></span>o baseline. </div><div>2.  Sulfonylure<span></span>as (Glipizide, Glimepiride, Glyburide)</div><div>a.  S<span></span>timulates insulin release fr<span></span>om pancreas</div><div>b.<span> <span> </span>Glipizide does not have an active me<span></span>tabolit<span></span>e, better choice f<span></span>or </span></div><div>those with renal failur<span></span>e</div><div>c.  Overall, increased incidenc<span></span>e of causing hypoglycemia</div><div>3.  Thiazolidinediones ( Act<span></span>os, Avandia)</div><div>a.  May exac<span></span>erbate he<span></span>art failure! Avoid use in most c<span></span>ardiac pa<span></span>tients </div></div><div></div></div>
<div><div><img><div>96<span> </span><span>Pos<span></span>t-Op Management</span></div><div>ENDOCRINE: <span>ADRENAL INSUFFICIENCY</span></div><div>Denition:</div><div> <span></span><span></span></div><div>Most c<span></span>ommonly occurs in critically ill patient<span></span>s due to subnormal </div><div>cortic<span></span>osteroid produc<span></span>tion. </div><div>Diagnosis: </div><div> <span></span><span></span></div><div>T<span></span>ot<span></span>al (random) serum c<span></span>ortisol: Low </div><div> <span></span><span></span></div><div>Morning serum cortisol c<span></span>oncentration: L<span></span>ow (&gt; 3mch/<span></span>dL)</div><div> <span></span><span></span></div><div>CTH S<span></span>timulation test:</div><div><span></span><span> </span><span><span></span><span></span><span></span><span></span></span></div><div><span></span><span> </span><span>Administr<span></span>ation of ACTH (1-24) or Cosyntropin:</span></div><div> <span></span><span></span></div><div>St<span></span>anford high dose tes<span></span>t (250mcg)</div><div> <span></span><span></span></div><div>A normal response is a rise in serum cortisol c<span></span>oncentration 30-60 </div><div><span></span><span></span><span></span><span></span></div><div> <span></span><span></span></div><div>A normal response to high dose A<span></span>CTH s<span></span>timulation test ex<span></span>cludes </div><div><span></span></div><div> <span></span><span></span></div><div>Low dose tes<span></span>t (1mcg<span></span>)</div><div> <span></span><span></span></div><div>A normal response is a rise in serum cortisol c<span></span>oncentration 20-30 </div><div><span></span><span></span><span></span><span></span></div><div>T<span></span>rea<span></span>tment: Str<span></span>ess Dose S<span></span>teroids</div><div> <span></span><span></span></div><div>Consider trea<span></span>tment when patient on &gt;2 pressors with hemodynamic </div><div>inst<span></span>ability</div><div> <span></span><span></span></div><div>Replacement with hydr<span></span>ocortisone:</div><div><span></span><span> </span><span>50mg IV Q6 hours or 100mg IV q8 hours</span></div><div> <span></span><span></span></div><div>Consider quick taper (over 3-5 days) onc<span></span>e hemodynamics improve </div><div>Referenc<span></span>es: </div><div><span></span><span></span></div></div><div></div></div>
<div><div><img><div>Procedur<span></span>es/De<span></span>vices<span> </span><span>97</span></div><div>PROCEDURES: <span>A<span></span>TRIAL ELEC<span></span>TROGRAMS</span></div><div> <span></span><span></span></div><div><span></span><span></span><span></span></div><div><span></span></div><div> <span></span><span></span></div><div>Requires the presc<span></span>eince of atrial tempor<span></span>ar<span></span>y epicardial wires </div><div>T<span></span>o perform:</div><div> <span></span><span></span></div><div>Obt<span></span>ain standard EC<span></span>G for baseline/<span></span>comparison</div><div> <span></span><span></span></div><div>For Atrial EC<span></span>G: Att<span></span>ach the two arm leads to the atrial wires (all o<span></span>ther leads </div><div>at<span></span>tached normally)</div><div><span></span><span> </span><span>A bipolar ECG will be r<span></span>ecorded in Lead I and unipolar EC<span></span>G in Lead II or III</span></div><div> <span></span><span></span></div><div>Interpre<span></span>ta<span></span>tion: Ev<span></span>aluate a<span></span>trial activity in rela<span></span>tion to QRS c<span></span>omplex </div><div>Interpre<span></span>tation e<span></span>xamples:</div><div> <span></span><span></span></div><div>Normal Sinus rhythm: Large a<span></span>trial spike on Atrial EC<span></span>G will correlat<span></span>e  </div><div>with P waves</div><div> <span></span><span></span></div><div>Junctional: No atrial spik<span></span>e present on Atrial ECG</div><div> <span></span><span></span></div><div><span></span><span></span></div><div>PROCEDURES: <span> </span></div><div>DIRECT C<span></span>URRENT CARDIOVERSION (DC<span></span>CV)</div><div>Supplies/Equipment</div><div>5. <span> </span><span></span></div><div>6. <span> </span><span><span></span></span></div><div>7. <span> </span><span>EKG machine </span></div><div>8. <span> </span><span>Monitoring equipment at bedside (bedside t<span></span>elemetr<span></span>y with 5 lead syst<span></span>em, </span></div><div><span></span><span></span><span></span></div><div>oxygen ac<span></span>cess and mask<span></span>, pulse o<span></span>ximetry, ambubag)</div><div>Proc<span></span>edure</div><div>Pre-Proc<span></span>edure Care St<span></span>eps:</div><div>1. <span> </span><span><span></span></span></div><div>a. <span></span><span>12 lead EKG</span></div><div>b.<span> <span></span><span>Pa<span></span>tent intravenous venous line (IV)</span></span></div><div>c. <span> </span><span>P<span></span>atient is connected t<span></span>o the following: telemetry with a 5-lead EKG </span></div><div><span></span><span></span></div><div>equipment, oxygen is available/<span></span>operational, ambu b<span></span>ag at bedside</div><div>2. <span> </span><span>Keep patient NPO f<span></span>or approximately 6 hours prior to pr<span></span>ocedure</span></div><div>3. <span> </span><span><span></span><span></span></span></div><div>4. <span> </span><span>Obt<span></span>ain written informed consent</span></div><div>5. <span> </span><span><span></span><span></span></span></div><div><span></span><span></span></div></div><div></div></div>
<div><div><img><div>98<span> </span><span>Procedures/Devices<span> </span>Procedur<span></span>es/De<span></span>vices<span> </span><span>99</span></span></div><div>For pa<span></span>tients on T<span></span>elemetry unit requiring DC<span></span>CV: (must be performed by </div><div>Cardiac Anesthesia)</div><div>1. <span> </span><span>P<span></span>age, call, or tex<span></span>t ICU Cardiac Anesthesia At<span></span>tending on call directly t<span></span>o set </span></div><div>up cardioversion</div><div>2. <span> </span><span>Call OR to book the case in the OR (this is f<span></span>or ICU at<span></span>tending billing </span></div><div>purposes)</div><div>Cardiac anesthesia on call f<span></span>or the OR should only be contacted for c<span></span>ardioversion </div><div>if ICU Att<span></span>ending is unable to perform the procedure.</div><div>PROCEDURES: <span>P<span></span>ACER WIRE (PW) REMOV<span></span>AL</span></div><div>Pre Remov<span></span>al Checklist: </div><div>1. <span> </span><span>Are PW capped with no evidence of rhythm issues on t<span></span>elemetr<span></span>y for 24 hours? </span></div><div><span></span><span></span></div><div>2. <span> </span><span>If pacing wires have no<span></span>t been capped yet, any pacing activity in last 24 hrs? </span></div><div>(Check with primar<span></span>y nurse and teleme<span></span>tr<span></span>y monitor). If not &gt; cap p<span></span>acing wires. </div><div>3. <span> </span><span>If PW already c<span></span>apped, for how long? (Usually requir<span></span>e wires to be c<span></span>apped for at </span></div><div>leas<span></span>t 4-6 hours before removal)</div><div>4. <span> </span><span>Is patient on any anti-c<span></span>oagulation including Heparin sub Q<span></span>/ IV infusion, </span></div><div>Arga<span></span>troban, Plavix, Coumadin, Pradaxa, X<span></span>arelto, Eliquis etc?</div><div>i. <span> </span><span>In gener<span></span>al, we do not s<span></span>tart non-r<span></span>e<span></span>versible antico<span></span>agulant agents (Plavix/</span></div><div>Pradax<span></span>a/Eliquis/Xarelt<span></span>o, etc.) until PW alr<span></span>eady removed</div><div>ii. <span> </span><span>If novel OAC ag<span></span>ent has been st<span></span>arted, check with surgical te<span></span>am regarding </span></div><div>timing of holding medication prior t<span></span>o PW remov<span></span>al </div><div>iii. <span> </span><span>If on SubQ heparin, hold Sub Q heparin 6-8 hrs bef<span></span>ore PW removal</span></div><div>iv<span></span>. <span> </span><span>If on heparin/<span></span>argatrob<span></span>an gtt, hold gtt for 6 hrs before PW r<span></span>emoval, and </span></div><div><span></span></div><div>v.<span></span><span> <span> </span><span>If on Coumadin, slowly titrate Coumadin dose until PW out, and only </span></span></div><div>remove PW with INR &lt; 2.0.</div><div>5. <span> </span><span>Was PW sutured in or oversewn to he<span></span>art? Double check sign-out list and </span></div><div>notes. *** In this c<span></span>ase PW are to be CUT A<span></span>T SKIN, not pulled ***</div><div>6. <span> </span><span>Has plan to remove PW been discussed with a<span></span>tt<span></span>ending or chief resident? </span></div><div>During Remov<span></span>al:</div><div> <span></span><span></span></div><div>Maintain smoo<span></span>th and steady s<span></span>trength</div><div> <span></span><span></span></div><div><span></span><span></span><span></span></div><div><span></span></div><div>swab</div><div>Aer R<span></span>emoval:</div><div> <span></span><span></span></div><div>Notify both p<span></span>atient &amp; primar<span></span>y RN to keep p<span></span>atient in bed for at leas<span></span>t 1 hour </div><div><span></span></div><div> <span></span><span></span></div><div>Instruct RN t<span></span>o watch for warning signs and symp<span></span>toms of tamponade such as:</div><div><span></span><span> </span><span>Lightheadedness</span></div><div><span></span><span> </span><span>Dizziness</span></div><div><span></span><span> </span><span>Diaphoresis</span></div><div><span></span><span> </span><span>Chest disc<span></span>omfort</span></div><div><span></span><span> </span><span>Decreased BP</span></div><div><span></span><span> </span><span>Increased HR</span></div><div> <span></span><span></span></div><div><span></span><span></span><span></span></div><div>6. <span> </span><span><span></span><span></span><span></span><span></span></span></div><div>i. <span> </span><span>Antico<span></span>agulation:</span></div><div>•<span> <span> </span>If dur<span></span>ation of atrial arrhythmia &lt; 48 hours, no antic<span></span>oagulation required</span></div><div>•<span> <span> </span>If dur<span></span>ation of atrial arrhythmia &gt; 48 hours, c<span></span>onsider anticoagulation in </span></div><div>conjunction with CHADs sc<span></span>ore</div><div>ii. <span> </span><span>K+ - consider replac<span></span>ement if K+ &lt; 3.4</span></div><div>7. <span> </span><span>Review baseline vital signs and SaO2 fr<span></span>om pulse oximeter</span></div><div>8. <span> </span><span><span></span></span></div><div>9. <span> </span><span>If tempor<span></span>ar<span></span>y p<span></span>acing wires present<span></span>- ensure att<span></span>ached to external p<span></span>acemaker </span></div><div>box and turn pac<span></span>emaker box on (consider placing p<span></span>atient on back up VVI </div><div>mode)</div><div>10. <span></span><span><span></span><span></span></span></div><div><span></span><span></span></div><div>placement is at le<span></span>ast six (6) inches away from implant<span></span>ed device</div><div>11. <span></span><span><span></span><span></span><span></span><span></span></span></div><div>i. <span> </span><span><span></span></span></div><div><span></span><span></span></div><div>at<span></span>tending provider’<span></span>s discretion)</div><div>ii. <span> </span><span><span></span><span></span></span></div><div>iii. <span> </span><span>Press “Sync” but<span></span>ton and ensure R wave aligns with synchr<span></span>onized </span></div><div>marker</div><div>iv<span></span>. <span> </span><span>Press rec<span></span>ord button to ensur<span></span>e recording paper is oper<span></span>ational</span></div><div>Proc<span></span>edure St<span></span>eps:</div><div>1. <span> </span><span>Perf<span></span>orm “Time out”</span></div><div>2. <span> </span><span>Anesthesiologis<span></span>t<span></span>/ICU APP adminis<span></span>ters anesthetic agent via IV with O2 on </span></div><div>patient</div><div>3. <span> </span><span>Vitals signs and SaO2 ar<span></span>e recor<span></span>ded e<span></span>very minute by RN</span></div><div>4. <span> </span><span>When anesthesiologis<span></span>t<span></span>/ICU APP det<span></span>ermines patient is adequately seda<span></span>ted, </span></div><div>he/she acknowledges to the APP tha<span></span>t patient is ready f<span></span>or DCCV</div><div>5. <span> </span><span>The APP performs the following:</span></div><div>i. <span> </span><span>Press the “Charg<span></span>e” butt<span></span>on and sta<span></span>tes loudly, “Char<span></span>ging”</span></div><div>ii. <span> </span><span>St<span></span>ates loudly, “<span></span>All clear!” and visually sweeps the bed to ensur<span></span>e no one </span></div><div>is touching the bed and wait<span></span>s for other t<span></span>eam members to verify they are </div><div>clear</div><div>iii. <span> </span><span>Press and hold the “Shock<span></span>” button</span></div><div>6. <span> </span><span><span></span><span></span><span></span></span></div><div>communica<span></span>tes with anesthesiologist t<span></span>o verify vital signs are st<span></span>able</div><div>7. <span> </span><span>If patient r<span></span>emains in sinus rhythm, anterior/pos<span></span>terior pads are removed fr<span></span>om </span></div><div><span></span><span></span></div><div>from pa<span></span>tient</div><div>8. <span> </span><span>If patient has e<span></span>arly re-initiation of atrial arrhythmia or remains in an atrial </span></div><div>arrhythmia, DCCV pr<span></span>ocedure is repea<span></span>ted with a higher number of joules.  APP </div><div><span></span><span></span></div><div>energy for the maximum of 3 shocks.</div><div>9. <span> </span><span>The APP follows current ACL<span></span>S protoc<span></span>ol for asystole, high degr<span></span>ee AV block or </span></div><div>ventricular arrhythmias and pages A<span></span>ttending Physician</div><div>10. <span></span><span>The APP c<span></span>ompletes the following:</span></div><div>i. <span> </span><span>Reviews post proc<span></span>edure EKG</span></div><div>ii. <span> </span><span>Any medication r<span></span>econciliation, if applic<span></span>able</span></div><div>iii. <span> </span><span>Document via Procedur<span></span>e Note: Include medication adminis<span></span>tered, # of </span></div><div>joules, # of shocks, post proc<span></span>edure rhythm, and any adverse events. </div></div><div></div></div>
<div><div><img><div>100<span> </span><span>Procedures/Devic<span></span>es<span> </span>Procedur<span></span>es/De<span></span>vices<span> </span><span>101</span></span></div><div>If the chest tube has purse s<span></span>trings: </div><div>1. <span> </span><span>With scalpel, cut the holding suture which is tied around the ches<span></span>t tube and </span></div><div>the purse strings on the dis<span></span>tal end, make sure le<span></span>ave enough purse string </div><div>length to tie. </div><div>2. <span> </span><span><span></span></span></div><div>3. <span> </span><span>Instruct the p<span></span>atient to tak<span></span>e deep breath in and hold bre<span></span>ath. (*T<span></span>ubes may be </span></div><div>pulled at end inspir<span></span>ation or end expir<span></span>ation, the import<span></span>ant point is that the </div><div>patient is no<span></span>t inspiring as the tube comes out) </div><div>4. <span> </span><span>Pull chest tube smoo<span></span>thly and quickly</span></div><div>5. <span> </span><span><span></span></span></div><div>removal, oper<span></span>ator immediat<span></span>ely tie down the purse string with sur<span></span>gical knot<span></span>s </div><div>X3 and cut excess s<span></span>tring with scalpel </div><div>6. <span> </span><span>Remind pa<span></span>tient to breath normally as soon as ches<span></span>t tube is removed </span></div><div>7. <span> </span><span>Cover the CT sit<span></span>e vaseline g<span></span>auze with dr<span></span>y dressing and tape </span></div><div>If the pa<span></span>tient does not have pur<span></span>se string to tie:</div><div>1. <span> </span><span>Cut the holding string and c<span></span>over the insertion site with Vaseline gauz<span></span>e quickly </span></div><div>while removing  the chest tube </div><div>2. <span> </span><span>Cover the Vaseline gauz<span></span>e with dr<span></span>y dressing and make sure the whole dr<span></span>essing </span></div><div>is sealed well with 2inch paper t<span></span>apes for @ leas<span></span>t 48 hrs before remove </div><div>dressing or shower</div><div>If chest tube is pigt<span></span>ail cathet<span></span>er placed per IR</div><div>1. <span> </span><span>See Pigtail r<span></span>emoval</span></div><div>Check list pos<span></span>t chest tube remov<span></span>al:</div><div> <span></span><span></span></div><div>Dispose all sharps in sharps cont<span></span>ainer<span></span>; dispose CT dr<span></span>ainage unit into doubled </div><div>red tr<span></span>ash bag</div><div> <span></span><span></span></div><div>If conc<span></span>ern or suspect post CT r<span></span>emoval P<span></span>TX, need to check CXR immediat<span></span>ely; if </div><div>no conc<span></span>ern for PT<span></span>X, do not need to check CXR</div><div> <span></span><span></span></div><div></div><div>extr<span></span>eme pain, pos<span></span>top PT<span></span>X etc.) during or pos<span></span>top procedure</div><div>Pos<span></span>t chest tube remo<span></span>val p<span></span>atient education:</div><div> <span></span><span></span></div><div>Keep occlusive dressing or s<span></span>tiches on for at leas<span></span>t 48 hrs, then remove and </div><div>clean site in shower (C<span></span>T stich could be r<span></span>emoved prior to discharg<span></span>e or on clinic </div><div>visit time)</div><div> <span></span><span></span></div><div>No soaking in ba<span></span>thtub for 1 week</div><div> <span></span><span></span></div><div>CT insertion sit<span></span>e will be assessed at follow up MD visit in 1-2 weeks </div><div> <span></span><span></span></div><div><span></span><span></span><span></span><span></span><span></span></div><div>increasing erythema on CT sites</div><div>Pigtail R<span></span>emoval (plac<span></span>ed by IR) </div><div>PROCEDURES: <span>RAPID SEQUENCE INDUC<span></span>TION</span></div><div>Simultaneous adminis<span></span>tration of a sedative and a neur<span></span>omuscular blocking </div><div><span></span><span></span><span></span></div><div>to f<span></span>acilita<span></span>te emerg<span></span>ent endotracheal intub<span></span>ation and to minimize the risk of </div><div>aspira<span></span>tion.  </div><div>Administ<span></span>er<span></span>:  </div><div>1) SEDA<span></span>TIVE; 2) P<span></span>ARAL<span></span>YTIC; 3) FL<span></span>USH</div><div>(Most Common combination is Etomidat<span></span>e and Rocuronium +/- propofol for side </div><div>eect prole)</div><div>If the pa<span></span>tient st<span></span>arts to exhibit s/sx o<span></span>f tamponade  </div><div>follow these s<span></span>teps:</div><div>1. <span> </span><span>1. <span> </span>If patient only has sympt<span></span>oms, but BP and HR are stable:</span></div><div>i. <span> </span><span>Order ST<span></span>A<span></span>T Echo </span></div><div>ii. <span> </span><span>Call Echo lab (x54160) to no<span></span>tify them of order and that the purpose is to </span></div><div>rule out tamponade</div><div>iii. <span> </span><span>Continue to monitor p<span></span>atient &amp; vitals closely. Run BP checks Q15 min.</span></div><div>iv<span></span>. <span> </span><span>Notify chief resident or a<span></span>ttending</span></div><div>v.<span></span><span> <span> </span><span>A<span></span>s soon as there is a change in vit<span></span>al signs, follow step 3. </span></span></div><div>2. <span> </span><span>If the patient’<span></span>s BP start<span></span>s to drop, but gener<span></span>al condition is OK</span></div><div>i. <span> </span><span><span></span></span></div><div>ii. <span> </span><span> <span> </span>Order S<span></span>TA<span></span>T Echo, c<span></span>all Echo lab and notify as above.  </span></div><div>iii. <span> </span><span> <span> </span>No<span></span>tify chief resident and at<span></span>tending that you have suspicion for </span></div><div>possible tamponade </div><div>iv<span></span>. <span> </span><span> <span> </span>Call IC<span></span>U team f<span></span>or possible transfer to back t<span></span>o ICU</span></div><div>3. <span> </span><span><span></span><span></span><span></span><span></span></span></div><div>decompensating quickly<span></span>, take all s<span></span>teps as listed above but notify on c<span></span>all </div><div>at<span></span>tending and OR that emer<span></span>gent surg<span></span>er<span></span>y is needed. If p<span></span>atient goes int<span></span>o </div><div>cardiac arres<span></span>t or mental st<span></span>atus st<span></span>arts to change, et<span></span>c </div><div>i. <span> </span><span>Activa<span></span>te Open chest code and r<span></span>apid transfusion prot<span></span>ocol. </span></div><div>ii. <span> </span><span>Open chest a<span></span>t bedside ASAP to rele<span></span>ase pressure on heart  </span></div><div>•<span><span> </span><span></span></span></div><div>•<span> <span> </span>Direc<span></span>t CPR/<span></span>cardiac massage if cardiac arr<span></span>est</span></div><div>•<span> <span> </span>S<span></span>traight t<span></span>o OR</span></div><div>Chest T<span></span>ube Removal:  </div><div>Things to c<span></span>onsider before CT r<span></span>emoval:</div><div> <span></span><span></span></div><div>If drainag<span></span>e &lt; 150 cc/24 hrs (some surg<span></span>eons are OK with drainage&lt;  200c<span></span>c/24 </div><div><span></span></div><div> <span></span><span></span></div><div>Is there any air leak fr<span></span>om chest tube? </div><div><span></span><span> </span><span><span></span></span></div><div><span></span><span> </span><span>If chest tube with persis<span></span>tent air leak, may switch to  wat<span></span>er seal overnight </span></div><div>and check CXR next AM, if no new  P<span></span>TX or previous existing P<span></span>TX in st<span></span>able </div><div>size-&gt; may remove chest tube (some<span></span>times needs to  clamp chest tube 1st </div><div>and repea<span></span>t CXR to rule out new PTX/increasing  P<span></span>TX size before r<span></span>emoval)</div><div> <span></span><span></span></div><div>Is there any P<span></span>TX on CXR?</div><div> <span></span><span></span></div><div>Assess pain control need: usually give fent<span></span>anyl 25-50 mcg IV or dilaudid 0.2mg </div><div>IV before proc<span></span>edure </div><div> <span></span><span></span></div><div>Grab ma<span></span>terials to use: sutur<span></span>e remov<span></span>al set or scalpel; multiple 4x4 g<span></span>auzes; </div><div>Vaseline gauz<span></span>e; hem clamp;  2 inch wide paper tapes; blue chux ; 2 red </div><div>biohazar<span></span>d trash bag</div><div> <span></span><span></span></div><div>Usually needs a 2nd person (RN or P<span></span>A/NP colleague to hold ches<span></span>t tube site </div><div>tissue toge<span></span>ther before kno<span></span>ts are tied or V<span></span>aseline gauze is placed)</div><div>Proc<span></span>edure:</div><div> <span></span><span></span></div><div>Place p<span></span>atient in bed with comf<span></span>ortable position and explain to the pa<span></span>tient </div><div>about the procedur<span></span>e process </div><div> <span></span><span></span></div><div>Remove chest tube sit<span></span>e dressing and assess the wound</div><div> <span></span><span></span></div><div>If there are 2-3  tubes c<span></span>onnected together with  Y<span></span>-connector<span></span>, need to clamp </div><div><span></span><span></span></div><div>chest tube remov<span></span>al </div></div><div></div></div>
<div><div><img><div>102<span> </span><span>Procedures/Devic<span></span>es<span> </span>Procedur<span></span>es/De<span></span>vices<span> </span><span>103</span></span></div><div>PROCEDURES: <span>BRONCHOSC<span></span>OPY</span></div><div>Indications f<span></span>or bronchoscopy:</div><div> <span></span><span></span></div><div>Hypoxemia</div><div> <span></span><span></span></div><div>Suspected airway obstruc<span></span>tion</div><div> <span></span><span></span></div><div>New CXR opacity</div><div> <span></span><span></span></div><div>Copious secretions</div><div> <span></span><span></span></div><div>T<span></span>o obt<span></span>ain Bronchial Alveolar Lavag<span></span>e (BAL)/sputum culture</div><div> <span></span><span></span></div><div>Pulmonar<span></span>y toile<span></span>ting</div><div>Set<span></span>ting up a bronchoscopy:</div><div> <span></span><span></span></div><div>Discuss with at<span></span>tending on ideal time and indic<span></span>ation</div><div> <span></span><span></span></div><div>Decide bronchoscope (full c<span></span>art) vs ambuscope (smaller screen, smaller </div><div>scope)</div><div><span></span><span> </span><span>Full cart br<span></span>onchoscope indicated f<span></span>or<span></span>:</span></div><div> <span></span><span></span></div><div>Thick secretions, c<span></span>opious secretions</div><div> <span></span><span></span></div><div>Copious bloody secretions</div><div> <span></span><span></span></div><div>At<span></span>tending pref<span></span>erence</div><div> <span></span><span></span></div><div>Call x37709 (RT ba<span></span>t phone for charge R<span></span>T)<span>. The<span></span>y will ask the following:</span></div><div><span></span><span> </span><span>P<span></span>atient name, location</span></div><div><span></span><span> </span><span>At<span></span>tending provider</span></div><div><span></span><span> </span><span>Indication</span></div><div><span></span><span> </span><span>Scope requir<span></span>ed (ambuscope vs bronchoscope)</span></div><div>Aer the br<span></span>onchoscopy:</div><div> <span></span><span></span></div><div><span></span><span></span><span></span></div><div> <span></span><span></span></div><div>Fill out the order requisition:</div><div><span></span><span> </span><span>Pneumonia diagnosis code: 498</span></div><div><span></span><span> </span><span>Gram s<span></span>tain and culture for BAL </span></div><div><span></span><span> </span><span><span></span><span></span></span></div><div> <span></span><span></span></div><div>Order post<span></span>-bronchoscopy CXR </div><div>DEVICES:<span> IABP</span></div><div>Indications</div><div> <span></span><span></span></div><div>Cardiogenic shock</div><div> <span></span><span></span></div><div>Unst<span></span>able angina</div><div> <span></span><span></span></div><div>Intrac<span></span>table ventricular dysrhythmias</div><div> <span></span><span></span></div><div>Threa<span></span>tening extension of MI</div><div> <span></span><span></span></div><div>Prophylactic support for PCI</div><div> <span></span><span></span></div><div>Prophylactic support for OR induc<span></span>tion</div><div> <span></span><span></span></div><div>Pos<span></span>t-op myocardial dysfunc<span></span>tion</div><div> <span></span><span></span></div><div>Inability to wean fr<span></span>om CPB</div><div> <span></span><span></span></div><div>RV support during L<span></span>VAD implanta<span></span>tion</div><div> <span></span><span></span></div><div>Contraindicat<span></span>ed in Aortic regurgitation, Aortic dissection, or with severe aortic </div><div>of peripheral atherosclerosis<span> </span></div><div>Placement/P<span></span>osition</div><div> <span></span><span></span></div><div>1-2cm below L subclavian artery and above the renal arter<span></span>y br<span></span>anches</div><div> <span></span><span></span></div><div>Tip should be between the 2nd &amp; 3rd Int<span></span>ercos<span></span>tal spac<span></span>e on CXR</div><div>Sedatives</div><div>Drug </div><div>Name</div><div>Class<span> </span><span>Benets<span> </span></span>Contr<span></span>a-</div><div>indications</div><div>Not<span></span>es<span> </span>Dose</div><div>Etomida<span></span>te<span> </span>Imidazole </div><div>derivative</div><div>Exc<span></span>ellent </div><div>sedation </div><div>with little </div><div>hypotension</div><div>Known to </div><div>suppress </div><div>adrenal cortisol </div><div>production</div><div>Use cautiously </div><div>if patient </div><div>has sepsis; </div><div>initial dose of </div><div>glucocortic<span></span>oid </div><div>may be needed</div><div>0.3 mg<span></span>/kg</div><div>Ketamine<span> </span>Phencyclidine </div><div>derivative, </div><div>dissociative </div><div>anesthetic</div><div>Stimulat<span></span>es  </div><div>catecholamine </div><div>release </div><div>Bronchodilation</div><div>Use in patients </div><div>with elevated </div><div>ICP or elevated </div><div>blood pressure is </div><div>controversial</div><div>May be an </div><div>excellent </div><div>induction agent </div><div>for patient<span></span>s with </div><div>bronchospasm, </div><div>septic </div><div>shock, <span>AND</span> </div><div>hemodynamic </div><div>compromise</div><div>1 to 2 mg<span></span>/kg</div><div>Midazolam<span> </span>Benzo- </div><div>diazepines</div><div>Pot<span></span>ent dose<span></span>-</div><div>related amnesic </div><div>properties</div><div>Dose-related </div><div>myocardial </div><div>depression </div><div>can result in </div><div>hypotension</div><div>0.2 to 0.3 </div><div>mg<span></span>/kg</div><div>Propofol<span> </span>Alkylphenol </div><div>derivative</div><div>Bronchodilation<span> </span>No absolute </div><div>contraindic<span></span>ations </div><div>Dose-related </div><div>hypotension</div><div>P<span></span>aralytics</div><div>Drug Name<span> </span>Class<span> </span>Contraindica<span></span>tions<span> </span>Not<span></span>es<span> </span>Dose</div><div>Succinylcholine<span> </span>Depolarizing </div><div>agent binds to </div><div>postsynap<span></span>tic ACh </div><div>recept<span></span>ors causing </div><div>continuous </div><div>stimulation</div><div>Hx or family hx of malignant </div><div>hyperthermia </div><div>Hyperkalemia or risk of </div><div>developing hyperkalemia </div><div>Upregulation of ACh </div><div>recept<span></span>ors predisposes pts to </div><div>hyperkalemia</div><div>Neuromuscular disease </div><div>involving denervation </div><div>(muscular dystrophy<span></span>, stroke </div><div>&gt;72hrs, spinal cord injury </div><div>&gt;72hrs, muscular dystrophy<span></span>, </div><div>ALS)</div><div>Rhabdomyolysis</div><div>Burn &gt; 72 hours old</div><div>Inherited myopathies</div><div>Crush injuries &gt;72hrs</div><div>Severe infection w/ exo<span></span>toxin </div><div>(tet<span></span>anus, botulism)</div><div>Note: Succinylcholine is saf<span></span>e </div><div>in myasthenia gr<span></span>avis</div><div>paralysis oc<span></span>curs </div><div>in 45 to 60 </div><div>seconds</div><div>duration appr<span></span>ox. </div><div>6- 10 min. </div><div>1.5 mg<span></span>/kg IV</div><div>Rocuronium<span> </span>Nondepolarizing </div><div>agent.</div><div>Competitively </div><div>inhibits ACh </div><div>recept<span></span>ors </div><div>preventing </div><div>depolarization </div><div>P<span></span>aralysis occurs </div><div>in approximat<span></span>ely </div><div>45 to 60 seconds</div><div>duration appr<span></span>ox. </div><div>45 minutes</div><div>1.0 mg<span></span>/kg</div><div>IBW</div><div>Vecuronium<span> </span>Nondepolarizing </div><div>agent.</div><div>P<span></span>aralysis occurs </div><div>w/in 2.5-3 min</div><div>Duration 25-40 </div><div>min.</div><div>0.08-0.1 </div><div>mg<span></span>/kg</div></div><div></div></div>
<div><div><img><div>104<span> </span><span>Procedures/Devic<span></span>es<span> </span>Procedur<span></span>es/De<span></span>vices<span> </span><span>105</span></span></div><div>Possible R<span></span>easons for Poor A<span></span>ugmentation</div><div> <span></span><span></span></div><div>P<span></span>atient’<span></span>s native str<span></span>oke volume &gt; IABP volume</div><div> <span></span><span></span></div><div>Indication of r<span></span>eadiness to we<span></span>an from IABP</div><div> <span></span><span></span></div><div>Balloon too small?</div><div> <span></span><span></span></div><div>Low SVR</div><div> <span></span><span></span></div><div>Hypovolemia</div><div> <span></span><span></span></div><div>IABP positioned too low</div><div> <span></span><span></span></div><div>Kinked ca<span></span>theter</div><div>T<span></span>riggers</div><div>Autopilo<span></span>t Mode </div><div> <span></span><span></span></div><div>Machine selects EK<span></span>G and AP (arterial pressure) sourc<span></span>e, trigger mode and </div><div>timing method as well as optimiz<span></span>es timing</div><div> <span></span><span></span></div><div>Machine continuously monitors the p<span></span>atient and chooses the best trigger </div><div>mode based on pa<span></span>tient condition</div><div>EKG</div><div> <span></span><span></span></div><div>Pre-set trigger mode</div><div>EKG P<span></span>eak</div><div> <span></span><span></span></div><div>Best for wide c<span></span>omplex rhythm</div><div> <span></span><span></span></div><div>Best for HR&gt;130bpm</div><div> <span></span><span></span></div><div>A Fib</div><div> <span></span><span></span></div><div>Best choic<span></span>e for var<span></span>ying R<span></span>-R inter<span></span>v<span></span>als</div><div> <span></span><span></span></div><div><span></span><span></span></div><div>Arterial Pressur<span></span>e</div><div> <span></span><span></span></div><div>Best trigg<span></span>er when EKG is unav<span></span>ailable or has lots of artifact</div><div> <span></span><span></span></div><div>T<span></span>riggered by the syst<span></span>olic up<span></span>-s<span></span>toke of the arterial pressure w<span></span>aveform</div><div> <span></span><span></span></div><div>Should be used during CPR</div><div>A P<span></span>ace</div><div> <span></span><span></span></div><div>T<span></span>riggered by the atrial p<span></span>acing spike</div><div> <span></span><span></span></div><div>Can only be used if patient 100% A p<span></span>aced</div><div>V P<span></span>ace</div><div> <span></span><span></span></div><div>T<span></span>riggered by the ventricular spike</div><div> <span></span><span></span></div><div>Can be used if patient V p<span></span>aced or AV pac<span></span>ed</div><div> <span></span><span></span></div><div>Pt must be 100% p<span></span>aced</div><div>Internal </div><div> <span></span><span></span></div><div><span></span><span></span><span></span><span></span></div><div>activity</div><div> <span></span><span></span></div><div>Used in situation when there is no c<span></span>ardiac output and no EKG</div><div>During CPR</div><div> <span></span><span></span></div><div>Arterial pressur<span></span>e trigger should be select<span></span>ed as this will synchronize c<span></span>ounter </div><div>pulsation to c<span></span>ardiac compr<span></span>essions</div><div>IABP Complications:</div><div> <span></span><span></span></div><div>Dist<span></span>al limb ischemia (most common c<span></span>omplication occurring in 10-15% of </div><div>patient<span></span>s) and compartment syndrome</div><div> <span></span><span></span></div><div>Infection and sepsis </div><div> <span></span><span></span></div><div>Thrombocytopenia</div><div><span></span><span> </span><span><span></span><span></span></span></div><div> <span></span><span></span></div><div> Balloon rupture, may le<span></span>ad to helium embolus</div><div> <span></span><span></span></div><div>Risk and complica<span></span>tions of insertion:</div><div><span></span><span> </span><span><span></span></span></div><div>cover<span></span>age</div><div><span></span><span> </span><span>If balloon is too low = decr<span></span>eased visceral or<span></span>gan perfusion (decreased </span></div><div>urine output) </div><div><span></span><span> </span><span>Aortic dissection during insertion </span></div><div>Basic Principles</div><div> <span></span><span></span></div><div><span></span><span></span><span></span></div><div>just prior t<span></span>o syst<span></span>ole</div><div> <span></span><span></span></div><div><span></span><span></span></div><div>aortic valve closure</div><div> <span></span><span></span></div><div>This combination f<span></span>avorable alters the myocar<span></span>dial oxygen supply: demand </div><div>ra<span></span>tio (Increased myoc<span></span>ardial perfusion with less work)</div><div> <span></span><span></span></div><div><span></span><span></span><span></span></div><div> <span></span><span></span></div><div>May be indicat<span></span>ed in RV failure:</div><div><span></span><span> </span><span>Improvement in RV perfusion from diast<span></span>olic augmentation </span></div><div><span></span><span> </span><span>Improvement in L<span></span>V function from unloading </span></div><div>Deation phase of IABP le<span></span>ads to</div><div> <span></span><span></span></div><div><span></span></div><div> <span></span><span></span></div><div>Increased s<span></span>troke volume</div><div> <span></span><span></span></div><div>Enhanced forward car<span></span>diac output</div><div>Ination phase of IABP le<span></span>ads to</div><div> <span></span><span></span></div><div><span></span><span></span></div><div> <span></span><span></span></div><div>Increased dias<span></span>tolic pressure</div><div> <span></span><span></span></div><div>Po<span></span>tential for increased c<span></span>oronar<span></span>y collat<span></span>eral circulation</div><div> <span></span><span></span></div><div>Increased sys<span></span>temic perfusion</div><div>Timing</div><div>Ination</div><div> <span></span><span></span></div><div>Rapid rise in aortic pressure which incre<span></span>ases O2 supply to coronaries</div><div> <span></span><span></span></div><div><span></span><span></span></div><div> <span></span><span></span></div><div>Augmented pressur<span></span>e should be &gt; systolic pressure</div><div>Deation</div><div> <span></span><span></span></div><div>Reduce aortic and end dias<span></span>tolic pressure, improving C<span></span>O</div><div> <span></span><span></span></div><div>Ass<span></span>is<span></span>t<span></span>ed<span></span> e<span></span>nd<span></span> d<span></span>ia<span></span>st<span></span>ol<span></span>ic<span></span> b<span></span>lo<span></span>od <span></span>pr<span></span>es<span></span>su<span></span>re<span></span> &lt;<span></span>/=<span></span> un<span></span>as<span></span>si<span></span>st<span></span>e<span></span>d <span></span>en<span></span>d <span></span>di<span></span>as<span></span>to<span></span>li<span></span>c <span></span>bl<span></span>oo<span></span>d <span></span>pr<span></span>es<span></span>su<span></span>re</div><div> <span></span><span></span></div><div>Assisted peak sys<span></span>tolic pressure should be &lt;unassist<span></span>ed peak systolic pressur<span></span>e   </div><div>IABP tracing a<span></span>t 1:2 ratio<span></span>. <span>IABP end diast<span></span>olic pressure is lower than the p<span></span>atient’<span></span>s </span></div><div>aortic end diast<span></span>olic pressure. The b<span></span>alloon assisted peak sys<span></span>tolic pressure is lower </div><div>than the syst<span></span>olic pressure tha<span></span>t is gener<span></span>ated without a pr<span></span>eceding assis<span></span>ted beat. </div></div><div></div></div>
<div><div><img><div>106<span> </span><span>Procedures/Devic<span></span>es<span> </span>Procedur<span></span>es/De<span></span>vices<span> </span><span>107</span></span></div><div>placed. The ventricular wire is the short<span></span>er one. Occasionally, 2 ventricular </div><div>wires are plac<span></span>ed (will be equal length) » either one can be used as the ground </div><div>lead.</div><div> <span></span><span></span></div><div>The ventricular wire is inserted int<span></span>o the nega<span></span>tive pole of the temporar<span></span>y </div><div>ext<span></span>ernal pac<span></span>emaker<span></span>. The skin wire is inserted in the positive pole.</div><div>Unipolar vs. Bipolar </div><div> <span></span><span></span></div><div>Unipolar wires consis<span></span>t of a single negative wire a<span></span>ttached t<span></span>o the epicardium </div><div>and an additional wire in the subcut<span></span>aneous tissue (positive). </div><div> <span></span><span></span></div><div>Bipolar syst<span></span>em  consis<span></span>t of a single wire with two conductors (positive and </div><div>nega<span></span>tive) which are both att<span></span>ached directly to the epicar<span></span>dium</div><div><span></span><span> </span><span><span></span><span></span></span></div><div>threshold to ob<span></span>tain capture and is less sensitive t<span></span>o electrical interferenc<span></span>e </div><div>when sensing comp<span></span>ared to unipolar sys<span></span>tem. </div><div>General Conc<span></span>ept<span></span>s </div><div>Stimula<span></span>tion or Capture Threshold</div><div> <span></span><span></span></div><div>Refers t<span></span>o the amount of energy delivered by the pulse genera<span></span>tor in order to </div><div>initiate depolariz<span></span>ation  (measured in milliamps).</div><div><span></span><span> </span><span>The usual st<span></span>arting point is 10mA and slowly increased until captur<span></span>e is </span></div><div>achieved.  </div><div> <span></span><span></span></div><div><span></span><span></span></div><div>electrodes.</div><div>How to de<span></span>termine appropria<span></span>te output threshold set<span></span>ting:</div><div> <span></span><span></span></div><div>Set RA<span></span>TE at leas<span></span>t 10 ppm <span>above</span> patient’<span></span>s intrinsic rat<span></span>e.</div><div> <span></span><span></span></div><div>Decrease OUTPUT<span></span>: Slowly turn OUTPUT dial counterclockwise until EC<span></span>G </div><div>shows loss of captur<span></span>e.</div><div> <span></span><span></span></div><div>Increase OUTPUT<span></span>: Slowly turn OUTPUT dial clockwise until ECG shows </div><div>consis<span></span>tent capture.</div><div>This value is the stimulation threshold.</div><div> <span></span><span></span></div><div>Set OUTPUT to a v<span></span>alue 1.5-2 <span>times</span><span> </span><span>greater</span><span> than the stimula<span></span>tio<span></span>n <span>Threshold v<span></span>alue.</span></span></div><div>This provides at least a 2:1 safe<span></span>ty margin.</div><div>T<span></span>roubleshooting F<span></span>ailure t<span></span>o Capture</div><div> <span></span><span></span></div><div>Possible Causes</div><div><span></span><span> </span><span></span></div><div> <span></span><span></span></div><div>Increase mA till c<span></span>apture</div><div><span></span><span> </span><span>Low ba<span></span>tter<span></span>y</span></div><div>IABP remov<span></span>al </div><div>See IABP removal Hosp<span></span>tial Protocol on Intr<span></span>aNet. </div><div>Referenc<span></span>es</div><div>Bojar<span></span>, Robert M. (2011) Manual of Perioper<span></span>ative Care in Adult Cardiac Surgery. (5th edition). </div><div> </div><div>DEVICES: <span>L<span></span>UMBAR DRAINS</span></div><div>1. <span> </span><span>Placed pre-oper<span></span>atively by cardiac anesthesia or Neur<span></span>o IR if patient has </span></div><div>complex anat<span></span>omy</div><div>2. <span> </span><span>Use “Lumbar Dr<span></span>ain” order set</span></div><div>3. <span> </span><span>Pos<span></span>t-opera<span></span>tive lumbar drain management:</span></div><div>i. <span> </span><span>Zer<span></span>o the transducer at right a<span></span>trium phlebostatic level</span></div><div>ii. <span> </span><span>Set the T<span></span>ransduc<span></span>er to 10mmHg</span></div><div>• <span> </span><span>L<span></span>eave the stopc<span></span>ock closed to the transducer ex<span></span>cept when measuring </span></div><div>hourly pressure</div><div>• <span> </span><span>Keep the dr<span></span>ain open to the patient t<span></span>o allow to continuous drainage</span></div><div>• <span> </span><span>When the ICP is above 10mmHg, the dr<span></span>ain will act as a pressure  </span></div><div><span></span><span></span></div><div>iii. <span> </span><span>Goal is to dr<span></span>ain ~10mL/hr when ICP &gt;10. Not to exc<span></span>eed drainage  </span></div><div>of 20mL/hr</div><div>iv<span></span>. <span> </span><span><span></span><span></span><span></span></span></div><div>v.<span></span><span> <span> </span><span>Maintain strict bed r<span></span>est with HOB at 30 degrees or less while ac<span></span>tively </span></span></div><div>draining</div><div>vi. <span> </span><span><span></span><span></span></span></div><div>patient and r<span></span>eopen when destination reached.</div><div>4. <span> </span><span>For more inf<span></span>ormation on ICP and prevention of spinal cor<span></span>d ischemia see </span></div><div>“Spinal Cord Ischemia <span>page 50 </span>under III. P<span></span>ost-oper<span></span>ative Managament</div><div> </div><div>DEVICES: <span>TEMPORAR<span></span>Y P<span></span>ACEMAKERS</span></div><div>Nomenclature</div><div>1st let<span></span>ter —<span> chamber<span></span>/chambers p<span></span>aced: A= atria, V= ventricle,  </span></div><div>D- dual (atria and ventricle)</div><div>2nd lett<span></span>er —<span> chamber/<span></span>chambers sensed: A= atria, V= ventricle,  </span></div><div>D- dual (atria and ventricle)</div><div>3rd let<span></span>ter —<span> how the pacemak<span></span>er responds to an event<span></span>:  I= inhibit, T<span></span>- trigger</span></div><div>T<span></span>emporary  P<span></span>acing T<span></span>echniques </div><div>T<span></span>ransvenous</div><div>Placed through intr<span></span>oducer into the right ventricle. Routinely placed in T<span></span>AVR pt<span></span>s </div><div>with Corevalves d/t increased risk f<span></span>or the de<span></span>velopment of heart block as the v<span></span>alve </div><div>continues to exp<span></span>and post deployment.</div><div>T<span></span>ranscut<span></span>aneous</div><div><span></span><span></span><span></span></div><div>positions. Disadvant<span></span>ages include requiring higher pacing thresholds and p<span></span>atient </div><div>discomfort.</div><div>Epicardial L<span></span>eads</div><div> <span></span><span></span></div><div>The wires in the right subcos<span></span>tal region ar<span></span>e atrial and in the <span></span> subcost<span></span>al </div><div>region are ventricular<span></span>.</div><div><span></span><span> </span><span>Min<span></span>ima<span></span>lly<span></span> in<span></span>vas<span></span>ive <span></span>val<span></span>ve <span></span>sur<span></span>ge<span></span>ri<span></span>es <span></span>the<span></span> A <span></span>and<span></span> V <span></span>wir<span></span>es <span></span>wil<span></span>l b<span></span>e i<span></span>n t<span></span>he <span></span>sam<span></span>e <span></span>pos<span></span>iti<span></span>on. </span></div><div> <span></span><span></span></div><div>T<span></span>ypically, a single ventricular wire (pacing le<span></span>ad) and a skin wire (ground) are </div></div><div></div></div>
<div><div><img><div>108<span> </span><span>Procedures/Devic<span></span>es<span> </span>Procedur<span></span>es/De<span></span>vices<span> </span><span>109</span></span></div><div>Modes of P<span></span>acing:     </div><div>Mode<span> </span>Advant<span></span>ages<span> </span>Disadvant<span></span>ages</div><div>AAI</div><div> <span></span><span></span></div><div>Single lead</div><div> <span></span><span></span></div><div>AV synchrony maint<span></span>ained</div><div> <span></span><span></span></div><div>Able to assess S<span></span>T changes</div><div> <span></span><span></span></div><div>Unable to use in AF</div><div> <span></span><span></span></div><div>Ventricular br<span></span>adycardia may </div><div>occur in presc<span></span>ense of high </div><div>grade A<span></span>V block</div><div> <span></span><span></span></div><div>Inst<span></span>ability of single atrial lead</div><div> <span></span><span></span></div><div>Higher risk of thin atrial wall</div><div>VVI</div><div> <span></span><span></span></div><div>Requires a single le<span></span>ad</div><div> <span></span><span></span></div><div>Useful in prescense of AF and </div><div>high grade A<span></span>V block</div><div> <span></span><span></span></div><div>AV synchrony los<span></span>t </div><div> <span></span><span></span></div><div>Unable to assess S<span></span>T changes</div><div> <span></span><span></span></div><div>Loss of atrial kick</div><div> <span></span><span></span></div><div>Risk of pac<span></span>emaker syndrome</div><div>DDO</div><div> <span></span><span></span></div><div>AV synchrony maint<span></span>ained</div><div> <span></span><span></span></div><div>Use in AF and high grade A<span></span>V </div><div>block</div><div> <span></span><span></span></div><div>Heart r<span></span>ate responsive</div><div> <span></span><span></span></div><div>Possible decr<span></span>eased </div><div>thrombotic events</div><div> <span></span><span></span></div><div>P<span></span>acemaker mediat<span></span>e endless<span></span>-</div><div>loop tachyc<span></span>ardia possible</div><div> <span></span><span></span></div><div>P<span></span>acemaker syndrome if </div><div>incorrec<span></span>tly set up</div><div> <span></span><span></span></div><div>May not be able to assess S<span></span>T’<span></span>s</div><div>DDI</div><div> <span></span><span></span></div><div>Uses two pacing leads (right </div><div>atrium and right ventricle) to </div><div>maintain minimum r<span></span>ate in </div><div>each cavity</div><div> <span></span><span></span></div><div>Used in the presence of sinus </div><div>bradyc<span></span>ardia with possible AV </div><div>conduction disor<span></span>ders or with </div><div>frequent atrial arrhythmia</div><div> <span></span><span></span></div><div>Must feel c<span></span>omfortable set<span></span>ting </div><div>ra<span></span>te and AV node delay</div><div> <span></span><span></span></div><div><span></span></div><div> </div><div>For remov<span></span>al of temporary pacing wires, <span>page 99</span><span> </span>(section V<span></span>, proc<span></span>edures, C<span></span>T and </div><div>PW removal) </div><div>Referenc<span></span>es: http://www.medtronic.c<span></span>om/us-en/index.html</div><div> </div><div>DEVICES: <span>ON Q PUMPS</span></div><div> <span></span><span></span></div><div>Non-narco<span></span>tic pain relief syst<span></span>em designed to deliver local anes<span></span>thetic to or near </div><div>the surgical sit<span></span>e via cathe<span></span>ters. </div><div> <span></span><span></span></div><div>The epidural or intr<span></span>athecal route uses small quantities of medic<span></span>ation to </div><div><span></span><span></span></div><div>provide t<span></span>arge<span></span>ted pain r<span></span>elief via multiple holes along the infusion segment of </div><div><span></span><span></span><span></span><span></span><span></span></div><div>distribution. </div><div> <span></span><span></span></div><div>Placed intr<span></span>a-operatively by the surgeon or APP f<span></span>or primarily patients rec<span></span>eiving </div><div>anterior thor<span></span>acot<span></span>omy incisions</div><div>Placing the Cathet<span></span>er</div><div>1. <span> </span><span>Gently hold T<span></span>-handle and remove protective guar<span></span>d. </span></div><div>2. <span> </span><span>Introducer Needle: Insert (bevel up) through the skin appr<span></span>oximately 3-5 cm </span></div><div>from surgical sit<span></span>e </div><div>3. <span> </span><span>Advanc<span></span>e introducer to desired loc<span></span>ation for c<span></span>athet<span></span>er placement. Introducers </span></div><div>with Luer lock may be connec<span></span>ted to a syringe to aspir<span></span>ate or inject a bolus of </div><div></div><div>4. <span> </span><span>While holding T<span></span>-handle 1, withdraw trocar 2 from she<span></span>ath </span></div><div> <span></span><span></span></div><div>Change ba<span></span>tter<span></span>y</div><div><span></span><span> </span><span><span></span><span></span></span></div><div> <span></span><span></span></div><div>At<span></span>tempt t<span></span>o re<span></span>verse the polarity of the le<span></span>ads by swapping the position </div><div>of the met<span></span>al leads into the p<span></span>acemaker cor<span></span>d</div><div><span></span><span> </span><span>Electrolyt<span></span>e abnormalities</span></div><div>Sensitivity</div><div> <span></span><span></span></div><div>Sensing refers t<span></span>o the ability of the gener<span></span>ator t<span></span>o detect (“see”) and r<span></span>ecognize </div><div>the intrinsic impulses of the myocardial tissue and t<span></span>o appropriat<span></span>ely respond </div><div>to what it de<span></span>tect<span></span>s.</div><div> <span></span><span></span></div><div>Sensitivity setting is me<span></span>asured in <span>millivolts</span>. </div><div><span></span><span> </span><span>T<span></span>ypical atrial 0.4 mV</span></div><div><span></span><span> </span><span>T<span></span>ypical ventricular 2.0 mV</span></div><div> <span></span><span></span></div><div>Progr<span></span>amming a higher sensitivity (higher number) makes the pac<span></span>emaker  </div><div>less sensitive<span> to intrinsic car<span></span>diac activity.</span></div><div> <span></span><span></span></div><div>Progr<span></span>amming a lower sensitivity (lower number) causes the pac<span></span>emaker to be </div><div>more sensitive <span>to intrinsic c<span></span>ardiac activity.</span></div><div>How to de<span></span>termine appropriat<span></span>e sensitivity setting:</div><div>1. <span> </span><span>Set r<span></span>ate a<span></span>t leas<span></span>t 10 ppm <span>below</span> patient’<span></span>s intrinsic rat<span></span>e.</span></div><div>2. <span> </span><span>Adjust output: Set OUTPUT to 0.1 mA (A OUTPUT f<span></span>or atrial threshold; V </span></div><div>OUTPUT for ventricular threshold).</div><div>3. <span> </span><span>Highlight SENSITIVITY (atrial or ventricular) </span></div><div>4. <span> </span><span>Decrease SENSITIVIT<span></span>Y: Slowly turn MENU P<span></span>ARAMETER dial </span></div><div><span></span><span></span></div><div>5. <span> </span><span>Increase SENSITIVIT<span></span>Y: Slowly turn MENU P<span></span>ARAMETER dial clockwise </span></div><div><span></span><span></span><span></span><span> </span></div><div>This value is the sensing threshold.</div><div>6. <span> </span><span>Set SENSITIVITY t<span></span>o half (or less) the threshold v<span></span>alue. </span></div><div>This provides at least a 2:1 safe<span></span>ty margin.</div><div>7. <span> </span><span>Rest<span></span>ore RA<span></span>TE and OUTPUT to previous values.</span></div><div>T<span></span>rouble Shooting Sensitivity</div><div>F<span></span>ailure to sense<span> is when the gener<span></span>ator does no<span></span>t recognize the heart’<span></span>s intrinsic </span></div><div>impulses.</div><div> <span></span><span></span></div><div>P<span></span>acemaker not sensitive enough t<span></span>o patient’<span></span>s intrinsic rhythm.</div><div><span></span><span> </span><span>Increase the sensitivity by lowering the m<span></span>V</span></div><div> <span></span><span></span></div><div><span></span></div><div> <span></span><span></span></div><div><span></span><span></span></div><div><span></span><span> </span><span>At<span></span>tempt t<span></span>o re<span></span>verse the polarity of the le<span></span>ads by swapping the position of </span></div><div>the met<span></span>al leads into the p<span></span>acemaker cor<span></span>d</div><div> <span></span><span></span></div><div>Low ba<span></span>tter<span></span>y<span></span>.</div><div> <span></span><span></span></div><div>Malfunction of pac<span></span>emaker or cable.</div><div>Over<span></span>-sensing: <span>P<span></span>acer sees too much (QRS, T w<span></span>ave, P wave and baseline)</span></div><div> <span></span><span></span></div><div>Decrease sensitivity by incr<span></span>easing the mV</div><div>Checking underlying rhythm</div><div> <span></span><span></span></div><div>Safest me<span></span>thod is to slowly turn down the rat<span></span>e as opposed to  disconnec<span></span>ting </div><div>the leads from g<span></span>enerator or p<span></span>ausing the pac<span></span>emaker as this gives time for the </div><div>patient’<span></span>s native conduction sys<span></span>tem to emerge</div></div><div></div></div>
<div><div><img><div>110<span> </span><span>Procedures/Devic<span></span>es<span> </span>Procedur<span></span>es/De<span></span>vices<span> </span><span>111</span></span></div><div><span></span><span> </span><span>Sponge (item # 195925)</span></div><div> <span></span><span></span></div><div><span></span><span></span><span></span></div><div>regular wound v<span></span>ac upon discharge</div><div>Discharging a pa<span></span>tient home with Wound VAC</div><div> <span></span><span></span></div><div>Ensure Case management is involved e<span></span>arly to ensure insuranc<span></span>e authoriza<span></span>tion </div><div>and supply deliver<span></span>y</div><div> <span></span><span></span></div><div>If short term Vac ther<span></span>apy is needed, consider Vac Via</div><div><span></span><span> </span><span>Can use placed on a p<span></span>atient for up t<span></span>o 4 days and then switched to we<span></span>t-to-</span></div><div>dr<span></span>y dressings if V<span></span>ac is no longer needed</div><div>V<span></span>ac Tips:</div><div> <span></span><span></span></div><div>St<span></span>anford Policy s<span></span>tates wound V<span></span>ac changes are t<span></span>o be done Monday, </div><div>Wednesday and Friday<span></span>.</div><div><span></span><span> </span><span>Use clinical judgment if wound vac w<span></span>as placed at an odd time. Product </span></div><div><span></span><span></span></div><div> <span></span><span></span></div><div>Cut the sponge t<span></span>o the size of the wound or larg<span></span>er never smaller than the </div><div>wound so that the dr<span></span>ape does not s<span></span>tick directly t<span></span>o the wound.</div><div> <span></span><span></span></div><div>Cut a big hole for tr<span></span>ack pad at leas<span></span>t the size of a quarter<span></span>.</div><div> <span></span><span></span></div><div><span></span><span></span></div><div> <span></span><span></span></div><div>When placing Wound VAC in clinic:</div><div> <span></span><span></span></div><div>If the VAC is a new placement<span></span>- the patient will be Admitt<span></span>ed to Obser<span></span>va<span></span>tion for </div><div>wound vac plac<span></span>ement and supply authorization via case manag<span></span>er (DO NOT </div><div>ADMIT VIA ED)</div><div> <span></span><span></span></div><div>If the VAC is es<span></span>tablished- patient should bring own supplies fr<span></span>om home for in </div><div>clinic changes</div><div>Prevena:</div><div> <span></span><span></span></div><div>For use with closed incisions</div><div> <span></span><span></span></div><div>Should be placed at the time of wound closur<span></span>e in the OR, can also be placed </div><div>later</div><div> <span></span><span></span></div><div>The pump bat<span></span>ter<span></span>y last<span></span>s for 7 days.</div><div> <span></span><span></span></div><div>Dressing should be remov<span></span>ed and wound checked prior t<span></span>o discharge </div><div>(even if before b<span></span>att<span></span>ery dies)</div><div> <span></span><span></span></div><div>When the bat<span></span>ter<span></span>y dies, the pump can be thrown aw<span></span>ay and the patient </div><div>removes the dressing and resumes normal wound c<span></span>are</div><div> <span></span><span></span></div><div>Risk for poor wound healing crit<span></span>eria (i.e. use of provena should be </div><div>considered)</div><div><span></span><span> </span><span>Obesity (BMI&gt;36)</span></div><div><span></span><span> </span><span>Diabetes (insulin-dependent, dialysis, or previous diabetic-induc<span></span>ed  </span></div><div>organ damag<span></span>e) </div><div><span></span><span> </span><span>COPD (f<span></span>orced expirat<span></span>or<span></span>y volume in 1 second &lt; 80%)  </span></div><div><span></span><span> </span><span>Bilater<span></span>al IMA take-down  </span></div><div><span></span><span> </span><span>COPD his<span></span>tor<span></span>y</span></div><div><span></span><span> </span><span>Corticos<span></span>teroid use</span></div><div><span></span><span> </span><span>Abnormally high preoper<span></span>ative cre<span></span>atinine ( &gt; 90th percentile) </span></div><div><span></span><span> </span><span>More intr<span></span>aopera<span></span>tive blood transfusions (3 or mor<span></span>e)  </span></div><div><span></span><span> </span><span>Longer length of oper<span></span>ation (&gt;4 hrs.) </span></div><div><span></span><span> </span><span>Previous known poor wound healing episode </span></div><div>5. <span> </span><span>Advanc<span></span>e catheter through she<span></span>ath until entire infusion segment is within </span></div><div>desired loca<span></span>tion </div><div>6. <span> </span><span>Coil cathe<span></span>ter and secure with adhesive s<span></span>trips </span></div><div>7. <span> </span><span>Apply occlusive dressing over insertion sit<span></span>e and coiled cathet<span></span>er. Keep </span></div><div><span></span><span></span></div><div>8. <span> </span><span>Connect ca<span></span>theter t<span></span>o pump tubing.</span></div><div>Pos<span></span>t-oper<span></span>ative period: </div><div> <span></span><span></span></div><div>Pumps are not manag<span></span>ed by pain ser<span></span>vice (do not p<span></span>age P<span></span>ain ser<span></span>vice with </div><div>questions), they are managed by the primary team</div><div> <span></span><span></span></div><div>The pump works by administ<span></span>ering a continuous infusion of bupiv<span></span>acaine </div><div>locally at the sit<span></span>e of the incision. </div><div> <span></span><span></span></div><div>The pump is used in adjunct with analgesics (T<span></span>ylenol, oxycodone, fent<span></span>anyl, </div><div>dilaudid). <span>While OnQ pump in place avoid c<span></span>oncurrent use with other </span></div><div>similar agents, i.<span></span>e. Lidocaine infusions </div><div> <span></span><span></span></div><div>Medication or<span></span>der<span></span>: Bupivac<span></span>aine 0.25% in 270mL @ 2mL/hr</div><div>Remov<span></span>al: </div><div> <span></span><span></span></div><div><span></span><span></span></div><div>medicine moving through the tubing. Y<span></span>ou may notice the outside b<span></span>ag on the </div><div>ball ge<span></span>tting looser with wrinkles over time</div><div> <span></span><span></span></div><div>The pump should be removed 24 hours before dischar<span></span>ge to allow for time to </div><div>ensure adequat<span></span>e pain c<span></span>ontrol using or<span></span>al pain medica<span></span>tions</div><div> <span></span><span></span></div><div>T<span></span>o Remove: remove the dressing, r<span></span>emove small suture anchoring pump to </div><div>skin, and pull the clear ca<span></span>theter<span></span>. The tube should come out easily. If it is har<span></span>d </div><div>to remove or s<span></span>tarts to s<span></span>tretch, st<span></span>op and call your doctor right away<span></span>.</div><div><span></span><span> </span><span>The end of the tube should have a colored tip so you know tha<span></span>t it is all </span></div><div>out. If the end of the tube does not have a colored tip<span></span>, call your doct<span></span>or </div><div>right away.</div><div><span></span><span> </span><span>The entire unit should be disposed of in the red biohaz<span></span>ard bins.</span></div><div>Referenc<span></span>es: Clark<span></span>, K. (2010). On-q cathe<span></span>ters and introducers. ON-Q P<span></span>ain Relief System. Retrieved </div><div>from http://www<span></span>.halyardhealth.c<span></span>om/media/155090/14-60-603-0-04.pdf<span></span>. </div><div>DEVICES:<span> WOUND VA<span></span>C</span></div><div>Ver<span></span>a o:</div><div> <span></span><span></span></div><div>Preferred over r<span></span>egular wound Vac for inpa<span></span>tients (may heal area f<span></span>aster)</div><div><span></span><span> </span><span>Normal saline is the solution of choice. Any topic<span></span>ally approved solution </span></div><div>can be placed int<span></span>o the Vac</div><div><span></span><span> </span><span><span></span></span></div><div> <span></span><span></span></div><div>T<span></span>ypical Settings: </div><div><span></span><span> </span><span>-125mmHg</span></div><div><span></span><span> </span><span>0-20 min wash ever<span></span>y 2-4 hours</span></div><div> <span></span><span></span></div><div>Grey foam c<span></span>an be used for packing tunneling areas or undermining tha<span></span>t is </div><div>hard to visualiz<span></span>e</div><div> <span></span><span></span></div><div>General principles: </div><div><span></span><span> </span><span>When changing the Vac, use the pad t<span></span>o estimate how much saline is </span></div><div></div><div><span></span><span> </span><span></span></div><div><span></span><span> </span><span><span></span><span></span></span></div><div></div><div> <span></span><span></span></div><div>Supplies needed (Central supply # 35047</div><div><span></span><span> </span><span>1000mL cont<span></span>ainer (item # 86309)</span></div><div><span></span><span> </span><span>Cassett<span></span>e ( item #195927)</span></div></div><div></div></div>
<div><div><img><div>112<span> </span><span>Referenc<span></span>e Material<span> </span>Referenc<span></span>e Material<span> </span><span>113</span></span></div><div>SURGEON PREFERENCES</div><div>Surgeon </div><div>Preferenc<span></span>es</div><div>Clinic</div><div>Woo</div><div>o <span> </span>Review all images and review surgical plan prior to clinic</div><div><span> </span></div><div>o <span> </span>2 week<span><span></span></span></div><div>Boyd</div><div>o <span> </span>Echo within 3-6 months for Valves</div><div>o <span> </span>Cath within 6 months (if CAD), within 1 year if most rec<span></span>ent was clean/Valve</div><div>o <span> </span>CT<span></span>a within 3-6 months for Ascending aorta</div><div>o <span> </span>Calculate ST<span></span>S score on all pa<span></span>tients pre clinic (use most recent or normal </div><div>creatinine)</div><div>o <span> </span>Calculate Syntax sc<span></span>ore for all CAD pa<span></span>tients </div><div>o <span> </span>All notes complet<span></span>ed same day of clinic</div><div><span> </span><span></span><span></span><span></span></div><div>thromboembolic event </div><div>For inpatient CABG consults— see Boyd Consult H&amp;P document</div><div>Lee</div><div>o <span> </span><span>Calculate ST<span></span>S score on all pa<span></span>tients pre clinic (use most recent or normal cr<span></span>eatinine)</span></div><div>o <span> </span>Echo within 3 months</div><div>o <span> </span>Cath within 6 months (if CAD), within 1 year if most rec<span></span>ent was clean/Valve</div><div>o <span> </span>CT<span></span>a within 3-6 months for Ascending aorta</div><div>o <span> </span>CT<span></span>a (vs CT L atrial mapping) needed for all pa<span></span>tient with prior history of ablation/</div><div>MAZE</div><div>o <span> </span>If pacemaker<span></span>, obtain make, model, implant<span></span>ation date</div><div>o <span> </span>Calculate ST<span></span>S score on all pa<span></span>tients pre-clinic (use most recent or normal </div><div>creatinine)</div><div>o <span> </span>PFTs if any smoking his<span></span>tor<span></span>y in last 10 ye<span></span>ars</div><div>o <span> </span>Carotid US if caro<span></span>tid bruit on exam, h/o prior T<span></span>AI or stroke, age &gt; 65, smoking </div><div>history, or family his<span></span>tor<span></span>y of str<span></span>oke </div><div>o <span> </span>Obtain bilater<span></span>al LE duplex US if history of vein stripping </div><div>o <span> </span>All notes complet<span></span>ed same day of clinic</div><div>o <span> </span>DO NOT HOLD ASA PRE-OPERA<span></span>TIVEL<span></span>Y</div><div>o <span> </span>Post ops: </div><div> <span> </span>o <span> </span>MAZE:</div><div> <span> </span><span>o <span> </span><span>1-month POV </span>– need ECG during clinic visit (may need TTE if p<span></span>atient’s  </span></div><div> <span></span><span>most rec<span></span>ent TTE prior to discharge had L<span></span>VEF&lt; 40%). </span></div><div> <span> </span><span>o <span> </span><span>3-month POV </span>-needs 72 hour Ziopat<span></span>ch as close to clinic visit as possible  </span></div><div> <span></span><span>and a TTE prior to visit. </span></div><div> <span> </span><span>o <span> </span><span>6-month POV </span>– needs 72 hour Ziopat<span></span>ch as close to clinic visit as possible. </span></div><div> <span> </span><span>o <span> </span><span>12- month POV </span>–needs 72 hou<span></span>r Ziopa<span></span>tch as close to c<span></span>linic visit a<span></span>s possible. </span></div><div> <span> </span><span>o <span> </span><span>Annually</span> with 72 hour Ziopatch. V<span></span>ALVE f<span></span>ollow up at 1 mos with Echo,  </span></div><div> <span></span><span>then annually</span></div><div> <span> </span>o <span> </span>CABG fu at 1 mos (Echo only needed if EF decre<span></span>ased at discharge or  </div><div> <span> </span>&lt; 40% pre op)</div><div> <span> </span>o <span> </span>Aortic surgery patients: FU @ 1, 3,6, and 12 months with CT sc<span></span>an</div><div>Fischbein<span> </span><span>o <span> </span></span>Pre op<span><span></span></span></div><div>o <span> </span>No Tissue consent for Aorta p<span></span>atients </div><div>Miller</div><div>Hiesinger<span> </span><span>o <span> </span>Review all images and review surgical plan prior to clinic</span></div><div>SURGEON PREFERENCES, C<span></span>ONTINUED</div><div>Surgeon </div><div>Preferenc<span></span>es</div><div>ICU<span> </span>T<span></span>ele</div><div>Woo<span> </span><span>o <span> </span>DC labs early if able</span></div><div>o <span> </span>Post op C<span></span>T c/a/p prior to discharge on </div><div>Acute T<span></span>ype A dissections only</div><div>o <span> </span>Ok to DC home same day PW removed</div><div>Boyd</div><div>o <span> </span>CABG patients 75mg Plavix daily x1 </div><div>year</div><div>o <span> </span>All patients 200mg PO amio daily </div><div></div><div>o <span> </span>SubQ heparin for  DVT prophylaxis </div><div>if no contraindic<span></span>ation</div><div>o <span> </span>Endocrine consult to manage DM if </div><div>elevated A1c</div><div>o <span> </span>Daily senna started while in IC<span></span>U</div><div>o <span> </span><span>FAS<span></span>T TRACK (all uncomplic<span></span>ated </span></div><div>CABG with normal EF)</div><div>POD #1:<span></span>0600;  Cordis/</div><div>Swan out by 1000 (even if still on </div><div><span></span></div><div><span></span></div><div><span></span><span></span><span></span></div><div>and Plavix</div><div>POD #2: Daily labs on case by case </div><div>basis. T<span></span>ransfer out of ICU</div><div>Overall consider<span></span>ations:<span><span></span></span></div><div>insulin gtt and s<span></span>tart diet as e<span></span>arly </div><div>as possible, ok to eat POD #0. Ok </div><div>to remove foley POD 1 even if on </div><div>diuretics. If waiting in IC<span></span>U for tele </div><div>bed, ensure P<span></span>T<span></span>/OT and patient </div><div>mobiliza<span></span>tion.</div><div>o <span> </span>DC labs early if able </div><div>o <span> </span>CABG patients 75mg Plavix daily x1 year</div><div>o <span> </span>All patients 200mg PO amio daily for </div><div></div><div>o <span> </span>No Iron on discharge</div><div>o <span> </span>Remove PW prior to CT</div><div>o <span> </span>SubQ heparin for DVT prophylaxis if no </div><div>contraindic<span></span>ation </div><div>o <span> </span>No imaging needed prior to discharge</div><div>o <span> </span>Acute Type A dissec<span></span>tion post op C<span></span>T @ </div><div>1month follow up appointment </div><div>o <span> </span>Endocrine consult to manage DM if </div><div>elevated A1c</div><div>o <span> </span>For routine CABG, goal is discharg<span></span>e by </div><div>at leas<span></span>t POD #5</div><div>o <span> </span>For myocardial bridge, DC P<span></span>aravertebr<span></span>al </div><div>cathet<span></span>er POD #3 with goal of discharge </div><div>by POD #4 </div><div>Lee<span> </span><span>o <span> </span>No IV amio gtt, boluses only</span></div><div>o <span> </span>No nicotine pat<span></span>ch for CABG</div><div>o <span> </span>Avoid Reglan (due to black box </div><div>warning and association with </div><div>tardive dyskinesia)</div><div>o <span> </span>No IV amio gtt, boluses only</div><div>o <span> </span>No nicotine pat<span></span>ch for CABG</div><div>o <span> </span>Coreg no bett<span></span>er than metoprolol f<span></span>or </div><div>Heart failur<span></span>e patients </div><div>o <span> </span>For LAA excision:  Inspra 25mg BID </div><div>o <span> </span>Avoid Reglan (due to black box warning </div><div>and association with tar<span></span>dive dyskinesia)</div><div>Fischbein<span> </span><span>o <span> </span>Do not wean ino<span></span>tropes without </span></div><div>discussing directly </div><div>o <span> </span>For patients on high dose pressors </div><div>or with high oxygen requirement<span></span>s, </div><div>discuss PO diet directly bef<span></span>ore </div><div>initiating </div><div>o <span> </span>For post op CABG patient<span></span>s, </div><div>continue NTG while on Epi if blood </div><div>pressure allows</div><div>o <span> </span>Start Epogen/Ir<span></span>on/Vit C in ICU for </div><div>post op anemia </div><div>o <span> </span>IV Lasix and KCL while inpatient</div><div>o <span> </span>Leave centr<span></span>al line in place</div><div>o <span> </span>PW remain in place until day prior to </div><div>discharge</div><div>o <span> </span>Prior to discharge:</div><div> <span> </span>o <span> </span>Echo all valves </div><div> <span> </span>o <span> </span><span>CT<span></span> al<span></span>l a<span></span>orta<span></span>s (<span></span>wit<span></span>h 3<span></span>D </span> <span> </span> </div><div> <span> </span>me<span></span>asurements </div><div>o <span> </span>Must approve all discharges</div><div>o <span> </span>No IV hydralazine in dissections</div><div>o <span> </span>PW out prior to CT if possible </div><div>Miller<span> </span><span>o <span> </span> Avoid hydralazine in Aortic </span></div><div>Dissections/<span></span>Aneur<span></span>ysm</div><div>o <span> </span>Prior to discharge:</div><div> <span> </span>o <span> </span>Echo all valves (once PW removed </div><div>and within 2kg pre op wt)</div><div> <span> </span>o <span> </span>CT all aortas (with 3D </div><div> <span> </span><span>measurements</span></div><div>o <span> </span>Must approve all discharges</div><div>o <span> </span>No IV hydralazine dissections</div><div>o <span> </span>For LAA excision: Inspra 25mg BID</div><div>Hiesinger<span> </span><span>o <span> </span>Post op imaging per p<span></span>atient- no<span></span>t </span></div><div>st<span></span>andard</div></div><div></div></div>
<div><div><img><div>114<span> </span><span>Referenc<span></span>e Material<span> </span>Referenc<span></span>e Material<span> </span><span>115</span></span></div><div>CARDIAC SURGER<span></span>Y PROCEDURE CLEARANCE</div><div>Dental Guidelines</div><div>Pre-op:</div><div> <span></span><span></span></div><div>Dental cle<span></span>arance will be obt<span></span>ained by schedules via clearanc<span></span>e letter</div><div> <span></span><span></span></div><div>T<span></span>o be cleared f<span></span>or cardiac sur<span></span>gery: </div><div><span></span><span> </span><span>Dental ex<span></span>am in last 6 months</span></div><div><span></span><span> </span><span>No evidence of current dent<span></span>al infection or anticipat<span></span>ed dental c<span></span>are needed </span></div><div>within the next 6 months (E<span></span>xcluding rest<span></span>oration or dentures) </div><div>Pos<span></span>t-Op:</div><div> <span></span><span></span></div><div>P<span></span>atients with valve r<span></span>epair or CABG SHOULD NOT have dent<span></span>al cleaning or work </div><div>done for at le<span></span>ast 3 months post<span></span>-op.</div><div> <span></span><span></span></div><div><span></span><span></span><span></span></div><div>material implant<span></span>ed SHOULD NOT have dental cleaning or work done f<span></span>or </div><div>at leas<span></span>t 6 months post-op and should t<span></span>ake prophylactic or<span></span>al antibiotics, </div><div>prescribed from their dentis<span></span>t<span></span>, before any pr<span></span>ocedures. (AHA guidelines)</div><div> <span></span><span></span></div><div>P<span></span>atients are enc<span></span>ouraged to follow up with their c<span></span>ardiologist recommenda<span></span>tion </div><div>before proc<span></span>eeding with dental work and reg<span></span>arding the need for prophylactic </div><div>antibiotics. </div><div>Colonosc<span></span>opy/Sigmoidosc<span></span>opy Guidelines</div><div>Pos<span></span>t-Op:</div><div> <span></span><span></span></div><div>P<span></span>atients SHOULD NOT have an elec<span></span>tive colonoscopy for at le<span></span>ast 6 months  </div><div>post op</div><div> <span></span><span></span></div><div>Prophylactic antibio<span></span>tics (usually IV given within 30 minutes of proc<span></span>edure) </div><div>should be considered f<span></span>or high risk patients only (presenc<span></span>e of prosthetic heart </div><div><span></span><span></span></div><div>hist<span></span>or<span></span>y of endocar<span></span>ditis)</div><div> <span></span><span></span></div><div>Prophylaxis IS NO<span></span>T recommended f<span></span>or patients with the following: isola<span></span>ted </div><div>ASD, ASD s/p repair with p<span></span>atch, post op CABG, v<span></span>alvar dysfunction, mitral v<span></span>alve </div><div>prolapse, presenc<span></span>e of cardiac pacemak<span></span>er </div><div>Referenc<span></span>es:</div><div>Oliver<span></span>, G., Lowry, A., Vernava, A., Hicks, T<span></span>., Burnstein, M., e<span></span>t. Al. (2000).  Antibiotics prophylaxis clinical </div><div>practic<span></span>e guideline: supporting documentation. The American Society of Colon and Rec<span></span>tal Surg<span></span>eons. </div><div>PRE-OP:<span> CHECK LIS<span></span>T</span></div><div> <span></span><span></span></div><div>H&amp;P </div><div><span></span><span> </span><span>Completed within 24 hours of pr<span></span>ocedure</span></div><div>OR</div><div><span></span><span> </span><span>Completed within 30 days, with H&amp;P int<span></span>er<span></span>v<span></span>al within 24 hours of </span></div><div>procedur<span></span>e</div><div> <span></span><span></span></div><div>Consent (good for 1 ye<span></span>ar) </div><div><span></span><span> </span><span>Procedur<span></span>e</span></div><div><span></span><span> </span><span>ICU</span></div><div><span></span><span> </span><span>Tissue/Study</span></div><div><span></span><span> </span><span>Refusal of blood product<span></span>s if patient does NOT c<span></span>onsent to blood </span></div><div>transfusion</div><div> <span></span><span></span></div><div>Pre op labs/imaging (must be complet<span></span>ed at S<span></span>tanf<span></span>ord within 30 days of </div><div>surgery)</div><div><span></span><span> </span><span><span></span></span></div><div><span></span><span> </span><span>CMP</span></div><div><span></span><span> </span><span>PT<span></span>, PTT</span></div><div><span></span><span> </span><span>HgbA1c</span></div><div><span></span><span> </span><span>Phosphorus</span></div><div><span></span><span> </span><span>Urinalysis, screen for culture</span></div><div><span></span><span> </span><span>T<span></span>ype and Screen (for outpatient, clot should be ex<span></span>tended for 30 days.  </span></div><div>For inpa<span></span>tient<span></span>, must be within 72 hours of pr<span></span>ocedure)</div><div><span></span><span> </span><span>RBCS <span>(R<span></span>efer to <span>page 116 </span>to know how many units t<span></span>o order ahead)</span></span></div><div><span></span><span> </span><span>EKG</span></div><div><span></span><span> </span><span>CXR (2V preferred) </span></div><div> <span></span><span></span></div><div>Day of surgery orders (found in order set #4658): </div><div><span></span><span> </span><span>Surgical prep<span></span>aration- clipping, antimicrobial showers x 2, Mepilex t<span></span>o </span></div><div>sacrum</div><div><span></span><span> </span><span>Surgical prophylaxis with antibio<span></span>tics (ON CALL)</span></div><div><span></span><span> </span><span>Peridex mouthw<span></span>ash (ON CALL)</span></div><div><span></span><span> </span><span>DVT prophylaxis </span></div><div> <span></span><span></span></div><div>Misc pre op</div><div><span></span><span> </span><span>Antico<span></span>agulation bridging with Loveno<span></span>x</span></div><div><span></span><span> </span><span>Radial artery har<span></span>vest work up</span></div><div><span></span><span> </span><span>Dental cle<span></span>arance </span></div><div><span></span><span> </span><span>Any other s<span></span>tudies needed (Cath, Echo<span></span>, CT<span></span>, et<span></span>c)</span></div><div>T<span></span>AAA Repair specic:</div><div>P<span></span>atients are pre-admit<span></span>ted day before surgery for lumbar dr<span></span>ain, epidural, and </div><div>bowel prep.</div><div><span></span><span> </span><span>P<span></span>age pain service to place epidur<span></span>al preferably day befor<span></span>e it is needed </span></div><div>(2-P<span></span>AIN)</div><div><span></span><span> </span><span><span></span></span></div><div><span></span><span> </span><span>Clear diet</span></div><div><span></span><span> </span><span>Bowel prep</span></div><div> </div></div><div></div></div>
<div><div><img><div>116<span> </span><span>Referenc<span></span>e Material<span> </span>Referenc<span></span>e Material<span> </span><span>117</span></span></div><div>PRE-OP:<span>CARDIAC SURGER<span></span>Y P<span></span>A<span></span>TIENT BL<span></span>OOD </span></div><div>MANAGEMENT PROGRAM</div><div>(Ref: Info redistribut<span></span>ed from CV Clinical Outc<span></span>omes; 2011: Stanford Maximum Surgical </div><div>Blood Order Schedule (MSBOS) Criteria)</div><div>Proc<span></span>edure:<span> </span>Type &amp; Scr<span></span>een and </div><div>Type &amp; Cr<span></span>oss (Y<span></span>/N)</div><div>Cardiac Surg<span></span>er<span></span>y </div><div>rec<span></span>ommended # RBC </div><div>units order pre-op</div><div>Combo Sx: “Low Risk<span></span>” Group:  <span> </span></div><div>(Includes: Iso CABG, Open &amp; Mini Valv<span></span>e Repair/Replac<span></span>e)</div><div>1st Sx: IsoCABG</div><div>Y<span> </span>2</div><div>1st Sx: Open A<span></span>VR</div><div>Y<span> </span>2</div><div>T<span></span>AVR (TFem, T<span></span>Apical, </div><div>T<span></span>Aortic)</div><div>Y<span> </span>4</div><div>1st Sx: V<span></span>alve + CABG OR </div><div>Multiple Valves</div><div>Y<span> </span>4</div><div>1st Sx: AoRoo<span></span>t (no arch) </div><div>Combo TD, CVG, AscAo</div><div>Y<span> </span>4</div><div>1st Sx: TD +/- Asc Arch</div><div>Y<span> </span>4</div><div>1st Sx: CV<span></span>G +/- Acs Arch </div><div>Y<span> </span>4</div><div> 1st Sx: Asc + Arch (no valv<span></span>e) </div><div>+/- descending </div><div>Y<span> </span>4</div><div>Redo Sx:  CABG + V<span></span>alve </div><div>Y<span> </span>4</div><div>Combo Sx: “High Risk” Gr<span></span>oup: <span> </span></div><div>(Includes: Redo TD, Redo CV<span></span>G, any 1st or Redo Arch Replac<span></span>e, Open Desc Ao, </div><div>and 1st or Redo T<span></span>AAA) <span> </span></div><div>Redo Sx:  TD +/- Arch</div><div>Y<span> </span>6</div><div>Redo Sx:  CVG +/- Ar<span></span>ch</div><div>Y<span> </span>6</div><div>Redo Sx:  CVG, No Ar<span></span>ch</div><div>Y<span> </span>6</div><div>Redo Sx:  Asc +/- Arch</div><div>Y<span> </span>6</div><div>Open Desc. Ao (All)</div><div>Y<span> </span>6</div><div>Open T<span></span>AAA (All)</div><div>Y<span> </span>6</div><div> </div><div>*Key:</div><div><span></span></div><div><span></span><span></span></div><div>TD= T<span></span>yrone David (aka: David V<span></span>, Valve Sparing)</div><div>Patients with Heparin allergy or HIT<span></span>; document in H&amp;P note and inform perfusion on </div><div>surgical day<span></span>. (Patient with Heparin allergy will rec<span></span>eive Argatroban, Bivalirudin  </div><div>or heparin.)</div><div>Pre-Op Blood Saving:</div><div> <span></span><span></span></div><div>Autolog<span></span>ous Donation:<span> P<span></span>atients can donate their own blood, c<span></span>an donate 6 </span></div><div>weeks before surg<span></span>er<span></span>y, incre<span></span>ase folic acid, vitamin C, iron supply (ask your </div><div>at<span></span>tending surg<span></span>eon if this is preferred)</div><div> <span></span><span></span></div><div>Jehovah<span></span>’s Witness:<span> P<span></span>atients Witnesses’ refusal of transfusions of whole </span></div><div>blood or its four primary components—red cells, whit<span></span>e cells, platelet<span></span>s and </div><div>plasma; can use use of fr<span></span>actions such as albumin, immunoglobulins and </div><div>hemophiliac prepar<span></span>ations &amp; cell saver<span></span>. (Watch<span></span>T<span></span>ower Society)</div><div><span></span><span> </span><span>Bloodless medicine program in proc<span></span>ess 1/2017. Refer to updated pr<span></span>otocol </span></div><div>for current pre-operative guidelines f<span></span>or patients who refuse blood </div><div>transfusion.</div><div> <span></span><span></span></div><div>Herbal Produc<span></span>ts: <span>P<span></span>otential interac<span></span>tions to avoid (JAC<span></span>C, 2010), (Alfalfa, </span></div><div>Angelica, Bilberry, Garlic, Ginger<span></span>, Ginko, Ginseng, Echinac<span></span>ea, Licorice, S<span></span>t<span></span>. </div><div>Johns Wart).  Can cause int<span></span>eractions with cardiac medic<span></span>ations &amp; increase </div><div>bleeding during surgery.</div><div>Intra-Op Blood Saving:</div><div> <span></span><span></span></div><div>Blood clot<span></span>ting agent/blood derived fraction ag<span></span>ents (Coseal/Tisseal/Floseal)</div><div> <span></span><span></span></div><div>Perfusion: </div><div><span></span><span> </span><span>Cell Saver<span></span>:  rec<span></span>overing blood lost during surgery and re-infusing it into </span></div><div>the patient. It is a major form of auto<span></span>transfusion. Cell processors ar<span></span>e </div><div>red cell w<span></span>ashing de<span></span>vices tha<span></span>t collect antico<span></span>agulated shed or recover<span></span>ed </div><div>blood, wash and separ<span></span>ate the red blood c<span></span>ells (RBC) by centrifug<span></span>ation, and </div><div>reinfuse the RBC. </div><div><span></span><span> </span><span><span></span><span></span></span></div><div><span></span><span> </span><span><span></span><span></span><span></span><span></span></span></div><div>PRE-OP: <span>CLAS<span></span>SIFICA<span></span>TIONS</span></div><div>C<span></span>CS Func<span></span>tional Classication of Angina</div><div>Class<span> </span>Descrip<span></span>tion</div><div>Class I<span> </span>Angina only during str<span></span>enuous or prolonged physical activity</div><div>Class II<span> </span>Slight limit<span></span>ation, with angina only during vigorous physical activity</div><div>Class III<span> </span>Symp<span></span>toms with ever<span></span>yday living activities  (i.e. moder<span></span>ate limit<span></span>ation)</div><div>Class IV<span> </span>Inability to perform any activity without angina or angina at r<span></span>est </div><div>(i.e. severe limit<span></span>ation)</div><div>St<span></span>aging Kidney Disease: <span>always document CKD Stage 3 or gr<span></span>eater</span></div><div>St<span></span>age<span> </span>Description</div><div>St<span></span>age I<span> </span>With normal of high GFR (GFR &gt; 90mL/min)</div><div>St<span></span>age II<span> </span>Mild CKD (GFR = 60-89mL/min)</div><div>St<span></span>age IIIa<span> </span>Moderat<span></span>e CKD (GFR = 45-59mL/min)</div><div>St<span></span>age IIIb<span> </span>Modera<span></span>te CKD (GFR = 30-44mL/min)</div><div>St<span></span>age IV<span> </span>Severe CKD (GFR = 15-29mL/min)</div><div>St<span></span>age V<span> </span>End St<span></span>age CKD (GFR &lt; 15mL/min)</div><div>GFR calculat<span></span>or Website:</div><div>http://www<span></span>.davita.c<span></span>om/gfr-calculat<span></span>or/</div><div>http://www<span></span>.kidne<span></span>y<span></span>.org<span></span>/prof<span></span>essionals/KDOQI/gfr_calcula<span></span>tor</div></div><div></div></div>
<div><div><img><div>118<span> </span><span>Referenc<span></span>e Material<span> </span>Referenc<span></span>e Material<span> </span><span>119</span></span></div><div>AC<span></span>C/<span></span>AHA Classica<span></span>tion of CHF</div><div>The AC<span></span>C/AHA cr<span></span>eated four classications fr<span></span>om risk for develop the </div><div>disease to sev<span></span>ere disability.</div><div>St<span></span>age<span> </span>Description</div><div>A (High risk for </div><div>developing CHF)</div><div>Hypertension, DM, F<span></span>amily history, CAD</div><div>B (Asymptomatic HF)<span> </span>Previous myocardial inf<span></span>arction (heart at<span></span>tack), valvular </div><div></div><div>C (Symptoma<span></span>tic HF)<span> </span>Struc<span></span>tural he<span></span>art disease, fatigue, low t<span></span>oleranc<span></span>e le<span></span>vel for </div><div>physical activity</div><div>D (Refr<span></span>actory  </div><div>end-st<span></span>age HF)</div><div>Severe limita<span></span>tions. Experienc<span></span>e symptoms even  </div><div>while at res<span></span>t<span></span>.</div><div>NYHA Func<span></span>tional Classica<span></span>tion</div><div>The NYHA classied heart failure int<span></span>o classes base on functional </div><div>limitations and sev<span></span>erity.</div><div>Class<span> </span>FUNC<span></span>TIONAL CAP<span></span>ACITY<span></span>: Pa<span></span>tient Symptoms</div><div>I (Normal)<span> </span>Few observable sx, no limitations in or<span></span>dinar<span></span>y physical activity</div><div>II (Mild)<span> </span>Mild obser<span></span>v<span></span>able sx and slight limitation during ordinary activity. </div><div>Comfort<span></span>able at res<span></span>t<span></span>.</div><div>III (Modera<span></span>te)<span> </span>Marked limitation in physic<span></span>al activity due to symp<span></span>toms even </div><div>during less than ordinary activity. Comfort<span></span>able only at rest.</div><div>IV (Severe)<span> </span>End-s<span></span>tage he<span></span>art failure. Severe limita<span></span>tions. Experienc<span></span>e </div><div>symptoms even while at r<span></span>est.</div><div>Class<span> </span>OB<span></span>JECTIVE ASSESSMENT</div><div>A<span> </span>No evidence of car<span></span>diovascular disease. No sympt<span></span>oms and no </div><div>limita<span></span>tion in ordinar<span></span>y physical activity<span></span>.</div><div>B<span> </span>Objective evidence of minimal car<span></span>diovascular disease. Mild </div><div>symptoms and slight limit<span></span>ation during ordinar<span></span>y activity<span></span>. </div><div>Comfort<span></span>able at res<span></span>t<span></span>.</div><div>C<span> </span>Objective evidence of modera<span></span>tely se<span></span>vere c<span></span>ardiac disease. </div><div>Marked limit<span></span>ation in activity due to symptoms, even during less </div><div>than ordinary activity. Comfort<span></span>able only at rest.</div><div>D<span> </span>Objec<span></span>tive e<span></span>vidence of severe c<span></span>ardiovascular disease. Severe </div><div>limita<span></span>tions. Experiences sympt<span></span>oms e<span></span>ven while at res<span></span>t<span></span>.</div><div>For Example:</div><div>A patient with minimal or no symp<span></span>toms but a large pressure gr<span></span>adient across the </div><div><span></span><span></span></div><div>Function capacity I, Objective Assessment D</div><div>A patient with severe angina syndr<span></span>ome but angiographically normal coronary </div><div><span>Functional Capacity IV<span></span>, Objective Assessment A</span></div><div>Other Helpful Scor<span></span>es/Resourc<span></span>es</div><div>NYHA Class </div><div>Website:</div><div>http://www<span></span>.heart.org/HEARTORG/Conditions/</div><div>HeartF<span></span>ailure/AboutHe<span></span>artFailur<span></span>e/Classes-of-Heart-</div><div>Failur<span></span>e_UCM_306328_Article.<span></span>jsp</div><div>Griepp Score<span> </span><span>The 1997 A<span></span>T<span></span>S paper by Randy Griepp and colleagues </span></div><div>describes an easy-<span></span>to-use risk of rupture calculat<span></span>or </div><div>developed by Abe DeAnda (Chief Resident 2000-</div><div>2001). If aortic dissection, RBG just adds 0.5 cm t<span></span>o </div><div>the descending thor<span></span>acic aortic and abdominal aorta </div><div>diameter numbers. Sever<span></span>al other calculator t<span></span>ools are </div><div>also on the spreadsheet.</div><div>    Referenc<span></span>e the </div><div>Cardiac Surgery </div><div>APP Shared Box </div><div>folder for this </div><div>information.</div><div>Syntax<span></span>core<span> </span><span>SYNT<span></span>AX score II crea<span></span>tes accura<span></span>te mortality predictions </span></div><div>to guide the choice be<span></span>tween PCI and CABG for </div><div>patient<span></span>s with multivessel cor<span></span>onary disease.</div><div>    http://</div><div>syntaxsc<span></span>ore.</div><div>com/</div><div> </div><div>PRE-OP: <span>NORMAL ECHO VAL<span></span>UES</span></div><div>Normal Echo V<span></span>alues</div><div>L<span></span>V Diastolic Dimension<span> </span>3.7-5.5cm</div><div>L<span></span>V Systolic Dimension<span> </span>2.0-4.0 cm</div><div>Interventricular septum (Diastole)<span> </span>0.6-1.1 cm</div><div>L<span></span>V Pos<span></span>terior Wall (Diastole)<span> </span>1.8-2.2 cm</div><div>L<span></span>VOT Diame<span></span>ter (Systole)<span> </span>1.8-2.2cm</div><div>Aortic Root (Dias<span></span>tole)<span> </span>2.0-3.7cm</div><div><span></span><span> </span><span>2.0-4.0cm</span></div><div><span></span><span> </span><span>&lt;20cm2</span></div><div><span></span><span> </span><span>16-28ml</span></div><div>RV Diastolic Dimension<span> </span>0.9-2.5cm</div><div> </div><div>Pulmonic Valve E<span></span>cho Values</div><div>Mild<span> </span>5-25mmHg</div><div>Moderat<span></span>e<span> </span>25-49mmHg</div><div>Severe<span> </span>&gt;50mmHg</div><div> </div><div>Aortic Valve E<span></span>cho Values</div><div>AS Grading<span> </span>Mean Gradient </div><div>(mmHg)</div><div>Peak V<span></span>elocity (m/s)<span> </span>AVA (cm2)</div><div>Normal<span> </span><span>&lt; 10<span> </span>&lt; 2.6<span> </span>&gt;2.5</span></div><div>Mild<span> </span><span>10-25<span> </span>2.6-2.9<span> </span>1.5-2.5</span></div><div>Modera<span></span>te<span> </span><span>20-45<span> </span>3.0-4.0<span> </span>1.0-1.5</span></div><div>Severe<span> </span><span>&gt;45<span> </span>&gt;4.0<span> </span>0.7-1.0</span></div><div>Critical<span> </span><span>&gt;50<span> </span>&gt;4.0<span> </span>&lt;0.7</span></div><div>AR Grading<span> </span>Central Jet width<span></span>*<span> </span>Regurgitant Volume </div><div>(per beat) </div><div>EROA (eectiv<span></span>e </div><div>Regurgit<span></span>ant oriace </div><div>area)</div><div>Mild<span> </span><span>&lt; 25% of L<span></span>VOT width<span> </span><span>&lt; 30mL<span> </span>&lt;0.1cm2</span></span></div><div>Modera<span></span>te<span> </span><span>25-65% of L<span></span>VOT width<span> </span>30-59mL<span> </span>0.1-0.3cm2</span></div><div>Severe<span> </span><span>&gt;65% of L<span></span>VOT width<span> </span>&gt;60mL<span> </span>&gt;0.3cm</span></div><div>T<span></span>ricuspid Valve Echo V<span></span>alues</div><div>Signicant tricuspid stenosis</div><div>Mean pressure gr<span></span>adient<span> </span>&gt;/= 5mmHg</div><div>Valve are<span></span>a<span> </span>&lt;/= 1cm2</div><div>T<span></span>ricuspid </div><div>Regurgitation</div><div>MILD<span> </span>MODERA<span></span>TE<span> </span>SEVERE</div><div>Jet area<span> </span>&lt; 5<span> </span>5-10<span> </span>&gt;10</div><div>RV<span></span>/RA/IVC Size<span> </span>Normal<span> </span>Normal or dilated<span> </span>Usually dialates</div></div><div></div></div>
<div><div><img><div>120<span> </span><span>Referenc<span></span>e Material<span> </span>Referenc<span></span>e Material<span> </span><span>121</span></span></div><div>Mitral V<span></span>alve Echo Values</div><div>MS grading<span> </span>Valve Are<span></span>a<span> </span>Mean gradient<span> </span>Pulmonar<span></span>y artery </div><div>pressure (mmHg)</div><div>Mild<span> </span><span>&gt;1.5 cm2<span> </span>&lt;5mmHg<span> </span>&lt;30mmHg</span></div><div>Modera<span></span>te<span> </span><span>1.0-1.5 cm2<span> </span>5-10mmHg<span> </span>30-50mmHg</span></div><div>Severe<span> </span><span>&lt;1.0cm2<span> </span>&gt;10mmHg<span> </span>&gt;50mmHg</span></div><div>MR grading <span> </span>Jet area<span> </span>Regurgit<span></span>ant Volume<span> </span><span>EROA (eective </span></div><div>Regurgit<span></span>ant oriace </div><div>area)</div><div>Mild<span> </span><span>&lt;20% of L<span></span>A are<span></span>a<span> </span><span>&lt;30mL<span> </span>&lt;0.2cm2</span></span></div><div>Modera<span></span>te<span> </span><span>20-40% of LA area<span> </span>30-59mL<span> </span>0.2-0.39 </span></div><div>Severe<span> </span><span>&gt;40% of LA area<span> </span>&gt;60mL<span> </span>&gt;0.40cm2</span></div><div>PRE-OP: <span>OB<span></span>T<span></span>AINING C<span></span>ONSENT<span></span>/PROCEDURE LIST</span></div><div>Procedur<span></span>e<span> </span>Correct verbiag<span></span>e for Consent</div><div>CABG<span> </span><span></span></div><div><span></span></div><div>• Does not need to include IMA (LIMA/RIMA) </div><div>Consent must specify conduit harvesting when applicable:</div><div>EVH= Endoscopic vein harvest</div><div>RAH= Endoscopic radial art<span></span>er<span></span>y harvest </div><div><span>CABG<span> </span></span><span></span><span></span></div><div>MIDCAB<span> </span><span><span></span><span></span></span></div><div>possible sterno<span></span>tomy, cardiopulmonary bypass on standby</div><div>T<span></span>AVR<span> </span>T<span></span>ransca<span></span>theter aortic valve replacement</div><div>• Include approach (tr<span></span>ansfemoral, transapical, or tr<span></span>ansaortic) </div><div>• Also include cardiopulmonary bypass on st<span></span>andby </div><div>• Also include transesophage<span></span>al echocardiogram</div><div>Mini MVR<span> </span>Right anterior thorac<span></span>otomy; mitral valve/r<span></span>eplacement repair on </div><div>cardiopulmonary bypass, possible sterno<span></span>tomy. </div><div>Mini AVR<span> </span>Minimally invasive aortic valve rep<span></span>air/replac<span></span>ement; on cardiopulmonary bypass</div><div>Hybrid MAZE<span> </span>Bilateral video assis<span></span>ted thoracoscopy; pulmonary vein isolation; with additional </div><div><span></span><span></span></div><div>MAZE; cardiopulmonary bypass on st<span></span>andby</div><div>Cox Maze<span> </span>Maze procedur<span></span>e on cardiopulmonar<span></span>y bypass</div><div>Myectomy<span></span>/</div><div>Myotomy</div><div>Myectomy<span></span>/myotomy with possible mitr<span></span>al valve repair<span></span>/replacement on </div><div>cardiopulmonary bypass</div><div>Myocardial bridge </div><div></div><div><span></span><span></span></div><div>Redo st<span></span>ern<span> </span>Redo sternotomy</div><div>LAA Excision<span> </span><span><span></span></span></div><div>Laser lead </div><div>extr<span></span>action</div><div>Laser lead extr<span></span>action with possible pacemaker g<span></span>enerator change; possible </div><div>sterno<span></span>tomy; Cardiopulmonar<span></span>y bypass on s<span></span>tandby</div><div></div><div>TEVAR<span> (CT sur<span></span>gery </span></div><div>attending is </div><div>surgical c<span></span>onsent </div><div>attending, Dr<span></span>. Dake </div><div>does not sign this </div><div>procedure <span></span>consent)</div><div><span></span></div><div>• Do not include Lumbar dr<span></span>ain (Anesthesia will consent separ<span></span>ately)</div><div>VSARR or Tirone </div><div>David (T<span></span>-David)</div><div>Valve sparing aortic r<span></span>oot replac<span></span>ement, possible aortic valve replacement on </div><div>cardiopulmonary bypass </div><div>Aortic <span></span>replacement<span> </span>Include f<span></span>ollowing when applicable: ascending aortic replac<span></span>ement<span></span>, desc<span></span>ending </div><div>aortic replacement, tot<span></span>al arch replacement, hemi-arch replacement, elephant </div><div><span></span></div><div>Aortic root <span> </span>Aortic r<span></span>oot replacement including aortic valve replac<span></span>ement on cardiopulmonar<span></span>y </div><div>bypass</div><div>TAA<span></span>A<span> </span><span>Thoraco<span></span>abdominal aortic aneur<span></span>ysm repair on car<span></span>diopulmonar<span></span>y bypass </span></div><div>SACP &amp; PHCA<span> </span>Under Deep Circulat<span></span>or<span></span>y Arrest</div><div>Heart transplant<span> </span>Heart transplant on c<span></span>ardiopulmonary bypass</div><div>VAD<span> </span>Ventricular assist device insertion on cardiopulmonary bypass </div><div>• Include type of device: Heartmat<span></span>e II or Heartware</div><div> </div><div> <span></span><span></span></div><div>Procedur<span></span>e consent<span> must be signed by someone who can perform the </span></div><div>procedur<span></span>e listed</div><div><span></span><span> </span><span>Ex: V<span></span>alve replacement = Att<span></span>ending<span></span>/resident</span></div><div><span></span><span> </span><span>Ex: Car<span></span>dioversion/Pigtail plac<span></span>ement = APP</span></div><div> <span></span><span></span></div><div>ICU consent <span>c<span></span>an be signed by APP</span></div><div> <span></span><span></span></div><div>Consent is good for 1 ye<span></span>ar</div><div> <span></span><span></span></div><div>Make sure all abbr<span></span>eviations are comple<span></span>tely spelled out<span></span>. <span>NO ABBREVIA<span></span>TIONS<span>.  </span></span></div><div> <span></span><span></span></div><div>Check blood consent box on bo<span></span>th forms and give patient tr<span></span>ansfusion packe<span></span>t (If </div><div>the patient r<span></span>efuses blood transfusion, use the additional blood refusal form)</div><div> <span></span><span></span></div><div>Median sterno<span></span>tomy DOES NOT need to be included on expec<span></span>ted “s<span></span>tandard </div><div>sterno<span></span>tomy” consents.  ONL<span></span>Y on “Possible St<span></span>ernotomy” cases (i.e. anterior </div><div>thorac<span></span>otomy, then “possible s<span></span>ternotomy” should also be included).</div><div> <span></span><span></span></div><div>NO SCRA<span></span>TCHES, CROS<span></span>S THROUGHS, OR SCRIBBLES ALLOWED ON C<span></span>ONSENT</div><div>PRE-OP:<span> PFT AND CARO<span></span>TID US INTEPRET<span></span>A<span></span>TION</span></div><div>Carotid Duple<span></span>x Ultrasound Criteria for Gr<span></span>ading Internal Carotid Art<span></span>ery Stenosis</div><div>Degree of </div><div>Stenosis (%)</div><div>ICA PSV (cm/2)<span> </span>ICU<span></span>/CCA P<span></span>SV </div><div>Ratio</div><div>ICA EDV (cm/2)<span> </span>Plaque Estimate </div><div>(%)</div><div>Normal<span> </span>&lt; 125<span> </span>&lt;2.0<span> </span>&lt;40<span> </span>None</div><div>&lt;50<span> </span>&lt;125<span> </span>&lt;2.0<span> </span>&lt;40<span> </span>&lt;50</div><div>50-69<span> </span>125-230<span> </span>2.0-4.0<span> </span>40-100<span> </span>&gt;50</div><div>&gt;70 to less than </div><div>near occlusion</div><div>&gt;230<span> </span>&gt;4.0<span> </span>&gt;100<span> </span>&gt;50</div><div>Near occlusion<span> </span>High, low, or not </div><div>detect<span></span>ed</div><div>Variable<span> </span>Variable<span> </span>Visible</div><div>T<span></span>otal oc<span></span>clusion<span> </span>Not detec<span></span>ted<span> </span>No<span></span>t applicable<span> </span>Not det<span></span>ected<span> </span>Visible, no lumen</div><div>*Plaque estimat<span></span>e (diameter reduction) with gray scale and c<span></span>olor Doppler ultrasound. ICA = internal </div><div>carotid art<span></span>er<span></span>y; CCA= common c<span></span>arotid arter<span></span>y; PSV = pe<span></span>ak systolic velocity; EDV = end- diast<span></span>olic velocity</div><div>*Intervention may be required prior t<span></span>o cardiac surgery on cardiopulmonary bypass if degree of </div><div>steno<span></span>sis is &gt; 90% unilater<span></span>al or &gt; 75% bilateral due t<span></span>o increased strok<span></span>e risk </div><div>Normal Value of Pulmonary Func<span></span>tion T<span></span>ests</div><div>** FEV1   <span> </span><span>80% to 120% </span></div><div>FVC<span> </span><span>80- 120%</span></div><div>Absolute FEV1/FVC ra<span></span>tio<span> </span>Within 5% of the predicted r<span></span>atio</div><div>TLC<span> </span>80-120%</div><div>FRC<span> </span>75-120%</div><div>RV<span> </span><span>75-120%</span></div><div>** DLC<span></span>O <span><span></span></span></div><div>Also known as TLC<span></span>O or Dsb </div><div>&gt;60% to  &lt;120%</div><div>**These are key for interpr<span></span>eting</div><div>Spirometry</div><div>Low FEV1/FVC</div><div>Obstruction</div><div>Bronchodilator</div><div>FEV1 unchanged/</div><div>partially </div><div>improved</div><div>(asthma or COPD)</div><div>Obstruction </div><div>Normalizes </div><div>(asthma)</div><div>DLCO</div><div>Low (COPD/</div><div>Emphysema/</div><div>bronchiolitis)</div><div>Normal/High</div><div>(asthma or COPD)</div><div>Normal</div><div>? Asthma</div><div>Bronchoprovocation </div><div>challenge</div><div>FEV1 </div><div>Decreased </div><div>(asthma more </div><div>likely)</div><div>No Change in FEV1 </div><div>(asthma unlikely)</div><div>DLCO</div><div>Low (anemia, </div><div>early ILD, </div><div>pulmonary </div><div>vascular </div><div>disease) </div><div>Normal/</div><div>High</div><div>Normal</div><div>Normal FEV1/</div><div>FVC</div><div>Low VC</div><div>Restriction</div><div>Confirm with </div><div>lung volumes</div><div>DLCO</div><div>Low</div><div>(ILD)</div><div>Normal (chest </div><div>wall/</div><div>neuromuscular)</div><div>Maximum </div><div>inspiratory/</div><div>expiratory </div><div>pressures</div><div>Low</div><div>(neuromuscular)</div></div><div></div></div>
<div><div><img><div>122<span> </span><span>Referenc<span></span>e Material<span> </span>Referenc<span></span>e Material<span> </span><span>123</span></span></div><div>PRE-OP:<span> PERIPROCEDURAL  </span></div><div>ANTIC<span></span>OAGUL<span></span>A<span></span>TION BRIDGING</div><div><div>Brand Name </div></div><div>(Generic Name)<span> </span><span>Half Life/Onset of Action<span> </span>Last dose of medi<span></span>cation Before Surgery:</span></div><div><div>If indicated: When<span></span> To Start Lovenox </div><div>(dosing=1mg/kg)</div></div><div><div>#           <span></span> </div><div>syringes</div></div><div>Notes<span> </span>Cath procedures</div><div>Coumadin </div><div><div>(Warfarin)       <span></span> <span></span> </div><div>Once daily dosing </div></div><div>20-60hours/3-5 days<span> </span>5 days before date of surgery</div><div><div>Start 2 days after d/c coumadin (inj Q12 <span></span>until day </div><div>before surgery.  Day before surgery just ONE </div><div>injection in the morning)</div></div><div>5</div><div><div>Example:  surgery date 4/10; last dose </div><div>Coumadin 4/5; off all one day, 4/6; start </div><div>Lovenox Q12 on 4/7; last Lovenox injec on </div><div>4/9 (morning before sx)</div></div><div><div>Hold 5 days prior for femoral access, </div><div>and if pt mod-high risk for clot <span></span>bridge </div><div>to Lovenox.  Hold 2 days prior for </div></div><div>radial access</div><div>Eliquis </div><div><div>(Apixaban)             <span></span> <span></span> </div></div><div>BID dosing </div><div>9-14hours/3-4 hours</div><div><div>5 days before date of surgery           <span></span> <span></span> <span></span> </div><div>(If CrCl &lt; 50 Hold 6-7 doses)</div></div><div><div>Start 1 day after d/c anticoagulant (inj Q12 unt<span></span>il day </div><div>before surgery.  Day before surgery just ONE </div><div>injection in the morning)</div></div><div>7</div><div><div>Example:  surgery date 4/10; last dose </div><div>Eliquis 4/5(am); start Lovenox Q12 on 4/<span></span>6; </div><div>last Lovenox injec on 4/9 (morning before </div></div><div>surgery)</div><div><div>Hold x 2 days:  the day before and </div><div>the day of Cath</div></div><div>Xarelto </div><div><div>(Rivorxaban)              <span></span> <span></span> </div><div>Once daily dosing</div></div><div>11-13 hours/2-4 hours</div><div><div>3 days before date of surgery           <span></span> <span></span> <span></span> </div><div>(If CrCl &lt; 30 Hold 3 doses)</div></div><div><div>Start 1 day after d/c anticoagulant (inj Q12 unt<span></span>il day </div><div>before surgery.  Day before surgery just ONE </div><div>injection in the morning)</div></div><div>3</div><div><div>Example:  surgery date 4/10; last dose </div><div>Xarelto 4/7(am); start Lovenox Q12 on 4/8; </div><div>last Lovenox injec on 4/9 (morning before </div></div><div>surgery)</div><div><div>Hold x 2 days:  the day before and </div><div>the day of Cath</div></div><div>Pradaxa </div><div><div>(Dabigatran)            <span></span> <span></span> </div></div><div>BID dosing </div><div>12-17hours /1 hour</div><div><div>5 days before date of surgery           <span></span> <span></span> <span></span> </div></div><div><div>Start 1 day after d/c anticoagulant (inj Q12 unt<span></span>il day </div><div>before surgery.  Day before surgery just ONE </div><div>injection in the morning)</div></div><div>7</div><div><div>Example:  surgery date 4/10; last dose </div><div>Pradaxa 4/5(am); start Lovenox Q12 on </div><div>4/6; last Lovenox injec on 4/9 (morning </div></div><div>before surgery)</div><div><div>Hold the night before and morning of </div><div>procedure.  Last dose will be in <span></span>the </div><div>morning the day before Cath</div></div><div>SAVAYSA</div><div><div> (endoxaban)             <span></span> <span></span> </div><div>Once daily dosing </div></div><div>10-14 hours/ 1-2 hours</div><div><div>3 days before date of surgery           <span></span> <span></span> <span></span> <span></span> </div><div>(If CrCl &lt; 30 Hold 3-4 doses)</div></div><div><div>Start 1 day after d/c anticoagulant (inj Q12 unt<span></span>il day </div><div>before surgery.  Day before surgery just ONE </div><div>injection in the morning)</div></div><div>3</div><div><div>Example: surgery date 4/10; last dose </div><div>Savaysa 4/7( AM); Lovenox BID 4/8 1 </div><div>lovenox inj AM only on 4/9. </div></div><div><div>Hold x2 days: the day before and the </div></div><div>day of Cath</div><div>Plavix <span>(Clopidogrel)</span></div><div>5 days before date of surgery</div><div><div>Start 1 day after anticoagulant held (inj Q12 until </div><div>day before surgery.  Day before surgery just ONE </div><div>injection in the morning)</div></div><div>7</div><div><div>Only bridge for pt&amp;apos;s taking Plav<span></span>ix for A.fib.  </div><div>If taking for Stents,<span></span> hold 5 days before </div><div>surgery and do not bridge</div></div><div>PLETAL<span> (cilostazol)</span></div><div><div>11-13 hours, reach steady state blood </div><div>levels within a few days.</div></div><div>5 days before date of surgery<span> </span>Does not need bridging</div><div>Asprin</div><div><div>If having valve surgery d/c 2 days before surgery date.  </div><div>If having CABG stop day before</div></div><div>Does not need bridging</div><div><div>If taking ASA 325mg, have patient </div><div>decrease dose to 81 mg as s<span></span>oon as </div><div>procedure scheduled</div></div><div>EFFIENT <span>(prasugrel)</span></div><div>7 hours /4 hours<span> </span>5-7 days before date of surgery<span> </span>Does not need bridging</div><div><div>Pre operative bridgi<span></span>ng with lovenox is requ<span></span>ired for all mecha<span></span>nical heart valves* &amp;  is onl<span></span>y need for atrial fibrilla<span></span>tion when CHAD score is H<span></span>igh** . For low clot risk,  hold an<span></span>ticoagulant per chart ab<span></span>ove. </div></div><div><div>Medications to <span>CONTINUE          <span></span> </span></div><div>to take morning of surgery</div></div><div>Medications to <span>STOP</span> before s<span></span>urgery</div><div><div>CHADS SCORE</div><div> Lovenox to Coumadi<span></span>n</div></div><div><div>Anti-seizure meds</div></div><div><div>ASA:<span></span> <span></span> <span></span> <span></span> <span></span> <span></span> </div><div>Valve Surgery= Last Dose 2 days before surgery       </div><div>CABG only: Stop day before surgery      CABG &amp; </div><div>Valve=Stop day before surgery    (Please follow </div><div>attending preference if different)</div></div><div><div>1 pt for each risk factor present<span>:                            </span></div><div>CHF, HTN, DM, PAD or MI, Age 65-74, </div><div>Female            <span></span> <span></span> <span></span> <span></span> <span></span> <span></span> <span></span> <span></span> </div><div>2 pts for each risk factor present</div></div><div>:                           </div><div><div>Age &gt; 74 years old, Prior stroke or TIA or </div><div>thromboembolism       <span></span> </div></div><div><div>1. Resume oral </div><div>anticoagulant and </div><div>lovenox evening after </div><div>procedure if no bleeding        <span></span> <span></span> </div><div>2. Resume oral </div><div>anticoagulant  + lovenox </div><div>post procedure day 1-3           <span></span> </div></div><div><div>Anti-Psych meds </div></div><div><div>Blood Thinners:<span> see above</span></div><div>SCORE / RISK**</div></div><div><div>Beta-blockers</div></div><div><div>NSAIDS:<span></span><span> stop 7 days before surgery</span></div><div>0-2 = LOW</div></div><div><div>Depression meds</div></div><div><div>Insulin:<span>  Insulin Am dose is normal the day before </span></div><div>surgery. Insulin PM dose is </div></div><div>½<span> dose the evening before </span></div><div><div>surgery. Nothing on the morning of surgery</div></div><div> 3-4 = MODERATE</div><div><div>Inhalers</div></div><div><div>Metformin<span>; stop 48 hours before surgery</span></div><div>5-6 = HIGH</div></div><div><div>Immunosuppressive meds</div></div><div><div>Stop ALL vitami<span></span>ns;<span>1 week prior to surgery</span></div><div>TIA IN PREVIOUS 3 MONTHS = HIGH</div></div><div><div>Methadone</div></div><div><div>Fish oil<span>; stop 5 days before surgery</span></div><div>SEVRE VALVULAR DISEASE = HIGH</div></div><div><div>Nitrates; (Imdur)</div></div><div><div>Herbs<span>; stop asap (many of these have anti-coag <span></span>effects)</span></div></div><div><div>Parkinson&amp;apos;s meds</div></div><div><div>Maltaq (dronedarone)<span>; DO NOT take day<span></span> <span></span>of surgery, </span></div><div>last dose is day before surgery.</div></div><div><div>Proton Pump Inhibitors (PPI&amp;apos;s)</div></div><div>*If Presence of Mechanical Mitral valve<span></span>: <span> </span>References:</div><div><div>Thyroid meds            <span></span> <span></span> <span></span> </div><div>Birth Control Pills</div></div><div><div>1. Last dose coumadin 7 days prior to s<span></span>urgery<span></span> <span></span> <span></span> </div><div>2. Bridge with lovenox as above    <span></span> <span></span> <span></span> <span></span> </div><div>3. <span>Admit to observation d<span></span>ay prior to surgery for </span></div><div>heparin drip (to be stopp<span></span>ed 6 hours before </div><div>surgery). </div></div><div><div>Pernod, G., Godier, A., Gozalo, C., </div><div>Tremey, B., Sie, P. (2010). French clinical </div><div>practice guidelines on the management of<span></span> </div><div>patients on vitamin K antagonist<span></span>s in at-risk </div><div>situations (overdose, risk of bleeding, <span></span>and </div><div>active bleeding). <span>Thrombosis Research, </span></div><div>126, e 167-e174. </div></div><div><div>Brunett, A.E., Mahan, C.E., Vaquez, </div><div>S.R.,Oertel, L.B., Gardcia, D.A.<span></span>, &amp; </div><div>Ansell, J. (2016) Guidance for the </div><div>practical management of direct <span></span>oral </div><div>anticoagulants (DOACs) in VTE </div><div>Treatment. <span>Journal of Thromb </span></div><div>Thrombolysis, 41 : 206-232. </div></div><div><div>Last updated 12/2016</div></div><div><div>                   Pre-procedure Anticoagulation Bridging Recommendations                                                                                                                                                                </div><div>for Cardiac surgery</div></div><div><div>3. Check INR post </div><div>proceudre day 4 and DC </div><div>lovenox if INR theraputic</div></div><div>POS<span></span>T<span></span>-OP: <span>IMAGING</span></div><div>Modality<span> </span>Inpatient Cont<span></span>act Info<span> </span>Misc</div><div>Echocardiogr<span></span>am  </div><div>(viewed in Xcelera)</div><div>Scheduling: 5-4160, 5-4159, </div><div>3-8988</div><div>Reading room: 3-9503</div><div>o <span> </span>Use T<span></span>AVR or TMVR echo order when </div><div>appropriate</div><div>CT (+/- angio) scan  </div><div>(viewed in Centricity)</div><div>Scheduling: 3-6885</div><div>Body reading room: 4-9617</div><div>CVI reading room: 6-2424</div><div>Chest re<span></span>ading room: 3-1346</div><div>Neuro reading r<span></span>oom: 4-3145</div><div>o <span> </span>Gated: ev<span></span>aluates c<span></span>oronaries (Note </div><div></div><div>comments) </div><div>o <span> </span>Pre and pos<span></span>t op aortic disease </div><div>include in comments: <span>Ple<span></span>ase </span></div><div>perform with 3D measurement<span></span>s </div><div>and images for tr<span></span>eatment </div><div>planning and surveillance<span> (use </span></div><div>smart phrase CT<span></span>ANGIO3DIMAGES)</div><div><span> </span></div><div>mapping) used for pre-op Maze </div><div>o <span> </span>Consider need for C<span></span>T chest vs C<span></span>T </div><div>Chest/<span></span>Abdomen/Pelvis</div><div>CT C<span></span>ORONAR<span></span>Y ANGIO  </div><div>(viewed in Centricity)</div><div>Scheduling: 3-6885</div><div>CVI reading room: 6-2424</div><div>o <span> </span>Limited s<span></span>tudy- concentr<span></span>ated on heart </div><div>and coronary arteries (does not </div><div>include thoracic aort<span></span>a)</div><div>o <span> </span>Will always be comple<span></span>ted gated </div><div><span> </span><span></span></div><div>in comments. If p<span></span>atient is in atrial </div><div><span></span></div><div><span></span></div><div>MRI (viewed in </div><div>Centricity)</div><div>Scheduling: 3-6855</div><div>Body reading room: 6-8591</div><div>Cardiac reading r<span></span>oom: </div><div>6-2424</div><div>Neuro reading r<span></span>oom:4-3145</div><div>Vascular lab: 5-5227</div><div>o <span> </span>For Aortic Disease, include c<span></span>omment<span></span>: </div><div>Please perform car<span></span>diac MRI (gated) </div><div>with cross hatching, r<span></span>efer to Dr. </div><div>Fleishman if unsure of prot<span></span>ocol. </div><div>US Carotid </div><div>(viewed in Centricity)</div><div>Vascular lab: 5-5227</div><div>Spirometry with DLCO </div><div>(results in Epic)</div><div>Inpatient: 3-6371</div><div>Adult pulmonary clinic: </div><div>5-7061</div><div>o <span> </span>PFT<span></span>s can be performed by Inpatient </div><div>beside respira<span></span>tor<span></span>y therapis<span></span>t (during </div><div></div><div>FDG PET CT Clinical </div><div>Cardiac Viability with </div><div>resting myoc<span></span>ardial </div><div>perfusion scan (viewed </div><div>in Centricity)</div><div>Scheduling: 3-6885</div><div>Body reading room: 4-9617</div><div>CVI reading room: 6-2424</div><div>Chest re<span></span>ading room: 3-1346</div><div>o <span> </span>Include in comments: t<span></span>esting </div><div>myocardial viability in CAD pa<span></span>tient as </div><div>pre-op work up for CABG</div><div>Venous Ultrasound </div><div>(viewed in Centricity)</div><div>Scheduling: 3-6855</div><div>Reading room: 8-2401</div><div>Arterial Ex<span></span>am/ABIs in </div><div>Vascular clinic (viewed </div><div>in Centricity)</div><div>Vascular lab: 5-5227</div><div>T<span></span>agged WBC scan  </div><div>(viewed in Centricity)</div><div>Nuclear Med scheduling: </div><div>4-4278</div><div>Nuclear Med re<span></span>ading room: </div><div>8-2414</div><div>Nuclear Med techs: 4-5684</div><div><span> </span></div><div>o <span> </span>Nuclear<span></span>- bone</div><div>Cardiac cath  </div><div>(viewed in LifeImage)</div><div>Cath lab ext<span></span>ension: 3-7676</div><div>Cath lab rec<span></span>overy: 3-9317</div><div>o <span> </span>T<span></span>o schedule inpatient, page </div><div>interventional cardiologist on call</div><div>EKG lab<span> </span>3-7121</div><div>1-4987</div><div>o <span> </span>Places long term c<span></span>ardiac monitors on </div><div>discharge</div><div>X-r<span></span>ay<span> </span>62198</div><div>Scheduling: 37030</div><div>Reading room: 87996</div><div>Endoscopy<span> </span>5-8117</div></div><div></div></div>
<div><div><img><div>124<span> </span><span>Referenc<span></span>e Material<span> </span>Referenc<span></span>e Material<span> </span><span>125</span></span></div><div>POS<span></span>T<span></span>-OP:<span> ABG INTERPRET<span></span>A<span></span>TION</span></div><div>pH<span>  /  <span>pC<span></span>O2<span> /  <span>paO2</span> /  <span>Sat %</span> /  <span>Base Decit</span> /  <span>Bicarb</span></span></span></span></div><div>Normal rang<span></span>e 7.35 – 7.45</div><div>&lt; 7.35 Acidosis</div><div>• <span> </span>Look at pCO2</div><div> <span> </span>o <span> </span>If High </div><div><span> <span> respira<span></span>tor<span></span>y acidosis</span></span></div><div> <span> </span>o <span> </span>If normal </div><div><span> <span> metabolic acidosis</span></span></div><div>• <span> </span>How to Fix it<span></span>: </div><div> <span> </span>o <span> </span>Respiratory acidosis: </div><div> <span>• <span> </span>Intubated: increase RR, tidal volume t<span></span>o  </span></div><div> <span>increase minute ventila<span></span>tion</span></div><div> <span>• <span> </span>Extuba<span></span>ted: decrease seda<span></span>tion, Bipap to  </span></div><div> <span>increase ventilation</span></div><div> <span> </span>o <span> </span>Metabolic acidosis:</div><div> <span>• <span> </span>Bicarbonate supplementation</span></div><div> <span>• <span> </span><span>Fu<span></span>rthe<span></span>r wor<span></span>kup f<span></span>or so<span></span>urce: <span></span>Flui<span></span>d status<span></span>, </span> </span></div><div> <span>BMP<span></span>, lactate, et<span></span>c</span></div><div>&gt; 7.45 Alkalosis</div><div>• <span> </span> Look at pCO2</div><div> <span> </span>o <span> </span>If Low </div><div><span> <span> respira<span></span>tor<span></span>y alkalosis</span></span></div><div> <span> </span>o <span> </span>If Normal </div><div><span> <span>Metabolic alk<span></span>alosis</span></span></div><div>• <span> </span>How to Fix it</div><div> <span> </span>o <span> </span>Respiratory alkalosis:</div><div> <span> </span><span>• <span> </span>If intubated: decrease RR, tidal volume</span></div><div> <span> </span><span>• <span> </span>If extubated: c<span></span>ontrol pain, anxiety<span></span>,  </span></div><div> <span>cause of hyperventilation (hypoxia?)</span></div><div> <span> </span>o <span> </span>Metabolic alkalosis:</div><div> <span> </span><span>• <span> </span>Further workup for source: BMP<span></span>, PRBC  </span></div><div> <span>transfusion, overdiur<span></span>esis, etc </span></div><div>pCO2 Normal r<span></span>ange: 35-45</div><div>pCO2 &lt; 35 Respir<span></span>ator<span></span>y alkalosis</div><div>• <span> </span>See pH box (Alkalosis)</div><div>pCO2 &gt;45 Respir<span></span>ator<span></span>y acidosis</div><div>• <span> </span>See pH box (Acidosis)</div><div>Base Decit normal: +/-2 mEq/L; Bicarb normal 22-30</div><div>This is calculated, no<span></span>t measured on the ABG</div><div>Metabolic Acidosis:<span><span></span></span></div><div>• <span> </span>See pH box (Acidosis) above</div><div>Metabolic Alk<span></span>alosis: <span>high bicarbonate, positive b<span></span>ase excess</span></div><div>• <span> </span>See pH box (Alkalosis) below</div><div>PaO2 Normal r<span></span>ange 60-200mmHg; Sat % Normal r<span></span>ange 92-100%</div><div>Increasing O2 c<span></span>ontent</div><div>• <span> </span>Increasing FiO2</div><div>• <span> </span>Increasing NC LPM</div><div>CXR/Ultrasound to assess f<span></span>or</div><div>• <span> </span>Pneumothorax</div><div><span> </span></div><div>• <span> </span>Hemothorax</div><div>• <span> </span>Pneumonia</div><div>Increase PEEP (on ventilat<span></span>or or CPAP<span></span>/BiPap) for </div><div>alveolar recruitment</div><div>Mobilize secretions:</div><div>• <span> </span>Chest PT</div><div>• <span> </span>Suctioning</div><div>• <span> </span>Mucolytics (ie Mucomyst)</div><div>Improve VQ mat<span></span>ching</div><div>• <span> </span>Inhaled bronchodilators (albuterol)</div><div>• <span> </span>Inhaled vasodilators (Flolan, iNO)</div><div>• <span> </span>IPPV<span></span>, incentive spiromet<span></span>er, acapella for </div><div>alveolar recruitment</div><div>• <span> </span>Consider stopping potential shunting </div><div>agents inhibiting hypoxic v<span></span>asoconstriction: </div><div>Clevidipine, Nicardipine, Nitroprusside, NT<span></span>G, </div><div></div><div>POS<span></span>T<span></span>-OP: <span>ADV<span></span>ANCED HEMODYNAMIC </span></div><div>MONIT<span></span>ORING &amp; PULMARY AR<span></span>TERY CA<span></span>THETERS</div><div>Par<span></span>ameter<span> </span>Normal Value</div><div>Cardiac Output (CO)<span> </span>4-8 L/min</div><div>Cardiac Index (CI)<span> </span>2.2-4 L/min/m2</div><div>CVP (central venous pr<span></span>essure aka Right atrial pressure)<span> </span>3-8 mmHg</div><div>P<span></span>A (pulmonar<span></span>y artery) Pressure<span> </span>Sys<span></span>tolic 15-30 mmHg (PAS)</div><div>Diastolic 5-12 mmHg (P<span></span>AD)</div><div>Mean 9-16 (P<span></span>AM)</div><div>PCWP (pulmonary capillar<span></span>y wedge pressure) <span> </span>4-12 mmHg</div><div>PVR (pulmonary vascular resistanc<span></span>e)<span> </span>37-250 dynes/sec/<span></span>cm5</div><div>RV (right ventricular) Pressure<span> </span>Systolic 15-30 mmHg</div><div>Diastolic 3-8 mmHg</div><div>SVR (systemic v<span></span>ascular resistanc<span></span>e)<span> </span>800-1200 dynes/sec/<span></span>cm5</div><div>Preload:<span><span></span><span></span></span></div><div> <span></span><span></span></div><div>Decreased volume, decr<span></span>eased preload</div><div> <span></span><span></span></div><div>Increased volume, incr<span></span>eased preload which may incre<span></span>ase MAP and CO</div><div>Aerlo<span></span>ad:<span> the resistanc<span></span>e that the heart has to overc<span></span>ome, during ever<span></span>y beat, to </span></div><div><span></span><span></span><span></span></div><div>Cardiac index:<span> the volume of blood pumped by the he<span></span>art<span></span>, per minute, per met<span></span>er </span></div><div>square of body surfac<span></span>e area. Cardiac Output = HR x S<span></span>troke Volume</div><div> <span></span><span></span></div><div>Increased C<span></span>O/CI: high circula<span></span>ting volume, increased strength of c<span></span>ontraction, </div><div>early septic shock, vasodila<span></span>tor<span></span>y st<span></span>ate</div><div> <span></span><span></span></div><div>Decreased C<span></span>O/CI: hypovolemia or decre<span></span>ase in ventricular strength of </div><div>contr<span></span>action</div><div>CVP: <span>used to appro<span></span>ximate Right Ventricular End Dias<span></span>tolic Pressur<span></span>e and assesses </span></div><div><span></span></div><div> <span></span><span></span></div><div>Low CVP: hypovolemia, decre<span></span>ased venous return</div><div> <span></span><span></span></div><div>High CVP: hyper<span></span>volemia, right sided heart f<span></span>ailure, tamponade </div><div>Mean Arterial Pr<span></span>essure (MAP):<span> Arterial pressure in the vessels perfusing org<span></span>ans. </span></div><div><span></span><span></span></div><div>syst<span></span>emic vascular resis<span></span>tance (SVR). MAP = [(2 x dias<span></span>tolic)+systolic] / 3</div><div> <span></span><span></span></div><div>Low MAP: hypovolemia, low car<span></span>diac output, or low SVR</div><div> <span></span><span></span></div><div>High MAP: hyper<span></span>volemia, high car<span></span>diac output<span></span>, or high SVR</div><div>Syst<span></span>emic Vascular Resis<span></span>tanc<span></span>e (SVR): <span>measurement of impedance or r<span></span>esistanc<span></span>e </span></div><div><span></span><span></span></div><div> <span></span><span></span></div><div>Increased SVR: hypo<span></span>thermia, vasocons<span></span>trictors, hypovolemia, low c<span></span>ardiac </div><div>output st<span></span>ate</div><div> <span></span><span></span></div><div>Decreased SVR: hyperthermia, v<span></span>asodilators, acidosis, early sep<span></span>tic shock  </div><div>P<span></span>arameter<span></span>s for RV Function/F<span></span>ailure: <span>used in contex<span></span>t of overall clinical pictur<span></span>e</span></div><div>Step-up:<span> <span>mean P<span></span>A pressure – CVP</span></span></div><div><span></span><span> </span><span>&gt;10: adequate RV function</span></div><div><span></span><span> </span><span>&lt; 10: conc<span></span>ern for R<span></span>V dysfunction</span></div><div>P<span></span>APi: <span>pulmonar<span></span>y artery pulsatility index = (P<span></span>A Systolic – P<span></span>A Diastolic) / CVP</span></div><div><span></span><span> </span><span>&gt;2: <span>adequate RV function</span></span></div><div><span></span><span> </span><span>1-2:<span> at risk for RV failur<span></span>e</span></span></div><div><span></span><span> </span><span>&lt; 1:<span> RV failure</span></span></div></div><div></div></div>
<div><div><img><div>126<span> </span><span>Referenc<span></span>e Material<span> </span>Referenc<span></span>e Material<span> </span><span>127</span></span></div><div>Figure 1 P<span></span>A Catheter Wav<span></span>eforms</div><div>Pulmonary Artery Pressure (P<span></span>A Pressure):<span> Blood pressur<span></span>e in the  </span></div><div>pulmonar<span></span>y artery</div><div> <span></span><span></span></div><div><span></span><span></span><span></span></div><div><span></span><span></span><span></span></div><div>Pulmonary Vascular Resis<span></span>tance: <span>me<span></span>asurement of impedance or resis<span></span>tance of </span></div><div><span></span><span></span></div><div> <span></span><span></span></div><div>Increased PVR: hypo<span></span>xia, hypercapnia, pulmonar<span></span>y vascular dise<span></span>ase, PE</div><div>Pulmonary Capillar<span></span>y Wedg<span></span>e Pressure (PCWP): <span>used to appro<span></span>ximate L<span></span>VEDP  </span></div><div><span></span><span></span><span></span></div><div><span></span><span></span><span></span></div><div> <span></span><span></span></div><div>High wedge pressur<span></span>e: L<span></span>V failure, tamponade (c<span></span>ardiac compression), or </div><div>volume overload </div><div>Management of Hemodynamic Der<span></span>angements</div><div>MAP<span> </span>CVP<span> </span>CO/<span></span>CI<span> </span>SVR<span> </span>T<span></span>reatment approach</div><div><span> </span><span> </span><span> </span><span> </span><span>Volume</span></div><div>Normal<span> </span><span><span> </span></span>Normal<span> </span><span><span> </span></span>Diuretic</div><div><span> </span><span> </span><span> </span><span> </span><span>Inotrope</span></div><div><span> </span><span> </span><span> </span><span> </span><span>Vasodilator</span></div><div><span> </span><span> </span><span> </span><span> </span><span>Inotrope/Vasodilator<span></span>/IABP</span></div><div><span> </span><span>Normal<span> </span></span><span> </span><span> </span><span>Vasoc<span></span>onstrictor</span></div><div>Referenc<span></span>es: </div><div>P<span></span>A Catheter Waveform imag<span></span>e: https://www.studyblue.c<span></span>om/notes/note/n/hemodynamic-monitoring/</div><div>deck/3727974</div><div>Bojar<span></span>, RM. (2011) Manual of perioperative c<span></span>are in adult cardiac sur<span></span>gery. (5th edition).</div><div>POS<span></span>T<span></span>-OP: <span>C<span></span>OMMON ICU DRIP<span></span>S</span></div><div>Inotr<span></span>opes/Vasopressors</div><div>Recep<span></span>tor<span> </span>Loca<span></span>tion<span> </span>Action</div><div>Alpha Adrenergeic<span> </span>Vascular w<span></span>alls</div><div>also found in the heart</div><div>Vasocons<span></span>triction</div><div>Increase dur<span></span>ation of </div><div>contr<span></span>action</div><div>Beta 1 Adr<span></span>energic<span> </span>Heart<span> </span>Incre<span></span>ase inotropy and </div><div>chronotropy<span></span>, minimal </div><div>vasoc<span></span>onstriction</div><div>Beta 2 Adr<span></span>energic<span> </span>Blood vessels<span> </span>vascular and nonv<span></span>ascular </div><div>smooth muscle relaxa<span></span>tion</div><div>Dopamine<span> </span>renal, splanchnic </div><div>(mesenteric), cor<span></span>onary, and </div><div>cerebr<span></span>al vascular beds</div><div>vasodilat<span></span>ation</div><div>Drug<span> </span>Mechanism of Action<span> </span>Dose<span> </span><span>Side eects</span></div><div>Epinephrine<span> </span>potent beta-1 adr<span></span>energic receptor activity </div><div>moderat<span></span>e beta-2 and alpha-1 adr<span></span>energic </div><div><span></span></div><div>0.01-.2 mcg<span></span>/</div><div>kg<span></span>/min</div><div>Increases heart r<span></span>ate</div><div>Can induce </div><div>tachy<span></span>arrhythmias and </div><div>ischemia</div><div>Dopamine<span> </span>1 t<span></span>o 2 mcg<span></span>/kg per minute</div><div>• <span> </span>Selective vasodilat<span></span>ation of renal, <span> </span></div><div> <span> </span>mesenteric, cerebral, and c<span></span>oronar<span></span>y beds</div><div>• <span> </span>may increases urine output d/t  </div><div><span> </span></div><div> <span> </span>and by inhibiting aldosterone and renal </div><div> <span> </span>tubular sodium </div><div>5 to 10 mcg/kg per minute</div><div>• <span> </span>stimulat<span></span>es beta-1 adrener<span></span>gic receptors w/  </div><div> <span> </span>increased cardiac output (s<span></span>troke volume)</div><div>• <span> </span>mild alpha adrenergic rec<span></span>eptor activation  </div><div> <span> </span>increases SVR</div><div>&gt;10 mcg<span></span>/kg per minute</div><div>• <span> </span>stimulation of alpha-adrener<span></span>gic receptors,  </div><div> <span> </span>causing vasocons<span></span>triction with an increased  </div><div> <span> </span>SVR</div><div>1-20mcg<span></span>/kg/</div><div>min</div><div>tachycar<span></span>dia, arrhythmias </div><div></div><div>mcg<span></span>/kg/minute</div><div>Milrinone<span> </span>Selective phosphodiesterase (PDE) inhibitor </div><div>in cardiac and vascular tissue, r<span></span>esulting in </div><div>vasodilation (pulmonary and systemic) and </div><div>increased inotr<span></span>opy with little chronotropic </div><div>activity.</div><div>.1-.5mcg<span></span>/kg/</div><div>min</div><div>Caution </div><div>with renal </div><div>impairment</div><div>May cause peripheral </div><div>vasodilation, </div><div>hypotension, and/<span></span>or </div><div>ventricular arrhythmia</div><div>Dobutamine<span> </span>Stimulat<span></span>es beta-1 adr<span></span>energic recep<span></span>tor, </div><div>increases inotr<span></span>opy and chronotropy and </div><div><span></span></div><div>2 to 20 mcg/</div><div>kg<span></span>/minute</div><div>Can cause hypotension</div><div>Vasopressin<span> </span>Increases cyclic adenosine monophosphate </div><div>(cAMP). Direct vasoc<span></span>onstrictor without </div><div><span></span><span></span></div><div>SVR &amp; MAP</div><div>.01-.04 units/</div><div>min</div><div>May decrease s<span></span>troke </div><div>volume and cardiac </div><div>output in myocardial </div><div>dysfunction or precipit<span></span>ate </div><div>ischemia in coronary </div><div>artery disease.</div><div>Norepinephrine<span> </span><span>S<span></span>timulates both alpha-1 and beta-1 adrener<span></span>gic </span></div><div>recept<span></span>ors; potent vasocons<span></span>triction &amp; modest </div><div>increase in car<span></span>diac output</div><div>1-20mcg<span></span>/min<span> </span><span></span></div><div>Phenylephrine<span> </span>Pure alpha-adrenergic agonist. Causes </div><div>vasocons<span></span>triction with minimal cardiac inotropy </div><div>or chronotropy<span></span>.</div><div>10-300mcg<span></span>/</div><div>min</div><div>May decrease s<span></span>troke </div><div>volume and cardiac </div><div>output in patients with </div><div>cardiac dysfunction</div><div><span></span></div><div>Isuprel<span> </span>Stimulates beta-1 adr<span></span>energic receptors.</div><div>Inotropic and chrono<span></span>tropic agent</div><div>1-10 mcg<span></span>/min<span> </span><span></span></div><div>adrenergic rec<span></span>eptor </div><div>causes vasodilation and a </div><div>decrease in MAP</div></div><div></div></div>
<div><div><img><div>128<span> </span><span>Referenc<span></span>e Material<span> </span>Referenc<span></span>e Material<span> </span><span>129</span></span></div><div>V<span></span>asodilators</div><div>Drug<span> </span>Mechanism of Action<span> </span>Dose<span> </span><span>Side eects</span></div><div>Clevidipine<span> </span>Calcium channel blocker<span></span>, ultra short-acting </div><div>selective arteriolar vasodila<span></span>tor, reduc<span></span>e </div><div><span></span></div><div>pressures or causing</div><div>1-16 mg<span></span>/hr<span> </span>Pulmonar<span></span>y shunt </div><div>physiology and hypoxia </div><div>from inhibition of hypoxic </div><div>vasocons<span></span>triction</div><div>Nicardipine<span> </span>A short-acting calcium channel blocker<span> </span>2.5-15mg<span></span>/hr  <span> </span>Contraindicated in </div><div>severe AS</div><div>Sodium </div><div>Nitroprusside</div><div>An arterial and venous vasodila<span></span>tor that </div><div><span></span></div><div>immediate onset of ac<span></span>tion</div><div>0.1- 3mcg<span></span>/</div><div>kg<span></span>/min</div><div>Prolong use (&gt;72hrs) and </div><div>high dose (&gt;3mcg<span></span>/kg/</div><div>min) can cause cyanide </div><div>and thiocyanate t<span></span>oxicity</div><div>Nitroglycerine<span> </span>A direct v<span></span>asodilator<span></span>, primarily venodialtor, </div><div>arteriodilator a<span></span>t high dose. </div><div>Adjunct therapy for HTN</div><div>0.1-2 mcg<span></span>/</div><div>kg<span></span>/min</div><div>Esmolol<span> </span><span><span></span></span></div><div>blocking agent</div><div>Dose: 25-</div><div>300mcg<span></span>/kg/</div><div>min</div><div>Large volume infusion, </div><div>may contribute t<span></span>o volume </div><div>overload</div><div>Labetalol<span> </span><span><span></span></span></div><div></div><div>Blocker<span></span>. </div><div>0.5-3 mg<span></span>/min</div><div>Hydralazine<span> </span><span>A direct-ac<span></span>ting arteriolar vasodilator <span> </span>10-20mg IV </span></div><div>push</div><div>Avoid in patients with </div><div>ischemic heart disease </div><div>and dissecting aneurysm</div><div>POS<span></span>T<span></span>-OP: <span>C<span></span>OMMON PO MEDS</span></div><div>Beta Block<span></span>ers</div><div>Drug<span> </span>Usual Dose<span> </span>Misc Info</div><div>Atenolol<span> </span>25-50mg PO qd<span> </span>Beta 1 selectivity, bet<span></span>ter for HR control </div><div>Metoprolol<span> </span>2.5-100mg qD<span> </span>Beta 1 selectivity<span></span>, better f<span></span>or HR control </div><div>T<span></span>oprol XL<span> </span>25-100mg qD<span> </span>Beta 1 selectivity, bet<span></span>ter for HR control</div><div>Avoid long acting BB in ICU, choose short acting </div><div>for easier titr<span></span>ation. </div><div>Carvedilol <span> </span>3.125-25mg BID<span> </span>Beta and Alpha block<span></span>age, better for Sys<span></span>tolic HF</div><div>Labetolol<span> </span>100-400mg PO QID<span> </span>Beta 2 and Alpha block<span></span>ade</div><div>Nevibolol (Bystolic) <span> </span>5-40mg PO qD<span> </span>Beta 1 selec<span></span>tivity</div><div>Beta Calcium Channel Block<span></span>ers</div><div>Drug<span> </span>Usual Dose<span> </span>Misc Info</div><div>Dihydropryidines: potent vasodilators, little or no eect on c<span></span>ontractility or conduction</div><div>     Amlodipine<span> </span>2.5-10mg PO qD<span> </span>Mainly for HTN &amp; angina</div><div>     Nicardipine<span> </span>20-40mg PO TID<span> </span>Mainly for HTN &amp; angina</div><div>     Nifedipine<span> </span>10-30mg PO/SL TID<span> </span>Mainly for HTN &amp; angina</div><div>Non dihydropryidines: eect cardiac c<span></span>ontractility and conduction</div><div>     Diltiazem<span> </span>30-60mg PO TID</div><div>180-360mg qD if long acting</div><div>Heart ra<span></span>te control/HTN</div><div>     Verap<span></span>amil<span> </span>80-160mg PO TID<span> </span>Useful for angina</div><div>Nitra<span></span>tes</div><div>Drug<span> </span>Usual Dose<span> </span>Misc Info</div><div>Isosorbide </div><div>mononitrat<span></span>e (Imdur)</div><div>20mg PO qD<span> </span>Wat<span></span>ch for Headache</div><div>Isosorbide dinitrat<span></span>e </div><div>(Isordil)</div><div>5-40mg PO TID<span> </span>Wat<span></span>ch for Headache</div><div>Nitropas<span></span>te<span> </span>1-3 in q3-4 hr<span> </span>Wat<span></span>ch for Headache</div><div>ACE inhibitors</div><div>(Avoid in acute r<span></span>enal dysfunction, adjust dose for moderate renal failure)</div><div>Drug<span> </span>Usual Dose<span> </span>Misc Info</div><div>Losartan (Coz<span></span>aar)<span> </span>25-100mg PO qD or in 2 divided </div><div>doses</div><div>Valsartan  (Diov<span></span>an)<span> </span>80-160mg PO qD</div><div>Irbesartan (Av<span></span>apro)<span> </span>150-300mg PO qD</div><div>Cadesartan (At<span></span>acand)<span> </span>8-32mg PO qD or in 2 divided </div><div>doses</div><div>Alpha Blockers</div><div>Drug<span> </span>Usual Dose<span> </span>Misc Info</div><div>Alpha 1 antagonist</div><div>     Doxazosin (Car<span></span>dura)<span> </span>1.0-8mg PO qD<span> </span>Good for BPH</div><div>     Prazosin (Minipress)<span> </span>1.0-7.5mg PO BID</div><div>     T<span></span>erazosin (hytrin)<span> </span>1-20mg PO qD<span> </span>Good for BPH, Slows HR, watch f<span></span>or  </div><div>orthost<span></span>atic h0tn</div><div>Alpha 2 antagonist</div><div>     Clonidine (Catapr<span></span>es)<span> </span>0.1-0.3mg PO BID<span> </span>Slows HR, good for nico<span></span>tine withdrawal sx.  </div><div>Rebound tachyc<span></span>ardia/hypertension if st<span></span>opped</div><div>Antiarrhythmics</div><div>Drug<span> </span>Usual Dose<span> </span>Misc Info</div><div>Amiodarone <span> </span>400mg PO TID, wean to </div><div>200mg qd</div><div>Class III, prolongs action pot<span></span>ential duration</div><div>Digoxin<span> </span>0.125-0.25mg PO qd<span> </span>Leads to incre<span></span>ased contractility through inhibition </div><div>of the Na/K+ A<span></span>TP<span></span>ase pump, promotes calcium </div><div></div><div>Direct suppression of AV node c<span></span>onduction </div><div>Monitor digoxin levels</div><div>Sotalol<span> </span>80mg PO TID<span> </span>Class III, prolongs action potential dura<span></span>tion</div></div><div></div></div>
<div><div><img><div>130<span> </span><span>Referenc<span></span>e Material<span> </span>Referenc<span></span>e Material<span> </span><span>131</span></span></div><div>Diuretics</div><div>Drug<span> </span>Usual Dose<span> </span>Misc Info</div><div>Loop diuretics</div><div>Furosemide (Lasix)<span> </span>10-100mg QID<span> </span>Needs k+ replacement</div><div>Bumex<span> </span>0.5-10mg daily<span> </span>Needs k+ replacement</div><div>If not responding to high dose Lasix, c<span></span>onsider </div><div>switching to Bumex</div><div>Thiazides</div><div>HCT<span></span>Z (Hydrodiuril)<span> </span>50-100mg qD</div><div>Chlorothiazide (Diuril)<span> </span>500mg IV qD</div><div>Metolazone </div><div>(Zarox<span></span>olyn)</div><div>5-20mg qD</div><div>Potassium sparing:</div><div>Eplerenone (Inspra)<span> </span>25-50mg qD</div><div>Spironolactone </div><div>(Aldactone)</div><div>25mg qD</div><div>Carbonic Anhydrase Inhibitor</div><div>Acet<span></span>azolamide </div><div>(Diamox)</div><div>250-500mg IV q6h<span> </span>Increased renal excr<span></span>etion of bicarbonate (used in </div><div>metabolic/<span></span>contraction alk<span></span>alosis)</div><div>Bojar<span></span>, R.M. (2011) Manual of perioperative c<span></span>are in adult cardiac sur<span></span>gery. (5th Edition).</div><div>POS<span></span>T<span></span>-OP: <span>DIAGNOSIS TR<span></span>ANSLA<span></span>TION EXAMPLES</span></div><div>Diagnosis T<span></span>ranslation E<span></span>xamples</div><div>When documenting:<span> </span>Consider<span></span>:</div><div>NPO, tube feeding, TPN, nutrition note: </div><div>diagnosis doc</div><div>Severe protein-calorie malnutrition, underweight</div><div>Altered ment<span></span>al st<span></span>atus, Delirium<span> </span>Encephalophathy<span></span>, type: acute delirium and etiology/cause</div><div>Chest pain<span> </span>Cause of chest pain, CHF<span></span>, MI, CAD</div><div>CHF<span></span>, ESHD<span> </span>Acuity and type of CHF</div><div>Myocardial infar<span></span>ction <span> </span>NSTEMI, STEMI (artery involved)</div><div>Hgb 7.5; 1L EBL, 2U PRBC given<span> </span>Acute blood loss anemia </div><div>Elevated BUN/Cr<span></span>eatinine<span> </span>Acute Kidney Injur<span></span>y and or/ A<span></span>TN</div><div>NA 125/150 with monitor and/<span></span>or treatment<span> </span>Hyponatremia/Hyperna<span></span>tremia</div><div>5,3”<span></span>, 297 lbs<span> </span>BMI &gt; 40, Morbid obesity, overweight</div><div>WBC: 2.0, RBC 2.50, Plt: 75, on chemo<span> </span>Pancytopenia due t<span></span>o chemo</div><div>Hypoxia, Hypoxic, Hyperc<span></span>apnic<span> </span>R<span></span>espiratory Failur<span></span>e (Acuity and Type)</div><div>Urosepsis, Meeting 2 out of 4 SIRS crit<span></span>eria<span> </span>Sepsis due to UTI</div><div>Pneumonia<span> </span>Pneumonia, specify etiology and/or causa<span></span>tive organism</div><div>Fever<span> </span>Link cause of fever</div><div>Hypotensive requir<span></span>e vasoac<span></span>tive drugs<span> </span><span>Shock and T<span></span>ype of Shock (Cardiogenic, Hypovolemic, post op, etc)</span></div><div>POS<span></span>T<span></span>-OP: <span>IIC<span></span>U ADMISSION REQUIREMENT<span></span>S</span></div><div>iICU Admission Criteria</div><div>IV infusions </div><div>(patient mus<span></span>t </div><div>have 3 or less)</div><div> <span></span><span></span></div><div>Dopamine: max r<span></span>ate 10 mcg<span></span>/kg<span></span>/min via centr<span></span>al line</div><div> <span></span><span></span></div><div>Milrinone 0.375mcg<span></span>/kg<span></span>/min max</div><div> <span></span><span></span></div><div>Amiodarone: centr<span></span>al line administra<span></span>tion strongly  </div><div>preferred. Ther<span></span>apy via PIV for 24 hours max. </div><div> <span></span><span></span></div><div>Arga<span></span>troban, heparin </div><div> <span></span><span></span></div><div>Insulin continuous infusion </div><div> <span></span><span></span></div><div>Diltiazem</div><div> <span></span><span></span></div><div>Ket<span></span>amine</div><div> <span></span><span></span></div><div>Esmolol (D1, CSU<span></span>, B2 only)</div><div> <span></span><span></span></div><div>Labetolol</div><div> <span></span><span></span></div><div>Nitroglycerin (f<span></span>or controlling chest p<span></span>ain, 1 hour max)</div><div>T<span></span>empor<span></span>ar<span></span>y </div><div>P<span></span>acemakers</div><div> <span></span><span></span></div><div>Semi-Permanent P<span></span>acemakers </div><div><span></span><span> </span><span>“Floating le<span></span>ad”<span></span>, T<span></span>ransvenous – not allowed</span></div><div><span></span><span> </span><span>“Fixed lead”<span></span>, with external g<span></span>enerator<span></span>- allowed</span></div><div><span></span><span> </span><span>Underlying rhythm/ra<span></span>te irrelevant </span></div><div> </div><div> <span></span><span></span></div><div>T<span></span>emporary Epicardial Wires</div><div><span></span><span> </span><span>If patient is p<span></span>acer dependent, underlying heart </span></div><div>ra<span></span>te must be &gt; 40 and be hemodynamically s<span></span>table</div><div>CP<span></span>AP<span></span>/BiP<span></span>AP</div><div> <span></span><span></span></div><div>Nasal CP<span></span>AP &amp; BIP<span></span>AP for patients es<span></span>tablished on a </div><div>nighttime CP<span></span>AP<span></span>/BiP<span></span>AP (nasal mask) at home for OSA</div><div> <span></span><span></span></div><div>Nasal CP<span></span>AP &amp; BIP<span></span>AP as a ne<span></span>w ther<span></span>apy for respirat<span></span>or<span></span>y </div><div><span></span></div><div>evaluation and for a maximum dur<span></span>ation of 4 hours. </div><div>Requires c<span></span>onsultation of ICU te<span></span>am</div><div> <span></span><span></span></div><div>Full f<span></span>ace mask CP<span></span>AP &amp; BiPAP f<span></span>or patients with OSA is </div><div>permitt<span></span>ed if trea<span></span>tment is an established home ther<span></span>apy and </div><div>patient is able t<span></span>o remove mask</div><div>High Flow </div><div>Nasal Cannula</div><div> <span></span><span></span></div><div>HFNC can be acc<span></span>epted once p<span></span>atients are on st<span></span>able </div><div><span></span><span></span></div><div> <span></span><span></span></div><div>P<span></span>atient must be evalua<span></span>ted ever<span></span>y 4 hours for increasing </div><div>oxygen requir<span></span>ements </div><div>Peric<span></span>ardial </div><div>Drains</div><div> <span></span><span></span></div><div>All Allowed</div><div>Pos<span></span>t Cath </div><div>proc<span></span>edure </div><div>patient<span></span>s</div><div> <span></span><span></span></div><div>F<span></span>ast T<span></span>rack T<span></span>AVRS</div><div> <span></span><span></span></div><div>Pos<span></span>t cardiac cath</div></div><div></div></div>
<div><div><img><div>132<span> </span><span>Referenc<span></span>e Material<span> </span>Referenc<span></span>e Material<span> </span><span>133</span></span></div><div>POS<span></span>T<span></span>-OP: <span>INR GOAL<span></span>S</span></div><div>Bioprosthe<span></span>tic </div><div>Aortic Valve</div><div>Bioprosthe<span></span>tic Mitral </div><div>Valve Replac<span></span>ement</div><div>Mechanical Aortic </div><div>Composite V<span></span>alve</div><div>Mechanical Aortic </div><div>Valve <span>S<span></span>tandard<span> </span></span></div><div>Mechanical Mitral </div><div>Valve </div><div>T<span></span>rans-catheter </div><div>Aortic Valve </div><div>Replacement</div><div>Atrial Fibrillation </div><div>Only</div><div>VTE Prophylaxis </div><div>INR Range (Goal)<span> </span>1.5-2.5<span> </span>2.0-3.0<span> </span>2.5-3.5 (3.0)<span> </span>2.0-3.0</div><div>Level of Evidence<span> </span>B<span> </span>B<span> </span>B<span> </span>B</div><div>Size of T<span></span>reatment </div><div></div><div>Class I<span> </span>Class I<span> </span>Class I<span> </span>Class I</div><div>Duration<span> </span>Lifelong VK<span></span>A<span> </span>Lifelong VKA<span> </span>Lifelong VKA</div><div>Level of Evidence<span> </span>A<span> </span>A<span> </span>A</div><div>Pos<span></span>t-op </div><div>Anticoagula<span></span>tion</div><div><span></span></div><div>surgery once post<span></span>-</div><div>operative bleed no </div><div>longer an issue.</div><div>(No bridge with </div><div>Heparin)</div><div><span></span></div><div>surgery once post<span></span>-</div><div>operative bleed no </div><div>longer an issue.</div><div>(No bridge with </div><div>Heparin)</div><div><span></span></div><div>surgery once post<span></span>-</div><div>operative bleed </div><div>no longer an issue. </div><div>(Bridge with </div><div>Heparin Po<span></span>st Op  </div><div>24-36 Hours)</div><div>Dual antiplatelet </div><div>with clopidogrel </div><div>75mg for 6 months  </div><div>if not on Coumadin</div><div>Unfractiona<span></span>ted </div><div>Heparin 5000 Units </div><div>Subcutaneously </div><div>ever<span></span>y  8 hours </div><div>unless patient is </div><div>bleeding <span>(100 cc </span></div><div>per hour or more)<span> </span></div><div>from Chest tubes</div><div>ASA Y<span></span>/N (dose)<span> </span>Y (81-325mg<span></span>)<span> </span>Y (75-100mg<span></span>)<span> </span>Y (75-100mg)<span> </span>Y (75-100mg<span></span>)<span> </span>Y (75-100mg)<span> </span>Y (75-100mg<span></span>) - </div><div>lifelong</div><div>(75mg-325mg)</div><div>Level of Evidence<span> </span>B<span> </span>A<span> </span>A<span> </span>A<span> </span>C</div><div>Size of T<span></span>reatment </div><div></div><div>Class IIa<span> </span>Class I<span> </span>Class I<span> </span>Class I<span> </span>Class IIb</div><div><span></span><span></span><span></span><span></span><span> </span></div><div>HITT = heparin induc<span></span>ed thrombocytopenia thrombosis</div><div>TIPS FOR CARDIA<span></span>C SURGERY (Blue/Green) ANTIC<span></span>OAGULA<span></span>TION</div><div>*If pa<span></span>tient has more than one indica<span></span>tion for Coumadin use the highest </div><div>INR go<span></span>al.</div><div>IF MECHANICAL MVR:  <span>patient<span></span>s should be started on hep<span></span>arin/arga<span></span>troban drip </span></div><div>post<span></span>op day 1 if no bleeding for bridging to Coumadin.</div><div>IF TEMPORARY P<span></span>ACING WIRES ARE S<span></span>TILL IN:<span> </span>DO NOT LET INR GET ABO<span></span>VE 2.0 </div><div>UNTIL THEY ARE REMOVED.<span>  S<span></span>tay on hep<span></span>arin/arga<span></span>troban drip until p<span></span>acing wires </span></div><div>removed.</div><div>Heparin/<span></span>Arga<span></span>troban drip needs to be st<span></span>opped for 6 hours<span> prior to pacing wir<span></span>e </span></div><div><span></span></div><div>IF ST<span></span>ARTING O<span></span>THER ANTICOAGULANT<span></span>S <span>(like Xarelt<span></span>o, Eliquis, Pradaxa, et<span></span>c.) DO </span></div><div>NOT S<span></span>TART UNTIL TEMPORARY P<span></span>ACING WIRES ARE REMOVED.  IF indicated, use </div><div>heparin/<span></span>argatrob<span></span>an drip until pacing wires are removed if indica<span></span>ted.</div><div>If on multiple blood thinning agents<span> (ie  Aspirin, Plavix, and Coumadin), discuss </span></div><div>with Cardiac Surg<span></span>er<span></span>y that this is ok<span></span>ay.</div><div>All patient<span></span>s are treated if blood t<span></span>est for HIT is positive, whether sympt<span></span>omatic or </div><div>not.  Length of therapy should depend on Hema<span></span>tologist’<span></span>s recommenda<span></span>tion.  </div><div> </div><div>*Additional risk fact<span></span>ors for thromboembolic events (AF<span></span>, previous thromboembolism, L<span></span>V </div><div>dysfunction, or hyperc<span></span>oagulable sta<span></span>te) or an older-gener<span></span>ation mechanical AVR (such as </div><div>ball-in-cag<span></span>e).</div><div>§ It is recommended t<span></span>o not st<span></span>art VKA until platelets have sub<span></span>st<span></span>antially recovered (i.e., </div><div>usually to at le<span></span>ast 150X109/L).  VKA should initially be given in low doses (maximum, </div><div>5 mg of warfarin) o<span></span>ver using higher doses (Grade 1C).  If VKA has already been s<span></span>tarted </div><div>when diagnosed with HIT<span></span>, vitamin K should be adminis<span></span>tered (Gr<span></span>ade 2C).  VKA should be </div><div>overlapped with a nonheparin antic<span></span>oagulant for a minimum of 5 days and until the INR is </div><div>within targ<span></span>et range (Gr<span></span>ade 1C).</div><div>1) <span> </span>Guyatt GH, Akl EA, Cr<span></span>owther M, et al. American College of Chest Physicians Antithr<span></span>ombotic </div><div>Therapy and Prevention of Thrombosis P<span></span>anel. Ex<span></span>ecutive summary: antithrombotic Therapy </div><div>and Prevention of Thrombosis, 9th ed: American Colleg<span></span>e of Chest Physicians Evidence-Based </div><div>Clinical Prac<span></span>tice Guidelines.  Chest. 2012 Feb;141(2 Suppl):7S-47S. </div><div>2) <span> </span>Januar<span></span>y CT<span></span>, Wann L<span></span>S, Alpert JS, et al. 2014 AHA/AC<span></span>C/HRS Guideline for the Management </div><div>of P<span></span>atients With Atrial Fibrillation: E<span></span>xecutive Summar<span></span>y: A Report of the American Colleg<span></span>e </div><div>of Cardiology/<span></span>American Heart Association T<span></span>ask Force on Pr<span></span>actice Guidelines and the Heart </div><div>Rhythm Society. J Am Coll Car<span></span>diol. 2014 Mar 28. Pii:S0735-1097(14)01739-2.</div><div>3) <span> </span>Kearon C, Akl E, Comerot<span></span>a A, et al. Antithrombotic therapy f<span></span>or VTE disease: Antithrombo<span></span>tic </div><div>Therapy and Prevention of Thrombosis, 9th ed: Americ<span></span>an College of Chest Physicians </div><div>Evidence-Based Clinical Pr<span></span>actice Guidelines. Chest. 2012 Feb; 141 (2 Suppl):e419S-94S.</div><div>4) <span> </span>Linkins LA, Dans AL, Moores LK, et al. T<span></span>reatment and prevention of heparin-induced </div><div>thrombocytopenia: Antithrombotic Ther<span></span>apy and Prevention of Thrombosis, 9th ed: American </div><div>College of Ches<span></span>t Physicians Evidence-Based Clinical Practic<span></span>e Guidelines. Chest. 2012 Feb; </div><div>141(2suppl):e495s-530S.</div><div>5) <span> </span>Nishimura RA, Otto CM, Bonow RO, e<span></span>t al. 2014 AHA/AC<span></span>C guideline for the management of </div><div>patient<span></span>s with valvular heart dise<span></span>ase; a report of the American College of Cardiology/<span></span>American </div><div>Heart Association T<span></span>ask Forc<span></span>e on Practice Guidelines. J Thorac Car<span></span>diovas Surg. 2014 Jul; </div><div>148(1):e1-e132. </div></div><div></div></div>
<div><div><img><div>134<span> </span><span>Referenc<span></span>e Material<span> </span>Referenc<span></span>e Material<span> </span><span>135</span></span></div><div>POS<span></span>T<span></span>-OP: <span>PROPHYLA<span></span>CTIC MEDICA<span></span>TIONS  </span></div><div>(GI, VA-PNA, D<span></span>VT<span></span>, INFECTION)</div><div>Common Prophylactic Medica<span></span>tions</div><div>Pre Op </div><div>(day of surgery)</div><div>ICU<span> </span>iICU</div><div>VA- PNA</div><div>• <span> </span>Peridex 0.12%, 15mL </div><div>swish and spit</div><div>• <span> </span>Peridex 0.12%, 15mL swish and spit </div><div>while intubated</div><div>• <span> </span>N/A</div><div>DVT</div><div>• <span> </span>No DVT prophylaxis </div><div>indicated</div><div>• <span> </span>SCDs</div><div>• <span> </span>Heparin 5000 units subQ q8 hours</div><div>• <span> </span>SCDs</div><div>• <span> </span>Consider subq </div><div>Heparin if not able </div><div>to ambulate</div><div>Surgical </div><div>Prophylaxis </div><div>• <span> </span>2g cefaz<span></span>olin  </div><div>(3g if &gt;120kg)</div><div>• <span> </span>Weight dosed </div><div>vancomycin if PCN </div><div>allergy</div><div>• <span> </span>Antimicrobial shower </div><div>x2 (PM and AM) before </div><div>surgery with either </div><div>chlorhexidine sponges </div><div>(per patient) or wipes </div><div>(per nurse)</div><div>• <span> </span>2g cefaz<span></span>olin (3g if &gt;120kg) x 3 doses </div><div>(24 hours)</div><div>• <span> </span>Weight dosed vancomycin if PCN </div><div>allergy x2 doses (24 hours)</div><div>• <span> </span>N/A</div><div>Lumbar </div><div>Drain</div><div><span> </span></div><div><span></span></div><div>placed</div><div><span> </span></div><div>drain in place</div><div>• <span> </span>N/A</div><div>GI</div><div>• <span> </span>N/A<span> </span>• <span> </span>IV or PO acid suppression therapy for:</div><div> <span> </span>o <span> </span>Mechanical ventilation &gt; 48 hours</div><div> <span> </span>o <span> </span>Plt count &lt; 50, INR &gt; 1.5, or P<span></span>TT 2x  </div><div> <span> </span>baseline</div><div> <span> </span>o <span> </span>Spinal cord injury</div><div> <span> </span>o <span> </span>Solid organ tr<span></span>ansplantation  </div><div> <span> </span>perioperatively in the ICU se<span></span>tting </div><div> <span> </span>o <span> </span>Use of two antiplatelet ag<span></span>ents </div><div> <span> </span>o <span> </span>Any two of the following: Sepsis,  </div><div> <span> </span>ICU st<span></span>ay &gt; 10 days, occult bleeding  </div><div> <span> </span>lasting &gt; 6 days, high dose st<span></span>eroids </div><div>*Ster<span></span>oid use with no other risk fact<span></span>ors </div><div>and NPO st<span></span>atus are NOT indic<span></span>ations for </div><div>stress ulc<span></span>er prophylaxis</div><div>• <span> </span>Acid suppression </div><div>therapy only if </div><div>patient previously </div><div>took at home for </div><div>GERD</div><div>• <span> </span>Literatur<span></span>e DOES </div><div>NOT support str<span></span>ess </div><div>ulcer prophylaxis </div><div>outside of the ICU </div><div>environment</div><div>POS<span></span>T<span></span>-OP: <span>SUPPLEMENT<span></span>AL O2 &amp; VENTILA<span></span>TOR </span></div><div>MANAGEMENT</div><div>Oxyg<span></span>en Administr<span></span>ation</div><div>1. <span> </span><span>Nasal cannula</span></div><div>a.<span> <span> </span><span><span></span><span></span><span></span><span></span><span></span><span></span><span></span><span></span><span></span><span></span><span></span></span></span></div><div>i. <span> </span>FiO2 = 20% + (4 x O2 L/min)</div><div>b.<span> <span> </span><span><span></span><span></span><span></span></span></span></div><div>2. <span> </span><span>F<span></span>ace mask</span></div><div>a. <span> </span><span><span></span></span></div><div>to det<span></span>ermine an accur<span></span>ate FiO2 deliver<span></span>y since 75% of inspir<span></span>ed volume is </div><div>room air</div><div>3. <span> </span><span>Venti mask</span></div><div>a. <span> </span><span>Delivers a precise oxygen c<span></span>oncentration in incr<span></span>ements of 24, 28, 31, 35, </span></div><div>and 40%</div><div>b.<span> <span> </span><span>Inspired volume is a mix of r<span></span>oom air and oxygen. Exhaled air is allowed to </span></span></div><div>exit the mask therefore C<span></span>O2 retention is minimal</div><div>4. <span> </span><span>Non-rebre<span></span>ather mask</span></div><div>a. <span> </span><span><span></span></span></div><div>b.<span> <span> </span><span>There is a one w<span></span>ay valve that prevents the pa<span></span>tient from breathing in r<span></span>oom </span></span></div><div>air<span></span>.  This ensures that a high oxygen conc<span></span>entration is delivered.  Risk of </div><div>CO2 r<span></span>etention</div><div>5. <span> </span><span><span></span></span></div><div>hypoxemia</div><div>a. <span> </span><span>FiO2 range 20-100%, Flow r<span></span>ange 20-50 L/min</span></div><div><span></span><span></span></div><div>b.<span> <span> </span><span><span></span></span></span></div><div>Consider transitioning t<span></span>o regular nasal c<span></span>annula once FiO2 we<span></span>aned to 40-</div><div></div><div>Non-Invasive P<span></span>ositive Pressure V<span></span>entilation (NIPPV)</div><div>1. <span> </span><span>Continuous Positive Airway Pressure (CP<span></span>AP)</span></div><div>a. <span> </span><span>Noninvasive ventilation mode tha<span></span>t delivers positive pressure throughout </span></div><div>the respir<span></span>atory cycle through specialized fac<span></span>e or nasal masks</div><div>b.<span> <span> </span><span>Prescriber mus<span></span>t specify PEEP and FiO2</span></span></div><div>2. <span> </span><span>Bilevel Positive Airway Pressure (Bip<span></span>ap)</span></div><div>a. <span> </span><span>Noninvasive ventilation mode tha<span></span>t delivers </span></div><div>b.<span> <span> </span><span>Prescriber mus<span></span>t set end-expirat<span></span>or<span></span>y pressure (EP<span></span>AP or PEEP) and IP<span></span>AP  </span></span></div><div>c. <span> </span><span>If Bipap is delivered using Dr<span></span>ager or L<span></span>TV vent, the ordered PS is additive </span></div><div>to the level of PEEP<span></span>.  i.e. PS 10 cmH2O &amp; PEEP 5 cmH2O will deliver a to<span></span>tal </div><div>IP<span></span>AP of 15cmH2O  </div><div>d. <span> </span><span>PS is not an additive to PEEP on Respir<span></span>onics Vision and V-60 devices</span></div><div>e. <span> </span><span>Consider placing NG/OG tube if IP<span></span>AP &gt; 20 cm H2O</span></div><div>Ventila<span></span>tor Modes: <span>the most frequently used modes in the CVICU ar<span></span>e </span></div><div>VC<span></span>-AC, VC<span></span>-SIMV and PSV</div><div>1. <span> </span><span>Volume-Controlled V<span></span>entilation (VCV) </span></div><div>a. <span> </span><span>VCV is volume-limited and time-cycled. </span></div><div>b.<span> <span> </span><span>Prescriber mus<span></span>t set a desired tidal volume, respir<span></span>ator<span></span>y r<span></span>ate</span></span></div><div>c. <span> </span><span>The vent will deliver the set VT with ever<span></span>y brea<span></span>th (machine or patient </span></div><div>triggered).  Airway pressure ak<span></span>a peak inspiratory pressure (PIP) will v<span></span>ar<span></span>y </div><div>based on lung mechanics (resis<span></span>tance/<span></span>complianc<span></span>e)</div><div>d. <span> </span><span>Vent setting p<span></span>arameters</span></div><div>i. <span> </span>Minut<span></span>e ventilation 8-10 L/min</div><div>ii.  Tidal Volume (VT) 8-10 mL/kg (&lt; 6 mL/kg for ARDS)</div><div>iii. Plat<span></span>eau air<span></span>way pr<span></span>essures &lt; 30 cm H2O</div><div>2. <span> </span><span>Pressure-Controlled V<span></span>entilation (PCV)</span></div><div>a. <span> </span><span>PCV is pressure-limited and time-cycled.  </span></div><div>b.<span> <span> </span><span>Prescriber mus<span></span>t set desired pressure limit, respir<span></span>ator<span></span>y r<span></span>ate, and </span></span></div><div>inspira<span></span>tory time (I:E ratio)</div><div>c. <span> </span><span><span></span></span></div><div><span></span><span></span><span></span><span></span><span></span></div><div>pressure for the dur<span></span>ation of the inspira<span></span>tory time.  VT will var<span></span>y based on </div><div>lung mechanics</div><div>d. <span> </span><span>Vent setting p<span></span>arameters</span></div><div>i. <span> </span>P<span></span>eak inspira<span></span>tor<span></span>y pressure &lt; 35 cm H2O</div><div>3. <span> </span><span>Assist Control Ventila<span></span>tion (ACV)</span></div><div>a. <span> </span><span>ACV can be either pressur<span></span>e or volume limited</span></div><div>b.<span> <span> </span><span>The ventilat<span></span>or delivers the same set parame<span></span>ters for both mandatory and </span></span></div><div>patient trigg<span></span>ered breaths.  </div></div><div></div></div>
<div><div><img><div>136<span> </span><span>Referenc<span></span>e Material<span> </span>Referenc<span></span>e Material<span> </span><span>137</span></span></div><div>4. <span> </span><span>Synchronized Int<span></span>ermittent Mandat<span></span>or<span></span>y Ventila<span></span>tion (SIMV)</span></div><div>a. <span> </span><span>A<span></span>ssis<span></span>ted breaths are synchr<span></span>onized to coincide with spont<span></span>aneous </span></div><div><span></span></div><div>5. <span> </span><span>Pressure-<span></span>Support Ventila<span></span>tion (PSV)</span></div><div>a. <span> </span><span></span></div><div>b.<span> <span> </span><span>The prescriber se<span></span>ts the pressure support level</span></span></div><div>c. <span> </span><span>Each breath is p<span></span>atient triggered and the tidal volume is determined by </span></div><div><span></span></div><div>6. <span> </span><span>Airway Pressure Release V<span></span>entilation (APRV) </span></div><div>a. <span> </span><span>Alternates be<span></span>tween high/low air<span></span>way pressure and is time-cycled (not </span></div><div>patient trigg<span></span>ered).  Most time is spent at high pressur<span></span>e with a brief c<span></span>ycle </div><div>to low pressur<span></span>e.  Purpose of this type of ventilation is to k<span></span>eep alveoli </div><div>recruited</div><div>7. <span> </span><span>Inverse Ratio Ventila<span></span>tion (IR<span></span>V)</span></div><div>a. <span> </span><span>This mode of ventilation uses a prolonged inspir<span></span>ator<span></span>y time (2:1) in </span></div><div>order to help pr<span></span>event alveolar collapse.  May be used for pa<span></span>tients </div><div>with refr<span></span>actory hypoxemia with conventional modes of ventila<span></span>tion.  </div><div><span></span><span></span><span></span></div><div>PEEP:<span> Pe<span></span>ak end expira<span></span>tory pressure</span></div><div>1. <span> </span><span>Therapeutic Uses: </span></div><div>a. <span> </span><span>P<span></span>atients admitted t<span></span>o ICU on ventilator will be set on PEEP 5cm H20</span></div><div>i. <span> </span>PEEP 5 c<span></span>onsidered a substitute for loss of normal br<span></span>eathing </div><div>“Physiologic PEEP” caused by the presenc<span></span>e of the ETT (endotracheal </div><div>tube)</div><div>ii.  Usually well tolerat<span></span>ed hemodynamically, not much recruitment/O2 </div><div></div><div>b.<span> <span> </span><span>Incre<span></span>asing PEEP to increase P<span></span>aO2</span></span></div><div>i. <span> </span>Incr<span></span>easing PEEP (by 2-5cm H20 increments) will incre<span></span>ase mean airway </div><div>pressure and open previously closed alveoli</div><div>ii.  Increases lung surf<span></span>ace are<span></span>a participating in g<span></span>as exchange</div><div>iii. Decre<span></span>ases VQ/intrapulmonar<span></span>y shunting by improving ventilation t<span></span>o </div><div>perfused lung</div><div>iv. A<span></span>s lung recruitment and P<span></span>aO2 improves, FiO2 may be weaned</div><div>c. <span> </span><span>Cautions with high PEEP</span></div><div>i. <span> </span>Incr<span></span>eased intrathor<span></span>acic pressure decreases venous r<span></span>eturn to the he<span></span>art</div><div>ii.  Increased PEEP leads t<span></span>o increased PVR, leading to mor<span></span>e strain on RV</div><div>iii. Decre<span></span>ased venous return and depressed RV performance may le<span></span>ad to </div><div><span></span></div><div>iv. Should not be used in patient<span></span>s with COPD (leads to incr<span></span>eased VQ </div><div>mismatch)</div><div>v.<span> <span> </span>Monitor for signs of “baro<span></span>trauma:” </span></div><div>1.  Caused by alveolar overdis<span></span>tention</div><div>2.  May present as: pneumothor<span></span>ax, subcutaneous emphysema, </div><div>pneumomediastinum</div><div>Lung Mechanics</div><div>1. <span> </span><span>End-inspira<span></span>tory Peak pressur<span></span>e</span></div><div>a. <span> </span><span><span></span><span></span><span></span></span></div><div>the airways, and elasticity of lungs and chest w<span></span>all</div><div>2. <span> </span><span>End-inspira<span></span>tory Plateau pressur<span></span>e</span></div><div>a. <span> </span><span>Pplat is a direct me<span></span>asurement of the elasticity of the lungs and chest w<span></span>all </span></div><div>(complianc<span></span>e)</div><div>b.<span> <span> </span><span><span></span></span></span></div><div>3. <span> </span><span>Tips</span></div><div>a. <span> </span><span>If peak pressure is elev<span></span>ated and plate<span></span>au pressure is unchang<span></span>ed, there is </span></div><div>an increased r<span></span>esistanc<span></span>e in the airways which may be due to secretions in </div><div>the ETT<span></span>, mucous plug, or acute br<span></span>onchospasm</div><div>b.<span> <span> </span><span>If bo<span></span>th peak and plat<span></span>eau pressures are eleva<span></span>ted, there is decreased </span></span></div><div>complianc<span></span>e of the lungs and/or ches<span></span>t wall.  Causes may include </div><div>pneumothor<span></span>ax<span></span>, at<span></span>electasis, acute pulmonary edema, worsening </div><div>pneumonia, or ARDS</div><div>c. <span> </span><span>If peak pressure is decr<span></span>eased, there is a problem with an air leak in the </span></div><div>ventilator sys<span></span>tem</div><div>d. <span> </span><span>PEEP increases plate<span></span>au pressure</span></div><div>CV-IC<span></span>U Interdisciplinary Rapid E<span></span>xtuba<span></span>tion Prot<span></span>ocol (I-REP)</div><div>1. <span> </span><span>Assess patient to determine if p<span></span>atient meets vent weaning crit<span></span>eria</span></div><div>a. <span> </span><span>Weaning criteria: </span></div><div>i. <span> </span>SpO2 &gt; 92% on FiO2 &lt; 60%</div><div>ii.  PEEP &lt; 8 cm H2O</div><div>iii. T<span></span>emp &gt; 35C</div><div>iv. Hemodynamically st<span></span>able</div><div>v.<span> <span> </span>Chest tube output st<span></span>able</span></div><div>vi. Spontaneous bre<span></span>athing noted (if pa<span></span>tient not over-brea<span></span>thing, </div><div>then reduce r<span></span>espiratory rate by 50% f<span></span>or up to 5 min to assess for </div><div>spontaneous br<span></span>eathing)</div><div>2. <span> </span><span>If patient mee<span></span>ts weaning criteria then reduc<span></span>e respiratory rat<span></span>e to zero as </span></div><div>toler<span></span>ated while maint<span></span>aining EtCO2 &lt; 50.  </div><div>a. <span> </span><span>Goal PSV -  PS 10, PEEP 5, and normal work of br<span></span>eathing with RSBI &lt; 100</span></div><div>3. <span> </span><span>If patient does no<span></span>t tolerate P<span></span>SV<span></span>, return to previous vent settings and r<span></span>eassess</span></div><div>4. <span> </span><span>If toler<span></span>ates P<span></span>SV<span></span>, check ABG and assess neuro to see if p<span></span>atient meet<span></span>s </span></div><div>extub<span></span>ation criteria.</div><div>a. <span> </span><span>Ex<span></span>tubation criteria</span></div><div>i. <span> </span>SpO2 &gt; 92% on FiO2 &lt; 50%</div><div>ii.  EtC<span></span>O2 st<span></span>able and within baseline +/- 10%</div><div>iii. pH &gt; 7.3</div><div>iv. PS 10 and PEEP 5</div><div>v.<span> <span> </span>RSBI &lt; 100 with normal work of brea<span></span>thing</span></div><div>vi. If patient does not mee<span></span>t criteria, reassess ever<span></span>y 15 min for a t<span></span>otal of 3 </div><div>cycles</div><div>5. <span> </span><span>If extub<span></span>ation criteria are met, then ok to extub<span></span>ate.  If patient is morbidly obese </span></div><div>or has a h/<span></span>o OSA then extubat<span></span>e to CP<span></span>AP 8-10 cm or Bipap 10/5 for 2 hours</div><div>6. <span> </span><span>If patient is r<span></span>eceiving inhaled Flolan, extuba<span></span>te to HFNC to continue Flolan </span></div><div>administr<span></span>ation </div><div>Miscellaneous </div><div>1. <span> </span><span>Do not change any ventila<span></span>tor settings unless in an emerg<span></span>enc<span></span>y<span></span>.  Please notify </span></div><div>respir<span></span>atory therapy te<span></span>am for all ventilat<span></span>or changes</div><div>2. <span> </span><span>Rapid-shallow bre<span></span>athing index (RBSI) = RR / Lit<span></span>ers of Tidal Volume</span></div><div>a. <span> </span><span>Goal RSBI &lt; 100</span></div><div>b.<span> <span> </span><span>Indica<span></span>tor for appropriateness f<span></span>or extubation (along with ment<span></span>al sta<span></span>tus, </span></span></div><div>amount of secretions, s<span></span>trength of cough, etc)</div><div>3. <span> </span><span>Indirect Calorimetry</span></div><div>a. <span> </span><span>Nutrition is important because <span></span>too few calories c<span></span>auses respiratory muscle </span></div><div>cat<span></span>abolism and muscle weakness.  T<span></span>oo many calories (particularly carbs) </div><div>increases me<span></span>tabolic rat<span></span>e and can result in respira<span></span>tor<span></span>y muscle fatigue or </div><div>hypercapnia due t<span></span>o increased C<span></span>O2 production</div><div>b.<span> <span> </span></span><span>b.<span> <span> </span>Indirect c<span></span>alorimetr<span></span>y is a measurement of r<span></span>esting energy expenditure </span></span></div><div>base<span></span>d o<span></span>n ox<span></span>ygen<span></span> con<span></span>sump<span></span>tion<span></span> (VO<span></span>2) <span></span>and <span></span>carb<span></span>on <span></span>diox<span></span>ide <span></span>prod<span></span>ucti<span></span>on <span></span>(VCO2)</div></div><div></div></div>
<div><div><img><div>138<span> </span><span>Referenc<span></span>e Material<span> </span>Referenc<span></span>e Material<span> </span><span>139</span></span></div><div>POS<span></span>T<span></span>-OP: <span>V<span></span>AD BOWEL REGIMEN PROT<span></span>OC<span></span>OL</span></div><div>St<span></span>andards of Pr<span></span>actice for V<span></span>AD patients t<span></span>o reduce P<span></span>ost<span></span>-po Ileus</div><div>VAD Quality Improvement</div><div>Vincent<span></span>a M. Grassano, RD, CNSC</div><div>Heart F<span></span>ailure Service/D1</div><div>1. <span> </span><span>Initiat<span></span>e bowel re<span></span>gimen the day of admission (Pre-op)</span></div><div>a. <span> </span><span>Senna 2 tabs BID</span></div><div>b.<span> <span> </span><span>Docusat<span></span>e 100mg BID</span></span></div><div>2. <span> </span><span>Escalat<span></span>e bowel regimen if no BM within 24 hours of sur<span></span>gery</span></div><div>a. <span> </span><span>Bisacodyl 10mg per rectum x1 oc<span></span>currence</span></div><div>b.<span> <span> </span><span>Magnesium Citr<span></span>ate 300mL x1 occurrenc<span></span>e (not for patient<span></span>s with renal </span></span></div><div>dysfunction)</div><div>c. <span> </span><span>Check potassium and magnesium</span></div><div>3. <span> </span><span>Adhere to Pr<span></span>e<span></span>-Op diet r<span></span>egimen</span></div><div>a. <span> </span><span>P<span></span>atient to receive die<span></span>t order for recommended PO Diet or TF </span></div><div>(carbohydr<span></span>ate c<span></span>ontaining meal) up to 24 hours bef<span></span>ore surger<span></span>y</div><div>b.<span> <span> </span><span>MD order f<span></span>or Liquid Diet (carbohydrat<span></span>e containing liquids ie juic<span></span>e or </span></span></div><div>Ensure clear) up t<span></span>o 6 hours prior to surger<span></span>y r<span></span>ather than NPO</div><div>c. <span> </span><span>P<span></span>atient to be NPO 6 hours prior to surgery</span></div><div>CVICU Servic<span></span>e / Immediate P<span></span>ost<span></span>-op</div><div>1. <span> </span><span>Resume bowel r<span></span>egimen POD #0</span></div><div>a. <span> </span><span>Senna syrup 10mL via feeding tube BID</span></div><div>b.<span> <span> </span><span>Incre<span></span>ase docusate solution 200mg via feeding tube BID</span></span></div><div>c. <span> </span><span>Add Miralax 1 pack<span></span>et BID</span></div><div>d. <span> </span><span>Bisacodyl 10mg per rectum daily</span></div><div>2. <span> </span><span>Keofeed plac<span></span>ed if unable to ex<span></span>tubate by POD #2</span></div><div>a. <span> </span><span>Allows for early nutrition</span></div><div>b.<span> <span> </span><span>Allows for immedia<span></span>te administra<span></span>tion of bowel regimen/medications</span></span></div><div>3. <span> </span><span>Initiation of Nutrition by POD #2  </span></div><div>(with the potential to mee<span></span>t estimated needs)</div><div>a. <span> </span><span>If intubated initia<span></span>te tube feeds</span></div><div>b.<span> <span> </span><span>Initiat<span></span>e Full liquid or Regular diet (sug<span></span>ar free clear liquid and clear liquid </span></span></div><div>diet do not have po<span></span>tential to meet estima<span></span>ted needs)</div><div>c. <span> </span><span>Supplements if needed</span></div><div>4. <span> </span><span>Escalat<span></span>e bowel regimen POD #4 if no bowel mov<span></span>ement or atus</span></div><div>a. <span> </span><span>Lactulose 20mg TID (NOTE: c<span></span>an cause abdominal discomfort and </span></div><div>cramping)</div><div>b.<span> <span> </span><span>Either: </span></span></div><div>i. <span> </span>Miner<span></span>al oil enema</div><div>ii.  Magnesium citrate (150-300mL) *(no<span></span>t for patients with r<span></span>enal </div><div>dysfunction)</div><div>5. <span> </span><span>KUB POD #5 if no BM of Fla<span></span>tus</span></div><div>6. <span> </span><span>T<span></span>aper down re<span></span>gimen if multiple bowel movement<span></span>s s/p bowel regimen</span></div><div>a. <span> </span><span>Docusate solution/<span></span>capsule 200mg BID: continue as scheduled</span></div><div>b.<span> <span> </span><span>Senna syrup 10mg BID: change scheduled t<span></span>o PRN</span></span></div><div>c. <span> </span><span>Miralax 1 pack<span></span>et BID: change scheduled to PRN</span></div><div>POS<span></span>T<span></span>-OP: <span>END OF LIFE CARE</span></div><div>Use these guidelines to tr<span></span>ansition a patient t<span></span>o comfort c<span></span>are and </div><div>perform discharg<span></span>e as deceased document<span></span>ation </div><div>1. <span> </span><span>F<span></span>amily, p<span></span>atient (if able), ICU team and surgic<span></span>al team agree to withdr<span></span>aw care</span></div><div>2. <span> </span><span>Discontinue <span>all order<span></span>s<span> in Epic (including medications, labs, nursing care </span></span></span></div><div>orders, et<span></span>c)</div><div>3. <span> </span><span>Order the <span>IP ICU End of Lif<span></span>e Order Set (#1791) <span>in Epic</span></span></span></div><div>a. <span> </span><span>Choose the appropriate analg<span></span>esics and anxiolytics as discussed with ICU </span></div><div>at<span></span>tending</div><div>b.<span> <span> </span><span>Order the Comf<span></span>ort Care code st<span></span>atus within the order set </span></span></div><div>4. <span> </span><span>Work with the ICU At<span></span>tending, bedside nurse and respira<span></span>tory care to determine </span></div><div>the sequence of support withdr<span></span>awal</div><div>5. <span> </span><span>Work with the resourc<span></span>e/charg<span></span>e RN to have Chaplain ser<span></span>vices av<span></span>ailable</span></div><div>6. <span> </span><span>Resourc<span></span>e/charg<span></span>e nurse will notify the T<span></span>ransplant Donor Network</span></div><div>7. <span> </span><span>Once the p<span></span>atient has passed, you or ano<span></span>ther licensed provider should </span></div><div>examine the pa<span></span>tient and declare Time of Death </div><div>a. <span> </span><span>Make note of this time, you will use it multiple times in document<span></span>ation</span></div><div>b.<span> <span> </span><span>Y<span></span>ou or the ICU at<span></span>tending should appro<span></span>ach the next of kin about autopsy </span></span></div><div>request</div><div>8. <span> </span><span> <span></span><span>Discharge as Dec<span></span>eased Documentation</span></span></div><div>a. <span> </span><span>Use the Discharge Naviga<span></span>tor and choose the “Discharge as Dece<span></span>ased” tab </span></div><div>locat<span></span>ed at the top of the Dischar<span></span>ge Naviga<span></span>tor</div><div>b.<span> <span> </span><span>Fill in the <span>De<span></span>ath Certica<span></span>te Worksheet <span>by selecting “New Reading” and </span></span></span></span></div><div><span></span></div><div>i. <span> </span>This will be used by Chaplain services to c<span></span>omplete the Death </div><div><span></span></div><div>ii.  <span>Call the Coroner </span>(408-793-1900) to report the de<span></span>ath</div><div>1.  They will ask you the patient’<span></span>s address (located in Demogr<span></span>aphics)</div><div>2.  They will ask Cause of Death and brief synopsis of wha<span></span>t happened</div><div>3.  Document the case/rele<span></span>ase number and the name of the person </div><div>you talk<span></span>ed to in the appropriate spac<span></span>e in Epic</div><div>iii. Complet<span></span>e the “Cause of Death” Document<span></span>ation</div><div>1.  “Cardiopulmonary arrest” is <span>No<span></span>t<span> a viable diagnosis</span></span></div><div>2.  When in doubt, ask the ICU at<span></span>tending what to lis<span></span>t</div><div>c. <span> </span><span>Complete the<span> Dec<span></span>eased Summar<span></span>y <span>within the navig<span></span>ator</span></span></span></div><div><span> </span><span></span><span></span></div><div>ii.  Select the ICU At<span></span>tending as the cosigner</div><div>d. <span> </span><span>Complete the <span>Discharge Summary</span></span></div><div><span> </span><span></span><span></span><span></span><span></span></div><div>ii.  Delete non-applicable sections as needed</div><div>iii. Same informa<span></span>tion as the Deceased Summar<span></span>y<span></span>, may copy-past<span></span>e </div><div>iv. List the Surgic<span></span>al at<span></span>tending as the cosigner </div><div>9. <span> </span><span>Write the <span>Discharg<span></span>e Order</span></span></div><div>a. <span> </span><span>Disposition: Deceased</span></div></div><div></div></div>
<div><div><img><div>140<span> </span><span>Referenc<span></span>e Material<span> </span>Referenc<span></span>e Material<span> </span><span>141</span></span></div><div>POS<span></span>T<span></span>-OP: <span>P<span></span>A<span></span>TIENT PROGRESSION CHECKLIS<span></span>T</span></div><div>P<span></span>atient Progression T<span></span>owar<span></span>ds Discharg<span></span>e</div><div> <span></span><span></span></div><div>P<span></span>ain- well controlled with or<span></span>al meds</div><div><span></span><span> </span><span>Remove OnQ (Bupivicaine pump) 1 day prior t<span></span>o discharge))</span></div><div> <span></span><span></span></div><div>Remove devices (Ches<span></span>t tubes, Pac<span></span>er wires, Foley, A-line)</div><div> <span></span><span></span></div><div>T<span></span>ransition to PO Medica<span></span>tions</div><div><span></span><span> </span><span>ASA, st<span></span>atin</span></div><div><span></span><span> </span><span>Bet<span></span>a-Blocker if applicable</span></div><div><span></span><span> </span><span>Need for Antico<span></span>agulation? T<span></span>ransition to PO antico<span></span>agulants</span></div><div><span></span><span> </span><span>Adequate diur<span></span>esis? T<span></span>ransition to PO diur<span></span>etics</span></div><div><span></span><span> </span><span>Do any medications r<span></span>equire prior authoriz<span></span>ation? (Consult with Case </span></div><div>manager)</div><div> <span></span><span></span></div><div>Commonly prescribed medica<span></span>tions requiring prior authoriz<span></span>ation </div><div>include: NOAC (Eliquis, xar<span></span>elto), oxycontin</div><div> <span></span><span></span></div><div>T<span></span>olerating die<span></span>t<span></span>, BM since sur<span></span>ger<span></span>y</div><div><span></span><span> </span><span>Pos<span></span>t-opera<span></span>tive imaging (consult with chief resident/surgical att<span></span>ending<span></span>) </span></div><div><span></span><span> </span><span>CT sc<span></span>an +/- Echo (surg<span></span>eon and opera<span></span>tion dependent)</span></div><div><span></span><span> </span><span>2-view CXR (done in radiology suite) at dry weight prior to discharge</span></div><div> <span></span><span></span></div><div><span></span><span></span></div><div> <span></span><span></span></div><div>PT ev<span></span>al: Home vs. home with home health therapy vs. Skilled Nursing F<span></span>acility</div><div><span></span><span> </span><span>Consult with E-29 Case Manager to s<span></span>tart referr<span></span>al process if needed</span></div><div><span></span><span> </span><span>Contac<span></span>t: 650-847-7453 (work cell-phone)</span></div><div> <span></span><span></span></div><div>Cardiac rehab: Discharg<span></span>e teaching</div><div><span></span><span> </span><span>Cardia Rehab ghos<span></span>t pager<span></span>: 1-5736 </span></div><div> <span></span><span></span></div><div>Est<span></span>ablish follow up appointments with Nurse Coordinat<span></span>or (PCP<span></span>, Cardiologist, </div><div>INR clinic, etc). Cont<span></span>act via cell-phone:</div><div><span></span><span> </span><span>Dr<span></span>. Boyd, Dr. Ha: <span>Sally Eastman</span> 650-627-6373</span></div><div><span></span><span> </span><span>Dr<span></span>. Woo: <span>Ashley Liang</span> 650-683-0114</span></div><div><span></span><span> </span><span>Dr<span></span>. Lee, Dr. Hiesing<span></span>er<span></span>: <span>Pres Lorenzo</span> 650-850-2828</span></div><div><span></span><span> </span><span>Dr<span></span>. Fischbein, Miller<span></span>: <span>Judi Lachenmyer</span> 650-498-7731 (ext 87731) </span></div><div>NO<span></span>TES</div></div><div></div></div>
<div><div><img><div>142<span> </span><span>Referenc<span></span>e Material<span> </span>Referenc<span></span>e Material<span> </span><span>143</span></span></div><div>NO<span></span>TES<span> </span>NO<span></span>TES</div></div><div></div></div>
<div><div><img><div>144<span> </span><span>Referenc<span></span>e Material</span></div><div>DEP<span></span>ARTMENT OF CARDIO<span></span>THORACIC  </div><div>SURGERY HANDBOOK<span></span>—<span></span>VERSION II</div><div>F<span></span>aculty Advisors:</div><div>Y<span></span>. Joseph Woo, MD</div><div>Jack H. Boyd, MD</div><div>Charles Hill, MD</div><div>Charlene Kell, EMBA, BSN, RN, C<span></span>CRN, FACHE, NEA-BC</div><div>Anson M. Lee, MD</div><div>Kapilkumar N. P<span></span>atel, MD</div><div> </div><div>Contributing Authors:</div><div>Scarlet<span></span>te Aliga-Cabamung<span></span>an, MS, RN, AGACNP-BC</div><div>Irina Axelrod, P<span></span>A-C</div><div>Christ<span></span>opher J. Bilb<span></span>ao, DO</div><div>Sarah Boo<span></span>th, ACNPC-AG, MSN, C<span></span>CRN</div><div>Zoe Chan, P<span></span>A-C</div><div>Kristie Duoss, MSN, ACNP<span></span>-BC</div><div>Clara Geor<span></span>ge, NP</div><div>Hilar<span></span>y C. Hammond, MMS, P<span></span>A-C</div><div>Christine Hartley, RN, MS, A<span></span>CNP-BC</div><div>Aleya Hyderi, P<span></span>A-C</div><div>Kelly Juarez, MP<span></span>AS, P<span></span>A-C</div><div>Y<span></span>ukfung Lee, P<span></span>A-C</div><div>Xin Ma, MMS, P<span></span>A-C </div><div>Erica Mikhli, P<span></span>A-C</div><div>Shari Miller<span></span>, PA-C, F<span></span>AP<span></span>ACVS</div><div>Mykl Morrissey, MSN, RN, AGACNP<span></span>-BC</div><div>Richard Quitevis, MS, RN, AGACNP<span></span>-BC</div><div>Hardeep Reddick, MBA, P<span></span>A-C</div><div>Suzanne Sewell, MSN, RN, FNP<span></span>-BC</div><div>Joe Simmons, MS,ACNP<span></span>-BC</div><div>Tim Shieh, P<span></span>A-C</div><div>Y<span></span>. Ke<span></span>vin Z<span></span>eng, MS, AGACNP<span></span>-BC, RN</div><div> </div><div>Contributing Editor<span></span>s: </div><div>Megan A<span></span>tashroo, MSN, RN-F<span></span>A, FNP-BC</div><div>Mar<span></span>y Sheridan Bilbao<span></span>, MPAS, P<span></span>A-C, FAP<span></span>ACVS</div><div>Corinne Pog<span></span>emiller, MMSc, P<span></span>A-C</div><div>Emily T<span></span>ognozzi, MMS, P<span></span>A-C</div><div>Disclaimers:</div><div>Although care has been t<span></span>aken to ensure the accur<span></span>acy of content of this </div><div>handbook, it should not be a substitute f<span></span>or clinical judgment<span></span>. Neither the </div><div>authors nor editors assume any liability for injuries and or damag<span></span>e relat<span></span>ed to this </div><div>publication.</div><div>For internal use only<span></span>, not for sale or re-distribution. Use f<span></span>or intended audience </div><div>only. No<span></span>t for pa<span></span>tient education.  </div></div><div></div></div>
</div>
<div>
<img>
</div>
</body>
</div>><span></span><span></span></div><div> <span></span><span></span></div><div>Grade 2 - P<span></span>aO2/FiO2 between 200 and 300</div><div> <span></span><span></span></div><div>Grade 3 - P<span></span>aO2/FiO2 &lt;200</div><div><span></span><span> </span><span>T<span></span>reatment</span></div><div> <span></span><span></span></div><div>T<span></span>reatment is f<span></span>ocused on providing supportive car<span></span>e</div><div> <span></span><span></span></div><div>For hypox<span></span>emia, increase FiO2 and PEEP<span></span>.  </div><div> <span></span><span></span></div><div>Consider increasing seda<span></span>tion to improve ventilator synchrony</div><div> <span></span><span></span></div><div>Avoid neuromuscular blockade (risk for myop<span></span>athy)</div><div> <span></span><span></span></div><div>Inhaled pulmonar<span></span>y v<span></span>asodilators such as iNO and Flolan are used to </div><div>improve ventilation-perfusion misma<span></span>tch and lower mean pulmonary </div><div>artery pressures</div><div> <span></span><span></span></div><div>Use lung prot<span></span>ective ventilation str<span></span>ate<span></span>gies with low tidal volume</div><div> <span></span><span></span></div><div>Diuresis for g<span></span>oal CVP &lt; 5</div><div> <span></span><span></span></div><div>Consider extr<span></span>acorporeal membr<span></span>ane oxygenation (ECMO) for p<span></span>atients </div><div>with severe PGD who do not respond t<span></span>o maximal conventional </div><div>trea<span></span>tment and inhaled pulmonar<span></span>y vasodilators</div><div> <span></span><span></span></div><div></div><div> <span></span><span></span></div><div>Acute Rejec<span></span>tion</div><div><span></span><span> </span><span>Acute cellular r<span></span>ejection</span></div><div> <span></span><span></span></div><div>A1 – Repea<span></span>t biopsy in 4-6 weeks</div><div> <span></span><span></span></div><div>T<span></span>reat b<span></span>ased on clinical symptoms</div><div> <span></span><span></span></div><div>A2-A3</div><div> <span></span><span></span></div><div>Methylprednisone 10 mg<span></span>/kg IV daily x 3d</div><div> <span></span><span></span></div><div>Valvyte 900 mg PO daily x14d</div><div> <span></span><span></span></div><div>Repea<span></span>t biopsy in 4-6 weeks</div><div> <span></span><span></span></div><div>A4</div><div> <span></span><span></span></div><div>Methylprednisone 10 mg<span></span>/kg IV daily x3d</div><div> <span></span><span></span></div><div>Valcyte 900 mg PO daily x14d</div><div> <span></span><span></span></div><div>Prednisone t<span></span>aper dose 1 mg<span></span>/kg over 14d then back to b<span></span>aseline dose</div><div> <span></span><span></span></div><div>Repea<span></span>t biopsy in 4-6 weeks</div><div><span></span><span> </span><span>Acute antibody mediat<span></span>ed rejection (AMR)</span></div><div> <span></span><span></span></div><div>Day 1-5</div><div> <span></span><span></span></div><div>Plasmapheresis daily x5d.  One volume exchang<span></span>e with albumin.  If </div><div><span></span></div><div> <span></span><span></span></div><div>Day 6-7</div><div> <span></span><span></span></div><div>IVIG 1 gm/kg (IBW) x2d.  </div><div> <span></span><span></span></div><div>Premedica<span></span>te with T<span></span>ylenol 650 mg PO and Benadr<span></span>yl 50 mg PO/IV </div><div>with each dose</div><div> <span></span><span></span></div><div>Days 8 &amp; 15</div><div> <span></span><span></span></div><div>Rituximab 375 mg<span></span>/sq meter BSA IV weekly x2 weeks</div><div> <span></span><span></span></div><div>For refr<span></span>actor<span></span>y AMR</div><div> <span></span><span></span></div><div>Consider the following:</div><div> <span></span><span></span></div><div><span></span><span></span></div><div>Rituximab and RA<span></span>TG dose.</div><div> <span></span><span></span></div><div>If patient has worsening AMR, c<span></span>an give 3-5 doses of RAT<span></span>G (1.5mg<span></span>/</div><div>kg<span></span>/<span></span>day) QOD.        </div><div> <span></span><span></span></div><div>Bortezomib IV</div><div> <span></span><span></span></div><div>Photopher<span></span>esis  </div><div>Referenc<span></span>es:</div><div>Moten et al. (2013). P<span></span>ostopera<span></span>tive T<span></span>ransplant in the Critical Care Unit. American Association of Critical </div><div>Care Nurses, 24(4): 345-350. </div><div><span></span><span></span></div><div>Lung T<span></span>ransplant Protoc<span></span>ol        </div></div><div></div></div>
<div><div><img><div>44<span> </span><span>Pos<span></span>t-Op Management<span> </span>Pos<span></span>t-Op Management<span> </span><span>45</span></span></div><div>POS<span></span>T<span></span>-OP:<span> <span>NEUROL<span></span>OGIC:<span> DELIRIUM</span></span></span></div><div> <span></span><span></span></div><div>Represents an acut<span></span>e change in a patient’<span></span>s mental st<span></span>atus that is associated </div><div>with a global impairment in c<span></span>ognitive function</div><div> <span></span><span></span></div><div>Common, incidence 8-10% over<span></span>all (up to 20% in elderly patients)</div><div> <span></span><span></span></div><div>Etiology frequently not cle<span></span>ar</div><div><span></span><span> </span><span>may result from microemboliz<span></span>ation associated with CPB and associa<span></span>ted </span></div><div>aortic manipulations</div><div><span></span><span> </span><span>may result from mild c<span></span>erebral hypo perfusion</span></div><div> <span></span><span></span></div><div><span></span></div><div>Common Contributing Causes:</div><div> <span></span><span></span></div><div>medication t<span></span>oxicity (including benzodiaz<span></span>epines and analgesics_</div><div> <span></span><span></span></div><div>met<span></span>abolic disturb<span></span>ances</div><div> <span></span><span></span></div><div>Prolonged IC<span></span>U st<span></span>ay</div><div> <span></span><span></span></div><div>alcohol withdr<span></span>awal</div><div> <span></span><span></span></div><div>low cardiac output syndromes</div><div> <span></span><span></span></div><div><span></span><span></span></div><div>threshold for c<span></span>erebral infar<span></span>ction</div><div> <span></span><span></span></div><div>hypoxia</div><div> <span></span><span></span></div><div>sepsis</div><div> <span></span><span></span></div><div>recent/new strok<span></span>e</div><div>Manifes<span></span>tations:</div><div> <span></span><span></span></div><div><span></span></div><div>wake cycle</div><div> <span></span><span></span></div><div>lethargy or agita<span></span>tion</div><div> <span></span><span></span></div><div>par<span></span>anoia and hallucinations</div><div>Ev<span></span>aluation:</div><div> <span></span><span></span></div><div>Consider psych consult for severe delirium </div><div> <span></span><span></span></div><div>review of current medications and drug levels</div><div> <span></span><span></span></div><div>identify possible hist<span></span>or<span></span>y of rec<span></span>ent alcoholism or subst<span></span>ance abuse</div><div> <span></span><span></span></div><div><span></span><span></span><span></span><span></span></div><div> <span></span><span></span></div><div>ABG, electrolyt<span></span>es, BUN, crea<span></span>tinine, CBC, Mg, calcium, cultures</div><div>Management:</div><div> <span></span><span></span></div><div><span></span></div><div> <span></span><span></span></div><div>correc<span></span>t metabolic abnormalities</div><div> <span></span><span></span></div><div>st<span></span>op inappropriat<span></span>e medications</div><div> <span></span><span></span></div><div>select appropria<span></span>te medica<span></span>tion to contr<span></span>ol agitation in the delirious st<span></span>ate</div><div><span></span><span> </span><span>Haldol 2.5-5mg PO/IV q6h mos<span></span>t commonly prescribed (risk of torsades)</span></div><div> <span></span><span></span></div><div>check daily EKG to ev<span></span>al QTC</div><div> <span></span><span></span></div><div>sometimes makes delirium worse!</div><div><span></span><span> </span><span>Seroquel 12.5-50mg, TID </span></div><div><span></span><span> </span><span>Precedex drip may be needed while in the IC<span></span>U. Consider PO version </span></div><div>(T<span></span>enex) </div><div><span></span><span> </span><span>Zyprex<span></span>a 5-10 mg daily</span></div><div> <span></span><span></span></div><div></div><div> <span></span><span></span></div><div>Use melatonin 3-6 mg qhs t<span></span>o help reorient sleep/wake cycle</div><div> <span></span><span></span></div><div>When in doubt, call psychiatry to aid in management</div><div> <span></span><span></span></div><div>Benzos may exac<span></span>erbate acute delirium and should be used only when </div><div>managing concurrent alc<span></span>ohol withdrawal</div><div> <span></span><span></span></div><div>Manage suspect<span></span>ed alcohol withdr<span></span>awal</div><div><span></span><span> </span><span>Benzos usually indica<span></span>ted for several days then should be gr<span></span>adually </span></div><div>taper<span></span>ed</div><div><span></span><span> </span><span><span></span><span></span><span></span></span></div><div>extub<span></span>ation if self-destructive behavior</div><div><span></span><span> </span><span>Also give thiamine 100 mg bid and folic acid 1 mg daily</span></div><div>Referenc<span></span>es:</div><div>Bojar<span></span>, Robert M. (2011) Manual of Perioper<span></span>ative Care in Adult Cardiac Surgery. (5th  <span></span>edition).</div><div>POS<span></span>T<span></span>-OP:<span> <span>NEUROL<span></span>OGIC:<span> P<span></span>AIN C<span></span>ONTROL</span></span></span></div><div>St<span></span>anding P<span></span>ain medication orders:</div><div>Ace<span></span>taminophen</div><div>Dosing:</div><div> <span></span><span></span></div><div>650 - 1000 mg, oral/r<span></span>ect<span></span>al, ever<span></span>y 6-8 hours (IV T<span></span>ylenol should ne<span></span>ver be used)</div><div><span></span><span> </span><span>Abnormal liver function: 500 mg ever<span></span>y 6 hours</span></div><div>Gabapentin</div><div>Dosing:</div><div> <span></span><span></span></div><div>CrCl &gt; 60: 300 mg, oral, thr<span></span>ee times daily</div><div> <span></span><span></span></div><div>CrCl &gt; 15 but &lt; 60: 100 mg, oral, thr<span></span>ee times daily</div><div> <span></span><span></span></div><div>CrCl &lt; 15 and dialysis: 100 mg, oral, daily</div><div><span></span><span> </span><span>If patient no<span></span>t sedated and having pain, it is re<span></span>asonable to titrate </span></div><div>gabapentin t<span></span>o 600 mg TID or <span>higher</span> over 2-3 days</div><div> <span></span><span></span></div><div>Works well in adjunt with T<span></span>ylenol</div><div> <span></span><span></span></div><div><span></span><span></span><span></span><span></span></div><div>discharge</div><div> <span></span><span></span></div><div><span></span></div><div>PRN P<span></span>ain Medication Orders:  </div><div>(must specify indication mild, moderat<span></span>e, or severe)</div><div>Oxyc<span></span>odone <span> 5-15 mg, oral, ever<span></span>y 3 hours as needed </span></div><div>Hydromorphone <span> 0.2-0.5 mg, intr<span></span>avenous, e<span></span>very 2 hours as needed</span></div><div>T<span></span>ramadol  <span>50 mg q6h prn CrCl &lt;30: avoid use</span></div><div><span></span><span> </span><span>Next s<span></span>tep if Tylenol no<span></span>t enough. Usually best for mild to moder<span></span>ate pain</span></div><div><span></span><span> </span><span><span></span><span></span></span></div><div>Ro<span></span>xicodone <span> 5-15 mg q4h prn</span></div><div><span></span><span> </span><span>Next s<span></span>tep if Tylenol and tr<span></span>amadol not enough for pain. Usually bes<span></span>t for </span></div><div>modera<span></span>te to severe p<span></span>ain. </div><div><span></span><span> </span><span><span></span><span></span><span></span></span></div><div>drowsiness/<span></span>delirium </div><div> <span></span><span></span></div><div>Delirium more prevalent in elderly</div><div>Per<span></span>coc<span></span>et  <span>5/325 mg 1-2 tab PO q4h prn p<span></span>ain</span></div><div><span></span><span> </span><span>Good for severe pain no<span></span>t relieved with roxicodone</span></div><div><span></span><span> </span><span>Do not use if pa<span></span>tient already on st<span></span>anding Tylenol given risk of T<span></span>ylenol </span></div><div>overdose</div></div><div></div></div>
<div><div><img><div>46<span> </span><span>Pos<span></span>t-Op Management<span> </span>Pos<span></span>t-Op Management<span> </span><span>47</span></span></div><div>Dilaudid <span> 2-4 mg PO q4h prn pain, 0.5-1mg IV q3h prn pain, PCA</span></div><div><span></span><span> </span><span>Used if pain not r<span></span>elie<span></span>ved by ro<span></span>xicodone</span></div><div><span></span><span> </span><span>Also grea<span></span>t for acute pain exac<span></span>erbations</span></div><div><span></span><span> </span><span>If require PCA, c<span></span>ontact pain service to help manage </span></div><div>Oxyc<span></span>odone <span>10-20mg PO q12 hours</span></div><div><span></span><span> </span><span>Consider if not achieving adequate PO p<span></span>ain control with short acting </span></div><div>Roxic<span></span>odone</div><div><span></span><span> </span><span>Scheduled q12 intervals. Short acting Roxic<span></span>odone can be taken in </span></div><div>addition for bre<span></span>akthrough pain</div><div>Ibuprofen  <span>400 mg, or<span></span>al, ever<span></span>y 6 hours as needed (Needs surgical te<span></span>am approval)</span></div><div><span></span><span> </span><span>CrCl &gt; 30 but &lt; 60 or age &gt; 65: 200 mg, or<span></span>al, ever<span></span>y 6 hours as needed</span></div><div><span></span><span> </span><span>CrCl &lt;30: avoid use</span></div><div><span></span><span> </span><span>Avoid use with dual antiplatele<span></span>t therapy</span></div><div>Ket<span></span>orolac  <span>15-30 mg, intravenous, ever<span></span>y 6 hours as needed (Needs surgical t<span></span>eam </span></div><div>approval)</div><div><span></span></div><div><span></span><span> </span><span>CrCl &lt;30: avoid use</span></div><div><span></span><span> </span><span>Avoid use with dual antiplatele<span></span>t therapy</span></div><div><span></span><span> </span><span>Only if oral r<span></span>oute unav<span></span>ailable; otherwise give oral pain medica<span></span>tion</span></div><div>IV pain medication IS NO<span></span>T the rst line for patients on the oor<span></span>. Consider increasing </div><div>the dose of oral meds for be<span></span>tter control. The goal is to prepar<span></span>e the patient for </div><div>discharge to home.</div><div>Additional medications y<span></span>ou may see that you can c<span></span>onsider<span></span>:</div><div>Fent<span></span>anyl<span>  25-50mg IV </span></div><div><span></span><span> </span><span>Reserve for severe pain not relieved by roxic<span></span>odone</span></div><div><span></span><span> </span><span>Commonly given prior to ches<span></span>t tube removal f<span></span>or pain prevention, but the </span></div><div>jur<span></span>y is out on whether this is nec<span></span>essar<span></span>y or not!</div><div><span></span><span> </span><span>Caution with this given heavily sedating </span></div><div>Lidocaine infusion  </div><div><span></span><span> </span><span>Commonly st<span></span>arted by ICU team</span></div><div><span></span><span> </span><span>Requires checking daily lidocaine levels</span></div><div><span></span><span> </span><span>Contraindic<span></span>ations:</span></div><div> <span></span><span></span></div><div>First and sec<span></span>ond degree heart block due to risk of worsening he<span></span>art </div><div>block. </div><div><span></span><span> </span><span></span></div><div> <span></span><span></span></div><div><span></span></div><div>numbness and unusual sensations around mouth, me<span></span>tallic t<span></span>aste in </div><div>mouth, ringing in the ears, or lightheadedness and dizziness</div><div> <span></span><span></span></div><div><span></span><span></span></div><div>nausea and vomiting, severe dizziness, decre<span></span>ased hearing, tremors, </div><div>changes in blood pressur<span></span>e and pulse. </div><div> <span></span><span></span></div><div>At serum levels grea<span></span>ter than 12 mcg<span></span>/ml: drowsiness, confusion, </div><div>muscle twitching, convulsions, loss of c<span></span>onsciousness, cardiac </div><div>arrhythmias, cardiac arres<span></span>t</div><div><span></span><span> </span><span><span></span><span></span><span></span></span></div><div>Ket<span></span>amine  <span>0.1 mg<span></span>/kg<span></span>/hr drip, intravenous, continuous</span></div><div><span></span><span> </span><span>Consult acute pain service</span></div><div>Local/R<span></span>egional anesthetic p<span></span>ain modalities</div><div>Epidural</div><div><span></span><span> </span><span>Managed by pain service</span></div><div><span></span><span> </span><span>Commonly used for T<span></span>AAA</span></div><div>Bupivacaine via On Q pump</div><div><span></span><span> </span><span>See referenc<span></span>e <span>page 109</span></span></div><div><span></span><span> </span><span>Commonly used for anterior thor<span></span>acotomy</span></div><div>P<span></span>aravertebr<span></span>al Nerve Block</div><div><span></span><span> </span><span>Managed by pain service</span></div><div><span></span><span> </span><span>Commonly used for myocardial bridg<span></span>e </span></div><div>POS<span></span>T<span></span>-OP:<span> <span>NEUROL<span></span>OGIC:<span> SEIZURES</span></span></span></div><div>A seizure is a “single event char<span></span>acterized by the abnormal exc<span></span>essive synchronized </div><div><span></span><span></span><span></span></div><div>(Kurle, 2010). </div><div>Etiology:</div><div> <span></span><span></span></div><div>The most c<span></span>ommon cause of seizures is str<span></span>oke, 43% within 24 hours of the </div><div>strok<span></span>e</div><div><span></span><span> </span><span>8.9% - hemispheric strok<span></span>e</span></div><div><span></span><span> </span><span>8.6% – ischemic strok<span></span>e</span></div><div><span></span><span> </span><span>10.6% - hemorrhagic strok<span></span>e</span></div><div> <span></span><span></span></div><div>Intraoper<span></span>ative hypoxia, or air or particulat<span></span>e emboli, metabolic </div><div>encephalop<span></span>athy<span></span>, cerebr<span></span>al edema</div><div> <span></span><span></span></div><div>Medications</div><div><span></span><span> </span><span>Lidocaine</span></div><div><span></span><span> </span><span>T<span></span>ranexamic acid (a pro-c<span></span>oagulant not used at SHC).  Amicar is used a<span></span>t </span></div><div><span></span><span></span><span></span></div><div>seizures (though higher r<span></span>ates of renal dysfunction) (Martin, 2011).</div><div><span></span><span> </span><span>Cefazolin (a r<span></span>are complica<span></span>tion), especially in patients with renal </span></div><div></div><div>function</div><div>Incidence:</div><div> <span></span><span></span></div><div>0.1% (CABG) to 5% (complex aortic) (Golds<span></span>tone et al, 2011, Manji et al, 2011, </div><div>McGar<span></span>vey et al, 2013)</div><div> <span></span><span></span></div><div>59% experience 1 recurr<span></span>ence (Manji, 2011), 89% of those are within 24 hours</div><div> <span></span><span></span></div><div>Most lik<span></span>ely to occur be<span></span>tween hours 5-8 postoper<span></span>atively<span> (Manji, 2012)</span></div><div>Risk fac<span></span>tors </div><div> <span></span><span></span></div><div>Intraop:</div><div><span></span><span> </span><span>Dura<span></span>tion of aortic cross-clamp time</span></div><div><span></span><span> </span><span></span></div><div><span></span><span> </span><span>Deep hypothermic circula<span></span>tor<span></span>y arrest</span></div><div><span></span><span> </span><span>Open chamber surgery</span></div><div><span></span><span> </span><span>Complex aortic repair (Sharma, 2014, Golds<span></span>tone, 2011)</span></div><div> <span></span><span></span></div><div>Pos<span></span>top:</div><div><span></span><span> </span><span>Met<span></span>abolic derang<span></span>ements (McGarve<span></span>y<span></span>, 2013)</span></div></div><div></div></div>
<div><div><img><div>48<span> </span><span>Pos<span></span>t-Op Management<span> </span>Pos<span></span>t-Op Management<span> </span><span>49</span></span></div><div>Considera<span></span>tions</div><div>Preopera<span></span>tive<span> </span>Note p<span></span>atients with preexis<span></span>ting seizure disorders and consult Neuro </div><div>Critical Care prior to sur<span></span>ger<span></span>y to make a pos<span></span>top plan.</div><div>Intraoper<span></span>ative<span> </span>These procedures may decr<span></span>ease the incidence of neurologic </div><div>complica<span></span>tions (Goldstone e<span></span>t al, 2011):</div><div> <span></span><span></span></div><div>Epi-aortic scanning before aortic c<span></span>annulation</div><div> <span></span><span></span></div><div></div><div> <span></span><span></span></div><div>Cerebral o<span></span>x<span></span>ygen sa<span></span>turation monitoring</div><div> <span></span><span></span></div><div>Retrogr<span></span>ade cerebral perfusion with hypo<span></span>thermia or deep </div><div>hypothermia during circulat<span></span>or<span></span>y arrest</div><div> <span></span><span></span></div><div>Echocardiogr<span></span>aphy-guided de-airing</div><div>Pos<span></span>toperative</div><div> <span></span><span></span></div><div>Review of medications and labs to identify  </div><div>pro-convulsive agent<span></span>s or toxic serum levels</div><div> <span></span><span></span></div><div>Generally are isola<span></span>ted events.  </div><div> <span></span><span></span></div><div><span></span><span></span><span></span></div><div><span></span><span></span></div><div>Neuro Critical Care t<span></span>eam</div><div>* The terms simple partial, complex partial, and sec<span></span>ondarily generalized are no </div><div>longer used</div><div>Classication<span> </span><span>Origin<span> </span>Clinical </span></div><div>manifest<span></span>ations</div><div>Guide to </div><div>trea<span></span>tment</div><div>Focal seizur<span></span>e </div><div>(previously </div><div>‘partial’)</div><div>Origin and spread </div><div>limited to one </div><div>hemisphere, </div><div>arising from the </div><div>subcortical or </div><div>neocortical r<span></span>egions</div><div>Can involve twitching of </div><div>a limb, a sense of fear<span></span>, an </div><div>unpleasant smell (aur<span></span>a) </div><div>and patient<span></span>s may be </div><div>conscious of having them </div><div>(Schachter<span></span>, 2016).</div><div>EEG, CT he<span></span>ad, </div><div>consider Keppr<span></span>a </div><div>load and BID </div><div>therapy<span></span>. Lorazepam </div><div>if not self-limiting.</div><div>Generalized<span> </span>St<span></span>arts in both </div><div>hemispheres </div><div>at once, arising </div><div>from a cortic<span></span>al </div><div>or subcortical </div><div>region, may be </div><div>asymmetric</div><div>Most c<span></span>ommonly tonic-</div><div>clonic (previously known </div><div>as grand mal, with </div><div>convulsive jerking in all </div><div>limbs), absence (previously </div><div>known as petit mal, with </div><div>st<span></span>aring or lip smacking, </div><div>and myoclonic seizures </div><div>(muscle spasms, can be </div><div></div><div>EEG, CT he<span></span>ad, </div><div>consider Keppr<span></span>a </div><div>load and </div><div>BID therapy<span></span>. </div><div>Loraz<span></span>epam, if not </div><div>self-limiting.</div><div>St<span></span>atus epilepticus </div><div>(SE)</div><div>Any type of seizure </div><div>can evolve into </div><div></div><div>“more than 30 </div><div>minutes of either </div><div>continuous seizur<span></span>e </div><div>activity or two or </div><div>more sequential </div><div>seizures without </div><div>full recovery of </div><div>consciousness </div><div>between </div><div>(American Epilepsy </div><div>Society Guideline, </div><div>2016)”<span></span>.</div><div>Charact<span></span>erized as </div><div>convulsive or non-</div><div>convulsive.  This is a </div><div>medical emergency<span></span>.</div><div>1st line – lor<span></span>azepam </div><div>or diazepam</div><div>2nd line – </div><div>fosphenytoin</div><div>3rd line –  </div><div>general anes<span></span>thesia</div><div>* See below for </div><div>doses</div><div>T<span></span>rea<span></span>tment</div><div> <span></span><span></span></div><div>Pharmacologic tre<span></span>atment is <span>not always nec<span></span>essar<span></span>y<span><span></span></span></span></div><div>seizure, especially if the etiology is obvious and addressed (ie, met<span></span>abolic </div><div>derang<span></span>ement).</div><div> <span></span><span></span></div><div>P<span></span>atients with <span>focal neur<span></span>ological decits, epileptiform dischar<span></span>ges on </span></div><div>EEG or structur<span></span>al brain lesions are a<span></span>t higher risk for repeat seiz<span></span>ures<span> and </span></div><div>should receive antic<span></span>onvulsive therapy (Kurle &amp; Rutecki, 2010).</div><div>Pharmacologic<span></span>al treatment:</div><div> <span></span><span></span></div><div>Loading f<span></span>ollowed by a maintenance dose of <span>levetir<span></span>acet<span></span>am (Keppra)<span> is </span></span></div><div><span></span><span></span><span></span><span></span></div><div></div><div><span></span><span> </span><span>Do<span><span></span><span></span></span></span></div><div> <span></span><span></span></div><div>Additional antiepileptic pharmaco<span></span>therapy based on the EEG, C<span></span>T<span></span>, and clinical </div><div>manifest<span></span>ations of the seizure(s) and response t<span></span>o treatment.</div><div> <span></span><span></span></div><div>T<span></span>o break a seiz<span></span>ure:</div><div><span></span><span> </span><span>1st line: IV <span>lor<span></span>azepam<span><span></span><span></span></span></span></span></div><div><span></span><span></span></div><div> <span></span><span></span></div><div><span></span><span></span></div><div>depression</div><div><span></span><span> </span><span>2nd line: IV <span>fosphenytoin</span> a<span></span>t 20mg<span></span>/kg, (can also do VP<span></span>A 40mg<span></span>/kg or </span></div><div>Keppra 60mg<span></span>/kg lo<span></span>ad – discuss with NCC). Fosphenytoin is bet<span></span>ter </div><div>toler<span></span>ated over Phenyt<span></span>oin.</div><div><span></span><span> </span><span>3rd line, gener<span></span>al anesthesia with <span>propofol or V<span></span>ersed gtts.</span></span></div><div>Seizures mus<span></span>t be <span>dierentiat<span></span>ed from myoclonus<span> (4 types)</span></span></div><div> <span></span><span></span></div><div>Physiologic (muscle jerks when falling asleep, c<span></span>auses no disability)</div><div> <span></span><span></span></div><div><span></span><span></span></div><div> <span></span><span></span></div><div>Epileptic (myoclonic jerks in the set<span></span>ting of epilepsy)</div><div> <span></span><span></span></div><div>Symptoma<span></span>tic (occurring in the setting of a sep<span></span>arate neurologic<span></span>al disorder) </div><div>(Caviness, 2015).</div><div>Calling a consult:</div><div> <span></span><span></span></div><div>Neuro Critical Care P<span></span>ager number: 14061</div><div> <span></span><span></span></div><div>Describe the seizure-like ac<span></span>tivity</div><div><span></span><span> </span><span>Evolution<span>: describe the p<span></span>at<span></span>tern (ie did it st<span></span>art with gaze deviation and </span></span></div><div>unilater<span></span>al shaking which then spread to the opposite side)</div><div><span></span><span> </span><span>Bilat<span></span>eral<span> or c<span></span>onvulsive involvement</span></span></div><div><span></span><span> </span><span>What were the eyes doing (nyst<span></span>agmus, gaze deviation et<span></span>c)</span></div><div><span></span><span> </span><span>T<span></span>ermination<span>: spont<span></span>aneously or with Ativan</span></span></div><div><span></span><span> </span><span>Physical ex<span></span>am ndings</span></div><div> <span></span><span></span></div><div>Autonomic chang<span></span>es in absence or foc<span></span>al seizures: tachycar<span></span>dia, </div><div>diaphoresis, exc<span></span>ess salivation, pupillary dilation, incontinence (K<span></span>urle &amp; </div><div>Rutecki, 2010).</div><div> <span></span><span></span></div><div>T<span></span>onic-clonic seizures: hypert<span></span>ension, tachycardia, met<span></span>abolic acidosis, </div><div>hypoxia, hyperc<span></span>arbia (Kurle &amp; Rutecki, 2010).</div><div>Diagnostic s<span></span>tudies:</div><div> <span></span><span></span></div><div>Head CT<span> without c<span></span>ontrast: Perf<span></span>orm early to identify potentially r<span></span>e<span></span>versible </span></div><div>causes (Goldst<span></span>one, 2011)</div><div> <span></span><span></span></div><div>Continuous EEG:<span> identify a focal are<span></span>a of seizure activity or the presenc<span></span>e of </span></div><div>non-convulsive s<span></span>tatus epilepticus (Marcuse, 2014)</div><div> <span></span><span></span></div><div>MRI: <span><span></span><span></span><span></span></span></div><div>devices (L<span></span>VAD, ECMO etc), Epicardial wir<span></span>es, certain ICD<span></span>/PPMs etc.</div></div><div></div></div>
<div><div><img><div>50<span> </span><span>Pos<span></span>t-Op Management<span> </span>Pos<span></span>t-Op Management<span> </span><span>51</span></span></div><div>POS<span></span>T<span></span>-OP:<span> <span>NEUROL<span></span>OGIC:<span> SPINAL C<span></span>ORD ISCHEMIA </span></span></span></div><div>Who<span></span>’s a<span></span>t risk? </div><div><span></span><span></span><span></span><span></span><span></span></div><div>branching art<span></span>eries (Interc<span></span>ostal arteries) pr<span></span>oviding blood supply to the spinal cord, </div><div>potentially r<span></span>esulting in spinal cord hypoperfusion, ischemia and infarc<span></span>tion</div><div>4. <span> </span><span>Endovascular rep<span></span>air </span></div><div>a. <span> </span><span>Incidence: SCI may occur in up t<span></span>o 4% of cases</span></div><div>b.<span> <span> </span><span><span></span><span></span><span></span></span></span></div><div>5. <span> </span><span>Open repair</span></div><div>a. <span> </span><span>Incidence: SCI may occur in up t<span></span>o 8% of cases</span></div><div>b.<span> <span> </span><span><span></span><span></span></span></span></div><div>Intra-op Me<span></span>asures to prevent spinal c<span></span>ord ischemia:</div><div>1. <span> </span><span>Minimize spinal cor<span></span>d ischemic time</span></div><div>2. <span> </span><span>Increase t<span></span>olerance to ischemia </span></div><div>a. <span> </span><span>Deliberat<span></span>e mild systemic hypothermia</span></div><div>b.<span> <span> </span><span>Ischemic prec<span></span>onditioning (“st<span></span>aged repair”) to allow development of </span></span></div><div>collat<span></span>eraliza<span></span>tion of blood supply</div><div>3. <span> </span><span>Augment spinal cor<span></span>d perfusion</span></div><div>a. <span> </span><span>Deliberat<span></span>e proximal and dist<span></span>al HTN</span></div><div>b.<span> <span> </span><span>C<span></span>SF drainage (via lumbar dr<span></span>ain placement pre-procedur<span></span>e)</span></span></div><div>c. <span> </span><span>Reimplanta<span></span>tion of spinal arteries</span></div><div>d. <span> </span><span>Preser<span></span>ve subclavian artery and hypogastric artery</span></div><div>4. <span> </span><span>Early detec<span></span>tion of spinal cord ischemia</span></div><div>a. <span> </span><span>Intra-oper<span></span>ative neurophysical monitoring (MEP mot<span></span>or e<span></span>voked po<span></span>tentials, </span></div><div>SSEP somat<span></span>osensor<span></span>y evoked potentials)</div><div>b.<span> <span> </span><span>Early and serial pos<span></span>t-op neuro exam</span></span></div><div>Pos<span></span>t-op IC<span></span>U Measures to pr<span></span>event spinal cord ischemia</div><div>1. <span> </span><span>CSF Dr<span></span>ainage:</span></div><div>a. <span> </span><span>Lumbar dr<span></span>ain typically placed pre-opera<span></span>tively by anesthesia.  </span></div><div>See <span>page 106.</span></div><div>b.<span> <span> </span><span>Go<span></span>al to optimize cer<span></span>ebral perfusion pr<span></span>essure (CPP): perfusion to spinal </span></span></div><div>cord</div><div>1. <span></span><span>Measured as CPP = Mean Art<span></span>erial Pressure – ICP</span></div><div>2. <span></span><span>We can decrease ICP by r<span></span>emoving CSF<span></span>, thus improving CPP</span></div><div>c. <span> </span><span>Goal ICP ~10 mmHg<span> (refer t<span></span>o ICU Lumb<span></span>ar drain protoc<span></span>ol)</span></span></div><div>1. <span></span><span>Lumbar dr<span></span>ain is set open to drain a<span></span>t 10mmHg (14cm H20)</span></div><div>2. <span></span><span>When/<span></span>if ICP is gr<span></span>eat<span></span>er than 10mmHg, the lumbar drain will act as a </span></div><div>“pop-o” valve and CSF will dr<span></span>ain</div><div>d. <span> </span><span>Must be careful t<span></span>o not OVER DRAIN C<span></span>SF too rapidly</span></div><div>1. <span></span><span>Symptomatic intr<span></span>acranial hypotension:</span></div><div>a. <span></span><span>Headache</span></div><div>b.<span> <span></span><span>Subdural hematoma</span></span></div><div>2. <span></span><span>Goal: may drain up t<span></span>o 10mL at a time, not t<span></span>o exceed 20mL/hr</span></div><div>2. <span> </span><span>Augment Mean Art<span></span>erial Blood Pressure</span></div><div>a. <span> </span><span>Goal hemodynamic par<span></span>ameters mus<span></span>t be discussed with the surgical </span></div><div>at<span></span>tending, as the patient may have r<span></span>esidual aneur<span></span>ysm/dissec<span></span>tion or </div><div>bleeding to t<span></span>ake into c<span></span>onsideration when es<span></span>tablishing goal MAP</div><div>b.<span> <span> </span><span><span></span><span></span></span></span></div><div>used to augment MAP</div><div>c. <span> </span><span>Typical MAP g<span></span>oal 90-100, CPP goal &gt;80</span></div><div>3. <span> </span><span>Early detec<span></span>tion through close neurologic monit<span></span>oring</span></div><div>a. <span> </span><span></span></div><div>b.<span> <span> </span><span>Q1H Pupillometry while CSF is dr<span></span>ained</span></span></div><div>4. <span> </span><span>May est<span></span>ablish blood transfusion goal f<span></span>or Hct &gt;25 to optimize perfusion</span></div><div>5. <span> </span><span>Lumbar dr<span></span>ain removal</span></div><div>a. <span> </span><span><span></span><span></span></span></div><div>b.<span> <span> </span><span>POD 2: Clamp x 24 hours</span></span></div><div>1. <span></span><span>Continue to monitor neuro exam, if chang<span></span>es, resume CSF drainag<span></span>e</span></div><div>c. <span> </span><span>POD 3: Remove if neuro exam int<span></span>act, monitor for HA or CSF dr<span></span>ainage post </span></div><div>removal. Fla<span></span>t for 6 hours post drain r<span></span>emoval </div><div>If The E<span></span>xam Changes:</div><div>1. <span> </span><span>Alert ICU at<span></span>tending and surgical te<span></span>am immediately</span></div><div>2. <span> </span><span>Increase MAP<span></span>/CPP</span></div><div>a. <span> </span><span>Increase dose of v<span></span>asopressors</span></div><div>b.<span> <span> </span><span>Consider blood/volume tr<span></span>ansfusion</span></span></div><div>3. <span> </span><span>Drain C<span></span>SF (safely) to decrease ICP and incr<span></span>ease CPP</span></div><div>a. <span> </span><span>Goal ICP &lt;10 </span></div><div>b.<span> <span> </span><span>Dr<span></span>ainage not to exc<span></span>eed 20mL/hr</span></span></div><div>4. <span> </span><span>Perf<span></span>orm thorough neurologic exam</span></div><div>a. <span> </span><span><span></span><span></span></span></div><div>b.<span> <span> </span><span><span></span></span></span></div><div>5. <span> </span><span>Consider consult to neur<span></span>ocritical care</span></div><div>6. <span> </span><span>Consider advanc<span></span>ed imaging (CT<span></span>/MRI) when st<span></span>abilized to assess extent of </span></div><div>infarc<span></span>t</div><div>Referenc<span></span>es:</div><div>Referenc<span></span>es Bojar, Robert M. (2011) Manual of P<span></span>erioperative Car<span></span>e in Adult Cardiac Surger<span></span>y<span></span>. (5th edition).</div><div> </div></div><div></div></div>
<div><div><img><div>52<span> </span><span>Pos<span></span>t-Op Management<span> </span>Pos<span></span>t-Op Management<span> </span><span>53</span></span></div><div>POS<span></span>T<span></span>-OP:<span> <span>NEUROL<span></span>OGIC:<span> S<span></span>TROKE / CV<span></span>A</span></span></span></div><div>Risk F<span></span>actors:</div><div>Pre-Op: </div><div> <span></span><span></span></div><div>Hist<span></span>or<span></span>y of previous s<span></span>troke or TIA (44% of p<span></span>atients with history of strok<span></span>e </div><div></div><div> <span></span><span></span></div><div>Comorbidities: HTN, DM, Smoking, PVD, Renal dysfunction</div><div> <span></span><span></span></div><div></div><div> <span></span><span></span></div><div>Age &gt; 75 (risk of up to 10%)</div><div> <span></span><span></span></div><div>Carotid dise<span></span>ase (Risk is less in unilateral s<span></span>tenosis but as high as 10-15% in </div><div>bilater<span></span>al stenosis &gt; 75%)</div><div> <span></span><span></span></div><div>Emergent sur<span></span>gery (Type A dissection)</div><div>Intra Op: </div><div> <span></span><span></span></div><div><span></span></div><div>CBP &gt; 2 hours</div><div> <span></span><span></span></div><div>High transfusion r<span></span>equirement (especially plat<span></span>elets)</div><div> <span></span><span></span></div><div>L<span></span>V thrombus</div><div> <span></span><span></span></div><div>Air emboliza<span></span>tion from opening of cardiac chamber</div><div> <span></span><span></span></div><div>Peri-oper<span></span>ative HTN or cardiac arres<span></span>t</div><div>Pos<span></span>t op:</div><div> <span></span><span></span></div><div></div><div>Pre-Op &amp; Perioper<span></span>ative prev<span></span>ention:</div><div> <span></span><span></span></div><div>Avoid hypotension, c<span></span>ontinue pre-operative ASA, consider need f<span></span>or pre-op </div><div>caro<span></span>tid studies </div><div>Incidence/Mechanism:</div><div> <span></span><span></span></div><div>Embolic, most c<span></span>ommon (~ 2/3 of post op strok<span></span>es)</div><div> <span></span><span></span></div><div>Cerebr<span></span>al hyper perfusion  </div><div> <span></span><span></span></div><div>Hemorrhagic  </div><div>Present<span></span>ation:</div><div> <span></span><span></span></div><div>Think<span> BE F<span></span>AST<span> (</span>B<span>alance, </span>E<span>yes (vision changes), </span>F<span>ac<span></span>e drooping, <span>A</span>rm </span></span></div><div>weakness, <span>S<span><span></span><span>T<span>ime — how long since onset of symptoms)</span></span></span></span></div><div>Physical E<span></span>xam:</div><div> <span></span><span></span></div><div>Full Neuro ex<span></span>am (CN 2-12)</div><div><span></span><span> </span><span>Str<span></span>engths of extr<span></span>emities</span></div><div><span></span><span> </span><span>Pupil exam</span></div><div> <span></span><span></span></div><div>“ Blown pupil:” something acutely b<span></span>ad is happening on one side (rising </div><div>ICP compresses ar<span></span>ea that holds one of optic nerves)</div><div> <span></span><span></span></div><div>“Fixed and dilat<span></span>ed” pupils – indicate a prolonged hypo<span></span>xic injur<span></span>y to the </div><div>brain. </div><div><span></span><span> </span><span>T<span></span>ongue midline</span></div><div>Work<span></span>-up:</div><div> <span></span><span></span></div><div>Call Str<span></span>oke code (dial 211)</div><div> <span></span><span></span></div><div>CT he<span></span>ad without contras<span></span>t, to rule in/<span></span>out hemorrhage</div><div> <span></span><span></span></div><div><span></span><span></span></div><div> <span></span><span></span></div><div>MRI/MRA brain with perfusion sequenc<span></span>es (Stroke pro<span></span>tocol) </div><div> <span></span><span></span></div><div>Carotid Doppler U<span></span>S study t<span></span>o evaluate f<span></span>or carotid occlusive dise<span></span>ase</div><div>Medical Management</div><div> <span></span><span></span></div><div>Blood pressure p<span></span>arameters as det<span></span>ermined by consulting teams, but </div><div>SBP should not exc<span></span>eed 180mmHg for ischemic and 140-160mmHg for </div><div>hemorrhagic cases</div><div> <span></span><span></span></div><div>Glucose c<span></span>ontrol between 80-140 mg<span></span>/dL as elev<span></span>ated levels &gt; 200 mg<span></span>/<span></span>dL during </div><div><span></span><span></span><span></span><span></span></div><div>neurologic outc<span></span>ome</div><div> <span></span><span></span></div><div>Avoid hyperthermia</div><div> <span></span><span></span></div><div>DC all antico<span></span>agulation as pa<span></span>tient’<span></span>s condition can worsen, or c<span></span>an be </div><div>contr<span></span>aindication for tP<span></span>A administr<span></span>ation</div><div> <span></span><span></span></div><div>ASA 162mg or 325mg orally or r<span></span>ect<span></span>ally</div><div> <span></span><span></span></div><div>Antiepileptic ther<span></span>apy as determined by consulting te<span></span>ams</div><div>Indications f<span></span>or surgery</div><div>General guidelines:</div><div> <span></span><span></span></div><div>P<span></span>atients with large hemispheric s<span></span>troke involving more than two-<span></span>thirds of MCA </div><div>territory (usually only on right-side)</div><div> <span></span><span></span></div><div>Development of herniation syndrome (i.e. ipsila<span></span>ter<span></span>al weakness on side of </div><div>strok<span></span>e, lower cranial neuropa<span></span>thies, lethargy)</div><div> <span></span><span></span></div><div>Uncontrolled intr<span></span>acranial pressure, as dic<span></span>tated by monitor</div><div>Surgical Pr<span></span>ocedures: </div><div> <span></span><span></span></div><div>Suboccipit<span></span>al craniectomy<span></span>/cr<span></span>aniotomy (for post<span></span>erior circulation)</div><div> <span></span><span></span></div><div>Cranio<span></span>tomy/Cr<span></span>aniectomy f<span></span>or evacuation of hemat<span></span>oma</div><div> <span></span><span></span></div><div>Hemicraniec<span></span>tomy</div><div> <span></span><span></span></div><div>Carotid endart<span></span>erectomy</div><div>Referenc<span></span>e:</div><div>Winn, H. Richard.  Y<span></span>ouman’<span></span>s Neurological Surg<span></span>ery, 6th ed.  2011.</div><div>CARDIAC: <span>A<span></span>TRIAL FIBRILLA<span></span>TION &amp;  </span></div><div>ELECTROL<span></span>YTE REPL<span></span>ACEMENT</div><div>Classication o<span></span>f AF:</div><div> <span></span><span></span></div><div>P<span></span>aroxysmal (self-<span></span>terminating) vs Persist<span></span>ent (sustained &gt; 7d) vs P<span></span>ermanent  </div><div>(typically &gt; 1 year and when c<span></span>ardioversion has failed or is forg<span></span>one)</div><div> <span></span><span></span></div><div>Valvular (rheumatic MV dise<span></span>ase, prosthetic v<span></span>alve, or valve repair) vs Non </div><div>valvular</div><div> <span></span><span></span></div><div>Lone AF = age &lt; 60 and w<span></span>/o clinical or echo evidence of c<span></span>ardiac disease </div><div>(including HTN)</div><div> <span></span><span></span></div><div><span></span><span></span><span></span></div><div>patient<span></span>s</div><div>Management of AF: (see below f<span></span>or treatment alg<span></span>orithm)</div><div> <span></span><span></span></div><div><span></span><span></span><span></span><span></span></div><div> <span></span><span></span></div><div>For uns<span></span>table p<span></span>atient<span></span>, car<span></span>diovert immediately if able</div><div> <span></span><span></span></div><div>If the patient c<span></span>ontinues to have episodes, consider antico<span></span>agulation  </div><div>(see CHADs score below)</div><div>Pos<span></span>t-oper<span></span>ative Electrolyt<span></span>e Goals:</div><div>Po<span></span>tassium (K+)<span> </span>5.0</div><div>Magnesium (Mg+)<span> </span>2.5</div><div>Calcium (CA+)<span> </span>8.0</div></div><div></div></div>
<div><div><img><div>54<span> </span><span>Pos<span></span>t-Op Management<span> </span>Pos<span></span>t-Op Management<span> </span><span>55</span></span></div><div>Rat<span></span>e Control for AF: (goal HR 60-80, 90-115 with e<span></span>xertion)</div><div>Agent<span> </span>Acut<span></span>e IV<span> </span>Maint (PO)<span> </span>Comments</div><div>Metopr<span></span>olol (BB)<span> </span>5mg over 2min, </div><div>may repea<span></span>t </div><div>q5min x3</div><div>25-100mg BID </div><div>or TID</div><div>↓BP (Rx w/</div><div>glucagon). </div><div>Wat<span></span>ch for CHF &amp; </div><div>Bronchospasm </div><div>Preferr<span></span>ed if CAD</div><div>Amiodarone<span> </span>150mg over 10 </div><div>min. Then 1mg<span></span>/</div><div>min 6 hours, </div><div>0.5mg<span></span>/min for </div><div>18 hours</div><div>400mg TID with </div><div>taper</div><div>Diltiazem (C<span></span>CB)<span> </span>0.25mg<span></span>/kg over </div><div>2 min, may </div><div><span></span></div><div>min. 5-15mg<span></span>/h </div><div>infusion</div><div>120-360mg<span></span>/<span></span>d in </div><div>divided doses</div><div></div><div>gluc). Wat<span></span>ch for </div><div>CHF<span></span>. Preferred if </div><div></div><div>levels</div><div>Ver<span></span>apamil (CCB)<span> </span>5-10mg over 2 </div><div>min, may repea<span></span>t </div><div>in 30 min</div><div>120-360mg<span></span>/<span></span>d in </div><div>divided doses</div><div></div><div>gluc). Wat<span></span>ch for </div><div>CHF<span></span>. Preferred if </div><div></div><div>levels</div><div>Propr<span></span>anolol (BB)<span> </span>1mg q2min<span> </span>80-240mg<span></span>/<span></span>d in </div><div>divided doses</div><div></div><div>glucagon). </div><div>Wat<span></span>ch for CHF &amp; </div><div>Bronchospasm</div><div>Preferred if CAD</div><div>Digoxin <span> </span>0.25mg q2h up to </div><div>1.5mg</div><div>0.125- 0.375mg </div><div>qday (adjust for </div><div>CrCl)</div><div>Consider in HR </div><div>or Low BP<span></span>. P<span></span>oor </div><div>exertional HR crtl.</div><div>Rhythm Control: </div><div>Amiodarone </div><div>(Class III)</div><div>5-7mg<span></span>/kg IV </div><div>over 30-60min </div><div><span>1mg<span></span>/min to </span></div><div>achieve 10g load</div><div>200-400mg qD </div><div>(most e<span></span>ective </div><div>drug)</div><div>↑QT but T<span></span>dP </div><div>rar<span></span>e. Pulm, liver<span></span>, </div><div>thyroid to<span></span>xicity<span></span>. </div><div>Check PFT<span></span>s, </div><div>LFT<span></span>s, TFT<span></span>s</div><div>Sot<span></span>alol (Class III)<span> </span>n/a<span> </span>90-160mg BID<span> </span><span><span></span><span></span></span></div><div></div><div>Propaf<span></span>enone </div><div>(Class IC)</div><div>600mg PO x1<span> </span>150-300mg TID<span> </span>PreRx w/</div><div>AVN blocker<span></span>. </div><div>Contraindic. If </div><div>structural or </div><div>ischemic heart </div><div>disease</div><div>Procainamide<span> </span>10-15mg<span></span>/kg IV </div><div>over 1 hr</div><div>1-2g bid of slow </div><div>release</div><div><span></span><span></span></div><div>PreRx w/<span></span>AVN </div><div>blocker</div><div>Consider need for Antic<span></span>oagulation:</div><div> <span></span><span></span></div><div><span></span><span></span><span></span><span></span></div><div> <span></span><span></span></div><div>Risk of strok<span></span>e ~ 4.5% per year in non valvular AF<span></span>. Risk factors include: prior </div><div>strok<span></span>e, TIA, DM, HTN, Older age (&gt;/= 65), HF<span></span>, CAD, EF &lt; 35%</div><div> <span></span><span></span></div><div>Who to tre<span></span>at<span></span>: </div><div><span></span><span> </span><span>Utilize CHAD Scor<span></span>e to evaluate pa<span></span>tient’<span></span>s risk and need for anticoagulation</span></div><div><span></span><span> </span><span><span></span><span></span></span></div><div>(with no hist<span></span>or<span></span>y), c<span></span>onsider need for short term (2-3 months pos<span></span>t op) </div><div>antico<span></span>agulation (discuss with at<span></span>tending)</div><div>Agent<span> </span>Class<span> </span>Dosing<span> </span>Time to </div><div>Peak  </div><div>Antico<span></span>ag- </div><div>ulation</div><div>Half-</div><div>life</div><div>Renal </div><div>E<span></span>xcre<span></span>tion </div><div>(%)</div><div>Antidot<span></span>e</div><div>W<span></span>a<span></span>r<span></span>f<span></span>a<span></span>ri<span></span>n </div><div>(Coumadin)</div><div>V<span></span>i<span></span>t <span></span>K </div><div>Antagonis<span></span>t</div><div>0<span></span>.<span></span>5-<span></span>10<span></span>mg </div><div>QD</div><div>3-5 days<span> </span><span>4<span></span>0 </span></div><div>hours</div><div>0<span> </span><span>Vitamin K</span></div><div>Clopidogrel (Plavix)<span> </span><span>P<span></span>l<span></span>a<span></span>t<span></span>e<span></span>l<span></span>e<span></span>t </span></div><div>inhibitor</div><div>7<span></span>5<span></span>mg <span></span> </div><div>QD</div><div>Prasugrel (Effient)<span> </span><span>P<span></span>l<span></span>a<span></span>t<span></span>e<span></span>le<span></span>t </span></div><div>inhibitor</div><div>5<span></span>-<span></span>10<span></span>mg </div><div>QD</div><div>7 <span></span> </div><div>hours</div><div>D<span></span>a<span></span>bi<span></span>g<span></span>a<span></span>tr<span></span>a<span></span>n </div><div>(Pradaxa)</div><div>D<span></span>i<span></span>r<span></span>ec<span></span>t </div><div>T<span></span>h<span></span>r<span></span>om<span></span>bi<span></span>n </div><div>inhibitor</div><div>150mg<span></span><span> </span></div><div>BID</div><div>1-2 hours<span> </span><span>1<span></span>4<span></span>-1<span></span>7 </span></div><div>hours</div><div>-80<span> </span>None</div><div>Rivaro<span></span>xaban </div><div>(Xarelto)</div><div>Fac<span></span>tor-Xa </div><div>Inhibitor</div><div>15-20mg </div><div>QD</div><div>2.5-4hours<span> </span>11-13 </div><div>hours</div><div>35<span> </span>None</div><div>Apixaban<span> </span></div><div>(Eliquis)</div><div>F<span></span>ac<span></span>t<span></span>o<span></span>r<span></span>-<span></span>X<span></span>a </div><div>Inhibitor</div><div>2<span></span>.<span></span>5-<span></span>5m<span></span>g </div><div>BID</div><div>3 hours<span> </span>8-15<span></span> </div><div>hours</div><div>25<span> </span>None</div><div>Endoxab<span></span>an<span></span><span> </span></div><div>(Savaysa)</div><div>F<span></span>ac<span></span>t<span></span>o<span></span>r<span></span>-<span></span>X<span></span>a </div><div>Inhibitor</div><div>6<span></span>0<span></span>mg <span></span> </div><div>QD</div><div>1-2 hours<span> </span>9-12<span></span><span> </span></div><div>hours</div><div>60<span> </span>None</div><div>CHAD Scor<span></span>e (&gt;2 equals indication for antic<span></span>oagulation)</div><div>C<span> </span><span><span></span><span></span></span></div><div>dysfunction)</div><div>H<span> </span>Hypertension</div><div>A  (2)<span> </span>Age &gt;/= 75</div><div>D<span> </span>DM</div><div>S (2)<span> </span>Prior strok<span></span>e or TIA or thromboembolism</div><div>V<span> </span>Vascular disease (P<span></span>AD, MI)</div><div>A<span> </span>Age 65-74</div><div>Sc<span> </span>Sex cat<span></span>egor<span></span>y female</div><div>Referenc<span></span>es:</div><div>Bojar<span></span>, Robert M. (2011) Manual of Perioper<span></span>ative Care in Adult Cardiac Surgery. (5th  <span></span>edition).</div></div><div></div></div>
<div><div><img><div>56<span> </span><span>Pos<span></span>t-Op Management<span> </span>Pos<span></span>t-Op Management<span> </span><span>57</span></span></div><div>CT Surgery Post</div><div>Op Atrial</div><div>Fibrillation</div><div>Treatment</div><div>Algorithm</div><div>CHRONIC?</div><div>NEW ONSET?<span> (will occur in 30-</span></div><div>40% of patients)</div><div>-The<span> </span>goal<span> </span>is<span> </span>always<span> </span>first<span> </span>NSR</div><div>-If<span> </span>NSR<span> </span>cannot<span> </span>be<span> </span>attained,<span> </span>the</div><div>goal<span> </span>then<span> </span>becomes<span> </span>rate<span> </span>control</div><div>STABLE?</div><div>UNSTABLE?</div><div>Amiodarone</div><div>150mg/min<span> </span>bolus<span> </span>+</div><div>drip<span> </span>@<span> </span>1mg/min</div><div>OR</div><div>Diltiazem<span> </span>0.25mg/</div><div>kg<span> </span>bolus<span> </span>+<span> </span>drip<span> </span>@</div><div>5mg/hr<span> </span>(titrate<span> </span>to</div><div>heart<span> </span>rate)</div><div>DCCV</div><div>(direct<span> </span>current</div><div>cardioversion)</div><div>Successful<span> </span>=</div><div>Converts<span> </span>to</div><div>Sinus</div><div>Unsuccessful</div><div>=<span> </span>Remains<span> </span>in</div><div>Afib</div><div>Continue<span> </span>Amio/</div><div>Diltiazem<span> </span>drip<span> </span>until</div><div>loaded</div><div>Repeat<span> </span>DCCV</div><div>Continue<span> </span>Amio/</div><div>Diltiazem<span> </span>drip<span> </span>until</div><div>loaded</div><div>Transition<span> </span>to<span> </span>PO</div><div>Amiodarone</div><div>starting<span> </span>with</div><div>400mg<span> </span>PO<span> </span>TID</div><div>Consider<span> </span>Daily</div><div>EKG<span> </span>to<span> </span>eval<span> </span>QT</div><div>interval.</div><div>AF<span> </span>reoccurs?</div><div>1.<span> </span>Restart<span> </span>Amio/</div><div>Diltiazem<span> </span>bolus<span> </span>+</div><div>drip</div><div>2.<span> </span>Consider</div><div>DCCV</div><div>3.<span> <span>Evaluate the </span></span></div><div>need for </div><div>Anticoagulation<span> </span></div><div>Remains<span> </span>in<span> </span>NSR<span> </span>&gt;</div><div>24-48<span> </span>hours</div><div>Discharge<span> </span>home</div><div>with<span> </span>amio<span> </span>taper</div><div>Amiodarone</div><div>150mg/min<span> </span>bolus<span> </span>+</div><div>drip<span> </span>@<span> </span>1mg/min</div><div>OR</div><div>Diltiazem<span> </span>0.25mg/</div><div>kg<span> </span>bolus<span> </span>+<span> </span>drip<span> </span>@</div><div>5mg/hr<span> </span>(titrate<span> </span>to</div><div>heart<span> </span>rate)</div><div>Afib<span> </span>persists</div><div>&gt;<span> </span>24<span> </span>hours</div><div>Converts<span> </span>to</div><div>Sinus</div><div>Continue<span> </span>amio<span> </span>drip</div><div>@<span> </span>1mg/min<span> </span>for<span> </span>6</div><div>hours<span> </span>followed<span> </span>by</div><div>0.5mg/min<span> </span>for<span> </span>18</div><div>hours</div><div>If HR or BP <span>↓<span>,<span> </span>first</span></span></div><div>decrease<span> </span>drip<span> </span>to</div><div>0.5mg<span> </span>early.<span> </span>If<span> </span>no</div><div>resolution,<span> </span>stop</div><div>drip.</div><div>S/P<span> </span>MAZE</div><div>Goal<span> </span>is<span> </span>RATE</div><div>CONTROL</div><div>1.<span> </span>Restart<span> </span>Home</div><div>meds</div><div>2.<span> </span>Restart<span> </span>home</div><div>anticoagulation</div><div>NSR</div><div>Heart<span> </span>rate<span> </span>&gt;<span> </span>60</div><div>Heart<span> </span>rate<span> </span>&lt;<span> </span>60</div><div>Hold<span> </span>home<span> </span>rate</div><div>controlling/</div><div>antiarrhythmic</div><div>medications</div><div>Restart<span> </span>home<span> </span>rate</div><div>controlling/</div><div>antiarrhythmic</div><div>medications</div><div>(Amio,<span> </span>Sotolol,<span> </span>etc)</div><div>NO<span> </span>MAZE</div><div>Atrial<span> </span>fibrillation</div><div>(will<span> </span>occur<span> </span>in<span> </span>30%</div><div>of<span> </span>patients)</div><div>Restart<span> </span>home</div><div>Antiarrhythmic/</div><div>anticoagulation</div><div>medications</div><div>MEDICATION DOSING  </div><div>Amiodarone bolus = 150mg/min over 10 min (max 6-8 boluses in first </div><div>24 hours)</div><div>Amiodarone drip = 1mg/min x 6 hours, then decrease to 0.5mg/min </div><div>x 18 hours (this will load the patient with 1g in the first 24 hours)</div><div>If patient becomes hypotensive (occurs in 25% of patients) decrease </div><div>the drip to 0.5mg/min early. </div><div>After 24 hours on the drip, transition to 400-1200mg PO per day in 2-</div><div>3 divided doses. Continue</div><div> this loading dose until you have reached </div><div>10g total (between IV and PO). Then decrease to maintenance dose </div><div>of 200-400mg/day</div><div>If QTC interval &gt; 500ms, decrease or discontinue Amiodarone. </div><div>Hypotension is more likely to occur in daily doses of Amiodarone &gt; </div><div>2g/day. <span>Amiodarone drip should be stopped if 2</span></div><div>nd</div><div> degree heart </div><div>block or higher occurs or if long pauses are present. </div><div>Loading dose of Amiodarone = 10g</div><div>D</div><div>iltiazem bolus = 0.25mg/kg over 2 min</div><div>Diltiazem drip = 5mg/hour and titrate based on heart rate</div><div>Due to strong negative inotropic effect, IV Beta blockers should be </div><div>avoided.<span> </span></div><div>For patients with</div><div>chronic atrial</div><div>fibrillation who have</div><div>undergone MAZE</div><div>procedure, 90% will</div><div>be in NSR at 1 year</div><div>post operatively</div><div>Restart<span> </span>home</div><div>medications/</div><div>anticoagulation</div><div>References</div><div>Lee, Richard. Atrial fibrillation and flutter </div><div>after cardiac surgery. In: UpToDate, Saperia, </div><div>SM (Ed.), UpToDate, Waltham, MA, 2016. </div><div>Only<span> </span>consider<span> </span>DCCV<span> </span>for<span> </span>post<span> </span>op</div><div>MAZE<span> </span>patients<span> </span>if<span> </span>patient<span> </span>is</div><div>unstable<span> </span>or<span> </span>rate<span> </span>is<span> </span>very<span> </span>fast</div><div>(DCCV<span> </span>will<span> </span>usually<span> </span>not<span> </span>work<span> </span>until</div><div>patient<span> </span>is<span> </span>4<span> </span>weeks<span> </span>post<span> </span>op)</div><div>Continue<span> </span>to</div><div>use<span> </span>IV<span> </span>Amio</div><div>bolus<span> </span>until</div><div>HR<span> </span>&lt;<span> </span>10</div><div>ANTICOAGULATION</div><div>1. Depends on attending preferences </div><div>2. Should be considered for any patient having paroxysmal atrial </div><div>fibrillation with CHAD score &gt; 2</div><div>SPECIAL CONSIDERATIONS</div><div>Those with a Low EF or mechanical Mitral valve may benefit from </div><div>early DCCV even if they are stable. </div><div>CARDIAC: <span>HEAR<span></span>T BL<span></span>OCKS</span></div><div>Pos<span></span>t-oper<span></span>ative tr<span></span>ansient disturbanc<span></span>es of AV nodal c<span></span>onduction are </div><div>more c<span></span>ommon in patients with:</div><div> <span></span><span></span></div><div>Low EF<span></span>, HTN</div><div> <span></span><span></span></div><div>Severe CAD </div><div> <span></span><span></span></div><div>Long Aortic clamp time</div><div> <span></span><span></span></div><div>Low intr<span></span>a-op myocardial t<span></span>empera<span></span>tures</div><div> <span></span><span></span></div><div>Aortic/mitral/tricuspid valve r<span></span>eplacement<span></span>/rep<span></span>air</div><div>Pos<span></span>t-oper<span></span>ative c<span></span>onduction abnormalities may occur bec<span></span>ause of:</div><div> <span></span><span></span></div><div>Myocardial edema</div><div> <span></span><span></span></div><div>Suturing</div><div> <span></span><span></span></div><div>Debridement near AV node/His bundle</div><div>First De<span></span>gree AV Block</div><div> <span></span><span></span></div><div>Prolonga<span></span>tion of PR inter<span></span>val</div><div> <span></span><span></span></div><div>T<span></span>reatment c<span></span>onsiderations: </div><div><span></span><span> </span><span>Epicardial DDD pacing</span></div><div><span></span><span> </span><span>Avoid nodal-blocking agents</span></div><div>Second De<span></span>gree AV Block: Mobitz Type I (Wenck<span></span>ebach)</div><div> <span></span><span></span></div><div>Progressive PR prolong<span></span>ation leading to non-c<span></span>onducting P wave with no QRS </div><div>complex</div><div> <span></span><span></span></div><div>T<span></span>reatment c<span></span>onsiderations:</div><div><span></span><span> </span><span>Epicardial DDD pacing </span></div><div><span></span><span> </span><span>Avoid nodal blocking agents</span></div><div> <span> </span>       ht<span></span>tp://www.zuniv.net/physiology/book/<span></span>chapter11.html</div><div>Second De<span></span>gree AV Block: Mobitz Type II</div><div> <span></span><span></span></div><div>Const<span></span>ant PR inter<span></span>vals and  </div><div>intermit<span></span>tent dropped QR<span></span>S  </div><div>complexes (no w<span></span>arning!)</div><div> <span></span><span></span></div><div></div><div>syst<span></span>em</div><div> <span></span><span></span></div><div>More likely t<span></span>o progress to  </div><div>complet<span></span>e heart block</div><div> <span></span><span></span></div><div>T<span></span>reatment c<span></span>onsiderations:</div><div><span></span><span> </span><span>Epicardial DDD pacing</span></div><div><span></span><span> </span><span>Stop all nodal blocking agents</span></div><div><span></span><span> </span><span>Consider permanent </span></div><div>pacemaker</div><div>Third Degr<span></span>ee (Complete) Heart Block:</div><div> <span></span><span></span></div><div>F<span></span>ailure of AV c<span></span>onduction of any atrial activity (AV disassociation)</div><div> <span></span><span></span></div><div>Variable r<span></span>ates for P and QRS c<span></span>omplexes</div><div> <span></span><span></span></div><div>T<span></span>reatment c<span></span>onsiderations:</div><div><span></span><span> </span><span>Epicardial DDD P<span></span>acing</span></div><div> <span></span><span></span></div><div>If atria in AF<span></span>/A.utter <span><span>must use VVI pacing</span></span></div><div><span></span><span> </span><span>Stop all nodal blocking agents</span></div><div><span></span><span> </span><span>Consider permanent pacemaker</span></div><div>Heart Block P<span></span>oem</div><div>If the <span>R</span> is far from <span>P</span>,  </div><div>then you have a <span>First De<span></span>gree</span></div><div>Long<span></span>er<span></span>, longer<span></span>, longer<span></span>—DROP!<span> </span></div><div>Then you have a <span>Wenckeb<span></span>ach</span></div><div>If some P’<span></span>s don’t go thr<span></span>ough,  </div><div>then you have a <span>Mobitz II</span></div><div>If <span>P</span>’<span></span>s and <span>Q</span>’<span></span>s don’t agree,  </div><div>then you have a <span>Third Degree </span></div></div><div></div></div>
<div><div><img><div>58<span> </span><span>Pos<span></span>t-Op Management<span> </span>Pos<span></span>t-Op Management<span> </span><span>59</span></span></div><div>AV Junctional Rhythm/<span></span>Junc<span></span>tional T<span></span>achycardia</div><div> <span></span><span></span></div><div>Occurs when junctional tissue has f<span></span>aster intrinsic r<span></span>ate than the sinus node</div><div> <span></span><span></span></div><div>“<span></span>Junctional escape rhythm:” HR &lt; 60bpm </div><div> <span></span><span></span></div><div>“<span></span>Junctional t<span></span>achycardia:” HR 70-130 bpm</div><div> <span></span><span></span></div><div>Could be associated with decr<span></span>eased car<span></span>diac output due to lack of </div><div>synchronous atrial and ventricular c<span></span>ontractions</div><div> <span></span><span></span></div><div>Diagnosis: regular r<span></span>ate with no visible P<span></span>-waves or retrogr<span></span>ade P waves</div><div> <span></span><span></span></div><div>T<span></span>reatment c<span></span>onsiderations:</div><div><span></span><span> </span><span>Stop all nodal blocking agents</span></div><div><span></span><span> </span><span>Chronotropic Be<span></span>ta-1 agonists to stimulate SA node (ie Isuprel, Dopamine, </span></div><div>Epinephrine)</div><div><span></span><span> </span><span>Epicardial atrial or DDD pacing</span></div><div>For more inf<span></span>ormation on Medtronic t<span></span>emporary pacemaker bo<span></span>x,</div><div> <span>See <span>page 106.</span></span></div><div>CARDIAC: <span>CHES<span></span>T P<span></span>AIN</span></div><div>The most important etiology in the di<span></span>erential diagnosis is myocardial ischemia. </div><div>Fortunately<span></span>, it is very uncommon in the post op cardiac sur<span></span>gery patient.</div><div>P<span></span>atient E<span></span>xam:</div><div> <span></span><span></span></div><div>Can the pain be repr<span></span>oduced by palpita<span></span>tion, positional changes, or deep </div><div>inspira<span></span>tion? If so, much less likely t<span></span>o be ischemic in nature. The most </div><div>common cause of ches<span></span>t pain following cardiac sur<span></span>ger<span></span>y is musculoskelet<span></span>al in </div><div>nature. </div><div>Obt<span></span>ain Ekg: </div><div> <span></span><span></span></div><div>Compare with pr<span></span>e op and early post op EKGs</div><div> <span></span><span></span></div><div><span></span><span></span><span></span></div><div>If Y<span></span>ou Suspect T<span></span>rue Angina Follow Mona:</div><div> <span></span><span></span></div><div>Morphine</div><div> <span></span><span></span></div><div>O2 via Nasal Cannula</div><div> <span></span><span></span></div><div>Nitroglycerin (0.4 SL or 1” Nitr<span></span>o Pas<span></span>te)</div><div> <span></span><span></span></div><div>ASA 325mg</div><div> <span></span><span></span></div><div>Bet<span></span>a Blocker (met<span></span>oprolol 5mg IV<span></span>, may repeat in 5 min. </div><div> <span></span><span></span></div><div>Cardiac Enzymes for 24 hours (q8H x3) --<span></span>T<span></span>roponin/Ck-MB, CK</div><div>Consider: </div><div> <span></span><span></span></div><div>Did the patient of angina pr<span></span>e op? If so, is the pain the same as the pain now? </div><div> <span></span><span></span></div><div>Any pre oper<span></span>ative ca<span></span>th to review? </div><div> <span></span><span></span></div><div><span></span><span></span><span></span></div><div> <span></span><span></span></div><div><span></span></div><div>pneumothor<span></span>ax<span></span>, pneumonia, pulmonary embolism, sternal wound infec<span></span>tion, </div><div>aortic dissection, GERD</div><div>For inpa<span></span>tient cardiac catheriz<span></span>ation procedures, p<span></span>age the inter<span></span>ventional </div><div>cardiology fellow on call to arr<span></span>ange.</div><div>CARDIAC: <span>PERICARDIAL T<span></span>AMPONADE</span></div><div>P<span></span>athophysiology: </div><div> <span></span><span></span></div><div><span></span><span></span></div><div><span></span></div><div> <span></span><span></span></div><div><span></span></div><div>Manifes<span></span>tations / Physical E<span></span>xam:</div><div> <span></span><span></span></div><div><span></span><span></span><span></span><span></span></div><div> <span></span><span></span></div><div><span></span><span></span></div><div> <span></span><span></span></div><div>Sudden st<span></span>op in chest tube output</div><div> <span></span><span></span></div><div>Equilibr<span></span>ation dias<span></span>tolic pressures</div><div> <span></span><span></span></div><div><span></span></div><div>early dias<span></span>tole) </div><div> <span></span><span></span></div><div><span></span></div><div>Diagnostics:</div><div> <span></span><span></span></div><div><span></span></div><div><span></span><span> </span><span>(If you have st<span></span>arted 2 inotropes, and given volume, and the pa<span></span>tient is </span></div><div>doing badly (CI &lt; 2.0), you mus<span></span>t rule out tamponade)</div><div> <span></span><span></span></div><div>Chest xr<span></span>ay (widened mediastinum)</div><div> <span></span><span></span></div><div>CBC, Coagulation s<span></span>tudies </div><div>T<span></span>rea<span></span>tment:</div><div> <span></span><span></span></div><div>Give volume, st<span></span>art an inotrope, alert surgical t<span></span>eam</div><div> <span></span><span></span></div><div>Assure chest tube pat<span></span>enc<span></span>y</div><div><span></span><span> </span><span>If visible clot within ches<span></span>t tube obstruc<span></span>ting drainag<span></span>e, discuss with surgical </span></div><div>resident/fellow about using suction ca<span></span>theter t<span></span>o suction out the ches<span></span>t </div><div>tube with st<span></span>erile technique</div><div> <span></span><span></span></div><div>If patient acut<span></span>ely decompensating, may require r<span></span>e-sterno<span></span>tomy in the  </div><div>ICU or OR</div><div>Delayed t<span></span>amponade: </div><div> <span></span><span></span></div><div><span></span><span></span></div><div>usually resolve comple<span></span>tely</div><div> <span></span><span></span></div><div><span></span><span></span><span></span></div><div>clinical sympt<span></span>oms as patients enter a low car<span></span>diac output stat<span></span>e </div><div><span></span><span> </span><span>Gradual incr<span></span>ease in cre<span></span>atinine/BUN</span></div><div><span></span><span> </span><span>Gradual incr<span></span>ease in heart r<span></span>ate</span></div><div><span></span><span> </span><span>Gradual decr<span></span>ease in urine output</span></div><div><span></span><span> </span><span>Decrease in ex<span></span>ercise toleranc<span></span>e</span></div><div> <span></span><span></span></div><div>Diagnostics: Echoc<span></span>ardiogram gold s<span></span>tandard</div><div> <span></span><span></span></div><div>T<span></span>reatment: as above if unst<span></span>able. If stable, c<span></span>onsider pericardial window vs </div><div>need to re-open ches<span></span>t in opera<span></span>ting room</div><div> </div></div><div></div></div>
<div><div><img><div>60<span> </span><span>Pos<span></span>t-Op Management<span> </span>Pos<span></span>t-Op Management<span> </span><span>61</span></span></div><div>CARDIAC:<span> RIGHT VENTRIC<span></span>ULAR F<span></span>AIL<span></span>URE</span></div><div>P<span></span>athophysiology</div><div> <span></span><span></span></div><div>The RV is a thin-walled, crescent<span></span>-shaped structure char<span></span>acterized by low </div><div>resist<span></span>ance, high complianc<span></span>e, and low impedence</div><div> <span></span><span></span></div><div><span></span></div><div> <span></span><span></span></div><div>Ventriculoart<span></span>erial coupling is a major determinant of RV function</div><div>Etiology</div><div>1. <span> </span><span>Preexisting RV dysfunction sec<span></span>ondar<span></span>y to severe coronary disease, pulmonary </span></div><div>hypertension, v<span></span>alvular heart disease, and/<span></span>or RV infarc<span></span>tion</div><div>2. <span> </span><span>Pos<span></span>tsurgical RV dysfunction secondary to long cardiopulmonary bypass </span></div><div>(CPB) time, suboptimal myocar<span></span>dial prot<span></span>ection, and/or c<span></span>oronar<span></span>y embolism</div><div>3. <span> </span><span><span></span><span></span><span></span><span></span></span></div><div>excessive blood tr<span></span>ansfusions, pulmonar<span></span>y embolism, prot<span></span>amine reaction, </div><div>ischemia-reperfusion injury, tension pneumothor<span></span>ax</div><div>4. <span> </span><span>RV pressure overload sec<span></span>ondar<span></span>y to intrinsic pulmonar<span></span>y disease, pulmonary </span></div><div>embolism, and/<span></span>or acute respira<span></span>tory distress syndrome (ARDS)</div><div>Diagnosis</div><div> <span></span><span></span></div><div>High right atrial pressur<span></span>e (RAP) and pulmonar<span></span>y capillary wedge (PCW) </div><div>pressure.  No<span></span>te this is unreliable when L<span></span>V dysfunction is also present</div><div> <span></span><span></span></div><div>May consider TTE to assess IV<span></span>C, tricuspid regurgita<span></span>tion, right ventricle size, </div><div>and sept<span></span>al positioning to guide volume sta<span></span>tus.  </div><div> <span></span><span></span></div><div>Monitor CVP tr<span></span>acing.  With worsening TR and RV dilation, will see rising V </div><div>wave on CVP tr<span></span>acing.  </div><div> <span></span><span></span></div><div>Calculate s<span></span>tep-up (mean P<span></span>A pressure - CVP pressure)</div><div><span></span><span> </span><span>Goal &gt; 10</span></div><div> <span></span><span></span></div><div>Calculate pulmonary arter<span></span>y pulsatility index (P<span></span>APi)</div><div><span></span><span> </span><span>Studied t<span></span>o predict RVAD need in L<span></span>VAD patient<span></span>s</span></div><div><span></span><span> </span><span>P<span></span>APi = (systolic P<span></span>A pressure - dias<span></span>tolic P<span></span>A pressure) / CVP</span></div><div> <span></span><span></span></div><div>P<span></span>APi &gt;2: good RV function</div><div> <span></span><span></span></div><div>P<span></span>APi 1-2: at risk for RV failure</div><div> <span></span><span></span></div><div>P<span></span>APi &lt;1: RV failure</div><div> <span></span><span></span></div><div>For more inf<span></span>ormation on Adv<span></span>anced hemodynamic monitoring and P<span></span>A </div><div>cathe<span></span>ters see <span>page 125.</span></div><div>Management</div><div>1. <span> </span><span>Prevent elevated pulmonary vascular resis<span></span>tance</span></div><div>a. <span> </span><span>Avoid hypoxemia, hyperc<span></span>apnia, and acidosis which increase PVR</span></div><div>2. <span> </span><span>Optimize pr<span></span>eload</span></div><div>a. <span> </span><span>Fluid Administr<span></span>ation</span></div><div>i. <span> </span>Adminis<span></span>ter cr<span></span>yst<span></span>alloids/c<span></span>olloids and/or blood pr<span></span>oducts slowly for low </div><div>cardiac output as long as CVP is low or within t<span></span>arget r<span></span>ange  </div><div>ii.  Do not give additional volume if the cardiac output/blood pressure </div><div>does not improve sinc<span></span>e additional volume may lead to worsening RV </div><div>function acc<span></span>ording to Fr<span></span>ank-S<span></span>tarling mechanism</div><div>b.<span> <span> </span><span>Fluid remov<span></span>al</span></span></div><div>i. <span> </span>Initia<span></span>te diuretics promptly f<span></span>or volume overload and RV dilation/TR.  </div><div>St<span></span>art with Lasix bolus of 10-50 mg IV<span></span>.  If no response to bolus, consider </div><div>rebolus, st<span></span>arting Lasix infusion, and/or adding Diuril IV<span></span>.  </div><div>ii.  If no response to Lasix/Diuril, consider swit<span></span>ching to Bumex infusion </div><div>or st<span></span>arting Nesiritide infusion.  (Note Nesiritide causes sys<span></span>temic </div><div><span></span><span></span></div><div>with loop diuretics).  </div><div>iii. If all the above interventions fail, initiat<span></span>e dialysis.</div><div>3. <span> </span><span><span></span></span></div><div>a. <span> </span><span>Flolan: inhaled epoprost<span></span>enol </span></div><div>i. <span> </span>Pr<span></span>ostacyclin inhibitor that is a pulmonary vasodilat<span></span>or</div><div>ii.  Starting dose 0.05 mc<span></span>g<span></span>/kg<span></span>/min.  When weaning ther<span></span>apy, titra<span></span>te down </div><div>by 0.01 mcg<span></span>/kg<span></span>/min as toler<span></span>ated</div><div><span></span><span></span></div><div>be st<span></span>opped if suspected </div><div>b.<span> <span> </span><span>iNO</span></span></div><div>i. <span> </span>Selec<span></span>tive pulmonar<span></span>y vasodilator only av<span></span>ailable in aerosol </div><div>administr<span></span>ation.  </div><div>ii.  Use only if patient not r<span></span>esponsive to inhaled Flolan</div><div>iii. S<span></span>tarting dose 20 ppm.  When weaning ther<span></span>apy, titr<span></span>ate down by 5 </div><div><span></span><span></span><span></span></div><div><span></span><span></span></div><div>c. <span> </span><span></span></div><div>i. <span> </span>Phosphodies<span></span>terase (PDE) inhibitor tha<span></span>t is both a pulmonar<span></span>y and </div><div>syst<span></span>emic vasodila<span></span>tor<span></span>.</div><div>ii.  Available in oral doses of 5-20 mg TID</div><div>4. <span> </span><span>Optimize c<span></span>ardiac output</span></div><div>a. <span> </span><span>Dopamine</span></div><div><span> </span><span></span><span></span></div><div>doses.</div><div>ii.  Drip rate r<span></span>anges between 1-5 mcg<span></span>/kg<span></span>/min.  May tr<span></span>ansfer out of ICU on </div><div>4 mcg<span></span>/kg<span></span>/min</div><div>b.<span> <span> </span><span>Epinephrine</span></span></div><div><span> </span><span></span><span></span><span></span><span></span><span></span></div><div>kg<span></span>/min</div><div>ii.  Drip rate r<span></span>anges between 0.01-0.2 mcg<span></span>/kg<span></span>/min.  Drip titr<span></span>ated by 0.01 </div><div>mcg<span></span>/kg<span></span>/min</div><div>iii. Import<span></span>ant considerations</div><div>1.  May cause arrthymias at higher doses</div><div>2.  Closely monitor CVP<span></span>/CI/lact<span></span>ates when titra<span></span>ting drip rate</div><div>c. <span> </span><span>Milrinone </span></div><div>i. <span> </span>PDE III inhibit<span></span>or. Provides ino<span></span>tropy and reduces PVR/SVR</div><div>ii.  Drip rate r<span></span>anges between 0.1 – 0.5 mcg<span></span>/kg<span></span>/min</div><div>iii. Import<span></span>ant considerations</div><div>1.  Long half-lif<span></span>e of 1.5-2 hours</div><div>d. <span> </span><span>Dobutamine</span></div><div><span> </span><span></span><span></span></div><div>SVR</div><div>ii.  Drip rate r<span></span>anges between 1-20 mcg<span></span>/kg<span></span>/min.  Half-lif<span></span>e 2 minutes</div><div>iii. Import<span></span>ant considerations</div><div>1.  Causes mild tachyc<span></span>ardia and hypotension</div><div>2.  Incre<span></span>ases myocardial o<span></span>xygen demand</div><div> <span></span><span></span></div><div>5. <span> </span><span>Optimize right he<span></span>art perfusion pressure</span></div></div><div></div></div>
<div><div><img><div>62<span> </span><span>Pos<span></span>t-Op Management<span> </span>Pos<span></span>t-Op Management<span> </span><span>63</span></span></div><div>a. <span> </span><span><span></span><span></span><span></span><span></span></span></div><div>b.<span> <span> </span><span>V<span></span>asopressin</span></span></div><div>i. <span> </span>May c<span></span>ause pulmonar<span></span>y vasodilation at low doses</div><div>ii.  Drip rate r<span></span>anges between 0.01-0.04 units/min</div><div>c. <span> </span><span>Norepinephrine</span></div><div><span> </span><span></span></div><div>ii.  Does increase PVR at higher doses</div><div>iii. Drip r<span></span>ate ranges be<span></span>tween 1-20 mcg<span></span>/min</div><div>d. <span> </span><span>Phenylephrine</span></div><div><span> </span><span></span></div><div>ii.  Like Norepinephrine dose incre<span></span>ase PVR at high doses</div><div>iii. Infusion r<span></span>ates 5-200 mcg<span></span>/min</div><div>6. <span> </span><span>Monitor adequat<span></span>e end organ perfusion:</span></div><div>a. <span> </span><span>SvO2 (either from CC<span></span>O swan or VBG)</span></div><div>b.<span> <span> </span><span>Lact<span></span>ate </span></span></div><div>c. <span> </span><span>UOP<span></span>/Creatinine</span></div><div>d. <span> </span><span>LFT’<span></span>s (R heart failure le<span></span>ads to hepatic cong<span></span>estion)</span></div><div>7. <span> </span><span><span></span><span></span><span></span></span></div><div>consider mechanical cir<span></span>culator<span></span>y support</div><div>a. <span> </span><span>RVAD</span></div><div>b.<span> <span> </span><span>VA ECMO</span></span></div><div>CARDIAC: <span>S<span></span>YS<span></span>TOLIC ANTERIOR MO<span></span>TION (SAM) </span></div><div>OF THE MITRAL V<span></span>AL<span></span>VE</div><div> <span></span><span></span></div><div><span></span><span></span><span></span></div><div>syst<span></span>ole.  T<span></span>ypically seen in patients with HOCM or mitr<span></span>al valve repair<span></span>.</div><div> <span></span><span></span></div><div>Consider in setting of worsening hypo<span></span>tension with increased inotr<span></span>opic </div><div>support</div><div> <span></span><span></span></div><div><span></span></div><div>intraventricular sep<span></span>tum, papillar<span></span>y muscle displacement, and redundant </div><div><span></span><span></span></div><div>Clinical pearls:</div><div>T<span></span>o prevent SAM, the goal is to slow the heart rate t<span></span>o prolong the L<span></span>V lling time </div><div> <span></span><span></span></div><div>Avoid inotropic support, use vasopr<span></span>essors in setting of hypotension</div><div> <span></span><span></span></div><div>Avoid hypovolemia, cautious use of diuretic ther<span></span>apy</div><div> <span></span><span></span></div><div>Once s<span></span>tabilized, consider be<span></span>ta blocker therapy f<span></span>or long term treatment </div><div> <span></span><span></span></div><div>Referenc<span></span>e<span> page 24 </span><span> </span></div><div>CARDIAC: <span>V<span></span>ASOPLEGIA</span></div><div> <span></span><span></span></div><div>Persis<span></span>tent hypot<span></span>ension<span> despite adequate cardiac output fr<span></span>om <span>low systemic </span></span></div><div>vascular resis<span></span>tanc<span></span>e</div><div> <span></span><span></span></div><div><span></span><span></span><span></span><span></span><span></span><span></span></div><div>response. Risk fac<span></span>tors include history of use of <span>ACE inhibitors, ARBs</span>, C<span></span>CBs, </div><div>Amiodarone, B-blockers, and Hep<span></span>arin.</div><div> <span></span><span></span></div><div>T<span></span>reatment:</div><div><span></span><span> </span><span><span></span></span></div><div><span></span><span> </span><span>Phenylephrine<span></span>Norepinephrine<span><span></span></span></span></div><div><span></span><span></span></div><div>needed</div><div><span></span><span> </span><span>Methylene Blue<span> (1-2mg<span></span>/kg bolus) inhibits NO synthase and is used in </span></span></div><div>the trea<span></span>tment of refractory hypotension</div><div>CARDIAC: <span>HEAR<span></span>T F<span></span>AIL<span></span>URE</span></div><div><span></span><span>pos<span></span>t surger<span></span>y because mos<span></span>t </span></div><div><span></span><span>pos<span></span>t surgical st<span></span>ate. However </span></div><div>there are some princip<span></span>als that can help you manage the patient<span></span>s. </div><div>Medications: </div><div> <span></span><span></span></div><div>Do not hold heart f<span></span>ailure medications (bet<span></span>a blockers, ACE inhibitors, </div><div>spironolact<span></span>one) for low blood pressure. Ac<span></span>cept a lower blood pressur<span></span>e </div><div>for heart f<span></span>ailure patients c<span></span>onsider giving them even if your systolic blood </div><div>pressure is in the 90’<span></span>s (e<span></span>ven in the high 80’<span></span>s in some cases). </div><div> <span></span><span></span></div><div><span></span><span></span></div><div>may be harmful in asymptoma<span></span>tic patients with low L<span></span>VEF and no symptoms of </div><div></div><div> <span></span><span></span></div><div>Bet<span></span>a blockers: </div><div><span></span><span> </span><span>Bet<span></span>a blockers should be used in all pa<span></span>tients with a reduced EF to pr<span></span>e<span></span>vent </span></div><div>symptoma<span></span>tic HF<span></span>, even if they do not have a history of MI.  </div><div><span></span><span> </span><span>Consider Coreg ins<span></span>tead of Metopr<span></span>olol for beta blockade: one s<span></span>tudy </span></div><div><span></span></div><div>Metopr<span></span>olol for heart f<span></span>ailure with reduced EF </div><div> <span></span><span></span></div><div>Aerlo<span></span>ad reduction:</div><div><span></span><span> </span><span><span></span><span></span></span></div><div>reduction due t<span></span>o kidney dysfunction. The kidneys will appreciate bet<span></span>ter </div><div><span></span><span></span></div><div>problem</div><div><span></span><span> </span><span><span></span><span></span><span></span></span></div><div>patient<span></span>s who cannot tolera<span></span>ted ACEs or ARBs or who are African Americ<span></span>an </div><div><span></span><span> </span><span>ACE inhibitors should be used in all p<span></span>atients with a reduced EF t<span></span>o prevent </span></div><div>symptoma<span></span>tic HF<span></span>, even if they do not have a history of MI. </div><div> <span></span><span></span></div><div>Diuretics: <span>See volume manag<span></span>ement below </span></div><div>Volume Manag<span></span>ement<span></span>: </div><div> <span></span><span></span></div><div>Don’t over<span></span>-diurese patients with pr<span></span>eser<span></span>ved ejection fraction. They are very </div><div>responsive to volume and c<span></span>ardiac output can disproportiona<span></span>tely drop with </div><div>minimal changes in prelo<span></span>ad. </div><div> <span></span><span></span></div><div>Consider Aldactone or Epler<span></span>enone for pa<span></span>tients that are on a bet<span></span>a blocker and </div><div>ace inhibitor without hyperk<span></span>alemia</div><div> <span></span><span></span></div><div>Lasix is a threshold drug- titr<span></span>ate daily dose until you see a r<span></span>esponse (for </div><div>example- if no response to 20mg daily<span></span>, increase40mg daily inst<span></span>ead of 20mg </div><div>BID). While inpatient, use IV<span></span>. </div><div> <span></span><span></span></div><div>20mg lasix IV = 40 PO = 1 Bumex IV= 10 T<span></span>orsemide PO </div><div> <span></span><span></span></div><div>Consider Diuril or Metolaz<span></span>one for pa<span></span>tients who are diuretic resis<span></span>tant</div><div> <span></span><span></span></div><div>If hyponatremic, it is lik<span></span>ely a hyper<span></span>volemic issue. Diuresis is the appropriate </div><div>response, r<span></span>ather than giving salt t<span></span>abs</div><div> <span></span><span></span></div><div>No pre hydr<span></span>ation for c<span></span>ardiac cathe<span></span>terization or C<span></span>T scan</div><div>Consults: </div><div> <span></span><span></span></div><div>Consider consult to he<span></span>art failure CNS for assis<span></span>tance with c<span></span>omplex patients or </div><div>if you have questions. They are also a gre<span></span>at education resour<span></span>ce for p<span></span>atients. </div><div>Enter as epic order<span></span>.</div></div><div></div></div>
<div><div><img><div>64<span> </span><span>Pos<span></span>t-Op Management<span> </span>Pos<span></span>t-Op Management<span> </span><span>65</span></span></div><div>PULMONARY<span></span>: <span>PLEURAL EFFUSIONS</span></div><div>Type of </div><div>Pleural </div><div>Eusion</div><div>Denition<span> </span><span>Presenta<span></span>tion:<span> </span>Common </span></div><div>causes</div><div>Pleural Fluid </div><div>Interpre<span></span>ta<span></span>tion </div><div>(Lights Criteria)</div><div>Diagnosis<span> </span>T<span></span>reatment </div><div>T<span></span>ransudate</div><div> <span></span><span></span></div><div></div><div>capillaries from: hydros<span></span>tatic </div><div>psi/<span></span>incre<span></span>ased pressure </div><div>(CHF<span></span>, etc) </div><div> <span></span><span></span></div><div></div><div>from nutrition, nephrotic </div><div>syndrome, cirrhosis)</div><div> <span></span><span></span></div><div>Usually occurs bilat<span></span>erally </div><div>Small eusion:<span> </span></div><div>likely </div><div>asymptomatic </div><div>Larger eusion:<span> </span></div><div>dyspnea, cough, </div><div>hypoxia</div><div>Physical exam: </div><div>percussion </div><div></div><div></div><div>absent brea<span></span>th </div><div>sounds over </div><div></div><div> <span></span><span></span></div><div>CHF (most </div><div>common - </div><div>90%)</div><div> <span></span><span></span></div><div>Cirrhosis</div><div> <span></span><span></span></div><div>Nephrosis</div><div> <span></span><span></span></div><div>Prot<span></span>ein ≤ 3 gm% </div><div> <span></span><span></span></div><div></div><div>protein/serum </div><div>protein&lt;0.5</div><div> <span></span><span></span></div><div></div><div>serum LDH &lt; 0.6 </div><div> <span></span><span></span></div><div></div><div>&lt; 2/3 upper limit </div><div>normal</div><div> <span></span><span></span></div><div>CXR P<span></span>A &amp; Lateral, </div><div>later<span></span>al decubitus</div><div> <span></span><span></span></div><div>CT may be indica<span></span>ted </div><div>to evaluat<span></span>e etiolog<span></span>y of </div><div></div><div> <span></span><span></span></div><div>US-Guided Diagnostic </div><div>horac<span></span>entesis  </div><div>c.  <span></span></div><div>protein &amp; lac<span></span>tate </div><div>hydrogenase </div><div></div><div>transudat<span></span>es vs. </div><div>exudates. </div><div>d. <span></span><span>b) PH, tot<span></span>al &amp; </span></div><div><span></span></div><div>counts, gluc<span></span>ose, </div><div>cytology, gram </div><div>st<span></span>ain, culture, etc </div><div><span></span></div><div>exudate subtypes (if </div><div>indicated)</div><div> <span></span><span></span></div><div>Correct underlying c<span></span>ondition</div><div> <span></span><span></span></div><div>Common in immediate pos<span></span>t op setting, </div><div>consider need for diur<span></span>esis</div><div> <span></span><span></span></div><div>Therapeutic thor<span></span>acentesis for severe dyspnea</div><div>E<span></span>xudate</div><div> <span></span><span></span></div><div></div><div>abnormal capillaries leaking </div><div></div><div>drainage such as c<span></span>ancer).</div><div> <span></span><span></span></div><div>Exudat<span></span>es imply local pleural </div><div>diseases</div><div> <span></span><span></span></div><div>Exudat<span></span>es – subtypes: </div><div>e. <span> </span><span>Empyema’<span></span>s: direct </span></div><div>infection of an exudat<span></span>es. </div><div>f.<span></span><span> <span> </span><span>Hemothorax: gross blood </span></span></div><div>in pleural sp<span></span>ace from </div><div>trauma. </div><div>g. <span> </span><span>Chylothorax: thor<span></span>acic </span></div><div>duct disruption causes </div><div>cholester<span></span>ol complex </div><div>accumulation, usually </div><div>associated with </div><div>lymphoma and thoracic </div><div>surgery.</div><div> <span></span><span></span></div><div>Can occur bilat<span></span>erally or </div><div>Unilater<span></span>ally </div><div>Usually </div><div>inammatory </div><div>causes:</div><div> <span></span><span></span></div><div>Bacterial </div><div>Pneumonia</div><div> <span></span><span></span></div><div>Cancer</div><div> <span></span><span></span></div><div>T<span></span>rauma</div><div> <span></span><span></span></div><div>Prot<span></span>ein ≥ 3 gm% </div><div> <span></span><span></span></div><div></div><div>protein/serum </div><div>protein &gt; 0.5</div><div> <span></span><span></span></div><div></div><div>serum LDH &gt; 0.6</div><div> <span></span><span></span></div><div></div><div>&gt; 2/3 upper limit </div><div>normal</div><div>Exudat<span></span>es associated with pneumonias = </div><div>par<span></span>apneumonic pleural eusions. </div><div>Step 1: tr<span></span>eat pneumonia. </div><div></div><div> <span></span><span></span></div><div><span></span></div><div><span></span></div><div>antibiotic.  </div><div> <span></span><span></span></div><div><span></span></div><div><span></span></div><div>thorac<span></span>ostomy  (ches<span></span>t tube) or surger<span></span>y<span></span>. </div><div> <span></span><span></span></div><div><span></span></div><div>decortica<span></span>tion usually)</div><div>Exudat<span></span>es associated with malignancy = </div><div>malignant pleural eusions <span>(L<span></span>ung or breast </span></div><div>cancer c<span></span>ommon)</div><div>T<span></span>reatment options:</div><div> <span></span><span></span></div><div>T<span></span>reat the canc<span></span>er</div><div> <span></span><span></span></div><div><span></span></div><div>may help with symptoms (shortness of bre<span></span>ath, </div><div>dyspnea, et<span></span>c). </div><div> <span></span><span></span></div><div>Pleurodesis.</div><div>PULMONARY<span></span>: <span>PNEUMO<span></span>THORAX</span></div><div>Presence of air or gas in the pleur<span></span>al cavity (ie, the potential space be<span></span>tween the </div><div>visceral and parie<span></span>tal pleura of the lung), which can impair o<span></span>xygenation and/or </div><div>ventilation</div><div>1. <span> </span><span>Etiology</span></div><div>a. <span> </span><span>Entering the pleural sp<span></span>ace during surgery or with sternal wire plac<span></span>ement</span></div><div>b.<span> <span> </span><span>Rup<span></span>tured bleb in pa<span></span>tient with underlying lung disease</span></span></div><div>c. <span> </span><span>Barotr<span></span>auma from alveolar overdis<span></span>tention during mechanical ventilation </span></div><div>may manifest as pneumo<span></span>thorax, subcutaneous emphysema or </div><div>pneumomediastinum </div><div>2. <span> </span><span>Clinical manifes<span></span>tations</span></div><div>a. <span> </span><span>Hypoxia, dyspnea, t<span></span>achypnea</span></div><div>b.<span> <span> </span><span>Airle<span></span>ak on chest tube: may indicate loose c<span></span>onnections along the drainage </span></span></div><div>syst<span></span>em or pneumothor<span></span>ax</div><div>c. <span> </span><span>Subcutaneous emphysema: may develop if air exists under positive </span></div><div>pressure where the pleur<span></span>a has been violated. </div><div>d. <span> </span><span>T<span></span>ension pneumothor<span></span>ax: <span>collapsed lung causing cardiac c<span></span>ompression, </span></span></div><div><span></span><span></span></div><div>output</div><div>e. <span> </span><span><span></span></span></div><div><span> </span><span></span></div><div>3. <span> </span><span> <span></span>T<span></span>reatment consider<span></span>ations</span></div><div>a. <span> </span><span><span></span></span></div><div>assure chest tube is a<span></span>ttached t<span></span>o suction, look for kinks in tubing</div><div>b.<span> <span> </span><span><span></span><span></span></span></span></div><div>oxygen and c<span></span>onsider placement of chest tube/pigtail </div><div>c. <span> </span><span>If patient asympt<span></span>omatic and pneumothorax small, appropria<span></span>te to </span></div><div>obser<span></span>ve with serial ches<span></span>t x-rays</div><div>Referenc<span></span>es:</div><div>Bojar<span></span>, Robert M. (2011) Manual of Perioper<span></span>ative Care in Adult Cardiac Surgery. (5th  <span></span>edition).</div><div> </div><div>PULMONARY<span></span>: <span>PULMONARY HYPER<span></span>TENSION</span></div><div>1. <span> </span><span>Etiology: relat<span></span>ed to primary pulmonar<span></span>y arterial HTN or secondary to </span></div><div>elevations of pressur<span></span>e in the pulmonar<span></span>y venous and capillar<span></span>y sys<span></span>tems</div><div>a. <span> </span><span>Chronic Pulmonar<span></span>y HTN</span></div><div>i. <span> </span>Cong<span></span>enital heart disease, Connec<span></span>tive tissue disease (lupus, </div><div>rheumatoid arthritis, scler<span></span>oderma), Medication/toxin induc<span></span>ed</div><div>ii.  Chronic thromboembolic disease</div><div>iii. <span>Lung dise<span></span>ase: </span></div><div><span> <span></span><span></span><span></span><span></span><span></span><span></span><span></span><span></span><span></span><span></span><span></span><span></span></span></div><div>OSA</div><div>2.  Result of pulmonary vascular remodeling from chr<span></span>onic hypoxia and </div><div></div><div>iv. <span>Le Heart Dise<span></span>ase: <span><span></span><span></span></span></span></div><div>venous pressure</div><div>1.  L<span></span>V systolic or dias<span></span>tolic heart f<span></span>ailure</div><div>2.  Mitral and aortic v<span></span>alve disease </div><div>b.<span> <span> </span><span>Acute Pulmonary HTN</span></span></div><div>i. <span> </span>Pr<span></span>otamine reac<span></span>tion</div><div>1.  T<span></span>ype 3 protamine r<span></span>eaction may result in<span> severe pulmonary </span></div><div>vasoc<span></span>onstriction, sys<span></span>temic v<span></span>asodilation<span> and</span> acute right heart </div><div>failure </div></div><div></div></div>
<div><div><img><div>66<span> </span><span>Pos<span></span>t-Op Management<span> </span>Pos<span></span>t-Op Management<span> </span><span>67</span></span></div><div>2.  T<span></span>ypically improves within 10 minutes of s<span></span>topping protamine</div><div>ii.  <span>Acidosis/Hypox<span></span>emia<span>: lead to increased pulmonary vascular </span></span></div><div>resist<span></span>ance</div><div>iii. T<span></span>ension Pneumothorax</div><div>iv. Pulmonar<span></span>y embolism</div><div>v.<span> <span> </span><span>Acute MR</span> (ie papillary muscle rupture)/<span>L<span></span>V failure<span> leading t<span></span>o high LA </span></span></span></div><div>pressure and pulmonary edema</div><div><span></span><span></span></div><div>2. <span> </span><span>T<span></span>reatment in the acut<span></span>e setting</span></div><div>a. <span> </span><span>Identify underlying cause/<span></span>contributing fact<span></span>ors</span></div><div>b.<span> <span> </span><span>Pulmonary Vasodilators</span></span></div><div>i. <span> </span><span>Indic<span></span>ations<span>: severe pulmonar<span></span>y hypertension (mP<span></span>AP &gt; 25 mmHg; RAP &gt; </span></span></div><div>15 mmHg; CI &lt; 2.0 L/min), right ventricular failure, ARDS with persis<span></span>tent </div><div>hypoxia (P:F &lt; 200), and pos<span></span>t-op lung tr<span></span>ansplant with reperfusion </div><div><span></span><span></span><span></span></div><div>ii.  Inhaled aerosol results in <span>dila<span></span>tion of the pulmonary vascular bed </span></div><div>thereby <span>reducing pulmonary artery pressure</span>, pulmonary vascular </div><div>resist<span></span>ance, and <span>right ventricular aerlo<span></span>ad<span>. This results <span>in improved </span></span></span></div><div>in VQ mismat<span></span>ch and oxygena<span></span>tion<span>.  </span></div><div>1.  <span>Flolan (epopros<span></span>teronol) *Preferr<span></span>ed*</span></div><div> <span> </span>a.  Av<span></span>ailable as IV or aerosol administr<span></span>ation.  IV administra<span></span>tion  </div><div> <span>(rar<span></span>ely used) causes syst<span></span>emic vasodilation</span></div><div> <span> </span><span>b.</span> <span> </span>Starting dose 0.05 mcg/kg<span></span>/min.  When weaning therapy,  </div><div> <span>titra<span></span>te down by 0.01 mcg<span></span>/kg<span></span>/min ever<span></span>y hour as toler<span></span>ated </span></div><div>2.  <span>iNO</span></div><div> <span> </span>a.  Only av<span></span>ailable in aerosol administr<span></span>ation.  </div><div> <span> </span><span>b.</span> <span> </span>Starting dose 20 ppm.  When we<span></span>aning therapy, titr<span></span>ate down by </div><div><span></span><span></span><span></span></div><div><span></span><span></span><span></span></div><div>iii. <span>Sildenal:</span> PDE inhibitor pr<span></span>e<span></span>vents de<span></span>grada<span></span>tion of cGMP and reduces </div><div>pulmonar<span></span>y v<span></span>ascular tone</div><div>a.  S<span></span>tarting dose 10-20mg TID</div><div><span><span> </span><span></span><span></span><span></span></span></div><div><span></span><span></span></div><div>Sussex, UK: Wiley-Blackwell</div><div> </div><div>PULMONARY<span></span>: <span>AC<span></span>UTE RESPIRA<span></span>T<span></span>ORY DIS<span></span>TRESS </span></div><div>SYNDROME (ARDS)</div><div>1. <span> </span><span>P<span></span>athophysiology</span></div><div>a. <span> </span><span><span></span></span></div><div>lungs</div><div>b.<span> <span> </span><span><span></span></span></span></div><div>capillaries</div><div>c. <span> </span><span>Results in non-cardiog<span></span>enic interstitial edema</span></div><div>d. <span> </span><span><span></span><span></span></span></div><div>e. <span> </span><span>Hypoxic and ventilator f<span></span>ailure </span></div><div>2. <span> </span><span>Pre-disposing conditions: </span></div><div>a. <span> </span><span><span></span><span></span></span></div><div><span> </span><span></span><span></span><span></span><span></span><span></span></div><div>however ARDS only occurs in &lt;1% of pa<span></span>tients underg<span></span>oing open heart </div><div>surgery</div><div>ii.  Sepsis</div><div>3. <span> </span><span>Diagnostic Crit<span></span>eria</span></div><div>a. <span> </span><span>Acute onset</span></div><div>b.<span> <span> </span><span><span></span><span></span><span></span><span></span></span></span></div><div>c. <span> </span><span>PCWP &lt;18, or no clinical evidence of L heart f<span></span>ailure, non-cardiogenic </span></div><div>pulmonar<span></span>y edema</div><div>d. <span> </span><span><span></span><span></span><span></span><span></span></span></div><div>i. <span> </span>P<span></span>/F r<span></span>atio = PaO2 ÷ FiO</div><div>1.  Ex: P<span></span>aO2 90 on FiO2 40% = 90 ÷ 0.4 = 225</div><div>ii.  <span>P<span></span>/F &lt; 200 is associated with signicant shunt and indic<span></span>ates ARDS</span></div><div>iii. P<span></span>/F 200-300 indicat<span></span>es acute lung injur<span></span>y</div><div>4. <span> </span><span>Management</span></div><div>a. <span> </span><span>Optimize hemodynamics and volume s<span></span>tatus, diurese when indica<span></span>ted</span></div><div>b.<span> <span> </span><span>Op<span></span>timize nutrition</span></span></div><div>c. <span> </span><span><span></span><span></span></span></div><div></div><div>d. <span> </span><span>Lung Prot<span></span>ective Ventilation (LPV) Pr<span></span>otoc<span></span>ol: <span>Limits ventilator induced </span></span></div><div>lung injur<span></span>y</div><div>i. <span> </span>Purpose: T<span></span>o maximize gas exchange using low tidal volumes (4-6 mL/</div><div>kg) and minimizing plateau pr<span></span>essures (&lt; 30 cm H2O) in all patients </div><div>with ARDS</div><div> <span></span><span></span><span></span></div><div></div><div>iii. <span>Goals: VT 6 mL/k<span></span>g, pH 7.30 – 7.45, Pplat &gt; 30 cm H2O, EIP</span></div><div>iv. Prescriber must de<span></span>termine ventilat<span></span>or mode (VCV or PCV) and PEEP </div><div>(st<span></span>andard or high)</div><div>v.<span></span><span> <span> </span>Volume Control Ventila<span></span>tion (VCV)</span></div><div>1.  Set VT at 8 mL/k<span></span>g using patient’<span></span>s predicted body weight (PBW).  </div><div>Slowly decrease VT by 1 mL/k<span></span>g until target VT is achieved </div><div>2.  Set respir<span></span>atory rate to b<span></span>aseline minute ventilation (do not exc<span></span>eed 35 </div><div>brea<span></span>ths/min)</div><div>3.  Add PEEP at 5-7 cm H2O to g<span></span>oal P<span></span>aO2 &gt; 55 and SaO2 &gt; 88% (see </div><div>table below)</div><div>4.  Adjust VT t<span></span>o achie<span></span>ve t<span></span>arget plate<span></span>au pressure (Pplat)</div><div> <span> </span>a.  If Ppla<span></span>t &gt; 30 cm H2O, decrease VT by 1 mL/kg until Pplat &lt; 30 or  </div><div> <span>VT 4 mL/kg</span></div><div> <span> </span><span>b.</span> <span> </span>If Pplat &lt; 25 and VT &lt; 6 mL/kg, increase VT by 1 mL/k<span></span>g until Pplat  </div><div> <span>&gt; 25 or VT 6 mL/kg</span></div><div> <span> </span>c.  If Pplat &lt; 30 and vent dysnchrony, may incr<span></span>ease VT by 1 mL/kg to <span></span> </div><div> <span>8 mL/kg and/<span></span>or increase sedation</span></div><div>5.  Adjust r<span></span>espiratory rate t<span></span>o achie<span></span>ve t<span></span>arget pH </div><div>6.  If pH &lt; 7.30, incre<span></span>ase RR to max 35 bre<span></span>aths/min</div><div>7.  If pH &lt; 7.15 and RR 35 bre<span></span>aths/min, incre<span></span>ase VT by 1 mL/kg to a max </div><div>of 8 mL/kg until pH &gt; 7.15</div><div>vi. <span></span> Pressure Control V<span></span>entilation (PCV)</div><div>1.  PCV is similar to above however end-inspira<span></span>tor<span></span>y pressure (EIP) is </div><div>adjust<span></span>ed to achieve goal VT (tidal volume).</div><div>2.  If EIP &lt; 10 cm H2O and VT &gt; 7 mL/kg, incre<span></span>ase EIP in order to </div><div>increase t<span></span>o a maximum EIP 35 cm H2O </div><div>3.  If EIP is decre<span></span>ased to 10 cm H2O &gt; PEEP and VT &gt; 7 mL/kg or if </div><div>patient exhibiting incr<span></span>eased work of breathing, c<span></span>onsider increasing </div><div>sedation.  If unable to incr<span></span>ease sedation, may incr<span></span>ease VT by 1 mL/</div><div>kg to max VT 8 mL/k<span></span>g.</div><div>4.  Once work of br<span></span>eathing decreased, decr<span></span>eased EIP b<span></span>ack to t<span></span>arge<span></span>t VT </div><div>5-7 mL/kg</div></div><div></div></div>
<div><div><img><div>68<span> </span><span>Pos<span></span>t-Op Management<span> </span>Pos<span></span>t-Op Management<span> </span><span>69</span></span></div><div>vii. PEEP<span></span>/FiO2 titration</div><div>1.  Goal SaO2 88-95% or P<span></span>aO2 55-80%</div><div>FiO2<span> </span>30%<span> </span>40%<span> </span>50%<span> </span>60%<span> </span>70%<span> </span>80%<span> </span>90%<span> </span>100%</div><div>St<span></span>andard PEEP<span> </span>5<span> </span>5-8<span> </span>8-10<span> </span>10<span> </span>10-14<span> </span>14<span> </span>14-18<span> </span>18-20</div><div>High PEEP<span> </span>8-10<span> </span>10-12<span> </span>12-14<span> </span>14-16<span> </span>16-18<span> </span>18-20<span> </span>20-22<span> </span>22-24</div><div>Sources:</div><div><span></span><span></span></div><div>UK: Wiley-Blackwell</div><div>Marino, P<span></span>. (2009). The Little ICU Book. Philadelphia, P<span></span>A: Lippincott Williams &amp; Wilkins</div><div> </div><div>PULMONARY<span></span>: <span>A<span></span>TELECT<span></span>ASIS</span></div><div>At<span></span>elect<span></span>asis:<span> collapse or closure of a lung r<span></span>esulting in reduced or absent gas </span></div><div>exchange</div><div>1. <span> </span><span>Etiology:</span></div><div>a. <span> </span><span>Obstructive: block<span></span>age in the pro<span></span>ximal air<span></span>way leads t<span></span>o nonventilated </span></div><div>alveoli that collapse</div><div>b.<span> <span> </span><span>P<span></span>assive/Compressive:<span><span></span></span></span></span></div><div><span></span></div><div>c. <span> </span><span><span></span><span></span><span>  pain (splinting), over-seda<span></span>tion, or prolonged </span></span></div><div>supine positioning</div><div>2. <span> </span><span>Clinical manifes<span></span>tations</span></div><div>a. <span> </span><span>Hypoxia, dyspnea</span></div><div>b.<span> <span> </span><span><span></span></span></span></div><div>c. <span> </span><span>Fever, elev<span></span>ated WBC count, PNA</span></div><div>3. <span> </span><span>T<span></span>reatment c<span></span>onsiderations</span></div><div>a. <span> </span><span>Identify and address underlying causes: </span></div><div>i. <span> </span>Achieve adequat<span></span>e pain control, decre<span></span>ase sedation</div><div> <span></span></div><div>iii. Assess for evidence of PNA and trea<span></span>t appropriately</div><div>b.<span> <span> </span><span>Alveolar R<span></span>ecruitment Maneuvers: </span></span></div><div>i. <span> </span>Using incr<span></span>eased PEEP via ventilator or CP<span></span>AP </div><div>1.  Incre<span></span>ase mean airway pressure to open closed alveoli t<span></span>o increase </div><div>surfac<span></span>e area for gas ex<span></span>change</div><div>2.  Decre<span></span>ase VQ mismat<span></span>ch/<span></span>intr<span></span>apulmonar<span></span>y shunting (improves </div><div>ventilation to perfused ar<span></span>eas)</div><div>ii.  Incentive spiromet<span></span>er. Goal volume &gt;1L.</div><div>1.  Maintains F<span></span>unctional Reser<span></span>ve Cap<span></span>acity (FRC)</div><div>2.  Prevents and improves a<span></span>telectasis</div><div>c. <span> </span><span>Bronchial Hygiene Therap<span></span>y (“Pulmonary T<span></span>oilet”)</span></div><div>1.  Purpose: T<span></span>o help loosen and mobilize pulmonary secretions </div><div>2.  Indications: mobiliz<span></span>ation of ret<span></span>ained secretions, atelec<span></span>tasis, optimize </div><div>deliver<span></span>y of bronchodila<span></span>tors</div><div>3.  Contraindic<span></span>ations: hemodynamic instability<span></span>, recent f<span></span>acial/<span></span>oral/<span></span>cranial </div><div><span></span><span></span><span></span><span></span></div><div>active hemoptysis, nause<span></span>a/vomiting, radiographic evidence of bled/</div><div>bullae, frac<span></span>tured ribs or unst<span></span>able chest, untreat<span></span>ed pneumothorax, and </div><div>compromised c<span></span>ardiac sta<span></span>tus or arrhythmias.</div><div>4.  Therapies (may be c<span></span>ombined with bronchodilating nebulizers for  </div><div></div><div>Acapella<span> </span>Intrapulmonary Per<span></span>cussive </div><div>Ventilation (IPV)</div><div>Chest Physio<span></span>therapy (CPT)</div><div>A resistive/vibr<span></span>ator<span></span>y device </div><div>that is used to open the </div><div>airways and provide </div><div>oscillating vibra<span></span>tions to help </div><div>loosen secretions</div><div>Pneumatic device that </div><div>delivers pressurized </div><div>minibursts of g<span></span>as at rates of </div><div>100-225 cycles per minute </div><div>through a mouthpiece t<span></span>o </div><div>achieve alveolar recruitment</div><div>T<span></span>echnique that uses manual </div><div>or mechanical ext<span></span>ernal </div><div>percussion and vibra<span></span>tion </div><div>to loosen secretions and </div><div>promote cle<span></span>arance</div><div>Sources:</div><div><span></span><span></span></div><div>UK: Wiley-Blackwell</div><div>Adams, G. (2006). On Call Surgery, 3rd Edition. Philadelphia, P<span></span>A: Saunders Elsevier</div><div>Marino, P<span></span>. (2009). The Little ICU Book. Philadelphia, P<span></span>A: Lippincott Williams &amp; Wilkins</div><div>GI: <span>AC<span></span>UTE HEP<span></span>A<span></span>TIC D<span></span>YSFUNCTION</span></div><div>About 25% of patients will develop transient hyperbilirubinemia a<span></span>er open heart </div><div>surgery, but f<span></span>ewer than 1% of patients will have signicant hepatocellular damage </div><div>leading to chronic hepatitis or liver failur<span></span>e</div><div>1. <span> </span><span>Risk F<span></span>actors</span></div><div>a. <span> </span><span>Preexisting liver dise<span></span>ase: </span></div><div>i. <span> </span>Elev<span></span>ated liver enzymes (AS<span></span>T<span></span>/AL<span></span>T), elevated bilirubin, or evidence of </div><div>synthetic dysfunction (low albumin, high INR)</div><div>ii.  Elevated bilirubin in p<span></span>atient w/hx CHF is s<span></span>trongest predic<span></span>tor of post-op </div><div>liver dysfunction</div><div>b.<span> <span> </span><span>Comorbidities: CHF (high right sided pressur<span></span>e leading to conges<span></span>tive </span></span></div><div>hepat<span></span>omegaly), DM, HTN</div><div>c. <span> </span><span>Preopera<span></span>tive cardiogenic shock: may have evidence of “shock liver” prior </span></div><div>to surg<span></span>er<span></span>y</div><div>d. <span> </span><span>Operative risk f<span></span>actors:</span></div><div>i. <span> </span>L<span></span>ong cardiopulmonar<span></span>y bypass time</div><div>ii.  Complex operations (ie c<span></span>ombined CABG-valve, multiple valves)</div><div>iii. Multiple blood tr<span></span>ansfusions</div><div>e. <span> </span><span>Post<span></span>-operative risk f<span></span>actors</span></div><div>i. <span> </span>L<span></span>ow cardiac output syndrome</div><div>ii.  Use of multiple inotropes/IABP</div><div>II.  <span>E<span></span>tiolog<span></span>y:<span> <span>may result f<span></span>rom either decreased liver perfusion or systemic </span></span></span></div><div>congestion</div><div>Hepat<span></span>ocellular Necrosis<span> </span>Hyperbilirubinemia</div><div> <span></span><span></span></div><div>Low car<span></span>diac output stat<span></span>es <span>(requiring </span></div><div>inotropes/v<span></span>asopressors) </div><div><span> decreased </span></div><div>hepatic perfusion</div><div> <span></span><span></span></div><div>Right heart failur<span></span>e/severe TR<span> <span></span></span></div><div>chronic passive hep<span></span>atic congestion</div><div> <span></span><span></span></div><div>Medications (T<span></span>ylenol, Plavix, sta<span></span>tins)</div><div> <span></span><span></span></div><div>Pos<span></span>t-tr<span></span>ansfusion hepatitis/CMV (late </div><div>manifest<span></span>ation)</div><div> <span></span><span></span></div><div>Hemolysis<span> (par<span></span>avalvular leak, long </span></div><div>pump run, sepsis, multiple transfusions, </div><div>ECMO, drugs)</div><div> <span></span><span></span></div><div>Intrahep<span></span>atic choles<span></span>tasis<span> (hep<span></span>atitis, </span></div><div>hepat<span></span>ocellular necrosis, TPN, b<span></span>acterial </div><div>infections, medica<span></span>tions, benign </div><div>cholest<span></span>asis)</div><div> <span></span><span></span></div><div>E<span></span>xtr<span></span>ahepatic cong<span></span>estion<span> (biliar<span></span>y tr<span></span>act </span></div><div>obstruction)</div></div><div></div></div>
<div><div><img><div>70<span> </span><span>Pos<span></span>t-Op Management<span> </span>Pos<span></span>t-Op Management<span> </span><span>71</span></span></div><div>2. <span> </span><span>Clinical manifes<span></span>tations</span></div><div>a. <span> </span><span>Jaundice</span></div><div>b.<span> <span> </span><span>Co<span></span>agulopathy</span></span></div><div>c. <span> </span><span>Refract<span></span>or<span></span>y acidosis</span></div><div>d. <span> </span><span>Hypoglycemia</span></div><div>e. <span> </span><span>Renal failure (hep<span></span>atorenal syndrome)</span></div><div>f.<span></span><span> <span> </span><span>Encephalopa<span></span>thy</span></span></div><div>3. <span> </span><span>Work<span></span>-up: <span>in addition to basic labs/LFT’<span></span>s consider further investigation with the </span></span></div><div>following</div><div>a. <span> </span><span>Order T<span></span>ot<span></span>al and Fractiona<span></span>ted bilirubin: </span></div><div>i. <span> </span>Mos<span></span>tly <span>Conjugat<span></span>ed<span> (Direct): biliary obstruction (s<span></span>tone, mass, PSC) or </span></span></div><div>cholest<span></span>asis (sepsis/hypoperfusion sta<span></span>tes, choles<span></span>tasis, TPN)</div><div>ii.  Mostly <span>Unconjug<span></span>ated<span> (Indirec<span></span>t): hemolysis, hepatic conges<span></span>tion/</span></span></div><div>decreased bili up<span></span>take (heart f<span></span>ailure)</div><div>b.<span> <span> </span><span>Assess for <span>hemolysis</span>: LDH, haptoglobin, plasma fr<span></span>ee hemoblogin, </span></span></div><div>reticulocyte c<span></span>ount</div><div>c. <span> </span><span>A<span></span>ssess for <span>right he<span></span>art failure<span>/ </span></span></span></div><div>TR: echo</div><div>d. <span> </span><span>A<span></span>ssess for <span>biliary obstruc<span></span>tion/cholecys<span></span>titis<span>: Alk Phos, right upper </span></span></span></div><div><span></span><span></span><span></span></div><div>i. <span> </span>Acut<span></span>e Cholec<span></span>ys<span></span>titis: gall bladder wall thickening, str<span></span>anding, </div><div></div><div>ii.  Stone/<span></span>obstruction: s<span></span>tone, ductal dilit<span></span>ation</div><div>e. <span> </span><span>Revie<span></span>w medica<span></span>tions for hepato<span></span>toxicity</span></div><div>f.<span></span><span> <span> </span><span>A<span></span>ssess for acut<span></span>e hepatitis: hepatitis p<span></span>anel</span></span></div><div>g. <span> </span><span>A<span></span>ssess for synthe<span></span>tic dysfunction: coag p<span></span>anel, albumin, glucose, lactat<span></span>e</span></div><div>h. <span> </span><span>A<span></span>ssess for encephalop<span></span>athy: exam, ammonia level</span></div><div>4. <span> </span><span>Management<span>: <span>elevat<span></span>ed bilirubin usually benign and self-limited post-oper<span></span>ative </span></span></span></div><div>occurrenc<span></span>e. Will gradually improve with normal hemodynamics unless severe </div><div>underlying liver pathology is present</div><div>a. <span> </span><span>Address underlying cause</span></div><div>i. <span> </span>Right he<span></span>art failure/TR: Refer t<span></span>o “Right Heart Failure<span></span>” section</div><div>ii.  Bilar<span></span>y obstruc<span></span>tion, consider:</div><div>1.  ERCP<span></span>/MRCP: for st<span></span>one in common bile duct w/<span></span>acute cholangitis (GI </div><div>medicine consult)</div><div>2.  P<span></span>ercut<span></span>aneous cholecystos<span></span>tomy tube (placed by IR)</div><div>3.  Cholecystec<span></span>tomy (General surgery consult)</div><div>b.<span> <span> </span><span>Monitor and tr<span></span>eat hypoglycemia</span></span></div><div>c. <span> </span><span>Judicious reversal of coagulop<span></span>athy if present</span></div><div>d. <span> </span><span>Avoid hepatot<span></span>oxic medications</span></div><div>e. <span> </span><span>If Ammonia elevated and evidence of enc<span></span>ephalopathy: consider </span></div><div>Lactulose 30 Q8</div><div>f.<span></span><span> <span> </span><span>Monitor for <span>lactic acidosis </span>(imp<span></span>aired lacta<span></span>te met<span></span>abolism) and correct pH </span></span></div><div>with sodium bicarb when indica<span></span>ted</div><div>Sources:</div><div><span></span><span></span></div><div>UK: Wiley-Blackwell</div><div>Roy-Chowdhury, N. Diagnostic appro<span></span>ach to the adult with jaundice or asymp<span></span>tomatic </div><div>hyperbilirubinemia. www.uptoda<span></span>te.com</div><div>GI: <span>C<span></span>ONSTIP<span></span>A<span></span>TION AND ILLEU<span></span>S</span></div><div>Cardiac Surg<span></span>er<span></span>y P<span></span>ost<span></span>-Operative Bo<span></span>wel regimen:</div><div>Medication<span> </span>Dose<span> </span>Frequency<span> </span>Onset of <span></span>Action</div><div>Docusate (Colac<span></span>e) <span> </span>200mg PO<span> </span>BID<span> </span>24-72 hours</div><div>Polyethylene Glyc<span></span>ol (Miralax)<span> </span>17g Pack<span></span>et<span> </span>Daily<span> </span>1-4 days</div><div>Senna (Senokot)<span> </span>2 tabs PO<span> </span>qHS PRN<span> </span>6-12 hours</div><div>Bisacodyl (Dulcolax) Supposit<span></span>or<span></span>y<span> </span>10mg Rec<span></span>tal<span> </span>Daily PRN<span> </span>15-60 minutes</div><div>Magnesium hydroxide (MOM)<span> </span>30mL Oral<span> </span>Q8 hours PRN</div><div>Magnesium Citrat<span></span>e<span> </span>150-300mL Oral<span> </span>Once<span> </span>30 minutes- 3 hours</div><div>Lactulose<span> </span>20mg<span> </span>TID<span> </span>Up to 24 -48 hours</div><div>St<span></span>anford BOMB<span> </span>Sterile wa<span></span>ter for </div><div>irrigation 300mL, </div><div>magnesium citrat<span></span>e </div><div>200mL, Glucerin Bulk </div><div>100% 199mL</div><div>Once<span> </span>Immediate</div><div> </div><div>*For VAD bowel r<span></span>egimen pro<span></span>tocol see r<span></span>eference mat<span></span>erials VAD BOWEL REGIMEN </div><div>page 138.</div><div>Ileus Management:</div><div> <span></span><span></span></div><div>Management of ileus s<span></span>tart<span></span>s with correc<span></span>tion of underlying medical conditions, </div><div>such as sepsis, electrolyt<span></span>e abnormalities, particularly hypokalemia, </div><div>hyponatremia, and hypomagnesemia. </div><div> <span></span><span></span></div><div>Consider need for NG or rect<span></span>al tube for decompression. F<span></span>or se<span></span>vere illeus- </div><div>consider c<span></span>onsult to general surg<span></span>er<span></span>y or GI. </div><div> <span></span><span></span></div><div>Bowel regimen for ileus manag<span></span>ement can include BID suppositor<span></span>y<span></span>/enema. </div><div>DO NOT U<span></span>SE PERIST<span></span>AL<span></span>TIC AGENT<span></span>S FOR ILLEUS MANAGEMENT<span></span>. </div><div> <span></span><span></span></div><div>For pro<span></span>tracted ileus, contr<span></span>ast studies may be r<span></span>equired to rule out mechanical </div><div>obstruction.</div><div> <span></span><span></span></div><div>Discontinue and limit the use of medica<span></span>tions that produce ileus (eg, opia<span></span>tes, </div><div>narco<span></span>tics), and use (NSAIDs) instead (unless c<span></span>ontraindicated). </div><div> <span></span><span></span></div><div>Advisable to delay or<span></span>al feeding until ileus resolves clinic<span></span>ally. Consider need </div><div></div><div> <span></span><span></span></div><div>Most cases of pos<span></span>toperative ileus r<span></span>esolve with watchful waiting and </div><div>supportive trea<span></span>tment<span></span>. </div><div><span></span><span>see <span>page 91.</span></span></div><div>GI: <span>POS<span></span>T<span></span>-OPERA<span></span>TIVE GI BLEEDING</span></div><div>1.<span> <span> </span><span>Upper GIB<span>: <span>may pr<span></span>esent<span></span> as he<span></span>matem<span></span>esis<span></span>, bloo<span></span>dy NG/<span></span>OG tub<span></span>e outp<span></span>ut, or m<span></span>elena </span></span></span></span></div><div>a. <span> </span><span>Most commonly fr<span></span>om: </span></div><div>i. <span> </span>S<span></span>tress ulcers (peptic, duodenal, g<span></span>astric)</div><div>ii.  Esophagogas<span></span>tritis</div><div>b.<span> <span> </span><span><span></span><span></span><span></span><span></span></span></span></div><div>reperfusion injury and increased gas<span></span>tric acidity from any of the following:</div><div> <span></span><span></span></div><div> <span></span></div><div>3.  Low car<span></span>diac output stat<span></span>es</div></div><div></div></div>
<div><div><img><div>72<span> </span><span>Pos<span></span>t-Op Management<span> </span>Pos<span></span>t-Op Management<span> </span><span>73</span></span></div><div>4.  Critical illness</div><div>c. <span> </span><span>Risk Fact<span></span>ors</span></div><div>i. <span> </span>Pr<span></span>e<span></span>-oper<span></span>ative: older age, history if PUD/GERD</div><div>ii.  Intra-opera<span></span>tive: long duration of CPB, valve oper<span></span>ations, re-operations</div><div>iii. P<span></span>ost-oper<span></span>ative: low CO, prolong<span></span>ed mechanical ventilation (&gt;48 hours), </div><div>co<span></span>agulopathy<span></span>, anticoagulation, anti-pla<span></span>telet therapy</div><div>d. <span> </span><span>Preventative measur<span></span>es</span></div><div><span> </span><span></span><span></span></div><div>mucosa that helps maint<span></span>ain mucosal struc<span></span>tural and functional </div><div>integrity </div><div>ii.  Acid suppression</div><div>1. <span></span>Indications for s<span></span>tress ulcer prophylaxis</div><div> <span></span><span></span></div><div>echanical ventilation for </div><div>&gt;48 hours</div><div> <span></span><span></span></div><div>Spinal cord injury</div><div> <span></span><span></span></div><div>Use of 2 anti-plt agents </div><div>(Plavix, ASA, cilost<span></span>azol, </div><div>ticagrelor<span></span>, dipyridamole)</div><div> <span></span><span></span></div><div>Coagulopa<span></span>thy (Plt &lt;50, INR </div><div>&gt;1.5, or PTT 2x b<span></span>aseline)</div><div> <span></span><span></span></div><div>Solid organ tr<span></span>ansplant in </div><div>ICU set<span></span>ting</div><div> <span></span><span></span></div><div>Any 2 of the following:</div><div><span></span><span> </span><span>Sepsis</span></div><div><span></span><span> </span><span>ICU st<span></span>ay &gt;7 days</span></div><div><span></span><span> </span><span>Occult bleed las<span></span>ting &gt;6 days</span></div><div><span></span><span> </span><span>High dose ster<span></span>oids w/daily dose </span></div><div> <span></span><span></span></div><div> &gt;250mg hydrocortisone</div><div> <span></span><span></span></div><div> &gt;50mg </div><div>methylprednisolone</div><div> <span></span><span></span></div><div>&gt;60mg prednisone</div><div> <span></span><span></span></div><div>&gt;10mg dexamethasone</div><div> <span></span><span></span></div><div>Hx GERD/GI ulc<span></span>ers/acid suppressant </div><div>therapy</div><div>2. <span></span>Prot<span></span>on pump inhibitors (PPI’<span></span>s):<span></span></div><div>H2 blockers in reducing incidenc<span></span>e of hemorrhagic gastritis and </div><div>ulcer<span></span>ation</div><div>a.  P<span></span>antopr<span></span>azole 40mg IV<span></span>/PO daily</div><div>b.<span> <span> </span>Use is not without risk!</span></div><div><span></span><span><span> </span><span></span><span></span></span></div><div> <span></span><span>ii. <span> </span>PPI use is independent risk factor f<span></span>or nosocomial PNA</span></div><div> <span></span><span>iii. <span> </span>May cause hypomagnasemia</span></div><div>3. <span></span>H2 Blockers: </div><div>a.  F<span></span>amotidine 20mg IV Q12</div><div>b.<span> <span> </span>Associated with thrombocytopenia</span></div><div>e. <span> </span><span>Tr<span></span>eatment consider<span></span>ations:</span></div><div><span> </span><span></span><span></span></div><div>1. <span></span><span>Correct co<span></span>agulopathy when indicat<span></span>ed</span></div><div>2. <span></span><span>Consider DDAVP for suspect<span></span>ed platelet dysfunction if uremia is pr<span></span>esent</span></div><div>3. <span></span><span>T<span></span>ransfuse blood if hemodynamically unst<span></span>able </span></div><div>ii.  Monitor vital signs for shock. Assess volume sta<span></span>tus</div><div>iii. Flush NG/OG tube if pr<span></span>esent</div><div>iv. <span>If bleeding continues, pa<span></span>tient is hemodynamically unst<span></span>able and/or </span></div><div>there is an inappropria<span></span>te response to blood tr<span></span>ansfusion consider </div><div>GI consult f<span></span>or EGD (esophagogastr<span></span>oduodenoscopy)</div><div><span><span> </span><span></span><span></span></span></div><div></div><div>vi. <span>Acid suppression (trea<span></span>tment dosing):</span></div><div>1.<span> <span></span>Pepcid 20mg IV q8</span></div><div>2. <span></span><span>Protonix 80mg IV push + c<span></span>ontinuous infusion 8mg<span></span>/hr </span></div><div>2. <span> </span><span>Lower GIB: <span>dark t<span></span>o bright red blood from the rectum. Color of blood is </span></span></div><div>associated with the length of time in the GI tr<span></span>act</div><div>a. <span> </span><span>Etiologies: </span></div><div>i. <span> </span>Hemorrhoids</div><div>ii.  Mesenteric ischemia/<span></span>ischemic colitis</div><div>1.  P<span></span>eriods of prolonged hypoperfusion fr<span></span>om</div><div>a.  Low c<span></span>ardiac output sta<span></span>te</div><div>b.<span> <span> </span>Atheroscler<span></span>otic embolism or mesenteric thr<span></span>ombosis</span></div><div>2.  May present as prof<span></span>ound ileus, abdominal pain out of proportion </div><div>3.  May be associated with elev<span></span>ated lacta<span></span>te, GIB, sepsis (bacterial </div><div>transloc<span></span>ation)</div><div>iii. Diverticulosis</div><div>iv. Arteriovenous malformations (A<span></span>VM’s): See L<span></span>VAD pos<span></span>t-oper<span></span>ative </div><div>consider<span></span>ations</div><div>v.<span> <span> </span>Ulcera<span></span>tion/tissue breakdown fr<span></span>om rect<span></span>al tube</span></div><div>b.<span> <span> </span><span>Work up:</span></span></div><div>i. <span> </span>E<span></span>xamine patient looking for hemorrhoid or tissue br<span></span>eakdown</div><div>ii.  Consider placing NG/OG tube to assess for presenc<span></span>e of upper GIB</div><div>iii. <span></span><span><span></span><span></span></span></div><div>1.<span> <span></span>Correct co<span></span>agulopathy when indicat<span></span>ed</span></div><div>2. <span></span><span>Consider DDAVP for suspect<span></span>ed platelet dysfunction if uremia is </span></div><div>present</div><div>3. <span></span><span>T<span></span>ransfuse blood if hemodynamically unst<span></span>able </span></div><div>iv. <span>If bleeding continues, pa<span></span>tient is hemodynamically unst<span></span>able and/or </span></div><div>there is an inappropria<span></span>te response to blood tr<span></span>ansfusion consider </div><div>GI consult f<span></span>or EGD and/or sigmo<span>idoscopy<span></span>/<span></span>colonoscopy </span></div><div>1.  If these are neg<span></span>ative, source may be small bowel</div><div>v.<span> <span> </span>KUB/CT sc<span></span>an to assess for evidence of ischemic bowel</span></div><div>1.  Pneumotosis (air in the bowel w<span></span>all), venous gas, bowel wall </div><div>thickening</div><div> <span></span><span></span><span></span><span></span></div><div>vi. Radionuclide scanning (ie tagg<span></span>ed RBC scan) to localize sourc<span></span>e of bleed</div><div>vii. Angiography: </div><div>1.  May be diagnostic and ther<span></span>apeutic if bleeding can be localized</div><div> <span></span><span></span></div><div>detec<span></span>tion</div><div>Sources:</div><div><span></span><span></span></div><div>UK: Wiley-Blackwell</div><div>Adams, G. (2006). On Call Surgery, 3rd Edition. Philadelphia, P<span></span>A: Saunders Elsevier</div><div>Marino, P<span></span>. (2009). The Little ICU Book. Philadelphia, P<span></span>A: Lippincott Williams &amp; Wilkins</div><div>GI: <span>MALNUTRITION (TUBE FEEDING/TPN)</span></div><div>T<span></span>ube Feeding: </div><div> <span></span><span></span></div><div>Consult with dietician to evalua<span></span>te adequate or<span></span>al intak<span></span>e vs need for tube </div><div>feeding.</div><div> <span></span><span></span></div><div>Use <span>IP GEN T<span></span>ube Feeding order se<span>t to plac<span></span>e the following orders:</span></span></div><div><span></span><span> </span><span>Consult to nutrition </span></div><div><span></span><span> </span><span>Place K<span></span>OF (Small bore feeding tube)</span></div><div> <span></span><span></span></div><div>If Feeding tube plac<span></span>ed via super user RN with Cortrak<span></span>, no need for K<span></span>UB </div></div><div></div></div>
<div><div><img><div>74<span> </span><span>Pos<span></span>t-Op Management<span> </span>Pos<span></span>t-Op Management<span> </span><span>75</span></span></div><div>to evaluat<span></span>e location</div><div> <span></span><span></span></div><div>If feeding tube is plac<span></span>ed without use of Cortrak<span></span>, obtain K<span></span>UB to ensure tip </div><div>of feeding tube is post pyloric</div><div> <span></span><span></span></div><div>If feeding tube is unable to be plac<span></span>ed post pyloric, consider use of </div><div>Reglan t<span></span>o promot<span></span>e motility<span></span>. </div><div> <span></span><span></span></div><div>In some cases, trickle tube feeds may be s<span></span>tarted while the tip </div><div>of feeding tube is in the st<span></span>omach (be<span></span>war<span></span>e of increased risk of </div><div>aspira<span></span>tion)</div><div><span></span><span> </span><span>T<span></span>ube feeds are typically s<span></span>tarted @ 20cc/hr and incr<span></span>eased by 20 q8 hours </span></div><div>until goal r<span></span>ate is achieved. (T<span></span>rickle or trophic TF rat<span></span>e 10-20cc/hr)</div><div><span></span><span> </span><span>Obt<span></span>ain daily labs: CMP<span></span>, Phos, Mag, Pre albumin (3x weekly)</span></div><div><span></span><span> </span><span>Glucose management via subQ insulin (Gluc<span></span>ose checks q6) or insulin drip </span></div><div>TPN= T<span></span>otal p<span></span>arenter<span></span>al nutrition </div><div> <span></span><span></span></div><div><span></span><span></span><span></span></div><div>Prolonged ileus. Consult with die<span></span>tician to assess nutrition needs. </div><div> <span></span><span></span></div><div>Needs centr<span></span>al access (TPN is administ<span></span>ered via dedicated line), c<span></span>onsider need </div><div>for PIC<span></span>C line placement. </div><div> <span></span><span></span></div><div>TPN must be order<span></span>ed by 1400.  Use IP GEN TPN/PPN Adult Protocol or<span></span>der set  </div><div>to place the f<span></span>ollowing orders</div><div><span></span><span> </span><span>Consult to nutrition  </span></div><div><span></span><span> </span><span>PICC Line plac<span></span>ement if needed for adequate acc<span></span>ess</span></div><div><span></span><span> </span><span>TPN + Lipids</span></div><div><span></span><span> </span><span>Obt<span></span>ain daily labs: CMP<span></span>, Phos, Mag, T<span></span>riglycerides</span></div><div><span></span><span> </span><span>Glucose c<span></span>ontrol via insulin placed in TPN mixture or Insulin drip (some </span></div><div>patient<span></span>s may require both)</div><div> <span></span><span></span></div><div><span></span><span></span><span></span><span></span></div><div>dysturb<span></span>ances, loss of gut barrier<span></span>, acalculus cholecystitis, refeeding syndr<span></span>ome, </div><div>&amp;  hyperosmolality</div><div>GU<span></span>/FEN: <span>ACID BASE DISTURBANCES </span></div><div>The normal buering systems of the body (bic<span></span>arbonate, hemoglobin, phosphate, </div><div>and protein) are f<span></span>requently overwhelmed by disease states or altered f<span></span>rom the </div><div>eects of car<span></span>diopulmonar<span></span>y bypass.</div><div>referenc<span></span>e see <span>page 124.</span></div><div>Met<span></span>abolic Acidosis: </div><div>accumulation of acids in the serum. </div><div>1. <span> </span><span>Anion Gap<span> = Na – (Cl + HCO3).  Normal A<span></span>G 8-12 mmol/L. </span></span></div><div>a. <span> </span><span>Correct for hypo<span></span>albuminemia.  AG + (2.5 x (4-albumin)).   </span></div><div>Elevated A<span></span>G &gt; 13 mmol/L</div><div>High Anion Gap Acidosis<span> </span>Normal Anion Gap Acidosis</div><div> <span></span><span></span></div><div>Lactic acidosis (see below)</div><div> <span></span><span></span></div><div>Renal failur<span></span>e (reduced acid </div><div>secretion)</div><div> <span></span><span></span></div><div>Rhabdomyolysis</div><div> <span></span><span></span></div><div>Medications (ASA, ethylene, </div><div>methanol)</div><div> <span></span><span></span></div><div>Keto<span></span>acidosis</div><div> <span></span><span></span></div><div>Diarrhea (high bicarb loss)</div><div> <span></span><span></span></div><div>Renal T<span></span>ubular Acidosis (loss of bicarb </div><div>resorption)</div><div> <span></span><span></span></div><div>Carbonic anhydrase inhibitors (ie Diamo<span></span>x, </div><div>increased bicarb secr<span></span>etion by kidneys)</div><div> <span></span><span></span></div><div>Hyperchloremia <span>(incre<span></span>ased HCl acid in </span></div><div>blood)</div><div> <span></span><span></span></div><div>Blood transfusions (addition of aci</div><div>2. <span> </span><span>Lactic acidosis</span></div><div>a. <span> </span><span>Type A: Imp<span></span>aired tissue oxygenation and anaerobic me<span></span>tabolism from </span></div><div>circulat<span></span>or<span></span>y f<span></span>ailure </div><div>i. <span> </span>IC<span></span>U, immediate post<span></span>-op considerations—May be result of:</div><div>1.  Pre-existing r<span></span>enal dysfunction</div><div>2.  Long pump runs</div><div>3.  Intraoper<span></span>ative vasopressor use</div><div>4.  Inadequate O2 delivery during bypass that c<span></span>ontributes to </div><div>splanchnic and renal ischemia with acidosis perpetua<span></span>ted by a low </div><div>cardiac output syndrome</div><div>ii.  Several days post<span></span>-op<span></span>—May be result of:</div><div>1.  Mesenteric ischemia</div><div>2.  Sepsis</div><div>3.  Acute hep<span></span>atic dysfunction (decreased lact<span></span>ate utiliz<span></span>ation)</div><div>4.  Low car<span></span>diac output stat<span></span>e, malperfusion</div><div>b.<span> <span> </span><span>T<span></span>ype B: Not associated with tissue hypo<span></span>xia. Low-dose Epinephrine </span></span></div><div><span></span><span></span></div><div>acid production. </div><div>i. <span> </span>No<span></span>t commonly seen</div><div>ii.  Consider when cardiac output is adequate and lac<span></span>tic acidosis seems </div><div>out of proportion with tissue perfusion</div><div>3. <span> </span><span>Adverse Eec<span></span>ts of Acidosis: <span>typically do no<span></span>t occur until pH is &lt; 7.2</span></span></div><div>a. <span> </span><span>Cardiovascular:<span> </span></span></div><div>i. <span> </span>Decr<span></span>eased contrac<span></span>tility and cardiac output, decreased liver and renal </div><div>perfusion</div><div> <span></span><span></span><span></span><span></span></div><div>iii. Incre<span></span>ased Pulmonar<span></span>y Vascular Resis<span></span>tance (may lead t<span></span>o Right heart </div><div>failure)</div><div><span></span><span></span></div><div>decreased SVR</div><div>v.<span> <span> </span>Increased risk of ventricular arrhythmias</span></div><div>b.<span> <span> </span><span>Respir<span></span>atory<span>:</span></span></span></div><div>i. <span> </span>Decr<span></span>eased respirat<span></span>or<span></span>y muscle strength</div><div>ii.  Dyspnea/tachypnea fr<span></span>om compensat<span></span>or<span></span>y mechanism</div><div>c. <span> </span><span>Metabolic<span>:</span></span></div><div>i. <span> </span>Hyper<span></span>glycemia (tissue insulin resist<span></span>ance)</div><div>ii.  Hyperkalemia</div><div>d. <span> </span><span>Neurologic<span>:</span></span></div><div>i. <span> </span>Inhibition of br<span></span>ain metabolism</div><div>ii.  Obtundation/<span></span>coma</div><div>4. <span> </span><span>T<span></span>reatment of Me<span></span>tabolic Acidosis</span></div><div>a. <span> </span><span>Identify and treat the underlying c<span></span>ause</span></div><div>i. <span> </span>Assess tissue perfusion and cardiac output: VBG/SvO2, Echo, P<span></span>A </div><div>cathe<span></span>ter C<span></span>O/CI</div><div> <span></span><span></span><span></span><span></span></div><div>iii. Assess for mesenteric ischemia: lact<span></span>ate, abdominal exam, KUB/C<span></span>T</div><div>iv. A<span></span>ssess for sepsis: CBC, pr<span></span>o<span></span>-calcit<span></span>onin, cultures, fever cur<span></span>ve</div><div>b.<span> <span> </span><span>Bicarbona<span></span>te supplementation</span></span></div><div>i. <span> </span>Normalizing pH may impr<span></span>ove cardiac function, improve </div><div><span></span><span></span></div><div>ii.  Goal is to r<span></span>aise the pH, not to correct bic<span></span>arbonate levels</div><div>iii. Keep in mind that IV Sodium bic<span></span>arb may result in:</div><div>1.  Hypernatremia—monit<span></span>or serial labs, consider D5W<span></span>/free water </div><div>supplementa<span></span>tion</div></div><div></div></div>
<div><div><img><div>76<span> </span><span>Pos<span></span>t-Op Management<span> </span>Pos<span></span>t-Op Management<span> </span><span>77</span></span></div><div>2.  Fluid overload fr<span></span>om hyperosmolarity—monitor CVP<span></span>/<span></span>exam, diurese </div><div>when appropriat<span></span>e</div><div> <span></span><span></span></div><div>SvO2</div><div>4.  Incre<span></span>ased CO2 pr<span></span>oduction from metabolism of bic<span></span>arbonate</div><div>a.  May result in <span>r<span></span>espirat<span></span>or<span></span>y acidosis <span>if pa<span></span>tient not adequately </span></span></div><div>ventilated</div><div>b.<span> <span> </span>Monitor ABG, incre<span></span>ase respiratory rat<span></span>e on ventilator if able</span></div><div>Respir<span></span>atory Acidosis</div><div>1. <span> </span><span>Common etiologies: <span>accumulation of C<span></span>O2 in blood due to hypoventilation</span></span></div><div>a. <span> </span><span>Medications: narc<span></span>otics, benzodiazepines, residual anes<span></span>thesia, paralytics</span></div><div>b.<span> <span> </span><span>S<span></span>troke/<span></span>intr<span></span>acranial bleed</span></span></div><div>c. <span> </span><span>Acute airway obstruction: sleep apnea, aspir<span></span>ation</span></div><div>d. <span> </span><span>Hx parenchymal lung disease (O2 delivery may decrease respir<span></span>ator<span></span>y </span></div><div>drive): COPD</div><div>e. <span> </span><span>Splinting<span></span>/Limit of inspiration due to p<span></span>ain</span></div><div>f.<span></span><span> <span> </span><span>Pneumothorax</span></span></div><div>Management:</div><div>a. <span> </span><span>T<span></span>reat reversible causes: ob<span></span>tain CXR, consider head C<span></span>T for acutely altered </span></div><div>mental s<span></span>tatus</div><div>b.<span> <span> </span><span>Consider Narc<span></span>an for narcotic over<span></span>dose: <span>Narcan 0.1-0.2 mg q2 minutes</span> </span></span></div><div>for partial r<span></span>e<span></span>versal</div><div>c. <span> </span><span><span>umaz<span></span>enil 0.2mg IV q30 </span></span></div><div>seconds-1min</div><div>d. <span> </span><span>Tr<span></span>eat hypoventilation</span></div><div>i. <span> </span>BiP<span></span>ap support ventilation (See Respirat<span></span>or<span></span>y Care under referenc<span></span>es)</div><div>ii.  Consider intubation </div><div>Met<span></span>abolic Alkalosis</div><div>1. <span> </span><span>Common etiologies:</span></div><div>a. <span> </span><span>Exc<span></span>essive diuresis leading to</span></div><div>i. <span> </span>P<span></span>otassium loss: direc<span></span>tly increases bicarb resorp<span></span>tion</div><div>ii.  Depletion of H+ ions and Chloride (acid loss)</div><div>iii. <span>“Contraction alk<span></span>alosis”<span> = Hypovolemia: stimulates aldos<span></span>terone </span></span></div><div><span></span><span></span></div><div>increased bic<span></span>arb resorption</div><div>b.<span> <span> </span><span>Acid loss from high NG tube output/<span></span>emesis</span></span></div><div>c. <span> </span><span>Sub-Acute/Chronic respir<span></span>ator<span></span>y acidosis: renal r<span></span>esponse to chronic </span></div><div>acidosis (ie increased bic<span></span>arbonate synthesis) takes 12 hours t<span></span>o become </div><div>apparent and is maximum a<span></span>t 3-5 days</div><div>d. <span> </span><span>Exc<span></span>essive bicarbonat<span></span>e administr<span></span>ation, or administr<span></span>ation of agent<span></span>s </span></div><div>met<span></span>abolized to bic<span></span>arb </div><div>i. <span> </span><span>Citr<span></span>ate (in blood produc<span></span>ts)<span> may result in metabolic alk<span></span>alosis</span></span></div><div>ii.  Lactat<span></span>e (in LR)</div><div>2. <span> </span><span>Adverse Eec<span></span>ts of Alkalosis (pH &gt;7.45)</span></div><div>a. <span> </span><span><span></span></span></div><div>b.<span> <span> </span><span><span></span><span></span></span></span></div><div>acidosis)</div><div>c.<span> <span> </span></span><span><span></span></span></div><div>d. <span> </span><span><span></span><span></span><span></span><span></span></span></div><div>potential hypo<span></span>xia</div><div>3. <span> </span><span>T<span></span>reatment of Acut<span></span>e Metabolic Alkalosis</span></div><div>a. <span> </span><span><span></span><span></span></span></div><div>b.<span> <span> </span><span>Gas<span></span>tris losses: acid suppressant therapy (H2 blockers or PPI’<span></span>s)</span></span></div><div>c. <span> </span><span>P<span></span>atients with tot<span></span>al body water overload (ie pos<span></span>t-opera<span></span>tive or CHF) </span></div><div>consider:</div><div>i. <span> </span>Diamo<span></span>x (acetaz<span></span>olamide): carbonic anhydr<span></span>ase inhibitor that inhibit<span></span>s </div><div>bicarbonat<span></span>e resorption in pr<span></span>oximal tubule</div><div>1.  Weak diur<span></span>etic when used alone</div><div>2.  Consider use in conjunc<span></span>tion with loop diuretic</div><div>ii.  K-sparing diure<span></span>tic (spironolactone/<span></span>eplerenone)</div><div>Respir<span></span>atory Alkalosis</div><div>1. <span> </span><span>Common Etiologies:<span> <span>decr<span></span>eased CO2 in blood stream due to hypoventilation</span></span></span></div><div>a. <span> </span><span>Hypoxia (increased r<span></span>espiratory drive)</span></div><div>b.<span> <span> </span><span>Anxiety</span></span></div><div>c. <span> </span><span>P<span></span>ain</span></div><div>d. <span> </span><span>Fever/infection/sepsis</span></div><div>2. <span> </span><span> <span></span><span>Management:<span> trea<span></span>t underlying cause  </span></span></span></div><div>Sources: </div><div><span></span><span></span></div><div>UK: Wiley-Blackwell</div><div>Adams, G. (2006). On Call Surgery, 3rd Edition. Philadelphia, P<span></span>A: Saunders Elsevier </div><div>GU<span></span>/FEN:<span> KIDNEY DISEASE</span></div><div>Acute Kidney Injury</div><div>Denition:</div><div> <span></span><span></span></div><div>Increase in serum cr<span></span>eatinine by 0.3mg<span></span>/dL or mor<span></span>e within 48 hours  </div><div>or</div><div> <span></span><span></span></div><div>Incr<span></span>eas<span></span>e i<span></span>n se<span></span>rum cr<span></span>eat<span></span>inine <span></span>to 1.<span></span>5 time<span></span>s b<span></span>aseli<span></span>ne o<span></span>r mor<span></span>e with<span></span>in the<span></span> las<span></span>t 7 <span></span>days <span></span> </div><div>or</div><div> <span></span><span></span></div><div>Urine output less than 0.5 mL/kg<span></span>/h for 6 hours</div><div>Cause:</div><div> <span></span><span></span></div><div><span></span><span></span></div><div>hypotension, hypovolemic, HF<span></span>, renal arter<span></span>y s<span></span>tenosis, renal vein thrombosis, </div><div>Cardiac t<span></span>amponade</div><div><span></span><span> </span><span><span></span><span></span><span></span></span></div><div>due to</div><div> <span></span><span></span></div><div><span></span></div><div> <span></span><span></span></div><div><span></span><span></span></div><div> <span></span><span></span></div><div><span></span><span></span><span></span><span></span></div><div> <span></span><span></span></div><div>Intra R<span></span>enal:<span> Problems with the kidney itself, A<span></span>TN/<span></span>AIN</span></div><div> <span></span><span></span></div><div>Pos<span></span>trenal:<span></span></div><div>kidney stone, BPH, obs<span></span>tructed urinar<span></span>y ca<span></span>theter etc;<span> a bladder scan or a pos<span></span>t </span></div><div>void residual t<span></span>o rule out urinary retention</div><div>Diagnosis:</div><div> <span></span><span></span></div><div><span></span><span></span></div><div> <span></span><span></span></div><div>Urinalysis: presence of pr<span></span>otein (albumin), hemoglobin, granular cas<span></span>ts, or </div><div>epithelial cell cas<span></span>ts may indicate AKI</div><div> <span></span><span></span></div><div>Urine sodium:</div><div><span></span><span> </span><span>FENa:<span><span></span><span></span></span></span></div><div>an oliguric patient (no<span></span>t accurat<span></span>e if patient has received r<span></span>ecent diuretic </div><div>therapy) </div><div>FENa, % = (UNA x SCr<span></span>/ SNA X UCr) x 100 </div><div> <span> </span><span>FENa &lt; 1 = pre renal dise<span></span>ase </span></div><div> <span> </span>FENa &gt; 2 = A<span></span>TN </div></div><div></div></div>
<div><div><img><div>78<span> </span><span>Pos<span></span>t-Op Management<span> </span>Pos<span></span>t-Op Management<span> </span><span>79</span></span></div><div><span></span><span> </span><span>FEU-rea (used f<span></span>or patient who have received r<span></span>ecent diuretic therapy) </span></div><div>FEU-rea, % = ((SCr x Urine Urea) x 100)) / BUN x Urine Creatinine </div><div> <span> </span>FEU-re<span></span>a &lt; 35% = pre renal disease </div><div> <span> </span>FEU-re<span></span>a &gt; 50% = ATN</div><div> <span></span><span></span></div><div>Oliguria:<span> &lt; 0.3ml/kg per hour or &lt; 500mL/<span></span>day of urine output</span></div><div> <span></span><span></span></div><div>Anuria: <span><span></span></span></div><div> <span></span><span></span></div><div>Renal US:<span> evalua<span></span>te for urinar<span></span>y tr<span></span>act obstruction, renal mass, and kidney size </span></div><div>(diagnosis hydronephrosis)</div><div>T<span></span>rea<span></span>tment: </div><div> <span></span><span></span></div><div> Focused on removing the c<span></span>ause of the kidney injur<span></span>y/ f<span></span>ailure. </div><div><span></span><span> </span><span>Discontinue nephro<span></span>toxic medications (NSAIDS, Iodina<span></span>ted contr<span></span>ast, </span></div><div>metformin, some antibio<span></span>tics such as gent<span></span>amicin.)</div><div><span></span><span> </span><span>Correct low BP or use ino<span></span>tropic meds to incr<span></span>ease heart func<span></span>tion to </span></div><div>provide good r<span></span>enal perfusion </div><div><span></span><span> </span><span>Avoid IV contr<span></span>ast if possible while crea<span></span>tinine is still up trending</span></div><div><span></span><span> </span><span>Correct urinary tract obs<span></span>truction if present (ie insertion of foley cathet<span></span>er)</span></div><div> <span></span><span></span></div><div>Continue to trend cr<span></span>eatinine and elec<span></span>trolytes closely (cautious electrolyt<span></span>e </div><div>replacement)</div><div> <span></span><span></span></div><div>Monitor volume s<span></span>ta<span></span>tus closely to ensure adequa<span></span>te hydration without volume </div><div>overload  </div><div><span></span><span> </span><span>Diuretics may be used for a limit<span></span>ed period to relive signs and symptoms </span></div><div>of volume overload. </div><div><span></span><span> </span><span><span></span><span></span></span></div><div> <span></span><span></span></div><div>Indications f<span></span>or dialysis: (consult renal) <span>A-E-I-O-U!</span> </div><div><span></span><span> </span><span>A: Acidosis (pH &lt; 7.1 in those that canno<span></span>t tolerate c<span></span>orrection with sodium </span></div><div>bicarb)</div><div><span></span><span> </span><span>E: Electrolyt<span></span>e Disturb<span></span>ances (ie. Hyperkalemia when k &gt; 6.5 and refrac<span></span>tor<span></span>y </span></div><div>to medical manag<span></span>ement)</div><div><span></span><span> </span><span>I: Inges<span></span>tion/Intoxic<span></span>ation</span></div><div><span></span><span> </span><span>O: Overload. (Refr<span></span>actor<span></span>y to diur<span></span>etics)</span></div><div><span></span><span> </span><span>U: Uremia (alter<span></span>ed mental s<span></span>tatus, uremic pla<span></span>telet<span></span>s)</span></div><div>Chronic Kidney Disease  </div><div>Denition:</div><div>St<span></span>age<span> </span>Descrip<span></span>tion </div><div>St<span></span>age I<span> </span>With normal of high GFR (GFR &gt; 90mL/min)</div><div>St<span></span>age II<span> </span>Mild CKD (GFR = 60-89mL/min)</div><div>St<span></span>age IIIa<span> </span>Modera<span></span>te CKD (GFR = 45-59mL/min)</div><div>St<span></span>age IIIb<span> </span>Moderat<span></span>e CKD (GFR = 30-44mL/min)</div><div>St<span></span>age IV<span> </span>Severe CKD (GFR = 15-29mL/min)</div><div>St<span></span>age V<span> </span>End St<span></span>age CKD (GFR &lt; 15mL/min)</div><div>Always document stage 3 ck<span></span>d or higher in h&amp;p, progress not<span></span>es, and </div><div>discharge summary</div><div>Pos<span></span>t op management: </div><div> <span></span><span></span></div><div>Monitor pos<span></span>t op crea<span></span>tinine closely. Not uncommon t<span></span>o see rising crea<span></span>tinine </div><div>in the initial post op period (Acut<span></span>e on Chronic Kidney Injur<span></span>y) but cre<span></span>atinine </div><div>should return t<span></span>o baseline by discharg<span></span>e if managed properly </div><div><span></span><span> </span><span>Ensure adequat<span></span>e blood pressure f<span></span>or renal perfusion</span></div><div><span></span><span> </span><span>Avoid nephrot<span></span>oxic agents (NSAIDs, metformin, c<span></span>ertain antibiotics)</span></div><div>Referenc<span></span>es: </div><div>Okusa, M.D., P<span></span>alevsky, P<span></span>.M., &amp; Scheidan, A.M. (2016). Overvie<span></span>w of the management of acut<span></span>e kidne<span></span>y injury </div><div>(acute renal f<span></span>ailure). Up to dat<span></span>e. </div><div>GU<span></span>/FEN:<span>SODIUM IMBALANCES</span></div><div>HYPERNA<span></span>TREMIA, serum NA &gt;145</div><div> <span></span><span></span></div><div>Etiologies:</div><div><span></span><span> </span><span>T<span></span>ube feeding due to lack of free wa<span></span>ter</span></div><div><span></span><span> </span><span>Ex<span></span>cessive water loss fr<span></span>om diuresis or diarrhea</span></div><div><span></span><span> </span><span>Salt loading from medic<span></span>ations (saline drips, sodium bicarb, albumin)</span></div><div> <span></span><span></span></div><div>T<span></span>o trea<span></span>t</div><div><span></span><span> </span><span>Add free wa<span></span>ter to tube f<span></span>eed formula in divided doses (ie 200mL q6h)</span></div><div><span></span><span> </span><span>Add D5W infusion</span></div><div><span></span><span> </span><span>And/<span></span>or encourage w<span></span>ater intake if able t<span></span>o take PO</span></div><div> <span></span><span></span></div><div><span></span></div><div> <span></span><span></span></div><div>Determine Ra<span></span>te of Correc<span></span>tion</div><div><span></span><span> </span><span>Chronic Hypernatr<span></span>emia<span>: present for &gt;48 hours</span></span></div><div> <span></span><span></span></div><div>Correct Sodium by NO MORE THAN 10-12mEq/<span></span>day</div><div> <span></span><span></span></div><div>Rapid correc<span></span>tion—at risk for <span>cerebr<span></span>al edema<span> (encephalopa<span></span>thy, </span></span></div><div>lethargy, seizur<span></span>es)</div><div><span></span><span> </span><span>Acute Hyperna<span></span>tremia<span>: present f<span></span>or &lt; 48 hours</span></span></div><div> <span></span><span></span></div><div>Correct Sodium t<span></span>o normal over 24 hours</div><div> <span></span><span></span></div><div>Monitor serum sodium frequently and adjus<span></span>t free water int<span></span>ake as necessary </div><div>HYPONA<span></span>TREMIA, serum NA &lt;135 </div><div>[mild 130-135, modera<span></span>te 120-129, severe &lt;120]</div><div> <span></span><span></span></div><div>Need to det<span></span>ermine type of hyponatremia:</div><div><span></span><span> </span><span>Hyper<span></span>volemic: Na dilution from ex<span></span>cessive tot<span></span>al body water</span></div><div> <span></span><span></span></div><div>Volume overload, CHF<span></span>, cirrhosis</div><div><span></span><span> </span><span>Hypovolemic: Na and/<span></span>or water loss</span></div><div> <span></span><span></span></div><div>Diarrhea, thiazide diure<span></span>tics</div><div><span></span><span> </span><span>Normovolemic hyponatremia </span></div><div> <span></span><span></span></div><div>Low salt int<span></span>ake, SIADH: syndrome of inappropriate antidiur<span></span>etic </div><div>hormone (Dx of exclusion)</div><div> <span></span><span></span></div><div>Low serum sodium in our pos<span></span>top pa<span></span>tients usually indicates to<span></span>tal body water </div><div>overload (hypervolemic hyponatremia)</div><div> <span></span><span></span></div><div>In our patient popula<span></span>tion, most of concern when Na &lt;130. Otherwise usually </div><div>just monit<span></span>or</div><div> <span></span><span></span></div><div>Symptoms help de<span></span>termine need to treat (ie he<span></span>adache, nausea, vomiting, </div><div>fa<span></span>tigue, gait dis<span></span>turbances, and confusion)</div><div> <span></span><span></span></div><div>Aim to corr<span></span>ect serum Sodium by 4-6mEq/<span></span>day, no more than 8mEq/<span></span>day</div><div> <span></span><span></span></div><div>Risk of rapid c<span></span>orrection: <span>osmotic demyelina<span></span>tion </span></div><div> <span></span><span></span></div><div><span></span><span></span><span></span><span></span></div><div> <span></span><span></span></div><div>If on IV medications, c<span></span>onsider giving them in NS versus the standing D5W – </div><div>will need to discuss this with the pharmacy</div><div><span></span><span> </span><span>If euvomic/hypovolemic hyponatremia: also c<span></span>onsider giving salt tablets </span></div><div>three times daily with meals.</div><div><span></span><span> </span><span>Also can tre<span></span>at with hypertonic 3% saline. If have to go this rout<span></span>e, consult </span></div><div>nephrology. </div><div> <span></span><span></span></div><div>Monitor serum sodium frequently</div><div> </div></div><div></div></div>
<div><div><img><div>80<span> </span><span>Pos<span></span>t-Op Management<span> </span>Pos<span></span>t-Op Management<span> </span><span>81</span></span></div><div>HEMA<span></span>T<span></span>OLOGY<span></span>: <span>ACUTE BL<span></span>OOD LOS<span></span>S ANEMIA AND </span></div><div>POS<span></span>T<span></span>-OPERA<span></span>TIVE BLEEDING</div><div>Acute blood loss anemia and bleeding are expected a<span></span>er cardiac surgery </div><div>(especially for cases on c<span></span>ardiopulmonary bypass)</div><div>Contributing fac<span></span>tors to pos<span></span>t op bleeding: </div><div>Plat<span></span>elets<span><span></span><span></span><span></span></span></div><div>Hemodilution occurs when the circuit is primed and this alone c<span></span>an reduce </div><div>platele<span></span>ts by 30-50% (Bojar<span></span>, 2011).  And the longer a patient is on byp<span></span>ass, the more </div><div><span></span><span></span><span></span></div><div>mechanical str<span></span>ess of going through the circuit, as well.</div><div>Hepariniza<span></span>tion: <span><span></span></span></div><div>prot<span></span>amine itself can will transiently r<span></span>educe the plat<span></span>elet count by about 30%.  </div><div><span></span><span></span></div><div>on board.  HIT alw<span></span>ays becomes a concern in a p<span></span>atient who is thrombocytopenic </div><div>and has received hep<span></span>arin.  This is an e<span></span>ven higher risk in pt<span></span>s who have been on </div><div>heparin gt<span></span>ts prior to going into surg<span></span>er<span></span>y and should be evaluated by tes<span></span>ting for </div><div>antibodies if the patient is showing signs of bo<span></span>th bleeding and clotting. (For more </div><div>information on HIT see p<span></span>age *** Section IV &gt; 6 &gt; 3. HIT)</div><div>Fibrinolysis: <span><span></span></span></div><div>ext<span></span>ent can be evaluat<span></span>ed using aPTT<span></span>, INR and D-Dimer but those are very non-</div><div><span></span><span></span><span></span></div><div>Incomple<span></span>te surgical hemos<span></span>tasis:<span> with ac<span></span>companying chest w<span></span>all bleeding or </span></div><div><span></span><span></span></div><div>anyone with friable tissues.</div><div>Preop medica<span></span>tions <span>can also play a role in postop bleeding.  Any p<span></span>atient who’<span></span>s </span></div><div>had ASA in the last 7 days will have circula<span></span>ting platelets tha<span></span>t are no longer </div><div><span></span><span></span></div><div>fondipar<span></span>anux within 48hrs prior to surgery may have worse postop bleeding since </div><div>neither can be comple<span></span>tely reversed with heparin. </div><div>Managing a bleeding pa<span></span>tient:  </div><div>Chest T<span></span>ubes</div><div> <span></span><span></span></div><div>Milk tubes as needed </div><div> <span></span><span></span></div><div>Careful assessment of hourly output</div><div>Warm pa<span></span>tient</div><div> <span></span><span></span></div><div>Hypothermia causes imp<span></span>aired platelet function and suppr<span></span>ession of </div><div>co<span></span>agulation casc<span></span>ade</div><div> <span></span><span></span></div><div>Active warming may be c<span></span>ontraindicated in some p<span></span>atients</div><div>Control HTN</div><div> <span></span><span></span></div><div>SNP<span></span>, NTG, nicar<span></span>dipine, etc.</div><div>Sedation/P<span></span>ain Control</div><div> <span></span><span></span></div><div>Continue sedation/<span></span>analgesia until bleeding slows and pa<span></span>tient is stable for </div><div>weaning<span></span>/<span></span>extuba<span></span>tion</div><div>Re-E<span></span>xploration</div><div> <span></span><span></span></div><div>Consider re-explora<span></span>tion for</div><div><span></span><span> </span><span>&gt;400ml/hr x 1hr</span></div><div><span></span><span> </span><span>&gt;300ml/hr x 2-3hrs</span></div><div><span></span><span> </span><span>&gt;200ml/hr x 4 hrs</span></div><div>Always consider Cardiac T<span></span>amponade as a dierential diagnosis, especially in the </div><div>immediate post<span></span>-operative period. For mor<span></span>e information on pericar<span></span>dial tamponade </div><div>see <span>see <span>page 59.</span></span></div><div>Lab V<span></span>alues to monitor:</div><div>PT<span></span>/INR</div><div> <span></span><span></span></div><div><span></span></div><div> <span></span><span></span></div><div><span></span><span></span><span></span><span></span><span></span><span></span><span></span><span></span><span></span></div><div> <span></span><span></span></div><div>T<span></span>reat eleva<span></span>ted INR with FFP</div><div>PTT</div><div> <span></span><span></span></div><div><span></span><span></span></div><div> <span></span><span></span></div><div>If elevated P<span></span>TT in isolation or with slight elevation in INR c<span></span>onsider treatment </div><div>with <span>Pro<span></span>tamine<span> </span></span></div><div>Plat<span></span>elet Count</div><div> <span></span><span></span></div><div>CPB can decre<span></span>ase platelet count as well as c<span></span>ause platele<span></span>t dysfunction</div><div> <span></span><span></span></div><div>Consider platele<span></span>t transfusion in bleeding p<span></span>atient with platelet &lt;100k or if </div><div>patient<span></span>s were taking ASA , Plavix, or IIB/IIIA inhibitors pre-op or are ur<span></span>emic</div><div>Fibrinogen</div><div> <span></span><span></span></div><div>Promot<span></span>es platelet aggreg<span></span>ation and enhances platele<span></span>t adhesion to the </div><div>endothelium</div><div> <span></span><span></span></div><div>Consider <span>transfusion of cryo if Fibrinog<span></span>en &lt;100 in bleeding patient</span></div><div>TEG</div><div>For TEG interpr<span></span>et<span></span>ation see <span>page 83.</span></div><div>Blood Product<span></span>s/Tr<span></span>ansfusion Threshold</div><div>PRBCs</div><div> <span></span><span></span></div><div>Clarify transfusion thr<span></span>eshold with surgeon</div><div> <span></span><span></span></div><div>Consider maintaining Hc<span></span>t  ~25 in an actively bleeding pa<span></span>tient</div><div> <span></span><span></span></div><div>Each unit should increase Hc<span></span>t by ~3%</div><div>CellSaver</div><div> <span></span><span></span></div><div>May cont<span></span>ain a small amount of heparin but is devoid of clotting f<span></span>actors</div><div> <span></span><span></span></div><div><span></span><span></span></div><div>Plat<span></span>elets</div><div> <span></span><span></span></div><div>Each unit should increase pla<span></span>telet count by ~42-60k per 6-pk</div><div>FFP</div><div> <span></span><span></span></div><div>Contains all clo<span></span>tting fact<span></span>ors</div><div> <span></span><span></span></div><div>4 units of FFP will incre<span></span>ase clotting fac<span></span>tors by~10%</div><div>Cryoprecipita<span></span>te</div><div> <span></span><span></span></div><div><span></span><span></span><span></span></div><div> <span></span><span></span></div><div><span></span><span></span><span></span></div><div> <span></span><span></span></div><div><span></span></div><div>Medications</div><div>Pro<span></span>tamine</div><div> <span></span><span></span></div><div>Given for elevat<span></span>ed PTT d/t residual heparin or rele<span></span>ase of heparin from tissue </div><div>st<span></span>ores</div><div> <span></span><span></span></div><div>25-50mg</div><div> <span></span><span></span></div><div>Half-life 5min, elimina<span></span>tion from blood s<span></span>tream in 20-30min</div><div> <span></span><span></span></div><div>Ex<span></span>cessive use of Prot<span></span>amine may increase ACT<span></span>, cause platelet dysfunction, </div><div><span></span></div></div><div></div></div>
<div><div><img><div>82<span> </span><span>Pos<span></span>t-Op Management<span> </span>Pos<span></span>t-Op Management<span> </span><span>83</span></span></div><div>DDAVP</div><div> <span></span><span></span></div><div>Increases the levels of cert<span></span>ain factors (VIII pr<span></span>ecursors, von Wildebrand’<span></span>s, </div><div>tissue-type plasminogen ac<span></span>tivator)</div><div> <span></span><span></span></div><div><span></span><span></span></div><div> <span></span><span></span></div><div>Can cause hypot<span></span>ension and peripheral vasodilat<span></span>ation</div><div>Feib<span></span>a</div><div> <span></span><span></span></div><div>F<span></span>actor Eight Inhibit<span></span>or Bypassing Ac<span></span>tivity</div><div> <span></span><span></span></div><div>Developed to trea<span></span>t bleeding in pts with Hemophilia A/B. </div><div> <span></span><span></span></div><div><span></span><span></span><span></span><span></span><span></span></div><div><span></span><span></span></div><div> <span></span><span></span></div><div><span></span><span></span></div><div>mostly when p<span></span>ts are given &gt;200unit<span></span>s/kg<span></span>/<span></span>day.  </div><div> <span></span><span></span></div><div>St<span></span>art with a quarter dose, or 250 units, up to a full dose of 1000 units f<span></span>or </div><div>severe bleeding.  </div><div> <span></span><span></span></div><div>FEIBA is made from human plasma, so the same risk of tr<span></span>ansmission of </div><div>infectious dise<span></span>ase is present as when you are giving blood products. </div><div> <span></span><span></span></div><div>Novo Seven</div><div> <span></span><span></span></div><div>Promot<span></span>es localized hemost<span></span>asis at site of tissue injury and improves INR</div><div> <span></span><span></span></div><div>Can cause syst<span></span>emic thrombosis</div><div>Imaging</div><div>CXR</div><div> <span></span><span></span></div><div></div><div>indicative of clo<span></span>t around the great vessels</div><div>Echo</div><div> <span></span><span></span></div><div>TTE or TEE </div><div>St<span></span>able acute blood loss anemia</div><div> <span></span><span></span></div><div><span></span><span></span><span></span><span></span></div><div>like “E<span></span>xpected acute blood loss anemia”</div><div> <span></span><span></span></div><div>Cont to monitor H/H daily or every other day. H/H usually returns t<span></span>o patients </div><div><span></span><span></span></div><div> <span></span><span></span></div><div>T<span></span>reatment: (once able to t<span></span>olerate PO medic<span></span>ations)</div><div><span></span><span> </span><span>Ferrous Sulf<span></span>ate, Slow FE 140mg PO BID</span></div><div><span></span><span> </span><span>Vitamin C 500mg PO BID</span></div><div><span></span><span> </span><span>Consider need for epogen injec<span></span>tion for severe anemia</span></div><div><span></span><span> </span><span>Oral Ir<span></span>on and Vit C are usually continued f<span></span>or 1 month post operatively </span></div><div>HEMA<span></span>T<span></span>OLOGY<span></span>: <span>TEG</span></div><div>TEG®<span> </span>Clot phase<span> </span>Normal Values<span> </span>Abnormalities<span> </span>T<span></span>reatment</div><div>R Time<span> </span><span>Clot initiation</span></div><div><span></span></div><div>4.6 - 8.8 min<span> </span><span><span></span><span></span></span></div><div>Shortened in hyperc<span></span>oagulable s<span></span>tat<span></span>es.</div><div>Increased R time </div><div>= FFP</div><div>K<span> </span><span>Clot Kinetics</span></div><div>Time taken t<span></span>o achie<span></span>ve a c<span></span>ertain level of clot s<span></span>trength</div><div>1.2 - 2.4 min<span> </span><span><span></span><span></span></span></div><div>and platelet dysfunc<span></span>tion.</div><div>Alpha </div><div>Angle</div><div>Clot Kinetics</div><div></div><div>takes plac<span></span>e ( rate of clot f<span></span>ormation)</div><div>57.7 - 72.9 deg<span> </span><span><span></span></span></div><div>thrombocytopenia, and platele<span></span>t dysfunction.</div><div>Decreased Angle </div><div>= Cr<span></span>yo</div><div>MA<span> </span><span>Clot S<span></span>trength</span></div><div>Maximal clot str<span></span>ength achie<span></span>ved via GP IIb/IIIa-</div><div><span></span><span></span></div><div>59.3 - 76.5 mm<span> </span><span><span></span><span></span></span></div><div><span></span><span></span></div><div>thrombocytopenia</div><div>Decreased MA = </div><div>Platelet<span></span>s</div><div>G<span> </span><span>Clot Strength</span></div><div>Maximal clot str<span></span>ength achie<span></span>ved via GP IIb/IIIa-</div><div><span></span><span></span></div><div>6.4 - 15.0 k d/</div><div>sec</div><div>Abnormally high in platelet hyper<span></span>coagulability.</div><div>EPL </div><div>(Estima<span></span>ted </div><div>Perc<span></span>ent of </div><div>L<span></span>ysis)</div><div>Clot L<span></span>ysis</div><div><span></span></div><div>0 - 15 %<span> </span><span><span> </span></span>Fibrinolysis  = </div><div>Aprotonin or </div><div>T<span></span>ransexamic Acid</div></div><div></div></div>
<div><div><img><div>84<span> </span><span>Pos<span></span>t-Op Management<span> </span>Pos<span></span>t-Op Management<span> </span><span>85</span></span></div><div>HEMA<span></span>T<span></span>OLOGY<span></span>: <span>HEP<span></span>ARIN INDUCED </span></div><div>THROMBOCY<span></span>T<span></span>OPENIA (HIT)</div><div>Epidemiology:</div><div> <span></span><span></span></div><div>1-5% of adults tre<span></span>ated with heparin, and a smaller proportion of those who </div><div>are tre<span></span>ated with low-molecular weight heparin, will develop heparin-induced </div><div>thrombocytopenia (HIT).</div><div> <span></span><span></span></div><div>HIT is associated with a high risk of venous and art<span></span>erial thrombosis if heparin </div><div>is not withdr<span></span>awn</div><div>Diagnosis:</div><div> <span></span><span></span></div><div>The initial signal is a <span>drop in<span><span></span><span></span><span></span></span></span></div><div>noticed, use the 4 T’<span></span>s score to c<span></span>alculate the lik<span></span>elihood of HIT<span></span>. </div><div> <span></span><span></span></div><div>If post op platelet c<span></span>ount is low, continue to observe and wait until at least POD </div><div>#3 prior to sending HIT panel</div><div>1. <span> </span><span>Thrombocytopenia</span></div><div><span></span><span> </span><span><span></span><span></span></span></div><div><span></span><span> </span><span><span></span><span></span></span></div><div><span></span><span> </span><span><span></span><span></span></span></div><div>2. <span> </span><span>Timing</span></div><div><span></span><span> </span><span><span></span><span></span></span></div><div><span></span></div><div><span></span><span> </span><span><span></span><span></span></span></div><div><span></span></div><div><span></span><span> </span><span><span></span><span></span></span></div><div><span></span></div><div>3. <span> </span><span>Thrombosis</span></div><div><span></span><span> </span><span></span></div><div><span></span><span> </span><span><span></span><span></span><span></span></span></div><div></div><div><span></span><span> </span><span>Other causes of thrombocytopenia  </span></div><div><span></span><span> </span><span><span></span></span></div><div><span></span><span> </span><span><span></span></span></div><div><span></span><span> </span><span><span></span></span></div><div>4. <span> </span>Other causes of thrombocytopenia:<span> </span></div><div><span></span><span> </span><span><span></span></span></div><div><span></span><span> </span><span><span></span></span></div><div><span></span><span> </span><span><span></span></span></div><div>Clinical Manifes<span></span>tations</div><div> <span></span><span></span></div><div>Thrombocytopenia, but r<span></span>arely with bleeding e<span></span>vents</div><div> <span></span><span></span></div><div>Markedly eleva<span></span>ted r<span></span>ate of thr<span></span>omboembolic events (venous &gt; arterial [4:1 </div><div>ra<span></span>tio])</div><div> <span></span><span></span></div><div><span></span><span></span><span></span><span></span></div><div>7 days)</div><div>Diagnosis</div><div> <span></span><span></span></div><div>HIT functional assay</div><div> <span></span><span></span></div><div>T<span></span>o order: User HIT panel to order HIT antibody (anti-platele<span></span>t factor 4 or PF4) </div><div>AND Functional assay</div><div><span></span><span> </span><span><span></span></span></div><div>Interpre<span></span>tation:</div><div>0-3 points = Low pr<span></span>obability</div><div>4-5 points = Intermedia<span></span>te </div><div>probability</div><div>6-8 points = High prob<span></span>ability </div><div><span></span><span> </span><span></span></div><div><span></span><span> </span><span>If the PF4 results are inde<span></span>terminate (0.4-2.0), the functional assay may be </span></div><div><span></span><span> </span></div><div>We ty<span></span>pic<span></span>ally se<span></span>nt functiona<span></span>l assay<span></span> at the same<span></span> time a<span></span>s HIT antibo<span></span>dy as </div><div>the fun<span></span>ctional assa<span></span>y is a<span></span> send o<span></span>ut lab that <span></span>requi<span></span>res 48-72 <span></span>hours<span></span> for <span></span>results. </div><div>Acute T<span></span>re<span></span>atment:</div><div> <span></span><span></span></div><div>When HIT is suspected, a HIT antibody and func<span></span>tional assay should be sent, </div><div>and all heparin should be disc<span></span>ontinued immediately<span></span>. </div><div> <span></span><span></span></div><div>An alternative antic<span></span>oagulant should be st<span></span>arted, <span>EVEN IF THERE IS NO OTHER </span></div><div>REASON FOR ANTIC<span></span>OAGULA<span></span>TION. <span>We typically use Arga<span></span>troban.</span></div><div> <span></span><span></span></div><div>Obt<span></span>ain bilateral LE ultr<span></span>asounds to rule out occult DVT<span></span>, which can dict<span></span>ate a </div><div>longer course of antic<span></span>oagulation (3-6 months if thrombosis present vs &lt; 1 </div><div>month if no thrombosis present)</div><div>Long t<span></span>erm treatment</div><div> <span></span><span></span></div><div><span></span></div><div> <span></span><span></span></div><div><span></span><span></span><span></span><span></span></div><div>until platele<span></span>t recovery (usually great<span></span>er than 100). Early initiation of coumadin </div><div>has been shown to exac<span></span>erbate thrombosis and should be avoided. </div><div> <span></span><span></span></div><div><span></span><span></span><span></span></div><div>be overlapped for 3-5 days. Coumadin should be continued f<span></span>or at least 1 </div><div>month. </div><div> <span></span><span></span></div><div>As a general rule<span>, p<span></span>atients with documented HIT should not be exposed t<span></span>o </span></div><div>heparin again.</div><div> <span></span><span></span></div><div>However, it has been shown tha<span></span>t heparin may be used again in pa<span></span>tients who </div><div>were previously HIT antibody positive if the pa<span></span>tient no longer has a positive </div><div>HIT ELISA antibody titer and the use of heparin is <span>absolut<span></span>ely necessary <span>(ex </span></span></div><div>cardiopulmonary bypass) </div><div>Referenc<span></span>es: </div><div>Cuker A &amp; Clines DB. (2012). How I tre<span></span>at heparin induced thrombocytopenia. Blood.  119: 2209-2218. </div><div> </div><div>HEMA<span></span>T<span></span>OLOGY<span></span>: <span>DEEP VEIN THROMBOSIS</span></div><div>Denition:</div><div> <span></span><span></span></div><div>Condition in which a blood clot (thrombus) f<span></span>orms in a view. The clot can limit </div><div><span></span></div><div> <span></span><span></span></div><div>Thrombus most c<span></span>ommonly occurs in the deep veins in the legs, thigh, or </div><div>pelvis (Deep Vein Thrombosis, or D<span></span>VT)</div><div>Risk F<span></span>actors: </div><div> <span></span><span></span></div><div>Obesity, smoking, he<span></span>art failure, hist<span></span>or<span></span>y of previous DVT<span></span>, immobility, canc<span></span>er, </div><div>some medications (such as: erythropoietin, birth contr<span></span>ol pills, hormone </div><div>replacement ther<span></span>apy)</div><div> <span></span><span></span></div><div>Undergoing a sur<span></span>gical proc<span></span>edure increases risk of DVT development</div><div> <span></span><span></span></div><div>Diagnosis: </div><div> <span></span><span></span></div><div>Classis symptoms include: swelling, p<span></span>ain, warmth, and redness of the </div><div><span></span><span></span></div><div> <span></span><span></span></div><div>Symptoms ar<span></span>e usually asymmetrical. Symmetrical swelling is unlike t<span></span>o </div><div>represent DVT</div><div> <span></span><span></span></div><div><span></span></div><div><span></span><span></span><span></span></div><div>increase risk of developing a DVT (ther<span></span>efore treatment with antic<span></span>oagulation is </div><div>not indica<span></span>ted)</div><div> <span></span><span></span></div><div><span></span><span></span><span>US RADIOL<span></span>OGY VEIN (UPPER/</span></div><div>L<span></span>OWER/BILA<span></span>TERAL) EX<span></span>TERMITIES RULE OUT DVT</div></div><div></div></div>
<div><div><img><div>86<span> </span><span>Pos<span></span>t-Op Management<span> </span>Pos<span></span>t-Op Management<span> </span><span>87</span></span></div><div> <span></span><span></span></div><div><span></span><span></span><span></span><span></span></div><div> <span></span><span></span></div><div>D-dimer may also be elevated in p<span></span>atients with DVT </div><div>Prevention &amp; T<span></span>re<span></span>atment </div><div> <span></span><span></span></div><div>The main goal of tr<span></span>eatment is to prevent a pulmonary embolism, preventing </div><div>DVT from bec<span></span>oming larger<span></span>, and pre<span></span>venting new blood clots fr<span></span>om forming</div><div> <span></span><span></span></div><div>Primary treatment is antic<span></span>oagulation for a minimum of 3 months</div><div><span></span><span> </span><span>Low molecular weight heparin (SubQ hep<span></span>arin or lovenox)</span></div><div><span></span><span> </span><span>Unfrac<span></span>tionated hep<span></span>arin (continuous heparin drip)</span></div><div><span></span><span> </span><span>Direct or<span></span>al anticoagulation: Riv<span></span>aroxaban (X<span></span>arelto), Dabigatr<span></span>an (Sayaysa), </span></div><div>and Apixaban (Eliquis) </div><div><span></span><span> </span><span>Coumadin with goal INR 2-3</span></div><div> <span></span><span></span></div><div>Pos<span></span>t op DVT prevention includes</div><div><span></span><span> </span><span>Bilate<span></span>arl LE SCDs on all patients</span></div><div><span></span><span> </span><span>SubQ heparin (if no c<span></span>ontraindic<span></span>ation) on pa<span></span>tients while in the ICU. </span></div><div>Continue for high risk pa<span></span>tients while on iICU. </div><div><span></span><span> </span><span>See referenc<span></span>e material see <span>page 134.</span></span></div><div>Referenc<span></span>es: </div><div>P<span></span>ai, M, Douketis, J. (2017) P<span></span>atient education: deep vein thrombosis (DVT) beyond the basics. Up t<span></span>o date. </div><div> </div><div>INFECTIOU<span></span>S DISEASE: <span>SEPSIS</span></div><div>Sepsis</div><div> <span></span><span></span></div><div><span></span><span></span></div><div> <span></span><span></span></div><div>Include two or more of the following:</div><div><span></span><span> </span><span>T<span></span>emperatur<span></span>e &gt; 38°C or &lt; 36°C</span></div><div><span></span><span> </span><span>Heart r<span></span>ate &gt; 90 bpm</span></div><div><span></span><span> </span><span>Respir<span></span>atory rate &gt; 20 bpm</span></div><div><span></span><span> </span><span>WBC count &gt; 12,000/mm3 or &lt; 4,000/mm3 or &gt; 10% immatur<span></span>e </span></div><div>neutrophils</div><div> <span></span><span></span></div><div>Clinical signs of org<span></span>an dysfunction</div><div><span></span><span> </span><span>Neuro: alter<span></span>ed LOC, hypo/hyperthermia</span></div><div><span></span><span> </span><span>Pulmonar<span></span>y: hypox<span></span>emia, ARDS</span></div><div><span></span><span> </span><span>Cardiac: hypot<span></span>ension</span></div><div><span></span><span> </span><span>Renal: AKI (Cr &gt; 2 mg<span></span>/<span></span>dL)</span></div><div><span></span><span> </span><span>GI: hyperbilirubinemia &gt; 2 mg<span></span>/<span></span>dL</span></div><div><span></span><span> </span><span><span></span></span></div><div><span></span><span> </span><span>Hyperlact<span></span>atemia </span></div><div>Septic Shock</div><div> <span></span><span></span></div><div>Severe sepsis with hypotension tha<span></span>t does not resolve with adequa<span></span>te volume </div><div>resuscit<span></span>ation</div><div> <span></span><span></span></div><div></div><div>Sepsis Screening T<span></span>ool</div><div> <span></span><span></span></div><div>Goals of Resuscit<span></span>ation</div><div> <span></span><span></span></div><div><span></span></div><div> <span></span><span></span></div><div>Goals:</div><div><span></span><span> </span><span>CVP 8-12 mmHg, MAP &gt; 65 mmHg, urine output &gt; 0.5 mL/kg<span></span>/hr<span></span>, Sc<span></span>vO2 &gt; </span></div><div>70% or SvO2 &gt; 65%, normal lact<span></span>ate levels</div><div>Surviving Sepsis Bundle</div><div> <span></span><span></span></div><div>Resuscit<span></span>ation</div><div><span></span><span> </span><span><span></span><span></span><span></span><span></span></span></div><div>large volumes of crystalloids ar<span></span>e required</div><div><span></span><span> </span><span><span></span><span></span><span></span></span></div><div>to maint<span></span>ain MAP &gt; 65</div><div><span></span><span> </span><span><span></span></span></div><div><span></span><span> </span><span>Add Epinephrine if additional agent needed to maint<span></span>ain MAP</span></div><div><span></span><span> </span><span>Vasopressin c<span></span>an be used in combination with Norepinephrine if unable </span></div><div>to maint<span></span>ain MAP</div><div><span></span><span> </span><span>Consider Dopamine in select<span></span>ed patients with marked L<span></span>V dysfunction.  Not </span></div><div>recommended f<span></span>or renal protection</div><div><span></span><span> </span><span><span></span></span></div><div>or CO subop<span></span>timal</div><div><span></span><span> </span><span><span></span></span></div><div>pressures and MAP<span></span>.  </div><div> <span></span><span></span></div><div>Diagnosis</div><div><span></span><span> </span><span>Obt<span></span>ain cultures before st<span></span>art of antimicrobial therapy if does not delay </span></div><div>trea<span></span>tment (&gt; 45 min)</div><div><span></span><span> </span><span>Blood cultures (one percut<span></span>aneous and one from each vascular device in </span></div><div>place &gt; 48 hours)</div><div><span></span><span> </span><span>Other possible sites of infec<span></span>tion (CSF<span></span>, sputum, urine, etc.)</span></div><div><span></span><span> </span><span><span></span><span></span></span></div><div> <span></span><span></span></div><div>Antimicrobial Ther<span></span>apy</div><div><span></span><span> </span><span>Administ<span></span>er broad spec<span></span>trum antibiotics within one hour of diagnosis</span></div><div><span></span><span> </span><span>Empiric combination antimicr<span></span>obial therapy for neutropenic p<span></span>atients or </span></div><div>highly multidrug-resist<span></span>ant infections</div><div><span></span><span> </span><span>Empiric antifungal ther<span></span>apy for high risk invasive candidiasis</span></div><div><span></span><span> </span><span>Reassess antibio<span></span>tics daily for descalation</span></div><div><span></span><span> </span><span>Limit antimicrobial ther<span></span>apy to 7-10 days *</span></div><div><span></span><span> </span><span>Limit empiric combination ther<span></span>apy to 3-5 days</span></div><div><span></span><span> </span><span>Narrow cover<span></span>age following suscep<span></span>tibility results</span></div><div><span></span><span> </span><span>St<span></span>op antimicrobial ther<span></span>apy if cause of SIRS is uninf<span></span>ectious</span></div><div> <span></span><span></span></div><div>Source Contr<span></span>ol</div><div><span></span><span> </span><span><span></span></span></div><div><span></span><span> </span><span>Radiographic imaging if needed</span></div><div><span></span><span> </span><span>Remove intr<span></span>avascular devices if po<span></span>tentially infected</span></div><div><span></span><span> </span><span><span></span><span></span><span></span></span></div><div><span></span><span> </span><span>Surgical resec<span></span>tion of infected tissues</span></div><div> <span></span><span></span></div><div>Other Support Modalities</div><div><span></span><span> </span><span>Mechanical ventilation</span></div><div><span></span><span> </span><span>Glucose c<span></span>ontrol</span></div><div><span></span><span> </span><span>Renal replac<span></span>ement therapy</span></div><div><span></span><span> </span><span>Blood product adminis<span></span>tration</span></div><div><span></span><span> </span><span>Nutrition</span></div><div><span></span><span> </span><span>Deep vein thrombus prophylaxis</span></div><div><span></span><span> </span><span>Str<span></span>ess ulcer prophylaxis</span></div><div><span></span><span> </span><span><span></span><span></span></span></div><div>resuscit<span></span>ation and v<span></span>asopressor ther<span></span>apy.  Indica<span></span>ted if random cortisol level </div><div>&lt;18 mg<span></span>/<span></span>dL in patient<span></span>s with septic shock</div><div> </div></div><div></div></div>
<div><div><img><div>88<span> </span><span>Pos<span></span>t-Op Management<span> </span>Pos<span></span>t-Op Management<span> </span><span>89</span></span></div><div>INFECTIOU<span></span>S DISEASE: <span>CELL<span></span>ULITIS</span></div><div>Microbiology:</div><div> <span></span><span></span></div><div>Most c<span></span>ommon pathogens are be<span></span>ta-hemolytic s<span></span>treptococ<span></span>ci (groups A, B, C, G, </div><div>and F), <span>Staphylococ<span></span>cus aureus<span>, including MRSA and gram-ne<span></span>gative aer<span></span>obic </span></span></div><div>bacilli</div><div> <span></span><span></span></div><div>Staphylococ<span></span>cus aureus: <span>Periorbit<span></span>al and orbital cellulitis and IV drug users</span></div><div> <span></span><span></span></div><div>Pseudomonas aeruginosa<span>: Diabetics and other immunoc<span></span>ompromised </span></div><div>patient<span></span>s</div><div> <span></span><span></span></div><div>Aeromonas hydrophila<span> and Vibrio <span>vulnicus</span>: Cellulitis caused by w<span></span>aterborne </span></div><div>pathog<span></span>ens</div><div> <span></span><span></span></div><div>Pasteur<span></span>ella multocida<span> and</span> Capnocytophaga canimorsus<span>: Cellulitis prec<span></span>eded </span></div><div>by bites</div><div> <span></span><span></span></div><div>Str<span></span>eptoc<span></span>occus<span> iniae</span>: Immunocompromised hos<span></span>ts</div><div> <span></span><span></span></div><div>Rare causes: Myc<span></span>obacterium, fungal (muc<span></span>ormycosis, aspergillosis, syphilis)</div><div>Diagnosis: </div><div> <span></span><span></span></div><div>For pa<span></span>tients with signs of systemic disease (f<span></span>e<span></span>ver or hypothermia, he<span></span>ar rate </div><div>[HR] &gt;100 bpm, or syst<span></span>olic blood pressure [SBP] &lt;90 mm Hg) include blood </div><div>cultures, drug suscep<span></span>tibility, CBC, crea<span></span>tinine, bicarbonat<span></span>e, CPK, and CRP </div><div>levels </div><div> <span></span><span></span></div><div>Consider use of CT or MRI if suspicious f<span></span>or deeper infection (os<span></span>teomyelitis/</div><div>mediastinis)</div><div>T<span></span>rea<span></span>tment</div><div>Medication<span> (see Stanf<span></span>ord Antibiogram).</span></div><div>First Line</div><div>T<span></span>reat 5–15 days or long<span></span>er, depending on response, and guided by culture when </div><div><span></span><span></span><span></span></div><div>cellulitis (5) [B]. Empiric ther<span></span>apy should be guided by local resist<span></span>ance pat<span></span>terns. </div><div><span></span><span></span><span></span></div><div> <span></span><span></span></div><div><span></span><span></span></div><div>strep<span></span>tococci and me<span></span>thicillin-susceptible S. aureus)</div><div><span></span><span> </span><span> Oral diclo<span></span>xacillin, cephalexin, clindamycin, or IV cef<span></span>azolin, oxacillin, or </span></div><div>nafcillin.</div><div> <span></span><span></span></div><div>P<span></span>arenteral ther<span></span>apy if severely ill or unable to tolera<span></span>te oral therapy</div><div><span></span><span> </span><span><span></span><span></span></span></div><div>cephalosporin; if penicillin-allergic, use clindamycin or v<span></span>ancomycin.</div><div> <span></span><span></span></div><div>Necrotizing f<span></span>asciitis and gas gangrene</div><div><span></span><span> </span><span>P<span></span>arenteral clindamycin and penicillin.</span></div><div> <span></span><span></span></div><div>In patient<span></span>s with recurrent infection underlying predisposing c<span></span>onditions, </div><div>previous episode of proven MRSA inf<span></span>ection, or sys<span></span>temic to<span></span>xicity, use agents </div><div>with activity agains<span></span>t MRSA</div><div><span></span><span> </span><span>P<span></span>arenteral v<span></span>ancomycin, daptomycin, linezolid or or<span></span>al trimethoprim-</span></div><div>sulfametho<span></span>xazole (TMP<span></span>/SMX), doxycycline or minocycline, or clindamycin </div><div>(3)[C].</div><div> <span></span><span></span></div><div>Mild early-suspect<span></span>ed streptoc<span></span>occal etiology</div><div><span></span><span> </span><span>Penicillin G, 600,000 U<span></span>, and then IM procaine penicillin at 600,000 U </span></div><div>q8h–12h.</div><div> <span></span><span></span></div><div>Recurrent s<span></span>treptococ<span></span>cal cellulitis</div><div><span></span><span> </span><span>Penicillin IV 250 mg b<span></span>.i.d., or if penicillin-allergic, use er<span></span>ythromycin 250 </span></div><div>mg b.i.d.</div><div>Alert</div><div> <span></span><span></span></div><div>If community-ac<span></span>quired MRSA is a concern, tr<span></span>eatment options (7–14 days) </div><div>include trimethoprim/sulf<span></span>amethox<span></span>azole: DS (160 mg TMP and 800 mg of SMX) </div><div>1–2 PO b.i.d. daily; do<span></span>x<span></span>ycycline: 100 mg PO b.i.d., or clindamycin: 300–600 mg </div><div>PO t.i.d.</div><div>Second Line</div><div> <span></span><span></span></div><div>Mild infection:</div><div> <span></span><span></span></div><div>If Penicillin aller<span></span>g<span></span>y: Er<span></span>ythromycin 500 mg PO q6h</div><div> <span></span><span></span></div><div><span></span><span></span></div><div>cellulitis at curr<span></span>ent estimated MR<span></span>SA levels.</div><div> <span></span><span></span></div><div>0.5 mg<span></span>/kg<span></span>/<span></span>d for 5–8 days) if partial response to antibiotics in hemorrhagic or </div><div>bullous cellulitis</div><div>Ongoing Care</div><div>Follow-Up R<span></span>ecommendations</div><div> <span></span><span></span></div><div>Repea<span></span>t blood count if patient is to<span></span>xic. Repeat lumbar punc<span></span>ture in case of </div><div>meningitis.</div><div> <span></span><span></span></div><div>Consider prophylaxis of deep vein thrombosis.</div><div> <span></span><span></span></div><div><span></span><span></span><span></span></div><div>bact<span></span>erial antigens. Symptomatic improvement usually oc<span></span>curs in 24–48 hours, </div><div>but visible improvement may t<span></span>ake up to 72 hours.</div><div> </div><div>INFECTIOU<span></span>S DISEASE: <span>PNEUMONIA</span></div><div>Description</div><div>Community-acquired pneumonia (CAP): L<span></span>ower-respira<span></span>tor<span></span>y trac<span></span>t infection no<span></span>t </div><div>acquired in a hospit<span></span>al, long-term c<span></span>are facility, or during o<span></span>ther recent cont<span></span>act with </div><div>the health car<span></span>e system </div><div>Hospital-ac<span></span>quired pneumonia (HAP): Pneumonia that occurs 48 hours or more </div><div><span></span></div><div>Ventilat<span></span>or-associated pneumonia (VAP): Pneumonia tha<span></span>t de<span></span>velops more than </div><div><span></span></div><div>Health car<span></span>e<span></span>–associat<span></span>ed pneumonia (HCAP): Pneumonia that occurs in a </div><div>nonhospitaliz<span></span>ed patient with ex<span></span>tensive health car<span></span>e cont<span></span>act<span></span>, such as:</div><div> <span></span><span></span></div><div>IV therapy or wound c<span></span>are within the pas<span></span>t 30 days</div><div> <span></span><span></span></div><div>Residing in a nursing home or long-<span></span>term care facility</div><div> <span></span><span></span></div><div>Hospitaliz<span></span>ation in an acute care hospit<span></span>al for 2 or more days within the  </div><div>pas<span></span>t 90 days</div><div> <span></span><span></span></div><div>Visited a hospit<span></span>al or hemodialysis clinic within the past 30 days (2)</div><div>Ev<span></span>aluation</div><div> <span></span><span></span></div><div>Symptoms: f<span></span>e<span></span>ver<span></span>, chills, cough, increased sputum, SOB, pleuritic CP<span></span>. Note </div><div>that the presenting symp<span></span>toms can be subtle – weakness, malaise, AMS</div><div> <span></span><span></span></div><div><span></span></div><div> <span></span><span></span></div><div>Other studies:</div><div><span></span><span> </span><span>Blood culture – before antibio<span></span>tic administra<span></span>tion</span></div><div><span></span><span> </span><span>ABG when patient is severely dyspneic or t<span></span>achypneic</span></div><div><span></span><span> </span><span>Consider tes<span></span>ting for Le<span></span>gionella (culture and urinary assay), Mycoplasma </span></div><div>(cold agglutinins), Pneumoc<span></span>cocus (urine antigen), Chlamydia (acute and </div><div>conv<span></span>alescent serology), or respirat<span></span>or<span></span>y vir<span></span>al panel if clinical course atypic<span></span>al </div><div>or enigmatic</div></div><div></div></div>
<div><div><img><div>90<span> </span><span>Pos<span></span>t-Op Management<span> </span>Pos<span></span>t-Op Management<span> </span><span>91</span></span></div><div><span></span><span> </span><span>Sputum gram s<span></span>tain and culture: while contr<span></span>oversial, it is helpful if </span></div><div>performed before antibio<span></span>tics; an adequate sample has &gt;25 PMNs and &lt; </div><div>10 epithelial cells.</div><div><span></span><span> </span><span>Consider HIV tes<span></span>ting if never previously tested or risk f<span></span>actors for HIV</span></div><div><span></span><span> </span><span>In Immunocompromised p<span></span>atients, consider diagnos<span></span>tic workup for </span></div><div>opportunistic p<span></span>athogens (PCP<span></span>, TB, fungi)</div><div> <span></span><span></span></div><div><span></span><span></span></div><div>microbiologic diagnosis reduc<span></span>es mortality compar<span></span>ed to empiric treatment. </div><div>Management</div><div> <span></span><span></span></div><div>Antibiotic re<span></span>gimen depends on severity of illness, potential for r<span></span>esist<span></span>ant </div><div>organisms or opportunis<span></span>tic pathogens</div><div> <span></span><span></span></div><div>Consult hospital antibiogr<span></span>am and antibiotic guidelines. Adjust for r<span></span>enal/</div><div><span></span></div><div>within 4-6 hours of present<span></span>ation</div><div> <span></span><span></span></div><div>Pseudomonas risk fac<span></span>tors: structur<span></span>al lung disease (bronchiect<span></span>asis), </div><div>cortic<span></span>osteroid ther<span></span>apy (&gt;10 mg of prednisone per day), broad spectrum </div><div>antibiotics for &gt; 7 d in the p<span></span>ast month, recent hospit<span></span>alization, malnutrition</div><div> <span></span><span></span></div><div>Community acquired MR<span></span>SA risk<span></span>: immunocompr<span></span>omised, injection drug use, </div><div><span></span><span></span><span></span></div><div>necrotizing pneumonia</div><div> <span></span><span></span></div><div>High risk of multi-drug resist<span></span>ant (MDR) pathogens: la<span></span>te-onset HAP or VAP </div><div><span></span></div><div>last 90 days, high frequency of antibio<span></span>tic resistanc<span></span>e in the community, </div><div>immunocompromised, or any risk f<span></span>actor for HCAP above. </div><div>Medication</div><div>Pa<span></span>tient Subset<span> </span>Common organisms<span> </span>Ex<span></span>ample empiric antibiotic therapy</div><div>CAP</div><div>- Inpatient</div><div>- Not in ICU</div><div> <span></span><span></span></div><div>T<span></span>ypical: <span>Streptoc<span></span>occus </span></div><div>pneumoniae, Haemophilus </div><div>inuenzae, </div><div> <span></span><span></span></div><div>Atypical: <span>Legionella </span>sp<span></span>., </div><div>Mycoplasma pneumoniae, </div><div>Chlamydophila <span></span>pneumoniae</div><div></div><div>Doxycycline 100mg PO BID</div><div>(if severe penicillin allergy, consider </div><div><span></span></div><div>CAP</div><div>- Inpatient</div><div>- In ICU</div><div>ASSESS risk of </div><div>MDR pathog<span></span>en </div><div>(see above)</div><div>As above plus drug resistant S. </div><div>penumoniae, St<span></span>aphylococcus </div><div>aureus, other gr<span></span>am-negative rods</div><div></div><div>Azithromycin 500mg PO/IV x 1 then</div><div>250mg PO/IV qday</div><div>If risk for CAMRSA: ADD V<span></span>ancomycin</div><div>If risk for Pseudomonas, Pipercillin/</div><div>tazob<span></span>actam 4.5 gm IV q 6h replaces </div><div></div><div>HCAP<span></span>, HAP<span></span>, VAP </div><div>(any acuity)</div><div>Assess risk of </div><div>MDR pathogen </div><div>(see above)</div><div>Staphylococ<span></span>cus aureus, </div><div>Pseudomonas aeruginosa, </div><div>drug-resistant Strept<span></span>ococcus </div><div>pneumoniae<span>, and other resis<span></span>tant </span></div><div>gram-neg<span></span>ative rods. </div><div><span></span></div><div>risk fact<span></span>ors for MDR pathog<span></span>ens – </div><div>empiric therapy should acc<span></span>ount for </div><div>each individual’<span></span>s risk factors and </div><div>level of acuity. </div><div>Low Risk of MDR pa<span></span>thogens:</div><div></div><div>Doxycycline 100mg PO BID AND</div><div>Vancomycin and chang<span></span>e doxyc<span></span>ycline to </div><div>azithromycin in ICU pa<span></span>tients. </div><div>High Risk of MDR pathog<span></span>ens:</div><div>Vancomycin AND</div><div>Pipercillin/tazob<span></span>actam 4.5gm IV q6h AND</div><div><span></span></div><div>INFECTIOU<span></span>S DISEASE:  </div><div>C. DIFF (CL<span></span>OSTRIDIUM DIFFIC<span></span>UL<span></span>T)</div><div>Causes: </div><div> <span></span><span></span></div><div>Produces ent<span></span>erotoxin ( t<span></span>oxin A ) and cytot<span></span>oxic ( toxin B )</div><div> <span></span><span></span></div><div>Associated with ALL antibiotics and hospitaliz<span></span>ation itself</div><div>Symptoms:  a v<span></span>ariety of syndromes are possible from asymp<span></span>tomatic inf<span></span>ection -&gt; </div><div>diarrhea -&gt; pseudomembr<span></span>anous (PMC) -&gt; toxin mega c<span></span>olon -&gt; fulminant colitis. </div><div> <span></span><span></span></div><div>Flu-like sympt<span></span>oms:  Fever, chills, abdominal pain, w<span></span>ater<span></span>y diarrhea. </div><div> <span></span><span></span></div><div>Fecal inc<span></span>ontinence common.</div><div>Diagnose: </div><div> <span></span><span></span></div><div><span></span></div><div> <span></span><span></span></div><div><span></span><span></span></div><div>a false positive sample</div><div> <span></span><span></span></div><div>Order only for p<span></span>atients who have had several wat<span></span>er<span></span>y stools. Cannot be </div><div>ret<span></span>est<span></span>ed before 7 days.</div><div> <span></span><span></span></div><div><span></span><span></span><span></span></div><div>48 hours. </div><div>T<span></span>rea<span></span>tment:  </div><div> <span></span><span></span></div><div>d/<span></span>c antibiotic if possible</div><div> <span></span><span></span></div><div>place in c<span></span>ontact isolation</div><div> <span></span><span></span></div><div>Mild: Metronidazole ( Flagyl ) IV</div><div> <span></span><span></span></div><div>Modera<span></span>te –severe: Vanc<span></span>omycin oral</div><div>DO NOT U<span></span>SE ANTI-PERIST<span></span>AL<span></span>TIC AGENT<span></span>S FOR C-DIFF<span></span>. </div><div>INFECTIOU<span></span>S DISEASE:<span> </span></div><div>URINARY TR<span></span>ACT INFECTION</div><div>Denitions:</div><div> <span></span><span></span></div><div>Lower UTI: Ure<span></span>thritis, cystitis</div><div> <span></span><span></span></div><div>Upper UTI: Pyelonephritis, renal/perinephric abscess</div><div> <span></span><span></span></div><div>Uncomplica<span></span>ted UTI: Lower UTI in a non-pregnant woman with normal GU </div><div>anatomy</div><div> <span></span><span></span></div><div>Complicat<span></span>ed UTI: Anyone else including upper UTI in women, any UTI in men, </div><div>pregnant women or women with s<span></span>tructural or neurological GU dise<span></span>ase.</div><div>Etiology/Risk F<span></span>act<span></span>ors:</div><div> <span></span><span></span></div><div>Organisms: SEEEKS PP: Serr<span></span>atia, E.Coli (80%), Enterobac<span></span>ter, Ent<span></span>ercoccus, </div><div>Klebsiella, St<span></span>aph. Saprophyticus, Proteus, P<span></span>seudomonas</div><div> <span></span><span></span></div><div>Risk F<span></span>actors: F<span></span>emale (short urethr<span></span>a), sexual intercourse, indwelling </div><div>urinar<span></span>y ca<span></span>theters, or recent ins<span></span>trumentation, diaphr<span></span>agm/spermicide use, </div><div><span></span><span></span></div></div><div></div></div>
<div><div><img><div>92<span> </span><span>Pos<span></span>t-Op Management<span> </span>Pos<span></span>t-Op Management<span> </span><span>93</span></span></div><div>T<span></span>rea<span></span>tment:</div><div> <span></span><span></span></div><div>Uncomplica<span></span>ted UTI: </div><div><span></span><span> </span><span><span></span><span></span><span></span></span></div><div>resist<span></span>ance is &gt; 20%</div><div> <span></span><span></span></div><div>Lower UTI in Pre<span></span>gnant women: </div><div><span></span><span> </span><span>Amoxicillin/Clauvulana<span></span>te (Augmentin) and Cephalexin are preferred</span></div><div> <span></span><span></span></div><div>Complicat<span></span>ed lower UTI: Remove ca<span></span>theter<span></span>/stent if pr<span></span>esent (high incidence of </div><div>Pseudomonas and Candida). </div><div><span></span><span> </span><span><span></span><span></span></span></div><div> <span></span><span></span></div><div>Uncomplica<span></span>ted pyelonephritis: Low grade fever<span></span>, WBC count only slightly </div><div>elevated, no nause<span></span>a/vomiting. </div><div><span></span><span> </span><span><span></span><span></span></span></div><div>Augmentin for 14 days. </div><div>ENDOCRINE: <span>AC<span></span>UTE HYPERGL<span></span>Y<span></span>CEMIA AND </span></div><div>DIABETES MANAGEMENT</div><div>1. <span> </span><span>General Pr<span></span>e op consider<span></span>ations: </span></div><div>a. <span> </span><span>Always obt<span></span>ain hemoglobin A1c on pre op labwork</span></div><div>b.<span> <span> </span><span>For outp<span></span>atients: instruc<span></span>t them to hold oral meds on the same morning </span></span></div><div>of OR day; if they are on basal  insulin, only give 1/3 -1/2 does the night </div><div>before or on the same morning of OR. </div><div>c. <span> </span><span><span></span></span></div><div>continue home DM meds( exc<span></span>ept metformin) &amp; insulin the night befor<span></span>e </div><div>surgery; hold oral meds and only give 1/2 -1/3 does basal insulin on the </div><div>same morning  of OR.</div><div>2. <span> </span><span>Hyperglycemia oc<span></span>curs in virtually all CT surgery patients due t<span></span>o:</span></div><div>a. <span> </span><span>A. <span> </span>Increased ex<span></span>trac<span></span>ellular glucose, decreased insulin secre<span></span>tions and </span></div><div>increase peripher<span></span>al resist<span></span>ance to insulin due to: </div><div>o <span> </span>exposure to extr<span></span>acorporeal circula<span></span>tion</div><div>o <span> </span>hypothermia</div><div>o <span> </span>release of endogenous ca<span></span>techolamines, cortisol, and glucagon</div><div>b.<span> <span> </span><span>P<span></span>ost-op g<span></span>oal blood gluc<span></span>ose is &lt; 180 mg<span></span>/<span></span>dL</span></span></div><div>c. <span> </span><span>For pa<span></span>tients with known high HgbA1c pre op or for any pa<span></span>tient </span></div><div>whose gluco<span></span>se is diicult to manag<span></span>e, low threshold t<span></span>o consult </div><div>Endocrine. </div><div>3. <span> </span><span>P<span></span>atients will be admitt<span></span>ed to the CVICU on an insulin drip. P<span></span>atient should </span></div><div>remain on an insulin drip until blood glucose r<span></span>emains within target r<span></span>ange </div><div>with st<span></span>able drip titrations (+/- no more than 1 f<span></span>or pas<span></span>t 4 hours)</div><div>a. <span> </span><span><span></span></span></div><div> </div><div>b.<span> <span> </span><span><span></span><span></span></span></span></div><div>NS @ 50mL/hr and d/<span></span>c D5 ½ NS.</div><div>Prepar<span></span>ation<span> </span>Onset<span> </span>Peak ac<span></span>tion<span> </span>Duration</div><div>Rapid Acting</div><div>Insulin Lispro (Humulog)</div><div>Insulin aspart (NovoLog)</div><div> </div><div>9-30 min </div><div>15 min</div><div> </div><div>30 min-2.5 hrs </div><div>30 min-1 hr</div><div> </div><div>3-4 hrs </div><div>1-3 hrs</div><div>Short Acting</div><div>Regular insulin </div><div>30 min- 1 hr<span> </span>2-5 hrs<span> </span>3-8 hrs</div><div>Intermediat<span></span>e Acting</div><div>NPH</div><div>1-4 hrs<span> </span>4-10 hrs<span> </span>10-16 hrs</div><div>Long Acting</div><div>Insulin glargine (Lantus)</div><div>2-4 hrs<span> </span>None<span> </span>24 hrs</div></div><div></div></div>
<div><div><img><div>94<span> </span><span>Pos<span></span>t-Op Management<span> </span>Pos<span></span>t-Op Management<span> </span><span>95</span></span></div><div>c. <span> </span><span>Special Circumst<span></span>ances</span></div><div>4. <span> </span><span>Preparing f<span></span>or discharge: </span></div><div>a. <span> </span><span>For patient<span></span>s with no previous histor<span></span>y of diabet<span></span>es, the goal is to wean </span></div><div><span></span></div><div>i. <span> </span>If no f<span></span>ormal diagnosis of Diabetes, but pre op A1C &gt; 6.4%, consider </div><div>consult to endocrine or initia<span></span>tion of oral anti diabetic agents</div><div>ii.  If  a patient is being discharg<span></span>ed home with any ne<span></span>w diabetic </div><div>medications (or<span></span>al or injection), Diabetes educa<span></span>tion must be order<span></span>ed </div><div>(~2 days prior to discharg<span></span>e) and complet<span></span>ed by with DM Nurse or the </div><div>bedside RN</div><div>iii. Diabetic t<span></span>each orders in Epic</div><div>1.  “Diabetes educ<span></span>ation” = Bedside Nursing</div><div>a.  Can also plac<span></span>e nursing communication order f<span></span>or RN to initiat<span></span>e </div><div>DM T<span></span>eaching Video</div><div>2.  Nsg Referr<span></span>al to Diabetes RN = CNS Specialis<span></span>t (*Preferred)</div><div>b.<span> <span> </span><span>For those p<span></span>atients with diabetes, slowly r<span></span>estart any or<span></span>al anti-diabetic </span></span></div><div>agents and or insulin. P<span></span>atients will lik<span></span>ely be on much lower doses of </div><div>medications or insulin a<span></span>t discharge than a<span></span>t pre op</div><div>i. <span> </span>Medic<span></span>ations can slowly be up titrat<span></span>ed as needed in the outpatient </div><div>setting as p<span></span>atients diet and appetit<span></span>e returns to normal</div><div>ii.  Oral Antidiabetic agent<span></span>s: </div><div>1.  Metformin</div><div>a.  Contr<span></span>aindicated in the presc<span></span>ence of renal dysfunction (Cre<span></span>at &gt; </div><div>~1.5)</div><div>b.<span> <span> </span>Metformin should t<span></span>emporarily be held pr<span></span>e and post </span></div><div>administr<span></span>ation of IV contras<span></span>t </div><div>c.  Typically held 48 hours prior t<span></span>o any major surger<span></span>y. R<span></span>esume </div><div><span></span><span></span></div><div>returned t<span></span>o baseline. </div><div>2.  Sulfonylure<span></span>as (Glipizide, Glimepiride, Glyburide)</div><div>a.  S<span></span>timulates insulin release fr<span></span>om pancreas</div><div>b.<span> <span> </span>Glipizide does not have an active me<span></span>tabolit<span></span>e, better choice f<span></span>or </span></div><div>those with renal failur<span></span>e</div><div>c.  Overall, increased incidenc<span></span>e of causing hypoglycemia</div><div>3.  Thiazolidinediones ( Act<span></span>os, Avandia)</div><div>a.  May exac<span></span>erbate he<span></span>art failure! Avoid use in most c<span></span>ardiac pa<span></span>tients </div></div><div></div></div>
<div><div><img><div>96<span> </span><span>Pos<span></span>t-Op Management</span></div><div>ENDOCRINE: <span>ADRENAL INSUFFICIENCY</span></div><div>Denition:</div><div> <span></span><span></span></div><div>Most c<span></span>ommonly occurs in critically ill patient<span></span>s due to subnormal </div><div>cortic<span></span>osteroid produc<span></span>tion. </div><div>Diagnosis: </div><div> <span></span><span></span></div><div>T<span></span>ot<span></span>al (random) serum c<span></span>ortisol: Low </div><div> <span></span><span></span></div><div>Morning serum cortisol c<span></span>oncentration: L<span></span>ow (&gt; 3mch/<span></span>dL)</div><div> <span></span><span></span></div><div>CTH S<span></span>timulation test:</div><div><span></span><span> </span><span><span></span><span></span><span></span><span></span></span></div><div><span></span><span> </span><span>Administr<span></span>ation of ACTH (1-24) or Cosyntropin:</span></div><div> <span></span><span></span></div><div>St<span></span>anford high dose tes<span></span>t (250mcg)</div><div> <span></span><span></span></div><div>A normal response is a rise in serum cortisol c<span></span>oncentration 30-60 </div><div><span></span><span></span><span></span><span></span></div><div> <span></span><span></span></div><div>A normal response to high dose A<span></span>CTH s<span></span>timulation test ex<span></span>cludes </div><div><span></span></div><div> <span></span><span></span></div><div>Low dose tes<span></span>t (1mcg<span></span>)</div><div> <span></span><span></span></div><div>A normal response is a rise in serum cortisol c<span></span>oncentration 20-30 </div><div><span></span><span></span><span></span><span></span></div><div>T<span></span>rea<span></span>tment: Str<span></span>ess Dose S<span></span>teroids</div><div> <span></span><span></span></div><div>Consider trea<span></span>tment when patient on &gt;2 pressors with hemodynamic </div><div>inst<span></span>ability</div><div> <span></span><span></span></div><div>Replacement with hydr<span></span>ocortisone:</div><div><span></span><span> </span><span>50mg IV Q6 hours or 100mg IV q8 hours</span></div><div> <span></span><span></span></div><div>Consider quick taper (over 3-5 days) onc<span></span>e hemodynamics improve </div><div>Referenc<span></span>es: </div><div><span></span><span></span></div></div><div></div></div>
<div><div><img><div>Procedur<span></span>es/De<span></span>vices<span> </span><span>97</span></div><div>PROCEDURES: <span>A<span></span>TRIAL ELEC<span></span>TROGRAMS</span></div><div> <span></span><span></span></div><div><span></span><span></span><span></span></div><div><span></span></div><div> <span></span><span></span></div><div>Requires the presc<span></span>eince of atrial tempor<span></span>ar<span></span>y epicardial wires </div><div>T<span></span>o perform:</div><div> <span></span><span></span></div><div>Obt<span></span>ain standard EC<span></span>G for baseline/<span></span>comparison</div><div> <span></span><span></span></div><div>For Atrial EC<span></span>G: Att<span></span>ach the two arm leads to the atrial wires (all o<span></span>ther leads </div><div>at<span></span>tached normally)</div><div><span></span><span> </span><span>A bipolar ECG will be r<span></span>ecorded in Lead I and unipolar EC<span></span>G in Lead II or III</span></div><div> <span></span><span></span></div><div>Interpre<span></span>ta<span></span>tion: Ev<span></span>aluate a<span></span>trial activity in rela<span></span>tion to QRS c<span></span>omplex </div><div>Interpre<span></span>tation e<span></span>xamples:</div><div> <span></span><span></span></div><div>Normal Sinus rhythm: Large a<span></span>trial spike on Atrial EC<span></span>G will correlat<span></span>e  </div><div>with P waves</div><div> <span></span><span></span></div><div>Junctional: No atrial spik<span></span>e present on Atrial ECG</div><div> <span></span><span></span></div><div><span></span><span></span></div><div>PROCEDURES: <span> </span></div><div>DIRECT C<span></span>URRENT CARDIOVERSION (DC<span></span>CV)</div><div>Supplies/Equipment</div><div>5. <span> </span><span></span></div><div>6. <span> </span><span><span></span></span></div><div>7. <span> </span><span>EKG machine </span></div><div>8. <span> </span><span>Monitoring equipment at bedside (bedside t<span></span>elemetr<span></span>y with 5 lead syst<span></span>em, </span></div><div><span></span><span></span><span></span></div><div>oxygen ac<span></span>cess and mask<span></span>, pulse o<span></span>ximetry, ambubag)</div><div>Proc<span></span>edure</div><div>Pre-Proc<span></span>edure Care St<span></span>eps:</div><div>1. <span> </span><span><span></span></span></div><div>a. <span></span><span>12 lead EKG</span></div><div>b.<span> <span></span><span>Pa<span></span>tent intravenous venous line (IV)</span></span></div><div>c. <span> </span><span>P<span></span>atient is connected t<span></span>o the following: telemetry with a 5-lead EKG </span></div><div><span></span><span></span></div><div>equipment, oxygen is available/<span></span>operational, ambu b<span></span>ag at bedside</div><div>2. <span> </span><span>Keep patient NPO f<span></span>or approximately 6 hours prior to pr<span></span>ocedure</span></div><div>3. <span> </span><span><span></span><span></span></span></div><div>4. <span> </span><span>Obt<span></span>ain written informed consent</span></div><div>5. <span> </span><span><span></span><span></span></span></div><div><span></span><span></span></div></div><div></div></div>
<div><div><img><div>98<span> </span><span>Procedures/Devices<span> </span>Procedur<span></span>es/De<span></span>vices<span> </span><span>99</span></span></div><div>For pa<span></span>tients on T<span></span>elemetry unit requiring DC<span></span>CV: (must be performed by </div><div>Cardiac Anesthesia)</div><div>1. <span> </span><span>P<span></span>age, call, or tex<span></span>t ICU Cardiac Anesthesia At<span></span>tending on call directly t<span></span>o set </span></div><div>up cardioversion</div><div>2. <span> </span><span>Call OR to book the case in the OR (this is f<span></span>or ICU at<span></span>tending billing </span></div><div>purposes)</div><div>Cardiac anesthesia on call f<span></span>or the OR should only be contacted for c<span></span>ardioversion </div><div>if ICU Att<span></span>ending is unable to perform the procedure.</div><div>PROCEDURES: <span>P<span></span>ACER WIRE (PW) REMOV<span></span>AL</span></div><div>Pre Remov<span></span>al Checklist: </div><div>1. <span> </span><span>Are PW capped with no evidence of rhythm issues on t<span></span>elemetr<span></span>y for 24 hours? </span></div><div><span></span><span></span></div><div>2. <span> </span><span>If pacing wires have no<span></span>t been capped yet, any pacing activity in last 24 hrs? </span></div><div>(Check with primar<span></span>y nurse and teleme<span></span>tr<span></span>y monitor). If not &gt; cap p<span></span>acing wires. </div><div>3. <span> </span><span>If PW already c<span></span>apped, for how long? (Usually requir<span></span>e wires to be c<span></span>apped for at </span></div><div>leas<span></span>t 4-6 hours before removal)</div><div>4. <span> </span><span>Is patient on any anti-c<span></span>oagulation including Heparin sub Q<span></span>/ IV infusion, </span></div><div>Arga<span></span>troban, Plavix, Coumadin, Pradaxa, X<span></span>arelto, Eliquis etc?</div><div>i. <span> </span><span>In gener<span></span>al, we do not s<span></span>tart non-r<span></span>e<span></span>versible antico<span></span>agulant agents (Plavix/</span></div><div>Pradax<span></span>a/Eliquis/Xarelt<span></span>o, etc.) until PW alr<span></span>eady removed</div><div>ii. <span> </span><span>If novel OAC ag<span></span>ent has been st<span></span>arted, check with surgical te<span></span>am regarding </span></div><div>timing of holding medication prior t<span></span>o PW remov<span></span>al </div><div>iii. <span> </span><span>If on SubQ heparin, hold Sub Q heparin 6-8 hrs bef<span></span>ore PW removal</span></div><div>iv<span></span>. <span> </span><span>If on heparin/<span></span>argatrob<span></span>an gtt, hold gtt for 6 hrs before PW r<span></span>emoval, and </span></div><div><span></span></div><div>v.<span></span><span> <span> </span><span>If on Coumadin, slowly titrate Coumadin dose until PW out, and only </span></span></div><div>remove PW with INR &lt; 2.0.</div><div>5. <span> </span><span>Was PW sutured in or oversewn to he<span></span>art? Double check sign-out list and </span></div><div>notes. *** In this c<span></span>ase PW are to be CUT A<span></span>T SKIN, not pulled ***</div><div>6. <span> </span><span>Has plan to remove PW been discussed with a<span></span>tt<span></span>ending or chief resident? </span></div><div>During Remov<span></span>al:</div><div> <span></span><span></span></div><div>Maintain smoo<span></span>th and steady s<span></span>trength</div><div> <span></span><span></span></div><div><span></span><span></span><span></span></div><div><span></span></div><div>swab</div><div>Aer R<span></span>emoval:</div><div> <span></span><span></span></div><div>Notify both p<span></span>atient &amp; primar<span></span>y RN to keep p<span></span>atient in bed for at leas<span></span>t 1 hour </div><div><span></span></div><div> <span></span><span></span></div><div>Instruct RN t<span></span>o watch for warning signs and symp<span></span>toms of tamponade such as:</div><div><span></span><span> </span><span>Lightheadedness</span></div><div><span></span><span> </span><span>Dizziness</span></div><div><span></span><span> </span><span>Diaphoresis</span></div><div><span></span><span> </span><span>Chest disc<span></span>omfort</span></div><div><span></span><span> </span><span>Decreased BP</span></div><div><span></span><span> </span><span>Increased HR</span></div><div> <span></span><span></span></div><div><span></span><span></span><span></span></div><div>6. <span> </span><span><span></span><span></span><span></span><span></span></span></div><div>i. <span> </span><span>Antico<span></span>agulation:</span></div><div>•<span> <span> </span>If dur<span></span>ation of atrial arrhythmia &lt; 48 hours, no antic<span></span>oagulation required</span></div><div>•<span> <span> </span>If dur<span></span>ation of atrial arrhythmia &gt; 48 hours, c<span></span>onsider anticoagulation in </span></div><div>conjunction with CHADs sc<span></span>ore</div><div>ii. <span> </span><span>K+ - consider replac<span></span>ement if K+ &lt; 3.4</span></div><div>7. <span> </span><span>Review baseline vital signs and SaO2 fr<span></span>om pulse oximeter</span></div><div>8. <span> </span><span><span></span></span></div><div>9. <span> </span><span>If tempor<span></span>ar<span></span>y p<span></span>acing wires present<span></span>- ensure att<span></span>ached to external p<span></span>acemaker </span></div><div>box and turn pac<span></span>emaker box on (consider placing p<span></span>atient on back up VVI </div><div>mode)</div><div>10. <span></span><span><span></span><span></span></span></div><div><span></span><span></span></div><div>placement is at le<span></span>ast six (6) inches away from implant<span></span>ed device</div><div>11. <span></span><span><span></span><span></span><span></span><span></span></span></div><div>i. <span> </span><span><span></span></span></div><div><span></span><span></span></div><div>at<span></span>tending provider’<span></span>s discretion)</div><div>ii. <span> </span><span><span></span><span></span></span></div><div>iii. <span> </span><span>Press “Sync” but<span></span>ton and ensure R wave aligns with synchr<span></span>onized </span></div><div>marker</div><div>iv<span></span>. <span> </span><span>Press rec<span></span>ord button to ensur<span></span>e recording paper is oper<span></span>ational</span></div><div>Proc<span></span>edure St<span></span>eps:</div><div>1. <span> </span><span>Perf<span></span>orm “Time out”</span></div><div>2. <span> </span><span>Anesthesiologis<span></span>t<span></span>/ICU APP adminis<span></span>ters anesthetic agent via IV with O2 on </span></div><div>patient</div><div>3. <span> </span><span>Vitals signs and SaO2 ar<span></span>e recor<span></span>ded e<span></span>very minute by RN</span></div><div>4. <span> </span><span>When anesthesiologis<span></span>t<span></span>/ICU APP det<span></span>ermines patient is adequately seda<span></span>ted, </span></div><div>he/she acknowledges to the APP tha<span></span>t patient is ready f<span></span>or DCCV</div><div>5. <span> </span><span>The APP performs the following:</span></div><div>i. <span> </span><span>Press the “Charg<span></span>e” butt<span></span>on and sta<span></span>tes loudly, “Char<span></span>ging”</span></div><div>ii. <span> </span><span>St<span></span>ates loudly, “<span></span>All clear!” and visually sweeps the bed to ensur<span></span>e no one </span></div><div>is touching the bed and wait<span></span>s for other t<span></span>eam members to verify they are </div><div>clear</div><div>iii. <span> </span><span>Press and hold the “Shock<span></span>” button</span></div><div>6. <span> </span><span><span></span><span></span><span></span></span></div><div>communica<span></span>tes with anesthesiologist t<span></span>o verify vital signs are st<span></span>able</div><div>7. <span> </span><span>If patient r<span></span>emains in sinus rhythm, anterior/pos<span></span>terior pads are removed fr<span></span>om </span></div><div><span></span><span></span></div><div>from pa<span></span>tient</div><div>8. <span> </span><span>If patient has e<span></span>arly re-initiation of atrial arrhythmia or remains in an atrial </span></div><div>arrhythmia, DCCV pr<span></span>ocedure is repea<span></span>ted with a higher number of joules.  APP </div><div><span></span><span></span></div><div>energy for the maximum of 3 shocks.</div><div>9. <span> </span><span>The APP follows current ACL<span></span>S protoc<span></span>ol for asystole, high degr<span></span>ee AV block or </span></div><div>ventricular arrhythmias and pages A<span></span>ttending Physician</div><div>10. <span></span><span>The APP c<span></span>ompletes the following:</span></div><div>i. <span> </span><span>Reviews post proc<span></span>edure EKG</span></div><div>ii. <span> </span><span>Any medication r<span></span>econciliation, if applic<span></span>able</span></div><div>iii. <span> </span><span>Document via Procedur<span></span>e Note: Include medication adminis<span></span>tered, # of </span></div><div>joules, # of shocks, post proc<span></span>edure rhythm, and any adverse events. </div></div><div></div></div>
<div><div><img><div>100<span> </span><span>Procedures/Devic<span></span>es<span> </span>Procedur<span></span>es/De<span></span>vices<span> </span><span>101</span></span></div><div>If the chest tube has purse s<span></span>trings: </div><div>1. <span> </span><span>With scalpel, cut the holding suture which is tied around the ches<span></span>t tube and </span></div><div>the purse strings on the dis<span></span>tal end, make sure le<span></span>ave enough purse string </div><div>length to tie. </div><div>2. <span> </span><span><span></span></span></div><div>3. <span> </span><span>Instruct the p<span></span>atient to tak<span></span>e deep breath in and hold bre<span></span>ath. (*T<span></span>ubes may be </span></div><div>pulled at end inspir<span></span>ation or end expir<span></span>ation, the import<span></span>ant point is that the </div><div>patient is no<span></span>t inspiring as the tube comes out) </div><div>4. <span> </span><span>Pull chest tube smoo<span></span>thly and quickly</span></div><div>5. <span> </span><span><span></span></span></div><div>removal, oper<span></span>ator immediat<span></span>ely tie down the purse string with sur<span></span>gical knot<span></span>s </div><div>X3 and cut excess s<span></span>tring with scalpel </div><div>6. <span> </span><span>Remind pa<span></span>tient to breath normally as soon as ches<span></span>t tube is removed </span></div><div>7. <span> </span><span>Cover the CT sit<span></span>e vaseline g<span></span>auze with dr<span></span>y dressing and tape </span></div><div>If the pa<span></span>tient does not have pur<span></span>se string to tie:</div><div>1. <span> </span><span>Cut the holding string and c<span></span>over the insertion site with Vaseline gauz<span></span>e quickly </span></div><div>while removing  the chest tube </div><div>2. <span> </span><span>Cover the Vaseline gauz<span></span>e with dr<span></span>y dressing and make sure the whole dr<span></span>essing </span></div><div>is sealed well with 2inch paper t<span></span>apes for @ leas<span></span>t 48 hrs before remove </div><div>dressing or shower</div><div>If chest tube is pigt<span></span>ail cathet<span></span>er placed per IR</div><div>1. <span> </span><span>See Pigtail r<span></span>emoval</span></div><div>Check list pos<span></span>t chest tube remov<span></span>al:</div><div> <span></span><span></span></div><div>Dispose all sharps in sharps cont<span></span>ainer<span></span>; dispose CT dr<span></span>ainage unit into doubled </div><div>red tr<span></span>ash bag</div><div> <span></span><span></span></div><div>If conc<span></span>ern or suspect post CT r<span></span>emoval P<span></span>TX, need to check CXR immediat<span></span>ely; if </div><div>no conc<span></span>ern for PT<span></span>X, do not need to check CXR</div><div> <span></span><span></span></div><div></div><div>extr<span></span>eme pain, pos<span></span>top PT<span></span>X etc.) during or pos<span></span>top procedure</div><div>Pos<span></span>t chest tube remo<span></span>val p<span></span>atient education:</div><div> <span></span><span></span></div><div>Keep occlusive dressing or s<span></span>tiches on for at leas<span></span>t 48 hrs, then remove and </div><div>clean site in shower (C<span></span>T stich could be r<span></span>emoved prior to discharg<span></span>e or on clinic </div><div>visit time)</div><div> <span></span><span></span></div><div>No soaking in ba<span></span>thtub for 1 week</div><div> <span></span><span></span></div><div>CT insertion sit<span></span>e will be assessed at follow up MD visit in 1-2 weeks </div><div> <span></span><span></span></div><div><span></span><span></span><span></span><span></span><span></span></div><div>increasing erythema on CT sites</div><div>Pigtail R<span></span>emoval (plac<span></span>ed by IR) </div><div>PROCEDURES: <span>RAPID SEQUENCE INDUC<span></span>TION</span></div><div>Simultaneous adminis<span></span>tration of a sedative and a neur<span></span>omuscular blocking </div><div><span></span><span></span><span></span></div><div>to f<span></span>acilita<span></span>te emerg<span></span>ent endotracheal intub<span></span>ation and to minimize the risk of </div><div>aspira<span></span>tion.  </div><div>Administ<span></span>er<span></span>:  </div><div>1) SEDA<span></span>TIVE; 2) P<span></span>ARAL<span></span>YTIC; 3) FL<span></span>USH</div><div>(Most Common combination is Etomidat<span></span>e and Rocuronium +/- propofol for side </div><div>eect prole)</div><div>If the pa<span></span>tient st<span></span>arts to exhibit s/sx o<span></span>f tamponade  </div><div>follow these s<span></span>teps:</div><div>1. <span> </span><span>1. <span> </span>If patient only has sympt<span></span>oms, but BP and HR are stable:</span></div><div>i. <span> </span><span>Order ST<span></span>A<span></span>T Echo </span></div><div>ii. <span> </span><span>Call Echo lab (x54160) to no<span></span>tify them of order and that the purpose is to </span></div><div>rule out tamponade</div><div>iii. <span> </span><span>Continue to monitor p<span></span>atient &amp; vitals closely. Run BP checks Q15 min.</span></div><div>iv<span></span>. <span> </span><span>Notify chief resident or a<span></span>ttending</span></div><div>v.<span></span><span> <span> </span><span>A<span></span>s soon as there is a change in vit<span></span>al signs, follow step 3. </span></span></div><div>2. <span> </span><span>If the patient’<span></span>s BP start<span></span>s to drop, but gener<span></span>al condition is OK</span></div><div>i. <span> </span><span><span></span></span></div><div>ii. <span> </span><span> <span> </span>Order S<span></span>TA<span></span>T Echo, c<span></span>all Echo lab and notify as above.  </span></div><div>iii. <span> </span><span> <span> </span>No<span></span>tify chief resident and at<span></span>tending that you have suspicion for </span></div><div>possible tamponade </div><div>iv<span></span>. <span> </span><span> <span> </span>Call IC<span></span>U team f<span></span>or possible transfer to back t<span></span>o ICU</span></div><div>3. <span> </span><span><span></span><span></span><span></span><span></span></span></div><div>decompensating quickly<span></span>, take all s<span></span>teps as listed above but notify on c<span></span>all </div><div>at<span></span>tending and OR that emer<span></span>gent surg<span></span>er<span></span>y is needed. If p<span></span>atient goes int<span></span>o </div><div>cardiac arres<span></span>t or mental st<span></span>atus st<span></span>arts to change, et<span></span>c </div><div>i. <span> </span><span>Activa<span></span>te Open chest code and r<span></span>apid transfusion prot<span></span>ocol. </span></div><div>ii. <span> </span><span>Open chest a<span></span>t bedside ASAP to rele<span></span>ase pressure on heart  </span></div><div>•<span><span> </span><span></span></span></div><div>•<span> <span> </span>Direc<span></span>t CPR/<span></span>cardiac massage if cardiac arr<span></span>est</span></div><div>•<span> <span> </span>S<span></span>traight t<span></span>o OR</span></div><div>Chest T<span></span>ube Removal:  </div><div>Things to c<span></span>onsider before CT r<span></span>emoval:</div><div> <span></span><span></span></div><div>If drainag<span></span>e &lt; 150 cc/24 hrs (some surg<span></span>eons are OK with drainage&lt;  200c<span></span>c/24 </div><div><span></span></div><div> <span></span><span></span></div><div>Is there any air leak fr<span></span>om chest tube? </div><div><span></span><span> </span><span><span></span></span></div><div><span></span><span> </span><span>If chest tube with persis<span></span>tent air leak, may switch to  wat<span></span>er seal overnight </span></div><div>and check CXR next AM, if no new  P<span></span>TX or previous existing P<span></span>TX in st<span></span>able </div><div>size-&gt; may remove chest tube (some<span></span>times needs to  clamp chest tube 1st </div><div>and repea<span></span>t CXR to rule out new PTX/increasing  P<span></span>TX size before r<span></span>emoval)</div><div> <span></span><span></span></div><div>Is there any P<span></span>TX on CXR?</div><div> <span></span><span></span></div><div>Assess pain control need: usually give fent<span></span>anyl 25-50 mcg IV or dilaudid 0.2mg </div><div>IV before proc<span></span>edure </div><div> <span></span><span></span></div><div>Grab ma<span></span>terials to use: sutur<span></span>e remov<span></span>al set or scalpel; multiple 4x4 g<span></span>auzes; </div><div>Vaseline gauz<span></span>e; hem clamp;  2 inch wide paper tapes; blue chux ; 2 red </div><div>biohazar<span></span>d trash bag</div><div> <span></span><span></span></div><div>Usually needs a 2nd person (RN or P<span></span>A/NP colleague to hold ches<span></span>t tube site </div><div>tissue toge<span></span>ther before kno<span></span>ts are tied or V<span></span>aseline gauze is placed)</div><div>Proc<span></span>edure:</div><div> <span></span><span></span></div><div>Place p<span></span>atient in bed with comf<span></span>ortable position and explain to the pa<span></span>tient </div><div>about the procedur<span></span>e process </div><div> <span></span><span></span></div><div>Remove chest tube sit<span></span>e dressing and assess the wound</div><div> <span></span><span></span></div><div>If there are 2-3  tubes c<span></span>onnected together with  Y<span></span>-connector<span></span>, need to clamp </div><div><span></span><span></span></div><div>chest tube remov<span></span>al </div></div><div></div></div>
<div><div><img><div>102<span> </span><span>Procedures/Devic<span></span>es<span> </span>Procedur<span></span>es/De<span></span>vices<span> </span><span>103</span></span></div><div>PROCEDURES: <span>BRONCHOSC<span></span>OPY</span></div><div>Indications f<span></span>or bronchoscopy:</div><div> <span></span><span></span></div><div>Hypoxemia</div><div> <span></span><span></span></div><div>Suspected airway obstruc<span></span>tion</div><div> <span></span><span></span></div><div>New CXR opacity</div><div> <span></span><span></span></div><div>Copious secretions</div><div> <span></span><span></span></div><div>T<span></span>o obt<span></span>ain Bronchial Alveolar Lavag<span></span>e (BAL)/sputum culture</div><div> <span></span><span></span></div><div>Pulmonar<span></span>y toile<span></span>ting</div><div>Set<span></span>ting up a bronchoscopy:</div><div> <span></span><span></span></div><div>Discuss with at<span></span>tending on ideal time and indic<span></span>ation</div><div> <span></span><span></span></div><div>Decide bronchoscope (full c<span></span>art) vs ambuscope (smaller screen, smaller </div><div>scope)</div><div><span></span><span> </span><span>Full cart br<span></span>onchoscope indicated f<span></span>or<span></span>:</span></div><div> <span></span><span></span></div><div>Thick secretions, c<span></span>opious secretions</div><div> <span></span><span></span></div><div>Copious bloody secretions</div><div> <span></span><span></span></div><div>At<span></span>tending pref<span></span>erence</div><div> <span></span><span></span></div><div>Call x37709 (RT ba<span></span>t phone for charge R<span></span>T)<span>. The<span></span>y will ask the following:</span></div><div><span></span><span> </span><span>P<span></span>atient name, location</span></div><div><span></span><span> </span><span>At<span></span>tending provider</span></div><div><span></span><span> </span><span>Indication</span></div><div><span></span><span> </span><span>Scope requir<span></span>ed (ambuscope vs bronchoscope)</span></div><div>Aer the br<span></span>onchoscopy:</div><div> <span></span><span></span></div><div><span></span><span></span><span></span></div><div> <span></span><span></span></div><div>Fill out the order requisition:</div><div><span></span><span> </span><span>Pneumonia diagnosis code: 498</span></div><div><span></span><span> </span><span>Gram s<span></span>tain and culture for BAL </span></div><div><span></span><span> </span><span><span></span><span></span></span></div><div> <span></span><span></span></div><div>Order post<span></span>-bronchoscopy CXR </div><div>DEVICES:<span> IABP</span></div><div>Indications</div><div> <span></span><span></span></div><div>Cardiogenic shock</div><div> <span></span><span></span></div><div>Unst<span></span>able angina</div><div> <span></span><span></span></div><div>Intrac<span></span>table ventricular dysrhythmias</div><div> <span></span><span></span></div><div>Threa<span></span>tening extension of MI</div><div> <span></span><span></span></div><div>Prophylactic support for PCI</div><div> <span></span><span></span></div><div>Prophylactic support for OR induc<span></span>tion</div><div> <span></span><span></span></div><div>Pos<span></span>t-op myocardial dysfunc<span></span>tion</div><div> <span></span><span></span></div><div>Inability to wean fr<span></span>om CPB</div><div> <span></span><span></span></div><div>RV support during L<span></span>VAD implanta<span></span>tion</div><div> <span></span><span></span></div><div>Contraindicat<span></span>ed in Aortic regurgitation, Aortic dissection, or with severe aortic </div><div>of peripheral atherosclerosis<span> </span></div><div>Placement/P<span></span>osition</div><div> <span></span><span></span></div><div>1-2cm below L subclavian artery and above the renal arter<span></span>y br<span></span>anches</div><div> <span></span><span></span></div><div>Tip should be between the 2nd &amp; 3rd Int<span></span>ercos<span></span>tal spac<span></span>e on CXR</div><div>Sedatives</div><div>Drug </div><div>Name</div><div>Class<span> </span><span>Benets<span> </span></span>Contr<span></span>a-</div><div>indications</div><div>Not<span></span>es<span> </span>Dose</div><div>Etomida<span></span>te<span> </span>Imidazole </div><div>derivative</div><div>Exc<span></span>ellent </div><div>sedation </div><div>with little </div><div>hypotension</div><div>Known to </div><div>suppress </div><div>adrenal cortisol </div><div>production</div><div>Use cautiously </div><div>if patient </div><div>has sepsis; </div><div>initial dose of </div><div>glucocortic<span></span>oid </div><div>may be needed</div><div>0.3 mg<span></span>/kg</div><div>Ketamine<span> </span>Phencyclidine </div><div>derivative, </div><div>dissociative </div><div>anesthetic</div><div>Stimulat<span></span>es  </div><div>catecholamine </div><div>release </div><div>Bronchodilation</div><div>Use in patients </div><div>with elevated </div><div>ICP or elevated </div><div>blood pressure is </div><div>controversial</div><div>May be an </div><div>excellent </div><div>induction agent </div><div>for patient<span></span>s with </div><div>bronchospasm, </div><div>septic </div><div>shock, <span>AND</span> </div><div>hemodynamic </div><div>compromise</div><div>1 to 2 mg<span></span>/kg</div><div>Midazolam<span> </span>Benzo- </div><div>diazepines</div><div>Pot<span></span>ent dose<span></span>-</div><div>related amnesic </div><div>properties</div><div>Dose-related </div><div>myocardial </div><div>depression </div><div>can result in </div><div>hypotension</div><div>0.2 to 0.3 </div><div>mg<span></span>/kg</div><div>Propofol<span> </span>Alkylphenol </div><div>derivative</div><div>Bronchodilation<span> </span>No absolute </div><div>contraindic<span></span>ations </div><div>Dose-related </div><div>hypotension</div><div>P<span></span>aralytics</div><div>Drug Name<span> </span>Class<span> </span>Contraindica<span></span>tions<span> </span>Not<span></span>es<span> </span>Dose</div><div>Succinylcholine<span> </span>Depolarizing </div><div>agent binds to </div><div>postsynap<span></span>tic ACh </div><div>recept<span></span>ors causing </div><div>continuous </div><div>stimulation</div><div>Hx or family hx of malignant </div><div>hyperthermia </div><div>Hyperkalemia or risk of </div><div>developing hyperkalemia </div><div>Upregulation of ACh </div><div>recept<span></span>ors predisposes pts to </div><div>hyperkalemia</div><div>Neuromuscular disease </div><div>involving denervation </div><div>(muscular dystrophy<span></span>, stroke </div><div>&gt;72hrs, spinal cord injury </div><div>&gt;72hrs, muscular dystrophy<span></span>, </div><div>ALS)</div><div>Rhabdomyolysis</div><div>Burn &gt; 72 hours old</div><div>Inherited myopathies</div><div>Crush injuries &gt;72hrs</div><div>Severe infection w/ exo<span></span>toxin </div><div>(tet<span></span>anus, botulism)</div><div>Note: Succinylcholine is saf<span></span>e </div><div>in myasthenia gr<span></span>avis</div><div>paralysis oc<span></span>curs </div><div>in 45 to 60 </div><div>seconds</div><div>duration appr<span></span>ox. </div><div>6- 10 min. </div><div>1.5 mg<span></span>/kg IV</div><div>Rocuronium<span> </span>Nondepolarizing </div><div>agent.</div><div>Competitively </div><div>inhibits ACh </div><div>recept<span></span>ors </div><div>preventing </div><div>depolarization </div><div>P<span></span>aralysis occurs </div><div>in approximat<span></span>ely </div><div>45 to 60 seconds</div><div>duration appr<span></span>ox. </div><div>45 minutes</div><div>1.0 mg<span></span>/kg</div><div>IBW</div><div>Vecuronium<span> </span>Nondepolarizing </div><div>agent.</div><div>P<span></span>aralysis occurs </div><div>w/in 2.5-3 min</div><div>Duration 25-40 </div><div>min.</div><div>0.08-0.1 </div><div>mg<span></span>/kg</div></div><div></div></div>
<div><div><img><div>104<span> </span><span>Procedures/Devic<span></span>es<span> </span>Procedur<span></span>es/De<span></span>vices<span> </span><span>105</span></span></div><div>Possible R<span></span>easons for Poor A<span></span>ugmentation</div><div> <span></span><span></span></div><div>P<span></span>atient’<span></span>s native str<span></span>oke volume &gt; IABP volume</div><div> <span></span><span></span></div><div>Indication of r<span></span>eadiness to we<span></span>an from IABP</div><div> <span></span><span></span></div><div>Balloon too small?</div><div> <span></span><span></span></div><div>Low SVR</div><div> <span></span><span></span></div><div>Hypovolemia</div><div> <span></span><span></span></div><div>IABP positioned too low</div><div> <span></span><span></span></div><div>Kinked ca<span></span>theter</div><div>T<span></span>riggers</div><div>Autopilo<span></span>t Mode </div><div> <span></span><span></span></div><div>Machine selects EK<span></span>G and AP (arterial pressure) sourc<span></span>e, trigger mode and </div><div>timing method as well as optimiz<span></span>es timing</div><div> <span></span><span></span></div><div>Machine continuously monitors the p<span></span>atient and chooses the best trigger </div><div>mode based on pa<span></span>tient condition</div><div>EKG</div><div> <span></span><span></span></div><div>Pre-set trigger mode</div><div>EKG P<span></span>eak</div><div> <span></span><span></span></div><div>Best for wide c<span></span>omplex rhythm</div><div> <span></span><span></span></div><div>Best for HR&gt;130bpm</div><div> <span></span><span></span></div><div>A Fib</div><div> <span></span><span></span></div><div>Best choic<span></span>e for var<span></span>ying R<span></span>-R inter<span></span>v<span></span>als</div><div> <span></span><span></span></div><div><span></span><span></span></div><div>Arterial Pressur<span></span>e</div><div> <span></span><span></span></div><div>Best trigg<span></span>er when EKG is unav<span></span>ailable or has lots of artifact</div><div> <span></span><span></span></div><div>T<span></span>riggered by the syst<span></span>olic up<span></span>-s<span></span>toke of the arterial pressure w<span></span>aveform</div><div> <span></span><span></span></div><div>Should be used during CPR</div><div>A P<span></span>ace</div><div> <span></span><span></span></div><div>T<span></span>riggered by the atrial p<span></span>acing spike</div><div> <span></span><span></span></div><div>Can only be used if patient 100% A p<span></span>aced</div><div>V P<span></span>ace</div><div> <span></span><span></span></div><div>T<span></span>riggered by the ventricular spike</div><div> <span></span><span></span></div><div>Can be used if patient V p<span></span>aced or AV pac<span></span>ed</div><div> <span></span><span></span></div><div>Pt must be 100% p<span></span>aced</div><div>Internal </div><div> <span></span><span></span></div><div><span></span><span></span><span></span><span></span></div><div>activity</div><div> <span></span><span></span></div><div>Used in situation when there is no c<span></span>ardiac output and no EKG</div><div>During CPR</div><div> <span></span><span></span></div><div>Arterial pressur<span></span>e trigger should be select<span></span>ed as this will synchronize c<span></span>ounter </div><div>pulsation to c<span></span>ardiac compr<span></span>essions</div><div>IABP Complications:</div><div> <span></span><span></span></div><div>Dist<span></span>al limb ischemia (most common c<span></span>omplication occurring in 10-15% of </div><div>patient<span></span>s) and compartment syndrome</div><div> <span></span><span></span></div><div>Infection and sepsis </div><div> <span></span><span></span></div><div>Thrombocytopenia</div><div><span></span><span> </span><span><span></span><span></span></span></div><div> <span></span><span></span></div><div> Balloon rupture, may le<span></span>ad to helium embolus</div><div> <span></span><span></span></div><div>Risk and complica<span></span>tions of insertion:</div><div><span></span><span> </span><span><span></span></span></div><div>cover<span></span>age</div><div><span></span><span> </span><span>If balloon is too low = decr<span></span>eased visceral or<span></span>gan perfusion (decreased </span></div><div>urine output) </div><div><span></span><span> </span><span>Aortic dissection during insertion </span></div><div>Basic Principles</div><div> <span></span><span></span></div><div><span></span><span></span><span></span></div><div>just prior t<span></span>o syst<span></span>ole</div><div> <span></span><span></span></div><div><span></span><span></span></div><div>aortic valve closure</div><div> <span></span><span></span></div><div>This combination f<span></span>avorable alters the myocar<span></span>dial oxygen supply: demand </div><div>ra<span></span>tio (Increased myoc<span></span>ardial perfusion with less work)</div><div> <span></span><span></span></div><div><span></span><span></span><span></span></div><div> <span></span><span></span></div><div>May be indicat<span></span>ed in RV failure:</div><div><span></span><span> </span><span>Improvement in RV perfusion from diast<span></span>olic augmentation </span></div><div><span></span><span> </span><span>Improvement in L<span></span>V function from unloading </span></div><div>Deation phase of IABP le<span></span>ads to</div><div> <span></span><span></span></div><div><span></span></div><div> <span></span><span></span></div><div>Increased s<span></span>troke volume</div><div> <span></span><span></span></div><div>Enhanced forward car<span></span>diac output</div><div>Ination phase of IABP le<span></span>ads to</div><div> <span></span><span></span></div><div><span></span><span></span></div><div> <span></span><span></span></div><div>Increased dias<span></span>tolic pressure</div><div> <span></span><span></span></div><div>Po<span></span>tential for increased c<span></span>oronar<span></span>y collat<span></span>eral circulation</div><div> <span></span><span></span></div><div>Increased sys<span></span>temic perfusion</div><div>Timing</div><div>Ination</div><div> <span></span><span></span></div><div>Rapid rise in aortic pressure which incre<span></span>ases O2 supply to coronaries</div><div> <span></span><span></span></div><div><span></span><span></span></div><div> <span></span><span></span></div><div>Augmented pressur<span></span>e should be &gt; systolic pressure</div><div>Deation</div><div> <span></span><span></span></div><div>Reduce aortic and end dias<span></span>tolic pressure, improving C<span></span>O</div><div> <span></span><span></span></div><div>Ass<span></span>is<span></span>t<span></span>ed<span></span> e<span></span>nd<span></span> d<span></span>ia<span></span>st<span></span>ol<span></span>ic<span></span> b<span></span>lo<span></span>od <span></span>pr<span></span>es<span></span>su<span></span>re<span></span> &lt;<span></span>/=<span></span> un<span></span>as<span></span>si<span></span>st<span></span>e<span></span>d <span></span>en<span></span>d <span></span>di<span></span>as<span></span>to<span></span>li<span></span>c <span></span>bl<span></span>oo<span></span>d <span></span>pr<span></span>es<span></span>su<span></span>re</div><div> <span></span><span></span></div><div>Assisted peak sys<span></span>tolic pressure should be &lt;unassist<span></span>ed peak systolic pressur<span></span>e   </div><div>IABP tracing a<span></span>t 1:2 ratio<span></span>. <span>IABP end diast<span></span>olic pressure is lower than the p<span></span>atient’<span></span>s </span></div><div>aortic end diast<span></span>olic pressure. The b<span></span>alloon assisted peak sys<span></span>tolic pressure is lower </div><div>than the syst<span></span>olic pressure tha<span></span>t is gener<span></span>ated without a pr<span></span>eceding assis<span></span>ted beat. </div></div><div></div></div>
<div><div><img><div>106<span> </span><span>Procedures/Devic<span></span>es<span> </span>Procedur<span></span>es/De<span></span>vices<span> </span><span>107</span></span></div><div>placed. The ventricular wire is the short<span></span>er one. Occasionally, 2 ventricular </div><div>wires are plac<span></span>ed (will be equal length) » either one can be used as the ground </div><div>lead.</div><div> <span></span><span></span></div><div>The ventricular wire is inserted int<span></span>o the nega<span></span>tive pole of the temporar<span></span>y </div><div>ext<span></span>ernal pac<span></span>emaker<span></span>. The skin wire is inserted in the positive pole.</div><div>Unipolar vs. Bipolar </div><div> <span></span><span></span></div><div>Unipolar wires consis<span></span>t of a single negative wire a<span></span>ttached t<span></span>o the epicardium </div><div>and an additional wire in the subcut<span></span>aneous tissue (positive). </div><div> <span></span><span></span></div><div>Bipolar syst<span></span>em  consis<span></span>t of a single wire with two conductors (positive and </div><div>nega<span></span>tive) which are both att<span></span>ached directly to the epicar<span></span>dium</div><div><span></span><span> </span><span><span></span><span></span></span></div><div>threshold to ob<span></span>tain capture and is less sensitive t<span></span>o electrical interferenc<span></span>e </div><div>when sensing comp<span></span>ared to unipolar sys<span></span>tem. </div><div>General Conc<span></span>ept<span></span>s </div><div>Stimula<span></span>tion or Capture Threshold</div><div> <span></span><span></span></div><div>Refers t<span></span>o the amount of energy delivered by the pulse genera<span></span>tor in order to </div><div>initiate depolariz<span></span>ation  (measured in milliamps).</div><div><span></span><span> </span><span>The usual st<span></span>arting point is 10mA and slowly increased until captur<span></span>e is </span></div><div>achieved.  </div><div> <span></span><span></span></div><div><span></span><span></span></div><div>electrodes.</div><div>How to de<span></span>termine appropria<span></span>te output threshold set<span></span>ting:</div><div> <span></span><span></span></div><div>Set RA<span></span>TE at leas<span></span>t 10 ppm <span>above</span> patient’<span></span>s intrinsic rat<span></span>e.</div><div> <span></span><span></span></div><div>Decrease OUTPUT<span></span>: Slowly turn OUTPUT dial counterclockwise until EC<span></span>G </div><div>shows loss of captur<span></span>e.</div><div> <span></span><span></span></div><div>Increase OUTPUT<span></span>: Slowly turn OUTPUT dial clockwise until ECG shows </div><div>consis<span></span>tent capture.</div><div>This value is the stimulation threshold.</div><div> <span></span><span></span></div><div>Set OUTPUT to a v<span></span>alue 1.5-2 <span>times</span><span> </span><span>greater</span><span> than the stimula<span></span>tio<span></span>n <span>Threshold v<span></span>alue.</span></span></div><div>This provides at least a 2:1 safe<span></span>ty margin.</div><div>T<span></span>roubleshooting F<span></span>ailure t<span></span>o Capture</div><div> <span></span><span></span></div><div>Possible Causes</div><div><span></span><span> </span><span></span></div><div> <span></span><span></span></div><div>Increase mA till c<span></span>apture</div><div><span></span><span> </span><span>Low ba<span></span>tter<span></span>y</span></div><div>IABP remov<span></span>al </div><div>See IABP removal Hosp<span></span>tial Protocol on Intr<span></span>aNet. </div><div>Referenc<span></span>es</div><div>Bojar<span></span>, Robert M. (2011) Manual of Perioper<span></span>ative Care in Adult Cardiac Surgery. (5th edition). </div><div> </div><div>DEVICES: <span>L<span></span>UMBAR DRAINS</span></div><div>1. <span> </span><span>Placed pre-oper<span></span>atively by cardiac anesthesia or Neur<span></span>o IR if patient has </span></div><div>complex anat<span></span>omy</div><div>2. <span> </span><span>Use “Lumbar Dr<span></span>ain” order set</span></div><div>3. <span> </span><span>Pos<span></span>t-opera<span></span>tive lumbar drain management:</span></div><div>i. <span> </span><span>Zer<span></span>o the transducer at right a<span></span>trium phlebostatic level</span></div><div>ii. <span> </span><span>Set the T<span></span>ransduc<span></span>er to 10mmHg</span></div><div>• <span> </span><span>L<span></span>eave the stopc<span></span>ock closed to the transducer ex<span></span>cept when measuring </span></div><div>hourly pressure</div><div>• <span> </span><span>Keep the dr<span></span>ain open to the patient t<span></span>o allow to continuous drainage</span></div><div>• <span> </span><span>When the ICP is above 10mmHg, the dr<span></span>ain will act as a pressure  </span></div><div><span></span><span></span></div><div>iii. <span> </span><span>Goal is to dr<span></span>ain ~10mL/hr when ICP &gt;10. Not to exc<span></span>eed drainage  </span></div><div>of 20mL/hr</div><div>iv<span></span>. <span> </span><span><span></span><span></span><span></span></span></div><div>v.<span></span><span> <span> </span><span>Maintain strict bed r<span></span>est with HOB at 30 degrees or less while ac<span></span>tively </span></span></div><div>draining</div><div>vi. <span> </span><span><span></span><span></span></span></div><div>patient and r<span></span>eopen when destination reached.</div><div>4. <span> </span><span>For more inf<span></span>ormation on ICP and prevention of spinal cor<span></span>d ischemia see </span></div><div>“Spinal Cord Ischemia <span>page 50 </span>under III. P<span></span>ost-oper<span></span>ative Managament</div><div> </div><div>DEVICES: <span>TEMPORAR<span></span>Y P<span></span>ACEMAKERS</span></div><div>Nomenclature</div><div>1st let<span></span>ter —<span> chamber<span></span>/chambers p<span></span>aced: A= atria, V= ventricle,  </span></div><div>D- dual (atria and ventricle)</div><div>2nd lett<span></span>er —<span> chamber/<span></span>chambers sensed: A= atria, V= ventricle,  </span></div><div>D- dual (atria and ventricle)</div><div>3rd let<span></span>ter —<span> how the pacemak<span></span>er responds to an event<span></span>:  I= inhibit, T<span></span>- trigger</span></div><div>T<span></span>emporary  P<span></span>acing T<span></span>echniques </div><div>T<span></span>ransvenous</div><div>Placed through intr<span></span>oducer into the right ventricle. Routinely placed in T<span></span>AVR pt<span></span>s </div><div>with Corevalves d/t increased risk f<span></span>or the de<span></span>velopment of heart block as the v<span></span>alve </div><div>continues to exp<span></span>and post deployment.</div><div>T<span></span>ranscut<span></span>aneous</div><div><span></span><span></span><span></span></div><div>positions. Disadvant<span></span>ages include requiring higher pacing thresholds and p<span></span>atient </div><div>discomfort.</div><div>Epicardial L<span></span>eads</div><div> <span></span><span></span></div><div>The wires in the right subcos<span></span>tal region ar<span></span>e atrial and in the <span></span> subcost<span></span>al </div><div>region are ventricular<span></span>.</div><div><span></span><span> </span><span>Min<span></span>ima<span></span>lly<span></span> in<span></span>vas<span></span>ive <span></span>val<span></span>ve <span></span>sur<span></span>ge<span></span>ri<span></span>es <span></span>the<span></span> A <span></span>and<span></span> V <span></span>wir<span></span>es <span></span>wil<span></span>l b<span></span>e i<span></span>n t<span></span>he <span></span>sam<span></span>e <span></span>pos<span></span>iti<span></span>on. </span></div><div> <span></span><span></span></div><div>T<span></span>ypically, a single ventricular wire (pacing le<span></span>ad) and a skin wire (ground) are </div></div><div></div></div>
<div><div><img><div>108<span> </span><span>Procedures/Devic<span></span>es<span> </span>Procedur<span></span>es/De<span></span>vices<span> </span><span>109</span></span></div><div>Modes of P<span></span>acing:     </div><div>Mode<span> </span>Advant<span></span>ages<span> </span>Disadvant<span></span>ages</div><div>AAI</div><div> <span></span><span></span></div><div>Single lead</div><div> <span></span><span></span></div><div>AV synchrony maint<span></span>ained</div><div> <span></span><span></span></div><div>Able to assess S<span></span>T changes</div><div> <span></span><span></span></div><div>Unable to use in AF</div><div> <span></span><span></span></div><div>Ventricular br<span></span>adycardia may </div><div>occur in presc<span></span>ense of high </div><div>grade A<span></span>V block</div><div> <span></span><span></span></div><div>Inst<span></span>ability of single atrial lead</div><div> <span></span><span></span></div><div>Higher risk of thin atrial wall</div><div>VVI</div><div> <span></span><span></span></div><div>Requires a single le<span></span>ad</div><div> <span></span><span></span></div><div>Useful in prescense of AF and </div><div>high grade A<span></span>V block</div><div> <span></span><span></span></div><div>AV synchrony los<span></span>t </div><div> <span></span><span></span></div><div>Unable to assess S<span></span>T changes</div><div> <span></span><span></span></div><div>Loss of atrial kick</div><div> <span></span><span></span></div><div>Risk of pac<span></span>emaker syndrome</div><div>DDO</div><div> <span></span><span></span></div><div>AV synchrony maint<span></span>ained</div><div> <span></span><span></span></div><div>Use in AF and high grade A<span></span>V </div><div>block</div><div> <span></span><span></span></div><div>Heart r<span></span>ate responsive</div><div> <span></span><span></span></div><div>Possible decr<span></span>eased </div><div>thrombotic events</div><div> <span></span><span></span></div><div>P<span></span>acemaker mediat<span></span>e endless<span></span>-</div><div>loop tachyc<span></span>ardia possible</div><div> <span></span><span></span></div><div>P<span></span>acemaker syndrome if </div><div>incorrec<span></span>tly set up</div><div> <span></span><span></span></div><div>May not be able to assess S<span></span>T’<span></span>s</div><div>DDI</div><div> <span></span><span></span></div><div>Uses two pacing leads (right </div><div>atrium and right ventricle) to </div><div>maintain minimum r<span></span>ate in </div><div>each cavity</div><div> <span></span><span></span></div><div>Used in the presence of sinus </div><div>bradyc<span></span>ardia with possible AV </div><div>conduction disor<span></span>ders or with </div><div>frequent atrial arrhythmia</div><div> <span></span><span></span></div><div>Must feel c<span></span>omfortable set<span></span>ting </div><div>ra<span></span>te and AV node delay</div><div> <span></span><span></span></div><div><span></span></div><div> </div><div>For remov<span></span>al of temporary pacing wires, <span>page 99</span><span> </span>(section V<span></span>, proc<span></span>edures, C<span></span>T and </div><div>PW removal) </div><div>Referenc<span></span>es: http://www.medtronic.c<span></span>om/us-en/index.html</div><div> </div><div>DEVICES: <span>ON Q PUMPS</span></div><div> <span></span><span></span></div><div>Non-narco<span></span>tic pain relief syst<span></span>em designed to deliver local anes<span></span>thetic to or near </div><div>the surgical sit<span></span>e via cathe<span></span>ters. </div><div> <span></span><span></span></div><div>The epidural or intr<span></span>athecal route uses small quantities of medic<span></span>ation to </div><div><span></span><span></span></div><div>provide t<span></span>arge<span></span>ted pain r<span></span>elief via multiple holes along the infusion segment of </div><div><span></span><span></span><span></span><span></span><span></span></div><div>distribution. </div><div> <span></span><span></span></div><div>Placed intr<span></span>a-operatively by the surgeon or APP f<span></span>or primarily patients rec<span></span>eiving </div><div>anterior thor<span></span>acot<span></span>omy incisions</div><div>Placing the Cathet<span></span>er</div><div>1. <span> </span><span>Gently hold T<span></span>-handle and remove protective guar<span></span>d. </span></div><div>2. <span> </span><span>Introducer Needle: Insert (bevel up) through the skin appr<span></span>oximately 3-5 cm </span></div><div>from surgical sit<span></span>e </div><div>3. <span> </span><span>Advanc<span></span>e introducer to desired loc<span></span>ation for c<span></span>athet<span></span>er placement. Introducers </span></div><div>with Luer lock may be connec<span></span>ted to a syringe to aspir<span></span>ate or inject a bolus of </div><div></div><div>4. <span> </span><span>While holding T<span></span>-handle 1, withdraw trocar 2 from she<span></span>ath </span></div><div> <span></span><span></span></div><div>Change ba<span></span>tter<span></span>y</div><div><span></span><span> </span><span><span></span><span></span></span></div><div> <span></span><span></span></div><div>At<span></span>tempt t<span></span>o re<span></span>verse the polarity of the le<span></span>ads by swapping the position </div><div>of the met<span></span>al leads into the p<span></span>acemaker cor<span></span>d</div><div><span></span><span> </span><span>Electrolyt<span></span>e abnormalities</span></div><div>Sensitivity</div><div> <span></span><span></span></div><div>Sensing refers t<span></span>o the ability of the gener<span></span>ator t<span></span>o detect (“see”) and r<span></span>ecognize </div><div>the intrinsic impulses of the myocardial tissue and t<span></span>o appropriat<span></span>ely respond </div><div>to what it de<span></span>tect<span></span>s.</div><div> <span></span><span></span></div><div>Sensitivity setting is me<span></span>asured in <span>millivolts</span>. </div><div><span></span><span> </span><span>T<span></span>ypical atrial 0.4 mV</span></div><div><span></span><span> </span><span>T<span></span>ypical ventricular 2.0 mV</span></div><div> <span></span><span></span></div><div>Progr<span></span>amming a higher sensitivity (higher number) makes the pac<span></span>emaker  </div><div>less sensitive<span> to intrinsic car<span></span>diac activity.</span></div><div> <span></span><span></span></div><div>Progr<span></span>amming a lower sensitivity (lower number) causes the pac<span></span>emaker to be </div><div>more sensitive <span>to intrinsic c<span></span>ardiac activity.</span></div><div>How to de<span></span>termine appropriat<span></span>e sensitivity setting:</div><div>1. <span> </span><span>Set r<span></span>ate a<span></span>t leas<span></span>t 10 ppm <span>below</span> patient’<span></span>s intrinsic rat<span></span>e.</span></div><div>2. <span> </span><span>Adjust output: Set OUTPUT to 0.1 mA (A OUTPUT f<span></span>or atrial threshold; V </span></div><div>OUTPUT for ventricular threshold).</div><div>3. <span> </span><span>Highlight SENSITIVITY (atrial or ventricular) </span></div><div>4. <span> </span><span>Decrease SENSITIVIT<span></span>Y: Slowly turn MENU P<span></span>ARAMETER dial </span></div><div><span></span><span></span></div><div>5. <span> </span><span>Increase SENSITIVIT<span></span>Y: Slowly turn MENU P<span></span>ARAMETER dial clockwise </span></div><div><span></span><span></span><span></span><span> </span></div><div>This value is the sensing threshold.</div><div>6. <span> </span><span>Set SENSITIVITY t<span></span>o half (or less) the threshold v<span></span>alue. </span></div><div>This provides at least a 2:1 safe<span></span>ty margin.</div><div>7. <span> </span><span>Rest<span></span>ore RA<span></span>TE and OUTPUT to previous values.</span></div><div>T<span></span>rouble Shooting Sensitivity</div><div>F<span></span>ailure to sense<span> is when the gener<span></span>ator does no<span></span>t recognize the heart’<span></span>s intrinsic </span></div><div>impulses.</div><div> <span></span><span></span></div><div>P<span></span>acemaker not sensitive enough t<span></span>o patient’<span></span>s intrinsic rhythm.</div><div><span></span><span> </span><span>Increase the sensitivity by lowering the m<span></span>V</span></div><div> <span></span><span></span></div><div><span></span></div><div> <span></span><span></span></div><div><span></span><span></span></div><div><span></span><span> </span><span>At<span></span>tempt t<span></span>o re<span></span>verse the polarity of the le<span></span>ads by swapping the position of </span></div><div>the met<span></span>al leads into the p<span></span>acemaker cor<span></span>d</div><div> <span></span><span></span></div><div>Low ba<span></span>tter<span></span>y<span></span>.</div><div> <span></span><span></span></div><div>Malfunction of pac<span></span>emaker or cable.</div><div>Over<span></span>-sensing: <span>P<span></span>acer sees too much (QRS, T w<span></span>ave, P wave and baseline)</span></div><div> <span></span><span></span></div><div>Decrease sensitivity by incr<span></span>easing the mV</div><div>Checking underlying rhythm</div><div> <span></span><span></span></div><div>Safest me<span></span>thod is to slowly turn down the rat<span></span>e as opposed to  disconnec<span></span>ting </div><div>the leads from g<span></span>enerator or p<span></span>ausing the pac<span></span>emaker as this gives time for the </div><div>patient’<span></span>s native conduction sys<span></span>tem to emerge</div></div><div></div></div>
<div><div><img><div>110<span> </span><span>Procedures/Devic<span></span>es<span> </span>Procedur<span></span>es/De<span></span>vices<span> </span><span>111</span></span></div><div><span></span><span> </span><span>Sponge (item # 195925)</span></div><div> <span></span><span></span></div><div><span></span><span></span><span></span></div><div>regular wound v<span></span>ac upon discharge</div><div>Discharging a pa<span></span>tient home with Wound VAC</div><div> <span></span><span></span></div><div>Ensure Case management is involved e<span></span>arly to ensure insuranc<span></span>e authoriza<span></span>tion </div><div>and supply deliver<span></span>y</div><div> <span></span><span></span></div><div>If short term Vac ther<span></span>apy is needed, consider Vac Via</div><div><span></span><span> </span><span>Can use placed on a p<span></span>atient for up t<span></span>o 4 days and then switched to we<span></span>t-to-</span></div><div>dr<span></span>y dressings if V<span></span>ac is no longer needed</div><div>V<span></span>ac Tips:</div><div> <span></span><span></span></div><div>St<span></span>anford Policy s<span></span>tates wound V<span></span>ac changes are t<span></span>o be done Monday, </div><div>Wednesday and Friday<span></span>.</div><div><span></span><span> </span><span>Use clinical judgment if wound vac w<span></span>as placed at an odd time. Product </span></div><div><span></span><span></span></div><div> <span></span><span></span></div><div>Cut the sponge t<span></span>o the size of the wound or larg<span></span>er never smaller than the </div><div>wound so that the dr<span></span>ape does not s<span></span>tick directly t<span></span>o the wound.</div><div> <span></span><span></span></div><div>Cut a big hole for tr<span></span>ack pad at leas<span></span>t the size of a quarter<span></span>.</div><div> <span></span><span></span></div><div><span></span><span></span></div><div> <span></span><span></span></div><div>When placing Wound VAC in clinic:</div><div> <span></span><span></span></div><div>If the VAC is a new placement<span></span>- the patient will be Admitt<span></span>ed to Obser<span></span>va<span></span>tion for </div><div>wound vac plac<span></span>ement and supply authorization via case manag<span></span>er (DO NOT </div><div>ADMIT VIA ED)</div><div> <span></span><span></span></div><div>If the VAC is es<span></span>tablished- patient should bring own supplies fr<span></span>om home for in </div><div>clinic changes</div><div>Prevena:</div><div> <span></span><span></span></div><div>For use with closed incisions</div><div> <span></span><span></span></div><div>Should be placed at the time of wound closur<span></span>e in the OR, can also be placed </div><div>later</div><div> <span></span><span></span></div><div>The pump bat<span></span>ter<span></span>y last<span></span>s for 7 days.</div><div> <span></span><span></span></div><div>Dressing should be remov<span></span>ed and wound checked prior t<span></span>o discharge </div><div>(even if before b<span></span>att<span></span>ery dies)</div><div> <span></span><span></span></div><div>When the bat<span></span>ter<span></span>y dies, the pump can be thrown aw<span></span>ay and the patient </div><div>removes the dressing and resumes normal wound c<span></span>are</div><div> <span></span><span></span></div><div>Risk for poor wound healing crit<span></span>eria (i.e. use of provena should be </div><div>considered)</div><div><span></span><span> </span><span>Obesity (BMI&gt;36)</span></div><div><span></span><span> </span><span>Diabetes (insulin-dependent, dialysis, or previous diabetic-induc<span></span>ed  </span></div><div>organ damag<span></span>e) </div><div><span></span><span> </span><span>COPD (f<span></span>orced expirat<span></span>or<span></span>y volume in 1 second &lt; 80%)  </span></div><div><span></span><span> </span><span>Bilater<span></span>al IMA take-down  </span></div><div><span></span><span> </span><span>COPD his<span></span>tor<span></span>y</span></div><div><span></span><span> </span><span>Corticos<span></span>teroid use</span></div><div><span></span><span> </span><span>Abnormally high preoper<span></span>ative cre<span></span>atinine ( &gt; 90th percentile) </span></div><div><span></span><span> </span><span>More intr<span></span>aopera<span></span>tive blood transfusions (3 or mor<span></span>e)  </span></div><div><span></span><span> </span><span>Longer length of oper<span></span>ation (&gt;4 hrs.) </span></div><div><span></span><span> </span><span>Previous known poor wound healing episode </span></div><div>5. <span> </span><span>Advanc<span></span>e catheter through she<span></span>ath until entire infusion segment is within </span></div><div>desired loca<span></span>tion </div><div>6. <span> </span><span>Coil cathe<span></span>ter and secure with adhesive s<span></span>trips </span></div><div>7. <span> </span><span>Apply occlusive dressing over insertion sit<span></span>e and coiled cathet<span></span>er. Keep </span></div><div><span></span><span></span></div><div>8. <span> </span><span>Connect ca<span></span>theter t<span></span>o pump tubing.</span></div><div>Pos<span></span>t-oper<span></span>ative period: </div><div> <span></span><span></span></div><div>Pumps are not manag<span></span>ed by pain ser<span></span>vice (do not p<span></span>age P<span></span>ain ser<span></span>vice with </div><div>questions), they are managed by the primary team</div><div> <span></span><span></span></div><div>The pump works by administ<span></span>ering a continuous infusion of bupiv<span></span>acaine </div><div>locally at the sit<span></span>e of the incision. </div><div> <span></span><span></span></div><div>The pump is used in adjunct with analgesics (T<span></span>ylenol, oxycodone, fent<span></span>anyl, </div><div>dilaudid). <span>While OnQ pump in place avoid c<span></span>oncurrent use with other </span></div><div>similar agents, i.<span></span>e. Lidocaine infusions </div><div> <span></span><span></span></div><div>Medication or<span></span>der<span></span>: Bupivac<span></span>aine 0.25% in 270mL @ 2mL/hr</div><div>Remov<span></span>al: </div><div> <span></span><span></span></div><div><span></span><span></span></div><div>medicine moving through the tubing. Y<span></span>ou may notice the outside b<span></span>ag on the </div><div>ball ge<span></span>tting looser with wrinkles over time</div><div> <span></span><span></span></div><div>The pump should be removed 24 hours before dischar<span></span>ge to allow for time to </div><div>ensure adequat<span></span>e pain c<span></span>ontrol using or<span></span>al pain medica<span></span>tions</div><div> <span></span><span></span></div><div>T<span></span>o Remove: remove the dressing, r<span></span>emove small suture anchoring pump to </div><div>skin, and pull the clear ca<span></span>theter<span></span>. The tube should come out easily. If it is har<span></span>d </div><div>to remove or s<span></span>tarts to s<span></span>tretch, st<span></span>op and call your doctor right away<span></span>.</div><div><span></span><span> </span><span>The end of the tube should have a colored tip so you know tha<span></span>t it is all </span></div><div>out. If the end of the tube does not have a colored tip<span></span>, call your doct<span></span>or </div><div>right away.</div><div><span></span><span> </span><span>The entire unit should be disposed of in the red biohaz<span></span>ard bins.</span></div><div>Referenc<span></span>es: Clark<span></span>, K. (2010). On-q cathe<span></span>ters and introducers. ON-Q P<span></span>ain Relief System. Retrieved </div><div>from http://www<span></span>.halyardhealth.c<span></span>om/media/155090/14-60-603-0-04.pdf<span></span>. </div><div>DEVICES:<span> WOUND VA<span></span>C</span></div><div>Ver<span></span>a o:</div><div> <span></span><span></span></div><div>Preferred over r<span></span>egular wound Vac for inpa<span></span>tients (may heal area f<span></span>aster)</div><div><span></span><span> </span><span>Normal saline is the solution of choice. Any topic<span></span>ally approved solution </span></div><div>can be placed int<span></span>o the Vac</div><div><span></span><span> </span><span><span></span></span></div><div> <span></span><span></span></div><div>T<span></span>ypical Settings: </div><div><span></span><span> </span><span>-125mmHg</span></div><div><span></span><span> </span><span>0-20 min wash ever<span></span>y 2-4 hours</span></div><div> <span></span><span></span></div><div>Grey foam c<span></span>an be used for packing tunneling areas or undermining tha<span></span>t is </div><div>hard to visualiz<span></span>e</div><div> <span></span><span></span></div><div>General principles: </div><div><span></span><span> </span><span>When changing the Vac, use the pad t<span></span>o estimate how much saline is </span></div><div></div><div><span></span><span> </span><span></span></div><div><span></span><span> </span><span><span></span><span></span></span></div><div></div><div> <span></span><span></span></div><div>Supplies needed (Central supply # 35047</div><div><span></span><span> </span><span>1000mL cont<span></span>ainer (item # 86309)</span></div><div><span></span><span> </span><span>Cassett<span></span>e ( item #195927)</span></div></div><div></div></div>
<div><div><img><div>112<span> </span><span>Referenc<span></span>e Material<span> </span>Referenc<span></span>e Material<span> </span><span>113</span></span></div><div>SURGEON PREFERENCES</div><div>Surgeon </div><div>Preferenc<span></span>es</div><div>Clinic</div><div>Woo</div><div>o <span> </span>Review all images and review surgical plan prior to clinic</div><div><span> </span></div><div>o <span> </span>2 week<span><span></span></span></div><div>Boyd</div><div>o <span> </span>Echo within 3-6 months for Valves</div><div>o <span> </span>Cath within 6 months (if CAD), within 1 year if most rec<span></span>ent was clean/Valve</div><div>o <span> </span>CT<span></span>a within 3-6 months for Ascending aorta</div><div>o <span> </span>Calculate ST<span></span>S score on all pa<span></span>tients pre clinic (use most recent or normal </div><div>creatinine)</div><div>o <span> </span>Calculate Syntax sc<span></span>ore for all CAD pa<span></span>tients </div><div>o <span> </span>All notes complet<span></span>ed same day of clinic</div><div><span> </span><span></span><span></span><span></span></div><div>thromboembolic event </div><div>For inpatient CABG consults— see Boyd Consult H&amp;P document</div><div>Lee</div><div>o <span> </span><span>Calculate ST<span></span>S score on all pa<span></span>tients pre clinic (use most recent or normal cr<span></span>eatinine)</span></div><div>o <span> </span>Echo within 3 months</div><div>o <span> </span>Cath within 6 months (if CAD), within 1 year if most rec<span></span>ent was clean/Valve</div><div>o <span> </span>CT<span></span>a within 3-6 months for Ascending aorta</div><div>o <span> </span>CT<span></span>a (vs CT L atrial mapping) needed for all pa<span></span>tient with prior history of ablation/</div><div>MAZE</div><div>o <span> </span>If pacemaker<span></span>, obtain make, model, implant<span></span>ation date</div><div>o <span> </span>Calculate ST<span></span>S score on all pa<span></span>tients pre-clinic (use most recent or normal </div><div>creatinine)</div><div>o <span> </span>PFTs if any smoking his<span></span>tor<span></span>y in last 10 ye<span></span>ars</div><div>o <span> </span>Carotid US if caro<span></span>tid bruit on exam, h/o prior T<span></span>AI or stroke, age &gt; 65, smoking </div><div>history, or family his<span></span>tor<span></span>y of str<span></span>oke </div><div>o <span> </span>Obtain bilater<span></span>al LE duplex US if history of vein stripping </div><div>o <span> </span>All notes complet<span></span>ed same day of clinic</div><div>o <span> </span>DO NOT HOLD ASA PRE-OPERA<span></span>TIVEL<span></span>Y</div><div>o <span> </span>Post ops: </div><div> <span> </span>o <span> </span>MAZE:</div><div> <span> </span><span>o <span> </span><span>1-month POV </span>– need ECG during clinic visit (may need TTE if p<span></span>atient’s  </span></div><div> <span></span><span>most rec<span></span>ent TTE prior to discharge had L<span></span>VEF&lt; 40%). </span></div><div> <span> </span><span>o <span> </span><span>3-month POV </span>-needs 72 hour Ziopat<span></span>ch as close to clinic visit as possible  </span></div><div> <span></span><span>and a TTE prior to visit. </span></div><div> <span> </span><span>o <span> </span><span>6-month POV </span>– needs 72 hour Ziopat<span></span>ch as close to clinic visit as possible. </span></div><div> <span> </span><span>o <span> </span><span>12- month POV </span>–needs 72 hou<span></span>r Ziopa<span></span>tch as close to c<span></span>linic visit a<span></span>s possible. </span></div><div> <span> </span><span>o <span> </span><span>Annually</span> with 72 hour Ziopatch. V<span></span>ALVE f<span></span>ollow up at 1 mos with Echo,  </span></div><div> <span></span><span>then annually</span></div><div> <span> </span>o <span> </span>CABG fu at 1 mos (Echo only needed if EF decre<span></span>ased at discharge or  </div><div> <span> </span>&lt; 40% pre op)</div><div> <span> </span>o <span> </span>Aortic surgery patients: FU @ 1, 3,6, and 12 months with CT sc<span></span>an</div><div>Fischbein<span> </span><span>o <span> </span></span>Pre op<span><span></span></span></div><div>o <span> </span>No Tissue consent for Aorta p<span></span>atients </div><div>Miller</div><div>Hiesinger<span> </span><span>o <span> </span>Review all images and review surgical plan prior to clinic</span></div><div>SURGEON PREFERENCES, C<span></span>ONTINUED</div><div>Surgeon </div><div>Preferenc<span></span>es</div><div>ICU<span> </span>T<span></span>ele</div><div>Woo<span> </span><span>o <span> </span>DC labs early if able</span></div><div>o <span> </span>Post op C<span></span>T c/a/p prior to discharge on </div><div>Acute T<span></span>ype A dissections only</div><div>o <span> </span>Ok to DC home same day PW removed</div><div>Boyd</div><div>o <span> </span>CABG patients 75mg Plavix daily x1 </div><div>year</div><div>o <span> </span>All patients 200mg PO amio daily </div><div></div><div>o <span> </span>SubQ heparin for  DVT prophylaxis </div><div>if no contraindic<span></span>ation</div><div>o <span> </span>Endocrine consult to manage DM if </div><div>elevated A1c</div><div>o <span> </span>Daily senna started while in IC<span></span>U</div><div>o <span> </span><span>FAS<span></span>T TRACK (all uncomplic<span></span>ated </span></div><div>CABG with normal EF)</div><div>POD #1:<span></span>0600;  Cordis/</div><div>Swan out by 1000 (even if still on </div><div><span></span></div><div><span></span></div><div><span></span><span></span><span></span></div><div>and Plavix</div><div>POD #2: Daily labs on case by case </div><div>basis. T<span></span>ransfer out of ICU</div><div>Overall consider<span></span>ations:<span><span></span></span></div><div>insulin gtt and s<span></span>tart diet as e<span></span>arly </div><div>as possible, ok to eat POD #0. Ok </div><div>to remove foley POD 1 even if on </div><div>diuretics. If waiting in IC<span></span>U for tele </div><div>bed, ensure P<span></span>T<span></span>/OT and patient </div><div>mobiliza<span></span>tion.</div><div>o <span> </span>DC labs early if able </div><div>o <span> </span>CABG patients 75mg Plavix daily x1 year</div><div>o <span> </span>All patients 200mg PO amio daily for </div><div></div><div>o <span> </span>No Iron on discharge</div><div>o <span> </span>Remove PW prior to CT</div><div>o <span> </span>SubQ heparin for DVT prophylaxis if no </div><div>contraindic<span></span>ation </div><div>o <span> </span>No imaging needed prior to discharge</div><div>o <span> </span>Acute Type A dissec<span></span>tion post op C<span></span>T @ </div><div>1month follow up appointment </div><div>o <span> </span>Endocrine consult to manage DM if </div><div>elevated A1c</div><div>o <span> </span>For routine CABG, goal is discharg<span></span>e by </div><div>at leas<span></span>t POD #5</div><div>o <span> </span>For myocardial bridge, DC P<span></span>aravertebr<span></span>al </div><div>cathet<span></span>er POD #3 with goal of discharge </div><div>by POD #4 </div><div>Lee<span> </span><span>o <span> </span>No IV amio gtt, boluses only</span></div><div>o <span> </span>No nicotine pat<span></span>ch for CABG</div><div>o <span> </span>Avoid Reglan (due to black box </div><div>warning and association with </div><div>tardive dyskinesia)</div><div>o <span> </span>No IV amio gtt, boluses only</div><div>o <span> </span>No nicotine pat<span></span>ch for CABG</div><div>o <span> </span>Coreg no bett<span></span>er than metoprolol f<span></span>or </div><div>Heart failur<span></span>e patients </div><div>o <span> </span>For LAA excision:  Inspra 25mg BID </div><div>o <span> </span>Avoid Reglan (due to black box warning </div><div>and association with tar<span></span>dive dyskinesia)</div><div>Fischbein<span> </span><span>o <span> </span>Do not wean ino<span></span>tropes without </span></div><div>discussing directly </div><div>o <span> </span>For patients on high dose pressors </div><div>or with high oxygen requirement<span></span>s, </div><div>discuss PO diet directly bef<span></span>ore </div><div>initiating </div><div>o <span> </span>For post op CABG patient<span></span>s, </div><div>continue NTG while on Epi if blood </div><div>pressure allows</div><div>o <span> </span>Start Epogen/Ir<span></span>on/Vit C in ICU for </div><div>post op anemia </div><div>o <span> </span>IV Lasix and KCL while inpatient</div><div>o <span> </span>Leave centr<span></span>al line in place</div><div>o <span> </span>PW remain in place until day prior to </div><div>discharge</div><div>o <span> </span>Prior to discharge:</div><div> <span> </span>o <span> </span>Echo all valves </div><div> <span> </span>o <span> </span><span>CT<span></span> al<span></span>l a<span></span>orta<span></span>s (<span></span>wit<span></span>h 3<span></span>D </span> <span> </span> </div><div> <span> </span>me<span></span>asurements </div><div>o <span> </span>Must approve all discharges</div><div>o <span> </span>No IV hydralazine in dissections</div><div>o <span> </span>PW out prior to CT if possible </div><div>Miller<span> </span><span>o <span> </span> Avoid hydralazine in Aortic </span></div><div>Dissections/<span></span>Aneur<span></span>ysm</div><div>o <span> </span>Prior to discharge:</div><div> <span> </span>o <span> </span>Echo all valves (once PW removed </div><div>and within 2kg pre op wt)</div><div> <span> </span>o <span> </span>CT all aortas (with 3D </div><div> <span> </span><span>measurements</span></div><div>o <span> </span>Must approve all discharges</div><div>o <span> </span>No IV hydralazine dissections</div><div>o <span> </span>For LAA excision: Inspra 25mg BID</div><div>Hiesinger<span> </span><span>o <span> </span>Post op imaging per p<span></span>atient- no<span></span>t </span></div><div>st<span></span>andard</div></div><div></div></div>
<div><div><img><div>114<span> </span><span>Referenc<span></span>e Material<span> </span>Referenc<span></span>e Material<span> </span><span>115</span></span></div><div>CARDIAC SURGER<span></span>Y PROCEDURE CLEARANCE</div><div>Dental Guidelines</div><div>Pre-op:</div><div> <span></span><span></span></div><div>Dental cle<span></span>arance will be obt<span></span>ained by schedules via clearanc<span></span>e letter</div><div> <span></span><span></span></div><div>T<span></span>o be cleared f<span></span>or cardiac sur<span></span>gery: </div><div><span></span><span> </span><span>Dental ex<span></span>am in last 6 months</span></div><div><span></span><span> </span><span>No evidence of current dent<span></span>al infection or anticipat<span></span>ed dental c<span></span>are needed </span></div><div>within the next 6 months (E<span></span>xcluding rest<span></span>oration or dentures) </div><div>Pos<span></span>t-Op:</div><div> <span></span><span></span></div><div>P<span></span>atients with valve r<span></span>epair or CABG SHOULD NOT have dent<span></span>al cleaning or work </div><div>done for at le<span></span>ast 3 months post<span></span>-op.</div><div> <span></span><span></span></div><div><span></span><span></span><span></span></div><div>material implant<span></span>ed SHOULD NOT have dental cleaning or work done f<span></span>or </div><div>at leas<span></span>t 6 months post-op and should t<span></span>ake prophylactic or<span></span>al antibiotics, </div><div>prescribed from their dentis<span></span>t<span></span>, before any pr<span></span>ocedures. (AHA guidelines)</div><div> <span></span><span></span></div><div>P<span></span>atients are enc<span></span>ouraged to follow up with their c<span></span>ardiologist recommenda<span></span>tion </div><div>before proc<span></span>eeding with dental work and reg<span></span>arding the need for prophylactic </div><div>antibiotics. </div><div>Colonosc<span></span>opy/Sigmoidosc<span></span>opy Guidelines</div><div>Pos<span></span>t-Op:</div><div> <span></span><span></span></div><div>P<span></span>atients SHOULD NOT have an elec<span></span>tive colonoscopy for at le<span></span>ast 6 months  </div><div>post op</div><div> <span></span><span></span></div><div>Prophylactic antibio<span></span>tics (usually IV given within 30 minutes of proc<span></span>edure) </div><div>should be considered f<span></span>or high risk patients only (presenc<span></span>e of prosthetic heart </div><div><span></span><span></span></div><div>hist<span></span>or<span></span>y of endocar<span></span>ditis)</div><div> <span></span><span></span></div><div>Prophylaxis IS NO<span></span>T recommended f<span></span>or patients with the following: isola<span></span>ted </div><div>ASD, ASD s/p repair with p<span></span>atch, post op CABG, v<span></span>alvar dysfunction, mitral v<span></span>alve </div><div>prolapse, presenc<span></span>e of cardiac pacemak<span></span>er </div><div>Referenc<span></span>es:</div><div>Oliver<span></span>, G., Lowry, A., Vernava, A., Hicks, T<span></span>., Burnstein, M., e<span></span>t. Al. (2000).  Antibiotics prophylaxis clinical </div><div>practic<span></span>e guideline: supporting documentation. The American Society of Colon and Rec<span></span>tal Surg<span></span>eons. </div><div>PRE-OP:<span> CHECK LIS<span></span>T</span></div><div> <span></span><span></span></div><div>H&amp;P </div><div><span></span><span> </span><span>Completed within 24 hours of pr<span></span>ocedure</span></div><div>OR</div><div><span></span><span> </span><span>Completed within 30 days, with H&amp;P int<span></span>er<span></span>v<span></span>al within 24 hours of </span></div><div>procedur<span></span>e</div><div> <span></span><span></span></div><div>Consent (good for 1 ye<span></span>ar) </div><div><span></span><span> </span><span>Procedur<span></span>e</span></div><div><span></span><span> </span><span>ICU</span></div><div><span></span><span> </span><span>Tissue/Study</span></div><div><span></span><span> </span><span>Refusal of blood product<span></span>s if patient does NOT c<span></span>onsent to blood </span></div><div>transfusion</div><div> <span></span><span></span></div><div>Pre op labs/imaging (must be complet<span></span>ed at S<span></span>tanf<span></span>ord within 30 days of </div><div>surgery)</div><div><span></span><span> </span><span><span></span></span></div><div><span></span><span> </span><span>CMP</span></div><div><span></span><span> </span><span>PT<span></span>, PTT</span></div><div><span></span><span> </span><span>HgbA1c</span></div><div><span></span><span> </span><span>Phosphorus</span></div><div><span></span><span> </span><span>Urinalysis, screen for culture</span></div><div><span></span><span> </span><span>T<span></span>ype and Screen (for outpatient, clot should be ex<span></span>tended for 30 days.  </span></div><div>For inpa<span></span>tient<span></span>, must be within 72 hours of pr<span></span>ocedure)</div><div><span></span><span> </span><span>RBCS <span>(R<span></span>efer to <span>page 116 </span>to know how many units t<span></span>o order ahead)</span></span></div><div><span></span><span> </span><span>EKG</span></div><div><span></span><span> </span><span>CXR (2V preferred) </span></div><div> <span></span><span></span></div><div>Day of surgery orders (found in order set #4658): </div><div><span></span><span> </span><span>Surgical prep<span></span>aration- clipping, antimicrobial showers x 2, Mepilex t<span></span>o </span></div><div>sacrum</div><div><span></span><span> </span><span>Surgical prophylaxis with antibio<span></span>tics (ON CALL)</span></div><div><span></span><span> </span><span>Peridex mouthw<span></span>ash (ON CALL)</span></div><div><span></span><span> </span><span>DVT prophylaxis </span></div><div> <span></span><span></span></div><div>Misc pre op</div><div><span></span><span> </span><span>Antico<span></span>agulation bridging with Loveno<span></span>x</span></div><div><span></span><span> </span><span>Radial artery har<span></span>vest work up</span></div><div><span></span><span> </span><span>Dental cle<span></span>arance </span></div><div><span></span><span> </span><span>Any other s<span></span>tudies needed (Cath, Echo<span></span>, CT<span></span>, et<span></span>c)</span></div><div>T<span></span>AAA Repair specic:</div><div>P<span></span>atients are pre-admit<span></span>ted day before surgery for lumbar dr<span></span>ain, epidural, and </div><div>bowel prep.</div><div><span></span><span> </span><span>P<span></span>age pain service to place epidur<span></span>al preferably day befor<span></span>e it is needed </span></div><div>(2-P<span></span>AIN)</div><div><span></span><span> </span><span><span></span></span></div><div><span></span><span> </span><span>Clear diet</span></div><div><span></span><span> </span><span>Bowel prep</span></div><div> </div></div><div></div></div>
<div><div><img><div>116<span> </span><span>Referenc<span></span>e Material<span> </span>Referenc<span></span>e Material<span> </span><span>117</span></span></div><div>PRE-OP:<span>CARDIAC SURGER<span></span>Y P<span></span>A<span></span>TIENT BL<span></span>OOD </span></div><div>MANAGEMENT PROGRAM</div><div>(Ref: Info redistribut<span></span>ed from CV Clinical Outc<span></span>omes; 2011: Stanford Maximum Surgical </div><div>Blood Order Schedule (MSBOS) Criteria)</div><div>Proc<span></span>edure:<span> </span>Type &amp; Scr<span></span>een and </div><div>Type &amp; Cr<span></span>oss (Y<span></span>/N)</div><div>Cardiac Surg<span></span>er<span></span>y </div><div>rec<span></span>ommended # RBC </div><div>units order pre-op</div><div>Combo Sx: “Low Risk<span></span>” Group:  <span> </span></div><div>(Includes: Iso CABG, Open &amp; Mini Valv<span></span>e Repair/Replac<span></span>e)</div><div>1st Sx: IsoCABG</div><div>Y<span> </span>2</div><div>1st Sx: Open A<span></span>VR</div><div>Y<span> </span>2</div><div>T<span></span>AVR (TFem, T<span></span>Apical, </div><div>T<span></span>Aortic)</div><div>Y<span> </span>4</div><div>1st Sx: V<span></span>alve + CABG OR </div><div>Multiple Valves</div><div>Y<span> </span>4</div><div>1st Sx: AoRoo<span></span>t (no arch) </div><div>Combo TD, CVG, AscAo</div><div>Y<span> </span>4</div><div>1st Sx: TD +/- Asc Arch</div><div>Y<span> </span>4</div><div>1st Sx: CV<span></span>G +/- Acs Arch </div><div>Y<span> </span>4</div><div> 1st Sx: Asc + Arch (no valv<span></span>e) </div><div>+/- descending </div><div>Y<span> </span>4</div><div>Redo Sx:  CABG + V<span></span>alve </div><div>Y<span> </span>4</div><div>Combo Sx: “High Risk” Gr<span></span>oup: <span> </span></div><div>(Includes: Redo TD, Redo CV<span></span>G, any 1st or Redo Arch Replac<span></span>e, Open Desc Ao, </div><div>and 1st or Redo T<span></span>AAA) <span> </span></div><div>Redo Sx:  TD +/- Arch</div><div>Y<span> </span>6</div><div>Redo Sx:  CVG +/- Ar<span></span>ch</div><div>Y<span> </span>6</div><div>Redo Sx:  CVG, No Ar<span></span>ch</div><div>Y<span> </span>6</div><div>Redo Sx:  Asc +/- Arch</div><div>Y<span> </span>6</div><div>Open Desc. Ao (All)</div><div>Y<span> </span>6</div><div>Open T<span></span>AAA (All)</div><div>Y<span> </span>6</div><div> </div><div>*Key:</div><div><span></span></div><div><span></span><span></span></div><div>TD= T<span></span>yrone David (aka: David V<span></span>, Valve Sparing)</div><div>Patients with Heparin allergy or HIT<span></span>; document in H&amp;P note and inform perfusion on </div><div>surgical day<span></span>. (Patient with Heparin allergy will rec<span></span>eive Argatroban, Bivalirudin  </div><div>or heparin.)</div><div>Pre-Op Blood Saving:</div><div> <span></span><span></span></div><div>Autolog<span></span>ous Donation:<span> P<span></span>atients can donate their own blood, c<span></span>an donate 6 </span></div><div>weeks before surg<span></span>er<span></span>y, incre<span></span>ase folic acid, vitamin C, iron supply (ask your </div><div>at<span></span>tending surg<span></span>eon if this is preferred)</div><div> <span></span><span></span></div><div>Jehovah<span></span>’s Witness:<span> P<span></span>atients Witnesses’ refusal of transfusions of whole </span></div><div>blood or its four primary components—red cells, whit<span></span>e cells, platelet<span></span>s and </div><div>plasma; can use use of fr<span></span>actions such as albumin, immunoglobulins and </div><div>hemophiliac prepar<span></span>ations &amp; cell saver<span></span>. (Watch<span></span>T<span></span>ower Society)</div><div><span></span><span> </span><span>Bloodless medicine program in proc<span></span>ess 1/2017. Refer to updated pr<span></span>otocol </span></div><div>for current pre-operative guidelines f<span></span>or patients who refuse blood </div><div>transfusion.</div><div> <span></span><span></span></div><div>Herbal Produc<span></span>ts: <span>P<span></span>otential interac<span></span>tions to avoid (JAC<span></span>C, 2010), (Alfalfa, </span></div><div>Angelica, Bilberry, Garlic, Ginger<span></span>, Ginko, Ginseng, Echinac<span></span>ea, Licorice, S<span></span>t<span></span>. </div><div>Johns Wart).  Can cause int<span></span>eractions with cardiac medic<span></span>ations &amp; increase </div><div>bleeding during surgery.</div><div>Intra-Op Blood Saving:</div><div> <span></span><span></span></div><div>Blood clot<span></span>ting agent/blood derived fraction ag<span></span>ents (Coseal/Tisseal/Floseal)</div><div> <span></span><span></span></div><div>Perfusion: </div><div><span></span><span> </span><span>Cell Saver<span></span>:  rec<span></span>overing blood lost during surgery and re-infusing it into </span></div><div>the patient. It is a major form of auto<span></span>transfusion. Cell processors ar<span></span>e </div><div>red cell w<span></span>ashing de<span></span>vices tha<span></span>t collect antico<span></span>agulated shed or recover<span></span>ed </div><div>blood, wash and separ<span></span>ate the red blood c<span></span>ells (RBC) by centrifug<span></span>ation, and </div><div>reinfuse the RBC. </div><div><span></span><span> </span><span><span></span><span></span></span></div><div><span></span><span> </span><span><span></span><span></span><span></span><span></span></span></div><div>PRE-OP: <span>CLAS<span></span>SIFICA<span></span>TIONS</span></div><div>C<span></span>CS Func<span></span>tional Classication of Angina</div><div>Class<span> </span>Descrip<span></span>tion</div><div>Class I<span> </span>Angina only during str<span></span>enuous or prolonged physical activity</div><div>Class II<span> </span>Slight limit<span></span>ation, with angina only during vigorous physical activity</div><div>Class III<span> </span>Symp<span></span>toms with ever<span></span>yday living activities  (i.e. moder<span></span>ate limit<span></span>ation)</div><div>Class IV<span> </span>Inability to perform any activity without angina or angina at r<span></span>est </div><div>(i.e. severe limit<span></span>ation)</div><div>St<span></span>aging Kidney Disease: <span>always document CKD Stage 3 or gr<span></span>eater</span></div><div>St<span></span>age<span> </span>Description</div><div>St<span></span>age I<span> </span>With normal of high GFR (GFR &gt; 90mL/min)</div><div>St<span></span>age II<span> </span>Mild CKD (GFR = 60-89mL/min)</div><div>St<span></span>age IIIa<span> </span>Moderat<span></span>e CKD (GFR = 45-59mL/min)</div><div>St<span></span>age IIIb<span> </span>Modera<span></span>te CKD (GFR = 30-44mL/min)</div><div>St<span></span>age IV<span> </span>Severe CKD (GFR = 15-29mL/min)</div><div>St<span></span>age V<span> </span>End St<span></span>age CKD (GFR &lt; 15mL/min)</div><div>GFR calculat<span></span>or Website:</div><div>http://www<span></span>.davita.c<span></span>om/gfr-calculat<span></span>or/</div><div>http://www<span></span>.kidne<span></span>y<span></span>.org<span></span>/prof<span></span>essionals/KDOQI/gfr_calcula<span></span>tor</div></div><div></div></div>
<div><div><img><div>118<span> </span><span>Referenc<span></span>e Material<span> </span>Referenc<span></span>e Material<span> </span><span>119</span></span></div><div>AC<span></span>C/<span></span>AHA Classica<span></span>tion of CHF</div><div>The AC<span></span>C/AHA cr<span></span>eated four classications fr<span></span>om risk for develop the </div><div>disease to sev<span></span>ere disability.</div><div>St<span></span>age<span> </span>Description</div><div>A (High risk for </div><div>developing CHF)</div><div>Hypertension, DM, F<span></span>amily history, CAD</div><div>B (Asymptomatic HF)<span> </span>Previous myocardial inf<span></span>arction (heart at<span></span>tack), valvular </div><div></div><div>C (Symptoma<span></span>tic HF)<span> </span>Struc<span></span>tural he<span></span>art disease, fatigue, low t<span></span>oleranc<span></span>e le<span></span>vel for </div><div>physical activity</div><div>D (Refr<span></span>actory  </div><div>end-st<span></span>age HF)</div><div>Severe limita<span></span>tions. Experienc<span></span>e symptoms even  </div><div>while at res<span></span>t<span></span>.</div><div>NYHA Func<span></span>tional Classica<span></span>tion</div><div>The NYHA classied heart failure int<span></span>o classes base on functional </div><div>limitations and sev<span></span>erity.</div><div>Class<span> </span>FUNC<span></span>TIONAL CAP<span></span>ACITY<span></span>: Pa<span></span>tient Symptoms</div><div>I (Normal)<span> </span>Few observable sx, no limitations in or<span></span>dinar<span></span>y physical activity</div><div>II (Mild)<span> </span>Mild obser<span></span>v<span></span>able sx and slight limitation during ordinary activity. </div><div>Comfort<span></span>able at res<span></span>t<span></span>.</div><div>III (Modera<span></span>te)<span> </span>Marked limitation in physic<span></span>al activity due to symp<span></span>toms even </div><div>during less than ordinary activity. Comfort<span></span>able only at rest.</div><div>IV (Severe)<span> </span>End-s<span></span>tage he<span></span>art failure. Severe limita<span></span>tions. Experienc<span></span>e </div><div>symptoms even while at r<span></span>est.</div><div>Class<span> </span>OB<span></span>JECTIVE ASSESSMENT</div><div>A<span> </span>No evidence of car<span></span>diovascular disease. No sympt<span></span>oms and no </div><div>limita<span></span>tion in ordinar<span></span>y physical activity<span></span>.</div><div>B<span> </span>Objective evidence of minimal car<span></span>diovascular disease. Mild </div><div>symptoms and slight limit<span></span>ation during ordinar<span></span>y activity<span></span>. </div><div>Comfort<span></span>able at res<span></span>t<span></span>.</div><div>C<span> </span>Objective evidence of modera<span></span>tely se<span></span>vere c<span></span>ardiac disease. </div><div>Marked limit<span></span>ation in activity due to symptoms, even during less </div><div>than ordinary activity. Comfort<span></span>able only at rest.</div><div>D<span> </span>Objec<span></span>tive e<span></span>vidence of severe c<span></span>ardiovascular disease. Severe </div><div>limita<span></span>tions. Experiences sympt<span></span>oms e<span></span>ven while at res<span></span>t<span></span>.</div><div>For Example:</div><div>A patient with minimal or no symp<span></span>toms but a large pressure gr<span></span>adient across the </div><div><span></span><span></span></div><div>Function capacity I, Objective Assessment D</div><div>A patient with severe angina syndr<span></span>ome but angiographically normal coronary </div><div><span>Functional Capacity IV<span></span>, Objective Assessment A</span></div><div>Other Helpful Scor<span></span>es/Resourc<span></span>es</div><div>NYHA Class </div><div>Website:</div><div>http://www<span></span>.heart.org/HEARTORG/Conditions/</div><div>HeartF<span></span>ailure/AboutHe<span></span>artFailur<span></span>e/Classes-of-Heart-</div><div>Failur<span></span>e_UCM_306328_Article.<span></span>jsp</div><div>Griepp Score<span> </span><span>The 1997 A<span></span>T<span></span>S paper by Randy Griepp and colleagues </span></div><div>describes an easy-<span></span>to-use risk of rupture calculat<span></span>or </div><div>developed by Abe DeAnda (Chief Resident 2000-</div><div>2001). If aortic dissection, RBG just adds 0.5 cm t<span></span>o </div><div>the descending thor<span></span>acic aortic and abdominal aorta </div><div>diameter numbers. Sever<span></span>al other calculator t<span></span>ools are </div><div>also on the spreadsheet.</div><div>    Referenc<span></span>e the </div><div>Cardiac Surgery </div><div>APP Shared Box </div><div>folder for this </div><div>information.</div><div>Syntax<span></span>core<span> </span><span>SYNT<span></span>AX score II crea<span></span>tes accura<span></span>te mortality predictions </span></div><div>to guide the choice be<span></span>tween PCI and CABG for </div><div>patient<span></span>s with multivessel cor<span></span>onary disease.</div><div>    http://</div><div>syntaxsc<span></span>ore.</div><div>com/</div><div> </div><div>PRE-OP: <span>NORMAL ECHO VAL<span></span>UES</span></div><div>Normal Echo V<span></span>alues</div><div>L<span></span>V Diastolic Dimension<span> </span>3.7-5.5cm</div><div>L<span></span>V Systolic Dimension<span> </span>2.0-4.0 cm</div><div>Interventricular septum (Diastole)<span> </span>0.6-1.1 cm</div><div>L<span></span>V Pos<span></span>terior Wall (Diastole)<span> </span>1.8-2.2 cm</div><div>L<span></span>VOT Diame<span></span>ter (Systole)<span> </span>1.8-2.2cm</div><div>Aortic Root (Dias<span></span>tole)<span> </span>2.0-3.7cm</div><div><span></span><span> </span><span>2.0-4.0cm</span></div><div><span></span><span> </span><span>&lt;20cm2</span></div><div><span></span><span> </span><span>16-28ml</span></div><div>RV Diastolic Dimension<span> </span>0.9-2.5cm</div><div> </div><div>Pulmonic Valve E<span></span>cho Values</div><div>Mild<span> </span>5-25mmHg</div><div>Moderat<span></span>e<span> </span>25-49mmHg</div><div>Severe<span> </span>&gt;50mmHg</div><div> </div><div>Aortic Valve E<span></span>cho Values</div><div>AS Grading<span> </span>Mean Gradient </div><div>(mmHg)</div><div>Peak V<span></span>elocity (m/s)<span> </span>AVA (cm2)</div><div>Normal<span> </span><span>&lt; 10<span> </span>&lt; 2.6<span> </span>&gt;2.5</span></div><div>Mild<span> </span><span>10-25<span> </span>2.6-2.9<span> </span>1.5-2.5</span></div><div>Modera<span></span>te<span> </span><span>20-45<span> </span>3.0-4.0<span> </span>1.0-1.5</span></div><div>Severe<span> </span><span>&gt;45<span> </span>&gt;4.0<span> </span>0.7-1.0</span></div><div>Critical<span> </span><span>&gt;50<span> </span>&gt;4.0<span> </span>&lt;0.7</span></div><div>AR Grading<span> </span>Central Jet width<span></span>*<span> </span>Regurgitant Volume </div><div>(per beat) </div><div>EROA (eectiv<span></span>e </div><div>Regurgit<span></span>ant oriace </div><div>area)</div><div>Mild<span> </span><span>&lt; 25% of L<span></span>VOT width<span> </span><span>&lt; 30mL<span> </span>&lt;0.1cm2</span></span></div><div>Modera<span></span>te<span> </span><span>25-65% of L<span></span>VOT width<span> </span>30-59mL<span> </span>0.1-0.3cm2</span></div><div>Severe<span> </span><span>&gt;65% of L<span></span>VOT width<span> </span>&gt;60mL<span> </span>&gt;0.3cm</span></div><div>T<span></span>ricuspid Valve Echo V<span></span>alues</div><div>Signicant tricuspid stenosis</div><div>Mean pressure gr<span></span>adient<span> </span>&gt;/= 5mmHg</div><div>Valve are<span></span>a<span> </span>&lt;/= 1cm2</div><div>T<span></span>ricuspid </div><div>Regurgitation</div><div>MILD<span> </span>MODERA<span></span>TE<span> </span>SEVERE</div><div>Jet area<span> </span>&lt; 5<span> </span>5-10<span> </span>&gt;10</div><div>RV<span></span>/RA/IVC Size<span> </span>Normal<span> </span>Normal or dilated<span> </span>Usually dialates</div></div><div></div></div>
<div><div><img><div>120<span> </span><span>Referenc<span></span>e Material<span> </span>Referenc<span></span>e Material<span> </span><span>121</span></span></div><div>Mitral V<span></span>alve Echo Values</div><div>MS grading<span> </span>Valve Are<span></span>a<span> </span>Mean gradient<span> </span>Pulmonar<span></span>y artery </div><div>pressure (mmHg)</div><div>Mild<span> </span><span>&gt;1.5 cm2<span> </span>&lt;5mmHg<span> </span>&lt;30mmHg</span></div><div>Modera<span></span>te<span> </span><span>1.0-1.5 cm2<span> </span>5-10mmHg<span> </span>30-50mmHg</span></div><div>Severe<span> </span><span>&lt;1.0cm2<span> </span>&gt;10mmHg<span> </span>&gt;50mmHg</span></div><div>MR grading <span> </span>Jet area<span> </span>Regurgit<span></span>ant Volume<span> </span><span>EROA (eective </span></div><div>Regurgit<span></span>ant oriace </div><div>area)</div><div>Mild<span> </span><span>&lt;20% of L<span></span>A are<span></span>a<span> </span><span>&lt;30mL<span> </span>&lt;0.2cm2</span></span></div><div>Modera<span></span>te<span> </span><span>20-40% of LA area<span> </span>30-59mL<span> </span>0.2-0.39 </span></div><div>Severe<span> </span><span>&gt;40% of LA area<span> </span>&gt;60mL<span> </span>&gt;0.40cm2</span></div><div>PRE-OP: <span>OB<span></span>T<span></span>AINING C<span></span>ONSENT<span></span>/PROCEDURE LIST</span></div><div>Procedur<span></span>e<span> </span>Correct verbiag<span></span>e for Consent</div><div>CABG<span> </span><span></span></div><div><span></span></div><div>• Does not need to include IMA (LIMA/RIMA) </div><div>Consent must specify conduit harvesting when applicable:</div><div>EVH= Endoscopic vein harvest</div><div>RAH= Endoscopic radial art<span></span>er<span></span>y harvest </div><div><span>CABG<span> </span></span><span></span><span></span></div><div>MIDCAB<span> </span><span><span></span><span></span></span></div><div>possible sterno<span></span>tomy, cardiopulmonary bypass on standby</div><div>T<span></span>AVR<span> </span>T<span></span>ransca<span></span>theter aortic valve replacement</div><div>• Include approach (tr<span></span>ansfemoral, transapical, or tr<span></span>ansaortic) </div><div>• Also include cardiopulmonary bypass on st<span></span>andby </div><div>• Also include transesophage<span></span>al echocardiogram</div><div>Mini MVR<span> </span>Right anterior thorac<span></span>otomy; mitral valve/r<span></span>eplacement repair on </div><div>cardiopulmonary bypass, possible sterno<span></span>tomy. </div><div>Mini AVR<span> </span>Minimally invasive aortic valve rep<span></span>air/replac<span></span>ement; on cardiopulmonary bypass</div><div>Hybrid MAZE<span> </span>Bilateral video assis<span></span>ted thoracoscopy; pulmonary vein isolation; with additional </div><div><span></span><span></span></div><div>MAZE; cardiopulmonary bypass on st<span></span>andby</div><div>Cox Maze<span> </span>Maze procedur<span></span>e on cardiopulmonar<span></span>y bypass</div><div>Myectomy<span></span>/</div><div>Myotomy</div><div>Myectomy<span></span>/myotomy with possible mitr<span></span>al valve repair<span></span>/replacement on </div><div>cardiopulmonary bypass</div><div>Myocardial bridge </div><div></div><div><span></span><span></span></div><div>Redo st<span></span>ern<span> </span>Redo sternotomy</div><div>LAA Excision<span> </span><span><span></span></span></div><div>Laser lead </div><div>extr<span></span>action</div><div>Laser lead extr<span></span>action with possible pacemaker g<span></span>enerator change; possible </div><div>sterno<span></span>tomy; Cardiopulmonar<span></span>y bypass on s<span></span>tandby</div><div></div><div>TEVAR<span> (CT sur<span></span>gery </span></div><div>attending is </div><div>surgical c<span></span>onsent </div><div>attending, Dr<span></span>. Dake </div><div>does not sign this </div><div>procedure <span></span>consent)</div><div><span></span></div><div>• Do not include Lumbar dr<span></span>ain (Anesthesia will consent separ<span></span>ately)</div><div>VSARR or Tirone </div><div>David (T<span></span>-David)</div><div>Valve sparing aortic r<span></span>oot replac<span></span>ement, possible aortic valve replacement on </div><div>cardiopulmonary bypass </div><div>Aortic <span></span>replacement<span> </span>Include f<span></span>ollowing when applicable: ascending aortic replac<span></span>ement<span></span>, desc<span></span>ending </div><div>aortic replacement, tot<span></span>al arch replacement, hemi-arch replacement, elephant </div><div><span></span></div><div>Aortic root <span> </span>Aortic r<span></span>oot replacement including aortic valve replac<span></span>ement on cardiopulmonar<span></span>y </div><div>bypass</div><div>TAA<span></span>A<span> </span><span>Thoraco<span></span>abdominal aortic aneur<span></span>ysm repair on car<span></span>diopulmonar<span></span>y bypass </span></div><div>SACP &amp; PHCA<span> </span>Under Deep Circulat<span></span>or<span></span>y Arrest</div><div>Heart transplant<span> </span>Heart transplant on c<span></span>ardiopulmonary bypass</div><div>VAD<span> </span>Ventricular assist device insertion on cardiopulmonary bypass </div><div>• Include type of device: Heartmat<span></span>e II or Heartware</div><div> </div><div> <span></span><span></span></div><div>Procedur<span></span>e consent<span> must be signed by someone who can perform the </span></div><div>procedur<span></span>e listed</div><div><span></span><span> </span><span>Ex: V<span></span>alve replacement = Att<span></span>ending<span></span>/resident</span></div><div><span></span><span> </span><span>Ex: Car<span></span>dioversion/Pigtail plac<span></span>ement = APP</span></div><div> <span></span><span></span></div><div>ICU consent <span>c<span></span>an be signed by APP</span></div><div> <span></span><span></span></div><div>Consent is good for 1 ye<span></span>ar</div><div> <span></span><span></span></div><div>Make sure all abbr<span></span>eviations are comple<span></span>tely spelled out<span></span>. <span>NO ABBREVIA<span></span>TIONS<span>.  </span></span></div><div> <span></span><span></span></div><div>Check blood consent box on bo<span></span>th forms and give patient tr<span></span>ansfusion packe<span></span>t (If </div><div>the patient r<span></span>efuses blood transfusion, use the additional blood refusal form)</div><div> <span></span><span></span></div><div>Median sterno<span></span>tomy DOES NOT need to be included on expec<span></span>ted “s<span></span>tandard </div><div>sterno<span></span>tomy” consents.  ONL<span></span>Y on “Possible St<span></span>ernotomy” cases (i.e. anterior </div><div>thorac<span></span>otomy, then “possible s<span></span>ternotomy” should also be included).</div><div> <span></span><span></span></div><div>NO SCRA<span></span>TCHES, CROS<span></span>S THROUGHS, OR SCRIBBLES ALLOWED ON C<span></span>ONSENT</div><div>PRE-OP:<span> PFT AND CARO<span></span>TID US INTEPRET<span></span>A<span></span>TION</span></div><div>Carotid Duple<span></span>x Ultrasound Criteria for Gr<span></span>ading Internal Carotid Art<span></span>ery Stenosis</div><div>Degree of </div><div>Stenosis (%)</div><div>ICA PSV (cm/2)<span> </span>ICU<span></span>/CCA P<span></span>SV </div><div>Ratio</div><div>ICA EDV (cm/2)<span> </span>Plaque Estimate </div><div>(%)</div><div>Normal<span> </span>&lt; 125<span> </span>&lt;2.0<span> </span>&lt;40<span> </span>None</div><div>&lt;50<span> </span>&lt;125<span> </span>&lt;2.0<span> </span>&lt;40<span> </span>&lt;50</div><div>50-69<span> </span>125-230<span> </span>2.0-4.0<span> </span>40-100<span> </span>&gt;50</div><div>&gt;70 to less than </div><div>near occlusion</div><div>&gt;230<span> </span>&gt;4.0<span> </span>&gt;100<span> </span>&gt;50</div><div>Near occlusion<span> </span>High, low, or not </div><div>detect<span></span>ed</div><div>Variable<span> </span>Variable<span> </span>Visible</div><div>T<span></span>otal oc<span></span>clusion<span> </span>Not detec<span></span>ted<span> </span>No<span></span>t applicable<span> </span>Not det<span></span>ected<span> </span>Visible, no lumen</div><div>*Plaque estimat<span></span>e (diameter reduction) with gray scale and c<span></span>olor Doppler ultrasound. ICA = internal </div><div>carotid art<span></span>er<span></span>y; CCA= common c<span></span>arotid arter<span></span>y; PSV = pe<span></span>ak systolic velocity; EDV = end- diast<span></span>olic velocity</div><div>*Intervention may be required prior t<span></span>o cardiac surgery on cardiopulmonary bypass if degree of </div><div>steno<span></span>sis is &gt; 90% unilater<span></span>al or &gt; 75% bilateral due t<span></span>o increased strok<span></span>e risk </div><div>Normal Value of Pulmonary Func<span></span>tion T<span></span>ests</div><div>** FEV1   <span> </span><span>80% to 120% </span></div><div>FVC<span> </span><span>80- 120%</span></div><div>Absolute FEV1/FVC ra<span></span>tio<span> </span>Within 5% of the predicted r<span></span>atio</div><div>TLC<span> </span>80-120%</div><div>FRC<span> </span>75-120%</div><div>RV<span> </span><span>75-120%</span></div><div>** DLC<span></span>O <span><span></span></span></div><div>Also known as TLC<span></span>O or Dsb </div><div>&gt;60% to  &lt;120%</div><div>**These are key for interpr<span></span>eting</div><div>Spirometry</div><div>Low FEV1/FVC</div><div>Obstruction</div><div>Bronchodilator</div><div>FEV1 unchanged/</div><div>partially </div><div>improved</div><div>(asthma or COPD)</div><div>Obstruction </div><div>Normalizes </div><div>(asthma)</div><div>DLCO</div><div>Low (COPD/</div><div>Emphysema/</div><div>bronchiolitis)</div><div>Normal/High</div><div>(asthma or COPD)</div><div>Normal</div><div>? Asthma</div><div>Bronchoprovocation </div><div>challenge</div><div>FEV1 </div><div>Decreased </div><div>(asthma more </div><div>likely)</div><div>No Change in FEV1 </div><div>(asthma unlikely)</div><div>DLCO</div><div>Low (anemia, </div><div>early ILD, </div><div>pulmonary </div><div>vascular </div><div>disease) </div><div>Normal/</div><div>High</div><div>Normal</div><div>Normal FEV1/</div><div>FVC</div><div>Low VC</div><div>Restriction</div><div>Confirm with </div><div>lung volumes</div><div>DLCO</div><div>Low</div><div>(ILD)</div><div>Normal (chest </div><div>wall/</div><div>neuromuscular)</div><div>Maximum </div><div>inspiratory/</div><div>expiratory </div><div>pressures</div><div>Low</div><div>(neuromuscular)</div></div><div></div></div>
<div><div><img><div>122<span> </span><span>Referenc<span></span>e Material<span> </span>Referenc<span></span>e Material<span> </span><span>123</span></span></div><div>PRE-OP:<span> PERIPROCEDURAL  </span></div><div>ANTIC<span></span>OAGUL<span></span>A<span></span>TION BRIDGING</div><div><div>Brand Name </div></div><div>(Generic Name)<span> </span><span>Half Life/Onset of Action<span> </span>Last dose of medi<span></span>cation Before Surgery:</span></div><div><div>If indicated: When<span></span> To Start Lovenox </div><div>(dosing=1mg/kg)</div></div><div><div>#           <span></span> </div><div>syringes</div></div><div>Notes<span> </span>Cath procedures</div><div>Coumadin </div><div><div>(Warfarin)       <span></span> <span></span> </div><div>Once daily dosing </div></div><div>20-60hours/3-5 days<span> </span>5 days before date of surgery</div><div><div>Start 2 days after d/c coumadin (inj Q12 <span></span>until day </div><div>before surgery.  Day before surgery just ONE </div><div>injection in the morning)</div></div><div>5</div><div><div>Example:  surgery date 4/10; last dose </div><div>Coumadin 4/5; off all one day, 4/6; start </div><div>Lovenox Q12 on 4/7; last Lovenox injec on </div><div>4/9 (morning before sx)</div></div><div><div>Hold 5 days prior for femoral access, </div><div>and if pt mod-high risk for clot <span></span>bridge </div><div>to Lovenox.  Hold 2 days prior for </div></div><div>radial access</div><div>Eliquis </div><div><div>(Apixaban)             <span></span> <span></span> </div></div><div>BID dosing </div><div>9-14hours/3-4 hours</div><div><div>5 days before date of surgery           <span></span> <span></span> <span></span> </div><div>(If CrCl &lt; 50 Hold 6-7 doses)</div></div><div><div>Start 1 day after d/c anticoagulant (inj Q12 unt<span></span>il day </div><div>before surgery.  Day before surgery just ONE </div><div>injection in the morning)</div></div><div>7</div><div><div>Example:  surgery date 4/10; last dose </div><div>Eliquis 4/5(am); start Lovenox Q12 on 4/<span></span>6; </div><div>last Lovenox injec on 4/9 (morning before </div></div><div>surgery)</div><div><div>Hold x 2 days:  the day before and </div><div>the day of Cath</div></div><div>Xarelto </div><div><div>(Rivorxaban)              <span></span> <span></span> </div><div>Once daily dosing</div></div><div>11-13 hours/2-4 hours</div><div><div>3 days before date of surgery           <span></span> <span></span> <span></span> </div><div>(If CrCl &lt; 30 Hold 3 doses)</div></div><div><div>Start 1 day after d/c anticoagulant (inj Q12 unt<span></span>il day </div><div>before surgery.  Day before surgery just ONE </div><div>injection in the morning)</div></div><div>3</div><div><div>Example:  surgery date 4/10; last dose </div><div>Xarelto 4/7(am); start Lovenox Q12 on 4/8; </div><div>last Lovenox injec on 4/9 (morning before </div></div><div>surgery)</div><div><div>Hold x 2 days:  the day before and </div><div>the day of Cath</div></div><div>Pradaxa </div><div><div>(Dabigatran)            <span></span> <span></span> </div></div><div>BID dosing </div><div>12-17hours /1 hour</div><div><div>5 days before date of surgery           <span></span> <span></span> <span></span> </div></div><div><div>Start 1 day after d/c anticoagulant (inj Q12 unt<span></span>il day </div><div>before surgery.  Day before surgery just ONE </div><div>injection in the morning)</div></div><div>7</div><div><div>Example:  surgery date 4/10; last dose </div><div>Pradaxa 4/5(am); start Lovenox Q12 on </div><div>4/6; last Lovenox injec on 4/9 (morning </div></div><div>before surgery)</div><div><div>Hold the night before and morning of </div><div>procedure.  Last dose will be in <span></span>the </div><div>morning the day before Cath</div></div><div>SAVAYSA</div><div><div> (endoxaban)             <span></span> <span></span> </div><div>Once daily dosing </div></div><div>10-14 hours/ 1-2 hours</div><div><div>3 days before date of surgery           <span></span> <span></span> <span></span> <span></span> </div><div>(If CrCl &lt; 30 Hold 3-4 doses)</div></div><div><div>Start 1 day after d/c anticoagulant (inj Q12 unt<span></span>il day </div><div>before surgery.  Day before surgery just ONE </div><div>injection in the morning)</div></div><div>3</div><div><div>Example: surgery date 4/10; last dose </div><div>Savaysa 4/7( AM); Lovenox BID 4/8 1 </div><div>lovenox inj AM only on 4/9. </div></div><div><div>Hold x2 days: the day before and the </div></div><div>day of Cath</div><div>Plavix <span>(Clopidogrel)</span></div><div>5 days before date of surgery</div><div><div>Start 1 day after anticoagulant held (inj Q12 until </div><div>day before surgery.  Day before surgery just ONE </div><div>injection in the morning)</div></div><div>7</div><div><div>Only bridge for pt&amp;apos;s taking Plav<span></span>ix for A.fib.  </div><div>If taking for Stents,<span></span> hold 5 days before </div><div>surgery and do not bridge</div></div><div>PLETAL<span> (cilostazol)</span></div><div><div>11-13 hours, reach steady state blood </div><div>levels within a few days.</div></div><div>5 days before date of surgery<span> </span>Does not need bridging</div><div>Asprin</div><div><div>If having valve surgery d/c 2 days before surgery date.  </div><div>If having CABG stop day before</div></div><div>Does not need bridging</div><div><div>If taking ASA 325mg, have patient </div><div>decrease dose to 81 mg as s<span></span>oon as </div><div>procedure scheduled</div></div><div>EFFIENT <span>(prasugrel)</span></div><div>7 hours /4 hours<span> </span>5-7 days before date of surgery<span> </span>Does not need bridging</div><div><div>Pre operative bridgi<span></span>ng with lovenox is requ<span></span>ired for all mecha<span></span>nical heart valves* &amp;  is onl<span></span>y need for atrial fibrilla<span></span>tion when CHAD score is H<span></span>igh** . For low clot risk,  hold an<span></span>ticoagulant per chart ab<span></span>ove. </div></div><div><div>Medications to <span>CONTINUE          <span></span> </span></div><div>to take morning of surgery</div></div><div>Medications to <span>STOP</span> before s<span></span>urgery</div><div><div>CHADS SCORE</div><div> Lovenox to Coumadi<span></span>n</div></div><div><div>Anti-seizure meds</div></div><div><div>ASA:<span></span> <span></span> <span></span> <span></span> <span></span> <span></span> </div><div>Valve Surgery= Last Dose 2 days before surgery       </div><div>CABG only: Stop day before surgery      CABG &amp; </div><div>Valve=Stop day before surgery    (Please follow </div><div>attending preference if different)</div></div><div><div>1 pt for each risk factor present<span>:                            </span></div><div>CHF, HTN, DM, PAD or MI, Age 65-74, </div><div>Female            <span></span> <span></span> <span></span> <span></span> <span></span> <span></span> <span></span> <span></span> </div><div>2 pts for each risk factor present</div></div><div>:                           </div><div><div>Age &gt; 74 years old, Prior stroke or TIA or </div><div>thromboembolism       <span></span> </div></div><div><div>1. Resume oral </div><div>anticoagulant and </div><div>lovenox evening after </div><div>procedure if no bleeding        <span></span> <span></span> </div><div>2. Resume oral </div><div>anticoagulant  + lovenox </div><div>post procedure day 1-3           <span></span> </div></div><div><div>Anti-Psych meds </div></div><div><div>Blood Thinners:<span> see above</span></div><div>SCORE / RISK**</div></div><div><div>Beta-blockers</div></div><div><div>NSAIDS:<span></span><span> stop 7 days before surgery</span></div><div>0-2 = LOW</div></div><div><div>Depression meds</div></div><div><div>Insulin:<span>  Insulin Am dose is normal the day before </span></div><div>surgery. Insulin PM dose is </div></div><div>½<span> dose the evening before </span></div><div><div>surgery. Nothing on the morning of surgery</div></div><div> 3-4 = MODERATE</div><div><div>Inhalers</div></div><div><div>Metformin<span>; stop 48 hours before surgery</span></div><div>5-6 = HIGH</div></div><div><div>Immunosuppressive meds</div></div><div><div>Stop ALL vitami<span></span>ns;<span>1 week prior to surgery</span></div><div>TIA IN PREVIOUS 3 MONTHS = HIGH</div></div><div><div>Methadone</div></div><div><div>Fish oil<span>; stop 5 days before surgery</span></div><div>SEVRE VALVULAR DISEASE = HIGH</div></div><div><div>Nitrates; (Imdur)</div></div><div><div>Herbs<span>; stop asap (many of these have anti-coag <span></span>effects)</span></div></div><div><div>Parkinson&amp;apos;s meds</div></div><div><div>Maltaq (dronedarone)<span>; DO NOT take day<span></span> <span></span>of surgery, </span></div><div>last dose is day before surgery.</div></div><div><div>Proton Pump Inhibitors (PPI&amp;apos;s)</div></div><div>*If Presence of Mechanical Mitral valve<span></span>: <span> </span>References:</div><div><div>Thyroid meds            <span></span> <span></span> <span></span> </div><div>Birth Control Pills</div></div><div><div>1. Last dose coumadin 7 days prior to s<span></span>urgery<span></span> <span></span> <span></span> </div><div>2. Bridge with lovenox as above    <span></span> <span></span> <span></span> <span></span> </div><div>3. <span>Admit to observation d<span></span>ay prior to surgery for </span></div><div>heparin drip (to be stopp<span></span>ed 6 hours before </div><div>surgery). </div></div><div><div>Pernod, G., Godier, A., Gozalo, C., </div><div>Tremey, B., Sie, P. (2010). French clinical </div><div>practice guidelines on the management of<span></span> </div><div>patients on vitamin K antagonist<span></span>s in at-risk </div><div>situations (overdose, risk of bleeding, <span></span>and </div><div>active bleeding). <span>Thrombosis Research, </span></div><div>126, e 167-e174. </div></div><div><div>Brunett, A.E., Mahan, C.E., Vaquez, </div><div>S.R.,Oertel, L.B., Gardcia, D.A.<span></span>, &amp; </div><div>Ansell, J. (2016) Guidance for the </div><div>practical management of direct <span></span>oral </div><div>anticoagulants (DOACs) in VTE </div><div>Treatment. <span>Journal of Thromb </span></div><div>Thrombolysis, 41 : 206-232. </div></div><div><div>Last updated 12/2016</div></div><div><div>                   Pre-procedure Anticoagulation Bridging Recommendations                                                                                                                                                                </div><div>for Cardiac surgery</div></div><div><div>3. Check INR post </div><div>proceudre day 4 and DC </div><div>lovenox if INR theraputic</div></div><div>POS<span></span>T<span></span>-OP: <span>IMAGING</span></div><div>Modality<span> </span>Inpatient Cont<span></span>act Info<span> </span>Misc</div><div>Echocardiogr<span></span>am  </div><div>(viewed in Xcelera)</div><div>Scheduling: 5-4160, 5-4159, </div><div>3-8988</div><div>Reading room: 3-9503</div><div>o <span> </span>Use T<span></span>AVR or TMVR echo order when </div><div>appropriate</div><div>CT (+/- angio) scan  </div><div>(viewed in Centricity)</div><div>Scheduling: 3-6885</div><div>Body reading room: 4-9617</div><div>CVI reading room: 6-2424</div><div>Chest re<span></span>ading room: 3-1346</div><div>Neuro reading r<span></span>oom: 4-3145</div><div>o <span> </span>Gated: ev<span></span>aluates c<span></span>oronaries (Note </div><div></div><div>comments) </div><div>o <span> </span>Pre and pos<span></span>t op aortic disease </div><div>include in comments: <span>Ple<span></span>ase </span></div><div>perform with 3D measurement<span></span>s </div><div>and images for tr<span></span>eatment </div><div>planning and surveillance<span> (use </span></div><div>smart phrase CT<span></span>ANGIO3DIMAGES)</div><div><span> </span></div><div>mapping) used for pre-op Maze </div><div>o <span> </span>Consider need for C<span></span>T chest vs C<span></span>T </div><div>Chest/<span></span>Abdomen/Pelvis</div><div>CT C<span></span>ORONAR<span></span>Y ANGIO  </div><div>(viewed in Centricity)</div><div>Scheduling: 3-6885</div><div>CVI reading room: 6-2424</div><div>o <span> </span>Limited s<span></span>tudy- concentr<span></span>ated on heart </div><div>and coronary arteries (does not </div><div>include thoracic aort<span></span>a)</div><div>o <span> </span>Will always be comple<span></span>ted gated </div><div><span> </span><span></span></div><div>in comments. If p<span></span>atient is in atrial </div><div><span></span></div><div><span></span></div><div>MRI (viewed in </div><div>Centricity)</div><div>Scheduling: 3-6855</div><div>Body reading room: 6-8591</div><div>Cardiac reading r<span></span>oom: </div><div>6-2424</div><div>Neuro reading r<span></span>oom:4-3145</div><div>Vascular lab: 5-5227</div><div>o <span> </span>For Aortic Disease, include c<span></span>omment<span></span>: </div><div>Please perform car<span></span>diac MRI (gated) </div><div>with cross hatching, r<span></span>efer to Dr. </div><div>Fleishman if unsure of prot<span></span>ocol. </div><div>US Carotid </div><div>(viewed in Centricity)</div><div>Vascular lab: 5-5227</div><div>Spirometry with DLCO </div><div>(results in Epic)</div><div>Inpatient: 3-6371</div><div>Adult pulmonary clinic: </div><div>5-7061</div><div>o <span> </span>PFT<span></span>s can be performed by Inpatient </div><div>beside respira<span></span>tor<span></span>y therapis<span></span>t (during </div><div></div><div>FDG PET CT Clinical </div><div>Cardiac Viability with </div><div>resting myoc<span></span>ardial </div><div>perfusion scan (viewed </div><div>in Centricity)</div><div>Scheduling: 3-6885</div><div>Body reading room: 4-9617</div><div>CVI reading room: 6-2424</div><div>Chest re<span></span>ading room: 3-1346</div><div>o <span> </span>Include in comments: t<span></span>esting </div><div>myocardial viability in CAD pa<span></span>tient as </div><div>pre-op work up for CABG</div><div>Venous Ultrasound </div><div>(viewed in Centricity)</div><div>Scheduling: 3-6855</div><div>Reading room: 8-2401</div><div>Arterial Ex<span></span>am/ABIs in </div><div>Vascular clinic (viewed </div><div>in Centricity)</div><div>Vascular lab: 5-5227</div><div>T<span></span>agged WBC scan  </div><div>(viewed in Centricity)</div><div>Nuclear Med scheduling: </div><div>4-4278</div><div>Nuclear Med re<span></span>ading room: </div><div>8-2414</div><div>Nuclear Med techs: 4-5684</div><div><span> </span></div><div>o <span> </span>Nuclear<span></span>- bone</div><div>Cardiac cath  </div><div>(viewed in LifeImage)</div><div>Cath lab ext<span></span>ension: 3-7676</div><div>Cath lab rec<span></span>overy: 3-9317</div><div>o <span> </span>T<span></span>o schedule inpatient, page </div><div>interventional cardiologist on call</div><div>EKG lab<span> </span>3-7121</div><div>1-4987</div><div>o <span> </span>Places long term c<span></span>ardiac monitors on </div><div>discharge</div><div>X-r<span></span>ay<span> </span>62198</div><div>Scheduling: 37030</div><div>Reading room: 87996</div><div>Endoscopy<span> </span>5-8117</div></div><div></div></div>
<div><div><img><div>124<span> </span><span>Referenc<span></span>e Material<span> </span>Referenc<span></span>e Material<span> </span><span>125</span></span></div><div>POS<span></span>T<span></span>-OP:<span> ABG INTERPRET<span></span>A<span></span>TION</span></div><div>pH<span>  /  <span>pC<span></span>O2<span> /  <span>paO2</span> /  <span>Sat %</span> /  <span>Base Decit</span> /  <span>Bicarb</span></span></span></span></div><div>Normal rang<span></span>e 7.35 – 7.45</div><div>&lt; 7.35 Acidosis</div><div>• <span> </span>Look at pCO2</div><div> <span> </span>o <span> </span>If High </div><div><span> <span> respira<span></span>tor<span></span>y acidosis</span></span></div><div> <span> </span>o <span> </span>If normal </div><div><span> <span> metabolic acidosis</span></span></div><div>• <span> </span>How to Fix it<span></span>: </div><div> <span> </span>o <span> </span>Respiratory acidosis: </div><div> <span>• <span> </span>Intubated: increase RR, tidal volume t<span></span>o  </span></div><div> <span>increase minute ventila<span></span>tion</span></div><div> <span>• <span> </span>Extuba<span></span>ted: decrease seda<span></span>tion, Bipap to  </span></div><div> <span>increase ventilation</span></div><div> <span> </span>o <span> </span>Metabolic acidosis:</div><div> <span>• <span> </span>Bicarbonate supplementation</span></div><div> <span>• <span> </span><span>Fu<span></span>rthe<span></span>r wor<span></span>kup f<span></span>or so<span></span>urce: <span></span>Flui<span></span>d status<span></span>, </span> </span></div><div> <span>BMP<span></span>, lactate, et<span></span>c</span></div><div>&gt; 7.45 Alkalosis</div><div>• <span> </span> Look at pCO2</div><div> <span> </span>o <span> </span>If Low </div><div><span> <span> respira<span></span>tor<span></span>y alkalosis</span></span></div><div> <span> </span>o <span> </span>If Normal </div><div><span> <span>Metabolic alk<span></span>alosis</span></span></div><div>• <span> </span>How to Fix it</div><div> <span> </span>o <span> </span>Respiratory alkalosis:</div><div> <span> </span><span>• <span> </span>If intubated: decrease RR, tidal volume</span></div><div> <span> </span><span>• <span> </span>If extubated: c<span></span>ontrol pain, anxiety<span></span>,  </span></div><div> <span>cause of hyperventilation (hypoxia?)</span></div><div> <span> </span>o <span> </span>Metabolic alkalosis:</div><div> <span> </span><span>• <span> </span>Further workup for source: BMP<span></span>, PRBC  </span></div><div> <span>transfusion, overdiur<span></span>esis, etc </span></div><div>pCO2 Normal r<span></span>ange: 35-45</div><div>pCO2 &lt; 35 Respir<span></span>ator<span></span>y alkalosis</div><div>• <span> </span>See pH box (Alkalosis)</div><div>pCO2 &gt;45 Respir<span></span>ator<span></span>y acidosis</div><div>• <span> </span>See pH box (Acidosis)</div><div>Base Decit normal: +/-2 mEq/L; Bicarb normal 22-30</div><div>This is calculated, no<span></span>t measured on the ABG</div><div>Metabolic Acidosis:<span><span></span></span></div><div>• <span> </span>See pH box (Acidosis) above</div><div>Metabolic Alk<span></span>alosis: <span>high bicarbonate, positive b<span></span>ase excess</span></div><div>• <span> </span>See pH box (Alkalosis) below</div><div>PaO2 Normal r<span></span>ange 60-200mmHg; Sat % Normal r<span></span>ange 92-100%</div><div>Increasing O2 c<span></span>ontent</div><div>• <span> </span>Increasing FiO2</div><div>• <span> </span>Increasing NC LPM</div><div>CXR/Ultrasound to assess f<span></span>or</div><div>• <span> </span>Pneumothorax</div><div><span> </span></div><div>• <span> </span>Hemothorax</div><div>• <span> </span>Pneumonia</div><div>Increase PEEP (on ventilat<span></span>or or CPAP<span></span>/BiPap) for </div><div>alveolar recruitment</div><div>Mobilize secretions:</div><div>• <span> </span>Chest PT</div><div>• <span> </span>Suctioning</div><div>• <span> </span>Mucolytics (ie Mucomyst)</div><div>Improve VQ mat<span></span>ching</div><div>• <span> </span>Inhaled bronchodilators (albuterol)</div><div>• <span> </span>Inhaled vasodilators (Flolan, iNO)</div><div>• <span> </span>IPPV<span></span>, incentive spiromet<span></span>er, acapella for </div><div>alveolar recruitment</div><div>• <span> </span>Consider stopping potential shunting </div><div>agents inhibiting hypoxic v<span></span>asoconstriction: </div><div>Clevidipine, Nicardipine, Nitroprusside, NT<span></span>G, </div><div></div><div>POS<span></span>T<span></span>-OP: <span>ADV<span></span>ANCED HEMODYNAMIC </span></div><div>MONIT<span></span>ORING &amp; PULMARY AR<span></span>TERY CA<span></span>THETERS</div><div>Par<span></span>ameter<span> </span>Normal Value</div><div>Cardiac Output (CO)<span> </span>4-8 L/min</div><div>Cardiac Index (CI)<span> </span>2.2-4 L/min/m2</div><div>CVP (central venous pr<span></span>essure aka Right atrial pressure)<span> </span>3-8 mmHg</div><div>P<span></span>A (pulmonar<span></span>y artery) Pressure<span> </span>Sys<span></span>tolic 15-30 mmHg (PAS)</div><div>Diastolic 5-12 mmHg (P<span></span>AD)</div><div>Mean 9-16 (P<span></span>AM)</div><div>PCWP (pulmonary capillar<span></span>y wedge pressure) <span> </span>4-12 mmHg</div><div>PVR (pulmonary vascular resistanc<span></span>e)<span> </span>37-250 dynes/sec/<span></span>cm5</div><div>RV (right ventricular) Pressure<span> </span>Systolic 15-30 mmHg</div><div>Diastolic 3-8 mmHg</div><div>SVR (systemic v<span></span>ascular resistanc<span></span>e)<span> </span>800-1200 dynes/sec/<span></span>cm5</div><div>Preload:<span><span></span><span></span></span></div><div> <span></span><span></span></div><div>Decreased volume, decr<span></span>eased preload</div><div> <span></span><span></span></div><div>Increased volume, incr<span></span>eased preload which may incre<span></span>ase MAP and CO</div><div>Aerlo<span></span>ad:<span> the resistanc<span></span>e that the heart has to overc<span></span>ome, during ever<span></span>y beat, to </span></div><div><span></span><span></span><span></span></div><div>Cardiac index:<span> the volume of blood pumped by the he<span></span>art<span></span>, per minute, per met<span></span>er </span></div><div>square of body surfac<span></span>e area. Cardiac Output = HR x S<span></span>troke Volume</div><div> <span></span><span></span></div><div>Increased C<span></span>O/CI: high circula<span></span>ting volume, increased strength of c<span></span>ontraction, </div><div>early septic shock, vasodila<span></span>tor<span></span>y st<span></span>ate</div><div> <span></span><span></span></div><div>Decreased C<span></span>O/CI: hypovolemia or decre<span></span>ase in ventricular strength of </div><div>contr<span></span>action</div><div>CVP: <span>used to appro<span></span>ximate Right Ventricular End Dias<span></span>tolic Pressur<span></span>e and assesses </span></div><div><span></span></div><div> <span></span><span></span></div><div>Low CVP: hypovolemia, decre<span></span>ased venous return</div><div> <span></span><span></span></div><div>High CVP: hyper<span></span>volemia, right sided heart f<span></span>ailure, tamponade </div><div>Mean Arterial Pr<span></span>essure (MAP):<span> Arterial pressure in the vessels perfusing org<span></span>ans. </span></div><div><span></span><span></span></div><div>syst<span></span>emic vascular resis<span></span>tance (SVR). MAP = [(2 x dias<span></span>tolic)+systolic] / 3</div><div> <span></span><span></span></div><div>Low MAP: hypovolemia, low car<span></span>diac output, or low SVR</div><div> <span></span><span></span></div><div>High MAP: hyper<span></span>volemia, high car<span></span>diac output<span></span>, or high SVR</div><div>Syst<span></span>emic Vascular Resis<span></span>tanc<span></span>e (SVR): <span>measurement of impedance or r<span></span>esistanc<span></span>e </span></div><div><span></span><span></span></div><div> <span></span><span></span></div><div>Increased SVR: hypo<span></span>thermia, vasocons<span></span>trictors, hypovolemia, low c<span></span>ardiac </div><div>output st<span></span>ate</div><div> <span></span><span></span></div><div>Decreased SVR: hyperthermia, v<span></span>asodilators, acidosis, early sep<span></span>tic shock  </div><div>P<span></span>arameter<span></span>s for RV Function/F<span></span>ailure: <span>used in contex<span></span>t of overall clinical pictur<span></span>e</span></div><div>Step-up:<span> <span>mean P<span></span>A pressure – CVP</span></span></div><div><span></span><span> </span><span>&gt;10: adequate RV function</span></div><div><span></span><span> </span><span>&lt; 10: conc<span></span>ern for R<span></span>V dysfunction</span></div><div>P<span></span>APi: <span>pulmonar<span></span>y artery pulsatility index = (P<span></span>A Systolic – P<span></span>A Diastolic) / CVP</span></div><div><span></span><span> </span><span>&gt;2: <span>adequate RV function</span></span></div><div><span></span><span> </span><span>1-2:<span> at risk for RV failur<span></span>e</span></span></div><div><span></span><span> </span><span>&lt; 1:<span> RV failure</span></span></div></div><div></div></div>
<div><div><img><div>126<span> </span><span>Referenc<span></span>e Material<span> </span>Referenc<span></span>e Material<span> </span><span>127</span></span></div><div>Figure 1 P<span></span>A Catheter Wav<span></span>eforms</div><div>Pulmonary Artery Pressure (P<span></span>A Pressure):<span> Blood pressur<span></span>e in the  </span></div><div>pulmonar<span></span>y artery</div><div> <span></span><span></span></div><div><span></span><span></span><span></span></div><div><span></span><span></span><span></span></div><div>Pulmonary Vascular Resis<span></span>tance: <span>me<span></span>asurement of impedance or resis<span></span>tance of </span></div><div><span></span><span></span></div><div> <span></span><span></span></div><div>Increased PVR: hypo<span></span>xia, hypercapnia, pulmonar<span></span>y vascular dise<span></span>ase, PE</div><div>Pulmonary Capillar<span></span>y Wedg<span></span>e Pressure (PCWP): <span>used to appro<span></span>ximate L<span></span>VEDP  </span></div><div><span></span><span></span><span></span></div><div><span></span><span></span><span></span></div><div> <span></span><span></span></div><div>High wedge pressur<span></span>e: L<span></span>V failure, tamponade (c<span></span>ardiac compression), or </div><div>volume overload </div><div>Management of Hemodynamic Der<span></span>angements</div><div>MAP<span> </span>CVP<span> </span>CO/<span></span>CI<span> </span>SVR<span> </span>T<span></span>reatment approach</div><div><span> </span><span> </span><span> </span><span> </span><span>Volume</span></div><div>Normal<span> </span><span><span> </span></span>Normal<span> </span><span><span> </span></span>Diuretic</div><div><span> </span><span> </span><span> </span><span> </span><span>Inotrope</span></div><div><span> </span><span> </span><span> </span><span> </span><span>Vasodilator</span></div><div><span> </span><span> </span><span> </span><span> </span><span>Inotrope/Vasodilator<span></span>/IABP</span></div><div><span> </span><span>Normal<span> </span></span><span> </span><span> </span><span>Vasoc<span></span>onstrictor</span></div><div>Referenc<span></span>es: </div><div>P<span></span>A Catheter Waveform imag<span></span>e: https://www.studyblue.c<span></span>om/notes/note/n/hemodynamic-monitoring/</div><div>deck/3727974</div><div>Bojar<span></span>, RM. (2011) Manual of perioperative c<span></span>are in adult cardiac sur<span></span>gery. (5th edition).</div><div>POS<span></span>T<span></span>-OP: <span>C<span></span>OMMON ICU DRIP<span></span>S</span></div><div>Inotr<span></span>opes/Vasopressors</div><div>Recep<span></span>tor<span> </span>Loca<span></span>tion<span> </span>Action</div><div>Alpha Adrenergeic<span> </span>Vascular w<span></span>alls</div><div>also found in the heart</div><div>Vasocons<span></span>triction</div><div>Increase dur<span></span>ation of </div><div>contr<span></span>action</div><div>Beta 1 Adr<span></span>energic<span> </span>Heart<span> </span>Incre<span></span>ase inotropy and </div><div>chronotropy<span></span>, minimal </div><div>vasoc<span></span>onstriction</div><div>Beta 2 Adr<span></span>energic<span> </span>Blood vessels<span> </span>vascular and nonv<span></span>ascular </div><div>smooth muscle relaxa<span></span>tion</div><div>Dopamine<span> </span>renal, splanchnic </div><div>(mesenteric), cor<span></span>onary, and </div><div>cerebr<span></span>al vascular beds</div><div>vasodilat<span></span>ation</div><div>Drug<span> </span>Mechanism of Action<span> </span>Dose<span> </span><span>Side eects</span></div><div>Epinephrine<span> </span>potent beta-1 adr<span></span>energic receptor activity </div><div>moderat<span></span>e beta-2 and alpha-1 adr<span></span>energic </div><div><span></span></div><div>0.01-.2 mcg<span></span>/</div><div>kg<span></span>/min</div><div>Increases heart r<span></span>ate</div><div>Can induce </div><div>tachy<span></span>arrhythmias and </div><div>ischemia</div><div>Dopamine<span> </span>1 t<span></span>o 2 mcg<span></span>/kg per minute</div><div>• <span> </span>Selective vasodilat<span></span>ation of renal, <span> </span></div><div> <span> </span>mesenteric, cerebral, and c<span></span>oronar<span></span>y beds</div><div>• <span> </span>may increases urine output d/t  </div><div><span> </span></div><div> <span> </span>and by inhibiting aldosterone and renal </div><div> <span> </span>tubular sodium </div><div>5 to 10 mcg/kg per minute</div><div>• <span> </span>stimulat<span></span>es beta-1 adrener<span></span>gic receptors w/  </div><div> <span> </span>increased cardiac output (s<span></span>troke volume)</div><div>• <span> </span>mild alpha adrenergic rec<span></span>eptor activation  </div><div> <span> </span>increases SVR</div><div>&gt;10 mcg<span></span>/kg per minute</div><div>• <span> </span>stimulation of alpha-adrener<span></span>gic receptors,  </div><div> <span> </span>causing vasocons<span></span>triction with an increased  </div><div> <span> </span>SVR</div><div>1-20mcg<span></span>/kg/</div><div>min</div><div>tachycar<span></span>dia, arrhythmias </div><div></div><div>mcg<span></span>/kg/minute</div><div>Milrinone<span> </span>Selective phosphodiesterase (PDE) inhibitor </div><div>in cardiac and vascular tissue, r<span></span>esulting in </div><div>vasodilation (pulmonary and systemic) and </div><div>increased inotr<span></span>opy with little chronotropic </div><div>activity.</div><div>.1-.5mcg<span></span>/kg/</div><div>min</div><div>Caution </div><div>with renal </div><div>impairment</div><div>May cause peripheral </div><div>vasodilation, </div><div>hypotension, and/<span></span>or </div><div>ventricular arrhythmia</div><div>Dobutamine<span> </span>Stimulat<span></span>es beta-1 adr<span></span>energic recep<span></span>tor, </div><div>increases inotr<span></span>opy and chronotropy and </div><div><span></span></div><div>2 to 20 mcg/</div><div>kg<span></span>/minute</div><div>Can cause hypotension</div><div>Vasopressin<span> </span>Increases cyclic adenosine monophosphate </div><div>(cAMP). Direct vasoc<span></span>onstrictor without </div><div><span></span><span></span></div><div>SVR &amp; MAP</div><div>.01-.04 units/</div><div>min</div><div>May decrease s<span></span>troke </div><div>volume and cardiac </div><div>output in myocardial </div><div>dysfunction or precipit<span></span>ate </div><div>ischemia in coronary </div><div>artery disease.</div><div>Norepinephrine<span> </span><span>S<span></span>timulates both alpha-1 and beta-1 adrener<span></span>gic </span></div><div>recept<span></span>ors; potent vasocons<span></span>triction &amp; modest </div><div>increase in car<span></span>diac output</div><div>1-20mcg<span></span>/min<span> </span><span></span></div><div>Phenylephrine<span> </span>Pure alpha-adrenergic agonist. Causes </div><div>vasocons<span></span>triction with minimal cardiac inotropy </div><div>or chronotropy<span></span>.</div><div>10-300mcg<span></span>/</div><div>min</div><div>May decrease s<span></span>troke </div><div>volume and cardiac </div><div>output in patients with </div><div>cardiac dysfunction</div><div><span></span></div><div>Isuprel<span> </span>Stimulates beta-1 adr<span></span>energic receptors.</div><div>Inotropic and chrono<span></span>tropic agent</div><div>1-10 mcg<span></span>/min<span> </span><span></span></div><div>adrenergic rec<span></span>eptor </div><div>causes vasodilation and a </div><div>decrease in MAP</div></div><div></div></div>
<div><div><img><div>128<span> </span><span>Referenc<span></span>e Material<span> </span>Referenc<span></span>e Material<span> </span><span>129</span></span></div><div>V<span></span>asodilators</div><div>Drug<span> </span>Mechanism of Action<span> </span>Dose<span> </span><span>Side eects</span></div><div>Clevidipine<span> </span>Calcium channel blocker<span></span>, ultra short-acting </div><div>selective arteriolar vasodila<span></span>tor, reduc<span></span>e </div><div><span></span></div><div>pressures or causing</div><div>1-16 mg<span></span>/hr<span> </span>Pulmonar<span></span>y shunt </div><div>physiology and hypoxia </div><div>from inhibition of hypoxic </div><div>vasocons<span></span>triction</div><div>Nicardipine<span> </span>A short-acting calcium channel blocker<span> </span>2.5-15mg<span></span>/hr  <span> </span>Contraindicated in </div><div>severe AS</div><div>Sodium </div><div>Nitroprusside</div><div>An arterial and venous vasodila<span></span>tor that </div><div><span></span></div><div>immediate onset of ac<span></span>tion</div><div>0.1- 3mcg<span></span>/</div><div>kg<span></span>/min</div><div>Prolong use (&gt;72hrs) and </div><div>high dose (&gt;3mcg<span></span>/kg/</div><div>min) can cause cyanide </div><div>and thiocyanate t<span></span>oxicity</div><div>Nitroglycerine<span> </span>A direct v<span></span>asodilator<span></span>, primarily venodialtor, </div><div>arteriodilator a<span></span>t high dose. </div><div>Adjunct therapy for HTN</div><div>0.1-2 mcg<span></span>/</div><div>kg<span></span>/min</div><div>Esmolol<span> </span><span><span></span></span></div><div>blocking agent</div><div>Dose: 25-</div><div>300mcg<span></span>/kg/</div><div>min</div><div>Large volume infusion, </div><div>may contribute t<span></span>o volume </div><div>overload</div><div>Labetalol<span> </span><span><span></span></span></div><div></div><div>Blocker<span></span>. </div><div>0.5-3 mg<span></span>/min</div><div>Hydralazine<span> </span><span>A direct-ac<span></span>ting arteriolar vasodilator <span> </span>10-20mg IV </span></div><div>push</div><div>Avoid in patients with </div><div>ischemic heart disease </div><div>and dissecting aneurysm</div><div>POS<span></span>T<span></span>-OP: <span>C<span></span>OMMON PO MEDS</span></div><div>Beta Block<span></span>ers</div><div>Drug<span> </span>Usual Dose<span> </span>Misc Info</div><div>Atenolol<span> </span>25-50mg PO qd<span> </span>Beta 1 selectivity, bet<span></span>ter for HR control </div><div>Metoprolol<span> </span>2.5-100mg qD<span> </span>Beta 1 selectivity<span></span>, better f<span></span>or HR control </div><div>T<span></span>oprol XL<span> </span>25-100mg qD<span> </span>Beta 1 selectivity, bet<span></span>ter for HR control</div><div>Avoid long acting BB in ICU, choose short acting </div><div>for easier titr<span></span>ation. </div><div>Carvedilol <span> </span>3.125-25mg BID<span> </span>Beta and Alpha block<span></span>age, better for Sys<span></span>tolic HF</div><div>Labetolol<span> </span>100-400mg PO QID<span> </span>Beta 2 and Alpha block<span></span>ade</div><div>Nevibolol (Bystolic) <span> </span>5-40mg PO qD<span> </span>Beta 1 selec<span></span>tivity</div><div>Beta Calcium Channel Block<span></span>ers</div><div>Drug<span> </span>Usual Dose<span> </span>Misc Info</div><div>Dihydropryidines: potent vasodilators, little or no eect on c<span></span>ontractility or conduction</div><div>     Amlodipine<span> </span>2.5-10mg PO qD<span> </span>Mainly for HTN &amp; angina</div><div>     Nicardipine<span> </span>20-40mg PO TID<span> </span>Mainly for HTN &amp; angina</div><div>     Nifedipine<span> </span>10-30mg PO/SL TID<span> </span>Mainly for HTN &amp; angina</div><div>Non dihydropryidines: eect cardiac c<span></span>ontractility and conduction</div><div>     Diltiazem<span> </span>30-60mg PO TID</div><div>180-360mg qD if long acting</div><div>Heart ra<span></span>te control/HTN</div><div>     Verap<span></span>amil<span> </span>80-160mg PO TID<span> </span>Useful for angina</div><div>Nitra<span></span>tes</div><div>Drug<span> </span>Usual Dose<span> </span>Misc Info</div><div>Isosorbide </div><div>mononitrat<span></span>e (Imdur)</div><div>20mg PO qD<span> </span>Wat<span></span>ch for Headache</div><div>Isosorbide dinitrat<span></span>e </div><div>(Isordil)</div><div>5-40mg PO TID<span> </span>Wat<span></span>ch for Headache</div><div>Nitropas<span></span>te<span> </span>1-3 in q3-4 hr<span> </span>Wat<span></span>ch for Headache</div><div>ACE inhibitors</div><div>(Avoid in acute r<span></span>enal dysfunction, adjust dose for moderate renal failure)</div><div>Drug<span> </span>Usual Dose<span> </span>Misc Info</div><div>Losartan (Coz<span></span>aar)<span> </span>25-100mg PO qD or in 2 divided </div><div>doses</div><div>Valsartan  (Diov<span></span>an)<span> </span>80-160mg PO qD</div><div>Irbesartan (Av<span></span>apro)<span> </span>150-300mg PO qD</div><div>Cadesartan (At<span></span>acand)<span> </span>8-32mg PO qD or in 2 divided </div><div>doses</div><div>Alpha Blockers</div><div>Drug<span> </span>Usual Dose<span> </span>Misc Info</div><div>Alpha 1 antagonist</div><div>     Doxazosin (Car<span></span>dura)<span> </span>1.0-8mg PO qD<span> </span>Good for BPH</div><div>     Prazosin (Minipress)<span> </span>1.0-7.5mg PO BID</div><div>     T<span></span>erazosin (hytrin)<span> </span>1-20mg PO qD<span> </span>Good for BPH, Slows HR, watch f<span></span>or  </div><div>orthost<span></span>atic h0tn</div><div>Alpha 2 antagonist</div><div>     Clonidine (Catapr<span></span>es)<span> </span>0.1-0.3mg PO BID<span> </span>Slows HR, good for nico<span></span>tine withdrawal sx.  </div><div>Rebound tachyc<span></span>ardia/hypertension if st<span></span>opped</div><div>Antiarrhythmics</div><div>Drug<span> </span>Usual Dose<span> </span>Misc Info</div><div>Amiodarone <span> </span>400mg PO TID, wean to </div><div>200mg qd</div><div>Class III, prolongs action pot<span></span>ential duration</div><div>Digoxin<span> </span>0.125-0.25mg PO qd<span> </span>Leads to incre<span></span>ased contractility through inhibition </div><div>of the Na/K+ A<span></span>TP<span></span>ase pump, promotes calcium </div><div></div><div>Direct suppression of AV node c<span></span>onduction </div><div>Monitor digoxin levels</div><div>Sotalol<span> </span>80mg PO TID<span> </span>Class III, prolongs action potential dura<span></span>tion</div></div><div></div></div>
<div><div><img><div>130<span> </span><span>Referenc<span></span>e Material<span> </span>Referenc<span></span>e Material<span> </span><span>131</span></span></div><div>Diuretics</div><div>Drug<span> </span>Usual Dose<span> </span>Misc Info</div><div>Loop diuretics</div><div>Furosemide (Lasix)<span> </span>10-100mg QID<span> </span>Needs k+ replacement</div><div>Bumex<span> </span>0.5-10mg daily<span> </span>Needs k+ replacement</div><div>If not responding to high dose Lasix, c<span></span>onsider </div><div>switching to Bumex</div><div>Thiazides</div><div>HCT<span></span>Z (Hydrodiuril)<span> </span>50-100mg qD</div><div>Chlorothiazide (Diuril)<span> </span>500mg IV qD</div><div>Metolazone </div><div>(Zarox<span></span>olyn)</div><div>5-20mg qD</div><div>Potassium sparing:</div><div>Eplerenone (Inspra)<span> </span>25-50mg qD</div><div>Spironolactone </div><div>(Aldactone)</div><div>25mg qD</div><div>Carbonic Anhydrase Inhibitor</div><div>Acet<span></span>azolamide </div><div>(Diamox)</div><div>250-500mg IV q6h<span> </span>Increased renal excr<span></span>etion of bicarbonate (used in </div><div>metabolic/<span></span>contraction alk<span></span>alosis)</div><div>Bojar<span></span>, R.M. (2011) Manual of perioperative c<span></span>are in adult cardiac sur<span></span>gery. (5th Edition).</div><div>POS<span></span>T<span></span>-OP: <span>DIAGNOSIS TR<span></span>ANSLA<span></span>TION EXAMPLES</span></div><div>Diagnosis T<span></span>ranslation E<span></span>xamples</div><div>When documenting:<span> </span>Consider<span></span>:</div><div>NPO, tube feeding, TPN, nutrition note: </div><div>diagnosis doc</div><div>Severe protein-calorie malnutrition, underweight</div><div>Altered ment<span></span>al st<span></span>atus, Delirium<span> </span>Encephalophathy<span></span>, type: acute delirium and etiology/cause</div><div>Chest pain<span> </span>Cause of chest pain, CHF<span></span>, MI, CAD</div><div>CHF<span></span>, ESHD<span> </span>Acuity and type of CHF</div><div>Myocardial infar<span></span>ction <span> </span>NSTEMI, STEMI (artery involved)</div><div>Hgb 7.5; 1L EBL, 2U PRBC given<span> </span>Acute blood loss anemia </div><div>Elevated BUN/Cr<span></span>eatinine<span> </span>Acute Kidney Injur<span></span>y and or/ A<span></span>TN</div><div>NA 125/150 with monitor and/<span></span>or treatment<span> </span>Hyponatremia/Hyperna<span></span>tremia</div><div>5,3”<span></span>, 297 lbs<span> </span>BMI &gt; 40, Morbid obesity, overweight</div><div>WBC: 2.0, RBC 2.50, Plt: 75, on chemo<span> </span>Pancytopenia due t<span></span>o chemo</div><div>Hypoxia, Hypoxic, Hyperc<span></span>apnic<span> </span>R<span></span>espiratory Failur<span></span>e (Acuity and Type)</div><div>Urosepsis, Meeting 2 out of 4 SIRS crit<span></span>eria<span> </span>Sepsis due to UTI</div><div>Pneumonia<span> </span>Pneumonia, specify etiology and/or causa<span></span>tive organism</div><div>Fever<span> </span>Link cause of fever</div><div>Hypotensive requir<span></span>e vasoac<span></span>tive drugs<span> </span><span>Shock and T<span></span>ype of Shock (Cardiogenic, Hypovolemic, post op, etc)</span></div><div>POS<span></span>T<span></span>-OP: <span>IIC<span></span>U ADMISSION REQUIREMENT<span></span>S</span></div><div>iICU Admission Criteria</div><div>IV infusions </div><div>(patient mus<span></span>t </div><div>have 3 or less)</div><div> <span></span><span></span></div><div>Dopamine: max r<span></span>ate 10 mcg<span></span>/kg<span></span>/min via centr<span></span>al line</div><div> <span></span><span></span></div><div>Milrinone 0.375mcg<span></span>/kg<span></span>/min max</div><div> <span></span><span></span></div><div>Amiodarone: centr<span></span>al line administra<span></span>tion strongly  </div><div>preferred. Ther<span></span>apy via PIV for 24 hours max. </div><div> <span></span><span></span></div><div>Arga<span></span>troban, heparin </div><div> <span></span><span></span></div><div>Insulin continuous infusion </div><div> <span></span><span></span></div><div>Diltiazem</div><div> <span></span><span></span></div><div>Ket<span></span>amine</div><div> <span></span><span></span></div><div>Esmolol (D1, CSU<span></span>, B2 only)</div><div> <span></span><span></span></div><div>Labetolol</div><div> <span></span><span></span></div><div>Nitroglycerin (f<span></span>or controlling chest p<span></span>ain, 1 hour max)</div><div>T<span></span>empor<span></span>ar<span></span>y </div><div>P<span></span>acemakers</div><div> <span></span><span></span></div><div>Semi-Permanent P<span></span>acemakers </div><div><span></span><span> </span><span>“Floating le<span></span>ad”<span></span>, T<span></span>ransvenous – not allowed</span></div><div><span></span><span> </span><span>“Fixed lead”<span></span>, with external g<span></span>enerator<span></span>- allowed</span></div><div><span></span><span> </span><span>Underlying rhythm/ra<span></span>te irrelevant </span></div><div> </div><div> <span></span><span></span></div><div>T<span></span>emporary Epicardial Wires</div><div><span></span><span> </span><span>If patient is p<span></span>acer dependent, underlying heart </span></div><div>ra<span></span>te must be &gt; 40 and be hemodynamically s<span></span>table</div><div>CP<span></span>AP<span></span>/BiP<span></span>AP</div><div> <span></span><span></span></div><div>Nasal CP<span></span>AP &amp; BIP<span></span>AP for patients es<span></span>tablished on a </div><div>nighttime CP<span></span>AP<span></span>/BiP<span></span>AP (nasal mask) at home for OSA</div><div> <span></span><span></span></div><div>Nasal CP<span></span>AP &amp; BIP<span></span>AP as a ne<span></span>w ther<span></span>apy for respirat<span></span>or<span></span>y </div><div><span></span></div><div>evaluation and for a maximum dur<span></span>ation of 4 hours. </div><div>Requires c<span></span>onsultation of ICU te<span></span>am</div><div> <span></span><span></span></div><div>Full f<span></span>ace mask CP<span></span>AP &amp; BiPAP f<span></span>or patients with OSA is </div><div>permitt<span></span>ed if trea<span></span>tment is an established home ther<span></span>apy and </div><div>patient is able t<span></span>o remove mask</div><div>High Flow </div><div>Nasal Cannula</div><div> <span></span><span></span></div><div>HFNC can be acc<span></span>epted once p<span></span>atients are on st<span></span>able </div><div><span></span><span></span></div><div> <span></span><span></span></div><div>P<span></span>atient must be evalua<span></span>ted ever<span></span>y 4 hours for increasing </div><div>oxygen requir<span></span>ements </div><div>Peric<span></span>ardial </div><div>Drains</div><div> <span></span><span></span></div><div>All Allowed</div><div>Pos<span></span>t Cath </div><div>proc<span></span>edure </div><div>patient<span></span>s</div><div> <span></span><span></span></div><div>F<span></span>ast T<span></span>rack T<span></span>AVRS</div><div> <span></span><span></span></div><div>Pos<span></span>t cardiac cath</div></div><div></div></div>
<div><div><img><div>132<span> </span><span>Referenc<span></span>e Material<span> </span>Referenc<span></span>e Material<span> </span><span>133</span></span></div><div>POS<span></span>T<span></span>-OP: <span>INR GOAL<span></span>S</span></div><div>Bioprosthe<span></span>tic </div><div>Aortic Valve</div><div>Bioprosthe<span></span>tic Mitral </div><div>Valve Replac<span></span>ement</div><div>Mechanical Aortic </div><div>Composite V<span></span>alve</div><div>Mechanical Aortic </div><div>Valve <span>S<span></span>tandard<span> </span></span></div><div>Mechanical Mitral </div><div>Valve </div><div>T<span></span>rans-catheter </div><div>Aortic Valve </div><div>Replacement</div><div>Atrial Fibrillation </div><div>Only</div><div>VTE Prophylaxis </div><div>INR Range (Goal)<span> </span>1.5-2.5<span> </span>2.0-3.0<span> </span>2.5-3.5 (3.0)<span> </span>2.0-3.0</div><div>Level of Evidence<span> </span>B<span> </span>B<span> </span>B<span> </span>B</div><div>Size of T<span></span>reatment </div><div></div><div>Class I<span> </span>Class I<span> </span>Class I<span> </span>Class I</div><div>Duration<span> </span>Lifelong VK<span></span>A<span> </span>Lifelong VKA<span> </span>Lifelong VKA</div><div>Level of Evidence<span> </span>A<span> </span>A<span> </span>A</div><div>Pos<span></span>t-op </div><div>Anticoagula<span></span>tion</div><div><span></span></div><div>surgery once post<span></span>-</div><div>operative bleed no </div><div>longer an issue.</div><div>(No bridge with </div><div>Heparin)</div><div><span></span></div><div>surgery once post<span></span>-</div><div>operative bleed no </div><div>longer an issue.</div><div>(No bridge with </div><div>Heparin)</div><div><span></span></div><div>surgery once post<span></span>-</div><div>operative bleed </div><div>no longer an issue. </div><div>(Bridge with </div><div>Heparin Po<span></span>st Op  </div><div>24-36 Hours)</div><div>Dual antiplatelet </div><div>with clopidogrel </div><div>75mg for 6 months  </div><div>if not on Coumadin</div><div>Unfractiona<span></span>ted </div><div>Heparin 5000 Units </div><div>Subcutaneously </div><div>ever<span></span>y  8 hours </div><div>unless patient is </div><div>bleeding <span>(100 cc </span></div><div>per hour or more)<span> </span></div><div>from Chest tubes</div><div>ASA Y<span></span>/N (dose)<span> </span>Y (81-325mg<span></span>)<span> </span>Y (75-100mg<span></span>)<span> </span>Y (75-100mg)<span> </span>Y (75-100mg<span></span>)<span> </span>Y (75-100mg)<span> </span>Y (75-100mg<span></span>) - </div><div>lifelong</div><div>(75mg-325mg)</div><div>Level of Evidence<span> </span>B<span> </span>A<span> </span>A<span> </span>A<span> </span>C</div><div>Size of T<span></span>reatment </div><div></div><div>Class IIa<span> </span>Class I<span> </span>Class I<span> </span>Class I<span> </span>Class IIb</div><div><span></span><span></span><span></span><span></span><span> </span></div><div>HITT = heparin induc<span></span>ed thrombocytopenia thrombosis</div><div>TIPS FOR CARDIA<span></span>C SURGERY (Blue/Green) ANTIC<span></span>OAGULA<span></span>TION</div><div>*If pa<span></span>tient has more than one indica<span></span>tion for Coumadin use the highest </div><div>INR go<span></span>al.</div><div>IF MECHANICAL MVR:  <span>patient<span></span>s should be started on hep<span></span>arin/arga<span></span>troban drip </span></div><div>post<span></span>op day 1 if no bleeding for bridging to Coumadin.</div><div>IF TEMPORARY P<span></span>ACING WIRES ARE S<span></span>TILL IN:<span> </span>DO NOT LET INR GET ABO<span></span>VE 2.0 </div><div>UNTIL THEY ARE REMOVED.<span>  S<span></span>tay on hep<span></span>arin/arga<span></span>troban drip until p<span></span>acing wires </span></div><div>removed.</div><div>Heparin/<span></span>Arga<span></span>troban drip needs to be st<span></span>opped for 6 hours<span> prior to pacing wir<span></span>e </span></div><div><span></span></div><div>IF ST<span></span>ARTING O<span></span>THER ANTICOAGULANT<span></span>S <span>(like Xarelt<span></span>o, Eliquis, Pradaxa, et<span></span>c.) DO </span></div><div>NOT S<span></span>TART UNTIL TEMPORARY P<span></span>ACING WIRES ARE REMOVED.  IF indicated, use </div><div>heparin/<span></span>argatrob<span></span>an drip until pacing wires are removed if indica<span></span>ted.</div><div>If on multiple blood thinning agents<span> (ie  Aspirin, Plavix, and Coumadin), discuss </span></div><div>with Cardiac Surg<span></span>er<span></span>y that this is ok<span></span>ay.</div><div>All patient<span></span>s are treated if blood t<span></span>est for HIT is positive, whether sympt<span></span>omatic or </div><div>not.  Length of therapy should depend on Hema<span></span>tologist’<span></span>s recommenda<span></span>tion.  </div><div> </div><div>*Additional risk fact<span></span>ors for thromboembolic events (AF<span></span>, previous thromboembolism, L<span></span>V </div><div>dysfunction, or hyperc<span></span>oagulable sta<span></span>te) or an older-gener<span></span>ation mechanical AVR (such as </div><div>ball-in-cag<span></span>e).</div><div>§ It is recommended t<span></span>o not st<span></span>art VKA until platelets have sub<span></span>st<span></span>antially recovered (i.e., </div><div>usually to at le<span></span>ast 150X109/L).  VKA should initially be given in low doses (maximum, </div><div>5 mg of warfarin) o<span></span>ver using higher doses (Grade 1C).  If VKA has already been s<span></span>tarted </div><div>when diagnosed with HIT<span></span>, vitamin K should be adminis<span></span>tered (Gr<span></span>ade 2C).  VKA should be </div><div>overlapped with a nonheparin antic<span></span>oagulant for a minimum of 5 days and until the INR is </div><div>within targ<span></span>et range (Gr<span></span>ade 1C).</div><div>1) <span> </span>Guyatt GH, Akl EA, Cr<span></span>owther M, et al. American College of Chest Physicians Antithr<span></span>ombotic </div><div>Therapy and Prevention of Thrombosis P<span></span>anel. Ex<span></span>ecutive summary: antithrombotic Therapy </div><div>and Prevention of Thrombosis, 9th ed: American Colleg<span></span>e of Chest Physicians Evidence-Based </div><div>Clinical Prac<span></span>tice Guidelines.  Chest. 2012 Feb;141(2 Suppl):7S-47S. </div><div>2) <span> </span>Januar<span></span>y CT<span></span>, Wann L<span></span>S, Alpert JS, et al. 2014 AHA/AC<span></span>C/HRS Guideline for the Management </div><div>of P<span></span>atients With Atrial Fibrillation: E<span></span>xecutive Summar<span></span>y: A Report of the American Colleg<span></span>e </div><div>of Cardiology/<span></span>American Heart Association T<span></span>ask Force on Pr<span></span>actice Guidelines and the Heart </div><div>Rhythm Society. J Am Coll Car<span></span>diol. 2014 Mar 28. Pii:S0735-1097(14)01739-2.</div><div>3) <span> </span>Kearon C, Akl E, Comerot<span></span>a A, et al. Antithrombotic therapy f<span></span>or VTE disease: Antithrombo<span></span>tic </div><div>Therapy and Prevention of Thrombosis, 9th ed: Americ<span></span>an College of Chest Physicians </div><div>Evidence-Based Clinical Pr<span></span>actice Guidelines. Chest. 2012 Feb; 141 (2 Suppl):e419S-94S.</div><div>4) <span> </span>Linkins LA, Dans AL, Moores LK, et al. T<span></span>reatment and prevention of heparin-induced </div><div>thrombocytopenia: Antithrombotic Ther<span></span>apy and Prevention of Thrombosis, 9th ed: American </div><div>College of Ches<span></span>t Physicians Evidence-Based Clinical Practic<span></span>e Guidelines. Chest. 2012 Feb; </div><div>141(2suppl):e495s-530S.</div><div>5) <span> </span>Nishimura RA, Otto CM, Bonow RO, e<span></span>t al. 2014 AHA/AC<span></span>C guideline for the management of </div><div>patient<span></span>s with valvular heart dise<span></span>ase; a report of the American College of Cardiology/<span></span>American </div><div>Heart Association T<span></span>ask Forc<span></span>e on Practice Guidelines. J Thorac Car<span></span>diovas Surg. 2014 Jul; </div><div>148(1):e1-e132. </div></div><div></div></div>
<div><div><img><div>134<span> </span><span>Referenc<span></span>e Material<span> </span>Referenc<span></span>e Material<span> </span><span>135</span></span></div><div>POS<span></span>T<span></span>-OP: <span>PROPHYLA<span></span>CTIC MEDICA<span></span>TIONS  </span></div><div>(GI, VA-PNA, D<span></span>VT<span></span>, INFECTION)</div><div>Common Prophylactic Medica<span></span>tions</div><div>Pre Op </div><div>(day of surgery)</div><div>ICU<span> </span>iICU</div><div>VA- PNA</div><div>• <span> </span>Peridex 0.12%, 15mL </div><div>swish and spit</div><div>• <span> </span>Peridex 0.12%, 15mL swish and spit </div><div>while intubated</div><div>• <span> </span>N/A</div><div>DVT</div><div>• <span> </span>No DVT prophylaxis </div><div>indicated</div><div>• <span> </span>SCDs</div><div>• <span> </span>Heparin 5000 units subQ q8 hours</div><div>• <span> </span>SCDs</div><div>• <span> </span>Consider subq </div><div>Heparin if not able </div><div>to ambulate</div><div>Surgical </div><div>Prophylaxis </div><div>• <span> </span>2g cefaz<span></span>olin  </div><div>(3g if &gt;120kg)</div><div>• <span> </span>Weight dosed </div><div>vancomycin if PCN </div><div>allergy</div><div>• <span> </span>Antimicrobial shower </div><div>x2 (PM and AM) before </div><div>surgery with either </div><div>chlorhexidine sponges </div><div>(per patient) or wipes </div><div>(per nurse)</div><div>• <span> </span>2g cefaz<span></span>olin (3g if &gt;120kg) x 3 doses </div><div>(24 hours)</div><div>• <span> </span>Weight dosed vancomycin if PCN </div><div>allergy x2 doses (24 hours)</div><div>• <span> </span>N/A</div><div>Lumbar </div><div>Drain</div><div><span> </span></div><div><span></span></div><div>placed</div><div><span> </span></div><div>drain in place</div><div>• <span> </span>N/A</div><div>GI</div><div>• <span> </span>N/A<span> </span>• <span> </span>IV or PO acid suppression therapy for:</div><div> <span> </span>o <span> </span>Mechanical ventilation &gt; 48 hours</div><div> <span> </span>o <span> </span>Plt count &lt; 50, INR &gt; 1.5, or P<span></span>TT 2x  </div><div> <span> </span>baseline</div><div> <span> </span>o <span> </span>Spinal cord injury</div><div> <span> </span>o <span> </span>Solid organ tr<span></span>ansplantation  </div><div> <span> </span>perioperatively in the ICU se<span></span>tting </div><div> <span> </span>o <span> </span>Use of two antiplatelet ag<span></span>ents </div><div> <span> </span>o <span> </span>Any two of the following: Sepsis,  </div><div> <span> </span>ICU st<span></span>ay &gt; 10 days, occult bleeding  </div><div> <span> </span>lasting &gt; 6 days, high dose st<span></span>eroids </div><div>*Ster<span></span>oid use with no other risk fact<span></span>ors </div><div>and NPO st<span></span>atus are NOT indic<span></span>ations for </div><div>stress ulc<span></span>er prophylaxis</div><div>• <span> </span>Acid suppression </div><div>therapy only if </div><div>patient previously </div><div>took at home for </div><div>GERD</div><div>• <span> </span>Literatur<span></span>e DOES </div><div>NOT support str<span></span>ess </div><div>ulcer prophylaxis </div><div>outside of the ICU </div><div>environment</div><div>POS<span></span>T<span></span>-OP: <span>SUPPLEMENT<span></span>AL O2 &amp; VENTILA<span></span>TOR </span></div><div>MANAGEMENT</div><div>Oxyg<span></span>en Administr<span></span>ation</div><div>1. <span> </span><span>Nasal cannula</span></div><div>a.<span> <span> </span><span><span></span><span></span><span></span><span></span><span></span><span></span><span></span><span></span><span></span><span></span><span></span></span></span></div><div>i. <span> </span>FiO2 = 20% + (4 x O2 L/min)</div><div>b.<span> <span> </span><span><span></span><span></span><span></span></span></span></div><div>2. <span> </span><span>F<span></span>ace mask</span></div><div>a. <span> </span><span><span></span></span></div><div>to det<span></span>ermine an accur<span></span>ate FiO2 deliver<span></span>y since 75% of inspir<span></span>ed volume is </div><div>room air</div><div>3. <span> </span><span>Venti mask</span></div><div>a. <span> </span><span>Delivers a precise oxygen c<span></span>oncentration in incr<span></span>ements of 24, 28, 31, 35, </span></div><div>and 40%</div><div>b.<span> <span> </span><span>Inspired volume is a mix of r<span></span>oom air and oxygen. Exhaled air is allowed to </span></span></div><div>exit the mask therefore C<span></span>O2 retention is minimal</div><div>4. <span> </span><span>Non-rebre<span></span>ather mask</span></div><div>a. <span> </span><span><span></span></span></div><div>b.<span> <span> </span><span>There is a one w<span></span>ay valve that prevents the pa<span></span>tient from breathing in r<span></span>oom </span></span></div><div>air<span></span>.  This ensures that a high oxygen conc<span></span>entration is delivered.  Risk of </div><div>CO2 r<span></span>etention</div><div>5. <span> </span><span><span></span></span></div><div>hypoxemia</div><div>a. <span> </span><span>FiO2 range 20-100%, Flow r<span></span>ange 20-50 L/min</span></div><div><span></span><span></span></div><div>b.<span> <span> </span><span><span></span></span></span></div><div>Consider transitioning t<span></span>o regular nasal c<span></span>annula once FiO2 we<span></span>aned to 40-</div><div></div><div>Non-Invasive P<span></span>ositive Pressure V<span></span>entilation (NIPPV)</div><div>1. <span> </span><span>Continuous Positive Airway Pressure (CP<span></span>AP)</span></div><div>a. <span> </span><span>Noninvasive ventilation mode tha<span></span>t delivers positive pressure throughout </span></div><div>the respir<span></span>atory cycle through specialized fac<span></span>e or nasal masks</div><div>b.<span> <span> </span><span>Prescriber mus<span></span>t specify PEEP and FiO2</span></span></div><div>2. <span> </span><span>Bilevel Positive Airway Pressure (Bip<span></span>ap)</span></div><div>a. <span> </span><span>Noninvasive ventilation mode tha<span></span>t delivers </span></div><div>b.<span> <span> </span><span>Prescriber mus<span></span>t set end-expirat<span></span>or<span></span>y pressure (EP<span></span>AP or PEEP) and IP<span></span>AP  </span></span></div><div>c. <span> </span><span>If Bipap is delivered using Dr<span></span>ager or L<span></span>TV vent, the ordered PS is additive </span></div><div>to the level of PEEP<span></span>.  i.e. PS 10 cmH2O &amp; PEEP 5 cmH2O will deliver a to<span></span>tal </div><div>IP<span></span>AP of 15cmH2O  </div><div>d. <span> </span><span>PS is not an additive to PEEP on Respir<span></span>onics Vision and V-60 devices</span></div><div>e. <span> </span><span>Consider placing NG/OG tube if IP<span></span>AP &gt; 20 cm H2O</span></div><div>Ventila<span></span>tor Modes: <span>the most frequently used modes in the CVICU ar<span></span>e </span></div><div>VC<span></span>-AC, VC<span></span>-SIMV and PSV</div><div>1. <span> </span><span>Volume-Controlled V<span></span>entilation (VCV) </span></div><div>a. <span> </span><span>VCV is volume-limited and time-cycled. </span></div><div>b.<span> <span> </span><span>Prescriber mus<span></span>t set a desired tidal volume, respir<span></span>ator<span></span>y r<span></span>ate</span></span></div><div>c. <span> </span><span>The vent will deliver the set VT with ever<span></span>y brea<span></span>th (machine or patient </span></div><div>triggered).  Airway pressure ak<span></span>a peak inspiratory pressure (PIP) will v<span></span>ar<span></span>y </div><div>based on lung mechanics (resis<span></span>tance/<span></span>complianc<span></span>e)</div><div>d. <span> </span><span>Vent setting p<span></span>arameters</span></div><div>i. <span> </span>Minut<span></span>e ventilation 8-10 L/min</div><div>ii.  Tidal Volume (VT) 8-10 mL/kg (&lt; 6 mL/kg for ARDS)</div><div>iii. Plat<span></span>eau air<span></span>way pr<span></span>essures &lt; 30 cm H2O</div><div>2. <span> </span><span>Pressure-Controlled V<span></span>entilation (PCV)</span></div><div>a. <span> </span><span>PCV is pressure-limited and time-cycled.  </span></div><div>b.<span> <span> </span><span>Prescriber mus<span></span>t set desired pressure limit, respir<span></span>ator<span></span>y r<span></span>ate, and </span></span></div><div>inspira<span></span>tory time (I:E ratio)</div><div>c. <span> </span><span><span></span></span></div><div><span></span><span></span><span></span><span></span><span></span></div><div>pressure for the dur<span></span>ation of the inspira<span></span>tory time.  VT will var<span></span>y based on </div><div>lung mechanics</div><div>d. <span> </span><span>Vent setting p<span></span>arameters</span></div><div>i. <span> </span>P<span></span>eak inspira<span></span>tor<span></span>y pressure &lt; 35 cm H2O</div><div>3. <span> </span><span>Assist Control Ventila<span></span>tion (ACV)</span></div><div>a. <span> </span><span>ACV can be either pressur<span></span>e or volume limited</span></div><div>b.<span> <span> </span><span>The ventilat<span></span>or delivers the same set parame<span></span>ters for both mandatory and </span></span></div><div>patient trigg<span></span>ered breaths.  </div></div><div></div></div>
<div><div><img><div>136<span> </span><span>Referenc<span></span>e Material<span> </span>Referenc<span></span>e Material<span> </span><span>137</span></span></div><div>4. <span> </span><span>Synchronized Int<span></span>ermittent Mandat<span></span>or<span></span>y Ventila<span></span>tion (SIMV)</span></div><div>a. <span> </span><span>A<span></span>ssis<span></span>ted breaths are synchr<span></span>onized to coincide with spont<span></span>aneous </span></div><div><span></span></div><div>5. <span> </span><span>Pressure-<span></span>Support Ventila<span></span>tion (PSV)</span></div><div>a. <span> </span><span></span></div><div>b.<span> <span> </span><span>The prescriber se<span></span>ts the pressure support level</span></span></div><div>c. <span> </span><span>Each breath is p<span></span>atient triggered and the tidal volume is determined by </span></div><div><span></span></div><div>6. <span> </span><span>Airway Pressure Release V<span></span>entilation (APRV) </span></div><div>a. <span> </span><span>Alternates be<span></span>tween high/low air<span></span>way pressure and is time-cycled (not </span></div><div>patient trigg<span></span>ered).  Most time is spent at high pressur<span></span>e with a brief c<span></span>ycle </div><div>to low pressur<span></span>e.  Purpose of this type of ventilation is to k<span></span>eep alveoli </div><div>recruited</div><div>7. <span> </span><span>Inverse Ratio Ventila<span></span>tion (IR<span></span>V)</span></div><div>a. <span> </span><span>This mode of ventilation uses a prolonged inspir<span></span>ator<span></span>y time (2:1) in </span></div><div>order to help pr<span></span>event alveolar collapse.  May be used for pa<span></span>tients </div><div>with refr<span></span>actory hypoxemia with conventional modes of ventila<span></span>tion.  </div><div><span></span><span></span><span></span></div><div>PEEP:<span> Pe<span></span>ak end expira<span></span>tory pressure</span></div><div>1. <span> </span><span>Therapeutic Uses: </span></div><div>a. <span> </span><span>P<span></span>atients admitted t<span></span>o ICU on ventilator will be set on PEEP 5cm H20</span></div><div>i. <span> </span>PEEP 5 c<span></span>onsidered a substitute for loss of normal br<span></span>eathing </div><div>“Physiologic PEEP” caused by the presenc<span></span>e of the ETT (endotracheal </div><div>tube)</div><div>ii.  Usually well tolerat<span></span>ed hemodynamically, not much recruitment/O2 </div><div></div><div>b.<span> <span> </span><span>Incre<span></span>asing PEEP to increase P<span></span>aO2</span></span></div><div>i. <span> </span>Incr<span></span>easing PEEP (by 2-5cm H20 increments) will incre<span></span>ase mean airway </div><div>pressure and open previously closed alveoli</div><div>ii.  Increases lung surf<span></span>ace are<span></span>a participating in g<span></span>as exchange</div><div>iii. Decre<span></span>ases VQ/intrapulmonar<span></span>y shunting by improving ventilation t<span></span>o </div><div>perfused lung</div><div>iv. A<span></span>s lung recruitment and P<span></span>aO2 improves, FiO2 may be weaned</div><div>c. <span> </span><span>Cautions with high PEEP</span></div><div>i. <span> </span>Incr<span></span>eased intrathor<span></span>acic pressure decreases venous r<span></span>eturn to the he<span></span>art</div><div>ii.  Increased PEEP leads t<span></span>o increased PVR, leading to mor<span></span>e strain on RV</div><div>iii. Decre<span></span>ased venous return and depressed RV performance may le<span></span>ad to </div><div><span></span></div><div>iv. Should not be used in patient<span></span>s with COPD (leads to incr<span></span>eased VQ </div><div>mismatch)</div><div>v.<span> <span> </span>Monitor for signs of “baro<span></span>trauma:” </span></div><div>1.  Caused by alveolar overdis<span></span>tention</div><div>2.  May present as: pneumothor<span></span>ax, subcutaneous emphysema, </div><div>pneumomediastinum</div><div>Lung Mechanics</div><div>1. <span> </span><span>End-inspira<span></span>tory Peak pressur<span></span>e</span></div><div>a. <span> </span><span><span></span><span></span><span></span></span></div><div>the airways, and elasticity of lungs and chest w<span></span>all</div><div>2. <span> </span><span>End-inspira<span></span>tory Plateau pressur<span></span>e</span></div><div>a. <span> </span><span>Pplat is a direct me<span></span>asurement of the elasticity of the lungs and chest w<span></span>all </span></div><div>(complianc<span></span>e)</div><div>b.<span> <span> </span><span><span></span></span></span></div><div>3. <span> </span><span>Tips</span></div><div>a. <span> </span><span>If peak pressure is elev<span></span>ated and plate<span></span>au pressure is unchang<span></span>ed, there is </span></div><div>an increased r<span></span>esistanc<span></span>e in the airways which may be due to secretions in </div><div>the ETT<span></span>, mucous plug, or acute br<span></span>onchospasm</div><div>b.<span> <span> </span><span>If bo<span></span>th peak and plat<span></span>eau pressures are eleva<span></span>ted, there is decreased </span></span></div><div>complianc<span></span>e of the lungs and/or ches<span></span>t wall.  Causes may include </div><div>pneumothor<span></span>ax<span></span>, at<span></span>electasis, acute pulmonary edema, worsening </div><div>pneumonia, or ARDS</div><div>c. <span> </span><span>If peak pressure is decr<span></span>eased, there is a problem with an air leak in the </span></div><div>ventilator sys<span></span>tem</div><div>d. <span> </span><span>PEEP increases plate<span></span>au pressure</span></div><div>CV-IC<span></span>U Interdisciplinary Rapid E<span></span>xtuba<span></span>tion Prot<span></span>ocol (I-REP)</div><div>1. <span> </span><span>Assess patient to determine if p<span></span>atient meets vent weaning crit<span></span>eria</span></div><div>a. <span> </span><span>Weaning criteria: </span></div><div>i. <span> </span>SpO2 &gt; 92% on FiO2 &lt; 60%</div><div>ii.  PEEP &lt; 8 cm H2O</div><div>iii. T<span></span>emp &gt; 35C</div><div>iv. Hemodynamically st<span></span>able</div><div>v.<span> <span> </span>Chest tube output st<span></span>able</span></div><div>vi. Spontaneous bre<span></span>athing noted (if pa<span></span>tient not over-brea<span></span>thing, </div><div>then reduce r<span></span>espiratory rate by 50% f<span></span>or up to 5 min to assess for </div><div>spontaneous br<span></span>eathing)</div><div>2. <span> </span><span>If patient mee<span></span>ts weaning criteria then reduc<span></span>e respiratory rat<span></span>e to zero as </span></div><div>toler<span></span>ated while maint<span></span>aining EtCO2 &lt; 50.  </div><div>a. <span> </span><span>Goal PSV -  PS 10, PEEP 5, and normal work of br<span></span>eathing with RSBI &lt; 100</span></div><div>3. <span> </span><span>If patient does no<span></span>t tolerate P<span></span>SV<span></span>, return to previous vent settings and r<span></span>eassess</span></div><div>4. <span> </span><span>If toler<span></span>ates P<span></span>SV<span></span>, check ABG and assess neuro to see if p<span></span>atient meet<span></span>s </span></div><div>extub<span></span>ation criteria.</div><div>a. <span> </span><span>Ex<span></span>tubation criteria</span></div><div>i. <span> </span>SpO2 &gt; 92% on FiO2 &lt; 50%</div><div>ii.  EtC<span></span>O2 st<span></span>able and within baseline +/- 10%</div><div>iii. pH &gt; 7.3</div><div>iv. PS 10 and PEEP 5</div><div>v.<span> <span> </span>RSBI &lt; 100 with normal work of brea<span></span>thing</span></div><div>vi. If patient does not mee<span></span>t criteria, reassess ever<span></span>y 15 min for a t<span></span>otal of 3 </div><div>cycles</div><div>5. <span> </span><span>If extub<span></span>ation criteria are met, then ok to extub<span></span>ate.  If patient is morbidly obese </span></div><div>or has a h/<span></span>o OSA then extubat<span></span>e to CP<span></span>AP 8-10 cm or Bipap 10/5 for 2 hours</div><div>6. <span> </span><span>If patient is r<span></span>eceiving inhaled Flolan, extuba<span></span>te to HFNC to continue Flolan </span></div><div>administr<span></span>ation </div><div>Miscellaneous </div><div>1. <span> </span><span>Do not change any ventila<span></span>tor settings unless in an emerg<span></span>enc<span></span>y<span></span>.  Please notify </span></div><div>respir<span></span>atory therapy te<span></span>am for all ventilat<span></span>or changes</div><div>2. <span> </span><span>Rapid-shallow bre<span></span>athing index (RBSI) = RR / Lit<span></span>ers of Tidal Volume</span></div><div>a. <span> </span><span>Goal RSBI &lt; 100</span></div><div>b.<span> <span> </span><span>Indica<span></span>tor for appropriateness f<span></span>or extubation (along with ment<span></span>al sta<span></span>tus, </span></span></div><div>amount of secretions, s<span></span>trength of cough, etc)</div><div>3. <span> </span><span>Indirect Calorimetry</span></div><div>a. <span> </span><span>Nutrition is important because <span></span>too few calories c<span></span>auses respiratory muscle </span></div><div>cat<span></span>abolism and muscle weakness.  T<span></span>oo many calories (particularly carbs) </div><div>increases me<span></span>tabolic rat<span></span>e and can result in respira<span></span>tor<span></span>y muscle fatigue or </div><div>hypercapnia due t<span></span>o increased C<span></span>O2 production</div><div>b.<span> <span> </span></span><span>b.<span> <span> </span>Indirect c<span></span>alorimetr<span></span>y is a measurement of r<span></span>esting energy expenditure </span></span></div><div>base<span></span>d o<span></span>n ox<span></span>ygen<span></span> con<span></span>sump<span></span>tion<span></span> (VO<span></span>2) <span></span>and <span></span>carb<span></span>on <span></span>diox<span></span>ide <span></span>prod<span></span>ucti<span></span>on <span></span>(VCO2)</div></div><div></div></div>
<div><div><img><div>138<span> </span><span>Referenc<span></span>e Material<span> </span>Referenc<span></span>e Material<span> </span><span>139</span></span></div><div>POS<span></span>T<span></span>-OP: <span>V<span></span>AD BOWEL REGIMEN PROT<span></span>OC<span></span>OL</span></div><div>St<span></span>andards of Pr<span></span>actice for V<span></span>AD patients t<span></span>o reduce P<span></span>ost<span></span>-po Ileus</div><div>VAD Quality Improvement</div><div>Vincent<span></span>a M. Grassano, RD, CNSC</div><div>Heart F<span></span>ailure Service/D1</div><div>1. <span> </span><span>Initiat<span></span>e bowel re<span></span>gimen the day of admission (Pre-op)</span></div><div>a. <span> </span><span>Senna 2 tabs BID</span></div><div>b.<span> <span> </span><span>Docusat<span></span>e 100mg BID</span></span></div><div>2. <span> </span><span>Escalat<span></span>e bowel regimen if no BM within 24 hours of sur<span></span>gery</span></div><div>a. <span> </span><span>Bisacodyl 10mg per rectum x1 oc<span></span>currence</span></div><div>b.<span> <span> </span><span>Magnesium Citr<span></span>ate 300mL x1 occurrenc<span></span>e (not for patient<span></span>s with renal </span></span></div><div>dysfunction)</div><div>c. <span> </span><span>Check potassium and magnesium</span></div><div>3. <span> </span><span>Adhere to Pr<span></span>e<span></span>-Op diet r<span></span>egimen</span></div><div>a. <span> </span><span>P<span></span>atient to receive die<span></span>t order for recommended PO Diet or TF </span></div><div>(carbohydr<span></span>ate c<span></span>ontaining meal) up to 24 hours bef<span></span>ore surger<span></span>y</div><div>b.<span> <span> </span><span>MD order f<span></span>or Liquid Diet (carbohydrat<span></span>e containing liquids ie juic<span></span>e or </span></span></div><div>Ensure clear) up t<span></span>o 6 hours prior to surger<span></span>y r<span></span>ather than NPO</div><div>c. <span> </span><span>P<span></span>atient to be NPO 6 hours prior to surgery</span></div><div>CVICU Servic<span></span>e / Immediate P<span></span>ost<span></span>-op</div><div>1. <span> </span><span>Resume bowel r<span></span>egimen POD #0</span></div><div>a. <span> </span><span>Senna syrup 10mL via feeding tube BID</span></div><div>b.<span> <span> </span><span>Incre<span></span>ase docusate solution 200mg via feeding tube BID</span></span></div><div>c. <span> </span><span>Add Miralax 1 pack<span></span>et BID</span></div><div>d. <span> </span><span>Bisacodyl 10mg per rectum daily</span></div><div>2. <span> </span><span>Keofeed plac<span></span>ed if unable to ex<span></span>tubate by POD #2</span></div><div>a. <span> </span><span>Allows for early nutrition</span></div><div>b.<span> <span> </span><span>Allows for immedia<span></span>te administra<span></span>tion of bowel regimen/medications</span></span></div><div>3. <span> </span><span>Initiation of Nutrition by POD #2  </span></div><div>(with the potential to mee<span></span>t estimated needs)</div><div>a. <span> </span><span>If intubated initia<span></span>te tube feeds</span></div><div>b.<span> <span> </span><span>Initiat<span></span>e Full liquid or Regular diet (sug<span></span>ar free clear liquid and clear liquid </span></span></div><div>diet do not have po<span></span>tential to meet estima<span></span>ted needs)</div><div>c. <span> </span><span>Supplements if needed</span></div><div>4. <span> </span><span>Escalat<span></span>e bowel regimen POD #4 if no bowel mov<span></span>ement or atus</span></div><div>a. <span> </span><span>Lactulose 20mg TID (NOTE: c<span></span>an cause abdominal discomfort and </span></div><div>cramping)</div><div>b.<span> <span> </span><span>Either: </span></span></div><div>i. <span> </span>Miner<span></span>al oil enema</div><div>ii.  Magnesium citrate (150-300mL) *(no<span></span>t for patients with r<span></span>enal </div><div>dysfunction)</div><div>5. <span> </span><span>KUB POD #5 if no BM of Fla<span></span>tus</span></div><div>6. <span> </span><span>T<span></span>aper down re<span></span>gimen if multiple bowel movement<span></span>s s/p bowel regimen</span></div><div>a. <span> </span><span>Docusate solution/<span></span>capsule 200mg BID: continue as scheduled</span></div><div>b.<span> <span> </span><span>Senna syrup 10mg BID: change scheduled t<span></span>o PRN</span></span></div><div>c. <span> </span><span>Miralax 1 pack<span></span>et BID: change scheduled to PRN</span></div><div>POS<span></span>T<span></span>-OP: <span>END OF LIFE CARE</span></div><div>Use these guidelines to tr<span></span>ansition a patient t<span></span>o comfort c<span></span>are and </div><div>perform discharg<span></span>e as deceased document<span></span>ation </div><div>1. <span> </span><span>F<span></span>amily, p<span></span>atient (if able), ICU team and surgic<span></span>al team agree to withdr<span></span>aw care</span></div><div>2. <span> </span><span>Discontinue <span>all order<span></span>s<span> in Epic (including medications, labs, nursing care </span></span></span></div><div>orders, et<span></span>c)</div><div>3. <span> </span><span>Order the <span>IP ICU End of Lif<span></span>e Order Set (#1791) <span>in Epic</span></span></span></div><div>a. <span> </span><span>Choose the appropriate analg<span></span>esics and anxiolytics as discussed with ICU </span></div><div>at<span></span>tending</div><div>b.<span> <span> </span><span>Order the Comf<span></span>ort Care code st<span></span>atus within the order set </span></span></div><div>4. <span> </span><span>Work with the ICU At<span></span>tending, bedside nurse and respira<span></span>tory care to determine </span></div><div>the sequence of support withdr<span></span>awal</div><div>5. <span> </span><span>Work with the resourc<span></span>e/charg<span></span>e RN to have Chaplain ser<span></span>vices av<span></span>ailable</span></div><div>6. <span> </span><span>Resourc<span></span>e/charg<span></span>e nurse will notify the T<span></span>ransplant Donor Network</span></div><div>7. <span> </span><span>Once the p<span></span>atient has passed, you or ano<span></span>ther licensed provider should </span></div><div>examine the pa<span></span>tient and declare Time of Death </div><div>a. <span> </span><span>Make note of this time, you will use it multiple times in document<span></span>ation</span></div><div>b.<span> <span> </span><span>Y<span></span>ou or the ICU at<span></span>tending should appro<span></span>ach the next of kin about autopsy </span></span></div><div>request</div><div>8. <span> </span><span> <span></span><span>Discharge as Dec<span></span>eased Documentation</span></span></div><div>a. <span> </span><span>Use the Discharge Naviga<span></span>tor and choose the “Discharge as Dece<span></span>ased” tab </span></div><div>locat<span></span>ed at the top of the Dischar<span></span>ge Naviga<span></span>tor</div><div>b.<span> <span> </span><span>Fill in the <span>De<span></span>ath Certica<span></span>te Worksheet <span>by selecting “New Reading” and </span></span></span></span></div><div><span></span></div><div>i. <span> </span>This will be used by Chaplain services to c<span></span>omplete the Death </div><div><span></span></div><div>ii.  <span>Call the Coroner </span>(408-793-1900) to report the de<span></span>ath</div><div>1.  They will ask you the patient’<span></span>s address (located in Demogr<span></span>aphics)</div><div>2.  They will ask Cause of Death and brief synopsis of wha<span></span>t happened</div><div>3.  Document the case/rele<span></span>ase number and the name of the person </div><div>you talk<span></span>ed to in the appropriate spac<span></span>e in Epic</div><div>iii. Complet<span></span>e the “Cause of Death” Document<span></span>ation</div><div>1.  “Cardiopulmonary arrest” is <span>No<span></span>t<span> a viable diagnosis</span></span></div><div>2.  When in doubt, ask the ICU at<span></span>tending what to lis<span></span>t</div><div>c. <span> </span><span>Complete the<span> Dec<span></span>eased Summar<span></span>y <span>within the navig<span></span>ator</span></span></span></div><div><span> </span><span></span><span></span></div><div>ii.  Select the ICU At<span></span>tending as the cosigner</div><div>d. <span> </span><span>Complete the <span>Discharge Summary</span></span></div><div><span> </span><span></span><span></span><span></span><span></span></div><div>ii.  Delete non-applicable sections as needed</div><div>iii. Same informa<span></span>tion as the Deceased Summar<span></span>y<span></span>, may copy-past<span></span>e </div><div>iv. List the Surgic<span></span>al at<span></span>tending as the cosigner </div><div>9. <span> </span><span>Write the <span>Discharg<span></span>e Order</span></span></div><div>a. <span> </span><span>Disposition: Deceased</span></div></div><div></div></div>
<div><div><img><div>140<span> </span><span>Referenc<span></span>e Material<span> </span>Referenc<span></span>e Material<span> </span><span>141</span></span></div><div>POS<span></span>T<span></span>-OP: <span>P<span></span>A<span></span>TIENT PROGRESSION CHECKLIS<span></span>T</span></div><div>P<span></span>atient Progression T<span></span>owar<span></span>ds Discharg<span></span>e</div><div> <span></span><span></span></div><div>P<span></span>ain- well controlled with or<span></span>al meds</div><div><span></span><span> </span><span>Remove OnQ (Bupivicaine pump) 1 day prior t<span></span>o discharge))</span></div><div> <span></span><span></span></div><div>Remove devices (Ches<span></span>t tubes, Pac<span></span>er wires, Foley, A-line)</div><div> <span></span><span></span></div><div>T<span></span>ransition to PO Medica<span></span>tions</div><div><span></span><span> </span><span>ASA, st<span></span>atin</span></div><div><span></span><span> </span><span>Bet<span></span>a-Blocker if applicable</span></div><div><span></span><span> </span><span>Need for Antico<span></span>agulation? T<span></span>ransition to PO antico<span></span>agulants</span></div><div><span></span><span> </span><span>Adequate diur<span></span>esis? T<span></span>ransition to PO diur<span></span>etics</span></div><div><span></span><span> </span><span>Do any medications r<span></span>equire prior authoriz<span></span>ation? (Consult with Case </span></div><div>manager)</div><div> <span></span><span></span></div><div>Commonly prescribed medica<span></span>tions requiring prior authoriz<span></span>ation </div><div>include: NOAC (Eliquis, xar<span></span>elto), oxycontin</div><div> <span></span><span></span></div><div>T<span></span>olerating die<span></span>t<span></span>, BM since sur<span></span>ger<span></span>y</div><div><span></span><span> </span><span>Pos<span></span>t-opera<span></span>tive imaging (consult with chief resident/surgical att<span></span>ending<span></span>) </span></div><div><span></span><span> </span><span>CT sc<span></span>an +/- Echo (surg<span></span>eon and opera<span></span>tion dependent)</span></div><div><span></span><span> </span><span>2-view CXR (done in radiology suite) at dry weight prior to discharge</span></div><div> <span></span><span></span></div><div><span></span><span></span></div><div> <span></span><span></span></div><div>PT ev<span></span>al: Home vs. home with home health therapy vs. Skilled Nursing F<span></span>acility</div><div><span></span><span> </span><span>Consult with E-29 Case Manager to s<span></span>tart referr<span></span>al process if needed</span></div><div><span></span><span> </span><span>Contac<span></span>t: 650-847-7453 (work cell-phone)</span></div><div> <span></span><span></span></div><div>Cardiac rehab: Discharg<span></span>e teaching</div><div><span></span><span> </span><span>Cardia Rehab ghos<span></span>t pager<span></span>: 1-5736 </span></div><div> <span></span><span></span></div><div>Est<span></span>ablish follow up appointments with Nurse Coordinat<span></span>or (PCP<span></span>, Cardiologist, </div><div>INR clinic, etc). Cont<span></span>act via cell-phone:</div><div><span></span><span> </span><span>Dr<span></span>. Boyd, Dr. Ha: <span>Sally Eastman</span> 650-627-6373</span></div><div><span></span><span> </span><span>Dr<span></span>. Woo: <span>Ashley Liang</span> 650-683-0114</span></div><div><span></span><span> </span><span>Dr<span></span>. Lee, Dr. Hiesing<span></span>er<span></span>: <span>Pres Lorenzo</span> 650-850-2828</span></div><div><span></span><span> </span><span>Dr<span></span>. Fischbein, Miller<span></span>: <span>Judi Lachenmyer</span> 650-498-7731 (ext 87731) </span></div><div>NO<span></span>TES</div></div><div></div></div>
<div><div><img><div>142<span> </span><span>Referenc<span></span>e Material<span> </span>Referenc<span></span>e Material<span> </span><span>143</span></span></div><div>NO<span></span>TES<span> </span>NO<span></span>TES</div></div><div></div></div>
<div><div><img><div>144<span> </span><span>Referenc<span></span>e Material</span></div><div>DEP<span></span>ARTMENT OF CARDIO<span></span>THORACIC  </div><div>SURGERY HANDBOOK<span></span>—<span></span>VERSION II</div><div>F<span></span>aculty Advisors:</div><div>Y<span></span>. Joseph Woo, MD</div><div>Jack H. Boyd, MD</div><div>Charles Hill, MD</div><div>Charlene Kell, EMBA, BSN, RN, C<span></span>CRN, FACHE, NEA-BC</div><div>Anson M. Lee, MD</div><div>Kapilkumar N. P<span></span>atel, MD</div><div> </div><div>Contributing Authors:</div><div>Scarlet<span></span>te Aliga-Cabamung<span></span>an, MS, RN, AGACNP-BC</div><div>Irina Axelrod, P<span></span>A-C</div><div>Christ<span></span>opher J. Bilb<span></span>ao, DO</div><div>Sarah Boo<span></span>th, ACNPC-AG, MSN, C<span></span>CRN</div><div>Zoe Chan, P<span></span>A-C</div><div>Kristie Duoss, MSN, ACNP<span></span>-BC</div><div>Clara Geor<span></span>ge, NP</div><div>Hilar<span></span>y C. Hammond, MMS, P<span></span>A-C</div><div>Christine Hartley, RN, MS, A<span></span>CNP-BC</div><div>Aleya Hyderi, P<span></span>A-C</div><div>Kelly Juarez, MP<span></span>AS, P<span></span>A-C</div><div>Y<span></span>ukfung Lee, P<span></span>A-C</div><div>Xin Ma, MMS, P<span></span>A-C </div><div>Erica Mikhli, P<span></span>A-C</div><div>Shari Miller<span></span>, PA-C, F<span></span>AP<span></span>ACVS</div><div>Mykl Morrissey, MSN, RN, AGACNP<span></span>-BC</div><div>Richard Quitevis, MS, RN, AGACNP<span></span>-BC</div><div>Hardeep Reddick, MBA, P<span></span>A-C</div><div>Suzanne Sewell, MSN, RN, FNP<span></span>-BC</div><div>Joe Simmons, MS,ACNP<span></span>-BC</div><div>Tim Shieh, P<span></span>A-C</div><div>Y<span></span>. Ke<span></span>vin Z<span></span>eng, MS, AGACNP<span></span>-BC, RN</div><div> </div><div>Contributing Editor<span></span>s: </div><div>Megan A<span></span>tashroo, MSN, RN-F<span></span>A, FNP-BC</div><div>Mar<span></span>y Sheridan Bilbao<span></span>, MPAS, P<span></span>A-C, FAP<span></span>ACVS</div><div>Corinne Pog<span></span>emiller, MMSc, P<span></span>A-C</div><div>Emily T<span></span>ognozzi, MMS, P<span></span>A-C</div><div>Disclaimers:</div><div>Although care has been t<span></span>aken to ensure the accur<span></span>acy of content of this </div><div>handbook, it should not be a substitute f<span></span>or clinical judgment<span></span>. Neither the </div><div>authors nor editors assume any liability for injuries and or damag<span></span>e relat<span></span>ed to this </div><div>publication.</div><div>For internal use only<span></span>, not for sale or re-distribution. Use f<span></span>or intended audience </div><div>only. No<span></span>t for pa<span></span>tient education.  </div></div><div></div></div>
</div>
<div>
<img>
</div>
</body>
</div>